,id,ticker,title,category,content,date,provider,url,article_id
202467,423983,MRK,The 4 Most Important Things to Know About Merck s Q4 Earnings Results,news,"Merck  NYSE MRK  is off to a rocky start in 2020  The company s blockbuster cancer drug  Keytruda  disappointed in a late stage clinical study targeting small cell lung cancer  Shortly afterward  Chinese biotech BeiGene announced positive results from a late stage study for tislelizumab  potentially setting up a battle between the drug and Keytruda in the big Chinese market 
Today  the year became even rockier  Merck reported its 2019 fourth quarter and full year results before the market opened on Wednesday  The drugmaker s shares fell around 3  in early trading  Here are the four most important things to know about Merck s Q4 update 

1  Solid sales growth    but not enough to satisfy Wall Street
Merck announced fourth quarter revenue of  11 87 billion  up 8  year over year and an increase of 9  on a constant currency basis  But this revenue growth wasn t quite enough to make Wall Street happy  The analysts  consensus Q4 revenue estimate was  11 98 billion 
Keytruda wasn t the problem  Sales for the cancer immunotherapy skyrocketed 45  year over year in Q4 to  3 1 billion  Neuromuscular blockade reversal drug Bridion also performed well  with sales jumping 22  to  313 million 
However  revenue from Merck s HPV vaccine  Gardasil 9  fell 17  from the prior year period to  693 million  This sales figure was negatively impacted by the company s previous borrowing of doses of the vaccine from the U S  Centers for Disease Control and Prevention s pediatric vaccine stockpile  In addition  Merck faced continued headwinds from pricing pressure for diabetes drugs Januvia and Janumet  as well as sales declines due to the loss of market exclusivity for several drugs  including Remicade  Zetia  and Vytorin 
2  A narrow earnings beat
While Merck fell a little short of meeting analysts  revenue expectations  it narrowly beat Wall Street s consensus Q4 earnings estimate  The company reported adjusted earnings per share  EPS  of  1 16  compared to the average analyst estimate of  1 15 
This result reflected solid 12  year over year growth  Merck s earnings growth of 29  based on generally accepted accounting principles  GAAP  was even more impressive   
3  Outlook for 2020
Merck expects full year 2020 sales will be between  48 8 billion and  50 3 billion  The midpoint of this range represents a year over year increase of 5 9   It is also slightly above analysts  full year 2020 revenue estimate of  49 53 billion 
The company expects full year 2020 non GAAP EPS between  5 62 and  5 77  up 9 7  year over year at the midpoint  Analysts projected 2020 adjusted EPS of  5 61 
4  A new spin off
Perhaps the biggest news from Merck s Q4 update was that it s planning to spin off its women s health  trusted legacy brands  and biosimilar products into a new stand alone company  Merck will retain its core oncology  vaccines  hospital  and animal health products businesses 
Why a spin off  Merck said that it  will allow both management teams to drive increased responsiveness to the particular needs of their patients and customers and achieve faster growth through focused and fit for purpose operating models   The most important words in that sentence were  achieve faster growth   Merck s Q4 growth would have looked a lot better without the drag of its older products 
The good news for investors is that Merck will remain an attractive dividend stock  Merck anticipates future dividend hikes and will strive to reach a payout ratio between 47  and 50  down the road  The spin off company is also expected to pay an incremental dividend 
This transaction won t happen immediately  though  Merck said that the spin off would likely be finalized in the first half of 2021  That means the positive and negative factors affecting the company in Q4 will carry over throughout 2020 ",2020-02-05,The Motley Fool,https://invst.ly/prhm9,2076931
202468,423984,MRK,Merck Announces a Big Planned Spinoff,news,"Merck  NYSE MRK  announced Wednesday its intention to spin off its women s health business   legacy brands  and biosimilars unit into an independent  publicly traded company  and reorient itself toward its higher growth businesses  The slimmed down Merck will focus on oncology  vaccines  hospital products  and animal health 
The transaction is planned as a tax free distribution of newly issued shares in the yet to be named spinoff company  Merck expects to receive a tax free payment of  8 billion to  9 billion from the new company   NewCo   when the deal closes in the first half of 2021 

Merck believes that spinning off the slower growing businesses will allow it to increase investments in its core growth areas and significantly expand its operating margin  management is targeting a non GAAP operating margin of more than 40  by 2024  compared with the current level in the mid 30  range   NewCo will have strong cash flows and growth opportunities in biosimilars  contraceptives  and fertility  as well as through the development of sales in foreign markets 
The pharmaceutical giant plans to maintain its current dividend of  2 44 per share after the spinoff  and expects that NewCo will pay a meaningful dividend that will be incremental to Merck s payout 
Investors may be concerned that this move makes Merck even more dependent on growth from its mega blockbuster cancer immunotherapy Keytruda  Wall Street gave the announcement  which arrived along with the release of a mixed fourth quarter earnings report  a cool reception  Shares were trading about 3  lower as of 1 30 p m  EST ",2020-02-05,The Motley Fool,https://invst.ly/prjli,2077072
202469,423985,MRK,Merck   Co Inc  MRK  Q4 2019 Earnings Call Transcript,news,"Merck   Co Inc  NYSE MRK Q4 2019 Earnings CallFeb 5  2020  8 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood morning  My name is Carlo  and I will be your conference operator today  At this time  I would like to welcome everyone to Merck   Company Quarter Four Sales and Earnings Conference Call   Operator Instructions  Thank you I would now like to turn the call over to Peter Dannenbaum  VP of Investor Relations  Please go ahead Peter Dannenbaum    Vice President of Investor RelationsThank you  Carlo  and good morning  Welcome to Merck s fourth quarter 2019 conference call  Today I m joined by Ken Frazier  our Chairman and Chief Executive Officer  Rob Davis  our Chief Financial Officer  Dr  Roger Perlmutter  President of Merck Research Labs  and Kevin Ali  who will be named Chief Executive Officer of the new company we have announced today  Each will have prepared remarks  In addition  I m also joined by Frank Clyburn  our Chief Commercial Officer  and Mike Nally  our Chief Marketing Officer  who will be available for the Q A portion of the call Before I turn the call over to Ken  I d like to point out a few items  You will see that we have items in our GAAP results such as acquisition related charges  restructuring cost and certain other items  You should note that we have excluded these from our non GAAP results and provide a reconciliation in our press release  We have also provided a table in our press release to help you understand the sales in the quarter for the business units and products I would like to remind you that some of the statements that we make during today s call may be considered forward looking statements within the meaning of the Safe Harbor provision of the US Private Securities Litigation Reform Act of 1995  Such statements are made based on the current beliefs of Merck s management and are subject to significant risks and uncertainties  If our underlying assumptions prove inaccurate or uncertainties materialize  actual results may differ materially from those set forth in the forward looking statements Our SEC filings  including Item 1A in the 2018 10 K identify certain risk factors and cautionary statements that could cause the Company s actual results to differ materially from those projected in any of our forward looking statements made this morning  Merck undertakes no obligation to publicly update any forward looking statements  You can see our SEC filings  as well as today s earnings release on merck com  We have also posted a presentation to the Investors section of merck com  which includes some of the highlights from our results and announcement With that  I d like to turn the call over to Ken Kenneth C  Frazier    Chairman and Chief Executive OfficerThank you  Peter  We are very pleased to speak with you this morning as we close out what we consider to be an exceptional year for Merck  And we are excited to announce our intention to create two leading growth companies through the spin off of our Women s Health  Legacy Brands and Biosimilar Products into a new company As you can see from our results and our 2020 guidance  Merck had an extraordinary year and is in a position of operational and financial strength driven by strong execution of our strategy and focus on our key growth drivers and innovative pipeline  It is this position of strength born of that focus that gives us the confidence to do what we believe will best position us to deliver even greater value to patients and shareholders Throughout my entire tenure as CEO we have consistently focused on science as core to our strategy to not only benefit the most patients  but also as a means of creating the most value  As you ve seen  Merck s portfolio have evolved from one focused largely on primary care products to one focused on Oncology  Vaccines  Hospital and Animal Health  It is this purposeful shift  coupled with greater prioritization and focus on key growth drivers that has led to the unprecedented growth that we are now experiencing  Going forward  we see even greater opportunities to invest behind our innovative growth drivers  In placing greater focus and prioritization behind these products  we must also think carefully about how to make the best possible use of the remainder of our expansive Human Health portfolio  which has comprised of more than 160 products in total Our responsibility to patients and shareholders has led us to think about how we can maximize the impact of this vast array of Human Health products  Therefore  after careful consideration over time  we ve made the decision to separate into two companies  one  a research intensive biopharmaceutical leader  the other  a new company focused on becoming a leader in Women s Health with the capability to realize the full potential of a portfolio of trusted and medically important legacy products and a rapidly expanding biosimilars business By spinning off NewCo as a distinct business  we can better prioritize and support a set of products that no longer fit in Merck s strategic framework  but which remains important to public health and the patients who rely on them  and which if managed and resourced appropriately  present real opportunities for growth  We re also mindful of the changing industry landscape and believe that evolving our operating model in this way will allow Merck to benefit from an even more intense focus on breakthrough science and innovation As I stated on our Investor Day in June  our mission and rich legacy of inventing to save and improve the lives is the foundation of our company  The separation of NewCo will help us in our aspiration to be the premier research intensive biopharmaceutical company by allowing us to focus on innovations that prevent and treat diseases  And over the past few years  we have seen how more focus and more prioritization leads to more growth  more efficiency and more value creation The spin off will also create significant opportunities for NewCo  As an independent company  NewCo will pursue its strategic intent of becoming a global leader in Women s Health  an area where the future opportunities are significant  In addition to the growth potential in Women s Health  NewCo s growth will be fueled by more fully realizing the full potential of a portfolio of trusted Legacy Brands and pain  dermatology  cardiovascular and other areas  as well as its rapidly expanding biosimilars business  This new company will have a strategic freedom to pursue additional growth opportunities through lifecycle management and targeted acquisitions and partnerships in Women s Health  dermatology and other fields NewCo will be led by a highly experienced leadership team including Kevin Ali  who has been named Chief Executive Officer  Kevin has a proven track record of leadership at Merck with deep experience in global pharmaceutical market and diverse therapeutic areas  In addition  NewCo s Board will be shared by Carrie Cox  who has extensive experience in pharmaceutical commercialization  particularly in Women s Health  as well as broad leadership and Board experience including as former Chairman and CEO of Humacyte  former Chairman of Array BioPharma and as President of Global Pharmaceuticals at Schering Plough prior to its merger with Merck  We are confident that the NewCo will be in experienced and capable hands with this leadership team Our industry faces emerging challenges such as the rising cost of innovation and increasing pressures around pricing and market access  In this environment  we must maximize our opportunities to act with greater operational agility  efficiency and productivity  As separate  more focused companies with more optimal resource allocation  both Merck and NewCo will be better positioned to continue to positively impact the lives of patients  improve global public health and achieve faster growth  As a result  we expect Merck shareholders to benefit through ownership of two focused companies each with attractive financial characteristics and growth profile In summary  we are seeing the benefit of focusing our organization on its best growth opportunities  As we look out to 2024  we believe the strength of our business is under appreciated  We are more confident than consensus on every key financial metric  including revenue  operating margins and EPS growth  Our commitment to maintaining and growing the Merck dividend is evidence of the confidence we have in the long term prospects for our business Our fundamental operating and financial strength allow us to take bold step to stay ahead of the curve by reshaping our operating structure  focusing and streamlining Merck  enabling Merck to become an even stronger  more agile and faster growing company  I strongly believe that this is the right thing for patients  for public health and for shareholders With that  I ll now pass it on to Rob to discuss our results and provide more details on the spin off  Rob Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerThanks  Ken  and good morning  everyone  I m excited to speak to you this morning about our 2019 results  as well as our decision to spin off a portion of our Human Health business  a decision that will enhance the value of both Merck and NewCo  2019 was a year of exceptional growth for our business with revenues increasing 13  and non GAAP EPS increasing 21  excluding the impact of foreign exchange  Our strong performance reflects the continued execution of our science led strategy and we expect our business momentum to continue  particularly as we enhance our focus on our key growth drivers through the spin off I ll start by highlighting our strong fourth quarter results before providing more details on the transaction and 2020 guidance  Total company revenues were  11 9 billion in the quarter  an increase of 8  year over year or 9  excluding the negative impact from foreign currency  Both our Human Health and Animal Health divisions contributed to the growth this quarter The remainder of my comments pertaining to sales will be on an ex exchange basis  Our Human Health revenues grew 8   led by products in oncology and hospitals  In Oncology  KEYTRUDA fourth quarter sales were  3 1 billion and for the full year sales exceeded  11 billion  representing 58  growth versus 2018  In the US  growth was driven by strong demand across all indications  KEYTRUDA continues to lead across many indications  including lung  bladder  and head and neck cancers with strong momentum in adjuvant melanoma and renal cell carcinoma  where we are seeing strong uptake across all patient subgroups  Outside the US  KEYTRUDA sales in the quarter grew 50  driven by lung globally with reimbursement for KEYNOTE 189 now secured across all major markets in the EU and strong uptake in lung following approvals in Japan and China We are also seeing positive uptake from early launches in both renal cell carcinoma and adjuvant melanoma in the EU and expect to see strong global growth as these and other new indications continue to rollout  Our results also reflect continued strength for both Lynparza and Lenvima  important products from our collaborations with AstraZeneca and Eisai respectively  Lynparza continues to have strong growth in ovarian cancer and maintains a greater than 60  total patient share in the PARP inhibitor class in the United States Growth of Lenvima benefited from the launch of the endometrial carcinoma indication in combination with KEYTRUDA  and continued strong demand with first line hepatocellular carcinoma where Lenvima is now the leading treatment agent  Our vaccines business declined this quarter due to the impact from the replenishment of GARDASIL to the CDC stockpile in 2018  and our borrowing from the stockpile in the fourth quarter of 2019  which notably impacted the year over year comparison of GARDASIL revenues by  245 million on a combined basis  Excluding these impacts  GARDASIL revenues grew 16  driven by continued strong underlying global demand Our Hospital business benefited from 24  growth in BRIDION  which reached  1 billion in annual sales for the first time  this quarter  Growth was largely driven by an increased share in the US reversal market  For the full year  we achieved strong growth of 14  in our Human Health business driven by our growth pillars across most geographies  Animal Health revenues increased 10  this quarter to  1 1 billion  Growth for the quarter was driven largely by the products acquired in the Antelliq acquisition Now  turning to the rest of our P L  my comments will be on a non GAAP basis  Gross margin was 72 6  in the quarter  a decrease of 240 basis points year over year  primarily reflecting the impact of unfavorable manufacturing variances and higher inventory write offs  Operating expenses of  5 2 billion increased 10  year over year  Administrative and promotional expenses drove higher SG A costs in the quarter  while clinical development spend and cost associated with our discovery efforts were responsible for the increase in R D expense Other income and expense was positively impacted by income from our equity securities portfolio  partially offset by higher net interest expense  Our effective tax rate for the quarter was 16 9   driven by lower and favorable earnings mix  Taken together  we earned  1 16 per share  an increase of 12  excluding exchange Now  turning to our announced spin off  As Ken noted  by further evolving our operating model and separating into two simpler  more focused and agile companies  both will be better positioned to respond to the changing external landscape  improved efficiency and accelerate growth  creating greater value for patients and shareholders than would be achieved as a single company Spinning off NewCo accelerates Merck s revenue growth by up to 1 percentage point on a compounded average basis through 2024  But more importantly  it allows Merck to enhance focus on its key growth drivers and robust pipeline  This gives us confidence that Merck will realize even greater incremental revenue growth over time  We will also benefit from more streamlined processes and operations  enabling further operating model efficiencies across the value chain For context  the products to be spun off into NewCo represent about 15  of Merck s Human Health revenues based on 2020 forecast  while consuming a much larger share of our operations and resources  In fact  separating NewCo will reduce Merck s Human Health manufacturing footprint by about 25   the number of products by 50  and the number of SKUs by 60  As a result of a more optimized operating model  Merck will achieve even higher operating margins over time  creating additional headroom to invest in innovation  which we continue to believe is the key to our long term growth and value creation as Ken has referenced  Merck will continue to benefit from broad commercial scale driven by its key growth pillars in Oncology  Vaccine  Hospital and Animal Health  as well as our diabetes franchise Merck will continue to have a strong balance sheet with significant cash flows and financial flexibility  which will allow for investments in innovation and meaningful business developments to augment its pipeline and portfolio  while continuing to return capital to shareholders  We expect to complete the transaction in the first half of 2021  Until then  we will remain focused on continuing to successfully execute our strategy and maintaining our strong financial and operational performance Now  let s move to our outlook for 2020  the year in which we continue to operate as a combined entity  My remaining comments will be on a non GAAP basis  We expect full year 2020 revenue to be between  48 8 billion and  50 3 billion  which represents 4  to 7  growth versus 2019  This range assumes a negative impact from foreign exchange of less than 1 percentage point  using mid January rates Our gross margin will be roughly 75 5   We expect operating expenses to increase by a low single digit rate year over year  due to higher R D spending as we remain committed to fully funding the meaningful opportunities in our pipeline  SG A expenses will remain tightly managed  We expect other expense of roughly  200 million  driven by higher net interest expense  We expect our tax rate to be roughly 17 5  to 18 5  for the year  We project average diluted shares to be 2 54 billion for 2020 and we expect EPS to be between  5 62 and  5 77  which represents growth of 8  to 11   including a roughly 1 5 percentage point negative impact from foreign exchange  using mid January rates Longer term  Merck continues to expect strong revenue growth driven by growing demand for our innovative products  When looking out to 2024  we believe our revenue growth potential is under appreciated  even more so as we begin to realize the benefits of this transaction  We continue to expect meaningful operating margin expansion over time  The separation of NewCo enables  1 5 billion in pre tax operating efficiencies  ratable over three years  While initially Merck s operating margins will decline slightly  we expect to achieve operating margins of greater than 40  in 2024  higher than Merck would have achieved as a combined company  The transaction is expected to result in  8 billion to  9 billion of proceeds from a special tax free dividend from NewCo  Merck s capital allocation priorities remain unchanged and we expect to maintain a very solid financial and credit profile First and foremost  we will fund our best growth opportunities through investments in R D  product launches and capacity expansion  and we believe the spin off allows us to better focus on these activities  Merck s dividend will be unaffected by this transaction and we anticipate future dividend increases from the current 2020 dividend of  2 44 per share post separation with a goal of achieving a 47  to 50  payout ratio over time  We will continue to have ample capacity for value enhancing business development and finally  we will continue to repurchase shares as a way to return excess cash to shareholders Turning now to NewCo s financial profile  The products represented by the new company portfolio are expected to achieve 2020 revenue of approximately  6 5 billion with an operating margin of approximately 45  as part of the Merck  As an independent company  NewCo is expected to achieve low single digit revenue growth off of a 2021 base of  6 billion to  6 5 billion  Taking into consideration  the cost to operate as an independent company operating margins from NewCo are expected to be in the mid 30  range and increase over time  And finally  we anticipate EBITDA margins to be in the low to mid 40  range in 2021 and also increase over time NewCo will have strong cash flows and a balance sheet position to invest in growth opportunities and expects to pay a meaningful dividend  which will be at least as competitive as any likely pure company and entirely incremental to Merck s dividend  In total  we expect combined EPS of NewCo and Merck together to initially be nominally lower than what Merck would have achieved without the spin off  but as a result of the incremental growth that NewCo will achieve stand alone  combined with the benefit of the operating efficiencies that Merck will realize  we expect that shareholders owning both companies will realize higher EPS within 12 months to 24 months In summary  we are confident that through the spin off both companies will have strong prospects for future success and sustainable profitable growth  given the clear benefits each will realize as independently operated entities including  enhanced strategic and operational focus on our key drivers to accelerate growth  improved agility to anticipate and respond to customer needs and evolving market dynamics  simplified operating models with reduced complexity and improved efficiencies  optimized capital structures and resource allocation to pursue their distinct strategic agendas  and improved financial profiles making for unique and compelling investment cases  We are excited by this opportunity to create two patient focused growth companies and look forward to continuing to deliver significant long term value to our patients and shareholders With that  I d like to turn the call over to Roger Roger M  Perlmutter    President of Merck Research LabsThanks  Rob  Looking back on 2019 and in particular on our fourth quarter results  there is much to celebrate  In December  our KEYNOTE 057 data were reviewed at an FDA Oncologic Drugs Advisory Committee meeting  which was followed three weeks later by FDA approval of KEYTRUDA as monotherapy for the treatment of certain patients with high risk non muscle invasive bladder cancer  This represents the 23rd FDA approved indication for KEYTRUDA  broadening still further the benefit that can be expected from the use of KEYTRUDA in the urologic setting KEYTRUDA also gained three new approvals in Japan during the fourth quarter as combination therapy and the first line treatment of advanced renal cell carcinoma  based on the KEYNOTE 426 study  and for the first line treatment of metastatic squamous cell carcinoma of the head and neck either as monotherapy or when combined with chemotherapy based on results of the KEYNOTE 048 trial  The KEYNOTE 048 data also permitted approval of KEYTRUDA in Europe with a similar indication  Finally  we gained approval of KEYTRUDA in China for the treatment of metastatic squamous cell carcinoma of the lung  in combination with chemotherapy based on data obtained in the KEYNOTE 407 study Substantial progress was also made in the registration of Lynparza  our leading PARP inhibitor that we are developing in collaboration with colleagues at AstraZeneca  At the December FDA Oncologic Drugs Advisory Committee  a majority of committee members supported the use of Lynparza as first line maintenance therapy for patients with germline BRCA mutated metastatic pancreatic cancer  whose disease had not progressed on at least 16 weeks of first line platinum based chemotherapy  All based on data from the Phase 3 POLO trial  which demonstrated a 47  reduction in the risk of disease progression or death in the Lynparza treatment arm  FDA granted approval for Lynparza in this setting at the end of 2019 I should also note that data from our PAOLA 1 trial of Lynparza were accepted by the FDA for priority review with a PDUFA date in the second quarter of this year  And PAOLA 1 maintenance Lynparza plus bevacizumab treatment of women with advanced ovarian cancer that have responded to first line platinum based chemotherapy plus bevacizumab reduced the risk of disease progression or death by 41   Additional file supporting the use of Lynparza in the treatment of men with mutation selected metastatic castrate resistant prostate cancers based on the results of the Phase 3 profound study was also accepted by the FDA for priority review with the PDUFA date in the second quarter of 2020 While we are clearly very active and advancing new cancer treatments during the fourth quarter  we also made important progress in other areas  For example  in the management of highly resistant bacterial infections  the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for RECARBRIO  our novel combination of imipenem  cilastatin  and relebactam for the treatment of infections due to aerobic gram negative bacteria with demonstrated resistance to other agent  RECARBRIO is also under priority review by the FDA and the treatment of adult patients with hospital acquired or ventilator associated bacterial pneumonia caused by susceptible organisms with a PDUFA date of June 4th Important progress was also made in cardiovascular medicine with the completion of the Phase 2 VICTORIA study  in which vericiguat and novel guanylate cyclase activator being developed in collaboration with colleagues at Bayer  was found to reduce the composite risk of heart failure hospitalization or cardiovascular mortality  as compared with placebo in patients with worsening heart failure with a reduced ejection fraction  who were receiving standard heart failure therapies Time does not permit me to list the many other regulatory and clinical milestones that we achieved in the fourth quarter  However  I cannot fail to note that ERVEBO  the first effective vaccine against an ebolavirus  was approved by the FDA and received conditional approval from the EMA for the prevention of disease caused by Zaire ebolavirus  We have now provided more than 275 000 doses of this vaccine by experimental and use protocols to support the efforts of the World Health Organization and other agencies attempting to halt the spread of ebolavirus disease in the Democratic Republic of the Congo Approvals have also been obtained at certain African nations  including Burundi  Zambia and the Democratic Republic of the Congo itself  which should greatly improve the process whereby individuals at high risk can be immunized  It has taken many years to reach this important moment  My colleagues and I feel privileged  who have contributed in this way to the control of an otherwise fatal diseases caused by the Zaire ebolavirus Lastly  I wish to comment on the spin off of the new company that we have announced this morning  I begin with a deep belief in the power of simplification to enhance productivity  My colleagues and I have important objectives over the next few years that will  we hope  improve treatment for malignant disease and heart failure and provide vaccines that reduce suffering from infectious diseases  Simplification of our corporate structure can only sharpen our focus on these critically important programs  I have confidence that we can achieve this increased focus internally  while providing the near term support necessary to implement NewCo to establish itself as a highly effective separate entity I ll now turn the call back to Ken Kenneth C  Frazier    Chairman and Chief Executive OfficerThank you  Roger  And before turning the call over to Kevin  I d like to take a few minutes to share with you some details on his background  Kevin brings a wealth of knowledge to NewCo based on three decades of pharmaceutical and commercial experience at Merck  His experience ranges from leading different regions  including our entire International Human Health business and the emerging markets region to leading markets such as Germany and Turkey Most recently  Kevin has been instrumental in evaluating Merck s options to optimize the entire Human Health portfolio and in envisioning what success looks like for NewCo  while providing invaluable counsel to me and the rest of the senior management team  I m confident that under Kevin s leadership NewCo will reach its full potential and drive greater value for patients  shareholders and employees And with that  I d like to turn the call over to Kevin Kevin Ali    Chief Executive Officer of NewCoThanks  Ken  and good morning  I m excited to share with you today the creation of our new company  which we believe has a remarkable opportunity to unleash the potential of a leading portfolio of assets in Women s Health  a rapidly growing biosimilars business and a portfolio of trusted and medically important Legacy Brands NewCo revenue was expected to be flat to declining through 2024 within Merck  due to limited investment and focus  However  we believe that by allocating the appropriate resources and by focusing management attention  NewCo will achieve sustainable growth and create value outside of Merck  Although revenues are expected to decline in 2021 versus 2020 to a base of approximately  6 billion to  6 5 billion  largely due to the loss of exclusivities of ZETIA in Japan  and NUVARING in the US  the new company will be well positioned to achieve low single digit revenue growth off of that base  As no new LOEs loom and we have identified lifecycle management and commercial investment opportunities  some are already under way NewCo will have a strong global scale and geographic diversification  And as a stand alone entity  we ll be better positioned to capitalize on attractive opportunities across it s portfolio  NewCo will pursue global leadership and sustainable growth in Women s Health through its growing contraceptive and fertility business  including NEXPLANON  which grew 14  in 2019 and is the leading implantable long acting reversible contraceptive worldwide with US patent protection through 2027 In fact  we expect NEXPLANON to be our first  1 billion Women s Health product  The growing  40 billion Women s Health market is highly fragmented with over 400 products in development industrywide  NewCo will be well positioned to capitalize on this attractive market opportunity to become an industry leader through investments in both organic growth and business development opportunities and to deliver better and more innovative and holistic care to women  NewCo growth will also be driven by biosimilars business in the early stages of a long term growth opportunity with three products currently on the market through its partnership with Samsung Bioepis Revenues of the three currently marketed products are expanding rapidly and are    and were approximately  250 million in 2019  NewCo is well positioned to benefit from increased biosimilar demand as markets around the world continue to seek healthcare cost savings through greater biosimilar adoption in a growing market The Women s Health and Biosimilar businesses will represent a larger proportion of NewCo s revenues over time  and are expected to account for more than 50  of sales by 2024  NewCo will also have the opportunity to realize the full potential of its portfolio of globally trusted Legacy Brands to increase focus and targeted investment  Importantly  the infrastructure and cash generation within this broad portfolio provides a scale  geographic reach and capital to support the growth opportunities that the Women s Health and Biosimilar business is present  In addition to its strong product portfolio  NewCo s global scale and geographic reach will serve as an important competitive advantage  The company will have the capability to potentially commercialize and distribute for other innovative industry players Finally  NewCo will be a highly profitable with stable and strong cash flows  As a stand alone company  it will be able to make the capital allocation decisions that best suit its long term interests  including organic and inorganic growth opportunities  paying a meaningful dividend  debt pay down or returning cash to shareholders through share repurchases In summary  I m very excited about the future of NewCo and the opportunity to work with Carrie Cox  This company will have a distinct opportunity to address the health needs of women around the world and to build off of important growth pillars such as NEXPLANON  pain and dermatology and biosimilars  As a focused company with dedicated resources  a strong global footprint  and talented and experienced employees  who embody the shared values of the Merck culture  NewCo will be better positioned to create value for patients and shareholders With that  I d like to turn the call back over to Peter Peter Dannenbaum    Vice President of Investor RelationsThank you  Kevin  We recognize today s upfront comments ran longer than normal  So we re prepared to extend the call beyond 9 00 AM  if necessary  So  Carlo  will you please line up the queue for Q A Questions and Answers OperatorThank you  sir  Ladies and gentlemen  we ll now begin the question and answer session   Operator Instructions  Our first question is from Chris Schott from JPMorgan  Please go ahead Chris Schott    JPMorgan    AnalystGreat  Thanks very much for the questions  Obviously a lot of news there today  I just had two really both related to the spin  I guess first on this  you mentioned you ve been considering deal like this or some structure for these assets for quite some time  I guess  why now on the timing  is there something that s either happened with the business or the pipeline that made this    make particular sense now versus  I guess  when you ve looked at this in the past And my second question is    I just want to make sure I m understanding the  1 5 billion in operating synergies correctly  Should we think about that as a net reduction in opex relative to what the combined company would have spent  Or is that savings that goes to RemainCo and should be balanced against some of the stand up costs that you re referring to with the NewCo  Thanks very much Kenneth C  Frazier    Chairman and Chief Executive OfficerOkay  So  this is Ken Frazier  Let me start with the why now  Reason why we re doing this now is that our fundamental and financial strength  which has been driven by the focus on our best opportunities for growth allows us now to do what strategically correct for the company in the long term  This is about taking actions today that will serve the long term growth and viability of Merck  as well as allowing products that no longer fit into our strategic framework to prosper in a new organizational structure So from our standpoint  this is the right time  A few years ago when we were looking at this  we saw the opportunity  but for example  the cash flow generation of our Legacy Products was being employed at that time and standing up our oncology business from which we grew from the ground up  and as you know  has been extremely successful  That success has been due to our ability to allocate capital to a business that we didn t have before and getting the entire organization focused and aligned around an opportunity that we had around KEYTRUDA and other compounds behind KEYTRUDA  So that is why we can do it now  And I said before  we are confident about our long term growth prospect  and one of the ways in which we try to manifest that is by saying we will maintain and grow the dividend on the Merck side irrespective of losing these brands Peter Dannenbaum    Vice President of Investor RelationsOkay  Rob on the efficiencies Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerGood morning  Chris  On your question  so the way you should think about the  1 5 billion of operating efficiencies  our incremental cost savings in Merck after the spin off is completed  The stand up cost that are required to support the new company are really contemplated if you take the fact that we commented that there s 45  operating margin for the new company within Merck and it goes to 35  roughly mid 30s after the stand up that 10 percentage point delta is really the stand up cost  So those are not    those are separate independent from the  1 5 billion of net benefits    net synergies that will be joined by Merck going forward in its operating results Peter Dannenbaum    Vice President of Investor RelationsNext question please  Carlo OperatorNext question is from Tim Anderson from Wolfe Research  Go ahead please Tim Anderson    Wolfe Research    AnalystThank you  A couple of questions on spin and then a science question  On the new company to be spun out  will that be doing real R D and have its own R D engine  When you talk about sustainable growth  I m just wondering  if probably that s going to come from genuine R D  And then on RemainCo  updated views on Animal Health  should we assume that this new split means that the remaining parent Merck company is even more likely than ever to keep the Animal Health in perpetuity And then last question is on the adjuvant IO opportunity  Roger  in my past discussions with you  you ve been highly confident the PD 1s will work in the adjuvant setting  recently we saw Roche field and bladder  there has been some timeline slippage  we haven t seen any adjuvant trial timelines pulled forward  no trial stopped at an interim unlike we have with metastatic disease in the PD 1  So my question to you is  are you still highly confident that PD 1s are going to work broadly across tumor types and adjuvant Peter Dannenbaum    Vice President of Investor RelationsThanks  Tim  Kevin  on the research and development capabilities of NewCo Kevin Ali    Chief Executive Officer of NewCoThanks and good morning  Tim  Yes  NewCo will have a high quality development capability and it s really well positioned to the partner of choice for other biopharmaceutical innovators  who are looking to realize commercial growth through our global scale and presence in selected international market to increase patient access  Over time  NewCo will build a research capability in selected therapeutic areas  starting with Women s Health as a core pillar of its business development strategy and then will move further from there Kenneth C  Frazier    Chairman and Chief Executive OfficerTim  on to your question about Animal Health  I ll start by saying  we never say what s going to happen in perpetuity  because we regularly review our entire portfolio and make decisions about which parts of that portfolio belong in our portfolio and which ones would be better off  As we look at Animal Health  we believe  if you look at its growth  if you look at its profitability  we continue to believe that we are in effect advantage owners of that business going forward  We also believe that  that is an important key growth pillar that actually helps us in the long run  As you know  there are ups and downs in the pharmaceutical business and having a business like vaccines  having a business like Animal Health gives us the long term stability that actually allows us to confidently pursue our R D mission Peter Dannenbaum    Vice President of Investor RelationsRight  And Roger  on vaccines Roger M  Perlmutter    President of Merck Research LabsTim  on the question of immuno oncology in the adjuvant setting  I can t speak generally about PD L1  PD 1 antagonist  when you talk about KEYTRUDA  First of all  of course KEYTRUDA is already effective in the adjuvant setting  as we shown in melanoma  And we also showed the effects in the neoadjuvant setting in breast cancer in the I SPY 2 study and as well in the 522 study most recently  and that is a combined neoadjuvant    adjuvant study and we ll be seeing the adjuvant data in not too long time  And you shouldn t really expect adjuvant data to be pulled forward  because by definition  patients who are receiving adjuvant therapy or patients who have better overall survival over a longer period of time  So unexpected to see those adjuvant results rollout with a    more defined cadence and I think that s exactly what we ll see and I m    I based on our success in two prior settings  I would think KEYTRUDA should be as successful in these settings as well  In general  it works better when used earlier Peter Dannenbaum    Vice President of Investor RelationsGreat  Next question please  Carlo OperatorNext question is from Steve Scala of Cowen  Go ahead please Steve Scala    Cowen and Company    AnalystThank you very much  One of the concerns investors have with Merck is the view that its outlook is heavily dependent on KEYTRUDA  And formation of NewCo would seem to increase this risk and concern  So Merck appears to not agree that this is a concern  and I m wondering if you can elaborate on why And then second  what was the rationale for leaving JANUVIA within Merck as opposed to NewCo  It seems placing JANUVIA within NewCo would have made Merck s outlook appreciably clear going forward  Thank you very much Kenneth C  Frazier    Chairman and Chief Executive OfficerWell  let me start on the JANUVIA question  We continue to believe that our diabetes franchise is going to be an important contributor to Merck now and into the future  We are also continuing to do significant research in the whole cardio metabolic area  So that s an area of focus for us going forward  In terms of the issue around KEYTRUDA concentration risks  we are mindful of that  we think KEYTRUDA revenues as a proportion of total revenues only increased by small amount  because of this I think the most important thing that I would say about KEYTRUDA is that right now we continue to see the benefits of our focus both in terms of R D and commercial execution going forward  we see it as driving more growth going forward for the company  but we also see the benefits of our other opportunities in oncology  we have more than KEYTRUDA  we have Lenvima and Lynparza  we also have 20 molecules behind that  We also have our vaccines business  our hospital and specialty business  So we are looking to optimize our entire portfolio and augment our pipeline through business development  that s how we see our future growth  not so much these brands  which as Kevin said  left to their own would probably decline more steeply than they are in the NewCo Steve Scala    Cowen and Company    AnalystGreat Peter Dannenbaum    Vice President of Investor RelationsRob  anything to add Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerYes  Steve  just to kind of build on your point about why JANUVIA in Merck as opposed to NewCo  as we looked at it  clearly  we continue to benefit from the fundamental cash flow and strength of that business gives  while it s not a growing business facility generating a lot of cash flow  But in the near term as we approach LOE we ll continue to be important for Merck  This is an important brand for us And frankly  if you look at the NewCo company  while the loss of exclusivity to Merck frankly does not affect our ability to deliver growth as we ve already commented  even through the loss of exclusivity in 2023 2024  we grow each and every year through that period  So we re able to absorb the loss of exclusivity benefit from the cash now that type of the cliff would be insurmountable to the new company And then finally  and Roger can comment on it in more detail  but we continue to do some pretty interesting science in the cardio metabolic area and feel exciting opportunities over there  And so  continue to see from a scientific perspective a fit as well for all those reasons  we felt keeping it within Merck made more sense than moving that over to the NewCo Peter Dannenbaum    Vice President of Investor RelationsGreat  Thanks  Next question please  Carlo OperatorNext question is from Andrew Baum of Citi  Go ahead please Andrew Baum    Citi    AnalystThank you  Couple of questions please  Firstly  you initiated your islatravir oral combination trials  Is there any possibility within that and being able to differentiate your combination versus Victoza  Phonetic  on the back of lesser weight gain given the absence of an integrase inhibitor  and while you re waiting for the long acting trials to complete  does that provide any kind of commercial advantage And the second question relates to TIGIT  one of your competitors  Roche  had indicated they re opening a Phase 3 program  They ve already run a head to head data in combination with that PD L1 and non small cell lung  I know that you have a program ongoing and have had for some time  Could you talk to your relative levels of excitement with the molecule and perhaps give us some timelines and when it may be able to enter registration trials  Thank you Peter Dannenbaum    Vice President of Investor RelationsRoger Roger M  Perlmutter    President of Merck Research LabsGreat  Thank you  Andrew  First of all  with respect to the islatravir combination  the reality is we really have to wait for the data  I think that we are very confident in the behavior of islatravir  which we ve demonstrated through our reasonably large Phase 2 studies and also  And also  we do work that we ve done with impactable person  It s a terrific molecule  it behaves extremely well  How it will behave with this in combination study or we have pretty good evidence that indicates to us that it will be a leading combination and especially valuable in treatment  We also know islatravir either by itself or potential in combination is a good preventive regimen  But we need to see the data from all of those and that s what we ll be getting And with regard to what I call TIGIT    what we call TIGIT  We do have a program and we have been working on this for some time  We have studies going on where we had tried to ask the question of whether this molecule in combination with KEYTRUDA behaves better than KEYTRUDA alone and is there any circumstance under which it can be used  We recognize that KEYTRUDA is a very impressive compound in the whole variety of different settings that we have to find the right place in which to use it  So we re enthusiastic about it and we re moving forward Peter Dannenbaum    Vice President of Investor RelationsThank you  Roger  Next question please  Carlo OperatorOur next question is from Louise Chen of Cantor  Go ahead please Louise Chen    Cantor Fitzgerald    AnalystHi  Thanks for taking my questions  So my first question to you is that you noted in the call that you are more confident than consensus on every metric through 2024  I was wondering  if you can elaborate more on what you think the street is missing here And then second question is just on KEYTRUDA in Japan  Curious  what kind of impact you assume for price cuts this year for KEYTRUDA in Japan  And is there another potential price cut coming  Thank you Peter Dannenbaum    Vice President of Investor RelationsRob Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerYes  Louise  this is Rob  Thanks for the question  Really  if you look at the comments that Ken made  he said we feel confident that the street under appreciates our revenue  our operating margin and our EPS growth as we look forward through time  And if you look at it in the components  clearly on revenue  we continue to believe all of our growth pillars have meaningful growth opportunity  and in most cases  continue to be under appreciated across oncology platform within the vaccines platform given GARDASIL and Animal Health  just to name a few So that story  which we ve been talking to you about over the last several quarters continues  And then  as you look beyond that  clearly with the spin off getting up to 1 percentage point improvement in our growth rate as a result of the spin itself that s even further growth it s not appreciated  not to mention the fact that we think through core focus and really directed efforts by our leadership team  we can drive even faster growth  So that is an important part as well  And then  as you look at operating margin  today we ve indicated that by 2024 or in 2024  we expect operating margins now as a result of what the spend enables  which enabling  1 5 billion of incremental cost efficiency on top of the already improving natural mix we ve been benefiting from in our business  We re going to achieve an operating margin of greater than 40  in 2024  and if you take that acceleration in operating margin combine it with potentially accelerated EPS  when you think about us deploying to  8 billion to  9 billion of proceeds from this transaction it puts us share repurchase for instance we can get further acceleration  So as you look out into 2024  that s why across those select factors  we believe the street under appreciates revenue  under appreciates operating margin under appreciates the EPS growth Peter Dannenbaum    Vice President of Investor RelationsAnd Frank  on the Japanese price cuts Frank Clyburn    Executive Vice President and Chief Commercial OfficerHi  Louise  It s Frank  In Japan  we did see or we will be seeing  I should say  in February of this year  a huge sales repricing of 17 5   We ve seen significant strong performance based on our lung cancer indications in Japan and because of the sales projection  February we ll see the price reduced 17 5   It s also important to note that we will face another significant reduction in April  That significant reduction is going to be within the same range as the first cut in February Important to note  that will have an impact likely on our Q1 results in Japan  but also as we take a step back when you look at the roll out renal cell carcinoma in our other indications in Japan  we do believe  despite the price cuts  Over time  we will be able to grow in Japan And then I want to reinforce that if we elevate outside of Japan  we still see very significant growth in 2020 and beyond as we continue to roll out many indications globally  very strong uptake we re continuing to see in Europe  and as Roger mentioned  we now have 23 indications in the US  So we feel very good about our outlook for KEYTRUDA  clearly the Japan repricing will have the near term impact in Japan with confident as we go forward Peter Dannenbaum    Vice President of Investor RelationsGreat  Thank you  Next question please  Carlo OperatorNext one is from Umer Raffat of Evercore  Go ahead please Umer Raffat    Evercore ISI    AnalystHi  Thanks so much for taking my questions and I d appreciate you bearing with me a little bit on it  I guess  let me start with this  a simple one  which is  can you confirm that the stand alone EPS goes down by about  1  That s first  Second  if I add up Women s Health  cardiology and diversified  that s about  6 billion  which is roughly what you re saying is what s being divested to the NewCo  But if the goal is to focus on the innovative and pharma in the RemainCo  I notice there is a  5 billion line for your other pharma  which is not being included  And I m curious why that is And finally  I think  it s very interesting that you re not doing a split  You re doing a spin  very specifically  And I also noticed when you talk about the proceeds you re mentioning biz dev before you mention share repurchase  So it almost seems to me that there might possibly be interest in replacing that lost dollar  So my question is  are you looking at a company which is more on the pipeline side  or is the focus more on a accretive deal  which gets to that dollar EPS back immediately  Thank you very much Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerYes  Thanks for the question  Umer  So as you look at  thinking about what is the subtraction  if you will  away from Merck by pulling out this business  and I know the math you re doing to get to roughly  1  The only thing I would advise you on is  I don t think you re giving any credit for the operating efficiencies  the  1 5 billion  which we said we will get ratably  so that s  500 million even in 2021  the first year  which is I think where your math is coming from  And you re not giving any credit to what we re doing with  8 billion to  9 billion of cash proceeds  But if you deploy that to share repurchase  in reality  is that dollar you re quoting then goes down to  0 60   0 70 in the range  So thinking of in terms of percentage  you re closer to 15  and we believe the answer is probably closer to 10  Peter Dannenbaum    Vice President of Investor RelationsUmer asked as well what s included in NewCo Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerYes  so if you look at the other line  the other pharma line picks up a lot of our hospital and specialty products and fixed up products like ZERBAXA  which is still early in its launch  but a product which we are very excited about  So as we looked at the portfolio  those products that are sitting in the hospital specialty space are ones that we continue to believe long term  create value for us and we wanted to maintain and then there is other to be launched revenue numbers sitting in there or products that are smaller in there as well  So it really is a profile products different than what we put into the NewCo and are very aligned with the core growth drivers that we ve already identified Peter Dannenbaum    Vice President of Investor RelationsAnd then I think Umer s last question was capital allocation priorities  combined with a question about what our interest in BD might be  So let s start with Rob and then turn it over to Ken Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerSo if you look at the capital allocation priorities  they really remain unchanged  First and foremost  we re going to ensure we appropriately fund research and development  we re going to fund the opportunity to launch new products and we re going to fund the capacity expansion that we have under way to ensure we have the capacity to meet what is very strong demand across all of our growth pillars in Vaccines  oncology and Animal Health  We will remain committed to the dividend  We ve talked about that you heard today  very importantly  we are not lowering the dividend as a result of the spin out of NewCo  we re going to hold our dividend at  2 44  which it is in 2020 and then grow it off of that base with a goal to get to 47  to 50  as a payout ratio  So you re actually going to see a maintain dividend  growing over time and then you have the benefit of the incremental dividend that NewCo is going to have  So all in all  you should have overall more dividend if you hold those stocks than we do today And then finally  as we ve always said  our goal is to use excess cash flow first and foremost for value creating business development  to the extent that we can t find those or we don t find ones that bring us the combination of strategy and value  We will return excess cash to shareholders moving forward  And specifically  as you look at the  89 billion of special dividend where we re going to receive from NewCo as a result of this transaction  as we said in the comments  it will be deployed either to business development or to share repurchase it will not be used for debt pay down  and that s why I believe it will be accretive over time Kenneth C  Frazier    Chairman and Chief Executive OfficerUmer  this is Ken  I think  you also asked about spin versus split  We still spin because we thought that was the quickest path in a tax efficient way of doing this for our shareholders  As it relates to business development  I ll just say as we ve always said  it s an important priority and first and foremost  we are always looking for the best science and innovation that will drive long term growth and value for shareholders  So we re still very much focused on those deals that augment our pipeline and you saw last year  we did a number of deals  about 80 transactions spanning licensing  technology deals and clinical collaborations  We ll continue to look for those opportunities to augment our pipeline with the best science Peter Dannenbaum    Vice President of Investor RelationsGreat  Next question please OperatorNext one is Geoff Meacham of Bank of America  Go ahead please Geoff Meacham    Bank of America Merrill Lynch    AnalystGood morning  everyone  Thanks for the question  just have a few  Rob  on the spin  I get the operating margin benefit to Merck longer term  but did I hear you right that op margins to be lower this year in post spin initially  And then with freed up capital  there is a spin effect where you guys have previously discussed on the moderation of R D investments looking to 2021 2022 And then  Frank  real quick  can you talk about the growth strategy in China for IO at this point with the NRDL decision in first line lung  I know  you guys just got approval in this indication November  Thank you Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerYes  Geoff  thanks for the question  So on your question about operating margin  if you look at what s NewCo is within Merck today is about 45   so it s obviously higher than Merck s operating margins  So it will be initially nominally dilutive when we pull it out in the first year  But importantly  because of the fact we are getting the operating efficiencies started even in the first year of  500 million and then growing with an additional  500 million in year two  another  500 million in year three  So cumulative  1 5 billion  that offsets a lot of that dilution  And so net when you look at it  it s only about 1 percentage point of dilution to our op margin in the first year and then very quickly  you re going to see our operating margins continue to grow  And by the time we get to over 40  by 2024  we will be at a rate higher than we would have achieved as a combined company  largely as a result of that  1 5 billion operating efficiency  So    and the then that was I think the first question The second one was what s happening with  I think  R D as we look at going forward  So we have never been capital constrained in what we re doing in R D  what s driving the inflection point  we ve talked about which is the slowdown of growth in R D in 2021 as a percent of sales  it s still going to grow  it s going to grow  it s just going to grow slower than sales in 2021  That inflection point is driven more by where we see the clinical programs at this time  if we find opportunities to invest and I m confident given the productivity that we ve seen from the labs this far  but they very well might do that  We will obviously increase our investment as those opportunities present themselves  But as of right now  our expectation is that inflection point continues to happen in 2021 Peter Dannenbaum    Vice President of Investor RelationsAnd Frank Frank Clyburn    Executive Vice President and Chief Commercial OfficerGeoff  in your question on China  first  I wanted to make sure that we do mention that our primary focus is on ensuring the safety of our employees  families and supporting the people of China  I think that s on all of our minds and also the continuity of supply of our Human Health medicines and vaccines and products  And we re going to have to see how China evolves  we ll likely see some impact in Q1 too early to quantify As far as your specific question on IO  our overall strategy as we ve discussed in particular as we rolled out in the self pay market  we still feel very confident on our position  We are still the only IO therapy that s approved in non small cell lung cancer  We recently got approval for KEYNOTE 407 in the squamous cell carcinoma population and we feel as though we have a very significant opportunity in the self pay market  And we ve also adjusted our patient assistance programs in China to increase the affordability for patients that we re trying to provide access to as we move forward  So we feel confident going forward in our growth prospects for KEYTRUDA in China Peter Dannenbaum    Vice President of Investor RelationsGreat  Next question please  Carlo OperatorNext one is Seamus Fernandez of Guggenheim  Your question please Seamus Fernandez    Guggenheim Securities    AnalystThanks for the question  So maybe just a follow up on one of Steve s questions  The concentration of the business  Merck s business to KEYTRUDA going forward  Can you just talk a little bit about the competitive pressure points that could emerge going forward  You talked a little bit about China  but there also are potential Chinese assets that could be introduced into the US following successful lung cancer clinical program  Just trying to get a better sense of the growth opportunity for KEYTRUDA and where you see potential pressure points  And if you could also comment on some of the administration efforts around international pricing  again  a potential risk point for KEYTRUDA  that would be helpful And then just as a follow up on for Roger  Roger  how quickly  the company emphasized a lot of vaccine opportunities for the business going forward  but most of them are Phase 1  How quickly could we see some of those programs advancing and potentially coming to market and maybe you could just tell us which one or two you re most excited to see in the near term  Thanks Peter Dannenbaum    Vice President of Investor RelationsGreat  thanks  So first  Frank  kind of the performance and outlook for KEYTRUDA Frank Clyburn    Executive Vice President and Chief Commercial OfficerYes  So on KEYTRUDA  as far as we    if we look back at 2019 we re one very pleased that our growth of 58  excluding exchange and almost  4 billion and eclipsing  11 billion in sales  We feel very well positioned as we ve been saying with regards to KEYTRUDA  not only with regards to our significant penetration in non small cell lung cancer within the US  but also the significant impact that we re having for patients with renal cell carcinoma  adjuvant melanoma  head and neck  as you heard Roger mention are recent approval non muscle invasive bladder cancer  So the breadth of our indications and the strength of our data gives us a lot of confidence to continue to grow In particular  not only in the US  but ex US and is especially as we roll out our broader indications in non small cell lung cancer and we re now reimbursed in Europe in all markets for lung  which I see is an important aspect of our growth in 2020  The other thing I would add on the concentration piece too  I think we tried to highlight that is not just about KEYTRUDA  it s Lynparza  it s Lenvima  it s our pipeline in oncology that we ve discussed  We also feel very good about our vaccine performance this year  GARDASIL this year grew 21   as well as our hospital and specialty products  we continue to see good growth with BRIDION  So from a concentration perspective  we feel very confident on the portfolio not only KEYTRUDA  but the breadth of opportunities that we have going forward Peter Dannenbaum    Vice President of Investor RelationsRight  Ken on pricing Kenneth C  Frazier    Chairman and Chief Executive OfficerOkay  So on the  Indecipherable  question specifically  we understand the administration s concern that certain countries don t pay their fair share of the cost of the innovation  We do keep continuing to make the point that incorporating additional price control is not the solution to the problem  We continue to work with the administration  the Congress and other stakeholders to provide a perspective  I think patient groups are also providing very strong perspective on these issues as it relates to that But if you take a step back and think about what we announced today  the reason why we re taking these kinds of proactive steps now is because we want to make sure that we position the company for long term growth and viability in the future environment  that s about being much more focused on innovation and it s about driving efficiency within our operating model  So this is about staying ahead of the curve rather than waiting until something happens in the pricing environment that we have to react to Peter Dannenbaum    Vice President of Investor RelationsRight  And Roger on vaccines Roger M  Perlmutter    President of Merck Research LabsRight  Seamus  thanks for the question  On vaccines  I mean  first of all  as you recognize  we have an enormously large program in pneumococcal conjugate vaccine with V114 program having 15 Phase 3 studies that are rolling out over the next 18 months  24 months  We re going to see a lot of those studies coming this year  in fact  And so you will be hearing a lot of data from those studies  which will ultimately permit filing  So that s a very near term opportunity  We have a lot of enthusiasm about our dengue virus vaccine  that vaccine incidentally is    we are collaborating with colleagues at Butantan  where they have a registration enabling study ongoing and that study will deliver results at some point  So that s pretty exciting as well In addition  of course  we have our CMV vaccine  We have a lot of interesting things going on respiratory syncytial virus and those programs are actually fairly advanced  So things are moving along quite well  I can t fail to mention the fact that the demand for GARDASIL 9 remains enormous and we have invested a huge amount of capital together with our manufacturing colleagues and building the additional capability to meet that demand and that will be rolling out in not too longer time and it will be very important obviously for the company Peter Dannenbaum    Vice President of Investor RelationsGreat  We have several more questioners in queue  We re going to have a hard stop at 9 15  but we re going to keep going  Next question please OperatorNext one is from Daina Graybosch of SVB Leerink  Go ahead please Daina Graybosch    SVB Leerink    AnalystHi  Thanks for the question  Two of them  First on NewCo  what do you see as the long term relationship between NewCo and Merck And then the next question for Roger  as you reflect on all the internal and external immuno oncology data that came out in 2019  what novel mechanisms are you most excited about  to add on top of KEYTRUDA to provide further benefit for patients Kenneth C  Frazier    Chairman and Chief Executive OfficerWell  in terms of the long term relationship that s to be decided as both companies look to their future and decide how they want to make sure that they optimize their best opportunities  So I can t say anything other than what we ve announced today in terms of the products that are going over  but obviously what I would say about NewCo that makes me excited is I think they will have many of the same standards and values that Merck has going forward Peter Dannenbaum    Vice President of Investor RelationsGreat  And Roger Roger M  Perlmutter    President of Merck Research LabsYes  Thanks for the question  Daina  The    in many respects  so things we re most excited about  you can tell by looking at the things that we re investing in  You can see that quite remarkably the Lenvima and as it s been demonstrated in the endometrial cancer registration combination with KEYTRUDA most recently  But we ve also seen really spectacular data in renal cell carcinoma  we presented those Phase 2 data  and we have ongoing Phase 3 data demonstrate that the protein tyrosine kinase inhibitors with special characteristics can combine very effectively with KEYTRUDA  We also have data which we presented in combination with Lynparza that are very impressive Let me have this very large set of new molecules  which some of which we prefer to already that include antibodies directed against other potential checkpoints Lag 3  TIGIT and a whole bunch of other things and there really are quite provocative data available now already in those settings  We re hopeful that we ll begin to tease out how best to use those things in combination  So a lots of exciting things going on here Peter Dannenbaum    Vice President of Investor RelationsRight  Next question please OperatorNext one is from David Risinger of Morgan Stanley  Go ahead please Peter Dannenbaum    Vice President of Investor RelationsDavid  are you on the line David Risinger    Morgan Stanley    AnalystSorry  Yes  Can you hear me now Kenneth C  Frazier    Chairman and Chief Executive OfficerYes David Risinger    Morgan Stanley    AnalystGreat  So I have a few questions  First  could you provide an update on where GARDASIL manufacturing supply stands and the GARDASIL revenue growth prospects in 2020  And then  Roger  could you discuss potential proof of concept results for Merck s early to mid stage pipeline to watch in 2020  And in addition  could you provide a framework for the timeline for the second pneumococcal vaccine that Merck is developing for infants  which would be added to V114 to offer broader coverage longer term  Thank you Peter Dannenbaum    Vice President of Investor RelationsGreat  I think  the first question is on GARDASIL supply and outlook  So Frank Frank Clyburn    Executive Vice President and Chief Commercial OfficerYes  Dave  so with regards to GARDASIL  we do continue to see very strong demand around the world  Currently our supply is not able to meet that demand  As we mentioned  we saw a growth of 21  this year  The growth we do believe will continue in 2020 will be slightly tempered from the rates you ve seen in 2019 and 2018  And we re focused with our manufacturing colleagues to do everything we can with contract manufacturers in the near term to try to help our supply  and then ultimately in 2023  as we ve been mentioning we ll be bringing on two new bulk manufacturing facilities that will really allow us to ramp our supply up to meet the strong demand that we re seeing globally Peter Dannenbaum    Vice President of Investor RelationsGreat  Roger  Speech Overlap Roger M  Perlmutter    President of Merck Research LabsSo  David  on the early to mid stage pipeline  well we ve already discussed that in a lot of programs in for oncology in combination with KEYTRUDA  but we have a lot of other areas  as well that are moving forward  Of course  building on the results of recent was in heart failure  the Phase 3 data which will be presented in the results for the near future and which are quite interesting  We actually have a lot of other interesting things going on in soluble guanylate cyclase activators  So that s an important area for us and something that we expect to see quite a lot of data on  And we re going to be seeing a lot of data on of course our vaccine programs that I mentioned just a few minutes ago  So there will be a lot of data coming forward in 2020 And speaking of vaccines  you mentioned the additional vaccine program  I think you were referring to V117 in the pediatric context  which is not an add on  but a separate and independent vaccine all by itself  And that program  which we just given the name to  will be moving forward shortly  We emphasize that the V11 core program is very far advanced with lots of Phase 3 data coming forward this year and next year and will be a leading program in both adult and pediatric settings  ultimately V116 and V117 will provide further coverage  so more to discuss there Peter Dannenbaum    Vice President of Investor RelationsGreat  Next question please OperatorNext one is from Terence Flynn of Goldman Sachs  Go ahead please Terence Flynn    Goldman Sachs    AnalystHi  Good morning  Thanks for taking the questions  Just maybe a couple on the spin as well  Does this change at all how you approach M A and business development from a timing perspective  Just wondering  if we shouldn t expect any sizable bolt ons until after the spin s completed  And then are there any tax rate implications that we need to consider  And then any update on the path forward for KEYTRUDA in neoadjuvant breast cancer regarding discussions with FDA and then when can we expect your Phase 3 frontline data and metastatic triple negative breast and is that important in terms of the conversations with the regulators  Thank you Peter Dannenbaum    Vice President of Investor RelationsOkay  I think we ll start with Ken and the timing of BD and our strategy around that Kenneth C  Frazier    Chairman and Chief Executive OfficerI expect to see no change in our approach to BD from a timing or strategy standpoint as a result of the spin  We still see the need to augment our pipeline going forward  and we see opportunities and we re going to be very focused on that Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerYes  And I would add to that point and then I ll address the tax question  As I said in the prepared remarks  but it s worth reemphasizing  we will have ample capital to do anything we want to do  So this also in a way constraints us from a capital perspective  But with regards to the tax rate  generally speaking  you should not see any meaningful change to our tax rate as a result of this transaction Roger M  Perlmutter    President of Merck Research LabsIn terms with respect to neoadjuvant breast cancer triple negative breast cancer of course the 522 data we presented at ASMO  the effective neoadjuvant in that setting  in terms of pathologic complete response is very clear  And we also had very provocative event free survival data that we discussed  There is more data that will be coming forward in that and we continue to have conversations with regulatory agencies about that study And you re right as we have an ongoing Phase 3 study in triple negative breast cancer that could yield data in principle that would have an impact on thinking with regard to the neoadjuvant study  but of course we have to wait to see the data  So that should be coming forward sometime relatively soon as well  It s event driven  of course  I don t know exactly when Peter Dannenbaum    Vice President of Investor RelationsGreat  We re going to squeeze in one last question please  Carlo OperatorLast one is Mara Goldstein from Mizuho  Go ahead please Mara Goldstein    Mizuho Securities    AnalystGreat  Thanks very much  Just a quick question on the NewCo spin off and the targets around achieving an R D organization and how should we think about that from a metric perspective  And then  just quickly on China  I know we ve covered it  but Merck has spoken to China as a component of growth strategy on a go forward basis and understanding that KEYTRUDA has been a part of that  but Merck has other portfolio of products in China  So I m wondering how much of NewCo s business is responsible for the growth in that region and how RemainCo will be able to advance its growth initiative in the absence of NRDL listing  which didn t occur as expected Peter Dannenbaum    Vice President of Investor RelationsSo the first question I believe was on R D metrics around NewCo  Rob or Kevin  I don t think we have much to add there at this point Robert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerClearly  I would just say that as we think about the 35  operating margin  growing over time that contemplates investments in research and development in the business  And so it is fully covered there is an assumption that they will be doing R D moving forward  and we feel like it s been adequately covered in a way we resourced these investments in the business and    Kevin wanted to add anything about R D other than he    what he said earlier Kevin Ali    Chief Executive Officer of NewCoI think just to recap what we said earlier  that over time we ll build more of the research and development capabilities as we start to do meaningful business development and start to see opportunities to start to do development Peter Dannenbaum    Vice President of Investor RelationsGreat  And the second question Kevin Ali    Chief Executive Officer of NewCoChina growth Peter Dannenbaum    Vice President of Investor RelationsChina growth  yes Frank Clyburn    Executive Vice President and Chief Commercial OfficerThis is Frank  With China  as we discussed and we re very pleased with the growth this year of 58   And our growth to your point is very broad based  it s KEYTRUDA  it s GARDASIL  it s Lynparza  it s Lenvima  it s our innovative portfolio has done very well JANUVIA is on the NRDL  Zepatier  Indecipherable  was recently placed on the NRDL  So we see our growth going forward in China and we see significant opportunities  obviously as I mentioned  we re all thinking about the coronavirus  we ll have to see how that unfolds  but nothing has changed in the mid to long term about our opportunities in China Kenneth C  Frazier    Chairman and Chief Executive OfficerOkay  Thank you all for joining us today  As I said in our third quarter call  we are confident that we re not complacent and this separation is evidence of just that  We are convinced that the decision is the right one for the business and we believe that now is the right time to capitalize on a position of strength to secure even stronger future for Merck  As a more focused research intensive biopharmaceutical company we ll be better positioned to carry out our mission of inventing to save and improve lives and drive lasting value for the patients and shareholders we exist to serve  Thank you very much Peter Dannenbaum    Vice President of Investor RelationsThank you all Operator Operator Closing Remarks Duration  77 minutesCall participants Peter Dannenbaum    Vice President of Investor RelationsKenneth C  Frazier    Chairman and Chief Executive OfficerRobert M  Davis    Executive Vice President  Global Services and Chief Financial OfficerRoger M  Perlmutter    President of Merck Research LabsKevin Ali    Chief Executive Officer of NewCoFrank Clyburn    Executive Vice President and Chief Commercial OfficerChris Schott    JPMorgan    AnalystTim Anderson    Wolfe Research    AnalystSteve Scala    Cowen and Company    AnalystAndrew Baum    Citi    AnalystLouise Chen    Cantor Fitzgerald    AnalystUmer Raffat    Evercore ISI    AnalystGeoff Meacham    Bank of America Merrill Lynch    AnalystSeamus Fernandez    Guggenheim Securities    AnalystDaina Graybosch    SVB Leerink    AnalystDavid Risinger    Morgan Stanley    AnalystTerence Flynn    Goldman Sachs    AnalystMara Goldstein    Mizuho Securities    Analyst
More MRK analysis
All earnings call transcripts",2020-02-05,The Motley Fool,https://invst.ly/prkcj,2077131
202470,423986,MRK,Is Merck s Decision to Slim Down a Buying Opportunity ,news,"On Wednesday  the multinational pharmaceutical giant Merck  NYSE MRK  revealed plans to carve out its women s health  legacy brands  and biosimilars units into a stand alone business  This strategic spinoff will reportedly transform the biopharma into a growth oriented business focused on branded cancer medicines  vaccines  hospital products  and animal health  The split is planned to take effect in the first half of 2021  
Merck s decision to slim down follows similar moves by peers AstraZeneca  NYSE AZN   Eli Lilly  NYSE LLY   GlaxoSmithKline  and Pfizer  NYSE PFE   All of these top pharmas have jettisoned one or more of their business segments in the past year in an effort to spotlight their newer growth products  For Merck in particular  this carve out will place an even greater focus on its top selling cancer immunotherapy medicine Keytruda   

Although Merck s brain trust reassured conservative minded income investors that it will continue to pay a respectable dividend  and the resultant spinoff will even pay a modest dividend as well   the drugmaker s shares still fell by almost 3  on the heels of this news  Is Merck s planned de merger actually a compelling buying opportunity  or was the market s initial pessimism warranted  Let s break down the big pharma s near term outlook to find out 
Opportunities and risks
The clear cut benefit from this planned spinoff is that it will spotlight the healthy growth of Keytruda  the neuromuscular blockade reversal drug Bridion  and the company s top flight vaccine portfolio  Before the split announcement  Wall Street was forecasting Merck s top line to rise by a pedestrian 2 2   on average  over the next five years  After this split  however  this key growth metric should improve markedly  thanks largely to the excision of several off patent medicines like the cholesterol drugs Zetia and Vytorin from its portfolio  
This strategic move does create some real problems  however  By shaving off its women s health  legacy brands  and biosimilars segments  the drugmaker will lose approximately 14  of its annual revenue  That s a big chunk of money that will no longer be available for shareholder rewards and business development activities  This higher top line growth will thus come at the substantial cost of significantly lower free cash flows    which obviously isn t sitting well with risk averse folks  
Going one step further  this split might ultimately force Merck to become an ultra aggressive player on the merger and acquisition  M A  scene  While acquisitions can turn out to be a boon for pharma companies  they can also turn into expensive misadventures  One of the core reasons the market hasn t warmed up to Pfizer s planned split  after all  is that the company arguably overpaid for most  if not all  of its recent acquisitions  Pfizer seemingly had no choice but to open up its pocketbook in order to boost its late stage pipeline ahead of this de merger  Merck  in turn  might end up in the same boat  
Time to buy 
Merck is clearly trying to take a page out of Astra s and Lilly s playbook  By excising noncore assets and pivoting toward oncology as a key growth driver  these two big pharmas have both turned into top performing growth stocks  Unfortunately  Merck probably won t follow in their footsteps  Astra and Lilly both sport broad portfolios of branded growth products  amassed over fairly lengthy time periods  The same can t exactly be said for Merck as things now stand  
The company has a lot of work to do to first dilute Keytruda s overall importance and  second  to build a stable of branded products capable of sustained  long term growth  That simple fact means that Merck will likely have to spin the wheel on the high risk M A roulette table soon  So  until the company begins this process in earnest  it might be best to stay on the sidelines ",2020-02-06,The Motley Fool,https://invst.ly/przxp,2077949
202471,423987,MRK,Bristol Myers Squibb and Merck going opposite ways with PD 1 inhibitors,news,"Q4 results for Merck  MRK  0 3   and Bristol Myers Squibb  BMY  2 3   present stark contrasts between their rival PD 1 inhibitors with the former clearly demonstrating superior execution in sales and expanding approved uses 
Merck s Keytruda  pembrolizumab  is the company s top seller  averaging over 75  growth per quarter over the past two years  Sales grew 45  yoy to  3 111M in Q4 2019 
BMY s Opdivo  nivolumab   briefly its top drug  now  2 again behind blood thinner Eliquis  has averaged almost 24  growth per quarter over the same time frame  but the trend has been steadily down since Q3 2018  Sales were  1 763M last quarter  down 2  from a year ago 
Keytruda growth quarter  Q4 2019   Q1 2018    45    62    58    55    66    80    89    151  
Opdivo growth quarter  same lookback    2    1    12    19    33    42    36    34  
Keytruda  initially OK d in the U S  in September 2014  is now approved for 15 cancers 
Opdivo  initially OK d in the U S  in December 2014  is approved for nine cancers ",2020-02-06,Seeking Alpha,https://invst.ly/ps2qu,2078275
202472,423988,MRK,Merck passes on KalVista DME candidate,news,"KalVista Pharmaceuticals  NASDAQ KALV  announces that its option agreement with Merck  NYSE MRK  related to KVD001  its candidate for the potential treatment of diabetic macular edema  DME   and future oral DME molecules has expired 
Merck had the option to in license KVD001 and future oral plasma kallikrein inhibitor programs for DME via paying a non refundable  37M fee to KalVista who now has no obligations to Merck and retains full ownership of all assets ",2020-02-10,Seeking Alpha,https://invst.ly/ptha4,2081096
202473,423989,MRK,Seattle Genetics  Astellas  and Merck Hit a Bladder Cancer Bullseye,news,"Astellas  OTC ALPMY   Seattle Genetics  NASDAQ SGEN   and Merck  NYSE MRK  have good news for new bladder cancer patients who aren t eligible for standard chemotherapy  Followup data from an ongoing clinical trial suggests that a combination of Padcev and Keytruda could become a new first line treatment for this underserved group  
Cooperation makes it happen
Keytruda from Merck is a protein that makes it hard for tumor cells to shut down the immune system when it attacks them  Padcev  from collaboration partners Astellas and Seattle Genetics  is a protein that delivers a dose of chemotherapy directly to tumor cells that present a telltale sign of malignancy on their surface called nectin 4 

Padcev earned approval in December as a treatment for bladder cancer patients whose tumors kept growing after treatment with Keytruda and similar drugs  Seattle Genetics had suggested getting Padcev into the mix with Keytruda at the same time would lead to better outcomes for patients  and Tuesday s data drop suggests this is the case 
Seattle Genetics previously released preliminary results that suggested the combination of Padcev and Keytruda was shrinking tumors  On Tuesday  Seattle Genetics and Astellas announced confirmed tumor responses from 33 of 45 patients treated with the combination  seven of whom achieved complete remission 
What matters most
Getting tumors to respond doesn t always lead to better outcomes  That s why the long term commercial success of this potential combination therapy will depend on overall survival results  This study hasn t been underway for long enough to produce data on that score yet 
So far  we know that an impressive 82  of patients given the combination therapy were still alive 12 months after beginning treatment  If this number holds up for another year  Padcev plus Keytruda could become the new standard of care ",2020-02-12,The Motley Fool,https://invst.ly/ptu-u,2081985
202486,424002,MRK,Merck EPS beats by  0 01  misses on revenue,news,"Merck  NYSE MRK   Q4 Non GAAP EPS of  1 16 beats by  0 01  GAAP EPS of  0 92 misses by  0 02 
Revenue of  11 87B   7 9  Y Y  misses by  60M 
Shares  0 75  PM 
Press Release",2020-02-05,Seeking Alpha,https://invst.ly/prclg,2076533
202487,424003,MRK,Merck to spin off women s health  biosimilar businesses,news,Merck   Co Inc said on Wednesday it was planning to spin off its women s health  biosimilar drugs and legacy products into a new publicly traded company The move that will allow the drugmaker to focus on key growth drivers like cancer drug Keytruda and vaccines The company  which expects the transaction to be completed by the first half of 2021  forecast operating efficiencies of over  1 5 billion by 2024 related to the spinoff ,2020-02-05,CNBC,https://invst.ly/prcok,2076544
202488,424004,MRK,Merck to sharpen focus on key growth drivers via spinout of non core units,news,"Aimed at driving strong growth in its key areas of oncology  vaccines  hospital and animal health  Merck  NYSE MRK  will spin off its women s health  legacy brands and biosimilars businesses into an as yet unnamed publicly traded company 
The company says the move will reduce its human health manufacturing footprint by  25  and the number of manufactured and marketed products by  50   It expects to achieve operating efficiencies greater than  1 5B by 2024 with non GAAP operating margins of more than 40  
It plans to use the  8B   9B special tax free dividend from the spinout for business development or share buybacks 
75  of the new company s sales will be generated ex U S  Sales growth should be low single digits from its base in 2021  Non GAAP operating margins should be in the mid 30s in the first year post separation and increase thereafter  It will have  8 5B   9 5B in initial debt  Cash flow from operations should be sufficiently robust to fund business development  debt repayment and a meaningful dividend  incremental to Merck s  
Merck will retain its 2020 dividend of  2 44 per share with future increases aimed at an eventual payout ratio of 47   50  ",2020-02-05,Seeking Alpha,https://invst.ly/prcze,2076566
202489,424005,MRK,Merck down 1  on Q4 results  announces spinoff to focus on key growth pillars,news,"Merck  MRK  Q4 results  Revenues   11 868M   7 9   
Net Income   2 357M   29 0    EPS   0 92   33 3    non GAAP Net Income   2 978M   8 5    non GAAP EPS   1 16   11 5   
Key Product Sales  Keytruda   3 111M   45    Januvia   Janumet   1 418M   3    Gardasil   Gardasil 9   693M   17    Proquad  M M R II and Varivax   481M   6    Bridion   313M   22    Isentress   Isentress HD   223M   20    Rotateq   227M   21    Pneumovax 23   334M   4    Simponi   205M   7    Implanon Nexplanon   206M   22   
2020 Guidance  Revenues   48 8B   50 3B vs   48 65B S P Capital IQ Consensus  GAAP EPS   4 57   4 72  Non GAAP EPS   5 62   5 77 vs   5 54 S P Capital IQ Consensus 
The company intends to focus on key growth pillars through the spinoff of women s health  trusted legacy brands and biosimilar products into a new company 
Shares are down 1  premarket 
Previously  Merck EPS beats by  0 01  misses on revenue  Feb  5 ",2020-02-05,Seeking Alpha,https://invst.ly/prdem,2076593
202490,424006,MRK,Is Merck Stuck in the Slow Lane ,news,"Merck   Co  Inc   NYSE  MRK  reported its fourth quarter financial results before the markets opened on Wednesday  The pharmaceutical giant said that it had  1 16 in EPS and  11 9 billion in revenue  That compared with consensus estimates of  1 15 in EPS and  11 98 billion in revenue  The same period of last year reportedly had  1 04 in EPS and  11 0 billion in revenue During the quarter worldwide sales increased by 8   or 9  excluding foreign exchange  This was largely driven by Keytruda sales increasing 46  year over year to  3 11 billion  Also  the increase was driven by growth in oncology  partially offset by the ongoing impacts of the loss of market exclusivity for several products Animal Health sales totaled  1 1 billion for the fourth quarter of 2019  an increase of 8  compared with the fourth quarter of 2018  Excluding the unfavorable effect from foreign exchange  Animal Health sales grew 10   Growth for the quarter was mainly driven by livestock products due to the Antelliq acquisition div connatix margin bottom  1 5em   div connatix img  margin  unset  Looking ahead to the 2020 full year  Merck expects to see EPS of  5 62 to  5 77 and revenue of  48 8 billion to  50 3 billion  Consensus estimates call for  5 61 in EPS and  49 53 billion in revenue for 2019 Kenneth C  Frazier  board chair and chief executive of Merck  commented As evidenced by our results and our 2020 guidance  Merck had an extraordinary year and is in a position of operational and financial strength  It is this position of strength  born of our focused execution  that gives us the confidence to spin off our Women s Health  trusted Legacy Brands and Biosimilar products into a new company  which will position us to deliver even greater value to patients and shareholders Shares of Merck traded down nearly 3  early Wednesday to  85 77  in a 52 week range of  72 23 to  92 64  The consensus price target is  99 35  
By Chris Lange",2020-02-05,247wallst,https://invst.ly/prfyn,2076796
202500,424016,MRK,FDA Approves Merck s Dificid for Infections in Children,news,"The U S  Food and Drug Administration approved Merck s  NYSE MRK  Dificid drug for children aged 6 months and older who have diarrhea caused by a specific bacterial infection called Clostridioides difficile  C  diff  
A tablet form of the drug was already approved for adults with diarrhea caused by the bacteria  In addition to expanding the approval for the tablet form to children  the FDA also approved an oral suspension of the drug that will be easier for children to take than the tablet 

Dificid isn t absorbed by the body  making it effective at treating infections of the gut that cause diarrhea  but ineffective at treating bacterial infections in other parts of the body  C  diff causes almost 500 000 infections annually in the U S   with about 29 000 of those patients dying within 30 days of initial diagnosis 
The drug seems to work as well as vancomycin  which is available as a generic  but appears to have a lower recurrence rate  In a clinical trial run by Merck s collaborator Astellas Pharma  Dificid eradicated the bacteria as well as vancomycin when measured two days after the 10 day treatment  Looking further out  at 30 days  68 4  of the children taking Dificid were cured of their infection that didn t return  compared to just 50  of children taking vancomycin 
Merck and Astellas ended up owning rights to the same drug through a series of acquisitions and licensing deals  Merck gained access to Dificid through its 2015 acquisition of Cubist Pharmaceuticals  which had acquired the drug s original developer  Optimer Pharmaceuticals  Before that  Astellas had licensed rights from Optimer to sell the drug in Japan and Europe  where it s marketed as Dificlir ",2020-01-27,The Motley Fool,https://invst.ly/pnmku,2068969
202501,424017,MRK,Is Merck Still a Strong Buy ,news,"Merck  NYSE MRK  has long been the apple of investors  eyes  both for its excellent financials and solid dividend payouts  The company enjoyed monumental sales growth in Q3  with aggregate profits reaching  12 4 billion and an overall revenue surge of 15   
Surpassing analysts  expectations  Merck elevated its full year earnings outlook to the  46 5 billion to  47 billion range  a notable rise from the anticipated profits of  45 2 billion to  46 2 billion  While Merck is known for a variety of pharmaceutical products  there was one drug in particular that accounted for the better part of its profits and forecast boost in Q3  its blockbuster anti cancer drug Keytruda  

Keytruda is an immunotherapy drug used to treat a wide range of cancers including melanoma  classical Hodgkin lymphoma  and non small cell lung cancer  Keytruda accounted for  3 1 billion of Merck s sales in Q3  representing a 62  increase in year over  year revenue  Over the first three quarters of 2019  Keytruda brought in nearly  8 billion in total revenue for Merck 
Keytruda has hit some roadblocks to label expansion of late  Considering that the drug has played and continues to play such an integral role in Merck s financial performance  you re not alone if you ve been wondering whether now is still a good time to buy this stock  
Here s what you need to know  
Merck shares dipped after lung cancer study disappointment  but it s no cause for alarm
On Jan  6  Merck announced that Keytruda had failed to meet one of its clinical markers in an important end phase small cell lung cancer study  Merck shares slumped accordingly in the second and third weeks of January  but subsequently bounced back to roughly the same price they had before the news broke 
While the study showed that using Keytruda alongside chemotherapy could slow the growth of small cell lung cancer  the results did not indicate that the drug would notably decrease the patient mortality rate  
Let s put these study results in perspective  Small cell lung cancer comprises approximately 1 10 of all instances of lung cancer  with only about six percent of patients reaching the five year mark after being diagnosed  
Moreover  Keytruda is currently part of more than 1 000 studies testing the drug s efficacy for various indications  The drug has already received the green light for the treatment of a dozen different tumor types following its first approval for melanoma almost six years ago  
Earlier in January  Merck achieved a landmark win when the FDA approved the use of Keytruda to treat a rare  high risk form of non muscle invasive bladder cancer that does not respond to conventional treatments 
While I m not dismissing the market s initial reaction  at this point  there s no reason to think that Merck has been dealt a blow it can t recover from 
Recent licensing deals could mean billions in revenue for Merck
At the beginning of January  Merck announced that it had entered a groundbreaking licensing and research partnership with Astex Pharmaceuticals and Taiho Pharmaceuticals  Merck shelled out  50 million in return for sole worldwide licensing rights to Taiho and Astex s small molecule inhibitor candidates  with the agreement that approximately  2 5 billion more in conditional payments be made based on product  trial  and regulatory performance 
The partnership is targeting inhibitors of KRAS  a common type of oncogene mutation in cancer 
Taiho s managing director Tehruhiro Utsugi  Ph D  stated the following in the company s press release   Taiho has used its unique and proprietary drug discovery platform to generate a number of small molecule inhibitors  This alliance builds on our KRAS research up to now  and together with MSD  Merck  it allows us to combine expertise to significantly accelerate the global research  development  and commercialization of a number of our mutant KRAS programs by accessing external talent and resources  
The small molecule oncology drug market is a multi billion dollar business  Merck s collaboration will see it merging pre clinical candidates and findings with Taiho and Astex to create a global research and product development powerhouse  As such  this strategic oncology alliance will likely bring a significant return on Merck s investment in the years to come 
Merck is in a strong financial position    for now 
Given Merck s healthy profits on a year over year basis and excellent Q3 results  the company appears to be in a strong financial position at present  Keep an eye out for Q4 earnings  which will be released in early February 
Merck s growing regulatory approvals for Keytruda are encouraging  despite the slight setback with its lung cancer study  Clearly  the greatest risk Merck may face is relying too heavily on Keytruda to fuel future growth 
However  Merck s most recent partnership with Astex and Taiho is a solid step toward diversification in the highly lucrative small molecule inhibitor sector  Right now  the future looks bright for this company  and its stock remains a viable buy ",2020-01-29,The Motley Fool,https://invst.ly/pok92,2070972
202502,424018,MRK,Merck withdraws Keytruda application in Europe for esophageal cancer,news,Merck  NYSE MRK  has withdrawn its marketing application in Europe seeking approval to use Keytruda  pembrolizumab  to treat cancer of the esophagus  The EMA determined that the data supporting the application were not sufficient to prove that treatment prolonged survival ,2020-01-31,Seeking Alpha,https://invst.ly/ppgl0,2072997
202503,424019,MRK,FDA accepts Merck application for expanded use of Recarbrio,news,"The FDA has accepted for review Merck s  NYSE MRK  supplemental marketing application seeking approval to use combo antibiotic Recarbrio  imipenem  cilastatin and relebactam  to treat adult patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  HABP VABP  caused by certain susceptible Gram negative microorganisms 
The agency s action date is June 4 
The FDA approved Recarbrio in June 2019 for complicated urinary tract and complicated intra abdominal bacterial infections 
Shares up 1  premarket on light volume ",2020-02-03,Seeking Alpha,https://invst.ly/pqeb6,2074363
202504,424020,MRK,Merck s Insomnia Drug Approved for Alzheimer s Patients,news,"Merck  NYSE MRK  received approval from the U S  Food and Drug Administration to market its insomnia drug Belsomra  suvorexant  for treating sleep disruption in patients with mild to moderate Alzheimer s disease  Belsomra was approved by the FDA for the general population in 2014  but Monday s decision allows Merck to include information on the drug s effectiveness in Alzheimer s patients in its prescribing information 
Last May  Merck reported the results of a phase 3 clinical trial of Belsomra in 285 Alzheimer s patients  announcing that the study had met its primary efficacy endpoint  After four weeks of treatment  total sleep time in the Belsoma group increased 73 4 minutes compared with 45 2 minutes in the placebo group  The most common adverse effect was drowsiness the next day 

Disruption of sleep wake patterns and difficulty sleeping is common among Alzheimer s patients  affecting about 40  of the population  and there s emerging evidence that poor sleep may contribute to the development of the disease and impairment of memory function 
Physicians use caution in prescribing the most popular sleep drugs such as Sanofi s Ambien to Alzheimer s patients because they may contribute to confusion and falls  Belsomra is the first drug to use a different mechanism that operates on the specific part of the brain that helps keep a person awake 
Sales of Belsomra by the pharmaceutical giant in 2018 were  260 million  up 24  from the year before ",2020-02-03,The Motley Fool,https://invst.ly/pqj-w,2074775
202505,424021,MRK,What to Expect When Merck Reports Before the Opening Bell,news,"Merck   Co  Inc   NYSE  MRK  is scheduled to release its fourth quarter financial results before the markets open on Wednesday  The consensus estimates are calling for  1 15 in earnings per share  EPS  and  11 98 billion in revenue  That would be better than the  1 04 per share and  11 0 billion reported in the same period of last year For the most recent quarter  Merck said it achieved another period of strong revenue and earnings growth as it continues to realize the benefits of sustained investment in research and development  At the time  management said that it was confident that the investments the company was making would allow it to convert cutting edge science into medicines and vaccines of great benefit to patients and value to shareholders During the third quarter  worldwide sales increased by 15   or 16  excluding foreign exchange  This was largely driven by Keytruda sales increasing 62  year over year to  3 1 billion and Human Health Vaccines Sales increasing 17  to  2 5 billion div connatix margin bottom  1 5em   div connatix img  margin  unset  The company also released full year guidance at that time calling for EPS of  5 12 to  5 17 and revenue of  46 5 billion to  47 0 billion  The consensus estimates now are  5 17 in EPS and  46 98 billion in revenue for the 2019 full year Excluding Tuesday s move  Merck stock had underperformed the broad markets with a gain of 14  in the past 52 weeks  However  the share price is up less than 1  in the past quarter Here s what analysts had to say about Merck ahead of the report 
UBS Group has a Buy rating with a  99 price target 
Cantor Fitzgerald rates it a Buy with a  95 price target 
Mizuho has a Buy rating with a  100 target price 
Morgan Stanley rates it as Overweight with a  95 target 
Merck stock traded up 1 5  to  88 67 a share on Tuesday  in a 52 week range of  72 23 to  92 64  The consensus price target is  99 35  


				ALSO READ  Jefferies Top Growth Stocks to Buy Are Red Hot Momentum and Technology Giants				


By Chris Lange",2020-02-04,247wallst,https://invst.ly/pq-jn,2075778
202515,424031,MRK,AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer,news,"AstraZeneca  NYSE AZN  and Merck  NYSE MRK  continue their quest to gain additional approvals for their blockbuster cancer drug Lynparza  The duo submitted a new application to the Food and Drug Administration for the drug as a treatment for prostate cancer that s resistant to androgen depletion therapy and has metastasized to other areas of the body 
The FDA gave the application a priority review  which cuts four months off the review cycle  The pharmaceutical companies expect to hear back from the agency in the second quarter of this year although a decision could come earlier 

Lynparza inhibits poly  ADP ribose  polymerase  PARP  proteins that are responsible for repairing nicks in DNA  Inhibition of PARP proteins results in DNA breaks that would normally be repaired through homologous recombination  so AstraZeneca and Merck tested the drug specifically in patients with mutations in genes responsible for homologous recombination repair 
The application is based on the results of the PROfound clinical trial that tested two groups of prostate cancer patients  In patients with mutations in BRCA1 2 or ATM  Lynparza reduced the risk of disease progression by 66  compared to patients taking either Johnson   Johnson s  NYSE JNJ  Zytiga or Astellas Pharma and Pfizer s  NYSE PFE  Xtandi  Lynparza also extended the time it took the disease to progress while the patient remained alive from a median of 3 6 months for Zytiga or Xtanti to 7 4 months for Lynparza 
In the overall population that included patients with mutations in other homologous recombination genes  Lynparza reduced the risk of progression by 51  and extended median progression free survival to 5 8 months  compared to 3 5 months for patients receiving Zytiga or Xtanti 
Lynparza is approved for ovarian  breast and pancreatic cancer  AstraZeneca booked Lynparza sales of  847 million in the first nine months of 2019 ",2020-01-21,The Motley Fool,https://invst.ly/pkxp4,2064090
202516,424032,MRK,Merck s Keytruda Could Face Direct Competition from New Chinese Drug,news,"Chinese drug developer BeiGene  NASDAQ BGNE  announced on Monday strong clinical results for its cancer immunotherapy  tislelizumab  A Phase 3 trial tested the drug alongside two other chemotherapy treatments in patients with non small cell lung cancer and successfully met its primary endpoints of improving patient survival rates  
The company also went on to say that it will go on to seek approval in China  Tislelizumab has already been approved in the country for treatment resistant Hodgkin lymphoma in patients that have already tried two previous cancer therapies  

Should it receive approval  tislelizumab would be directly competing with Merck s  NYSE MRK  own cancer superdrug  Keytruda  which was approved to treat non small cell lung cancer in China last year 
Further details
Keytruda brought in over  10 billion in global sales in 2019  Although most of that came from the U S  market  the sheer population of the Chinese market means that Keytruda sales in this area could easily overtake U S  sales in the future 
However  tislelizumab s approval could siphon away market share from Keytruda  Both drugs are similar in that they block a specific protein known as PD 1  programmed cell death protein 1   This protein is responsible for stopping the immune system from destroying a cell  The idea is that by inhibiting this protein in cancer cells  the immune system will target them more efficiently and prevent them from spreading 
Tislelizumab had originally been bought by Celgene back in 2017  However  the pharmaceutical giant ended up backing down from the agreement  giving back the rights of the drug to BieGene and paying a  150 million termination fee in the process ",2020-01-21,The Motley Fool,https://invst.ly/pk-0j,2064270
202517,424033,MRK,Merck sues Teva to block entry of generic Dificid,news,"Merck  MRK  1 1   has filed patent infringement litigation in New Jersey against Teva Pharmaceutical Industries  TEVA  1 6   in a move to block the market entry of the latter s generic version of antibiotic Dificid  fidaxomicin  
Merck claims that Teva s candidate infringes on five Dificid patents  one expiring in January 2024 and four in January 2028  It sued Teva in 2015 over the same patents  case still pending  ",2020-01-21,Seeking Alpha,https://invst.ly/pk-3b,2064276
202518,424034,MRK,Should Investors Be Worried About Merck s Keytruda ,news,"Merck s  NYSE MRK  cancer immunology drug  Keytruda  is already one of the best selling drugs in the world and is well on track to becoming the No  1 drug by revenue within the next few years  Having already been approved to treat a number of different cancer types  Keytruda is poised to play a crucial role in the company s future sales growth 
Over the past couple of weeks  however  Keytruda has been hit by some mixed  if not outright disappointing  clinical results  Let s take a closer look at some of these developments and whether they should worry pharmaceutical investors 

The lung cancer trial setback
The most notable setback so far in 2020 for the drug involved a phase 3 trial treating small cell lung cancer  SCLC   Merck announced on Jan  7 that Keytruda failed to extend the lifespan of patients who are diagnosed with the condition  although it helped slow down cancer progression in combination with chemotherapy 
It s worth noting that other major cancer drugs that work similarly to Keytruda have also failed to see positive results in the SCLC patient population  Bristol Myers Squibb s Opdivo failed to show strong results in a late stage clinical trial  later failing another trial in treating non small cell lung cancer  Small cell and non small cell are the two main types of lung cancer  with small cell cancer cells appearing small and round under a microscope while non small cell cancer cells appear larger  The small cell cancer cells spread more aggressively than their non small cell counterparts  and patients diagnosed with SCLC have fewer treatment options open to them than patients diagnosed with non small cell lung cancer  NSCLC  
Keytruda and Opdivo are both PD 1 inhibitors  a type of drug that suppresses PD 1  programmed cell death 1  proteins in the body  which is responsible for signaling to the immune system to avoid specific cells  The idea is that the body s immune system will turn back on and aggressively target the cells that don t have this protein    in this instance  cancer cells 
However  drugs that operate in a different manner have had a measure of success in treating SCLC  They include AstraZeneca s Imfiniz and Roche s Tecentriq  both of which target the slightly different PD L1 pathway  Tecentriq  in particular  has been approved as a first line treatment for patients with SCLC 
Is this a big deal 
Investors should remember that SCLC accounts for only 10  to 15  of all lung cancer cases  with the vast majority being a type of non small cell lung cancer  For this latter category  Keytruda has already received approval from the Food and Drug Administration  FDA  as a treatment  albeit for patients who aren t suitable for surgery or chemoradiation  Even if Keytruda ends up failing to capture the smaller SCLC market and cedes it to other drugmakers  the NSCLC population    which is represents 85  to 90  of all lung cancer patients    is a massive market in and off itself  Current estimates predict that the global NSCLC market size will reach  43 7 billion by 2026 
However  Keytruda isn t strictly a lung cancer drug  it s approved to treat a variety of other cancers like lymphoma  melanoma  gastric  cervical  and head and neck cancer  whether by itself or in combination with other drugs  When you add all these potential markets together  a setback in the relatively narrow small cell lung cancer indication becomes even less worrisome 
It s also worth mentioning that Keytruda has a plethora of ongoing studies  and of course not every study is going to yield positive results  A simple search on the internet will reveal a number of clinical flops  most notable of which are a late stage breast cancer trial that fell apart in May 2019  Another notable failure came from two phase 3 trials concerning Keytruda s effectiveness in treating multiple melanoma  a type of cancer that affects a specific type of white blood cell    the plasma cells    found primarily in the bone marrow  
It s to be expected that Keytruda won t hit a clinical home run every time a study comes out  In the big picture  however  things look pretty solid 
What about the potential competition 
Looking at the domestic U S  market  which accounts for the majority of Keytruda s revenue  Merck faces perhaps the most competition from Roche s Tecentriq  Despite bringing in only one tenth the gross revenue of Keytruda in 2018  it is seen as the top front runner behind Merck s cancer drug  holding an edge in clinical results in treating SCLC  While not a short term threat  Tecentriq poses an increasing  long term risk  to Keytruda s position  according to Wall Street analysts 
In international markets  such as China  local competitors are popping up that can siphon away market share  Just recently  BeiGene announced strong results for its non small cell lung cancer drug  tislelizumab  which  if it receives regulatory approval  would directly compete with Keytruda in China 
Both in the U S  and internationally  however  it s unlikely that Keytruda s dominance will be shaken up too much in the next year or two  However  within five to 10 years  it s definitely possible that rival drugs could catch up with  or even overtake  Keytruda in terms of market share  Keytruda is also protected from generic competition for several more years  with its patent protection expiring in 2028  
Future Keytruda catalysts to watch for
Keytruda is predicted to reach over  10 billion in annual revenue for 2019  and is well on track to reach peak annual sales of  22 5 billion by 2025  Neither competition nor the occasional clinical setback is likely to do much to change this 
However  there still are some major catalysts for the cancer drug that investors might want to keep an eye on  Most notably  results from a phase 3 trial in the realm of breast cancer is expected to come out in the first quarter while another phase 3 trial for renal cell cancer expected around April  
As for Merck s stock  it trades at a reasonable 25 2 price to earnings  P E  ratio  much lower than AstraZeneca s 63 1 P E but a bit pricier than Bristol Myers  19 4  In some ways  it s surprising that Merck doesn t trade at a higher premium considering Keytruda s revenue projections  but I wouldn t say the stock is underpriced  Overall  I d say Merck looks like a pretty good buy at the moment  with Keytruda s financial and clinical positions remaining unthreatened for at least the next couple of years ",2020-01-23,The Motley Fool,https://invst.ly/plxj8,2066106
202519,424035,MRK,FDA OKs expanded use for Merck s Dificid,news,"The FDA approves Merck s  NYSE MRK  macrolide antibacterial med Dificid  fidaxomicin  for the treatment of Clostridioides  formerly Clostridium  difficile associated diarrhea  CDAD  in children aged six months and older 
Previously it was approved for CDAD in patients at least 18 years old ",2020-01-27,Seeking Alpha,https://invst.ly/pncr5,2068250
202527,424043,MRK,Merck s Keytruda Misses an Important Lung Cancer Goal,news,"Merck s cancer immunotherapy finally hit a stumbling block in a pivotal study with lung cancer patients that caused the stock to slip 1 5  on Tuesday morning  It s more than a little surprising because Keytruda has been taking huge steps toward becoming the world s top selling drug since Merck   Co   NYSE MRK  revealed game changing lung cancer trial results in 2016  
During a study with small cell lung cancer that hadn t received any treatment for their disease before  adding Keytruda to standard chemotherapy failed to produce a significant overall survival benefit  

Merck was quick to point out that it took significantly longer for patients treated with Keytruda in combination with chemotherapy to show signs of their disease worsening than for those given standard chemotherapy on its own  But because overall survival is the gold standard  a label expanding approval to treat newly diagnosed patients doesn t seem likely 
It could be worse for Merck
Third quarter sales of Keytruda jumped 62  higher than the same period last year to an annualized  12 4 billion  largely because of increasing sales as a first line treatment for non small cell lung cancer  NSCLC   Merck s shares haven t been hammered down very far because the recent failure involved small cell lung cancer  SCLC   which makes up around 15  of all new cancer diagnoses 
Lung cancer isn t the most commonly diagnosed malignancy  but it still claims more lives than any other  With a tight grip in the first line setting for around 85  of lung cancer patients who receive a lung cancer diagnosis of the non small cell variety  Keytruda s still likely to become the world s top selling drug within another year or two ",2020-01-07,The Motley Fool,https://invst.ly/pexp1,2054090
202528,424044,MRK,Merck Weighs on Dow After Clinical Trial Miss,news,"Investing com   Drugmaker Merck was a drag on the Dow Jones in midday trading Tuesday as the blue chip index struggled to follow the S P and Nasdaq into positive territory 
Merck  NYSE MRK  shares dropped 2 2  following a disappointing clinical trial for its market leading lung cancer treatment 
The company said after the bell Monday that its drug Keytruda did not meet a statistically significant goal in treating non small cell lung cancer in combination with chemotherapy in a phase 3 trial 
Merck s loss of a little more than  2 accounted for more than 13 points of the Dow s 31 point loss 
Keytruda has been approved to treat non small cell lung cancer  which accounts for around 85  of lung cancer cases  and currently holds a dominant position in that market 
Small cell lung cancer accounts for about 10  to 15  of all cases of lung cancer  Merck said  It said the five year survival rate for patients diagnosed in the U S  with any stage of SCLC is estimated to be 6  
   Reuters contributed to this report ",2020-01-07,Investing.com,https://www.investing.com/news/stock-market-news/merck-weighs-on-dow-after-clinical-trial-miss-2054155,2054155
202529,424045,MRK,FDA OKs Merck s Keytruda for treatment resistant bladder cancer,news,The FDA approves Merck s  NYSE MRK  Keytruda  pembrolizumab  as monotherapy for the treatment of patients with Bacillus Calmette Guerin  BCG  unresponsive  high risk  non muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy  bladder removal  ,2020-01-08,Seeking Alpha,https://invst.ly/pflea,2055418
202530,424046,MRK,Merck s Blockbuster Drug Wins Key New FDA Approval,news,"One of the world s most successful drugs  Merck s  NYSE MRK  Keytruda  stands to become even more prominent following an important new approval  The U S  Food and Drug Administration  FDA  gave it the green light for the treatment of a particularly stubborn type of bladder cancer 
The FDA s approval covers high risk  non muscle invasive bladder cancer that has not responded to the Bacillus Calmette Guerin vaccine  The approval is not broad  it applies only to patients who have already received other forms of treatment  and cannot or are unwilling to have their bladders surgically removed 

Nevertheless  it is certain to be in demand for such treatments  Merck acknowledged this in its press release announcing the approval  saying that Keytruda  will be a new clinical option for a patient population that previously had limited FDA approved therapies available  
Keytruda already has a set of FDA approvals covering other forms of cancer  including those that attack the skin and lungs  It is an immunotherapy treatment  meaning that it mobilizes the body s immune system to identify and eliminate cancer cells  
Keytruda received its first green light from the regulator in 2014  Over the past few years  its popularity has rocketed higher  In Merck s most recently reported quarter  sales of the drug rose by 62  on a year over year basis  The revenue from Keytruda alone was  3 1 billion    nearly 25  of the company s total top line for the period 
In spite of the FDA s nod  the price of the high profile pharmaceutical stock did not move significantly on Wednesday  Merck s shares closed slightly lower on the day ",2020-01-08,The Motley Fool,https://invst.ly/pfmcg,2055502
202531,424047,MRK,Pharma Stock Roundup  BMY  GSK  SNY Q4 Results  MRK Earnings   Split ,opinion,"This week Merck   NYSE MRK    Bristol Myers   NYSE BMY    Sanofi   NASDAQ SNY    Glaxo   NYSE GSK   and Novo Nordisk   NYSE NVO   reported fourth quarter earnings and sales  In a surprising move  Merck announced plans to spin off its Women Health products  legacy drugs and biosimilars into a new company  Merck  Bristol Myers  Sanofi and AbbVie   NYSE ABBV   provided pipeline and regulatory updates Recap of the Week s Most Important Stories Earnings Update  beat estimates for both earnings and sales in the fourth quarter  While earnings rose almost 30   total revenues increased 33   mainly driven by the addition of Celgene s products  The company expects earnings of  6 00  6 20 per share and revenues in the range of  40 5 billion  42 5 billion in 2020   and Sanofi s fourth quarter results were mixed as both companies beat estimates for earnings but missed the same for sales While Merck s earnings rose 12  year over year  sales rose 8   Pharmaceutical segment sales rose 7  as higher sales in oncology and hospital business were offset by lower vaccines sales  In 2020  Merck expects revenues to be in the range of  48 8 billion    50 3 billion  while earnings are expected to be in the range of  5 62  5 77 For double digit growth in the Specialty Care and Vaccines was offset by persistent sluggishness in Diabetes and Cardiovascular franchises and a weak performance in the Consumer HealthCare unit in the quarter  Sanofi expects earnings to grow approximately 5  at constant exchange rate  CER  in 2020 missed on earnings and sales in the fourth quarter  Pharmaceuticals segment sales were down 4  at CER as the company s established drugs continued to decline  However  the company s new products from every segment performed well in the reported quarter  especially Shingrix  Glaxo expects earnings to decline in the range of 1  to 4  at CER in 2020 Novo Nordisk s earnings were in line while sales slightly missed estimates  Sales in the Diabetes and Obesity Care segment increased 7  at CER while that in the Biopharmaceuticals segment increased 2   Novo Nordisk expects 3 6  sales growth at CER for 2020 Merck to Separate Into Two Companies  Along with the earnings release  Merck revealed plans to spin off its women s healthcare unit  biosimilar drugs and legacy products into an independent public company  The move is expected to allow it to focus on its core areas  oncology  vaccines  hospital and animal health  Merck expects the spinoff to be completed by the first half of 2021  Meanwhile  Merck s supplemental new drug application  seeking approval for itsnew antibacterial injection  for another indication   hospital acquired and ventilator associated bacterial pneumonia  HABP VABP    was accepted by the FDA  With the FDA granting priority review to the application  a decision is expected on Jun 4  The application was based on data of the pivotal phase III RESTORE IMI 2 study  Recarbrio is a fixed combination of relebactam with imipenem cilastatin The FDA also approved updating the label of Merck s insomnia drug Belsomra  suvorexant  C IV to include data from a study evaluating Belsomra for the treatment of insomnia in people with mild to moderate Alzheimer s disease dementia  Belsomra is presently approved to treat insomnia characterized by difficulties with sleep onset and or sleep maintenance Sanofi s Multiple Sclerosis Candidate Meets Goal in Study  Sanofi s investigational brain penetrant BTK inhibitor  SAR442168 met the primary endpoint in a phase II study in relapsing multiple sclerosis  Data from the study showed that SAR442168 significantly reduced disease activity associated with multiple sclerosis as measured by magnetic resonance imaging  MRI   Sanofi claims that SAR442168 has the potential to address sources of multiple sclerosis damage in the brain and could transform the way the disease is treated  Sanofi plans to initiate four phase III studies on SAR442168 in relapsing and progressing forms of multiple sclerosis by mid 2020 Bristol Myers Withdraws Opdivo European Application in Lung Cancer  Bristol Myers withdrew an application in the European Union  The application sought approval of plus Yervoy for the first line treatment of advanced non small cell lung cancer  The application  which was based on data from the CheckMate   227 study  is also under review in the United States with a PDUFA date of May 15  The company does not plan to re file the application in the EU Glaxo Signs Deal with CEPI to Make Vaccine to Fight Coronavirus  Glaxo announced a collaboration deal with Coalition for Epidemic Preparedness Innovations to make its established pandemic vaccine adjuvant platform technology accessible to the latter to develop a vaccine for the 2019 nCoV virus Separately  the European Medicines Agency  EMA  accepted Glaxo s marketing application seeking approval of belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma  The application has been accepted for accelerated assessment by the EMA s Committee for Human Medicinal Products  CHMP   A biologics license application  BLA  for belantamab mafodotin is under priority review in the United States AbbVie Rinvoq Meets Goal in 2nd Psoriatic Arthritis Study  AbbVie s second phase III study evaluating Rinvoq  upadacitinib  for active psoriatic arthritis met the primary as well as key secondary endpoints  The study  SELECT PsA 1  evaluated Rinvoq in active psoriatic arthritis adult patients who had an inadequate response to other bDMARDs  Top line data from the study showed that both doses of Rinvoq  15 mg and 30 mg  once daily  met the primary endpoint of ACR20 response or at least a 20  reduction in the number of both tender and swollen joint counts  at week 12 versus placebo  After 12 weeks of treatment  ACR20 response was achieved in 71  of the patients receiving the 15 mg oral once daily dose of Rinvoq and 79  of the patients taking the 30 mg dose versus 36  for patients in the placebo group  Also  the 30 mg dose of Rinvoq achieved superiority to Humira in terms of ACR20 response at week 12  whereas both doses achieved non inferiority to Humira  Rinvoq was approved for the treatment of moderate to severe rheumatoid arthritis in the United States in August and in Europe in December last year The NYSE ARCA Pharmaceutical Index rose 2 2  in the last five trading sessions 
Large Cap Pharmaceuticals Industry 5YR   ReturnHere is how the seven major stocks performed in the last five trading sessions  Last week  Bristol Myers recorded the maximum gain  5 2   while Glaxo declined the most  6   In the past six months  Bristol Myers has risen the most  41 9   while Merck recorded the lowest gain  1 2    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for fourth quarter 2019 results of Allergan  NYSE AGN  and AstraZeneca and regular pipeline and regulatory updates next week Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 7  per year These 7 were selected because of their superior potential for immediate breakout ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-bmy-gsk-sny-q4-results-mrk-earnings--split-200505737,200505737
202532,424048,MRK,Seattle Genetics  SGEN  Q4 Earnings Top  Adcetris Drives Sales,opinion,Seattle Genetics  Inc    NASDAQ SGEN   incurred an adjusted loss of 22 cents per share for the fourth quarter of 2019  narrower than the Zacks Consensus Estimate of 45 cents and also the year ago loss of 57 cents Adjusted loss in the quarter excluded a market to market net investment income related to Seattle Genetics  common stock holdings in Immunomedics  Inc Revenues of  289 8 million were up 66 1  year over year  primarily driven by higher royalty revenues in the reported quarter and sales from the lead drug Adcetris  The top line also comprehensively beat the Zacks Consensus Estimate of  224 million Shares of Seattle Genetics have soared 82 5  in the past year versus the  decrease of 0 7  Quarter in DetailSeattle Genetics  top line mainly comprises product revenues  collaboration and license agreement revenues plus royalties Adcetris generated net sales of  166 2 million in the United States and Canada  up 26  year over year  Improved sales of the drug were owing to its label expansions for frontline CD30 expressing peripheral T cell lymphoma  PTCL  and frontline Hodgkin s lymphoma HL  which led to an increase in the number of PTCL patients being treated with Adcetris Newly launched Padcev generated  0 2 million sales in the quarter  On the fourth quarter conference call  management seemed pleased with the uptake of Padcev so far  which exceeded its internal predictions  Padcev is Seattle Genetics  second drug to be approved by the FDA Collaboration and license agreement revenues of  51 1 million significantly surged year over year  In the reported quarter  Seattle Genetics received a milestone fee from GlaxoSmithKline   NYSE GSK   and an upfront payment from BeiGene for entering into a licensing agreement to develop a preclinical product candidate to treat cancer Royalty revenues of  72 3 million soared from the year ago quarter s  24 6 million  In the reported quarter  Seattle Genetics received a one time  40 million milestone from Japan s Takeda Pharmaceutical as Adcetris sales crossed  400 million in the latter s territory during 2019  The company records royalty revenues on the sales of Adcetris from Takeda in the ex U S  markets and outside and to a lesser extent  on the sales of Polivy under Seattle Genetics  collaboration with Roche   OTC RHHBY   Research and development  R D  expenses of  201 1 million escalated 34 2  year over year  During the fourth quarter earnings conference  management informed that R D expenses were high  primarily due to higher investment in developing the late stage pipeline candidates Selling  general and administrative  SG A  expenses rose 44 9  year over year to  115 2 million  mainly on account of costs pertaining to the launch of Adcetris in frontline setting and costs related to preparations for the launches of Padcev and tucatinib Full Year ResultsFor 2019  Seattle Genetics generated revenues of  916 7 million  reflecting 40  growth year over year Adcetris recognized sales of  627 7 million in 2019  up 32  year over year 2020 OutlookSeattle Genetics projects Adcetris  full year net sales in the range of  675  700 million  denoting modest growth The company expects collaboration and license revenues in the band of  30  50 million while royalty revenues are anticipated within  105  115 million Seattle Genetics expects SG A expenses within  475  525 million  R D is estimated in the bracket of  860  950 million Other Pipeline Updates In December 2019  the FDA granted accelerated approval to Padcev for the treatment of patients with advanced metastatic urothelial cancer  who had received treatment with both a checkpoint inhibitor  PD 1 PD L1  and platinum based chemotherapy  Following this nod  Padcev became the first FDA approved drug for treating the given patient population In January 2020  Seattle Genetics and Astellas together with pharma giant Merck   NYSE MRK   initiated the phase III EV 302 study on the combination of Padcev and the latter s PD 1 L1 inhibitor Keytruda  pembrolizumab  with or without chemotherapy compared to chemotherapy alone for treating patients with previously untreated metastatic urothelial cancer In the same month  Seattle Genetics and Astellas initiated the phase II EV 202 study to evaluate Padcev as monotherapy for a range of solid tumors including non small cell lung  head and neck  gastric esophageal as well as breast cancers Meanwhile  Seattle Genetics submitted a new drug application  NDA  to the FDA for its oral tyrosine kinase inhibitor tucatinib in December 2019  The NDA was submitted seeking approval of tucatinib in combination with Roche s Herceptin  trastuzumab  and Xeloda  capecitabine  to treat patients with locally advanced metastatic HER2 positive breast cancer including those with brain metastases  having received at least three prior HER2 directed agents separately or in combination for the neoadjuvant  adjuvant or metastatic setting Seattle Genetics  Inc  Price  Consensus and EPS Surprise   Zacks RankSeattle Genetics currently carries a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 7  per year These 7 were selected because of their superior potential for immediate breakout ,2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/seattle-genetics-sgen-q4-earnings-top-adcetris-drives-sales-200505795,200505795
202533,424049,MRK,What s In Store For AstraZeneca  AZN  This Earnings Season ,opinion,"AstraZeneca plc   NYSE AZN   is scheduled to report fourth quarter and full year 2019 results on Feb 14The company s earnings beat estimates in each of the past four quarters with the average surprise being 36 96   AstraZeneca PLC Price and EPS Surprise
     
Shares of AstraZeneca have increased 36  in the past year compared with the  s increase of 13 7    In the last reported quarter  AstraZeneca delivered a positive earnings surprise of 11 11  Factors at PlaySales of newer medicines  mainly cancer drugs Lynparza  Tagrisso and Imfinzi are expected to have benefited the company s top line in the fourth quarter by offsetting lower sales of many other legacy medicines Product sales in the third quarter benefited from favorable inventory and gross to net movements  However  the benefits were absent this time around Continued underlying demand growth and strong uptake in the first line setting are likely to have pushed up sales of Tagrisso in the quarter Sales of Lynparza  which is marketed in collaboration with Merck   NYSE MRK    are likely to have been driven by expanded use in ovarian and breast cancer  In December  the FDA granted approval to Lynparza as a first line maintenance treatment in germline BRCA mutated metastatic pancreatic cancer  However  this label expansion is unlikely to have contributed to the drug s sales in the fourth quarter Fourth quarter sales of Imfinzi are likely to have benefited from strong demand trends in the United States  especially in lung cancer indications AstraZeneca s other major drugs like Fasenra  Brilinta and Farxiga are likely to have contributed to sales growth the soon to be reported quarter However  please note that increased competition and formulary plan changes for competitors  drugs hurt sales of Farxiga in the United States in the third quarter  We expect these factors to have hurt sales in the fourth quarter as well Sales of AstraZeneca s COPD drug Symbicort s have been declining due to pricing pressure and competition  These factors are likely to have impacted fourth quarter sales of the drug as well Sales of AstraZeneca s major legacy drugs have been declining due to rising generic competition  The trend is likely to have continued in the fourth quarter On the fourth quarter conference call  we expect management to discuss launch plans for AstraZeneca and partner Japan s Daiichi Sankyo s trastuzumab deruxtecan  which was approved by the FDA in metastatic breast cancer in December 2019 under the brand name  Enhertu Earnings WhispersOur proven model does not conclusively predict an earnings beat for AstraZeneca in this reporting cycle  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that is not the case here as you will see below Earnings ESP  AstraZeneca s Earnings ESP is 0 00  as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at 53 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AstraZeneca carries a Zacks Rank  3 Stock to Consider Here are two biotech stocks that have the right combination of elements to beat on earnings this time around Karyopharm Therapeutics Inc    NASDAQ KPTI   has an Earnings ESP of  3 05  and a Zacks Rank  3  The company is scheduled to release fourth quarter results on Feb 27 Nektar Therapeutics   NASDAQ NKTR   has an Earnings ESP of  8 36  and a Zacks Rank  3 Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2020-02-10,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-astrazeneca-azn-this-earnings-season-200506372,200506372
202534,424050,MRK,Incyte s  INCY  Capmatinib NDA Gets Priority Review From FDA ,opinion,Incyte Corporation   NASDAQ INCY   announced that the FDAaccepted and granted Priority Review to the new drug application  NDA  for capmatinib  which is an investigational  oral selective MET inhibitor  The company is seeking approval of capmatinib for the treatment of first line and previously treated patients with locally advanced or metastatic MET exon 14 skipping  METex14  mutated non small cell lung cancer  NSCLC    a type of lung cancer with a particularly poor prognosis  If approved  the candidate will be the first therapy to specifically target METex14 mutated advanced lung cancer The Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment  prevention or diagnosis of a serious disease  This designation shortens the FDA review period following the acceptance of the NDA to six months compared to 10 months for standard review Shares of the company have lost 7 7  in the past year compared with the  s decline of 1 3   The NDA submission was supported by positive primary results from the GEOMETRY mono 1 study   Data from the study showed that treatment with capmatinib demonstrated promising efficacy in patients with locally advanced or metastatic NSCLC that harbors MET exon 14 skipping mutation The primary endpoint was overall response rate  ORR based on the Blinded Independent Review Committee  BIRC  assessment per RECIST v1 1  The overall response rate among treatment naive patients receiving capmatinib was 68  and 41  for previously treated patients  The median duration of response was also clinically meaningful  irrespective of the prior line of therapy In September 2019  the FDA also granted Breakthrough Therapy designation to capmatinib for the first line treatment of patients with metastatic MET exon14 skipping mutated NSCLC We remind investors that capmatinib was licensed to Novartis   NYSE NVS   by Incyte in 2009  Per the agreement  Incyte granted Novartis exclusive worldwide development and commercialization rights to capmatinib and certain back up compounds in all indications Also  competition is stiff in the NSCLC market with several big pharma companies having approved drugs for the same  including Merck s   NYSE MRK   Keytruda  AstraZeneca s   NYSE AZN   Tagrisso and Roche s Tecentriq Incyte currently has a Zacks Rank  4  Sell   You can see  Incyte Corporation Price    Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020  Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-02-10,Zacks Investment Research,https://www.investing.com/analysis/incytes-incy-capmatinib-nda-gets-priority-review-from-fda-200506466,200506466
202542,424058,MRK,Merck receives FDA approval for Ebola vaccine,news," Reuters    The U S  Food and Drug Administration said on Thursday it approved drugmaker Merck   Co s  N MRK  Ebola vaccine Ervebo  making it the first FDA authorised vaccine against the deadly virus 
The vaccine was used by the World Health Organization and Democratic Republic of the Congo as an investigational vaccine to help reduce Ebola virus disease  EVD  outbreaks in few West African countries from 2014 to 2016 
The Ebola virus  which causes haemorrhagic fever and spreads from person to person through direct contact with body fluids  has killed more than 2 100 people in Congo since the middle of the year  making it the second largest Ebola outbreak in history 
The vaccine  which is administered as a single dose injection  will help to prevent EVD caused by Zaire ebolavirus in patients aged 18 years and older  the regulator said in a statement 
Merck welcomed the FDA s decision  describing it as an important milestone in the fight against the deadly virus 
In November  Merck received approval from the European Commission to market Ervebo  less than a month after a European medicines panel backed the first ever vaccine against the virus ",2019-12-20,Reuters,https://www.investing.com/news/stock-market-news/merck-receives-fda-approval-for-ebola-vaccine-2045700,2045700
202543,424059,MRK,Merck teams up with Taiho Pharma and Astex Pharma in cancer,news,"Merck  NYSE MRK  inks an exclusive global research collaboration and license agreement with Taiho Pharmaceutical Co   Ltd  and Otsuka Pharmaceutical Co   OTCPK OTSKF  unit Astex Pharmaceuticals aimed at developing small molecule inhibitors against several drug targets in cancer  including the KRAS oncogene 
Under the terms of the deal  the three companies will combine their preclinical candidates and know how  Merck will have an exclusive global license to the programs and will pay Taiho and Astex  50M upfront  up to  2 5B in milestones and tiered royalties on net sales  Merck will fund R D and will be responsible for worldwide commercialization  Taiho retains co commercialization rights in Japan with an option to promote in certain areas of Southeast Asia ",2020-01-06,Seeking Alpha,https://invst.ly/pe7tf,2052981
202544,424060,MRK,Will Eylea   Dupixent Drive Regeneron s  REGN  Q4 Earnings ,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   is scheduled to release fourth quarter 2019 results on Feb 6  before the opening bell The company has a decent track record  In the last reported quarter  the company beat earnings expectations by 5 37   It surpassed earnings estimates by 4 32   on average  in the last four quarters Regeneron Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    
 Let s see how things are shaping up for the upcoming announcement Why a Likely Earnings BeatOur proven model predicts an earnings beat for Regeneron this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Regeneron has an Earnings ESP of  5 39  as the Zacks Consensus Estimate is pegged at  6 90 and the Most Accurate Estimate at  7 28 Zacks Rank  The company has a Zacks Rank  3  You can see  Factors at PlayRegeneron s key drug  Eylea  drove performance in the first nine months of 2019  a trend that most likely continued in the fourth quarter  Eylea was developed in collaboration with Bayer  DE BAYGN  AG   OTC BAYRY    The drug is approved in the United States  the EU  Japan and other countries for the treatment of neovascular age related macular degeneration  wet AMD   diabetic macular edema  DME  and macular edema following retinal vein occlusion  which includes macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion Apart from Eylea  investors will be focusing on Dupixent s performance and label expansion Asthma drug Dupixent s sales were impressive in the first nine months of 2019 on continuous label expansion and the trend is expected to have continued in the fourth quarter  Label expansion of the drug in the last few months has most likely boosted sales further  In October 2019  the EC approved Dupixent in chronic rhinosinusitis with nasal polyposis  CRSwNP   The European Commission approved another label expansion of the drug to include adolescents aged 12 17 years with moderate to severe atopic dermatitis  AD   who are candidates for systemic therapy Investors will also focus on the performance of PCSK9 inhibitor  Praluent and Libtayo  Sales of Libtayo came in at  51 5 million in the third quarter  Sales have most likely recorded a sequential growth in the fourth quarter  Libtayo is being jointly developed by Regeneron and Sanofi   NASDAQ SNY   under a global collaboration agreement Praluent sales came in at  69 7 million in the third quarter  In April 2019  the FDA approved a label expansion of the drug to reduce the risk of heart attack  stroke and unstable angina requiring hospitalization of adults suffering from established cardiovascular  CV  disease  Hence  this is likely to have driven sales in the fourth quarter Apart from top line numbers  investors will focus on Regeneron s pipeline updates  The supplemental Biologics License Application  sBLA  for asthma drug Dupixent  dupilumab  has been accepted by the FDA for Priority Review  The company is seeking approval of the drug as an add on maintenance treatment for children 6 11 years with moderate to severe AD  whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable  The FDA set an action date of May 26  2020 Investors will also be keen on an update on the company s collaboration agreement with Sanofi  In December 2019  Regeneron and Sanofi announced their intent to simplify their antibody collaboration for Kevzara and Praluent by restructuring it into a royalty based agreement  Under the proposed restructuring  Sanofi is expected to gain sole global rights to Kevzara and sole ex U S  rights to Praluent  Regeneron is expected to gain sole U S  rights to Praluent  The existing collaboration relating to Dupixent will remain unchanged following the restructuring Share Price PerformanceRegeneron s stock has lost 20 5  in the past year compared with the  s decline of 9 1  Another Stock to ConsiderHere is another stock you may want to consider  as our model shows that this too has the right combination of elements to post an earnings beat this quarter Merck   NYSE MRK   has an Earnings ESP of  1 05  and a Zacks Rank  3  The company is scheduled to release results on Feb 5 Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/will-eylea--dupixent-drive-regenerons-regn-q4-earnings-200504026,200504026
202545,424061,MRK,Factors Setting The Tone For Bristol Myers  BMY  Q4 Earnings,opinion,"Bristol Myers Squibb Company   NYSE BMY   is scheduled to report fourth quarter 2019 results on Feb 6  before market open The company s shares have rallied 23 8  in the past year compared with the  s growth of 10 2   Bristol Myers has an excellent track record  The company delivered a positive earnings surprise of 8 30   on average  in the trailing four quarters  In the last reported quarter  the company delivered a positive earnings surprise of 10 38  Bristol Myers Squibb Company Price  Consensus and EPS Surprise
    Let s see how things are shaping up for the upcoming announcement Factors Driving GrowthBristol Myers  key immuno oncology drug  Opdivo  is likely to have maintained its stellar performance in the to be reported quarter  The drug  which is approved for multiple indications  generated sales of  5 4 billion in the first nine months of 2019  increasing 10  year over year  Sales for the third quarter came in at  1 8 billion  The momentum is likely to have continued in the fourth quarter  owing to demand resulting from the rapid commercial acceptance of the drug for several indications  including melanoma  renal cell carcinoma  hepatocellular carcinoma and second line non small cell lung cancer  NSCLC  Blood thinner drug  Eliquis  witnessed strong growth in the first nine months of 2019 and was the top revenue generator in the third quarter with sales of  1 9 billion  a trend that most likely continued in the fourth quarter propelled by market share increases Arthritis drug  Orencia  raked in sales of  2 2 billion in the first nine months of 2019  up 10  year over year  and  767 million in the third quarter  The drug has most likely boosted the top line in the fourth quarter as well   In December 2019  the FDA has granted Breakthrough Therapy designation to Orencia  for the prevention of moderate to severe acute graft versus host disease  GvHD  in hematopoietic stem cell transplants from unrelated donors Oncology drug  Sprycel  is also likely to have maintained momentum However  the virology business has most likely witnessed a decline in the fourth quarter In November 2019  Bristol Myers completed the acquisition of Celgene Corporation  NASDAQ CELG  following the receipt of regulatory approval from all government authorities as required by the merger agreement The acquisition added oncology drug  Revlimid  to Bristol Myers portfolio  Revlimid sales came in at  2 8 billion in the third quarter of 2019  up 13  year over year  driven primarily by the adoption of the triplet therapy for myeloma  resulting in increases in treatment duration and market share  Similar contributions are expected in the fourth quarter as well In November 2019  the FDA approved Celgene s Reblozyl for the treatment of anemia in adult patients with beta thalassemia  who require regular red blood cell  RBC  transfusions  The drug was developed in collaboration with Acceleron Pharma Inc    NASDAQ XLRN    The top line is likely to have got a boost from the incremental contribution of Reblozyl Apart from the top and bottom line numbers  investors will focus on updates on label expansion of drugs  In December 2020  the European Commission  EC  approved a new indication for Revlimid  lenalidomide   in combination with rituximab  anti CD20 antibody   for the treatment of adult patients with previously treated follicular lymphoma  Key Anticipated UpdatesBristol Myers recently withdrew its application in the European Union  EU  for the combination of Opdivo  nivolumab  and Yervoy  ipilimumab  for the treatment of advanced non small cell lung cancer  NSCLC  based on data from CheckMate 227 Though the Committee for Medicinal Products for Human Use  CHMP  acknowledged the integrity of the patient data  it determined that a full assessment of the application was not possible following the multiple protocol changes the company made in response to the rapidly evolving science and data  Consequently  Bristol Myers has no plans to resubmit this application in the EU In January 2020  the FDA granted a Priority Review status to the Opdivo Yervoy combination for the treatment of first line NSCLC The FDA has accepted the supplemental Biologics License Application  sBLA  and granted Breakthrough Therapy designation to the combination for the treatment of patients with advanced hepatocellular carcinoma  HCC  previously treated with sorafenib  The FDA granted a Priority Review to the application  with a Prescription Drug User Fee Act  PDUFA  goal date of Mar 10  2020 Earnings WhispersOur proven model does not conclusively predict an earnings beat for Bristol Myers this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  Unfortunately  that is not the case here  as you will see below  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Earnings ESP for Bristol Myers is  2 64  as the Zacks Consensus Estimate stands at 88 cents and the Most Accurate Estimate stands at 86 cents Zacks Rank  The company currently carries a Zacks Rank  3 Stocks to ConsiderHere are some stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Merck   NYSE MRK   has an Earnings ESP of  1 05  and a Zacks Rank  3  The company is scheduled to release results on Feb 5  You can see  Regeneron   NASDAQ REGN   has an Earnings ESP of  5 39  and a Zacks Rank  3  The company is scheduled to release results on Feb 6 Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/factors-setting-the-tone-for-bristolmyers-bmy-q4-earnings-200503983,200503983
202546,424062,MRK,Bristol Myers  Opdivo Yervoy NSCLC Application In EU Withdrawn,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced the withdrawal of its application in the European Union  EU  for the combination of anti PD 1 antibody Opdivo  nivolumab  and Yervoy  ipilimumab  for the treatment of advanced non small cell lung cancer  NSCLC  based on data from the CheckMate 227 study  The application was initially filed in 2018 for patients with first line NSCLC  who have tumor mutational burden 
However  the application was later amended to include the statistically significant overall survival data  a co primary endpoint  from CheckMate 227 Part 1a  evaluating Opdivo plus Yervoy versus chemotherapy in patients whose tumors expressed PD L1  1  
Per the company  Europe s Committee for Medicinal Products for Human Use  CHMP  stated that it was not possible to assess the data provided by the company because of  multiple protocol changes  it made in the study 
Bristol Myers has no intention of refiling the application anytime soon  In January 2020  the FDA granted a Priority Review for the combination of Opdivo and Yervoy for the treatment of first line NSCLC based on data from Part 1 of the phase III CheckMate  227 study 
Shares of Bristol Myers have rallied 24 7  in the past year  outperforming the  growth of 10 2  

 
We note that Opdivo is currently approved in many countries  including the United States  the EU and Japan  for several cancer indications  The company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  The Opdivo and Yervoy combination is approved for the treatment of patients with unresectable or metastatic melanoma and intermediate or poor risk  previously untreated advanced renal cell carcinoma  RCC  
The combination is also approved for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  metastatic colorectal cancer  CRC   which has progressed following treatment with a fluoropyrimidine  oxaliplatin and irinotecan 
Label expansion of Opdivo into additional indications would lend the product access to a higher patient population and increase its commercial potential significantly 
However  the drug is facing competitive challenges in the United States from Merck s   NYSE MRK   PD L1 inhibitor  Keytruda 
Zacks Rank   Other Stocks to Consider
Bristol Myers currently carries a Zacks Rank  3  Hold   
A few better ranked stocks from the healthcare space are Pfizer  Inc    NYSE PFE   and Roche Holding  SIX ROG  AG   OTC RHHBY    While Pfizer sports a Zacks Rank  1  Strong Buy   Roche carries a Zacks Rank  2  You can see  
Pfizer s earnings per share estimates have moved up from  2 62 to  2 77 for 2020 and from  2 73 to  2 81 for 2021 in the past 90 days  The company delivered a positive earnings surprise of 7 46   on average  in three of the last four quarters 
Roche s earnings per share estimates have increased from  2 61 to  2 66 for 2020 in the past 60 days Bristol Myers Squibb Company Price
 

    
Free  Zacks  Single Best Stock Set to Double 
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all  This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible 
Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivoyervoy-nsclc-application-in-eu-withdrawn-200504171,200504171
202547,424063,MRK,Will Opdivo   Eliquis Drive Bristol Myers  BMY  Q4 Earnings ,opinion,Bristol Myers    NYSE BMY   immuno oncology drug  Opdivo  which is approved for multiple oncology indications  fueled the top line in the third quarter of 2019  The uptake of the drug continued to be strong in metastatic and adjuvant melanoma  and first line renal cell carcinoma in the United States  In fact  the trend most likely continued in the fourth quarter  However  the size of the eligible pool of second line lung cancer patients declined in the third quarter and the same most likely prevailed in the fourth quarter In international markets  Opdivo is likely to have benefited from the uptake in renal and adjuvant melanoma Apart from the drug s sales  investors will also look forward to key pipeline updates on the ongoing studies of Opdivo  Bristol Myers recently withdrew its application in the European Union  EU  for the combination of Opdivo and Yervoy in advanced non small cell lung cancer  NSCLC   based on data from CheckMate 227 Though the Committee for Medicinal Products for Human Use  CHMP  acknowledged the integrity of the patient data  it determined that a full assessment of the application was not possible following the multiple protocol changes the company made in response to the rapidly evolving science and data  Consequently  Bristol Myers has no plans to resubmit this application in the EU In January 2020  the FDA granted a Priority Review status to the Opdivo Yervoy combination for the treatment of first line NSCLC Investors will be focusing on further updates on the same as competition is stiff in this space from the likes of Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq The FDA accepted the supplemental Biologics License Application  sBLA  and granted Breakthrough Therapy designation to the combination for the treatment of patients with advanced hepatocellular carcinoma  HCC  previously treated with sorafenib  The FDA granted a Priority Review to the application  with a Prescription Drug User Fee Act  PDUFA  goal date of Mar 10  2020 Eliquis delivered a stellar performance during the first nine months of 2019  propelled by increased share in the novel oral anticoagulant  NOAC  market  a trend that most likely continued in the fourth quarter  Per the company  Eliquis is now the number one oral anticoagulant in multiple countries outside the United States The third quarter saw continued stable demand for Sprycel in the United States and the same is likely to have continued in the fourth quarter Meanwhile  in November 2019  Bristol Myers completed the impending acquisition of Celgene Corporation  NASDAQ CELG   The acquisition added blockbuster oncology drug  Revlimid  to its portfolio  The drug is expected to have significantly contributed to the company s fourth quarter performance In November 2019  the FDA approved Celgene s Reblozyl for the treatment of anemia in adult patients with beta thalassemia  who require regular red blood cell  RBC  transfusions  The top line is likely to have got a boost from the incremental contribution of Reblozyl The Zacks Consensus Estimate for fourth quarter sales and earnings is pegged at  6 14 billion and 88 cents  respectively Bristol Myers  shares have gained 25  in the past year compared with the  s growth of 0 9   Apart from these  investors will focus on further updates on the company s pipeline progress  Bristol Myers submitted a Biologics License Application  BLA  to the FDA for lisocabtagene maraleucel  liso cel   its autologous anti CD19 chimeric antigen receptor  CAR  T cell immunotherapy  comprising individually formulated CD8  and CD4  CAR T cells for the treatment of adult patients with relapsed or refractory  R R  large B cell lymphoma  LBCL  after at least two prior therapies Zacks Rank   A Stock to ConsiderBristol Myers currently carries a Zacks Rank  3  Hold  A better ranked stock in the same space is Pfizer   NYSE PFE    which carries a Zacks Rank  1  Strong Buy   You can see  Pfizer s earnings estimates have increased to  2 77 from  2 65 in the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ,2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/will-opdivo--eliquis-drive-bristolmyers-bmy-q4-earnings-200504430,200504430
202548,424064,MRK,Merck s Recarbrio Gets FDA Priority Review For New Indication,opinion,Merck   Co    NYSE MRK   announced that the supplemental new drug application  sNDA  seeking approval of its new antibacterial injection Recarbrio for a new indication has been accepted by the FDA  The sNDA has been filed to get Recarbrio approved to treat adult patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  HABP VABP  caused by certain susceptible Gram negative microorganisms  With the FDA granting a priority review to the sNDA  a decision is expected on Jun 4  2020 Recarbrio is a fixed combination of relebactam and imipenem cilastatin  Recarbrio was approved for the treatment of adults with complicated urinary tract infections and complicated intra abdominal bacterial infections caused by certain susceptible gram negative bacteria in July last year The sNDA submission is based on the results of the pivotal phase III RESTORE IMI 2 study Shares of the company have gained 13 6  in the past year compared with the  s growth of 10 9   In a separate release  the company announced that the FDA approved updating the label of its insomnia drug Belsomra  suvorexant  C IV to include data from a study  evaluating the drug for the treatment of insomnia in people with mild to moderate Alzheimer s disease dementia  Belsomra is presently approved to treat insomnia  characterized by difficulties with sleep onset and or sleep maintenance The update is based on the data from a multi site 4 week polysomnography study  in which Belsomra demonstrated a statistically significant improvement in both Total Sleep Time  TST  and Wake After Sleep Onset  WASO  measures compared to those treated with placebo  as assessed objectively by polysomnography  Merck   Co   Inc  Price     Zacks Rank and Stocks to ConsiderMerck currently has a Zacks Rank  3  Hold  A few better ranked stocks from the healthcare space are Pfizer  Inc    NYSE PFE    Sanofi   NASDAQ SNY   and Roche Holding  SIX ROG  AG   OTC RHHBY    While Pfizer sports a Zacks Rank  1  Strong Buy   Sanofi and Roche carry a Zacks Rank  2  Buy   You can see  Pfizer s earnings per share estimates have moved up from  2 62 to  2 77 for 2020 and from  2 73 to  2 81 for 2021 in the past 90 days  The company delivered a positive earnings surprise of 7 46   on average  in three of the last four quarters Sanofi s earnings per share estimates have moved up from  3 26 to  3 29 for 2019 and from  3 45 to  3 49 for 2020 in the past 60 days  The company delivered a positive earnings surprise of 8 25   on average  in the last four quarters Roche s earnings per share estimates have increased from  2 61 to  2 66 for 2020 in the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops   Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ,2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/mercks-recarbrio-gets-fda-priority-review-for-new-indication-200504423,200504423
202549,424065,MRK,Should You Buy Merck  MRK  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Merck   Co   Inc    NYSE MRK   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Merck is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for MRK in this report In fact  the Most Accurate Estimate for the current quarter is currently at  1 15 per share for MRK  compared to a broader Zacks Consensus Estimate of  1 14 per share  This suggests that analysts have very recently bumped up their estimates for MRK  giving the stock a Zacks Earnings ESP of  1 05  heading into earnings season Merck   Co   Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that MRK has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Merck  and that a beat might be in the cards for the upcoming report 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ,2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-merck-mrk-ahead-of-earnings-200504419,200504419
202555,424071,MRK,Roche Submits Application For Tecentriq Avastin Combo In HCC,opinion,Roche   OTC RHHBY   announced the submission of a supplemental Biologics License Application  sBLA  to the FDA for the label expansion of immuno oncology drug  Tecentriq  atezolizumab  Roche is seeking approval of Tecentriq in combination with Avastin  bevacizumab  for the treatment of patients with unresectable hepatocellular carcinoma  HCC   who have not received prior systemic therapy The application was based on the results of the phase III IMbrave150 study The FDA is reviewing the application under the Real Time Oncology Review pilot program  which should result in an efficient review process to ensure the availability of safe and effective treatments for patients as early as possible In July 2018  the FDA granted Breakthrough Therapy designation to the combo for the above mentioned indication  based on data from an ongoing phase Ib trial A potential label expansion in the promising HCC space will boost sales of the drug  HCC  the most common form of liver cancer  is an aggressive disease as more than 750 000 people worldwide are diagnosed with HCC every year Tecentriq is approved in the United States and the EU either alone or in combination with targeted therapies and or chemotherapies in various forms of non small cell and small cell lung cancer  certain types of metastatic urothelial cancer  and PD L1 positive metastatic triple negative breast cancer  Roche has an extensive development program for Tecentriq  including multiple ongoing and planned phase III studies across several types of lung  genitourinary  skin  breast  gastrointestinal  gynecological  and head and neck cancers  The program includes studies evaluating the drug as monotherapy as well as in combination with other drugs We note that Exelixis    NASDAQ EXEL   Cabometyx is already approved for the treatment of HCC Roche s shares have jumped 28 3  in the past year compared with the  s 16 2  growth While the uptake of Tecentriq has been strong  it is currently facing stiff competition from immuno oncology therapies like Merck s   NYSE MRK   Keytruda and Bristol Myers    NYSE BMY   Opdivo in various indications Roche currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained an impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-26,Zacks Investment Research,https://www.investing.com/analysis/roche-submits-application-for-tecentriqavastin-combo-in-hcc-200501746,200501746
202556,424072,MRK,Old Dominion  ODFL  To Report Q4 Earnings  What s In Store ,opinion,"Old Dominion Freight Line   NASDAQ ODFL    which joined the coveted S P 500 Index on Dec 9  2019  is scheduled to report fourth quarter 2019 results on Feb 6  before market open The Zacks Consensus Estimate for fourth quarter 2019 earnings has been revised downward 4 8  in the past 60 days  Given this backdrop  let s delve into the factors that might have influenced the company s performance in the quarter Old Dominion s quarterly performance is likely to have been dented by a decline in LTL  Less Than Truckload  tonnage due to a soft freight environment  The Zacks Consensus Estimate for fourth quarter LTL tonnage per day hints at a 2  decline from the figure reported for the July September period  LTL shipments are also likely to have declined during the December end period due to soft freight demand Another key metric   operating ratio  operating expenses as a percentage of revenues    is likely to have suffered mainly due to lackluster revenues  The Zacks Consensus Estimate for fourth quarter operating ratio is pegged at 81   higher than the 79  reported for the September end quarter  Notably  lower the value the better  High capital expenditures are also likely to have eroded the bottom line for the soon to be reported quarter However  LTL revenue per hundredweight is likely to have increased in the fourth quarter partly owing to favorable pricing in the October December period  The Zacks Consensus Estimate for fourth quarter LTL revenue per hundredweight hints at an almost 1  improvement from the figure reported for the third quarter Old Dominion Freight Line  Inc  Price and EPS Surprise
    What Does the Zacks Model Say The proven Zacks model does not conclusively predict an earnings beat for Old Dominion in the fourth quarter of 2019  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  However  that is not the case here as elaborated below  You can see  Earnings ESP  Old Dominion has an Earnings ESP of  1 87  as the Most Accurate Estimate is pegged at  1 75  lower than the Zacks Consensus Estimate of  1 78  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Old Dominion carries a Zacks Rank  4  currently Highlights of Q3 EarningsIn the last reported quarter  Old Dominion s earnings of  2 05 per share missed the Zacks Consensus Estimate of  2 11  Moreover  the bottom line fell 3 3  year over year  Quarterly revenues of  1 048 5 million also fell short of the consensus mark of  1 059 2 million and edged down nearly 1   year over year Stocks to ConsiderInvestors may consider Spirit Airlines   NYSE SAVE    Merck   Co    NYSE MRK   and Frontline Ltd    NYSE FRO   as these stocks possess the right combination of elements to come up with earnings beats in their next releases Spirit Airlines has an Earnings ESP of  3 24  and currently holds a Zacks Rank of 2  The company will release fourth quarter earnings numbers on Feb 5 Merck has an Earnings ESP of  1 05  and currently carries a Zacks Rank of 3  The company will release quarterly numbers on Feb 5 Frontline is a Zacks  1 Ranked stock and has an Earnings ESP of  41 18   The company is slated to report fourth quarter figures on Feb 28 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/old-dominion-odfl-to-report-q4-earnings-whats-in-store-200503578,200503578
202566,424082,MRK,Bristol Myers posts better than expected results  Opdivo growth slows,news,"By Michael Erman
NEW YORK  Reuters    U S  drugmaker Bristol Myers Squibb Co  N BMY  reported higher than expected third quarter profit on Thursday  helped by strong sales of blood thinner Eliquis  even as growth of its blockbuster cancer treatment Opdivo slowed 
Bristol Myers  which is set to buy biotechnology company  Celgene Corp   O CELG  for  74 billion later this year  posted net earnings of  1 35 billion  or 83 cents a share  in the quarter  down from  1 9 billion  or  1 16 a share  last year 
Excluding one time items  the company said it earned  1 17 a share  exceeding analysts  expectations of  1 07 a share  according to IBES data from Refinitiv 
The company raised both ends of its full year adjusted earnings forecast range by 5 cents and now expects a profit of  4 25 to  4 35 per share  Analysts had been estimating the company will earn  4 28 a share in 2019 
Sales of cancer immunotherapy Opdivo rose only 1  from a year ago to  1 82 billion  roughly in line with Wall Street expectations  Once viewed as the company s most important growth driver  Opdivo sales have hovered around  1 8 billion a quarter for the past four quarters 
Meanwhile  Merck   Co s  N MRK  rival drug Keytruda brought in nearly  3 2 billion in the third quarter  up 67  from the previous year 
There has been widespread investor concern over the dominance of Keytruda  as it has become the go to treatment for newly diagnosed advanced lung cancer  the most lucrative oncology market  Bristol Myers is hoping recent positive results in two clinical trials will help improve Opdivo s position in lung cancer 
Eliquis  which Bristol shares with  Pfizer  Inc  N PFE   continues to be a bright spot  Its sales rose 22  to  1 93 billion  while analysts were estimating  1 85 billion 
Sales of rheumatoid arthritis drug Orencia and leukemia treatment Sprycel also were stronger than analysts had forecast 
Revenue in the quarter rose 6  from a year ago to  6 billion  also topping Wall Street expectations of  5 89 billion 
Bristol Myers shares closed up 2  at  56 87 on the New York Stock Exchange on Wednesday ",2019-10-31,Reuters,https://www.investing.com/news/stock-market-news/bristolmyers-posts-betterthanexpected-results-opdivo-growth-slows-2008638,2008638
202567,424083,MRK,Horizon Therapeutics Gets FDA Approval For Eye Drug Tepezza,opinion,"Horizon Therapeutics plc   NASDAQ HZNP   announced that the FDA has granted approval to Tepezza  teprotumumab trbw  as a treatment for patients with thyroid eye disease   TED    Previously  the FDA had set an action date of Mar 8  2020 With this approval  Tepezza becomes the first FDA approved medicine for the treatment of active TED  which has a significant unmet need  An FDA advisory committee had recommended the approval of the drug in December last year The company will conduct a post marketing study to evaluate safety of Tepezza in a larger patient population  as part of the discussion with the advisory committee Shares of Horizon Therapeutics were up 2  in pre market trading on Jan 22  following the early approval  The company s shares have surged 74 9  in the past year against the  s decline of 1 4   The company had filed a biologics license application for Tepezza in July 2019 based on data from the phase III confirmatory study  OPTIC  and positive phase II results  TED is a rare  autoimmune disease in which the insulin like growth factor receptor  IGF 1R  is overexpressed on eye tissues The OPTIC study found that significantly more patients treated with teprotumumab had a meaningful improvement in proptosis  or bulging of the eye  as compared to placebo  82 9  of teprotumumab patients compared to 9 5  of placebo patients   All secondary endpoints were also met  The study was initiated after the phase II study demonstrated clinically meaningful and highly statistically significant results in reducing proptosis and in the symptoms of TED  as measured by overall treatment response While developing novel therapies for rare disease  Horizon Therapeutics is also focused on label expansion of key drugs like Krystexxa  Actimmune  Procysbi and Ravicti In October 2019  the company initiated the PROTECT study  evaluating the effect of Krystexxa on serum uric acid levels in kidney transplant patients with uncontrolled gout  Actimmune is currently being developed in combination with Roche s   OTC RHHBY   Herceptin  or Bristol Myers    NYSE BMY   Opdivo and Merck s   NYSE MRK   Keytruda  targeting several cancer indications Horizon Therapeutics reports through the Orphan and Rheumatology segment  and the Inflammation segment  The company s net sales in the first nine months of 2019 were  936 5 million  up almost 10  year over year  Tepezza s approval is likely to boost its sales in 2020 Horizon Therapeutics Public Limited Company Price
    Zacks RankHorizon Therapeutics currently has a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/horizon-therapeutics-gets-fda-approval-for-eye-drug-tepezza-200500620,200500620
202568,424084,MRK,BioLineRx Concludes Recruitment In Pancreatic Cancer Study,opinion,BioLineRx Ltd    NASDAQ BLRX   announced that it has completed patient recruitment in the triple combination arm of the ongoing phase IIa COMBAT KEYNOTE 202 study on Motixafortide  BL 8040  for treating second line metastatic pancreatic cancer  The candidate  a CXCR4 inhibitor  is currently being evaluated in combination with Merck s   NYSE MRK   PD L1 inhibitor Keytruda  pembrolizumab  and chemotherapy for addressing the given indication Per the press release  the primary endpoint of the study is to see the objective response rate  ORR  while the secondary endpoints include overall survival  progression free survival and disease control rate  DCR   Patients were treated with Motixafortide monotherapy priming treatment for five days followed by combination cycles of chemotherapy  Onivyde 5 fluorouracil leucovorin   Keytruda and Motixafortide until progression BioLineRx plans to announce progression free and overall survival data from the triple combination arm of the above mentioned study in mid 2020 Shares of BioLineRx have plunged 73 3  in the past year against the  increase of 1 4  We remind investors that in December 2019  BioLineRx reported preliminary data from the triple combination arm of the phase IIa COMBAT KEYNOTE 202 study  which showed that  treatment with the triple combo led to a 32  ORR and 77  DCR from the 22 patients evaluated at the time Earlier this month  Motixafortide was granted an orphan drug designation by the European Commission  EC  for the treatment of pancreatic cancer  The candidate already received the same designation in the United States from the FDA for treating the same indication Notably  BioLineRx has a collaboration agreement with Genentech  a unit of Roche   OTC RHHBY    for evaluating Motixafortide in combination with Tecentriq  atezolizumab  in two phase Ib II studies for solid tumor Zacks Rank   Key PickBioLineRx currently carries a Zacks Rank  3  Hold   A better ranked stock in the same sector is KalVista Pharmaceuticals  Inc    NASDAQ KALV    sporting a Zacks Rank  1  Strong Buy   You can see  KalVista s loss per share estimates have narrowed 17 6  for 2020 over the past 60 days  The stock has gained 6 8  in the past year The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/biolinerx-concludes-recruitment-in-pancreatic-cancer-study-200501063,200501063
202569,424085,MRK,Roche s Urothelial Cancer Study On Tecentriq Disappoints ,opinion,Roche   OTC RHHBY   announced that the late stage study on immuno oncology drug Tecentriq for the indication of muscle invasive urothelial cancer  MIUC  failed The phase III  open label  randomized  controlled study  IMvigor010  is designed to evaluate the efficacy and safety of adjuvant treatment with Tecentriq in 809 patients with MIUC  who are at high risk for recurrence following resection  The primary endpoint is disease free survival  DFS  as assessed by investigator  which is defined as the time from randomization to invasive urothelial cancer recurrence or death The study did not meet its primary endpoint of DFS compared to observation in patients with MIUC Urothelial cancer is the most common type of bladder cancer and MIUC is a type of urothelial cancer spreads into the muscle of the bladder  ureter or renal pelvis Nevertheless  the safety for Tecentriq was consistent with the known safety profile of the drug and no new safety signals were identified Tecentriq is approved in the United States and the EU either alone or in combination with targeted therapies and or chemotherapies in various forms of non small cell and small cell lung cancer  certain types of metastatic urothelial cancer  and PD L1 positive metastatic triple negative breast cancer A potential label expansion in additional indications will boost sales of the drug further In addition to the ongoing phase III studies in early and advanced bladder cancer  Roche has an extensive development program for Tecentriq  including multiple ongoing and planned phase III studies across several types of lung  genitourinary  skin  breast  gastrointestinal  gynecological  and head and neck cancers  The program includes studies evaluating Tecentriq both alone and in combination with other drugs Roche s shares have gained 32 2  in the past year compared with the  s 17 2  growth  While the uptake of Tecentriq has been strong  it is currently facing stiff competition from immuno oncology therapies like Merck s   NYSE MRK   Keytruda  AstraZeneca s   NYSE AZN   Imfinzi and Bristol Myers    NYSE BMY   Opdivo in various indications Roche currently carries a Zacks Rank  2  Buy   You can see  Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/roches-urothelial-cancer-study-on-tecentriq-disappoints-200501445,200501445
202573,424089,MRK,Merck quarterly profit falls on deal related charge,news," Reuters    Drugmaker  Merck   Co  Inc  N MRK  reported a drop in third quarter profit on Tuesday  hit by a  982 million charge related to its acquisition of Peloton  NASDAQ PTON  Therapeutics 
Net income fell to  1 90 billion  or 74 cents per share  from  1 95 billion  or 73 cents per share  a year earlier 
Sales rose to  12 40 billion from  10 79 billion ",2019-10-29,Reuters,https://www.investing.com/news/stock-market-news/merck-quarterly-profit-falls-on-dealrelated-charge-2006397,2006397
202574,424090,MRK,Blueprint Medicines Posts Data From NSCLC Study On Pralsetinib,opinion,Blueprint Medicines Corporation   NASDAQ BPMC   announced top line data from a phase I II study on its investigational precision therapy pralsetinib  which is being developed for addressing previously treated patients with receptor tyrosine RET fusion non small cell lung cancer  NSCLC   The ARROW study evaluated once daily oral  pralsetinib in 80 patients with RET fusion positive NSCLC who received prior treatment with platinum based chemotherapy Data from the study showed that treatment with pralsetinib led to an objective response rate  ORR  of 61  and prolonged durability in the given patient population  95  of patients had tumor shrinkage with 14  experiencing complete regression of target tumors  However  the median duration of response  DOR  was not reached The study evaluated 26 patients with treatment na ve RET fusion positive NSCLC  Per independent central review  the ORR was 73  with 12  patients achieving a complete response  Importantly  all the patients showed tumor shrinkage Along with announcing the top line data from the ARROW study  Blueprint Medicines initiated the rolling submission of new drug application  NDA  to the FDA for pralsetinib to address the RET fusion positive NSCLC indication  Notably  pralsetinib is also being studied for RET mutant medullary thyroid carcinoma  MTC   The company plans to complete the NDA submission for pralsetinib in the first quarter of 2020 to treat NSCLC while the same for the MTC indication is expected to be filed in the second quarter Additionally  Blueprint Medicines plans to begin a phase III AcceleRET Lung study on pralsetinib for treating patients with first line RET fusion positive NSCLC later this month  The study will evaluate the potential of pralsetinib to extend progression free survival  PFS  compared to the platinum based chemotherapy with or without Merck s   NYSE MRK   anti PD 1 therapy Keytruda  pembrolizumab  Shares of Blueprint Medicines have rallied 24 9  in the past year against the  decline of 4 2  We remind investors that Blueprint Medicines  lead pipeline candidate avapritinib  an inhibitor of KIT and PDGFRA proteins  is being evaluated in several late stage studies for cancer indications In August 2019  the FDA accepted the new drug application  NDA  for avapritinib to treat patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors  GIST  regardless of any earlier therapy  and the fourth line GIST   The FDA has set an action date of Feb 14  2020 for both indications Currently  Blueprint Medicines has no approved product in its portfolio  Revenues generated by the company are drawn from its partnerships with Roche   OTC RHHBY   and CStone Pharmaceuticals for the development of its pipeline candidates  Therefore  a potential nod to avapritinib will lower the company s excessive dependence on its partners for revenues and help boost its growth prospects Zacks Rank   Key PickBlueprint Medicines currently carries a Zacks Rank  3  Hold   A better ranked stock in the biotech sector is Emergent Biosolutions Inc    NYSE EBS    which sports a Zacks Rank  1  Strong Buy   You can see  Emergent s earnings estimates have moved 5 6  north for 2020 over the past 60 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/blueprint-medicines-posts-data-from-nsclc-study-on-pralsetinib-200497626,200497626
202575,424091,MRK,Nektar Up 25  As Bristol Myers Expands Bempeg Collaboration ,opinion,"Nektar Therapeutics   NASDAQ NKTR   announced a revision to its strategic collaboration agreement related to development of bempegaldesleukin  bempeg  with pharma giant Bristol Myers   NYSE BMY    The companies have agreed to a new joint development plan  per which they plan to initiate new registrational studies to evaluate bempeg in combination with Bristol Meyrs  PD 1 inhibitor  Opdivo  as a treatment for adjuvant melanoma and muscle invasive bladder cancer Shares of Nektar surged nearly 25  on Jan 10 following the announcement as the new deal suggests Bristol Myers  confidence in the combination regimen  However  the company s shares are down 35 2  in the past year against the  s increase of 0 7  Per the previous agreement  the companies are already conducting three registrational studies evaluating bempeg Opdivo immunotherapy regimen as a first line treatment for metastatic melanoma  cisplatin ineligible metastatic urothelial cancer and metastatic renal cell carcinoma   RCC    The companies will evaluate the combination regimen in adjuvant melanoma and muscle invasive bladder cancer  per the new deal  Data from the registrational studies can support regulatory submission seeking approval for the regimen Moreover  Bristol Myers will separately fund and conduct a phase I II study  evaluating the combination regimen  under the new deal terms  It will be a dose optimization study  followed by an expansion study in patients with non small cell lung cancer in the first line setting Bristol Myers stated that it may continue to expand the ongoing registrational program to include new indications  The company is also committed to develop new bempeg combination regimens  which may include collaboration deals with other companies to develop bempeg based regimens in indications not covered under the deal with Nektar Apart from new registrational studies  Bristol Myers and Nektar also plan to conduct a new phase I II study for evaluation of bempeg plus Opdivo in combination with Pfizer s   NYSE PFE   kidney cancer drug  Inlyta  axitinib   in treatment naive RCC patients Successful development of bempeg plus Opdivo regimen in first line setting for multiple cancer indications will certainly increase prospects for both Nektar and Bristol Myers  However  the immunotherapy segment is attracting significant interest from new players along with pharma companies who have established drugs  Merck s   NYSE MRK   Keytruda  Roche s Tecentriq  Pfizer s Bavencio and Opdivo are leading drugs in this segment Nektar Therapeutics Price
    Zacks RankNektar currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/nektar-up-25-as-bristolmyers-expands-bempeg-collaboration-200498292,200498292
202576,424092,MRK,AstraZeneca To End Phase III Study On Fish Oil Heart Drug,opinion,AstraZeneca plc   NYSE AZN   announced plans to discontinue a late stage outcomes study evaluating its cholesterol medicine  Epanova to reduce the risk of cardiovascular disease in patients with mixed dyslipidaemia  MDL  or high triglyceride  TG  levels The decision to stop the STRENGTH study was taken based on the recommendation of an independent Data Monitoring Committee as it was unlikely to demonstrate a benefit to patientsEpanova  a fish oil derived tablet  is presently marketed in the United States as an adjunct to diet to reduce TG levels in adult patients with severe hypertriglyceridemia  If the STRENGTH study would have been successful and Epanova was subsequently approved for the CV indication  it would have broadened the drug s label and made it eligible to treat an expanded patient population and thereby bring in higher sales AstraZeneca said it would take a charge of up to  100 million related to inventories  which will hurt its earnings in the fourth quarter Shares of AstraZeneca have rallied 37 6  in the past year compared with the  s increase of 13 2    Meanwhile  another company  Acasti Pharma   NASDAQ ACST   announced that a phase III study evaluating its krill oil derived candidate CaPre for the treatment of severe hypertriglyceridemia failed to reach statistical significance for the primary endpoint of reducing triglycerides by 20   Acasti s stock plummeted 65  on Monday in response  However  gaining from AstraZeneca and Acasti s failures  shares of Amarin Corporation   NASDAQ AMRN   were up 4 2  on Monday as its fish oil derived drug Vascepa was approved to lower CV risk in patients with high triglyceride levels late last year In a separate press release  AstraZeneca and partner Merck   NYSE MRK   announced that the FDA has granted priority review to a supplemental new drug application  sNDA  for their PARP inhibitor Lynparza  The sNDA is seeking approval of Lynparza as a first line maintenance treatment in women suffering from advanced ovarian cancer regardless of their biomarker status or surgical outcome  The sNDA is based on data from the PAOLA 1 study  With the FDA granting priority review  a decision is expected in the second quarter of 2020  Lynparza is already approved as a first line maintenance treatment for patients with BRCA mutated advanced ovarian cancer  based on the SOLO 1 study AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-to-end-phase-iii-study-on-fish-oil-heart-drug-200498670,200498670
202577,424093,MRK,BioLineRx s Pancreatic Cancer Drug Gets Orphan Drug Tag In EU,opinion,BioLineRx Ltd    NASDAQ BLRX   announced that the European Commission  EC  has granted an orphan drug designation to its lead oncology program Motixafortide  BL 8040  for the treatment of pancreatic cancer  The candidate  a CXCR4 inhibitor  is currently being evaluated in a phase IIa study in combination with Merck s   NYSE MRK   PD L1 inhibitor Keytruda  pembrolizumab  and chemotherapy for addressing the given indication The prestigious tag for Motixafortide was based on a positive opinion from the European Medicines Agency s  EMA  Committee for Orphan Medicinal Products  COMP   The candidate already received the same status in the United States from the FDA for treating pancreatic cancer The EMA usually grants orphan medicinal product status to drugs that target serious or life threatening conditions which are being developed to treat  prevent or diagnose diseases or conditions affecting not more than five in 10 000 people in the region  In addition to providing BioLineRx with certain benefits and incentives  this status will allow Motixafortide to enjoy a period of market exclusivity in the EU  if approved Shares of BioLineRx were up 3 4  following this news on Tuesday  However  the stock has plunged 73 1  in the past year against the rise of 1 4  Last month  BioLineRx reported encouraging initial data from the triple combination arm of the ongoing phase IIa COMBAT KEYNOTE 202 study on Motixafortide for treating second line metastatic pancreatic cancer  This served as the basis for the orphan drug tag Moreover  BioLineRx has a collaboration agreement with Genentech  a unit of Roche   OTC RHHBY   for evaluating Motixafortide in combination with Tecentriq  atezolizumab  in two phase Ib II studies for solid tumor Meanwhile  Motixafortide is being investigated in a phase IIb study in consolidation acute myeloid leukemia  AML  and in a phase III study on stem cell mobilization for autologous bone marrow transplantation Zacks Rank   Key PickBioLineRx currently carries a Zacks Rank  3  Hold   A better ranked stock in the same sector is Karyopharm Therapeutics Inc    NASDAQ KPTI    sporting a Zacks Rank  1  Strong Buy   You can see  Karyopharm s loss per share estimates have narrowed 0 5  for 2020 over the past 60 days  The stock has soared 81 7  in the past year Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/biolinerxs-pancreatic-cancer-drug-gets-orphan-drug-tag-in-eu-200498981,200498981
202585,424101,MRK,AstraZeneca s Lynparza Gets FDA Nod For Pancreatic Cancer,opinion,"AstraZeneca   NYSE AZN   and Merck   NYSE MRK   announced that the FDA has approved their PARP inhibitor  Lynparza  as maintenance treatment for BRCA mutated  gBRCAm  metastatic pancreatic adenocarcinoma  pancreatic cancer  in patients whose disease has progressed at least 16 weeks following first line platinum based chemotherapy regimen  Patients will be selected based on an FDA approved companion diagnostic for Lynparza With this approval  Lynparza becomes the first PARP inhibitor to be approved for treating biomarker selected patients with advanced pancreatic cancer  The decision was expected as the FDA Oncologic Drugs Advisory Committee had recommended the approval earlier this month  The drug is under review in Europe for similar indication  with a decision expected in the first half of 2020 Lynparza is already approved for multiple indications in advanced ovarian cancer and metastatic breast cancer Shares of AstraZeneca have rallied 31 7  in the past year compared with the  s increase of 12  The recent approval for Lynparza in pancreatic cancer was based on positive data from the phase III POLO study  Data from the study showed that treatment with Lynparza tablets  300mg twice daily  led to statistically significant and clinically meaningful improvement in the primary endpoint of progression free survival compared to placebo  Patients treated with Lynparza achieved a 47  reduction in risk of disease progression or death compared to placebo Per the press release  460 000 new patients were diagnosed with pancreatic cancer globally in 2018  Most patients are diagnosed with the disease at metastatic stage  Current treatment options mostly include surgery  chemotherapy and radiotherapy  which represent a significant opportunity for Lynparza In the first nine months  sales from the drug grew 93  year over year to  847 million on the back of several label expansions  especially first line ovarian cancer  AstraZeneca expects it to reach blockbuster status this year The drug is also being evaluated in different studies for a range of tumor types including prostate and gastric cancers as well as earlier line settings for breast cancer Other FDA approved PARP inhibitors include Clovis Oncology s Rubraca  Glaxo s   NYSE GSK   Zejula and Pfizer s   NYSE PFE   Talzenna  Lynparza enjoys advantage in the PARP inhibitor segment as it is approved for the most number of oncology indications AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-12-30,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-lynparza-gets-fda-nod-for-pancreatic-cancer-200495662,200495662
202586,424102,MRK,Pfizer Merck KGaA s Bavencio Positive In Bladder Cancer Study,opinion,"Pfizer Inc    NYSE PFE   along with Germany based partner Merck KGaA announced positive data from interim analysis of a phase III study evaluating their PD L1 inhibitor Bavencio  avelumab   The JAVELIN Bladder 100 study is evaluating Bavencio plus best supportive care   BSC   as a first line maintenance therapy  following induction chemotherapy in patients with locally advanced metastatic urothelial carcinoma  a form of bladder cancer    UC   compared to BSC alone  The study met its primary endpoint of overall survival   OS   Interim data from the study showed that patients in the Bavencio arm achieved statistically significant improvement in OS compared to patients receiving BSC alone  current standard of care  Pfizer stated in the press release that Bavencio becomes the first immunotherapy to significantly prolong OS as first line maintenance treatment for advanced urothelial carcinoma  Detailed data from study will be presented at any upcoming medical congress and submitted to the FDA for approval In 2017  Bavnecio had received accelerated approval in the United States as a treatment for locally advanced or metastatic UC with disease progression on or after platinum containing chemotherapy or who had disease progression within 12 months of treatment with a platinum containing neoadjuvant or adjuvant chemotherapy regimen  Data from the JAVELIN Bladder 100 study will also support Bavencio s continued approval in the indication Shares of Pfizer have decreased 10 1  in the past year against the  s rise of 12 2   Notably  Bavencio is one of the key candidates in Pfizer s oncology pipeline  Per the company  the Bavencio development program  known as JAVELIN  involves more than 10 000 patients currently being investigated across 15 tumor types including head and neck  non small cell lung  urothelial and others  Although Bavencio is currently approved for three relatively smaller indications  it might emerge as a key long term growth driver for Pfizer on future label expansion approvals Bavencio had a mixed 2019  While the drug failed in two clinical studies evaluating it in  and  cancer  it was approved by the FDA for treating  cancer in combination with Pfizer s Inlyta Bavencio faces stiff competition from other approved PD L1 inhibitors in the market  such as Merck s   NYSE MRK   blockbuster drug Keytruda  pembrolizumab   Bristol Myers    NYSE BMY   Opdivo  nivolumab  and AstraZeneca s   NYSE AZN   Imfinzi  durvalumab  Pfizer Inc  Price
    Zacks RankPfizer currently carries a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2020-01-06,Zacks Investment Research,https://www.investing.com/analysis/pfizermerck-kgaas-bavencio-positive-in-bladder-cancer-study-200496985,200496985
202587,424103,MRK,Exelixis To Expand Prostate Cancer Cohort Of Cabometyx Study ,opinion,Exelixis  Inc    NASDAQ EXEL   announced that it plans to further expand the metastatic castration resistant prostate cancer  CRPC  cohort of the phase Ib study  COSMIC 021 The trial is evaluating the combination of lead drug Cabometyx and Roche s   OTC RHHBY   Tecentriq in patients with locally advanced or metastatic solid tumors The decision to expand the cohort was based on continued encouraging efficacy and safety data  The cohort  which was previously expanded from 30 to 80 patients in July 2019  will now include up to 130 patients The expansion of the cohort by an additional 50 patients will enable Exelixis to further document how the combination will benefit this patient population  as the company is evaluating its potential regulatory plans for the combination and preparing to initiate a phase III study  An additional 50 patients with metastatic CRPC  130 total   who have histologically or cytologically confirmed adenocarcinoma of the prostate  are being enrolled in the study We note that COSMIC 021 is a multicenter  phase Ib  open label study that is divided into two parts   a dose escalation phase and an expansion cohort phase  The dose escalation phase of the study determined the optimal dose of Cabometyx to be 40 mg daily when given in combination with Tecentriq  1200 mg infusion once every 3 weeks   The study includes 24 cohorts and aims to enroll up to 1 732 patients with advanced or metastatic solid tumors  including CRPC  renal cell carcinoma  RCC   hepatocellular carcinoma  HCC   non small cell lung cancer  NSCLC   colorectal cancer  ovarian cancer and urothelial carcinoma  UC   among others  The primary objective in the expansion stage of this trial is to determine the objective response rate in each cohort The company s shares have lost 19 8  in the past year compared with the  s decline of 2 2   Cabometyx tablets are already approved in the United States for the treatment of patients with advanced RCC and those with HCC  who have been previously treated with Bayer   OTC BAYRY   s Nexavar The label expansion of the drug will further boost sales  However  competition is stiff from the recently approved combination therapies for RCC  The FDA has approved Merck s   NYSE MRK   Keytruda in combination with Inlyta for the first line treatment of patients with advanced RCC Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan in 2016  In 2017  the company granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan Exelixis currently carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-07,Zacks Investment Research,https://www.investing.com/analysis/exelixis-to-expand-prostate-cancer-cohort-of-cabometyx-study-200497230,200497230
202600,424116,MRK,Reuters asks judge to release secret Propecia documents,news,"By Dan Levine SAN FRANCISCO  Reuters    Reuters asked a U S  judge on Thursday to unseal documents filed in court regarding potential risks associated with Propecia  Merck   Co s popular baldness drug   The motion was filed in federal court in Brooklyn  New York  after a Reuters article on Wednesday revealed accusations that Merck did not fully disclose on Propecia s label the incidence and duration of sexual dysfunction in men who took Propecia in clinical trials  Those allegations are contained in court filings that had been intended to be filed under seal  Read the Reuters report  Federal District Judge Brian Cogan has allowed Merck to keep secret internal company documents in litigation brought by Propecia users against the company  A faulty redaction allowed Reuters to view some of the details in a plaintiff s brief  but the underlying Merck documents cited in that brief are still sealed  Those are the documents the Reuters motion seeks to make public    This is a case of tremendous importance that has been sealed without on the record findings explaining that sealing   Reuters argued in its motion to intervene in the case   The First Amendment precludes such an outcome    Merck did not respond to a request for comment  The company previously told Reuters it  stands behind the safety and efficacy of Propecia  and noted that the drug has been prescribed safely to millions of men since the late 1990s   A June 25 Reuters investigation revealed how judges have allowed the makers of dozens of consumer products to file under seal in their courts information that is pertinent to public health and safety  They often do so without explanation  though in most jurisdictions  they are required to provide one  Read the Reuters investigation  The investigation found that hundreds of thousands of Americans have been killed or seriously injured over the past couple of decades by allegedly defective products    drugs  cars  medical devices and other products    while evidence that could have alerted consumers and regulators to potential danger remained under seal   More than 1 100 Propecia related lawsuits filed across the U S  against Merck were consolidated before Judge Cogan in so called multidistrict litigation  MDL   Merck agreed to settle most of them last year for  4 3 million  to be divided among the plaintiffs  Prior to the settlement  plaintiffs  lawyers cited internal company communications to allege that in revisions to the drug s original label  Merck understated the number of men who experienced sexual symptoms in clinical trials  and how long those symptoms lasted  Merck settled before responding to the allegation in court   Under U S  law  court filings are presumed to be public  and the bar for secrecy is particularly high for the Propecia documents Reuters seeks to unseal  the motion states  because they are essential to plaintiffs  claim that the drug causes persistent sexual side effects   
 These documents should not remain under seal absent the most compelling reasons   Reuters argued  Read the Reuters motion ",2019-09-12,Reuters,https://www.investing.com/news/stock-market-news/reuters-asks-judge-to-release-secret-propecia-documents-1976939,1976939
202601,424117,MRK,Bristol Myers  Revlimid Combo Gets EU Nod For New Indication,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that the European Commission  EC  has approved a new indication for Revlimid  lenalidomide  in combination with Roche s Rituxan  rituximab  for the treatmentof adult patients with previously treated follicular lymphoma  FL  The approval of Revlimid and Rituxan  R2  was mainly based on results from the phase III AUGMENT study  which evaluated the efficacy and safety of the combination versus Rituxan plus placebo in patients with previously treated FL  Per the study  patients treated with R2 showed statistically significant improvement in the primary endpoint of progression free survival  PFS   as evaluated by an independent review committee  compared with Rituxan plus placebo In addition to AUGMENT  findings from the MAGNIFY study were included to support the safety and efficacy data on Revlimid plus rituximab in patients with relapsed or refractory FL  including the rituximab refractory FL patients Bristol Myers  stock has rallied 85 6  year to date compared with the  s growth of 9 1  We remind investors that R  received approval for previously treated FL and previously treated marginal zone lymphoma in May  It was the first FDA approved combination treatment regimen for patients with these indolent forms of non Hodgkin s lymphoma  NHL  that does not include chemotherapy Revlimid is approved for the treatment of multiple myeloma  It is also approved for the treatment of patients with mantle cell lymphoma  MCL   whose disease has relapsed or progressed after two prior therapies The drug was added to Bristol Myers  portfolio after it acquired Celgene  NASDAQ CELG   Bristol Myers Squibb Company Price    Zacks Rank   Other Stocks to ConsiderBristol Myers currently has a Zacks Rank  2  Buy  A few similar ranked stocks in the large cap pharma sector are GlaxoSmithKline plc    NYSE GSK     Pfizer Inc    NYSE PFE   and Merck   Co  Inc    NYSE MRK    You can see  GlaxoSmithKline s earnings per share estimates have increased from  3 00 to  3 25 for 2019 and from  2 99 to  3 11 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 17 23   on average Pfizer s earnings per share estimates have increased from  2 81 to  2 96 for 2019 and from  2 52 to  2 59 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 8 73   on average Merck s earnings per share estimates have increased from  4 90 to  5 15 for 2019 and from  5 35 to  5 49 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 51   on average Just Released  Zacks  7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year  These 7 were selected because of their superior potential for immediate breakout ,2019-12-22,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-revlimid-combo-gets-eu-nod-for-new-indication-200494440,200494440
202602,424118,MRK,AstraZeneca Gets FDA Nod For New Breast Cancer Drug Enhertu,opinion,"AstraZeneca   NYSE AZN   and its Japan based partner Daiichi Sankyo Company announced that the FDA has granted accelerated approval to their antibody drug conjugate candidate  trastuzumab deruxtecan for metatstaic breast cancer  The drug will be available as monotherapy for unresectable or metastatic HER2 positive breast cancer in patients who have received two or more prior anti HER2 based regimens in the metastatic setting  The drug will be marketed by the trade name of Enhertu The approval to Enhertu came much earlier than expected  It is the first approval for the antibody drug conjugate in any indication  In October  the FDA had granted priority review to the biologics license application seeking approval for Enhertu  A decision was expected in the second quarter of 2020  Earlier than expected approval for the drug was presumably due to impressive results in a clinical study The approval was based on data from registrational phase II DESTINY Breast01  which evaluated Enhertu in HER2 positive unresectable and or metastatic breast cancer patients who have received prior treatment with Roche s   OTC RHHBY   Herceptin  trastuzumab   Kadcyla  trastuzumab emtansine  or Perjeta  pertuzumab   Data from the study showed that 60 3  of the patients treated with Enhertu achieved confirmed objective response rate  While 4 3  patients achieved complete response  56  patients had partial response  The patients also achieved a median progression free survival of 16 4 months We remind investors that AstraZeneca acquired joint development and commercialization rights to this promising cancer candidate from Japan s Daiichi Sankyo in April this year for approximately  6 9 billion  AstraZeneca will have to pay  125 million in milestone payment to Daiichi Sankyo  following the approval  Following the launch of Enhertu  Daiichi Sankyo will recognize future sales of the drug and AstraZeneca will report its share of gross profit margin from the sales in the United States as collaboration revenues The drug is currently under review in Japan  Apart from breast cancer  trastuzumab deruxtecan is also being developed to treat other HER2 expressing cancers including gastric cancer  advanced colorectal cancer and lung cancer AstraZeneca s stock has rallied 32 8  this year so far compared with the  s rise of 11 8    In a separate press release  AstraZeneca announced that it has agreed to divest commercial rights to breast cancer drug  Arimidex  and prostate cancer drug  Casodex  in a number of European  African and other countries to French company  Juvise Pharmaceuticals for  181 million upfront payment  The company has lost compound patent protection for these drugs in these regions  The divestment is a part of the company s broader strategy of reducing itsportfolio of mature medicines to reallocate resources towards developing the pipeline of new medicines  It had divested its rights to these drugs in the United States in 2017 AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   Some better ranked large cap drug stocks are GlaxoSmithKline   NYSE GSK   and Merck   NYSE MRK    Both the companies carry a Zacks Rank  2  Buy   You can see  Glaxo s shares have risen 23 8  this year so far  Its earnings estimates for 2020 have gone up 4  in the past 60 days Merck s shares have gained 19 9  this year  Its earnings estimates have increased 2 6  for 2019 over the past 60 days Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2019-12-22,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-gets-fda-nod-for-new-breast-cancer-drug-enhertu-200494429,200494429
202603,424119,MRK,ImmunoGen Lead Drug Gets Nod For Accelerated Approval Pathway  Revised ,opinion,"ImmunoGen  Inc    NASDAQ IMGN   announced that the FDA has advised to conduct a new single arm pivotal study  which can support accelerated approval for its lead candidate  mirvetuximab soravtansine  in ovarian cancer  We note that the FDA had recommended a new monotherapy study on the candidate in May  following the failure of phase III study   FORWARD 1 Based on the FDA s guidance  the company is planning to initiate a pivotal study  SORAYA  in patients with platinum resistant ovarian cancer whose tumors express high levels of FR alpha and who have received prior treatment with Roche s   OTC RHHBY   Avastin  bevacizumab   The company is expected to start enrolling patients in the SORAYA study by the next quarter  with top line data expected to be available by mid 2021  The company is anticipating to file a regulatory application in the second half of 2021  seeking accelerated approval for mirvetuximab soravtansine  if the study is completed successfully Shares of ImmunoGen gained 18 8  on Dec 17 following the announcement  Investors cheered the news as a single arm  pivotal study is likely to reduce the time to get an approval for mirvetuximab soravtansine   The company s shares have gained 13 8  so far this year compared with the  s increase of 13 2   Please note that the company announced in March that its FORWARD 1 study failed to meet the primary endpoint of progression free survival   PFS    The FORWARD 1 study evaluated the efficacy of mirvetuximab soravtansine as a single agent therapy compared to chemotherapy for the treatment of patients with platinum resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens  However  the overall response rate   ORR   for the candidate was higher tin the study compared to patients who were treated with chemotherapy The SORAYA study will evaluate the candidate in patients with platinum resistant ovarian cancer whose tumors express high levels of FR  and have received up to three prior treatments  including at least one with Avastin  However  the primary endpoint of the study will be ORR instead of PFS as in FORWARD 1 study Meanwhile  the company stated on its third quarter earnings call that it has met with the FDA to review the design of a phase III study   MIRASOL   which will compare mirvetuximab soravtansine head to head with single agent chemotherapy in platinum resistant ovarian cancer patients with high folate receptor alpha expression  The company expects to initiate enrollment in the study by the year end  It is planning to use this study as a confirmatory study  which will support continued approval for mirvetuximab soravtansine  if it gets accelerated approval based on SORAYA study data  Top line data from MIRASOL study is anticipated in the first half of 2022 A phase Ib II FORWARD II study is evaluating mirvetuximab soravtansine in combination with Avastin or Merck s   NYSE MRK   Keytruda for treating cancerous tumors especially with medium or high FR  expression levels Apart from mirvetuximab soravtansine  the company is also developing another pipeline candidate  IMGN632  in several early  to mid stage studies as monotherapy or in combination with Celgene s Vidaza or AbbVie   NYSE ABBV    Roche s Venclexta for treating acute myeloid leukemia and other oncology indications ImmunoGen  Inc  Price
    Zacks RankImmunoGen currently carries a Zacks Rank  3  Hold   You can see   We are reissuing this article to correct a mistake  The earlier article on this topic  issued on December 18  2019  should no longer be relied upon  ",2019-12-24,Zacks Investment Research,https://www.investing.com/analysis/immunogen-lead-drug-gets-nod-for-accelerated-approval-pathway-revised-200494610,200494610
202604,424120,MRK,5 Stocks From Top Ranked Industries Ready To Explode In 2020,opinion,"2019 has been a great year for Wall Street as major stock market indexes reached new highs and yielded solid returns on multiple occasions  While uncertainties surrounding the U S  China trade deal  global economic slowdown and Brexit worries were key concerns in 2019  macro economic environment is likely to improve as we enter into a new decade Business sentiments and the prospects for a number of industries seem bright  Investors are likely to see changes from various macro factors  which include expected easing in monetary policy  rebound in oil markets and improving outlook in Europe The U S  China trade deal will continue to play a major role in 2020  The completion of the phase one of the deal is likely to improve business sentiments and expected to serve as a fundamental catalyst for global markets  The deal is expected to drive equity markets and will position the global economy on a growth trajectory After cutting its benchmark rates for the third time in October 2019  the U S  Federal Reserve kept interest rates unchanged in its December meeting  Also  the central bank signaled that it may leave the rates on hold through next year  The Fed s move augurs well for consumer confidence and expansion of economic activities in 2020 Most importantly  the U S  economy remains fundamentally stable  Courtesy of increasing consumer confidence  lower unemployment level and gradual wage growth  the economy and stock markets are well poised for growth in 2020 Top Ranked Industries Poised to Grow in 2020A favorable job scenario  high consumer sentiment and easing monetary policy provides additional upside to a fundamentally sound U S  economy  The momentum in the equity markets is also expected to continue next year Given these factors  it will be prudent for investors to add a few stocks in the portfolio that are fundamentally strong and belong to top ranked industries  This is important because a rising tide will elevate all boats in an industry  as positive developments in the industry are likely to boost stocks across the board We have employed the  to filter five stocks from top ranked industries  top 10   that are poised to perform well in 2020  Our back testing shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than two to one Moreover  we have refined the screening to include our  to single out the stocks that can potentially beat the market  Our research shows that stocks with a  of A or B when combined with a Zacks Rank  1  Strong Buy  or  2  Buy   offer the best upside potential  You can see  Lastly  we targeted the stocks whose Zacks Consensus Estimate for 2020 earnings have been moving up lately Our Key PicksFUJIFILM Holdings Corporation   OTC FUJIY     The Tokyo based company is a leading global producer of photographic imaging products  healthcare and document solutions  It belongs to the  industry  which currently ranks 1 out of more than 250 industries  The stock currently sports a Zacks Rank  1 and has a VGM score of A  Earnings estimates for fiscal 2020 have jumped 7 9  in the past 60 days to  3 67 per share  The company s shares have gained 22 2  year to date Fujifilm Holdings Corp  Price and Consensus     Lithia Motors  Inc    NYSE LAD    This Medford  OR based company is one of the largest providers of personal transportation solutions in the United States  It belongs to the  industry  which ranks 8  or top 3    The stock currently sports a Zacks Rank  1 and has a VGM score of A  Earnings estimates for 2020 have jumped 4 2  in the past 60 days to  13 52 per share  The company s shares have surged 94 5  year to date Lithia Motors  Inc  Price and Consensus     Merck   Co   Inc    NYSE MRK    The Kenilworth  NJ based leading global biopharmaceutical company belongs to the  industry  which currently ranks 14  or Top 6    The stock currently carries a Zacks Rank  2 and has a VGM score of A  Earnings estimates for 2020 have inched up 0 9  in the past 60 days to  5 49 per share  The company s shares have gained 19 7  year to date  Merck   Co   Inc  Price and Consensus     
Sally Beauty Holdings  Inc    NYSE SBH    The Denton  TX based company is an international specialty retailer and distributor of professional beauty products  It belongs to the  industry  which currently ranks 25  or Top 10    The stock currently sports a Zacks Rank  1 and has a VGM score of B  Earnings estimates for fiscal 2020 rose 6 9  in the past 60 days to  2 33 per share  The company s shares have gained 6  year to date Sally Beauty Holdings  Inc  Price and Consensus     
Acushnet Holdings Corp    NYSE GOLF    The Fairhaven  MA based company is a global leader in the designing  developing  manufacturing and distributing performance driven golf products  It belongs to the  industry  which currently ranks 12  or Top 5    The stock currently carries a Zacks Rank  2 and has a VGM score of A  Earnings estimates for 2020 rose 2 4  in the past 60 days to  1 69 per share  The company s shares have gained 54 6  year to date Acushnet Holdings Corp  Price and Consensus     
Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 top tickers for the entirety of 2020 These 10 are painstakingly hand picked from over 4 000 companies covered by the Zacks Rank  They are our primary picks to buy and hold ",2019-12-29,Zacks Investment Research,https://www.investing.com/analysis/5-stocks-from-topranked-industries-ready-to-explode-in-2020-200495429,200495429
202618,424134,MRK,Bayer could benefit from home advantage in St  Louis Roundup cancer trial  experts,news,By Tina Bellon ST  LOUIS  Reuters     Bayer AG   DE BAYGn   facing an upcoming trial in St  Louis over allegations that its Roundup weed killer causes cancer  has recruited Missouri based expert witnesses to make its case in a place where it has century old roots but where juries often hit companies with huge damages  Four expert witnesses Bayer is seeking to admit hail from Missouri universities  and some legal experts said the company is trying to clinch its first favorable Roundup verdict by emphasizing its reputation as a major local employer   Bayer on Tuesday announced it would create an additional 500  high paying  jobs in the St  Louis area  The Bayer unit that makes the glyphosate based herbicide  the former  Monsanto   NYSE MON  Co  was founded in St  Louis in 1901  Monsanto employed 5 400 full time employees in the St  Louis area as of May 2018  according to company statements  The trial in St  Louis County Circuit Court  expected to begin on Aug  19  was brought by Illinois resident Sharlean Gordon  who says she was diagnosed with non Hodgkin s lymphoma after using Roundup for around 14 years at her home  It is the fourth trial over Roundup and the first one outside of California  where three juries hit Bayer with verdicts as large as  2 billion  Bayer is appealing those verdicts   Bayer denies glyphosate or Roundup cause cancer  saying decades of studies have shown glyphosate to be safe  The company said it looked forward to presenting the scientific evidence to juries  It said the experts in the upcoming St  Louis trial are at the top of their field and were selected for their expertise  not their Missouri ties  The Germany based company has lost nearly 40 billion euros   33 75 billion  in market valuation since the first Roundup jury verdict in August 2018  Bayer last month announced it had set up a committee to help resolve the litigation  saying it would  constructively engage  in court mandated mediation talks  NEW WITNESSES Bayer has said in court papers and hearings that juries in California s traditionally liberal Bay Area  where the first three trials took place  were unfairly influenced by news coverage of the trials and harbored negative attitudes toward Monsanto in part because of its development of genetically modified seeds  The company s experts in those cases came mostly from states other than California  In the St  Louis trial  Bayer is so far seeking to admit a total of 14 scientific expert witnesses  None previously testified in the Roundup litigation   Of the more than 13 400 Roundup claims nationwide that have yet to go to trial  about 75  have been filed in St  Louis city or county courts  according to plaintiffs  lawyers  Those courts have a history of issuing large punitive damages against companies and have often been criticized by business groups for issuing favorable plaintiffs rulings   By suing in the county where Bayer s crop science business is headquartered  plaintiffs can also take advantage of procedural rules allowing them to compel live testimony from executives who work locally  In the California trials  jurors only saw video depositions of Monsanto executives   David Noll  a professor at Rutgers Law School  said Bayer appeared to be hiring local experts to appeal to St  Louis jurors    They  are not seen as hired guns  flying in from afar  but     can explain the case in a way local jurors understand   Noll said  But Alexandra Lahav  a law professor at the University of Connecticut  said Bayer could simply be using new experts that the company thinks would have a better rapport with the jury and  not necessarily because the experts are local    Counting on a more favorable jury pool in a company s backyard is not a new tactic   New Jersey based Merck   Co  N MRK   which in the early 2000s faced thousands of lawsuits by patients over its Vioxx painkiller  won several trials in New Jersey  which plaintiffs lawyers at the time attributed to the company s strong ties to the state  Merck in 2013 settled some 27 000 Vioxx claims for  4 85 billion ,2019-07-22,Reuters,https://www.investing.com/news/stock-market-news/bayer-could-benefit-from-home-advantage-in-st-louis-roundup-cancer-trial-experts-1929978,1929978
202619,424135,MRK,Bristol Myers posts strong second quarter earnings as Eliquis  Orencia surprise,news,"By Michael Erman NEW YORK  Reuters    Bristol Myers Squibb Co  N BMY   which is set to buy biotechnology company  Celgene Corp   O CELG  for  74 billion  posted better than expected second quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia  Shares of the New York based drugmaker were up 4 8  at  45 30 in afternoon trading  The earnings follow mixed results released on Wednesday from a closely watched lung cancer trial of its blockbuster immunotherapy Opdivo in combination with either chemotherapy or its other immuno oncology drug  Yervoy   While some of the drug data was disappointing  there was enough positivity for the combination of Opdivo and Yervoy that would suggest there is potential for that to gain share for a longer period of time   said Jeremy Bryan  portfolio manager at Gradient Investments  Sales of Eliquis  which Bristol Myers shares with  Pfizer  Inc  N PFE   rose 24  to  2 04 billion  while Orencia sales rose 9  to  778 million  both exceeding Wall Street expectations  Opdivo sales rose 12  to  1 82 billion  Despite the solid growth for Opdivo  there has been widespread investor concern over the dominance of rival drug Keytruda from Merck   Co  N MRK  in the lucrative lung cancer market  Keytruda has surpassed Opdivo in sales in recent quarters and the company said it expects additional pressure on Opdivo sales next year  The latest lung cancer data is unlikely to allay those concerns   Opdivo combined with chemotherapy failed to extend overall survival more than chemotherapy alone as an initial treatment for advanced non squamous non small cell lung cancer  NSCLC   Keytruda plus chemotherapy has demonstrated a survival benefit in clinical trials  Opdivo did extend overall survival when used with Yervoy in certain NSCLC patients  Some analysts and investors have suggested that one reason Bristol launched its bid for Celgene was over concerns about Opdivo losing ground to Keytruda  Bristol said it still expects the Celgene deal to close in late 2019 or early 2020  Excluding one time items  the drugmaker said it earned  1 18 a share for the quarter  beating analysts  expectations by 11 cents  according to IBES data from Refinitiv  Bristol Myers increased its full year profit forecast by 10 cents and now expects to earn  4 20 to  4 30 a share   Revenue in the quarter was  6 27 billion  topping Wall Street expectations of  6 11 billion  
The company reported a net profit of  1 43 billion  or 87 cents a share  compared with  373 million  or 23 cents a share  a year earlier ",2019-07-25,Reuters,https://www.investing.com/news/stock-market-news/bristolmyers-posts-strong-second-quarter-earnings-as-eliquis-orencia-surprise-1934678,1934678
202620,424136,MRK,Merck Co Earnings  Revenue Beat in Q2,news,"Investing com   Merck Co  NYSE MRK  reported second quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 3 on revenue of  11 76B  Analysts polled by Investing com anticipated EPS of  1 16 on revenue of  10 95B  That compared to EPS of  1 06 on revenue of  10 47B in the same period a year earlier  The company had reported EPS of  1 22 on revenue of  10 82B in the previous quarter 
 
Merck Co follows other major Healthcare sector earnings this month
On July 16  J J reported second quarter EPS of  2 58 on revenue of  20 56B  compared to forecasts of EPS of  2 46 on revenue of  20 29B 
Novartis ADR earnings beat analysts  expectations on July 18  with second quarter EPS of  1 34 on revenue of  11 76B  Investing com analysts expected EPS of  1 21 on revenue of  11 49B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-07-30,Investing.com,https://www.investing.com/news/stock-market-news/merckco-earnings-revenue-beat-in-q2-1938660,1938660
202621,424137,MRK,Pfizer s Xtandi Gets FDA Nod For Expanded Patient Group,opinion,Pfizer  Inc    NYSE PFE   and partner Astellas announced that the FDA has approved its supplemental new drug application  sNDA  looking for label expansion of its cancer drug  Xtandi in men with metastatic castration sensitive prostate cancer  mCSPC  Until now  Xtandi was approved to treat metastatic and non metastatic castration resistant prostate cancer  With data from ARCHES study approved to be included in the label of Xtandi  it can treat a broader prostate cancer patient population  Xtandi is now approved for three indications in advanced prostate cancer   non metastatic and metastatic CRPC and mCSPC mCSPC is a form of prostate cancer that has spread to other parts of the body but still  responds to a medical or surgical treatment to lower testosterone levels The sNDA was based on data from the phase III ARCHES study  data from which demonstrated that Xtandi in combination with androgen deprivation therapy   ADT   significantly reduced the risk of radiographic progression or death by 61  compared to ADT alone  The sNDA is also supported by data from an Astellas supported study  ENZAMET  which also met the primary endpoint of overall survival  A similar application is also under review in the EU and Japan Xtandi was added to Pfizer s portfolio with the acquisition of Medivation in September 2016  While Pfizer sells Xtandi in the United States in partnership with Astellas  the latter owns the marketing right outside the U S  markets  Pfizer recorded Xtandi alliance revenues of  594 million in the first nine months of 2019 In a separate press release  the board of directors of Pfizer declared a dividend of 38 cents per share for first quarter of 2020  The quarterly dividend amounts to an annual dividend of  1 52 per share  which represents an increase of almost 6  from the previous annual dividend of  1 44 per share  quarterly dividend of 36 cents   The dividend is payable on Mar 6  2020 to shareholders of record at the close of business on Jan 31  2020 Pfizer s shares were up more than 2  on Monday  in response to the positive news  Pfizer s shares have declined 10 4  this year so far against an increase of 8 9  for the    Pfizer currently carries a Zacks Rank  2  Buy   Some other top ranked large cap pharma stocks are Roche Holding  SIX ROG  AG   OTC RHHBY    Bristol Myers   NYSE BMY   and Merck   NYSE MRK    all with a Zacks Rank  2  You can see  Shares of Roche have gained 24 2  this year so far  Earnings estimates for 2019 have risen 0 8  while that for 2020 have increased 1 2  over the past 60 days Bristol Myers  earnings estimates have increased 4 4  and 11 8   respectively  for 2019 and 2020 over the past 60 days  The stock is up 22 1  this year so far Merck s stock is up 16 8  this year so far  Its earnings estimates have risen 5 1  for 2019 and 2 6  for 2020 over the past 60 days Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all  This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/pfizers-xtandi-gets-fda-nod-for-expanded-patient-group-200493208,200493208
202622,424138,MRK,Novartis  Asthma Candidate Fails In LUSTER Phase III Studies,opinion,Novartis AG   NYSE NVS   announced top line results from its pivotal  global  phase III LUSTER 1 and LUSTER 2 studies evaluating the efficacy and safety of the investigational oral  once daily  DP2 receptor antagonist  fevipiprant  QAW039   The studies aimed to determine the efficacy  safety and tolerability of the candidate in addition to the current standard of care in severe asthma patients  The studies included 894  LUSTER 1  and 877  LUSTER 2  patients aged above or equal to 12 years  all of whom suffer from inadequately controlled moderate severe asthma  receiving Global Initiative for Asthma  GINA  Steps 4 and 5 standard of care  SoC  asthma therapy  inhaling mid to high dose corticosteroids  ICS  and at least one additional controller The analysis of the studies showed that the candidate did not meet the clinically relevant threshold for a reduction in the rate of moderate to severe exacerbation compared to placebo over a 52 week treatment period for either of the doses  150mg   450 mg   Fevipiprant was generally well tolerated  with treatment emergent adverse events generally balanced across groups and comparable to placebo  However  the totality of these results does not support further development of fevipiprant in asthma Novartis  stock has increased 8 5  year to date compared with the  s 9 9  growth Novartis continues to invest into respiratory medicines  In  October  the company announced mixed results from the phase III IRIDIUM study on investigational  once daily  inhaled QVM149  indacaterol acetate  glycopyrronium bromide and mometasone furoate or IND GLY MF  QVM149 demonstrated statistically significant improvement in lung function as compared to QMF149  indacaterol acetate and mometasone furoate or IND MF   thereby meeting the primary endpoint in asthma patients  whose disease was uncontrolled on treatment with a long acting beta agonist inhaled corticosteroid  LABA ICS  However  the key secondary endpoint   improvement in the Asthma Control Questionnaire  ACQ 7  score for IND GLY MF versus IND MF   was not met We note that IRIDIUM is the largest study in the phase III PLATINUM clinical development program  which evaluates the inhaled combinations   QVM149 and QMF149 The company s Xolair is already approved for the treatment of moderate to severe  or severe  persistent allergic asthma  The company has a collaboration agreement with Roche   OTC RHHBY   for the same in the United States  Novartis AG Price    Zacks Rank   Stocks to ConsiderNovartis currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the large cap pharma sector are GlaxoSmithKline plc    NYSE GSK   and Merck   Co  Inc    NYSE MRK    both carrying a Zacks Rank  1  Strong Buy   You can see  GlaxoSmithKline s earnings per share estimates have increased from  3 00 to  3 17 for 2019 and from  2 99 to  3 10 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 17 23   on average Merck s earnings per share estimates have increased from  4 90 to  5 15 for 2019 and from  5 35 to  5 49 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 51   on average Free  Zacks  Single Best Stock Set to Double Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all  This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/novartis-asthma-candidate-fails-in-luster-phase-iii-studies-200493128,200493128
202623,424139,MRK,ImmunoGen Lead Drug Gets Nod For Accelerated Approval Pathway,opinion,"ImmunoGen  Inc    NASDAQ IMGN   announced that the FDA has advised to conduct a new single arm pivotal study  which can support accelerated approval for its lead candidate  mirvetuximab soravtansine  in ovarian cancer  We note that the FDA had  a new monotherapy study on the candidate in May  following the  of phase III study   FORWARD 1 Based on the FDA s guidance  the company is planning to initiate a pivotal study  SORAYA  in patients with platinum resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received prior treatment with Roche s   OTC RHHBY   Avastin  bevacizumab   The company is expected to start enrolling patients in the SORAYA study by the next quarter  with top line data expected to be available by mid 2021  The company is anticipating to file a regulatory application in the second half of 2021  seeking accelerated approval for mirvetuximab soravtansine  if the study is completed successfully Shares of ImmunoGen gained 18 8  on Dec 17 following the announcement  Investors cheered the news as a single arm  pivotal study is likely to reduce the time to get an approval for mirvetuximab soravtansine   However  the company s shares have decreased 3 7  so far this year against the  s increase of 11 8  Please note that the company announced in March that its FORWARD 1 study failed to meet the primary endpoint of progression free survival   PFS    The FORWARD 1 study evaluated the efficacy of mirvetuximab soravtansine as a single agent therapy compared to chemotherapy for the treatment of patients with platinum resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens  However  the overall response rate   ORR   for the candidate was higher tin the study compared to patients who were treated with chemotherapy The SORAYA study will evaluate the candidate in patients with platinum resistant ovarian cancer whose tumors express high levels of FR  and have received up to three prior treatments  including at least one with Avastin  However  the primary endpoint of the study will be ORR instead of PFS as in FORWARD 1 study Meanwhile  the company stated on its third quarter earnings call that it has met with the FDA to review the design of a phase III study   MIRASOL   which will compare mirvetuximab soravtansine head to head with single agent chemotherapy in platinum resistant ovarian cancer patients with high folate receptor alpha expression  The company expects to initiate enrollment in the study by the year end  It is planning to use this study as a confirmatory study  which will support continued approval for mirvetuximab soravtansine  if it gets accelerated approval based on SORAYA study data  Top line data from MIRASOL study is anticipated in the first half of 2022 A phase Ib II FORWARD II study is evaluating mirvetuximab soravtansine in combination with Avastin or Merck s   NYSE MRK   Keytruda for treating cancerous tumors especially with medium or high FR  expression levels Apart from mirvetuximab soravtansine  the company is also developing another pipeline candidate  IMGN632  in several early  to mid stage studies as monotherapy or in combination with Celgene s Vidaza or AbbVie   NYSE ABBV    Roche s Venclexta for treating acute myeloid leukemia and other oncology indications ImmunoGen  Inc  Price
    Zacks RankImmunoGen currently carries a Zacks Rank  3  Hold   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/immunogen-lead-drug-gets-nod-for-accelerated-approval-pathway-200493431,200493431
202624,424140,MRK,FDA Panel Laps Up Merck s Keytruda   Lynparza For New Maladies,opinion,Merck   Co   Inc    NYSE MRK   announced that the FDA s Oncologic Drugs Advisory Committee  ODAC  has voted  9 4  in favor of approving its blockbuster PD L1 inhibitor Keytruda for the treatment of patients with high risk  non muscle invasive bladder cancer  NMIBC   Currently  there are limited number of non surgical treatment options available for the given patient population The committee s discussions were based on the supplemental biologics license application  sBLA  for Keytruda  to which the FDA has granted a priority review earlier this month  The sBLA was based on data from the phase II KEYNOTE 057 study  Through this  the company is seeking approval of Keytruda  as a monotherapy to treat certain patients with high risk NMIBC  unresponsive to the widely used Bacillus Calmette Guerin  BCG  therapy in the management of bladder cancer With the FDA granting priority review to the sBLA  Merck expects a decision in January 2020  Notably  the regulatory agency is not bound by the committee s guidance but takes its advice into consideration Shares of Merck have rallied 16 5  so far this year compared with the  increase of 9 9  In separate press release  Merck along with partner AstraZeneca plc   NYSE AZN   announced that ODAC also voted  7 5  in favor of a nod to their PARP inhibitor Lynparza as a first line maintenance monotherapy for pancreatic cancer In August 2019  the FDA accepted and granted a priority review to the supplemental new drug application  sNDA  for Lynparza with respect to the given indication  A decision from the regulatory body is expected in the fourth quarter of this year This sNDA was based on data from the phase III POLO study  which evaluated Lynparza as maintenance monotherapy versus placebo in patients with germline BRCA mutated metastatic pancreatic cancer whose disease has not progressed for at least 16 weeks following first line platinum based chemotherapy A similar filing in the EU for use of Lynparza tablets for BRCAm pancreatic cancer is currently under review with a decision pending in the first half of 2020 Additionally  Merck announced that its Animal Health division has completed the acquisition of Vaki  a maker of fish farming and wild fish conservation monitoring equipment  from Pentair plc   NYSE PNR    The financial terms of the deal were not disclosed Zacks Rank   Another Key PickMerck currently carries a Zacks Rank  2  Buy   Another top ranked stock in the large cap pharma sector is Bristol Myers Squibb Company   NYSE BMY    which carries the same Zacks Rank as Merck  You can see  Bristol Myers  earnings estimates have been revised 4 4  upward for 2019 and 11 6  for 2020 over the past 60 days  The stock has rallied 23 4  year to date 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/fda-panel-laps-up-mercks-keytruda--lynparza-for-new-maladies-200493461,200493461
202634,424150,MRK,Sanofi  SNY  Looks Good  Stock Adds 6 2  In Session,opinion,Sanofi  PA SASY    NASDAQ SNY   was a big mover last session  as the company saw its shares rise more than 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  45 02 to  47 17 in the past one month time frame The company has seen one negative estimate revision in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So  make sure to keep an eye on this stock going forward  to see if this recent move higher can last Sanofi currently has a Zacks Rank  3  Hold  while its  is negative Sanofi Price   Investors interested in the Large Cap Pharmaceuticals industry may consider Merck   Co   Inc    NYSE MRK    which has a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Is SNY going up  Or down  Predict to see what others think Up or Down5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-12-10,Zacks Investment Research,https://www.investing.com/analysis/sanofi-sny-looks-good-stock-adds-62-in-session-200491784,200491784
202635,424151,MRK,Roche s  RHHBY  SBLA For Asthma Drug Xolair Accepted By FDA,opinion,Roche Holding  SIX ROG  AG s   OTC RHHBY   subsidiary  Genentech  announced that the FDA has accepted the supplemental Biologics License Application  sBLA  for its allergic asthma drug  Xolair  omalizumab   The sBLA is filed for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids  The FDA is expected to make a decision on the approval of the same by the third quarter of 2020   If approved  Xolair will become the first antibody to help reduce the size of nasal polyps and improve symptoms by targeting and blocking immunoglobulin E  IgE  We note that Xolair is already approved for the treatment of moderate to severe  or severe  persistent allergic asthma in people aged six years or older whose asthma symptoms are not controlled by inhaled corticosteroids  and for chronic idiopathic urticaria  CIU  in people aged 12 years or older who continue to have hives that are not controlled by H1 antihistamines  This sBLA is supported by results from the phase III POLYP 1 and POLYP 2 studies  which showed that Xolair met both co primary and multiple secondary endpoints  The drug significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps  CRSwNP  in both studies The results showed that Xolair  an injectable biologic medicine designed to target and block IgE  was well tolerated  while safety profile was consistent with that observed in previous studies in patients with moderate to severe allergic asthma and CIU  The company s shares have rallied 23 5  in the year so far compared with the  s growth of 8 0  The label expansion of the drug for this indication should boost sales  given the demand  Nasal polyps is a common and potentially debilitating condition in adults  impacting 13 million people in the United States  Roche is making efforts to expand its portfolio beyond oncology into immunology  Apart from Xolair  the company s immunology portfolio includes Actemra for rheumatoid arthritis  Rituxan for rheumatoid arthritis granulomatosis with polyangiitis  microscopic polyangiitis and pemphigus vulgaris  PV   Pulmozyme for cystic fibrosis  and Esbriet for idiopathic pulmonary fibrosis  IPF   Roche has a collaboration agreement with Novartis   NYSE NVS   for Xolair  Roche Holding AG Price    Zacks Rank   Other Stocks to ConsiderRoche currently carries a Zacks Rank  2  Buy  A few similar ranked stocks in the biotech sector are GlaxoSmithKline plc    NYSE GSK   and Merck   Co  Inc    NYSE MRK    You can see  GlaxoSmithKline s earnings per share estimates have increased from  2 98 to  3 17 for 2019 and from  3 01 to  3 10 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 17 23   on average Merck s earnings per share estimates have increased from  4 91 to  5 15 for 2019 and from  5 37 to  5 49 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 51   on average 5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth  Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-12-10,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-sbla-for-asthma-drug-xolair-accepted-by-fda-200491844,200491844
202636,424152,MRK,Sanofi  Regeneron To Amend Agreement For Kevzara   Praulent,opinion,"Sanofi  PA SASY    NASDAQ SNY   and its collaboration partner  Regeneron Pharmaceuticals   NASDAQ REGN   intend to restructure their antibody collaboration into a royalty based agreement for Kevzara  sarilumab  and Praluent  alirocumab   However  the terms of the agreement related to blockbuster drug  Dupixent  also included in the antibody collaboration  will remain unchanged Under the proposed changes to the agreement  Sanofi is likely to gain sole rights to Kevzara globally and to Praulent in ex U S  markets  Moreover  Regeneron will likely have sole U S  rights to Praluent  Global development and commercialization expenses for Kevzara will be borne by Sanofi  Regeneron will be responsible for the development and commercialization of Praulent in the United States while Sanofi will undertake such activities for the drug in ex U S  markets  The restructuring of the antibody collaboration will likely be finalized by the first quarter of 2020 Under the existing collaboration  the companies co commercialize Kevzara and Praluent in the United States while Sanofi carries out marketing of these drugs in ex U S  markets  Any late stage development costs related to label expansion of these two drugs is shared by the companies  The profit and loss on these two drugs are shared equally in the United States and in pre determined ratio in ex U S  markets Sanofi has stated that the amendment to the agreement is being done to increase efficiency and streamline operations related to Kevzara and Praulent  We expect the amendment of the collaboration agreement to a royalty based one to help Sanofi simplify monetization of these drugs  if it decides to divest rights in the future Sanofi and Regeneron also have a collaboration agreement to develop immuno oncology therapies  The amendment to the antibody collaboration is not likely to have any impact on this collaboration Sanofi s shares were up 6 2  on Dec 10 following the announcement  Shares of the company have gained 10 8  so far this year compared with the  s increase of 7 3  We note that Sanofi had hinted at monetizing its stake in Regeneron  following the expiry of the lock up period earlier this week while announcing a new  at its Capital Markets Day  We note that Sanofi held 21 7  stake in Regeneron as of Dec 31  2018 Under the new framework  the company announced that it is discontinuing all its research activities in diabetes and cardiovascular area and focusing on high growth franchises included under its Specialty Care global business units  In 2019  sales at the Specialty Care franchises grew the most with Immunology franchise leading the growth  The company has also prioritized six investigational therapies  including fitusiran  venglustat and nirsevimab  and expects these to be potentially practice changing therapies in areas of high unmet patient need Sanofi Price
    Zacks Rank   Stocks to ConsiderSanofi currently carries a Zacks Rank  3  Hold  A couple of better ranked large cap pharma stocks are Merck   Co   NYSE MRK   and Bristol Myers Squibb Company   NYSE BMY    Both companies carry a Zacks Rank  2  Buy   You can see  Merck s earnings estimates increased from  5 11 to  5 15 for 2019 and from  5 44 to  5 49 for 2020 over the past 30 days  The company delivered a positive earnings surprise in the trailing four quarters  the average beat being 12 51   Share price of the company has increased 16 6  so far this year Bristol Myers  earnings estimates increased from  4 33 to  4 38 for 2019 and from  5 30 to  5 66 for 2020 over the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  the average beat being 8 3   Share price of the company has increased 19 5  so far this year 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-12-10,Zacks Investment Research,https://www.investing.com/analysis/sanofi-regeneron-to-amend-agreement-for-kevzara--praulent-200491832,200491832
202637,424153,MRK,AstraZeneca s Imfinzi Gets China Nod For Stage III NSCLC,opinion,"AstraZeneca   NYSE AZN   announced that China s National Medical Products Administration has granted marketing authorization for its PD L1 inhibitor  Imfinzi  durvalumab   Following the approval  Imfinzi will be available for the treatment of unresectable  stage III non small cell lung cancer   NSCLC   in patients whose disease has not progressed following concurrent platinum based chemotherapy and radiation therapy   CRT   This is the first approval for Imfinzi and for any immunotherapy in this patient population in China  The drug is already approved for this patient population in 54 countries and regions  including the United States and Europe This year so far  AstraZeneca s shares have risen 26 8  compared with the  s growth of 8  The approval was based on data from the phase III PACIFIC study  which evaluated platinum based CRT followed by Imfinzi in patients with unresectable  stage III  locally advanced   regardless of PD L1 status  Imfinzi was administered in patients whose disease has not progressed following the CRT  The regimen used in the PACIFIC study has become the global standard of care for the treatment of unresectable Stage III NSCLC The latest data from the PACIFIC study  in June showed that more than half of the unresectable  stage III NSCLC patient population treated with Imfinzi was alive  following three years of treatment  The overall survival rate   OS   was 57  for patients treated with Imfinzi compared with 43 5  for placebo  Moreover  the drug was the only immunotherapy to demonstrate overall survival at three years in this patient population Imfinzi generated sales of  1 04 billion in the first nine months of 2019  up 182  year over year  mainly driven by strong demand in lung cancer patients  The approval in China is likely to boost sales further  The drug is set to achieve blockbuster status by this year Apart from the lung cancer indication  Imfinzi is also approved for second line advanced bladder cancer  The company is also evaluating the drug for multiple cancers  either alone or in combination with other regimens  including phase III trials in combination with tremelimumab in hepatocellular carcinoma  liver cancer   in earlier settings in NSCLC  small cell lung cancer  metastatic urothelial cancer and head and neck squamous cell carcinoma among others Immunotherapies are the latest trend in cancer treatment and an effective one  However  we note that the immunotherapy segment for cancer indications is getting competitive with several approved immunotherapies including Merck s   NYSE MRK   Keytruda  Bristol Myers    NYSE BMY   Opdivo and Roche s   OTC RHHBY   Tecentriq  Several other pharma companies are also developing immunotherapies in different stages on clinical studies In a separate release  AstraZeneca and its Japanese partner  Daiichi Sankyo  announced detailed data from the phase II DESTINY Breast01 study  evaluating their antibody drug conjugate candidate  trastuzumab deruxtecan  in third or late line HER2 positive metastatic breast cancer  The companies had announced successful completion of the study in May Data from the study demonstrated that patients treated with trastuzumab deruxtecan monotherapy achieved an objective response rate of 60 9   Disease control rate achieved by patients was 97 3   Median duration of response and progression free survival were 14 8 months and 16 4 months  respectively  The estimated overall survival at one year was 86  The companies are developing the candidate in five pivotal studies for several cancer indications including HER2 expressing metastatic breast and gastric cancer AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-imfinzi-gets-china-nod-for-stage-iii-nsclc-200492144,200492144
202638,424154,MRK,Roche s  RHHBY  Tecentriq Combo Succeeds In Melanoma Study,opinion,Roche   OTC RHHBY   announced that the late stage study on immuno oncology drug  Tecentriq  atezolizumab   in combination with Cotellic  cobimetinib  and Zelboraf  vemurafenib  was successful in skin cancer patients The phase III IMspire150 study compared the efficacy and safety of Tecentriq plus Cotellic and Zelboraf to the combination of placebo plus Cotellic and Zelboraf in patients with previously untreated BRAF V600 mutation positive advanced melanoma The study met its primary endpoint of progression free survival  Results from the study showed that the addition of Tecentriq to Cotellic and Zelboraf helped in the reduction of the risk of disease worsening or death compared to placebo plus Cotellic and Zelboraf The safety profile observed in IMspire150 was consistent with the known safety profiles of the individual drugs Tecentriq is approved in the United States  EU and other countries  either alone or in combination with targeted therapies and or chemotherapies in various forms of non small cell and small cell lung cancer  certain types of metastatic urothelial cancer  and in PD L1 positive metastatic triple negative breast cancer  The potential label expansion in additional indications will boost sales of the drug  which came in at CHF 1 3 billion in the first nine months of 2019 Exelixis    NASDAQ EXEL   Cotellic  in combination with Zelboraf  is already approved in the United States and Europe for the treatment of people with melanoma that has spread to other parts of the body or cannot be removed by surgery and has a BRAF V600 mutation Meanwhile  Roche has an extensive development program for Tecentriq as a monotherapy or in combination with other drugs  These include multiple phase III studies underway across different types of lung cancer  and multiple ongoing and planned phase III studies in genitourinary  skin  breast  gastrointestinal  gynecological  and head and neck cancers Last week  the drug was approved in combination with chemotherapy  Abraxane  paclitaxel protein bound  nab paclitaxel  and carboplatin  for the initial  first line  treatment of adults with metastatic  non squamous  non small cell lung cancer  NSCLC  Immuno oncology therapies like Merck s   NYSE MRK   Keytruda and Bristol Myers    NYSE BMY   Opdivo are approved for various types of skin cancer Shares of Roche have rallied 23 7  so far this year compared with the  s growth of 8 9   Roche has one of the strongest oncology portfolios  The company s efforts to develop the portfolio beyond oncology have been impressive as well Roche currently carries a Zacks Rank  2  Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-12-12,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-tecentriq-combo-succeeds-in-melanoma-study-200492403,200492403
202647,424163,MRK,Health Care  Merck Eye Bullish Breakouts,opinion,"The Health Care Select Sector SPDR ETF  NYSE XLV  has lagged the S P 500  NYSE SPY  for the past few years  Is that trend about to end  It sure could and we should find out very soon 
The above chart looks at the Health Care S P Ratio  XLV SPY   which shows that it has created a series of lower highs and lower lows inside of falling channel  1   Over the past 6 months  the ratio has seen a series of higher lows  reflecting out performance of XLV relative to the broader markets 
The ratio is testing a support resistance line at  2   If the ratio breaks out at  2   it would suggest that health care stocks will continue to outperform the broad markets 
Are any stocks in the health care field creating a bullish pattern  Absolutely 
Merck








The trend for Merck   Company  NYSE MRK  remains up  The company has  over the past few months  been looking to create a bullish ascending triangle  Two thirds of the time  this pattern leads to higher price 
Merck is attempting a bullish breakout at  1   If successful  expect it to do very well in the weeks to come ",2019-12-05,Chris Kimble,https://www.investing.com/analysis/health-care-merck-eye-bullish-breakouts-200490496,200490496
202648,424164,MRK,AstraZeneca s Lynparza Gets China Nod In First Line Setting ,opinion,"AstraZeneca Plc    NYSE AZN   and partner Merck   Co   Inc    NYSE MRK   announced that China s National Medical Products Administration   NMPA   has approved a label expansion of its PARP inhibitor  Lynparza  olaparib   The NMPA has approved Lynparza as a first line maintenance therapy for BRCA mutated  BRCAm  advanced ovarian cancer  It is the first regulatory approval for a PARP inhibitor in first line maintenance setting in China We note that Lynparza is already marketed in the United States and Europe for a similar indication  Moreover  the drug is already available in China for platinum sensitive relapsed ovarian cancer  regardless of BRCA status and germline BRCAm HER2 negative metastatic breast cancer The approval in the first line setting was based on data from the pivotal phase III SOLO 1 study  which demonstrated that Lynparza tablets led to a statistically significant and clinically meaningful improvement in progression free survival   PFS   compared to placebo in women with BRCAm advanced ovarian cancer who were in complete or partial response  following first line standard platinum based chemotherapy In the Lynparza arm  60  of the patients were progression free at 36 months compared with 27  in the placebo arm  Lynparza reduced the risk of disease progression or death by 70  compared to placebo  following response to platinum based chemotherapy This year so far  AstraZeneca s shares have risen 25 3  compared with the  s growth of 6 9  Lynparza  presently marketed for advanced ovarian cancer and breast cancer  is in different studies for a range of tumor types including prostate  pancreatic and gastric cancers as well as earlier line settings for ovarian and breast cancers AstraZeneca is developing Lynparza as a first line maintenance treatment in combination with Roche s   OTC RHHBY   Avastin  bevacizumab  in women suffering from advanced ovarian cancer regardless of their biomarker status or surgical outcome  In September  the company  data from a phase III study which demonstrated Lynparza s potential to improve PFS in this patient population Other PARP inhibitors available in the United States are Glaxo s   NYSE GSK   Zejula and Clovis Oncology s Rubraca  These companies are also looking to launch PARP inhibitors in China Meanwhile  AstraZeneca is focusing on expanding in China and will further increase its contribution to the development of healthcare in China  In November  the company announced setting up of a  1 billion fund to support domestic companies and partners in China  It is also bringing other drugs to cater to the Chinese market So far in 2019  Emerging Markets represent AstraZeneca s largest market in terms of product sales primarily driven by strong growth in China AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-lynparza-gets-china-nod-in-firstline-setting-200490693,200490693
202649,424165,MRK,Bristol Myers   BMY  Lymphoma Drug Meets Goals In Key Study,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that the TRANSCEND NHL 001 study on experimental candidate lisocabtagene maraleucel  liso cel  was successful Liso cel is an investigational chimeric antigen receptor  CAR  T cell therapy designed to target CD19  which is a surface glycoprotein expressed during normal B cell development and maintained following the malignant transformation of B cells The long term follow up data from the pivotal TRANSCEND NHL 001 study demonstrated that patients with relapsed refractory large B cell lymphomas experienced a high rate of durable responses with low incidence of severe cytokine release syndrome and neurologic events  The study met its primary and secondary endpoints Among the patients evaluable for efficacy  n 256   the overall response rate was 73   with 53  of patients achieving a complete response  Responses were similar across all patient subgroups Moreover  responses with liso cel were seen across patient groups  including high risk patients such as those with refractory disease  older patients and those with high tumor burden  The data were presented during an oral session at the 2019 ASH Annual Meeting in Orlando  FL We note that TRANSCEND NHL 001 is an open label  multicenter  pivotal phase I study to determine the safety  pharmacokinetics and antitumor activity of liso cel in patients with relapsed refractory B cell non Hodgkin lymphoma  including diffuse large B cell lymphoma  high grade B cell lymphoma  primary mediastinal B cell lymphoma  follicular lymphoma Grade 3B and mantle cell lymphoma Based on the positive results from the study  Bristol Myers plans to submit a Biologics License Application to the FDA by the end of the year The candidate was added to Bristol Myers  portfolio with the acquisition of Celgene Corporation  NASDAQ CELG  for  74 billion  Additionally  each shareholder will receive one tradeable Contingent Value Right  CVR  for each share of Celgene  which will entitle the holder to receive a one time potential payment of  9 00 in cash upon the receipt of the FDA approval for ozanimod  by Dec 31  2020   liso cel  JCAR017   by Dec 31  2020  and bb2121  by Mar 31  2021   in their respective indications The successful development and commercialization of the candidate will strengthen and diversify Bristol Myers s oncology portfolio  given the fact that its lead immuno oncology drug Opdivo is facing stiff competition from the likes of Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq Shares of Bristol Myers have gained 15 4  so far this year  outperforming the  s growth of 7 2   Earlier  Bristol Myers and partner Acceleron Pharma Inc    NASDAQ XLRN   announced the FDA s notification that Reblozyl  luspatercept aamt  will not be reviewed at the Oncologic Drugs Advisory Committee   ODAC   meeting scheduled for Dec 18  2019  following the late cycle review meeting on Dec 4  2019 The agency has informed Bristol Myers that the original Prescription Drug User Fee Act  PDUFA  or target action date of Apr 4  2020  for its supplemental Biologics License Application for Reblozyl remains the same Bristol Myers is seeking approval of Reblozyl  an erythroid maturation agent representing a new class of therapy  for the treatment of anemia in adult patients with very low  to intermediate risk myelodysplastic syndromes  MDS   who have ring sideroblasts and require red blood cell  RBC  transfusions The FDA recently approved the drug for the treatment of anemia in adult patients with beta thalassemia  who require regular RBC transfusions Bristol Myers currently carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-lymphoma-drug-meets-goals-in-key-study-200491185,200491185
202658,424174,MRK,Merck Co Earnings  Revenue Beat in Q1,news,"Investing com   Merck Co  NYSE MRK  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 22 on revenue of  10 82B  Analysts polled by Investing com anticipated EPS of  1 05 on revenue of  10 47B  That compared to EPS of  1 05 on revenue of  10 04B in the same period a year earlier  The company had reported EPS of  1 04 on revenue of  11B in the previous quarter 

Merck Co follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Pfizer earnings Beat analysts  expectations on Tuesday  with first quarter EPS of  0 85 on revenue of  13 12B  Investing com analysts expected EPS of  0 75 on revenue of  13B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-30,Investing.com,https://www.investing.com/news/stock-market-news/merckco-earnings-revenue-beat-in-q1-1850406,1850406
202659,424175,MRK,Esperion s Promising Drugs Under Review  Funds A Concern,opinion,"We issued an updated research report on Esperion Therapeutics   NASDAQ ESPR   on Nov 27  Shares of the company have gained 12 6  so far this year compared with the  s growth of 10 9  There is no marketed drug in the company s portfolio  Meanwhile  it has filed regulatory applications for pipeline candidates   bempedoic acid as monotherapy and in combination with Merck s   NYSE MRK   Zetia  ezetimibe   The applications have been accepted and are under review in the United States as well as Europe  The company is looking to get the oral therapies approved for the treatment of elevated LDL C  bad cholesterol  in patients with hypercholesterolemia receiving maximally tolerated statins or Zetia and having an inadequate response A decision from the FDA on the monotherapy regimen is expected by Feb 21  2020  while a decision on the combination therapy should come by Feb 26  2020  The FDA has informed the company that it will not hold an advisory committee meeting for discussing the new drug applications  which is likely to accelerate the review process The regulatory applications were filed based on encouraging data from multiple pivotal studies evaluating bempedoic acid monotherapy and combination therapy Data from four phase III studies evaluating bempedoic acid monotherapy  presented previously  demonstrated that treatment with the therapy led to an additional 18  reduction in LDL C over 31  LDL C reduction in statin treated patients on maximally tolerated statin Data from the phase III study evaluating bempedoic acid Zetia combination pill showed that the regimen reduced bad cholesterol by 35  compared with 24  for Zetia  20mg  monotherapy  20  for bempedoic acid and 3  for placebo in patients receiving maximally tolerated statins Moreover  the targeted indications represent a significant opportunity for the company  It is estimated that 78 million people in the United States have high levels of LDL C  73 million in Europe and 30 million in Japan  Of these  an estimated 40 million patients in the United States are using statins  which is intolerable in 5 20   The company signed a deal with Daiichi Sankyo Europe in January for the commercialization of the candidates in the region  This deal has already boosted Esperion s cash resources  A potential approval will likely drive the share price of the company  However  any regulatory setback related to the company s pipeline candidates will be a major disappointment for the company Meanwhile  the company completed enrollment in the CLEAR cardiovascular outcomes study and expects to conclude the same in the second half of 2020  The study is evaluating bempedoic acid for the occurrence of major cardiovascular events in statin averse patients with or at high risk of cardiovascular disease Esperion had  244 8 million as of Sep 30  sufficient to fund operations till operating cash flow remains positive  However  timely availability of funds is necessary for the successful commercialization of the company s drugs  following a potential approval  In June  Esperion entered a revenue interest purchase agreement of  200 million with an investor group to extend its resources  However  these funds may prove inadequate for the successful launch of the drugs as the company s operating expenses are significantly high Moreover  Esperion s candidates will face significant competition from PCSK9 inhibitors   Sanofi   NASDAQ SNY   Regeneron s   NASDAQ REGN   Praluent and Amgen s Repatha   already marketed for similar indications  The Medicines Company s PCSK9 inhibitor  inclisiran  is under review in the United States  with a decision expected by year end  Inclisran will also come with twice a year dosing benefit  Moreover  Novartis has offered to acquire The Medicines Company Esperion Therapeutics  Inc  Price
    Zacks RankEsperion currently has a Zacks Rank  4  Sell  You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-11-28,Zacks Investment Research,https://www.investing.com/analysis/esperions-promising-drugs-under-review-funds-a-concern-200488639,200488639
202660,424176,MRK,AstraZeneca s  AZN  Imfinzi Gets FDA Priority Tag For SCLC,opinion,AstraZeneca plc s   NYSE AZN   regulatory application looking for label expansion of its PD L1 inhibitor Imfinzi was accepted and granted priority by the FDA  The supplemental biologics license application  sBLA  sought approval of Imfinzi for the first line treatment of extensive stage small cell lung cancer  SCLC    the most aggressive type of lung cancer  With the FDA granting priority review designation  a decision is expected in the first quarter of 2020 The sBLA was based on positive results from the phase III CASPIAN study  Data from the study  presented previously  showed that treatment with Imfinzi plus platinum based chemotherapy led to a statistically significant and clinically meaningful improvement in overall survival  OS  versus chemotherapy alone  The median OS was 13 0 months in the Imfinzi plus chemotherapy arm versus 10 3 months for standard of care medicines  which means the risk of death was reduced by 27  on treatment with Imfinzi plus chemotherapyShares of AstraZeneca have rallied 27 6  this year so far compared with the  s increase of 6 4    Imfinzi Is presently marketed as a monotherapy for patients with locally advanced  unresectable  stage III  non small cell lung cancer  whose disease has not progressed following platinum based chemotherapy concurrent with radiation therapy  Other than this early stage lung cancer indication  Imfinzi is also marketed for second line advanced bladder cancer  Imfinzi is also being evaluated for multiple other cancers  either alone or in combination with other regimens  and has bright long term prospects Imfinzi recorded sales of  1 05 billion in the first nine months of 2019  mainly driven by strong demand in lung cancer patients  If Imfinzi is approved for SCLC  it can cater to a broader lung cancer patient population  which can bring in additional sales  It also improves the drug s competitive position against other PD 1 and PD L1 inhibitors Other PD L1 inhibitors on the market are Merck s   NYSE MRK   Keytruda  Bristol Myers    NYSE BMY   Opdivo  Roche s Tecentriq and Pfizer s   NYSE PFE   Bavencio  While  and  are approved to treat SCLC in third  or later line setting   in combination with chemotherapy was approved this year for first line extensive stage SCLC indication AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-azn-imfinzi-gets-fda-priority-tag-for-sclc-200489250,200489250
202661,424177,MRK,Pfizer Astellas Xtandi Gets Nod In China For Prostate Cancer  Revised ,opinion,Pfizer  Inc  s   NYSE PFE   partner Astellas announced that the Chinese regulatory authority has approved their cancer drug Xtandi The drug was approved by China National Medical Products Administration  NMPA  on Nov 18 to treat men with metastatic castration resistant prostate cancer  CRPC  who are asymptomatic or mildly symptomatic and had disease progression despite androgen deprivation therapy  ADT   The new drug application  NDA  seeking approval in China was based on data from an Asian multinational phase III study  Asian PREVAIL  involving Asian patients of which approximately 200 were Chinese  The efficacy and safety data from the study was consistent with the results from the pivotal global phase III PREVAIL study in the same patient population Pfizer s shares have declined 12 9  this year so far against its  s 5 9  increase  Xtandi is already approved to treat metastatic and non metastatic castration resistant prostate cancer in the United States  It is under review in the United States for metastatic hormone sensitive prostate cancer  PDUFA date in December 2019  Xtandi was added to Pfizer s portfolio with the acquisition of Medivation in September 2016  While Pfizer sells Xtandi in the United States in partnership with Astellas  the latter owns the drug s marketing rights outside the U S  markets  Pfizer recorded Xtandi alliance revenues of  594 million in the first nine months of 2019 Pfizer currently carries a Zacks Rank  2  Buy   Other large cap pharma stocks with the same Zacks Rank as Pfizer include Roche   OTC RHHBY    Bristol Myers   NYSE BMY   and Merck   NYSE MRK    You can see  Shares of Roche have gained 22 8  this year so far  Earnings estimates for 2019 have risen 1 2  while the same for 2020 increased almost 2  over the past 60 days Bristol Myers  earnings estimates have increased 2 1  and 9 5   respectively  for 2019 and 2020 over the past 60 days  The stock has rallied 11  this year Merck s stock is up 14 3  this year so far  Its earnings estimates have risen almost 4 9  for 2019 and 2  for 2020 over the past 60 days  We are reissuing this article to correct a mistake  The original article  issued on Nov 27  2019  should no longer be relied upon  ,2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/pfizerastellas-xtandi-gets-nod-in-china-for-prostate-cancer-revised-200489819,200489819
202669,424185,MRK,Merck Reports In Line Q4 Results  Shares Slip,news,"Investing com   Shares in Merck edged lower in premarket trade on Friday despite reporting fourth quarter revenue and profit that came in slightly above analysts  expectations 
The company reported earnings per share of  1 04  above the consensus estimate of  1 03  while revenue came in at  11 0 billion  just topping estimates for  10 94 billion 
After recording revenue of  42 3 billion in 2018  Merck forecast that full year sales for 2019 would be between  43 2 and  44 7 billion  The midpoint of that range suggests a modest slowdown in growth to just under 4  this year from 5 4  in 2018 
The Dow component expects earnings to grow slightly faster this year  at a clip of around 7   It predicted full year adjusted earnings per share of  4 57 to  4 72  compared to  4 34 in 2018 
 We enter 2019 with good momentum  anticipating the many opportunities afforded by our broad and differentiated portfolio and pipeline   Kenneth C  Frazier  Merck s chairman and chief executive officer  said in the press release 
At 7 04 AM ET  12 04 GMT   shares in Merck  NYSE MRK  lost 0 35  to  74 17 in premarket trade 
Merck Co follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Pfizer earnings matched analyst s expectations on Tuesday  with fourth quarter EPS of  0 64 on revenue of  13 98B  Investing com analysts expected EPS of  0 64 on revenue of  13 96B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-02-01,Investing.com,https://www.investing.com/news/stock-market-news/merckco-earnings-revenue-beat-in-q4-1766341,1766341
202670,424186,MRK,Here s Why AstraZeneca s  AZN  Shares Are Up Year To Date ,opinion,AstraZeneca plc  s   NYSE AZN   stock has rallied 24 9  this year so far  outperforming the rise of 4 7    The company s outperformance has been backed by quite a few positive developments on the regulatory and pipeline front  strong performance of its relatively newer drugs and decent quarterly results New Drugs Enable Return to GrowthAstraZeneca returned to product sales growth in the second half of 2018 with the momentum continuing in 2019 on the back of its newer drugs  mainly cancer medicines Lynparza  Tagrisso and Imfinzi  Patent expirations have been hurting its product sales growth since 2010  However  sales of AstraZeneca s newer medicines soared 81  in 2018 and 77  in the first half of 2019 as almost every product it launched in recent years has done well  The company is confident of seeing growth in the long term  driven by sales of its new medicines  namely Tagrisso  Imfinzi  Lynparza  Farxiga and Fasenra Emerging Markets  A Key Top Line DriverEmerging markets represent AstraZeneca s largest market in terms of product sales and accounted for 33  of its total product sales in 2018 and 35  in 2019 so far  Revenues from the emerging markets climbed 8  in 2017  12  in 2018 and 26  in the first nine months of 2019  supported by strong growth in China  The company is looking to make additional investments in China  In fact  in the Emerging Markets  countries outside China are also starting to contribute more with sales in the ex China markets rising 12  in 2019 so far  Thus  AstraZeneca s operations in the emerging markets should place it well  going forward Pipeline DevelopmentsAstraZeneca delivered well on its R D pipeline with meaningful data readouts and regulatory updates announced this year Late stage studies on key pipeline candidates  such as anifrolumab for systemic lupus erythematosus and Breztri Aerosphere PT010  fixed dose triple combination inhaler  met primary endpoints  Also  several late stage studies evaluating AstraZeneca s successful cancer drugs like Lynparza  Imfinzi  Calquence and Tagrisso demonstrated improved survival rates in expanded patient populationsThis year s new drug approvals include Breztri Aerosphere in Japan and Qternmet XR Qtrilmet  a combination of Farxiga and Onglyza plus metformin  in the United States and Europe Key approvals for line extensions of newer drugs in 2019 so far include Lynparza for front line ovarian cancer in Japan and the EU as well as for breast cancer in the EU  and Farxiga Forxiga for type I diabetes in the EU and Japan  Notably  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK   In April 2019  AstraZeneca acquired joint development and commercialization rights to an innovative antibody drug conjugate  ADC  trastuzumab deruxtecan from Japan s Daiichi Sankyo  A regulatory application seeking approval of trastuzumab deruxtecan for metastatic breast cancer was granted a priority review by the FDA in October with decision expected in the second quarter of 2020 Several other pipeline and regulatory events are scheduled for the rest of this year  This includes an NDA filing in the United States for roxadustat  which has been developed to treat anemia in patients with chronic kidney disease  AstraZeneca also awaits the FDA decision in the United States and Europe on regulatory applications seeking use of Lynparza tablets for BRCAm pancreatic cancer later this year ConclusionAstraZeneca  which currently carries a Zacks Rank  3  Hold   has its share of challenges  These include generic competition for its core products  stiff contest in its diabetes franchise and pricing pressure on its respiratory franchise  However  we believe  the company s newer drugs  upcoming product launches  aggressive cost cutting efforts and a promising late stage pipeline should keep the stock afloat through the remaining year and probably next year too Some better ranked large cap pharma stocks are GlaxoSmithKline   NYSE GSK   and Novo Nordisk   NYSE NVO    both carrying a Zacks Rank  2  Buy  Glaxo s earnings estimates have increased 4 1  for 2019 and 0 3  for 2020 over the past 60 days  The company s shares have increased 15 3  this year so far Shares of Novo Nordisk have risen 24 3  this year so far  Earnings estimates for 2019 and 2020 have risen 0 8  and 1 0   respectively  over the past 60 days 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ,2019-11-18,Zacks Investment Research,https://www.investing.com/analysis/heres-why-astrazenecas-azn-shares-are-up-year-to-date-200485963,200485963
202671,424187,MRK,Pfizer Astellas Xtandi Gets Nod In China For Prostate Cancer,opinion,Pfizer  Inc  s   NYSE PFE   partner Astellas announced that the Chinese regulatory authority has approved their cancer drug Xtandi The drug was approved by China National Medical Products Administration  NMPA  on Nov 18 to treat men with metastatic castration resistant prostate cancer  CRPC  who are asymptomatic or mildly symptomatic and had disease progression despite androgen deprivation therapy  ADT   The new drug application  NDA  seeking approval in China was based on data from an Asian multinational phase III study  Asian PREVAIL  involving Asian patients of which approximately 200 were Chinese  The efficacy and safety data from the study was consistent with the results from the pivotal global phase III PREVAIL study in the same patient population Pfizer s shares have declined 11 4  this year so far against its  s 5 9  increase   Xtandi is already approved to treat metastatic and non metastatic castration resistant prostate cancer in the United States  It is under review in the United States for hormone sensitive prostate cancer  PDUFA date in December 2019  and in mid stage development for advanced breast cancer and hepatocellular carcinoma Xtandi was added to Pfizer s portfolio with the acquisition of Medivation in September 2016  While Pfizer sells Xtandi in the United States in partnership with Astellas  the latter owns the drug s marketing rights outside the U S  markets  Pfizer recorded Xtandi alliance revenues of  594 million in the first nine months of 2019 Pfizer currently carries a Zacks Rank  2  Buy   Other large cap pharma stocks with the same Zacks Rank as Pfizer include Roche   OTC RHHBY    Bristol Myers   NYSE BMY   and Merck   NYSE MRK    You can see  Shares of Roche have gained 24 7  this year so far  Earnings estimates for 2019 have risen 1 2  while the same for 2020 increased almost 2  over the past 60 days Bristol Myers  earnings estimates have increased 2 1  and 9 5   respectively  for 2019 and 2020 over the past 60 days  The stock has rallied 9 1  this year Merck s stock is up 14 3  this year so far  Its earnings estimates have risen almost 4 9  for 2019 and 2  for 2020 over the past 60 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-11-27,Zacks Investment Research,https://www.investing.com/analysis/pfizerastellas-xtandi-gets-nod-in-china-for-prostate-cancer-200488306,200488306
202681,424197,MRK,Pfizer Merck KGaA s Bavencio Fails In 2nd Gastric Cancer Study,opinion,"Pfizer Inc    NYSE PFE   along with Germany based partner Merck KGaA announced top line data from a phase III study evaluating their PD L1 inhibitor Bavencio  avelumab   The JAVELIN Gastric 100 study evaluated Bavencio as a first line maintenance therapy following induction chemotherapy in patients with unresectable  locally advanced metastatic HER2 negative gastric cancer compared to continuation of chemotherapy or best supportive care 
Top line results showed that treatment with Bavencio did not lead to superior overall survival when compared to the standard of care in the overall intent to treat population or the PD L1 positive population  thereby failing to meet the primary endpoint of the study 
However  no new safety signals were seen and the safety profile of Bavencio witnessed in this study was similar to what was earlier observed across the JAVELIN program 
Gastric or gastroesophageal junction  GEJ  cancer study covers a hard to treat patient population with significant unmet medical need for additional treatments  Notably  this is the second gastric cancer study on Bavencio  which failed  In November 2017  another phase III gastric cancer study  JAVELIN Gastric 300  evaluating Bavencio monotherapy in the third line setting missed the primary endpoint 
Bavencio is presently approved for the treatment of Merkel cell carcinoma and metastatic urothelial carcinoma  Bavencio in combination with Pfizer s another cancer drug Inlyta  axitinib  is also approved in the United States for the first line treatment of advanced renal cell carcinoma  RCC   the most common form of kidney cancer 
Last month  the European Commission approved this Bavencio plus Inlyta combo for the first line treatment of patients with advanced RCC 
Shares of Pfizer have decreased 15 2  so far this year against the  rise of 3 6  

Notably  Bavencio is one of the key candidates in Pfizer s oncology pipeline  Per the company  the Bavencio development program  known as JAVELIN  involves more than 10 000 patients currently being investigated across 15 tumor types including head and neck  non small cell lung  urothelial and others 
Bavencio faces stiff competition from other approved PD L1 inhibitors in the market  such as Merck s   NYSE MRK   blockbuster drug Keytruda  pembrolizumab   Bristol Myers    NYSE BMY   Opdivo  nivolumab  and AstraZeneca s   NYSE AZN   Imfinzi  durvalumab  
Zacks Rank
Pfizer currently carries a Zacks Rank  3  Hold  You can see  
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-11-11,Zacks Investment Research,https://www.investing.com/analysis/pfizermerck-kgaas-bavencio-fails-in-2nd-gastric-cancer-study-200484391,200484391
202682,424198,MRK,Merck s Ebola Vaccine Gets Conditional Approval In Europe,opinion,Merck   Co   Inc    NYSE MRK   announced that the European Commission has granted conditional marketing approval to its investigational vaccine for Ebola Zaire disease  V920  The vaccine  which has been approved for active immunization of individuals 18 years of age or older  will be marketed by the trade name of Ervebo With the approval  Merck can initiate manufacturing of licensed doses in Germany  These doses are expected to be available in the third quarter of 2020Merck s shares have risen 9  this year so far compared with the  s increase of 3 6    The European Commission s conditional approval was expected as last month  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  gave a positive opinion  recommending conditional marketing approval of Ervebo  Ervebo is under priority review in the United States with a FDA decision expected on Mar 14 next year Some other companies like Inovio Pharmaceuticals    NASDAQ INO   and Regeneron   NASDAQ REGN   are also currently evaluating Ebola vaccine candidates  Regeneron has four investigational therapies for Ebola virus infection in its pipeline  In August  Glaxo   NYSE GSK   granted exclusive technology license of its Ebola vaccine candidates to Sabin Vaccine Institute  which now takes care of development of the prophylactic candidate vaccines against the deadly Ebola Zaire  Ebola Sudan and Marburg virus Vaccine is an important therapeutic area for Merck  The company has several marketed vaccines in its portfolio like Gardasil Gardasil 9  ProQuad M M R II Varivax  RotaTeq  Pneumovax 23 and Zostavax  Among these  human papillomavirus vaccine  Gardasil Gardasil 9 is a key top line driver of the company  recording sales of more than  3 billion in the first nine months of 2019 Apart from the Ebola vaccine candidate  Merck is studying an investigational 15 valent pneumococcal conjugate vaccine candidate  V114  in late stage studies  The candidate is being developed as a preventive treatment for invasive pneumococcal disease in pediatric as well as adult patients Merck currently carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-11-11,Zacks Investment Research,https://www.investing.com/analysis/mercks-ebola-vaccine-gets-conditional-approval-in-europe-200484583,200484583
202683,424199,MRK,Bristol Myers  Opdivo Yervoy SBLA For HCC Gets Priority Review,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the FDA has accepted and granted priority review designation to a supplemental Biologics License Application  sBLA  for the label expansion of Opdivo  nivolumab  in combination with Yervoy  The sBLA is seeking to get the dual immuno oncology therapy approved in patients with advanced hepatocellular carcinoma   HCC    previously treated with Bayer s   OTC BAYRY   chemotherapy  Nexavar  sorafenib   HCC is the most common type of liver cancer  The FDA is expected to give its decision on Mar 10  2020 The submission was based on data from the phase I II CheckMate 040 study investigating Opdivo Yervoy combo in advanced HCC patients after prior treatment with Nexavar  Data from the study presented at the 2019 American Society of Clinical Oncology   ASCO   Annual Meeting showed that treatment with Opdivo plus Yervoy yielded objective response rate of 31  and median duration of response of 17 5 months   Meaningful responses were observed across treatment arms We note that the FDA also granted Breakthrough Therapy Designation to this dual immuno oncology therapy for previously treated advanced HCC patients Shares of Bristol Myers  shares have increased 11 9  so far this year compared with the  s rise of 3 7  We note that Opdivo became the first PD 1 immune checkpoint inhibitor to gain regulatory approval in July 2014  It is currently approved in several countries  including the United States  the EU and Japan  for several cancer indications Meanwhile  the company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  Label expansion of the drug into additional indications would give the product access to a higher patient population and increase its commercial potential significantly In a major achievement  Bristol Myers successfully  a pivotal study evaluating Opdivo plus low dose Yervoy in advanced non small cell lung cancer patients in first line setting in October  Although Opdivo is approved for treating lung cancer in second or later line setting  the drug is yet to receive approval in first line lung cancer indication  Lung cancer is the most common form of cancer representing a significant market opportunity  Other immuno oncology drugs namely Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq have competitive advantage over Opdivo as they are already approved for first line lung cancer  We expect the success in this pivotal study to change the scenario for Opdivo going forward Bristol Myers Squibb Company Price
    Zacks RankBristol Myers currently carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-11-12,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivoyervoy-sbla-for-hcc-gets-priority-review-200484507,200484507
202684,424200,MRK,AstraZeneca Merck s Selumetinib NDA Gets FDA Priority Status ,opinion,AstraZeneca plc   NYSE AZN   and partner Merck   NYSE MRK   announced that the FDA has accepted the new drug application  NDA  seeking approval of MEK 1 2 inhibitor selumetinib for the treatment of pediatric patients with neurofibromatosis type 1  NF1  related plexiform neurofibromas  PN   an incurable genetic condition With the FDA granting priority review to the NDA  a decision is expected in the second quarter of 2020  The NDA filing was based on positive data from the SPRINT phase II study  testing selumetinib as an oral monotherapy in pediatric patients aged three years or older with inoperable NF1 related PN  Results from the study have shown that selumetinib shrank tumors in children and young adults with NF1 and may improve symptoms such as pain and reduced mobility resulting from tumors  which develop in many people with NF1 AstraZeneca s shares have rallied 24 7  this year so far compared with the  s growth of 3 8    Please note that selumetinib was granted Breakthrough Therapy status and Orphan Drug designation by the FDA in April 2019 and February 2018  respectively  and Orphan designation by the European Medicines Agency  EMA  in August 2018 for the same indication AstraZeneca and Merck are jointly developing and commercializing selumetinib globally for multiple cancer types  per a deal signed in July 2017  Meanwhile  under the same deal  the companies also share development and commercialization of successful PARP inhibitor  Lynparza In a separate press release  AstraZeneca announced that the European Commission has granted marketing approval to its Qtrilmet modified release tablets for type II diabetes  Qtrilmet is a combination of AstraZeneca s other diabetes drugs Farxiga  dapagliflozin  and Onglyza  saxagliptin  plus metformin  It was approved by the FDA with the trade name of Qternmet XR in May Zacks Rank and Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Some better ranked large cap pharma stocks are GlaxoSmithKline   NYSE GSK   and Novo Nordisk   NYSE NVO    both enjoying a Zacks Rank  2  Buy  Glaxo s earnings estimates have increased 6 2  for 2019 and 2  for 2020 over the past 60 days  The company s shares have increased 14 8  this year so far Shares of Novo Nordisk have risen 25 7  this year so far  Earnings estimates for 2019 and 2020 have risen 0 8  and 1 0   respectively  over the past 60 days Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sh eraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-11-14,Zacks Investment Research,https://www.investing.com/analysis/astrazenecamercks-selumetinib-nda-gets-fda-priority-status-200485637,200485637
202694,424210,MRK,Merck s Keytruda OK d in Europe for adjuvant advanced melanoma,news,The European Commission approves Merck s  NYSE MRK  Keytruda  pembrolizumab  for the adjuvant treatment of adult patients with Stage III melanoma and lymph node involvement who have undergone complete resection Now read ,2018-12-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/mercks-keytruda-okd-in-europe-for-adjuvant-advanced-melanoma-1723446,1723446
202695,424211,MRK,Merck in licenses NASH T2D candidate,news,Merck  NYSE MRK  exercises its option to license monoclonal antibody NGM313 from NGM Biopharmaceuticals for the potential treatment of nonalcoholic steatohepatitis  NASH  and type 2 diabetes  T2D   The companies have been collaborating since 2015 Merck will have exclusive global rights to develop  manufacture and commercialize the candidate  renamed MK 3655  NGM will receive a  20M upfront  milestones and tiered low double digit to mid teen royalties on net sales  NGM retains an option  in effect when MRK launches its first Phase 3 study  to participate in up to half of global cost and revenue MRK plans to initiate a Phase 2b trial in NASH patients with or without diabetes NGM313 is an agonist of the   Klotho FGFR1c receptor complex which plays a key role in obesity  plasma insulin  triglycerides and glucose levels  It has the potential as a once per month injectable insulin sensitizer Now read ,2019-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-inlicenses-nasht2d-candidate-1736064,1736064
202696,424212,MRK,Novartis  Generics Unit To Buy Aspen s Japanese Operations,opinion,Novartis AG s   NYSE NVS   generic unit Sandoz announced that it has entered an agreement to acquire the Japanese business of Aspen Global Incorporated  AGI   a wholly owned subsidiary of Aspen Pharmacare Holdings Limited Per the agreement  Sandoz agreed to pay EUR 300 millioninitially  plus a deferred amount not expected to exceed EUR100 million based on certain conditions being met  The transaction is expected to complete in the first half of 2020 Shares of the company have gained 3  year to date compared with the  s growth of 3 7  Further  AGI inked a five year manufacturing and supply agreement  with an additional two year extension option  with Sandoz  The deal will be effective from the transaction s closure for the supply of active pharmaceutical ingredients  semi finished and finished goods related to the portfolio of divested brands The acquisition will enable Sandoz to expand its presence in the third largest generics marketplace globally  The transaction will fortify Sandoz s pipeline of hospital generic and biosimilar products with a dedicated sales  marketing and medical organization  thereby enhancing its ability to serve patients and customers in the hospital channel Aspen s portfolio in Japan consists of about 20 products  which generated annual sales of EUR 130 million for the fiscal year ending in 2019  Aspen s products include off patent branded medicines  with a focus on anesthetics  including Xylocaine   specialty brands  including Imuran  and local brands In a separate release  Novartis announced positive interim results from the final part of its phase IIb FLIGHT FXR adaptive design study The interim analysis showed that higher doses of tropifexor  140 Mu g and 200 Mu g  resulted in improvements in several key biomarkers of non alcoholic steatohepatitis  including hepatic fat fraction  alanine aminotransferase and body weight  with favorable safety after 12 weeks of treatment   These results confirm previous interim results and demonstrate a favorable safety profile for tropifexor  Full 48 week biopsy data from the study are expected in the second quarter of 2020   Novartis AG Price    Zacks Rank   Stocks to ConsiderNovartis currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the biotech sector are Bristol Myers Squibb Company   NYSE BMY    GlaxoSmithKline plc    NYSE GSK   and Merck   Co  Inc    NYSE MRK    all sporting a Zacks Rank  2  Buy   You can see   Bristol Myers  earnings per share estimates have increased from  4 28 to  4 33 for 2019 and from  5 16 to  5 30 for 2020 in the past 60 days  The company delivered a positive earnings surprise the trailing four quarters by 8 30  on average   GlaxoSmithKline s earnings per share estimates have increased from  2 89 to  3 08 for 2019 and from  2 96 to  3 02 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 17 23  on average Merck s earnings per share estimates have increased from  4 89 to  5 06 for 2019 and from  5 35 to  5 44 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters by 12 51  on average 5 Stocks Set to Double Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth  Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-10,Zacks Investment Research,https://www.investing.com/analysis/novartis-generics-unit-to-buy-aspens-japanese-operations-200484241,200484241
202704,424220,MRK,Ebola spreads to major Congo city,news,The second largest Ebola outbreak in history has spread to Butembo  a major city with more than 1M residents in eastern Congo Health experts now worry whether the stock of an experimental vaccine supplied by Merck  NYSE MRK  will stand up to the epidemic s demands Without the teams that have vaccinated more than 41K people so far  the outbreak could have already seen more than 10K Ebola cases  vs  the current 471   according to Congo s health ministry Previously  Congo Ebola outbreak second largest in history  Nov  30 2018 Now read ,2018-12-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/ebola-spreads-to-major-congo-city-1715853,1715853
202705,424221,MRK,Roche teams up with Merck to develop new companion test for Keytruda,news,Roche  OTCQX RHHBY  0 5   will collaborate with Merck  MRK  0 4   to develop a new companion diagnostic test to identify appropriate patients for anti PD 1 therapy  this is  Keytruda  pembrolizumab   Specifically  the immunohistochemistry test will assess mismatch repair deficiency  MMR  in solid tumors via the detection of four MMR proteins MMR describes rapidly mutating cancer cells Now read ,2018-12-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/roche-teams-up-with-merck-to-develop-new-companion-test-for-keytruda-1718165,1718165
202706,424222,MRK,Exelixis  EXEL  Q3 Earnings Beat On Strong Cabometyx Sales,opinion,"Exelixis  Inc    NASDAQ EXEL   delivered better than expected results for third quarter 2019  wherein both earnings and revenues beat estimates on strong performance by Cabometyx The company s shares have lost 11 7  in the year so far compared with the  s decline of 0 9   Exelixis reported earnings of 31 cents  easily beating the Zacks Consensus Estimate of 20 cents  However  the bottom line declined from 41 cents in the year ago quarter Net revenues came in at  271 7 million  increasing from  225 4 million in the year ago quarter and surpassing the Zacks Consensus Estimate of  228 38 million Quarter in DetailNet product revenues came in at  191 8 million  up 17 7  from the year ago quarter  driven by continued growth of Cabometyx in the United States for the treatment of advanced renal cell carcinoma  RCC  Cabometyx received another FDA approval for the treatment of patients with hepatocellular carcinoma  who have been previously treated with sorafenib  in January  The label expansion of the drug for this indication in the United States also boosted sales The drug generated  187 4 million of revenues  Patient demand grew 14  year over year but declined 4  sequentially  Prescriber base grew by 40  year over year and 7  sequentially Cometriq  cabozantinib capsules   for the treatment of medullary thyroid cancer  generated  4 4 million in net product revenues Total collaboration revenues were  79 9 million  up from  62 5 million in the year ago quarter  primarily owing to the recognition of a  50 0 million milestone from Exelixis  collaboration with Ipsen Pharma SAS for the achievement of  250 0 million of net sales from cabozantinib in its territories over four consecutive fiscal quarters In the reported quarter  research and development expenses more than doubled to  97 3 million due to increases in clinical trial costs  license and other collaboration costs  and personnel expenses   Selling  general and administrative  SG A  expenses were  51 3 million  up 6 6  year over year  driven by increase in personnel expenses and stock based compensation Pipeline UpdateThe pipeline progress in the year so far has been encouraging In July  Exelixis announced an exclusive collaboration  option and license agreement with Aurigene  an India based biotechnology company focused on oncology and inflammatory disorders  to in license as many as six programs  Per the agreement  Exelixis made an upfront payment of  10 0 million for exclusive options to license three pre existing programs from Aurigene  The companies selected three additional Aurigene led drug discovery programs on mutually agreed upon targets  in exchange for supplemental option payments totaling  7 5 million In the same month  Exelixis amended the protocol for COSMIC 021  the phase Ib trial of cabozantinib in combination with Roche s   OTC RHHBY   Tecentriq  atezolizumab  in patients with locally advanced or metastatic solid tumors  Based on preliminary encouraging activity and safety data  the original immunotherapy refractory non small cell lung cancer and metastatic castration resistant prostate cancer  CRPC  cohorts were expanded to 80 patients each  Additionally  four new cohorts   two expansion and two exploratory   in metastatic CRPC settings were included in the trial In October  Ipsen announced Health Canada s approval of Cabometyx for the first line treatment of adults with advanced RCC  Hence  Exelixis is eligible to receive a milestone payment of  3 0 million  which will be recognized as revenues in the fourth quarter of 2019 In October  the company filed a patent infringement lawsuit against MSN Pharmaceuticals  Inc  following the receipt of a Paragraph IV certification notice letter from the latter stating that it had filed an ANDA with the FDA requesting the approval to market a generic version of Cabometyx tablets  following the expiration of the Cabometyx composition of matter patent   U S  Patent No  7 579 473   which expires on Aug 14  2026   Per Exelixis  the effective date of any FDA approval for the ANDA would be a date not earlier than the expiration of U S  Patent No  8 877 776 on Oct 8  2030  2019 GuidanceR D expenses are now expected around  350 million  previous guidance  between  330 million and  350 million  and SG A expenses around  240 million  previous guidance  between  220 million and  240 million  Our TakeExelixis  earnings and sales beat estimates in the third quarter despite increasing competition from the recently approved combination therapies  Earlier this year  the FDA approved Merck s   NYSE MRK   Keytruda in combination with Pfizer s   NYSE PFE   Inlyta for the first line treatment of patients with advanced RCC  Competition has further intensified with the FDA approval of a combination regimen of Bavencio  avelumab  and Inlyta for the same   Given the increasing use of these therapies  we expect investors to focus on the label expansions of cabozantinib in the ongoing combination trials Exelixis  Inc  Price  Consensus and EPS Surprise
    Zacks RankExelixis currently carries a Zacks Rank  4  Sell   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/exelixis-exel-q3-earnings-beat-on-strong-cabometyx-sales-200480965,200480965
202715,424231,MRK,Merck s Frazier to remain CEO of the U S  drugmaker beyond 2019,news," Reuters    Merck   Co Inc  N MRK  Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019  the drugmaker said on Wednesday  after it scrapped a policy requiring its CEOs to retire at the age of 65  Frazier  who will turn 65 in December 2019  took the helm of the U S  pharmaceutical company in 2011  On his watch  the company s stock price has doubled and its cancer immunotherapy Keytruda has raked in blockbuster sales  becoming one of the leading products in a new generation of oncology treatments   CEO succession has been our top priority  and removing the mandatory retirement policy enables the Board to make the best decision concerning the timing of that transition   Merck s lead director Leslie Brun said in a statement  Frazier made headlines last year when he became the first business leader to leave U S  President Donald Trump s now disbanded manufacturing council following Trump s comments on a white nationalist rally held in Charlottesville  Virginia  The grandson of a sharecropper  and son of a janitor  Frazier s appointment to CEO in 2011 made him the only black person leading one of the major U S  or European drugmakers  Frazier made his name at Merck as the company s general counsel  steering the company through daunting litigation over Vioxx  its widely used painkiller that was withdrawn from the market in 2004 after being linked to heart attacks  Merck eventually paid nearly  5 billion to settle some 27 000 lawsuits brought by those who claimed to have been harmed by the popular arthritis treatment  As chief executive  Frazier has focused the company around the development Keytruda  which has racked up approvals to treat numerous types of cancer  including lung cancer  Analysts expect annual Keytruda sales to reach nearly  11 billion by 2020 and keep climbing from there  according to Thomson Reuters data  Under Frazier  Merck also announced price cuts for some of its medicines in July  including a 60 percent reduction on a hepatitis C treatment  after Trump criticized drugmakers for failing to help reduce healthcare costs for consumers  
Merck s shares were up 21 cents at  70 86 on Wednesday ",2018-09-26,Reuters,https://www.investing.com/news/stock-market-news/merck-ceo-to-stay-post-65-after-company-amends-retirement-policy-1624240,1624240
202716,424232,MRK,Scientists behind game changing cancer immunotherapies win Nobel medicine prize,news,"By Simon Johnson and Kate Kelland STOCKHOLM LONDON  Reuters    American James Allison and Japanese Tasuku Honjo won the 2018 Nobel Prize for Physiology or Medicine on Monday for game changing discoveries about how to harness and manipulate the immune system to fight cancer  The scientists  work in the 1990s has since swiftly led to new and dramatically improved therapies for cancers such as melanoma and lung cancer  which had previously been extremely difficult to treat   The seminal discoveries by the two Laureates constitute a landmark in our fight against cancer   the Nobel Assembly at Sweden s Karolinska Institute said as it awarded the prize of nine million Swedish crowns   1 million   Allison and Honjo showed releasing the brakes on the immune system can unleash its power to attack cancer  The resulting treatments  known as immune checkpoint blockade  have  fundamentally changed the outcome  for some advanced cancer patients   the Nobel institute said  Medicine is the first of the Nobel Prizes awarded each year  The prizes for achievements in science  literature and peace were created in accordance with the will of dynamite inventor and businessman Alfred Nobel and have been awarded since 1901  The literature prize will not be handed out this year after the awarding body was hit by a sexual misconduct scandal  A Swedish court on Monday found a man at the center of the scandal guilty of rape and sentenced him to two years in jail  REVOLUTIONIZED CANCER TREATMENT  Allison s and Honjo s work focused on proteins that act as brakes on the immune system   preventing the body s main immune cells  known as T cells  from attacking tumors effectively  Allison  a professor at the University of Texas MD Anderson Cancer Center  worked on a protein known as CTLA 4 and realized that if this could be blocked  a brake would be released   It immediately occurred to me  and some of the people in my lab  that maybe we can use this to unleash the immune system to attack cancer cells   Allison told a news conference after getting the prize  Honjo  a professor at Kyoto University since 1984  separately discovered a second protein called PD 1 and found that it too acted as an immune system brake  but with a different mechanism  The discoveries led to the creation of a multibillion dollar market for new cancer medicines  Bristol Myers Squibb s  N BMY  CTLA 4 therapy Yervoy was the first such drug to win approval  in 2011  However  it is medicines targeting PD 1 blockade that have proved a bigger commercial hit  led by Merck   Co s  N MRK  Keytruda in 2014  These and rival drugs from Roche  S ROG   AstraZeneca  L AZN    Pfizer   N PFE  and Sanofi  PA SASY  now offer new options for patients with melanoma  lung and bladder cancers  Sales of such medicines  which are given as infusions  are expected to reach some  15 billion this year  according to Thomson Reuters consensus forecasts  Some analysts see eventual revenues of  50 billion  Honjo  who is now 76  told a news conference in Tokyo he was honored to get the Nobel  but his work was not yet done   I would like to keep on doing my research    so that this immune treatment could save more cancer patients   he said  Japanese Prime Minister Shinzo Abe congratulated Honjo in a phone call  telling him   I believe the achievements of your research have given cancer patients hope and light   Allison told a news conference he was in a  state of shock  hours after learning from his son that he had won a Nobel prize   As a basic scientist  to have my work really impact people is just one of the best things   he said   I think it s everybody s dream  And I ve been lucky enough to do work that is benefiting people now    Commenting on the award  Kevin Harrington  a professor at the Institute of Cancer Research in London  said the work had revolutionized cancer treatment  
 We ve gone from being in a situation where patients were effectively untreatable to having a range of immunotherapy options that  when they work  work very well indeed   he said in a statement   For some patients we see their tumors shrink or completely disappear and are effectively cured  ",2018-10-01,Reuters,https://www.investing.com/news/world-news/2018-nobel-medicine-prize-awarded-for-cancer-research-1629619,1629619
202717,424233,MRK,FDA OKs expanded use for Merck s Gardasil 9 HPV vaccine,news,The FDA approves the use of Merck s  NYSE MRK  HPV vaccine Gardasil 9 in women and men ages 27   45 years  Previously  it was approved for females and males ages 9   26 years Now read ,2018-10-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-expanded-use-for-mercks-gardasil-9-hpv-vaccine-1634685,1634685
202718,424234,MRK,Dynavax up 18  premarket on SD 101   Keytruda data in melanoma,news,Dynavax Technologies  NASDAQ DVAX  is up 18  premarket on light volume on the heels of its announcement of preliminary data from its ongoing Phase 1b 2 clinical trial evaluating SD 101 combined with Merck s  NYSE MRK  KEYTRUDA  pembrolizumab  in patients with advanced melanoma na ve to anti PD 1 L1 therapy  The results were presented at ESMO in Munich The overall response rate  ORR  in the group receiving no more than 2 mg of SD 101 was 70   n 33 47  while the ORR in the group receiving 8 mg of SD 101 was 48   n 19 40  The six month progression free survival rate  PFS  in the less than or equal to 2 mg group was 85   Suggested median PFS was 15 2 months Response rates appeared similar regardless of PD 1 status SD 101 is an intratumoral Toll like receptor 9  TLR9  agonist designed to modulate the tumor microenvironment and prime T cells to generate a systemic anti tumor response Now read ,2018-10-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/dynavax-up-18-premarket-on-sd101--keytruda-data-in-melanoma-1653451,1653451
202719,424235,MRK,Merck Q3 top line up 5   non GAAP EPS up 7   raises non GAAP EPS guidance,news,Merck  MRK  Q3 results  Revenues   10 794M   4 5    Net Income   1 950M  Non GAAP Net Income   3 178M   4 1    EPS   0 73  Non GAAP EPS   1 19   7 2   Key Product Sales  KEYTRUDA   1 889M   80 4    JANUVIA   JANUMET   1 490M   2 3    GARDASIL   GARDASIL 9   1 048M   55 3    PROQUAD  M M R II and VARIVAX   525M   1 2    ISENTRESS   ISENTRESS HD   275M   11 3    ZETIA   VYTORIN   257M   44 4    NUVARING   234M   9 3   2018 Guidance  Revenues   42 1B   42 7B from  42B   42 8B  GAAP EPS   2 41   2 47 from  2 51   2 59  Non GAAP EPS   4 30   4 36 from  4 22   4 30 Shares are up 1  premarket Previously  Merck beats by  0 05  misses on revenue  Oct  25 Now read ,2018-10-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-q3-top-line-up-5-nongaap-eps-up-7-raises-nongaap-eps-guidance-1659393,1659393
202720,424236,MRK,Merck  Bristol Myers profits rise on cancer drug sales,news,By Michael Erman and Manas Mishra  Reuters    Merck   Co Inc  N MRK  and Bristol Myers Squibb Co  N BMY  posted better than expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno oncology treatments  But shares of both U S  drugmakers fell as investors worry about a plan the Trump administration is expected to unveil on Thursday aimed at lowering prices the government s Medicare healthcare program pays for specialty drugs like cancer treatments  Bristol Myers pioneered cancer immunotherapy with Yervoy and later its blockbuster drug Opdivo  But Merck   Co s  N MRK  rival treatment Keytruda has seized a dominant position in lung cancer   the most lucrative oncology market   and Bristol Myers  shares have suffered  Keytruda sales exceeded those for Opdivo for the second straight quarter  It has been amassing approvals as a standalone therapy and in combination with other drugs to treat several forms of cancers  and has become the leader in both new patient starts and total patient volume   Keytruda sales rose more than 80 percent to  1 89 billion for the quarter  slightly beating analyst estimates  Bristol s Opdivo had sales of  1 79 billion  beating analyst estimates by around  100 million  Yervoy also performed better than expected with sales of  382 million in the quarter  Bristol Myers shares were down 2 4 percent at  47 68 in early trading  while Merck shares fell 2 5 percent to  68 80  Bristol Myers  shares had been down 20 percent so far this year  while Merck s shares were up 25 percent  as each new clinical success for Keytruda weighed on Bristol shares  SunTrust Robinson Humphrey analyst John Boris said the expected announcement from U S  President Donald Trump  is a direct shot against the immuno oncology players   MERCK TO BUYBACK SHARES  RAISE DIVIDEND Merck reported adjusted earnings of  1 19 per share  beating analysts  average estimate by 5 cents  according to Refinitiv data  Revenue rose 4 5 percent to  10 79 billion  falling short of Wall Street expectations of  10 88 billion  The company also announced a  10 billion share buyback and raised its quarterly dividend by 15 percent   Expectations were high coming into the quarter  but we think these results should still be well received and allow for continued confidence    Credit Suisse   SIX CSGN  analyst Vamil Divan said in a note  Merck said it plans to spend  16 billion on capital projects through 2022  up from its previous projection of  12 billion  to increase manufacturing capacity in oncology  vaccines and animal health   We are confident in our future growth prospects   said Merck Chief Executive Kenneth Frazier  who will remain in the role beyond 2019 after the company scrapped its mandatory retirement age      Merck also saw strong growth from Gardasil  its vaccine to prevent HPV related cancers  Gardasil sales grew 55 percent to  1 05 billion  helped by increased demand in China and Australia  and its growth should be helped by recently expanded U S  approval to treat people up to age 45   Bristol Myers  said it earned  1 09 a share  excluding special items  topping analysts  average expectations by 18 cents  Revenue rose 8 percent to  5 69 billion  just shy of Wall Street estimates of  5 72 billion  Sales of blood clot preventer Eliquis  which Bristol shares with  Pfizer  Inc  N PFE   rose 28 percent from last year to  1 58 billion  but fell short of analyst expectations of  1 67 billion   Bristol Myers  effective tax rate was 11 8 percent in the quarter  It now expects a full year adjusted tax rate of 17 percent  at the bottom end of its previous forecast ,2018-10-25,Reuters,https://www.investing.com/news/stock-market-news/merck-bristolmyers-profits-rise-on-cancer-drug-sales-1659820,1659820
202721,424237,MRK,Why Earnings Season Could Be Great For Merck  MRK ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Merck   Co   Inc    NYSE MRK   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Merck is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for MRK in this report In fact  the Most Accurate Estimate for the current quarter is currently higher than the broader Zacks Consensus Estimate of  1 25 per share  This suggests that analysts have very recently bumped up their estimates for MRK  giving the stock a Zacks Earnings ESP of  0 16  heading into earnings season Merck   Co   Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that MRK has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see Clearly  recent earnings estimate revisions suggest that good things are ahead for Merck  and that a beat might be in the cards for the upcoming report Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-10-27,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-merck-mrk-200479159,200479159
202731,424247,MRK,Congo approves more experimental Ebola treatments as cases rise,news,"KINSHASA  Reuters    Democratic Republic of Congo has approved four more experimental treatments against the deadly Ebola virus  the health ministry said as it raced to contain an outbreak in its violence torn east  Health authorities last week started administering the U S  developed mAb114 treatment to Ebola patients  the first time such a treatment had been used against an active outbreak  The health ministry said in a daily bulletin late on Tuesday that the 10 patients who received mAb114 since Aug  11 have experienced a  positive evolution   but the outbreak has continued to grow   The four additional treatments approved by Congo s ethics committee are Remdesivir  made by Israel s Gilead Sciences  NASDAQ GILD   ZMapp  an intravenous treatment made by San Diego s Mapp Pharmaceutical  Japanese drug Favipiravir  and one referred to as Regn3450   3471   3479   Remdesivir was administered to its first patient in the town of Beni on Tuesday  who is doing well  the ministry said in its bulletin  Six new cases and four new deaths have been confirmed from the haemmorhagic fever  which causes vomiting and severe diarrhea  the ministry said   That brings the total number of deaths to 59 and confirmed cases to 75 since last month  Congo  whose heavily forested interior makes its a natural home for Ebola  is at the forefront of a global campaign to combat the virus  which killed more than 11 000 people when it swept through West Africa from 2013 2016   The Central African country has experienced ten Ebola outbreaks since the virus was discovered in northern Congo in 1976   more than twice as many as any other country   and 33 people died in a flare up in the northwest that ended last month   In addition  a vaccine manufactured by Merck  NYSE MRK   which proved effective against the earlier outbreak in northwestern Congo  has been administered to 1 693 health workers and contacts of Ebola patients  Insecurity in Congo s eastern borderlands with Uganda has continued to complicate the response  with some contacts of Ebola patients located in so called  red zones   which are off limits to emergency responders due to militia activity  
Instead  local health workers in those areas are monitoring the contacts and no Ebola cases have yet been confirmed there ",2018-08-22,Reuters,https://www.investing.com/news/world-news/congo-approves-more-experimental-ebola-treatments-as-cases-rise-1582750,1582750
202732,424248,MRK,RXi Pharma files for equity offering,news,RXi Pharmaceuticals  NASDAQ RXII  has filed a preliminary prospectus for a public offering of units  each consisting of one share of common stock and one warrant to purchase one share of common  Pricing  volume and terms have yet to be announced Now read ,2018-09-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/rxi-pharma-files-for-equity-offering-1595167,1595167
202733,424249,MRK,Roche steps up efficiency drive to take sting out of biosimilars,news,"By John Miller and Ben Hirschler LONDON ZURICH  Reuters    Roche  S ROG   the world s biggest producer of cancer drugs  is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut price copies of three mega brands from its famed U S  Genentech biotech stable   Even though the Swiss company has some of the pharmaceutical industry s most admired research and development labs  it is now battling to increase medicine sales as its biotech portfolio ages and rivalry intensifies  Chief Executive Severin Schwan told Reuters he was confident he could fill the sales gap but expects only  moderate growth  into 2019   helped by newer drugs such as Ocrevus for multiple sclerosis  MS    before a  re acceleration  around 2021 22   If you have such a sharp portfolio shift as we have now  then of course you have to reallocate resources in a more dramatic way   Schwan said   That s what we are doing   The company will have to run fast to stand still  Roche estimates it could have a  10 billion sales gap to fill by 2022 from rival incursions into cancer treatment  territory the Swiss drugmaker has long dominated  Roche s three best selling drugs   all for cancer   had combined sales of  21 billion last year  accounting for 40 percent of overall sales  But the drugs   Rituxan  Herceptin and Avastin   now face a steep decline  due to cheap near copies  known as biosimilars  made by rivals including Switzerland s  Novartis   S NOVN  and South Korea s Celltrion  KS 068270   Adding to the pain  a key technology patent will expire next year  lopping another  600 million or so from cash flow  In Europe  where biosimilars are already making deep inroads  Roche s cost cutting is more advanced  with some commercial operations being trimmed back  Now  the United States is on the block with Roche cutting 223 positions at Genentech s South San Francisco campus  The company is also streamlining global business units as part of a separate  wide reaching move that could impact scores of jobs  It is a prescription that investors are likely to appreciate   There is room to improve efficiency in the business   said Berenberg analyst Alistair Campbell  BOLT ON ACQUISITIONS  Still  Roche intends to ring fence research and development  R D  and is sticking by a long standing strategy of using only small to mid sized bolt on acquisitions to shore up its drugs pipeline  rather than buying in a big new medicine business  To some extent that is pragmatic   Typically  we cannot make the economics work   Schwan said  The shifting sands mean Roche may look rather different when it finally emerges from the shadow of biosimilars  with non cancer drugs playing an increasingly important role   a trend already being set by Ocrevus in MS and Hemlibra for haemophilia  In particular  while other companies including  Pfizer  Inc  N PFE  have pulled back in neuroscience  Roche hopes to restock its medicine cabinet with drugs against autism  Alzheimer s and Huntington s disease  These are high risk  high reward diseases but Roche believes its understanding of the latest science means it could become as well known for treatments of brain and nervous system disorders as for cancer   The jury is still out   Schwan said   There is actually now a reasonable chance that we diversify into other areas in a meaningful way   Meanwhile  its cancer R D effort continues  Schwan acknowledged Roche s Tecentriq immunotherapy had lost ground to Merck   Co s  N MRK  Keytruda in first line lung cancer treatment but he still sees important new opportunities  notably in certain hard to treat forms of breast cancer  Among Roche s biggest potentials is a bispecific antibody  a dual action drug that brings tumor cells and immune cells closer together to fight blood cancers  One patient who failed previous treatments  including CAR T cell therapy in which the body s immune cells are reprogrammed  achieved full remission for a year after getting Roche s experimental bispecific therapy  it reported on Thursday   
 If you see such a response for very  very sick patients like that  that of course is extremely promising   Schwan said   That is one of our molecules we put a lot of hope into  ",2018-09-13,Reuters,https://www.investing.com/news/stock-market-news/roche-steps-up-efficiency-drive-to-take-sting-out-of-biosimilars-1609524,1609524
202739,424255,MRK,Ebola vaccinations to begin in eastern Congo,news,Vaccinations against a new Ebola outbreak in eastern Democratic Republic of Congo  believed to have killed 33 people  are due to begin on Wednesday The experimental vaccine  which is manufactured by Merck  NYSE MRK   proved successful during its first wide scale usage against an outbreak in northwestern Congo that was declared over less than two weeks ago More than 3 000 doses remain in stock in the capital Kinshasa Now read ,2018-08-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/ebola-vaccinations-to-begin-in-eastern-congo-1561090,1561090
202740,424256,MRK,Congo starts vaccinating health workers against Ebola,news,"By Fiston Mahamba MANGINA  Congo  Reuters    Congolese officials and the World Health Organization began vaccinating health workers against the deadly Ebola virus on Wednesday  to try to halt an outbreak in Congo s volatile east   A Reuters witness on a visit to Mangina  the village in eastern Democratic Republic of Congo where the epidemic was declared  saw health workers in protective suits administering the injections  So far 43 people are believed to have been infected in North Kivu and Ituri provinces  including 36 who have died  the health ministry said on Tuesday   We are putting all our energy and all our expertise to quickly control this epidemic   Health Minister Oly Ilunga told journalists at the start of the vaccination campaign   All the measures of prevention are in place  The vaccination is the last phase  It will enable us to break the chain of transmission of this epidemic    More than 900 contacts of those infected have been identified for monitoring  although security is an issue in the area where militia groups operate  WHO said   The disease  which causes fever  vomiting and diarrhea  is spread through direct contact with body fluids   Around 40 health workers are expected to be vaccinated today  by end of the week  once all the necessary steps are in place  vaccination of community contacts and their contacts will commence   WHO spokesman Tarik Jasarevic said  WHO has said that analysis of genetic sequencing showed it was a separate outbreak from the one 2 500 km  1 500 miles  away in the northwest that ended less than two weeks ago after killing 33 people    but the same Zaire strain  This is Congo s 10th Ebola outbreak since the virus was first identified near northern Congo s Ebola river   There is a huge fear among the local population   Kaswera Mathumo  a medical worker at a clinic in Mangina  where the vaccinations were taking place  said  The experimental vaccine being used  which is manufactured by Merck  NYSE MRK   proved successful during its first wide scale usage against the previous outbreak in Equateur Province   More than 3 000 doses remain in stock in the capital Kinshasa  allowing authorities to deploy them quickly to affected areas  But they face security challenges in eastern Congo  a region bubbling with conflicts over land and ethnicity stoked by decades of on off war   
Local authorities announced on Tuesday that 14 bodies had been discovered in the town of Tubameme  about 40 km  25 miles  northeast of the epicenter of the outbreak in the town of Mangina  suspected to have been killed by a militia group ",2018-08-08,Reuters,https://www.investing.com/news/world-news/congo-starts-vaccinating-health-workers-against-ebola-1565831,1565831
202741,424257,MRK,Ziopharm up 24  after Q2 report,news,Ziopharm Oncology  ZIOP  24 3   is up on below average volume after reporting Q2 results after the close yesterday that were inline with expectations  Highlights Net loss    17 5M   loss share    0 12   Cash and equivalents at quarter end   40 4M IND to be filed next quarter for Phase 1 study using Sleeping Beauty platform to generate T cells that express personalized T cell receptors  TCRs  to target cancer cell neoantigens in patients with solid tumors Work ongoing to address FDA clinical hold on third generation Phase 1 study of CD19 specific T cells produced in under two days with Sleeping Beauty  Agency has requested additional information related to chemistry  manufacturing and controls  CMC   The timing on the start of the trial may be impacted Phase 1 study of CD33 specific CAR T therapy for acute myeloid leukemia is ongoing  Decision by year end on whether to transition the therapy to Sleeping Beauty Collaboration partner Merck  NYSE MRK  KGaA  OTCPK MKGAY  0 6   has selected two targets using Sleeping Beauty  Preclinical work completed Now read ,2018-08-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/ziopharm-up-24-after-q2-report-1567959,1567959
202742,424258,MRK,Taro Pharmaceutical misses by  0 62  misses on revenue,news,Taro Pharmaceutical  NYSE TARO   Q1 EPS of  1 71 misses by  0 62 Revenue of  154 62M   4 2  Y Y  misses by  24 92M Press ReleaseNow read ,2018-08-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/taro-pharmaceutical-misses-by-062-misses-on-revenue-1568859,1568859
202743,424259,MRK,Roundup cancer verdict sends Bayer shares sliding,news,"By Ludwig Burger FRANKFURT  Reuters    Bayer  DE BAYGn  shares plunged as much as 14 percent on Monday  losing about  14 billion in value  after newly acquired  Monsanto   NYSE MON  was ordered to pay  289 million in damages in the first of possibly thousands of U S  lawsuits over alleged links between a weedkiller and cancer  After the verdict in favor of a California school groundskeeper with terminal cancer  Monsanto faces more than 5 000 similar lawsuits across the United States over claims it did not warn of the cancer risks of glyphosate based weedkillers  including its Roundup brand  Monsanto  bought by Bayer this year for  63 billion  said that it would appeal against the jury s verdict in California  which is the latest episode in a long running debate over claims that exposure to Roundup can cause cancer  The case by plaintiff Dewayne Johnson  filed in 2016  was fast tracked for trial due to the severity of his non Hodgkin s lymphoma  a cancer of the lymph system that he alleges was caused by Roundup and Ranger Pro  another Monsanto glyphosate herbicide   The jury s verdict is at odds with the weight of scientific evidence  decades of real world experience and the conclusions of regulators around the world that all confirm glyphosate is safe and does not cause non Hodgkin s lymphoma   Bayer said in a statement  Having closed the Monsanto takeover  Bayer is only awaiting the approval of some final antitrust related asset sales before folding it into its own organization  It did not negotiate any payments from Monsanto shareholders for Roundup related litigation  Bayer shares were down 11 2 percent at 82 93 euros at 1320 GMT  the worst performing stock on the Stoxx Europe 600 index  STOXX   and on track to close at their lowest in almost five years   Barclays   LON BARC  analysts said Bayer was in for a  litigious headache    Whilst an appeal is certain and may indeed likely result in the penalty being moderated at a minimum if not reversed altogether  a large number of similar pending cases will now likely multiply   Berenberg analyst Alistair Campbell said resolving the issue could cost Bayer  5 billion  citing a rough estimate based on a past product liability settlements such as Merck   Co Inc s  N MRK   4 9 billion settlement over painkiller Vioxx or Bayer s  4 2 billion total settlement over the Baycol cholesterol drug  The controversy could also affect future revenues  Genetically modified  GM  crops that withstand glyphosate are a main source of cash for Monsanto  mainly generated in North and South America  where the technology is widely accepted  The health worries could further darken the outlook for a product category following the emergence of weeds that have grown resistant to the herbicide   We think the risk of withdrawal is extremely low  but if it materialized it would be a major blow to the transaction value paid for the company   said Berenberg s Campbell  SCIENTIFIC DEBATE Discovered by the Monsanto chemist John E  Franz in 1970  patent free glyphosate herbicides are now sold by the global crop protection industry despite the dispute over its safety  The U S  court ruling caught many Bayer investors off guard as no hard evidence of a causal link to cancer had been produced so far  The World Health Organization s  WHO  cancer arm in 2015 classified glyphosate as  probably carcinogenic to humans   but the U S  Environmental Protection Agency in September 2017 concluded a decades long assessment of glyphosate risks and found the chemical was not likely carcinogenic to humans  A Reuters report in October showed that the WHO s cancer agency dismissed and edited findings from a draft of its review of glyphosate that were at odds with its final conclusion that the chemical probably causes cancer  In Europe  the EU Commission in December drew criticism for renewing the license for glyphosate  Germany and France have meanwhile taken steps to phase out use of the weedkiller  The U S  case may prompt some retailers to curb sales of Roundup products  Homebase  one of Britain s largest home and garden improvement retailers  is reviewing the sale of glyphosate containing products in the light of the jury s decision  a spokeswoman said  Glyphosate exposed stocks also plunged in Asia and particularly in Australia where a withering drought has already hit herbicide sales  Australian chemical maker  Nufarm Ltd   AX NUF   which Macquarie Bank analysts estimate earns about a fifth of its revenue from glyphosate based products  plunged almost 17 percent to a more than two year low  
Its top shareholder  Japan s Sumitomo Chemical Co Ltd  T 4005   shed 3 percent  while Australian rural services firm Elders Ltd  AX ELD   which retails herbicides  fell 11 percent ",2018-08-13,Reuters,https://www.investing.com/news/stock-market-news/bayer-shares-down-after-monsanto-ordered-to-pay-damages-1571017,1571017
202744,424260,MRK,AstraZeneca s Triple Combo COPD Inhaler Gets CRL From FDA,opinion,AstraZeneca plc   NYSE AZN   announced that the FDA has given a complete response letter to its new drug application  NDA  looking for approval of its investigational triple combination therapy  PT010 for chronic obstructive pulmonary disease  COPD  PT010 is a combination of budesonide  an ICS with glycopyrronium  a long acting muscarinic antagonist  LAMA  and formoterol fumarate  a long acting beta agonists  LABA  therapy  PT010 can be delivered using AstraZeneca s Aerosphere Delivery Technology Japan s Ministry of Health  Labour and Welfare approved PT010 in June by the trade name of Breztri Aerosphere to relieve symptoms of COPD  The candidate is also under review in the EU and China The NDA was based on data from the KRONOS study  which compared PT010 to AstraZeneca s own dual combination therapies   Bevespi Aerosphere  Symbicort Turbuhaler  and PT009   in COPD indication  AstraZeneca said that it will meet with the FDA to discuss the next steps including submission of data from another study   ETHOS   on PT010 for review  ETHOS data was not included in the NDA as the study was incomplete at that time  Last month  AstraZeneca announced that the ETHOS study  which evaluated PT010 in patients with moderate to very severe COPD  met the primary endpoint  In the study  Breztri Aerosphere showed a statistically significant reduction in the rate of moderate or severe exacerbations   the primary endpoint   at both standard and low budesonide doses compared with Bevespi and PT009 in the abovementioned COPD patients who have had a history of exacerbation s  in the previous year We remind investors that Glaxo   NYSE GSK   also markets a once daily  single inhaler triple combination therapy  Trelegy Ellipta for COPD  Trelegy Ellipta is a combination of fluticasone furoate   an ICS  umeclidinium   a LAMA and vilanterol   a LABA therapy  Trelegy Ellipta is delivered in Glaxo s Ellipta dry powder inhaler  Theravance Biopharma  Inc    NASDAQ TBPH   has an economic interest in Trelegy Ellipta and earns royalties on its sales In a separate press release  AstraZeneca announced that it is divesting global rights to its acid reflux medicine  Losec  omeprazole  and other medicines containing omeprazole to Germany s pharma company  Cheplapharm  The divestment of the global commercial rights  excluding China  Japan  the United States and Mexico  of these mature medicines  will allow the company to focus on three main therapy areas   Oncology  Cardiovascular  Renal and Metabolism  and Respiratory  For the deal  AstraZeneca will get a payment of approximately  243 million from Cheplapharm on closure  plus sales contingent milestones of up to  33 million in 2021 and 2022  Earlier  AstraZeneca had divested the commercial rights to Losec and other omeprazole medicines in the United States  Japan and Mexico Recently  at the European Society of Medical Oncology  ESMO  congress in Barcelona  Spain  AstraZeneca and partner Merck   NYSE MRK   presented detailed data from two late stage label expansion studies on their PARP inhibitor  Lynparza  Data from the PAOLA 1 study showed that  added to bevacizumab as a first line maintenance treatment reduced the risk of disease progression or death by 41  in women suffering from advanced ovarian cancer regardless of their biomarker status or surgical outcome  Meanwhile  in the phase III PROfound study  Lynparza doubled the time without radiographic disease progression in an advanced prostate cancer patient population At ESMO  AstraZeneca also presented new data from the phase III FLAURA study  which demonstrated superior overall survival benefit of Tagrisso to standard of care medicines in patients with EGFR mutated non small cell lung cancer 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-02,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-triplecombo-copd-inhaler-gets-crl-from-fda-200469844,200469844
202753,424269,MRK,IZEA signs definitive agreement to acquire TapInfluence,news,IZEA  IZEA  2 8   has reached a definitive agreement to acquire leading SaaS influencer marketing platform  TapInfluence  Inc   in a part cash  part stock transaction valued at  7 08M  IZEA s stock price as of market close on July 11   IZEA will acquire TapInfluence through a merger agreement and TapInfluence will become a wholly owned subsidiary of IZEA upon closing  TapInfluence s revenues for the year ended Dec  31  2017 were   5 9M and its gross billings were   18 2M  The company expects to close the merger transaction prior to month end  Now read ,2018-07-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/izea-signs-definitive-agreement-to-acquire-tapinfluence-1527241,1527241
202754,424270,MRK,Merck profit beats on Keytruda strength  raises full year forecast,news, Reuters    Drugmaker Merck   Co  N MRK  on Friday raised its full year profit forecast after beating Wall Street estimates for quarterly profit as sales of blockbuster cancer drug Keytruda nearly doubled  Sales of Keytruda rose 89 2 percent to  1 67 billion  edging past sales of its rival immunotherapy Opdivo made by Bristol Myers Squibb  N BMY   Analysts had expected Keytruda sales of  1 59 billion  according to  Credit Suisse   SIX CSGN   Keytruda and rival Bristol Myers Squibb s  N BMY  Opdivo have piled up approvals for a wide range of cancers  Both the cancer drugs work by triggering the immune system to attack tumors but Merck leads in lung cancer treatments  both alone and in combination with chemotherapy   For a graphic on  Keytruda vs Opdivo  click   Shares of the Dow component rose 1 4 percent to  64 9 before the bell  They have risen nearly 14 percent this year  outpacing a 7 1 percent rise in the S P 500 healthcare index  SPXHC  and the 3 3 percent rise in the blue chip index  DJI   Sales of Merck s cancer preventing Gardasil vaccines rose 30 percent to  608 million in the quarter and that of animal health unit rose 14 1 percent to  1 09 billion   Analysts and investors have been calling for a separation of the unit  but Merck has stressed in the past that it is an important  pillar of growth  and provides diversification from Keytruda   Merck s total sales rose 5 4 percent to  10 47 billion  The company now expects full year adjusted profit to be between  4 22 and  4 30 per share  up from prior guidance of between  4 16 and  4 28 per share  Net income attributable to the company fell to  1 71 billion  or 63 cents per share  in the second quarter ended June 30  from  1 95 billion  or 71 cents per share  a year earlier  Excluding items  the company earned  1 06 per share  ahead of the average analyst estimate of  1 03 per share  according to Thomson Reuters I B E S ,2018-07-27,Reuters,https://www.investing.com/news/stock-market-news/mercks-quarterly-profit-falls-12-percent-1548558,1548558
202755,424271,MRK,Congo declares new Ebola outbreak in eastern province,news,"By Fiston Mahamba GOMA  Democratic Republic of Congo  Reuters    Four people have tested positive for Ebola in eastern Democratic Republic of Congo just days after another outbreak that killed 33 people in the northwest was declared over  the health ministry said on Wednesday  Twenty people have already died from hemorrhagic fevers in and around Mangina  a densely populated town about 30 km  18 miles  southwest of the city of Beni and 100 km from the Ugandan border  the ministry said in its statement  without saying when the deaths occurred  A team of 12 experts from Congo s health ministry will arrive in Beni on Thursday to set up a mobile lab  the ministry said  The World Health Organization has started moving staff and supplies to the area  WHO chief Tedros Adhanom Ghebreyesus said  They head to a region where deep security problems could complicate efforts to contain the virus  About 1 000 civilians have been killed by armed groups and government soldiers around Beni since 2014  and the wider region of North Kivu holds over 1 million displaced people    This is an active conflict zone  The major barrier will be safely accessing the affected population   Peter Salama  WHO Deputy Director General of emergency preparedness and response  said in a statement   Jeremy Konyndyk  an aid expert at the Center for Global Development  said other recent Ebola outbreaks had fortunately been in relatively safe and stable areas    North Kivu is a different story  which makes me a little nervous   he said  The area also has strong trade with neighboring Rwanda and Uganda  raising the risk of the virus moving internationally  Julie Hall  chief of staff at the International Federation of the Red Cross  said the Ebola response in North Kivu would be a  highly complex  operation  The ministry said no evidence linked this outbreak with the last one  which began in April and occurred over 2 500 km  1 553 miles  away in northwestern Congo  BATS AND BODY FLUIDS This is the central African country s 10th outbreak since 1976  when the virus was discovered near the eponymous Ebola river in the north  That is more than twice as many as any other country  Ebola is believed to be spread over long distances by bats and can turn up in bush meat sold at food markets throughout Congo  Once present in humans  it causes hemorrhagic fever  vomiting and diarrhea and is spread through direct contact with body fluids  An outbreak concentrated in the West African countries of Sierra Leone  Liberia and Guinea killed at least 11 300 people between 2013 and 2016   Congolese and international health officials were credited with responding rapidly to the last outbreak  including by deploying an experimental vaccine manufactured by Merck  NYSE MRK   one of several vaccines being developed against Ebola  But the Merck vaccine is designed to be used against the Zaire strain of Ebola  and there has been no confirmation of the strain in the latest outbreak  with the WHO calling it only  presumptive Ebola    A WHO spokesman declined to comment on possible vaccine use  Aside from the vaccine  the key factors in halting the previous outbreak appeared to be aggressive tracing of potential patients and the speed of the response  The WHO said the fact that it already had staff and equipment in place would give it a head start against the new outbreak   Ebola is a constant threat in DRC  What adds to our confidence in the country s ability to respond is the transparency they have displayed once again   WHO head Tedros said   
 We will fight this one as we did the last  ",2018-08-01,Reuters,https://www.investing.com/news/stock-market-news/congo-declares-new-ebola-outbreak-in-eastern-province-1555693,1555693
202756,424272,MRK,WHO warns there may be no vaccine option for new Ebola outbreak,news,"By Tom Miles and Fiston Mahamba GENEVA GOMA  Reuters    It may be impossible to use a vaccine to tackle Democratic Republic of Congo s new Ebola outbreak that has caused four confirmed cases  including two health workers  a senior World Health Organization  WHO  official said on Thursday   Officials have not confirmed the particular strain of Ebola causing the outbreak  which may have killed 20 people  but WHO s emergency response chief Peter Salama said it could be the Zaire  Sudan or Bundibugyo strain  If it is the Zaire strain  the Merck  N MRK  vaccine used in the last Ebola outbreak may be an option  otherwise the situation will be much more complex  and we may not have any vaccine options   he told Reuters at WHO s headquarters in Geneva    The majority of the cases occurred in the second half of July     When the provincial medical teams have looked back     they have noted cases that could be consistent with Ebola that began even in May but it s far too early to say   Salama said  The cases are spread over tens of kilometers  he said  International experts set up a laboratory on Thursday in the city of Beni  30 km  18 miles  from where the outbreak was declared  WHO and Congolese officials said  Officials from the United Nations  World Bank  WHO Congo s Ministry of Health  including Health Minister Oly Ilunga  will support a team already on the ground  Congo declared the outbreak on Wednesday  just days after another that killed 33 people in the northwest was declared over  The 20 died in and around Mangina  a densely populated town in North Kivu province about 30 km  18 miles  southwest of the city of Beni and 100 km from the Ugandan border  The ministry has not made public when the deaths occurred  Another six who are still living are showing signs of fever  of which four tested positive   The Government Partner delegation is holding its first meeting to organize the response   North Kivu governor Julien Paluku tweeted   Already a     team from Kinshasa is installing a laboratory and a single coordination center   But eastern Congo is a tinderbox of conflicts over land and ethnicity stoked by decades of on off war and this could hamper efforts to contain the virus  About 1 000 civilians have been killed by armed groups and government soldiers around Beni since 2014  and the wider region of North Kivu holds over 1 million displaced people  
 The response is already in place   David Gressly  United Nations Deputy Special Representative Congo  told journalists in Beni   We  the U N  mission  will offer logistical support and if needed security support  We are all     here to see how we can organize this as fast as possible  ",2018-08-02,Reuters,https://www.investing.com/news/world-news/who-says-ebola-team-arrives-in-congo-1557445,1557445
202757,424273,MRK,Tyme Initiates Pivotal Stage Of Pancreatic Cancer Study,opinion,Tyme Technologies  Inc    NASDAQ TYME    announced that it has commenced the pivotal stage of the TYME 88 Panc study to evaluate the clinical benefits of its lead cancer metabolism based therapies  CMBT  candidate  oral SM 88  racemetyrosine   for third line treatment of patients with metastatic pancreatic cancer  Enrollment is expected to begin in the fourth quarter of 2019 at leading pancreatic cancer research centers across the United States  SM 88 is a combination therapy that uses a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells  breaking down their defenses and making them vulnerable to oxidative stress and death Shares of the company have slumped 54 8  year to date against the  s growth of 5 2  TYME 88 Panc study is a multi center  randomized  1 1   controlled pivotal study that will evaluate the efficacy and safety of SM 88 used with MPS  methoxsalen  phenytoin  sirolimus  in patients with metastatic adenocarcinoma of the pancreas  whose disease has progressed or recurred and have received two lines of prior systemic therapy  The primary endpoint of the study will be overall survival  OS   Key secondary endpoints will be progression free survival  PFS   clinical benefit response rate  CBR   defined as patients achieving stable disease or better  circulating tumor cells  CTCs  and quality of life  QOL   The phase II portion of the TYME 88 Panc study was presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer in Barcelona  Spain  in July 2019  The study demonstrated encouraging OS trends in patients with advanced pancreatic cancer Advanced pancreatic cancer is a difficult to treat cancer with the lowest survival rates among all cancer types  There are several companies developing treatments for this disease  In February  AstraZeneca plc   NYSE AZN   and partner Merck s   NYSE MRK   PARP inhibitor  Lynparza  met the primary endpoint in a late stage study evaluating it as the first line maintenance treatment in germline BRCA mutated metastatic pancreatic cancer Zacks Rank   Another Stock to ConsiderCurrently  Tyme is a Zacks Rank  1  Strong Buy  stock Another top ranked stock in the same space is FibroGen Inc    NASDAQ FGEN    carrying a Zacks Rank  1  You can see  FibroGen s loss per share estimates have narrowed from  1 09 to 37 cents for 2019 and from 32 cents to 18 cents for 2020 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  the average beat being 346 59      Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/tyme-initiates-pivotal-stage-of-pancreatic-cancer-study-200468383,200468383
202758,424274,MRK,Here s Why AstraZeneca  AZN  Is Outperforming Its Industry ,opinion,AstraZeneca plc  s   NYSE AZN   stock has rallied 19 3  this year so far  outperforming the decrease of 0 8   The company s outperformance has been backed by quite a few positive developments on the regulatory and pipeline front  strong performance of its relatively newer drugs as well as a bullish outlook for the second half of the year New Drugs Enable Return to GrowthNewer drugs like Brilinta  cardiovascular   Lynparza  ovarian cancer   Farxiga Forxiga  type II diabetes  and Tagrisso  lung cancer  are driving top line growth  with AstraZeneca launching them in more markets and in an increased number of indications  Tagrisso became AstraZeneca s biggest medicine in 2019  Brilinta and Farxiga achieved blockbuster status in 2017  exceeding  1 billion in sales  In fact  AstraZeneca expects Imfinzi and Lynparza to achieve blockbuster status by this year  This means five of its newer medicines  Tagrisso  Brilinta  Farxiga  Imfinzi and Lynparza  will have blockbuster status by the end of this year  AstraZeneca is looking for further label expansions of these drugs AstraZeneca returned to product sales growth in 2018  The momentum continues in 2019 so far mainly on the back of its newer drugs  Patent expirations have been hurting its product sales growth since 2010  Sales of AstraZeneca s newer medicines rose 81  in 2018 and 77  in the first half of 2019 as almost every new product it has launched in recent years has done well  The company is confident of seeing growth for several years driven by sales of its new medicines  Tagrisso  Imfinzi  Lynparza  Farxiga and Fasenra Positive Pipeline DevelopmentsAstraZeneca delivered well on its R D pipeline with meaningful data readouts and regulatory updates announced this year Late stage studies on key pipeline candidates  anifrolumab for systemic lupus erythematosus and Breztri Aerosphere PT010  fixed dose triple combination inhaler  met primary endpoints  Also  several late state studies evaluating AstraZeneca s successful cancer drugs  Lynparza  Calquence and Tagrisso demonstrated improved survival rates in expanded patient populationsThis year s new drug approvals include Breztri Aerosphere in Japan and Qternmet XR  a combination of Farxiga and Onglyza plus metformin  in the United States Key approvals for line extensions of newer drugs in 2019 so far include that for Lynparza in front line ovarian cancer in Japan and EU and for breast cancer in EU  and Farxiga Forxiga for type I diabetes in EU and Japan  Notably  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK   In April 2019  AstraZeneca acquired joint development and commercialization rights to an innovative antibody drug conjugate  ADC   trastuzumab deruxtecan  from Japan s Daiichi Sankyo  A regulatory application seeking approval of trastuzumab deruxtecan in metastatic breast cancer is expected to be filed with the FDA later this year Several other pipeline and regulatory events are scheduled for 2019  This includes NDA filing for roxadustat  which has been developed to treat anemia in patients with chronic kidney disease in the United States  AstraZeneca also expects to file regulatory applications for Calquence to get approval for the larger chronic lymphocytic leukemia indication  in frontline and in the relapsed recurrent disease setting  later this year ConclusionAstraZeneca  which currently carries a Zacks Rank  2  Buy   has its share of challenges  These include generic competition for its core products  stiff competition in its diabetes franchise and pricing pressure on its respiratory franchise  However  we believe  the company s newer drugs  upcoming product launches  aggressive cost cutting efforts and a promising late stage pipeline should keep the stock afloat through the rest of the year Some other top ranked large cap pharma stocks include Sanofi   NASDAQ SNY   and Novartis   NYSE NVS     Both carry a Zacks Rank  2   You can see  Novartis  earnings estimates for 2019 have gone up 1 8  while that for 2020 have increased 1 1  over the past 30 days  Novartis stock has returned 15 9  so far in 2019 Shares of Sanofi have risen 10 2  this year so far  Earnings estimates for 2019 and 2020 have risen 0 9  and 1 1   respectively over the past 60 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/heres-why-astrazeneca-azn-is-outperforming-its-industry-200468441,200468441
202759,424275,MRK,Here s Why Sanofi  SNY  Is Outperforming Its Industry Of Late,opinion,Sanofi  PA SASY  s   NASDAQ SNY   shares have outperformed the industry this year so far  It has risen 7 1  in the said time frame against the  decrease of 0 8   The company s performance has been backed by quite a few positive developments on the regulatory and pipeline front mainly related to its new successful drug Dupixent  strong performance of its Specialty Care segment  as well as a decent earnings performance in the first half of the year Sanofi s Specialty Care segment  particularly  is on a strong footing with recent FDA approval of new drugs Libtayo and Cablivi  and Dupixent for its second indication in asthma  Dupixent was approved for the asthma indication in the United States in October 2018 and in EU in May 2019  It had gained approval for the first indication   atopic dermatitis in adults   in 2017  Please note that Sanofi markets Dupixent in partnership with Regeneron   NASDAQ REGN   Dupixent generated sales of  825 million in the first half of 2019  up 175 3  year over year  Sales were driven by continued growth in atopic dermatitis indication and rapid uptake in new asthma indication Meanwhile  Dupixent was launched for adolescent atopic dermatitis and for chronic rhinosinusitis with nasal polyposis in the United States in mid March and June  respectively  It was approved to treat adolescent atopic dermatitis in Europe last month  All these label expansions should drive sales of this key drug higher in the future quarters The performance of Sanofi s Vaccines and Consumer Healthcare franchises has also improved of late Sanofi s R D pipeline is strong and has delivered important results with several positive data read outs and the achievement of regulatory milestones this year Late stage studies on key pipeline candidates  asthma candidate  REGN3500 and refractory multiple myeloma candidate  isatuximab  met primary endpoints This year s new drug approvals include Libtayo for advanced cutaneous squamous cell carcinoma in the EU and Cablivi for a rare blood disorder called acquired thrombotic thrombocytopenic purpura in the United States  Key approvals for line extensions include the ones mentioned above for Dupixent and approvals to include cardiovascular outcomes data on the label of its PCSK9 inhibitor  Praluent in Europe and the United States Sanofi  which currently carries a Zacks Rank  2  Buy   has its share of challenges like weak performance of the Diabetes unit  generic competition for many drugs and slower than expected uptake of core products like Praluent  However  we believe  continued strong performance of its Specialty Care unit mainly Dupixent  upcoming product launches  aggressive cost cutting efforts and a promising late stage pipeline should keep the stock afloat through the rest of the year Some other top ranked large cap pharma stocks include Merck   NYSE MRK   and Novartis   NYSE NVS    both carrying a Zacks Rank  2  You can see  Shares of Merck have risen 11  this year so far  Earnings estimates for 2019 and 2020 have risen 3 8  and 1 9   respectively over the past 60 days Novartis  earnings estimates for 2019 have gone up 1 8  while that for 2020 have increased 1 1  over the past 30 days  Novartis stock has returned 15 9  so far in 2019 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/heres-why-sanofi-sny-is-outperforming-its-industry-of-late-200468432,200468432
202760,424276,MRK,AstraZeneca Merck s Lynparza Improves PFS In Frontline Study,opinion,AstraZeneca   NYSE AZN   presented detailed data from a phase III study evaluating the company s and Merck s   NYSE MRK   PARP inhibitor  Lynparza  for a broader advanced ovarian cancer patient population at the European Society of Medical Oncology  ESMO  congress in Barcelona  SpainThe PAOLA 1 study evaluated Lynpazra as a first line maintenance treatment in combination with Roche s   OTC RHHBY   Avastin  bevacizumab  versus Avastin alone in women suffering from advanced ovarian cancer regardless of their biomarker status or surgical outcome Data from the study showed that Lynparza improved progression free survival  PFS   or the time the abovementioned women lived without disease progression  to a median of 22 1 months versus 16 6 months in the Avastin arm in the broad population  Lynparza added to bevacizumab reduced the risk of disease progression or death by 41  in the overall patient population Meanwhile  in a sub group of patients   homologous recombination deficiency  HRD  positive newly diagnosed advanced ovarian cancer patients   treatment with Lynparza plus bevacizumab reduced the risk of disease progression or death by 67   Please note that HRD positive patients represent about half of ovarian cancer cases Shares of AstraZeneca have rallied 19 2  this year so far against the  s decrease of 0 6  In August  the companies had announced top line data from the same study  Back then  the company had said that treatment with Lynparza plus Avastin led to a statistically significant and clinically meaningful improvement in PFS in the intent to treat population versus Avastin alone Lynparza is presently approved as first line maintenance treatment for BRCAm advanced ovarian cancer  following response to platinum based chemotherapy based on data from the phase III SOLO 1 study  If approved for first line maintenance indication based on PAOLA 1 study  Lynparza can be prescribed to a much wider population including those who do not have the BRCA mutation  This can significantly increase the market for the drug Lynparza  presently marketed for advanced ovarian cancer and breast cancer  is also in different studies for a range of tumor types including prostate  pancreatic and gastric cancers as well as earlier line settings for ovarian and breast cancers Lynparza is part of AstraZeneca s strong oncology portfolio  Oncology sales now comprise around 35  of AstraZeneca s total product sales  surging 50  in 2018 and 58  in the first half of 2019  In the same period  Lynparza generated sales of  520 million  up 93  year over year Glaxo   NYSE GSK   also presented positive detailed data from the phase III PRIMA study evaluating its PARP inhibitor  Zejula  niraparib   as monotherapy for maintenance therapy of women with first line ovarian cancer  who had received platinum based chemotherapy  Data demonstrated that Zejula significantly reduced the risk of disease progression or death by 38   irrespective of biomarker status Zacks Rank AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-29,Zacks Investment Research,https://www.investing.com/analysis/astrazenecamercks-lynparza-improves-pfs-in-frontline-study-200469220,200469220
202761,424277,MRK,Glaxo s Zejula Betters PFS In First Line Ovarian Cancer Study,opinion,"GlaxoSmithKline plc   NYSE GSK   presented positive detailed data from the phase III PRIMA study evaluating its PARP inhibitor  Zejula  niraparib   as monotherapy for maintenance therapy of women with first line ovarian cancer who have received platinum based chemotherapy  Data demonstrated that Zejula  when given as monotherapy  significantly reduced the risk of disease progression or death by 38   irrespective of biomarker status The company had announced in July that the PRIMA study met its primary endpoint of progression free survival   PFS    Detailed data from the study were presented at the 2019 European Society for Medical Oncology   ESMO   congress Zejula is currently approved as a maintenance treatment for patients with recurrent ovarian cancer Shares of Glaxo have rallied 10 8  so far this year against the  s decrease of 0 6   The PRIMA study evaluated Zejula monotherapy in women who responded to first line treatment with platinum based chemotherapy including those with high risk of disease progression  Data from the study showed that risk of disease progression was reduced by 60   50  and 32  in patients with BRCA mutant tumors  HRD positive BRCA wild type tumors and HRD negative tumors  respectively Glaxo claims that Zejula is the first PARP inhibitor to achieve significant improvement in PFS as monotherapy in first line maintenance setting for ovarian cancer Moreover  a pre planned interim analysis of overall survival   OS   showed that OS was numerically favorable for Zejula compared to placebo in overall population  Interim OS showed that 91  of patients were alive at 24 months compared to 85  for placebo in HRD positive ovarian cancer patient group  while 81  of HRD negative patients were alive at 24 months versus 59  for placebo Notably  Zejula was added to Glaxo s portfolio  following the acquisition of Tesaro in January this year  The drug generated sales of  99 million in the first half of 2019 Apart from the PRIMA study  Zejula is being evaluated in the pivotal phase III BRAVO study to treat patients with germline BRCA mutated  metastatic breast cancer  The drug is also being examined in several combination studies  Zejula in combination with Merck s   NYSE MRK   anti PD 1 inhibitor  Keytruda  pembrolizumab  is being studied for treating metastatic triple negative breast cancer and advanced platinum resistant ovarian cancer  Moreover  Zejula plus Roche s   OTC RHHBY   Avastin  bevacizumab  is being studied in patients with recurrent  platinum sensitive ovarian cancer In June  the FDA granted priority review to Glaxo s supplemental new drug application  sNDA   looking to expand Zejula s label for treating ovarian cancer in patients who have received three or more chemotherapy regimens  The FDA is expected to make a decision on Oct 24  2019 Meanwhile  AstraZeneca   NYSE AZN   also presented encouraging data at ESMO from a phase III study evaluating its PARP inhibitor  Lynparza  in combination with Roche s Avastin as first line maintenance treatment for newly diagnosed advanced ovarian cancer  irrespective of biomarker status or outcome from previous surgery  Data from the study showed that the combination regimen reduced the risk of disease progression or death by 41   AstraZeneca develops Lynparza in collaboration with Merck  The drug is already approved in the first line maintenance setting for ovarian cancer patients who have responded to platinum based chemotherapy GlaxoSmithKline plc Price
    Zacks RankGlaxo currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-29,Zacks Investment Research,https://www.investing.com/analysis/glaxos-zejula-betters-pfs-in-firstline-ovarian-cancer-study-200469261,200469261
202771,424287,MRK,Latecomer Sanofi looks to catch next wave of cancer therapies,news,"By Matthias Blamont PARIS  Reuters    Sanofi  PA SASY  missed the boat on immune system boosting cancer drugs  Now it s trying to catch up   The French drugmaker has hired John Reed  the former top scientist at oncology market leader Roche to head its group research operations  And it is now focusing on a pipeline of 10 medicines that it hopes will help it get a piece of the  100 billion a year cancer drug market  Dmitri Wiederschain  head of Sanofi s immuno oncology research  acknowledged the company had failed to capitalize on the takeoff of immunotherapy   drugs that activate the body s immune system to attack tumor cells   in the early 2010s   But he said the group could now gain an edge in the next waves of immunotherapy treatments  which include combining different drugs to better target cancer   It is of course a very competitive space but we now have  foundation assets  to form a better rationale for combinations   he told Reuters in an interview  citing immunotherapy approaches known as PD 1  TGFBeta and the antibody CD38    If you look across the biopharmaceutical landscape  Sanofi is the only company which has all three assets in its own pipeline or partnered with Regeneron   Wiederschain said  Sanofi teamed with U S firm Regeneron in 2007 to increase its presence in biotech medicine   Immunotherapy is the fastest growing part of the cancer drug segment  with sales expected to top  25 billion a year by 2021  according to analyst forecasts compiled by Thomson Reuters  Frederic Ponchon  a manager at Sycomore Asset Management which holds 6 7 million Sanofi shares  said the French company was unlikely to rival cancer leaders like Switzerland s Roche and U S  firm Merck  NYSE MRK    Co soon   They could enjoy occasional breakthroughs but it won t carry a lot of weight in their overall sales   he said    We can see that Sanofi takes cancer seriously but you must remember R D cycles are very long  So I would say Sanofi won t be a great player in oncology but it may have some successes from time to time    Sanofi s main business areas include drugs for diabetes  heart diseases and vaccines  with cancer treatments making up only about 4 percent of sales  Its cancer drug sales totaled  1 7 billion last year  compared with Roche s  25 9 billion  CROWDED MARKET Sanofi has not always been behind the curve in oncology  in the 1990s  it produced top selling cancer drugs such as Taxotere and Eloxatin   However it has been seven years since the company launched its last one  Zaltrap  which targets metastatic colorectal cancer and had sales of 75 million euros   87 million  last year  In the meantime  companies such as Bristol Myers Squibb and Merck   Co have developed their immunotherapy blockbusters  New treatments  if successful  can fetch more than  100 000 a year  In Sanofi s current cancer pipeline  only one has made it to regulatory review in the United States and the European Union  immunotherapy agent cemiplimab to treat cutaneous squamous cell carcinoma  Regeneron is its partner on the project   The company expects to submit for U S  regulatory review another of its cancer candidates  isatuximab  to treat multiple myeloma later this year or in early 2019   With over 2 000 drugs in the cancer immunotherapy space  the competitive landscape has never been more crowded as each firm seeks its own proprietary version of often similar drugs   There is clearly huge market potential but also a very large number of players  it is the toughest issue here   Nicolas Baudouin  a director at ratings agency Standard   Poor s said of immunotherapy  Many of the immunotherapy drugs work in only a minority of patients  which companies hope to improve by combining drugs that target tumors in different ways  This area  where Sanofi says it can be successful  has proven a challenge for drugmakers so far  Earlier this year  a study showed an experimental drug developed by U S Incyte had failed to bolster the effectiveness of Merck s blockbuster Keytruda to treat skin cancer patients  Roche also failed a key combination trial last month in colorectal cancer  ACQUISITIONS Wiederschain said molecular oncology  which targets a tumor based on its genetic makeup  would also be a future differentiator   It is about understanding better what drives the growth of cancer tissues  how the cells works and proliferation in the body   This has led Sanofi to launch early stage trials in breast cancer using molecular oncology technology  Newly appointed research chief Reed will start the job on July 1  when industry veteran Elias Zerhouni retires   Under Zerhouni s leadership  Sanofi has tried to improve research and development productivity but still struggled to find enough new products to offset the impact of weak diabetes drug sales   It has also been looking to acquisitions to fill its pipeline   
It struck two big deals in January  agreeing to buy U S haemophilia specialist Bioverativ for  11 6 billion and Belgium s Ablynx  which is developing an experimental drug for a rare blood disorder  for 3 9 billion euros ",2018-06-20,Reuters,https://www.investing.com/news/stock-market-news/latecomer-sanofi-looks-to-catch-next-wave-of-cancer-therapies-1499674,1499674
202772,424288,MRK,Bristol Myers to divest French OTC drug unit   Reuters,news,Reuters reports that Bristol Myers Squibb  BMY  0 4   has hired two investment banks to find a buyer for its OTC drugs business in France that generated revenues of 425M euros in 2017 The unit  which could fetch 1B euros or more  should attract buyout firms and German generics shop Stada  according to sources  The auction process should commence after the summer Now read ,2018-07-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/bristolmyers-to-divest-french-otc-drug-unit--reuters-1518998,1518998
202773,424289,MRK,Hitting cancer early  AstraZeneca s bid to outmaneuver rivals,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca  L AZN  suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit  Yet today two thirds of analysts tracked by Thomson Reuters recommend the stock  making it one of the sector s biggest consensus buys  and CEO Pascal Soriot says he is  absolutely  happy to carry on into the 2020s as he chases early use of modern cancer drugs   I don t have any plans to retire anytime soon   he told Reuters  Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance  it can still win elsewhere by targeting tumors before they have spread around the body  That is the second element of a twin track strategy to differentiate AstraZeneca in the hot area of immune system boosting drugs  which has seen rivals   led by Merck   Co  N MRK    leap ahead in late stage or metastatic disease  The idea that immunotherapy may actually work best in less sick patients is logical  since the immune system s natural role is to destroy nascent tumors  Indeed  some cancer doctors believe this could become the main battleground in future   It s not yet prime time     but in the long run I think we will move immunotherapy to a more front line early disease situation and I hope we will be treating more patients in that setting than in late stage disease   said John Haanen  an oncologist at the Netherlands Cancer Institute  JUMP START AstraZeneca already has a jump start here  since its Imfinzi immunotherapy is the new standard of care in treating early inoperable stage III lung cancer  That win follows a decision to run a study in this setting ahead of competitors   It was a smart move by AstraZeneca and they are now absolutely in business   said Haanen  Imfinzi sales will be a major focus for investors when the company reports half year results on July 26  Competitor Merck last month presented similar stage III results from a small study  but a larger trial using Bristol Myers Squibb s  N BMY  Opdivo drug recently stopped recruiting patients  suggesting direct competition is not imminent  AstraZeneca hopes to build on this lead in the so called adjuvant setting  where drugs are given after surgery to keep the cancer from coming back  Its BR 31 immunotherapy trial with Imfinzi was the first to start adjuvant therapy for lung cancer and the company thinks it could be the first to complete a major trial  with disease free survival data due in 2020   We are certainly hopeful to be the first   said David Berman  the group s head of immuno oncology   Berman jumped ship from Bristol Myers three years ago and believes his new employer has hit on a winning strategy   By moving to early stage you can actually leapfrog competitors who are ahead of you in stage IV   he said  Still  the race is on in both the adjuvant and neoadjuvant setting  where treatment precedes surgery  With each trial taking several years  picking winners is not easy   If everyone is similar on timing  then it is going to come down to data   said Liberum analyst Roger Franklin  who rates AstraZeneca a hold  HOW LONG TO TREAT  Lung cancer is by far the biggest killer among cancers and the top commercial opportunity for so called PDx immunotherapy infusions expected to be worth  15 billion in sales this year  according to Thomson Reuters  consensus forecasts  AstraZeneca estimates the majority of lung cancer patients are being diagnosed relatively early in the disease  when there is a better chance of a cure  One issue that concerns doctors is how long patients treated post surgery should take immunotherapy drugs  especially given that they cost nearly  150 000 a year  Most of the adjuvant trials now under way against various cancers are designed to give drugs for one year  Haanen is skeptical   Do you really need a year s treatment  Probably not   AstraZeneca is also pushing its early treatment mantra beyond immunotherapy with its lung cancer pill Tagrisso  which works is targeted at patients with specific genetic mutations that are particularly common in the booming Chinese market  With a clear lead in this particular treatment area  AstraZeneca has time to build out its Tagrisso business in early disease through two big ongoing clinical trials  Dan Mahony  a healthcare fund manager at Polar Capital  is bullish on AstraZeneca s prospects but reluctant to predict how the fight will play out in the long term  
Still  he says   There s more going on at AstraZeneca than met the eye a year ago  ",2018-07-06,Reuters,https://www.investing.com/news/stock-market-news/hitting-cancer-early-astrazenecas-bid-to-outmaneuver-rivals-1519658,1519658
202774,424290,MRK,Clovis Gains Rights To Pre Clinical Cancer Program For  12M,opinion,"Clovis Oncology  Inc    NASDAQ CLVS   announced that it has entered into a global licensing and collaboration agreement with privately held  Germany based biotech 3B Pharmaceuticals GmbH  The deal grants Clovis U S  and global rights  excluding Europe  to fibroblast activation protein alpha  FAP  targeted radiopharmaceutical program  3B Pharmaceuticals retains rights in Europe related to the FAP program  Please note that FAP is highly expressed in several epithelial cancers  including more than 90  of breast  lung  colorectal and pancreatic carcinomas  Under the collaboration agreement  the initial focus will be on developing a peptide targeted radionuclide therapy  PTRT  and imaging agent targeting FAP  Clovis will conduct global clinical studies and will solely bear the expenses during pre clinical stage of development  Clovis expects to file an Investigational New Drug   IND   application for FAP targeted radiopharmaceutical therapy in the second half of 2020 Per the terms of the deal  Clovis will pay  12 million in upfront payment to 3B Pharmaceuticals  Clovis is also liable to pay certain development and regulatory milestone payments and commercial royalties on any potential future sales related to products developed under the program Meanwhile  Clovis and 3B Pharmaceuticals intend to collaborate on a discovery program for three additional targets for radionuclide therapy  3B Pharmaceuticals will be responsible for discovery activities and Clovis will be responsible for IND enabling studies So far this year  Clovis  stock has declined 74 5  against the  s increase of 0 6   Please note that Clovis has one marketed drug   Rubraca   in its portfolio  This PARP inhibitor is approved as a maintenance treatment for recurrent ovarian cancer  irrespective of BRCA mutation  in second line setting  The drug is also approved as third or later line treatment for BRCA mutant ovarian cancer  Clovis is focused on expanding Rubraca s label into other cancer indications The company recorded revenues of  66 1 million in the first six months of 2019  solely from sales of Rubraca  registering growth of nearly 56  year over year However  the company faces stiff competition from large cap pharma companies including AstraZeneca   NYSE AZN    Merck   NYSE MRK   and Glaxo   NYSE GSK    which also market PARP inhibitors for ovarian cancer and are developing them for breast  prostate and other cancer indications  The diversification of Clovis  pipeline through the acquisition of FAP program may help the company to fight competition in the long run Clovis Oncology  Inc  Price
    Zacks RankClovis currently has a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/clovis-gains-rights-to-preclinical-cancer-program-for-12m-200467560,200467560
202775,424291,MRK,Bristol Myers  Opdivo Gains Positive CHMP View For New Dose,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion recommending the approval of a four week dosing schedule for its high profile immuno oncology drug Opdivo  nivolumab  as an adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease having undergone complete resection The committee has recommended the approval for flexible dosing options of a flat dosing schedule of Opdivo 240 mg infused over 30 minutes every two weeks or 480 mg infused over 60 minutes every four weeks for the above mentioned patient population Shares of Bristol Myers have lost 3 8  so far this year against the  increase of 0 1  We remind investors that Opdivo is Bristol Myers  primary growth driver  It is currently approved in the United States  the EU  Japan and other countries for several cancer indications  The blockbuster drug generated sales of  3 6 billion in the first half of 2019  reflecting a rise of 15  year over year  The company is further working on expanding the drug s label Earlier this month  Bristol Myers announced long term pooled efficacy and safety results from the phase III CheckMate 017 and CheckMate 057 studies on Opdivo in patients with previously treated  advanced non small cell lung cancer  NSCLC  The outcomes showed that at five years  patients treated with Opdivo continued to experience long term overall survival  OS  benefit compared to docetaxel  Treatment with Opdivo was associated with a 5 year OS rate of 13 4  compared to 2 6  with docetaxel in previously treated NSCLC patients However  competition is stiff in the NSCLC market  Opdivo faces severe rivalry from Merck s   NYSE MRK   PD L1 inhibitor Keytruda  which commands a strong place in the first line NSCLC market  Other PD L1 inhibitors available in the same space are AstraZeneca s   NYSE AZN   Imfinzi and Roche s   OTC RHHBY   Tecentriq Opdivo s label expansion into additional indications would give the product access to a higher patient population and increase its commercial potential significantly Zacks RankBristol Myers currently has a Zacks Rank  3  Hold   You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-09-24,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivo-gains-positive-chmp-view-for-new-dose-200467996,200467996
202776,424292,MRK,Menlo  MNLO  Completes Enrollment In Phase II Pruritus Study ,opinion,"Menlo Therapeutics Inc    NASDAQ MNLO   announced that it has completed patient enrollment in its phase II study evaluating the safety and efficacy of once daily oral serlopitant for the treatment of chronic pruritus  itch  of unknown origin  CPUO   
The phase II study is designed to evaluate the reduction in pruritus with serlopitant compared to placebo over a ten week treatment period based on a 4 point responder analysis on the worst itch numeric rating scale  WI NRS   which is a standard measure of itch  The study enrolled 233 patients  who experienced pruritus for at least six months prior to enrollment with no identified underlying cause for the pruritus 
Serlopitant  a small molecule  highly selective neurokinin 1  NK 1  receptor antagonist  is being developed for the treatment of prurigo nodularis  PN   psoriasis and CPUO 
Shares of the company have gained 12 6  so far this year against the  s decline of 3 2  

 
The company has completed four double blind phase II studies in more than 1 000 patients with pruritus and observed clinically relevant and statistically significant improvements in pruritus in patients treated with serlopitant compared to patients treated with placebo in three of the four studies 
Menlo is also enrolling patients in two phase III studies  which will evaluate the candidate in patients with pruritus associated with PN in the United States and Europe  Data from the study is anticipated in the first half of 2020 
The successful development of serlopitant in these ongoing studies is critical for Menlo s growth prospects  The company had in licensed serlopitant from Merck   NYSE MRK   in 2012 
There are several pharma companies developing treatments for pruritus  Vanda Pharmaceuticals Inc  s   NASDAQ VNDA   Tradipitant  VLY 686   a small molecule neurokinin 1 receptor antagonist  is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis  gastroparesis and motion sickness 
Zacks Rank   A Stock to Consider
Currently  Menlo is a Zacks Rank  3  Hold  stock 
A better ranked stock in the biotech sector is Acorda Therapeutics Inc    NASDAQ ACOR    carrying a Zacks Rank  1  Strong Buy   at present  You can see  
Acorda s loss per share estimates for the current year narrowed from  3 51 to  2 74 over the past 60 days  The company recorded a positive earnings surprise in the preceding four quarters  the average beat being 69 68      
5 Stocks Set to Double 
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth  Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/menlo-mnlo-completes-enrollment-in-phase-ii-pruritus-study-200468088,200468088
202777,424293,MRK,BioLineRx Begins Part 2 Of Phase I IIa Study On Solid Tumors,opinion,BioLineRx Ltd    NASDAQ BLRX   announced the dosing of the first patient in the part 2 of the phase I IIa study on AGI 134  AGI 134 is a synthetic alpha Gal glycolipid in development for solid tumors and highly differentiated from other cancer immunotherapies  The study will evaluate the safety and tolerability of AGI 134 at doses up to the recommended dose in multiple solid tumor types and a wide array of biomarkers  and validate AGI 134 s mechanism of action  Further  efficacy will be assessed by clinical and pharmacodynamic parameters  The company expects initial results from the part 2 of the study by 2020 end The company initiated the part 2 of the studyafter the successful completion of the part 1 and the determination of the recommended dose  In preclinical studies  AGI 134 led to regression of established primary tumors and prevented the growth of secondary tumors  The candidate also triggered a vaccine effect that may prevent the development of future metastases Shares of the company have plunged 59 2  year to date against the  s growth of 5 3  AGI 134 is the second leading oncology product in the company s portfolio  However  its lead program   BL 8040  is a cancer therapy platform currently being evaluated in a phase IIa study in pancreatic cancer  in combination with Merck   Co  s   NYSE MRK   Keytrudaand chemotherapy  The company has a collaboration agreement with Merck  It also has an ongoing collaboration agreement with Roche Holding  SIX ROG  AG s   OTC RHHBY   subsidiary  Genentech  evaluating BL 8040 in combination with the latter s Tecentriq  atezolizumab  in two phase Ib II solid tumor studies  BioLineRx Ltd  Price     Zacks Rank   A Stock to ConsiderCurrently  BioLineRxis a Zacks Rank  3  Hold  stock A better ranked stock in the same space is FibroGen Inc    NASDAQ FGEN    carrying a Zacks Rank  1  Strong Buy   You can see  FibroGen s loss per share estimates have narrowed from  1 09 to 37 cents for 2019 and from 32 cents to 18 cents for 2020 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  the average beat being 346 59      Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/biolinerx-begins-part-2-of-phase-iiia-study-on-solid-tumors-200468353,200468353
202783,424299,MRK,First Ebola vaccines given as WHO seeks to beat Congo outbreak,news,"By Kate Kelland LONDON  Reuters    A vaccination campaign aimed at beating an outbreak of Ebola in Congo began on Monday in the port city of Mbandaka  where four cases of the deadly disease have been confirmed  Use of the VSV EBOV shot   an experimental vaccine developed by Merck  NYSE MRK    marks a  paradigm shift  in how to fight Ebola  said the World Health Organization s head of emergency response  and means regions with Ebola outbreaks can in future expect more than just containment of an outbreak with basic public health measures such as isolation and hygiene  The shot is designed for use in so called ring vaccination plans  When a new Ebola case is diagnosed  all people who might have been in recent contact with the patient are traced and vaccinated to keep the disease from spreading   It s the first time in the midst of an outbreak     that we re using this as a way to stem transmission   WHO s Peter Salama said in a telephone interview   It s an important moment that changes the way we ve seen Ebola for 40 years   The same strategy was used to test Merck s vaccine in Guinea in late 2015  towards the end of an Ebola outbreak in West Africa from 2013 to 2016  The trial results showed it was safe and gave very high levels of protection against Ebola   Around 30 Guinean health workers who were directly involved in that 2015 vaccine trial have traveled to Congo and will help with the immunisations there  Salama said  Ebola causes hemorrhagic fever  vomiting and diarrhea and spreads through contact with the bodily fluids of an infected person  More than 11 300 people died in the West Africa epidemic  This latest outbreak has killed 25 people since early April  according to the WHO  It is Congo s ninth since the disease made its first known appearance near the country s Ebola river in the 1970s  Cases in Mbandaka  a port city on the Congo river  have raised concern that the virus could spread downstream to the capital  Kinshasa  which has a population of 10 million  Salama  who visited Congo after the Ebola outbreak was first reported on May 8  said up to 1 000 people   first in Mbandaka and then in Bikoro and other affected areas  could be vaccinated within the next week  Some 7 300 doses are already in Congo  and hundreds of thousands more are available in a stockpile built up by Merck   If we need any more we can ship it within days   he said   We re fine for vaccine supply  that s not an issue  The issue is going to be making sure we find every contact  track them down and get them vaccinated if they agree   Congolese health ministry data show four cases of Ebola confirmed in Mbandaka s Wangata neighborhood and two suspected cases  One patient has died  For every case  up to 150 contacts will be offered the vaccine  Salama said he was particularly concerned about the  unknowns  of the outbreak   namely the potential numbers of cases in the village of Iboko  where no roads go and even helicopters have trouble landing   I m actually very worried about Iboko because we have four new suspected cases there and it s very  very remote  We ve tried to land helicopters there several times  but we need the community to clear the airstrip  and they haven t fully cleared it yet   Salama said   And when you haven t got people on the ground  it s very hard to assess the extent of the outbreak  I m worried there are many more cases than we ve been able to identify so far   
 WHO spokesman corrects name of village in paragraphs 14 and 15 to Iboko from Ikobo ",2018-05-21,Reuters,https://www.investing.com/news/world-news/first-ebola-vaccines-given-as-who-seeks-to-beat-congo-outbreak-1455651,1455651
202784,424300,MRK,Idera Pharma down 11  despite encouraging tilsotolimod data in melanoma,news,Investors appear disappointed with interim data from a Phase 1 2 clinical trial  ILLUMINATE 204  assessing  Idera Pharmaceuticals    IDRA  10 7   tilsotolimod in metastatic melanoma patients who failed to respond to PD 1 inhibitor therapy  The results were presented at ASCO in Chicago The overall response rate was 38   n 8 21   including two complete responses  in advanced melanoma patients receiving the combination of tilsotolimod  an intratumorally administered toll like receptor 9 agonist  and Bristol Myers Squibb s  BMY  4 4   Yervoy  ipilimumab  after switching from Merck s  MRK  2 2   Keytruda  pembrolizumab   The ORR was only 13  in patients who switched to Yervoy alone  Median duration of response has not been reached  The disease control rate  responders   stable cancer  was 71   n 15 21  Enrollment of up to 60 subjects should be completed by year end A Phase 3 study  ILLUMINATE 301  assessing tilsotolimod   ipilimumab compared to ipilimumab alone in anti PD 1 refractory melanoma was launched last quarter Now read ,2018-06-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/idera-pharma-down-11-despite-encouraging-tilsotolimod-data-in-melanoma-1479054,1479054
202785,424301,MRK,Horizon  HZNP  Up 36 7  YTD  Pipeline Development In Focus,opinion,Shares of Horizon Therapeutics plc   NASDAQ HZNP   have surged 36 7  year to date against the  s decline of 1 9  The company has been focusing on expanding its orphan drug business  This is evident from its long range plan  wherein the orphan drug business is expected to constitute approximately 60  of net sales in 2020  The company has been quite active on the acquisition front over the last few quarters Earlier in the month  the FDA accepted the Biologics License Application  BLA  for the company s investigational medicine  teprotumumab  for the treatment of active thyroid eye disease  TED   and granted it Priority Review designation  If approved  teprotumumab would be the first FDA approved medicine for the treatment of active TED  Teprotumumab is a fully human monoclonal antibody  mAb  and a targeted inhibitor of the IGF 1R  The candidate was added to the company s portfolio after the acquisition of River Vision in 2017  The company submitted a BLA to the FDA for teprotumumab in July 2019  If approved  this will boost sales for the company Horizon is working on the label expansion of its marketed drugs   Procysbi  Actimmune and Ravicti This July  the company announced the FDA s acceptance of its new drug application  NDA  for Procysbi  Cysteamine Bitartrate  delayed release oral granules in packets  If approved  this new dosage form will be another administration option for patients  in addition to the currently available Procysbi delayed release capsules  These capsules are FDA approved for children aged one year or older and adults living with nephropathic cystinosis  The agency is expected to make a decision in 2020 Actimmune is currently approved for the treatment of chronic granulomatous disease  CGD  and severe malignant osteopetrosis  SMO   Horizon is working to increase awareness about the drug among patients and physicians  An investigator initiated study at the Moffitt Cancer Center is underway and enrolling patients  The study is evaluating Actimmune in combination with Roche Holding  SIX ROG  AG s   OTC RHHBY   Herceptin  Perjeta and Taxol and aims to determine the optimal dosing and treatment combination in certain advanced breast cancer patients  The company has collaborated with the Fox Chase Cancer Center to evaluate the drug in combination with Bristol Myers Squibb Company s   NYSE BMY   Opdivo in a phase I dosing study for the treatment of kidney and bladder cancer  The National Cancer Institute is evaluating Actimmune in combination with Merck   Co s   NYSE MRK   Keytruda in a phase II study to treat cutaneous t cell lymphoma patients  Also  a dose ranging study is evaluating the drug in combination with Bristol Myers  Taxol and Roche s Herceptin and Perjeta in a certain type of advanced breast cancer During the first half of 2019  the company generated double digit net sales growth in its orphan and rheumatology segment  driven by continued momentum from Krystexxa  its medicine for uncontrolled gout and the main growth driver  Based on this  the company  raised its guidance for full year 2019 net sales to  1 28  1 30 billion from the previous guidance of  1 26  1 28 billion  Horizon currently has a Zacks Rank  3  Hold   You can see Horizon Pharma Public Limited Company Price   Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/horizon-hznp-up-367-ytd-pipeline-development-in-focus-200464117,200464117
202786,424302,MRK,Momentum ETFs   Stocks In Focus As Trump Delays Tariff Hike,opinion,President Donald Trump delayed the next planned tariff increase of 5  on  250 billion of Chinese goods by two weeks from Oct 1 to Oct 15 as  a gesture of goodwill   The tariff delay request was made by the Vice Premier of China  Liu He  on account of the 70th anniversary of the People s Republic of China on Oct 1 The move came following China s decision to exempt some U S  goods from its tariffs  scheduled to take effect from Sep 17  Beijing revelead its first batch of tariff exemptions for 16 types of U S  products  including some anti cancer drugs and lubricants  as well as animal feed ingredients including whey and fish meal  according to a Ministry of Finance statement on its website  read    The latest development in the tariff war has been welcomed by the global stock markets  leading to increased demand for riskier assets  It signals that the two countries are trying to diffuse the prolonged trade war  which has been roiling the global markets for more than a year  Notably  top officials from the United States and China are expected to resume talks in early October While the broader stock market is expected to move higher  momentum investing will likely take charge as investors seek higher returns in a short span  Momentum investing looks to fetch profits from buying hot stocks that have shown an uptrend over the past few weeks or months  As such  we have presented five ETFs and stocks that could lead to outperformance on tariff delay news  Further  these could even beat broader market returns in the coming months if these trends prevail iShares Edge MSCI USA Momentum Factor ETF This fund provides exposure to large and mid cap stocks that exhibit relatively higher price momentum by tracking the MSCI USA Momentum Index  It charges 15 bps in fees per year and is a popular choice with AUM of  10 5 billion  read    Invesco DWA Momentum ETF This fund tracks the Dorsey Wright Technical Leaders Index  which measures the performance of companies that demonstrate powerful relative strength characteristics  It has amassed  1 6 billion in its asset base and charges 63 bps in annual fees Invesco S P MidCap Momentum ETF This ETF follows the S P Midcap 400 Momentum Index  which is designed to identify mid cap firms having the highest momentum scores  XMMO has AUM of  574 2 million and expense ratio of 0 39  VictoryShares USAA MSCI USA Value Momentum ETF This fund tracks the MSCI USA Select Value Momentum Blend Index  which offers exposure to large and mid cap companies that have higher exposure to value and momentum factors while also maintaining moderate turnover and lower realized volatility than traditional capitalization weighted indexes  It has accumulated  476 7 million in AUM and charges 0 20  in expense ratio  read    SPDR Russell 1000 Momentum  NYSE ONEO  Focus ETF With AUM of  433 1 million  this product targets large cap securities with a combination of core factors  high value  high quality  and low size characteristics  and a focus factor comprising high momentum characteristics  It follows the Russell 1000 Momentum Focused Factor Index and charges an annual fee of 20 bps  The fund has a Zacks ETF Rank  3  Hold  Kirkland Lake Gold Ltd    TSX KL  This company is engaged in the acquisition  exploration  development  and operation of gold properties  It has witnessed solid earnings estimate revision of 16 cents for this year over the past 30 days and has an expected earnings growth rate of 75   The stock has a Zacks Rank  1  Strong Buy  and a Momentum Score of A  You can see  Lululemon Athletica Inc    NASDAQ LULU  This company designs and retails athletic clothing for women  men  and female youth  It witnessed solid earnings estimate revision of 10 cents for this year over the past 30 days with an expected growth rate of 23 18   The stock has a Zacks Rank  2  Buy  and Momentum Score of A Merck   Co  Inc    NYSE MRK  This company provides healthcare solutions worldwide  It offers therapeutic and preventive agents to treat cardiovascular  type 2 diabetes  chronic hepatitis C virus  HIV 1 infection  intra abdominal  fungal infection  insomnia  and inflammatory diseases  The stock saw positive earnings estimate revision of a penny for this year in a month and has an estimated growth rate of 12 67   It has a Zacks Rank  2 and Momentum Score of A Ally Financial Inc    NYSE ALLY  It provides various financial products and services to consumers  businesses  automotive dealers  and corporate customers primarily in the United States and Canada  The stock has an estimated earnings growth of 11 98  for this year  The stock has a Zacks Rank  1 and a Momentum Score of A  read    Zumiez Inc    NASDAQ ZUMZ  It operates as a specialty retailer of apparel  footwear  accessories  and hardgoods for young men and women  The stock witnessed solid earnings estimate revision of 27 cents for fiscal year  ending Jan 2020  in a month with an expected growth rate of 20 67   Zumiez has a Zacks Rank  1 and Momentum Score of A Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/momentum-etfs--stocks-in-focus-as-trump-delays-tariff-hike-200464172,200464172
202787,424303,MRK,Renal Cell Carcinoma Space In Focus  Some Key Developments,opinion,Renal cell carcinoma  RCC  is the most common form of kidney cancer in adults as about nine out of 10 kidney cancer patients are diagnosed with it  Per statistics  approximately 403 000 cases of kidney cancer were diagnosed worldwide in 2018 and about 175 000 deaths occurred due to the disease Recently  AVEO Pharmaceuticals   NASDAQ AVEO   announced positive updated data from a late stage TIVO 3 study on its vascular endothelial growth factor  VEGF  tyrosine kinase inhibitor  TKI  Fotivda  tivozanib  for the treatment of patients with highly refractory metastatic RCC Last week  the European Commission approved the label expansion of Merck s   NYSE MRK   PD L1 inhibitor  Keytruda  in combination with Pfizer s   NYSE PFE   Inlyta  axitinib  for the first line treatment of advanced RCC  In April 2019  the FDA had approved this combination for the same indication Given its market potential  most pharma biotech bigwigs are scurrying to grab a larger chunk of this pie  Evidently  the focus is on better and effective treatments  While Pfizer s Sutent has long been used as a treatment for advanced RCC  the focus  of late  has shifted to checkpoint inhibitor containing regimens in combination with a TKI as the first line option for RCC patients like Keytruda  anti PD 1 therapy  and Inlyta  a TKI  In May 2019  the FDA approved the combination regimen of Bavencio  avelumab  and Inlyta for the first line treatment of patients with advanced RCC  The approval was based on positive results from the phase III JAVELIN renal 101 study Another important player in this space is Exelixis   NASDAQ EXEL   whose lead drug Cabometyx is approved for both previously treated patients and treatment na ve advanced RCC patients  The company is currently focusing on evaluating Cabometyx s potential in combination with immune checkpoint inhibitors to determine if such combinations further improve outcomes for patients  CheckMate 9ER  a phase III study  is evaluating Cabometyx in combination with Bristol Myers    NYSE BMY   Opdivo in previously untreated advanced or metastatic RCC  Exelixis has also initiated COSMIC 313  a phase III study evaluating the triplet combination of cabozantinib  Opdivo and Yervoy versus the combination of Opdivo and Yervoy in patients with previously untreated advanced intermediate  or poor risk RCC Bristol Myers  immuno oncology drug Opdivo is already approved for the treatment of patients with advanced RCC who have received prior anti angiogenic therapy  In addition  Opdivo in combination with Yervoy is also indicated for the treatment of patients with intermediate or poor risk  previously untreated advanced RCC  The results from the phase III CheckMate 214 study showed that treatment with Opdivo plus low dose Yervoy continued to demonstrate long term survival benefits in patients with previously untreated advanced or metastatic RCC as compared to Sutent However  there have been a few setbacks as well  In 2018  Roche   OTC RHHBY   withdrew its application with the FDA seeking approval of PD L1 inhibitor Tecentriq  atezolizumab  and anti VEGF drug Avastin  bevacizumab  as a treatment for advanced or metastatic RCC Given the spate of new approvals  competition is expected to be stiff in this space  As the survival rates for advanced and metastatic RCC are really low  it remains to be seen which regimen emerges as the market leader in the long run  We expect investor focus to remain on updates from the ongoing studies in this indication Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/renal-cell-carcinoma-space-in-focus-some-key-developments-200464387,200464387
202788,424304,MRK,Roche Reports Positive Data On Tecentriq   NMOSD Drug  Revised  ,opinion,Roche   OTC RHHBY   announced positive data on the immuno oncology drug  Tecentriq  atezolizumab   from a late stage study in patients with advanced non small cell lung cancer  NSCLC  The phase III IMpower110 study evaluated Tecentriq as a first line  initial  monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine  chemotherapy  in advanced NSCLC without ALK or EGFR mutations  Wild Type or WT  An interim analysis showed that the study met its primary endpoint  Tecentriq monotherapy demonstrated a statistically significant overall survival  OS  benefit in patients with high PD L1 expression  TC3 IC3 WT  compared with only chemotherapy The safety of the drug was consistent with its known safety profile and no new safety signals were identified Hence  the study will continue until a final analysis is conducted in patients with lower levels of PD L1 expression These new data further reinforce Tecentriq s ability to treat this set of patients  Roche will submit these data to the FDA and the EMA and also present the same at an upcoming medical congress We remind investors that Tecentriq is already approved in the United States and Europe either alone or in combination with targeted therapies and or chemotherapies in various forms of non small cell and small cell lung cancer  certain types of metastatic urothelial cancer  and PD L1 positive metastatic triple negative breast cancer The label expansion will boost sales of the drug  which posted 141  growth in sales in the first half of 2019  driven by the new indications of triple negative breast cancer and extensive stage small cell lung cancer Presently  Roche has nine phase III lung cancer studies underway  evaluating Tecentriq as a monotherapy or in combination with other medicines across different types of lung cancer  Apart from lung cancer  Tecentriq is being evaluated in multiple ongoing and planned phase III studies across genitourinary  skin  breast  gastrointestinal  gynecological  and head and neck cancers either as a monotherapy or in combination with other therapies While the market of NSCLC present immense potential  competition is stiff in this space  Immuno oncology therapies like Merck s   NYSE MRK   Keytruda  AstraZeneca s   NYSE AZN   Imfinzi and Bristol Myers    NYSE BMY   Opdivo are approved for various types of lung cancer Concurrently  Roche presented positive phase III SAkuraStar study results for pipeline candidate satralizumab as monotherapy for neuromyelitis optica spectrum disorder  NMOSD  at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis  ECTRIMS  Satralizumab targets the interleukin 6  IL 6  receptor  a key driver of rare  debilitating central nervous system disorder  NMOSD  The study results showed that satralizumab monotherapy achieved a 55  reduction in the risk of relapses compared to placebo in the overall population  NMOSD patients   Results also showed that there was a 74  reduction in the risk of relapse for satralizumab monotherapy as compared to placebo in NMOSD patients Shares of Roche have gained 9 1  so far this year against the  s decline of 1 2   Roche s efforts to develop its portfolio beyond oncology have been impressive  The company currently has a dozen investigational drugs in development for diseases like multiple sclerosis  Alzheimer s disease  Huntington s disease  spinal muscular atrophy  Parkinson s disease and autism Roche currently carries a Zacks Rank  2  Buy   You can see   We are reissuing this article to correct a mistake  The original article  issued on September 12  2019  should no longer be relied upon  ,2019-09-13,Zacks Investment Research,https://www.investing.com/analysis/roche-reports-positive-data-on-tecentriq--nmosd-drug-revised-200464295,200464295
202789,424305,MRK,Roche s New Perjeta Combo Meets Goal In Breast Cancer Study,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that its new investigational fixed dose combination  FDC  of Perjeta  pertuzumab  and Herceptin  trastuzumab  has met the primary endpoint of non inferiority in the phase III FeDeriCa study 
In the study  the new FDC  which is administered by subcutaneous  SC  injection in combination with intravenous  IV  chemotherapy  demonstrated non inferior levels of Perjeta in the blood compared to the standard IV infusion of Perjeta   Herceptin and chemotherapy in patients with HER2 positive early breast cancer  eBC  
This new FDC of Perjeta   Herceptin in combination with chemotherapy is administered under the skin  thus providing a faster treatment option for the given patient population  The FDC of Perjeta and Herceptin is a new SC formulation  which uses Halozyme Therapeutics    NASDAQ HALO   Enhanze drug delivery technology 
Per the company  the SC administration of the new FDC takes around eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose  This is a significant reduction in administration time compared to the infusion of a loading dose of Perjeta and Herceptin using the standard IV formulations that takes approximately 150 minutes and almost 60 150 minutes for the subsequent maintenance dose 
Roche plans to present full data from the above study at an upcoming medical conference  The company also plans to submit the results to the FDA and the EMA for regulatory approvals 
Perjeta in combination with Herceptin and chemotherapy  the Perjeta based regimen  is already approved by the FDA as an adjuvant  after surgery  treatment of HER2 positive eBC patients  who are at a high risk of recurrence 
We would like to remind investors that Roche has a strong presence in the oncology market  Particularly  it dominates the breast cancer space with solid demand for its HER2 franchise drugs  namely Herceptin  Perjeta and Kadcyla 
However  competition looms large on the HER2 positive breast cancer space  Puma Biotech s   NASDAQ PBYI   Nerlynx  neratinib  is also approved for use as an extended adjuvant treatment of HER2 positive early stage breast cancer in adult patients  who were previously treated with Roche s Herceptin based adjuvant therapy 
Shares of Roche have increased 9 1  so far this year versus the  decrease of 1 2  

In a separate press release  Roche announced new six year data from the phase III study on its multiple sclerosis  MS  drug Ocrevus  ocrelizumab   The longer term data from the OPERA I  OPERA II and ORATORIO extension studies showed that an early and continuous treatment with Ocrevus for six or more years led to a reduced risk of disability progression in patients with relapsing MS  RMS  and primary progressive MS  PPMS  
The results were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis held in Sweden 
Zacks Rank   Another Key Pick
Roche currently carries a Zacks Rank  2  Buy   Another stock worth considering in the large cap pharma sector is Merck   Co   Inc    NYSE MRK    which carries the same Zacks Rank as Roche  You can see  
Merck s earnings estimates have been revised 3 2  upward for 2019 and 1 3  for 2020 over the past 60 days  The stock has rallied 9  year to date 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-13,Zacks Investment Research,https://www.investing.com/analysis/roches-new-perjeta-combo-meets-goal-in-breast-cancer-study-200464605,200464605
202801,424317,MRK,Fuse takes Fidelity funding to expand its bite sized learning system,news,"By Eric Auchard
LONDON  Reuters    Fuse Universal  a learning management platform which companies use to train employees on phones and computers  has raised  20 million in expansion funding from Eight Roads Ventures  Fidelity International s venture arm  the company said on Wednesday 
Fuse has sought to reinvent how corporate learning management systems work by enabling employees to view short  bite sized training clips online or offline  on their smartphones or tablet devices  or from their desks 
The Fuse system is used by more than 100 companies for employee training  including Merck  NYSE MRK   EY  International Hotel Group  Spotify  N SPOT  and  Vodafone   L VOD   It works as a standalone learning management system or as an overlay to older learning platforms 
Vodafone says 50 percent of its UK retail workforce using the system viewed Fuse short courses outside of working hours  with peak usage occurring while traveling to and from work 
While breaking with the formal text and graphic presentations common to traditional knowledge sharing systems that are designed for learning administrators but receive low scores for employee engagement  Fuse also supplies analytics to ensure compliance targets are met  a major selling point 
The company ranks as one of Europe s leading next generation learning platforms  according to a recent survey of dozens of regional and global players in the learning management systems industry by human resources consulting research firm Fosway Group 
Eight Road Ventures said the funding will allow Fuse to expand to reach its increasingly global customer base  It will also allow the firm to invest in educational technology  including machine learning and augmented reality 
Michael Treskow  a partner at Eight Roads Ventures  will join the Fuse board 
The 10 year old London based Fuse took  10 million  7 4 million pounds  in private equity funding in 2015 
Chief Executive Steve Dineen  a veteran of the corporate training field  built and sold Fuel  his previous learning management firm  in 2007  before founding Fuse ",2018-05-09,Reuters,https://www.investing.com/news/technology-news/fuse-takes-fidelity-funding-to-expand-its-bitesized-learning-system-1437994,1437994
202802,424318,MRK,New Ebola outbreak hits Congo,news,The deadly hemorrhagic disease Ebola has resurfaced again  with the WHO revealing 32 potential cases of the disease  including 18 deaths  in the Democratic Republic of the Congo Experimental Ebola vaccines are under development  such as leading candidate   Merck s  NYSE MRK  rVSV ZEBOV   but they have not been fully tested for safety or effectiveness Now read ,2018-05-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/new-ebola-outbreak-hits-congo-1444662,1444662
202803,424319,MRK,In Congo outbreak  Ebola vaccine faces reality tests,news,"By Kate Kelland LONDON  Reuters    An experimental Ebola vaccine to be deployed in an outbreak in Democratic Republic of Congo has conquered some major scientific hurdles in giving high protection  but it now faces extreme real world tests including heat  humidity  language barriers and lack of roads  Because it is not yet licensed  the Merck  NYSE MRK    Co vaccine has been offered to Congo under a  compassionate use  protocol agreed by national and international health and ethics authorities   This means fully informed  signed consent is needed from every person who wants the shot  And in the current Ebola outbreak  that makes logistical  cultural and language barriers the ultimate challenges  global health specialists say  The hurdles illustrate how hard it can be to move from laboratory to real life  especially in remote communities with no functioning health systems  The Congo outbreak is a chance to reality test a vaccine against a disease epidemic that can t be replicated in controlled environments   This is going to need a highly sophisticated operation in one of the most difficult places on earth   said Peter Salama  the World Health Organization s deputy director general for emergency preparedness and response   It s very hot and very humid  and we re talking about hundreds of kilometers of densely forested areas   The shot is designed for use in a so called  ring vaccination   When a new Ebola case is diagnosed  all people who might have been in recent contact with them are traced and vaccinated to try and prevent the disease s spread  The vaccine supplies so far will be enough to vaccinate 50 rings of 150 people  according to the WHO  It said that as of May 15  527 contacts of Ebola cases and suspected cases had been identified and were being followed up  Health workers will need to use translators for several local languages and explain the vaccine to leaders from different communities  Salama said  Limited communications  health facilities and electricity  as well as the need to keep the vaccine in a  cold chain  at  60 to  80 degrees Celsius will also present challenges   If any of these elements fails  the vaccine s potential to protect 100 percent of those immunized will go unrealized   These are make or break issues   said Salama  who visited Congo last weekend   There s a lot of complex logistics and social science here    CONTACTS Results of a trial using the ring vaccination technique with the Merck shot  which is known as VSV EBOV  in Guinea in West Africa in 2015 showed 100 percent protection in those vaccinated immediately  Health experts working to contain the Congo outbreak  which was first reported on May 8  say a cold chain will be in place to get the vaccines from Congo s capital Kinshasa to the affected areas within a few days  Then the shot could be given to local frontline medical  burial and hospital workers who volunteer for it as early as next week   There have been 44 suspected  probable or confirmed Ebola cases in this outbreak in Congo s Equateur province  and 23 people have died   The WHO said on Thursday it became more concerned when a case was confirmed in Mbandaka  a city of about a million people which is connected to Kinshasa by the Congo River  Jeremy Farrar  a specialist in infectious diseases and director of the Wellcome Trust global health charity  told Reuters the epidemic now had  all the features of something that could turn really nasty    You can t overrespond in this scenario   he said   But the vaccine must be seen in the context of an overarching public health response  Critically that means early diagnosis  early isolation  safe burials and understanding the social context  The vaccine can only be a part of the solution   ACCEPTANCE  Experts also caution that acting too hastily could jeopardize the potential success of a vaccine deployment  Micaela Serafini  a medical director for the international charity Medecins Sans Fronti res  MSF  who is helping coordinate the response to the Congo outbreak  said its teams are planning for at least 45 minutes of discussion and information sharing with each person  with a translator present  before signed consent would be obtained   Then  she told Reuters  medical teams would probably return the following day to administer the vaccine   What we need to avoid at all costs is an uncontrolled situation in the communities affected   she said   Even though the vaccine has still yet to get a license  the emergency response teams say its safety and efficacy data is strong  And despite lingering suspicions in some of the more remote parts of Africa of western medicines  experts anticipate widespread public acceptance  Congo s health minister Oly Ilunga signaled on Thursday that his government was fully behind the shot s use   The vaccine will help us save lives in the Equateur province  in the DRC and in neighboring countries  The vaccine allows us to limit the virus  so we must use it   he said  Merck and the GAVI vaccine alliance have said a stockpile of more than 300 000 doses of the shot is available for emergency use in an epidemic  Salama and Serafini said one tricky task may be managing a scenario where larger groups of people not identified as high risk contacts of a Ebola case might demand the vaccine for themselves or their family   
 We want to make sure we are engaging whole communities so that the broader community understands what we are doing and why   said Salama   That is particularly important when you re not targeting everyone  because naturally people will ask   How come you re vaccinating that person but not me   ",2018-05-18,Reuters,https://www.investing.com/news/stock-market-news/in-congo-outbreak-ebola-vaccine-faces-reality-tests-1453244,1453244
202804,424320,MRK,Merck Sees Hammer Chart Pattern  Time To Buy ,opinion,Merck   Co   Inc    NYSE MRK   has been struggling lately  but the selling pressure may be coming to an end soon  That is because MRK recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 5 estimates have gone higher  compared to none lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if MRK stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2019-09-10,Zacks Investment Research,https://www.investing.com/analysis/merck-sees-hammer-chart-pattern-time-to-buy-200463710,200463710
202805,424321,MRK,4 Big Drugmakers Boasting Impressive Oncology Pipelines,opinion,"There has been a significant uptick in demand for cancer drugs and subsequent growth of the cancer research market owing to the widespread occurrence of the disease  Cancer is second only to heart disease when it comes to claiming lives  According to a report by the American Cancer Society  more than 1 76 million new cancer cases are expected to be diagnosed in 2019  which creates significant need for effective cancer medication Allied Market Research estimates the global cancer drugs market to be worth more than  176 billion by 2025  The factors contributing to growth of the oncology cancer drugs market are rapid progress of drugmakers  cancer pipelines and increase in the number of collaborations between pharmaceutical companies  which has lowered the cost burden  increased demand for personalized medicines and boosted demand in developing nations  Companies focused on making innovative cancer drugs are in great demand for buyouts The traditional cancer treatments include surgery  radiation and chemotherapy  However  targeted therapy  immunotherapy  gene therapy  hormone therapy  precision medicine and other new novel therapies are slowly making their way into clinics to improve  supplement or replace traditional cancer treatments  Advances in new treatments have attracted investors  attention and made cancer a hot investing area lately It goes without saying that all big pharma companies are working hard to bring innovative cancer treatments to market as well as expand the labels of their marketed oncology drugs to capture a share of this growing market  These pharma biotech giants have significant financial resources at their disposal and have even collaborated to pool their resources and technology Here we discuss four pharma giants  which possess the industry s strongest oncology pipeline portfolios AstraZeneca   NYSE AZN  AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline  Oncology sales now comprise around 35  of total product sales for AstraZeneca  It has some high profile cancer drugs in its portfolio like Tagrisso  Lynparza  Faslodex and Imfinzi  which are among its top medicines AstraZeneca s cancer drugs are being studied in several label expansion studies  which can expand their eligible patient populations  It also has a few oncology candidates in its pipeline Imfinzi  which is marketed for second line advanced bladder cancer and early stage lung cancer  is being evaluated for multiple cancers  either alone or in combination with other regimens  Lynparza  presently marketed for advanced ovarian cancer and breast cancer in partnership with Merck   NYSE MRK    is also in different studies for a range of tumor types including prostate  pancreatic and gastric cancers as well as earlier line settings for ovarian cancer and breast cancer  Tagrisso is also being evaluated in earlier line settings for lung cancer  Another new cancer drug in AstraZeneca s portfolio is Calquence  acalabrutinib   which is approved for previously treated mantle cell lymphoma  AstraZeneca expects to file regulatory applications for Calquence to get approval for the larger chronic lymphocytic leukemia indication  in frontline and in the relapsed recurrent disease setting  later this year Key oncology candidates in late stage development include selumetinib  pediatric neurofibromatosis type 1  and savolitinib  non small cell lung carcinoma  NSCLC    In April 2019  AstraZeneca acquired joint development and commercialization rights to an innovative antibody drug conjugate  trastuzumab deruxtecan from Japan s Daiichi Sankyo  A regulatory application seeking approval for trastuzumab deruxtecan in metastatic breast cancer is expected to be filed with the FDA in the second half of 2019 Pfizer   NYSE PFE  Pfizer gained FDA approval for four innovative cancer medicines in the last four months of 2018  which is likely to boost its oncology sales  These include Daurismo  glasdegib  for previously untreated AML  Lorbrena  lorlatinib  for second line non small cell lung cancer  Vizimpro  dacomitinib  for advanced NSCLC with EGFR activating mutations and Talzenna  talazoparib   an orally available PARP inhibitor for advanced breast cancer Two leukemia treatments   Besponsa for relapsed refractory acute lymphoblastic leukemia and Mylotarg for newly diagnosed CD33 positive acute myeloid leukemia were approved in the United States in the third quarter of 2017 Meanwhile  Pfizer is also working on expanding the label of its key breast cancer drug Ibrance and prostate cancer drug  Xtandi Pfizer s newest immunotherapy  Bavencio  though approved for two small indications currently  is being considered a significant future top line driver for this New York based pharma giant if it can gain label expansion approvals  Pfizer has 30 ongoing studies in the avelumab development program involving more than 9 000 patients across 15 tumor types Importantly  Pfizer is gradually venturing into the oncology biosimilars space  Pfizer s biosimilar versions of Roche s cancer drugs Herceptin  Avastin and Rituxan were approved by the FDA in 2019  Biosimilar versions of Herceptin and Avastin are already approved in the EU while that of Rituxan is under review in the EU Finally  the July acquisition of Array BioPharma for  11 4 billion has strengthened its cancer portfolio  Array launched its only commercial medicine  Braftovi plus Mektovi  as a treatment for BRAF mutant melanoma  last year  The combination medicine is also being evaluated in label expansion studies for other cancer types including metastatic colorectal cancer with BRAF mutation Merck Merck s oncology portfolio pipeline  though revolving around just its revolutionary anti PD 1 therapy  Keytruda  can be said to be one of the strongest in the industry Keytruda is already approved for use in 20 cancer indications across 12 different tumor types in the United States  Keytruda is continuously growing and expanding into new indications and markets globally  Keytruda sales are gaining particularly from strong momentum in the indication of first line lung cancer  In fact  the Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 1000 studies  including more than 600 combination studies  Undoubtedly  Keytruda has strong future growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwide Meanwhile  Merck has profit sharing deals with AstraZeneca for Lynparza selumetinib and Japan s Eisai for Lenvima for several types of cancer Bristol Myers   NYSE BMY  Bristol Myers PD 1 inhibitor  Opdivo  has been performing impressively  The company is working on expanding the label of Opdivo further  alone or in combination therapies with Yervoy and other anti cancer agents Further  Bristol Myers  cancer portfolio includes multiple myeloma drug  Empliciti and leukemia drug  Sprycel  which contribute significantly to the top line  In addition  Bristol Myers is evaluating other immune system pathways for the treatment of cancer  These pathways may help the company bring to market potentially transformational immunotherapies   in combination or as monotherapy   to help fight different types of cancers Most importantly its pending acquisition of Celgene  NASDAQ CELG  for approximately  74 billion should boost its oncology franchise by adding blockbuster drugs like Revlimid and Pomalyst and several pipeline candidates across solid tumors and hematologic malignancies While Merck and Bristol Myers currently carry a Zacks Rank  2  Buy   AstraZeneca has a Zacks Rank  3  Hold   Pfizer holds a Zacks Rank of 4  Sell  You can see  Others Not Far BehindAbbVie s   NYSE ABBV   key cancer drug and also what it calls a  pipeline in a molecule   Imbruvica  is currently approved for quite a few indications across different cancer types  Imbruvica has multi billion dollar potential  Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments  AbbVie is also studying another key cancer drug  Venclyxto Venclexta to expand the label to address the broader relapsed refractory chronic lymphocytic leukemia patient population  expand into earlier lines of therapy  and broaden into other hematologic malignancies like multiple myeloma and acute myeloid leukemia Roche   OTC RHHBY   dominates the breast cancer space  There is strong demand for its HER2 franchise drugs like Herceptin  Perjeta and Kadcyla  Apart from its strong breast cancer franchise  Roche s oncology portfolio also boasts lung cancer drugs like Avastin  Tecentriq and Tarceva and hematology medicines like MabThera Rituxan  Gazyva  and Venclexta   Newly approved cancer medicines are Polivy Alcensa and Rozlytrek  Label expansion efforts are ongoing for almost all these cancer drugs Swiss drugmaker Novartis    NYSE NVS   oncology portfolio was significantly boosted by the approval of breast cancer drug  Kisqali and CAR T cell therapy Kymriah in 2017  Novartis also boasts many experimental cancer drugs in its R D pipeline including a couple of biosimilar versions of popular cancer drugs ConclusionCompetition in the cancer market is fierce and not all pipeline candidates will be successful  However  pharma biggies have enough late stage cancer programs in their portfolios and there are chances of quite a few rollouts in the coming years Large Cap Pharmaceuticals Industry 5YR   Return
 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-09-10,Zacks Investment Research,https://www.investing.com/analysis/4-big-drugmakers-boasting-impressive-oncology-pipelines-200463700,200463700
202806,424322,MRK,Bristol Myers   BMY  Opdivo Shows Long Term Survival Benefit,opinion,Bristol Myers Squibb Company   NYSE BMY   announced long term pooled efficacy and safety results from the phase III CheckMate 017 and CheckMate 057 studies in patients with previously treated  advanced non small cell lung cancer  NSCLC  Shares of the company have lost 3 2  in the year so far against the  s growth of 1 9  At five years  patients treated with Opdivo  nivolumab  continuedto experience long term overall survival  OS  benefit versus docetaxel  Treatment with Opdivo was associated with a 5 year OS rate of 13 4  compared with 2 6  with docetaxel in previously treated NSCLC patients The OS benefit with the drug was observed across all patient subgroups  including those with PD L1 expression on  1  of tumor cells  Further  the safety profile for Opdivo was consistent with prior findings in the second line setting  and no new safety signals were observed with the longer follow up  Only two of the 70 patients currently on study experienced a new treatment related select adverse event  AE  between years 3 and 4  There were no new treatment related select AEs reported between years 4 and 5 among the 55 patients still on study This pooled analysis represents the longest follow up of previously treated NSCLC patients treated with Immuno Oncology therapy in phase III randomized studies Opdivo is Bristol Myers  primary growth driver  It is currently approved in the United States  the EU  Japan and other countries for several cancer indications  The company is working on expanding the label of the drug further Nevertheless  competition is stiff in the NSCLC market  Merck s   NYSE MRK   PD L1 inhibitor  Keytruda  commands a strong place in the first line NSCLC market  Other PD L1 inhibitors available in the market are AstraZeneca s   NYSE AZN   Imfinzi and Roche s   OTC RHHBY   Tecentriq Bristol Myers currently sports a Zacks Rank  1  Strong Buy   You can see  Bristol Myers Squibb Company Price    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-09-10,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-opdivo-shows-longterm-survival-benefit-200463764,200463764
202807,424323,MRK,Roche  RHHBY  Reports Positive Data On Tecentriq   MS Drug ,opinion,Roche   OTC RHHBY   announced positive data on the immuno oncology drug  Tecentriq  atezolizumab   from a late stage study in patients with advanced non small cell lung cancer  NSCLC  The phase III IMpower110 study evaluated Tecentriq as a first line  initial  monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine  chemotherapy  in advanced NSCLC without ALK or EGFR mutations  Wild Type or WT  An interim analysis showed that the study met its primary endpoint  Tecentriq monotherapy demonstrated a statistically significant overall survival  OS  benefit in patients with high PD L1 expression  TC3 IC3 WT  compared with only chemotherapy The safety of the drug was consistent with its known safety profile and no new safety signals were identified Hence  the study will continue until a final analysis is conducted in patients with lower levels of PD L1 expression These new data further reinforce Tecentriq s ability to treat this set of patients  Roche will submit these data to the FDA and the EMA and also present the same at an upcoming medical congress We remind investors that Tecentriq is already approved in the United States and Europe either alone or in combination with targeted therapies and or chemotherapies in various forms of non small cell and small cell lung cancer  certain types of metastatic urothelial cancer  and PD L1 positive metastatic triple negative breast cancer The label expansion will boost sales of the drug  which posted 141  growth in sales in the first half of 2019  driven by the new indications of triple negative breast cancer and extensive stage small cell lung cancer Presently  Roche has nine phase III lung cancer studies underway  evaluating Tecentriq as a monotherapy or in combination with other medicines across different types of lung cancer  Apart from lung cancer  Tecentriq is being evaluated in multiple ongoing and planned phase III studies across genitourinary  skin  breast  gastrointestinal  gynecological  and head and neck cancers either as a monotherapy or in combination with other therapies While the market of NSCLC present immense potential  competition is stiff in this space  Immuno oncology therapies like Merck s   NYSE MRK   Keytruda  AstraZeneca s   NYSE AZN   Imfinzi and Bristol Myers    NYSE BMY   Opdivo are approved for various types of lung cancer Concurrently  Roche presented positive phase III SAkuraStar study results for pipeline candidate satralizumab as monotherapy for neuromyelitis optica spectrum disorder  NMOSD  at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis  ECTRIMS  Satralizumab targets the interleukin 6  IL 6  receptor  a key driver of rare  debilitating central nervous system disorder  NMOSD  The study results showed that satralizumab monotherapy achieved a 55  reduction in the risk of relapses compared to placebo in the overall population  NMOSD patients   Results also showed that there was a 74  reduction in the risk of relapse for satralizumab monotherapy as compared to placebo in NMOSD patients Shares of Roche have gained 9 1  so far this year against the  s decline of 1 2  Roche s efforts to develop its portfolio beyond oncology have been impressive  The company currently has a dozen investigational drugs in development for diseases like multiple sclerosis  Alzheimer s disease  Huntington s disease  spinal muscular atrophy  Parkinson s disease and autism Roche currently carries a Zacks Rank  2  Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-reports-positive-data-on-tecentriq--ms-drug-200464067,200464067
202812,424328,MRK,Keytruda sales power Merck to quarterly beat,news,"By Tamara Mathias  Reuters    Drugmaker Merck   Co  N MRK  reported a better than expected first quarter profit on Tuesday  helped by a more than 150 percent rise in sales of cancer drug Keytruda  Merck is increasingly reliant on the blockbuster medicine  which is positioned to become the leading player in a new generation of oncology treatments and rival Bristol Myers Squibb s  N BMY  Opdivo  Both drugs harness the body s immune system to recognize and fight cancer cells  but last month s survival data from trials of the treatments gave Keytruda an edge over Opdivo  according to industry experts  Keytruda raked in sales of  1 46 billion in the quarter  ahead of  1 40 billion estimated by analysts  according to Thomson Reuters I B E S  Revenue from the drug accounted for nearly 15 percent of Merck s total sales  helped by its expanded approval to treat various forms of cancer  Sales of Bristol Myers Squibb s Opdivo surged 34 percent to  1 51 billion in the latest quarter   Merck raised its full year forecast for adjusted earnings to between  4 16 and  4 28 per share from between  4 08 and  4 23 per share estimated previously  Net income fell 52 5 percent to  736 million  or 27 cents per share  hurt by a  1 4 billion charge related to a collaboration with Eisai Co Ltd  the company said  Merck Keytruda sales    Excluding items  Merck earned  1 05 per share  ahead of analysts  estimates of  1 per share   Revenue rose 6 4 percent to  10 04 billion  but missed estimates of  10 11 billion  
Merck s shares rose 1 1 percent to  59 50 before the bell ",2018-05-01,Reuters,https://www.investing.com/news/stock-market-news/keytruda-powers-merck-to-firstquarter-beat-1423440,1423440
202813,424329,MRK,Too many cancer drugs  Crowded market gives investors pause,news,"By Ben Hirschler LONDON  Reuters    In London s world famous Great Ormond Street children s hospital  Dr  Karin Straathof is excited about a new cell based medicine that offers hope for toddlers with incurable nerve tissue cancer  Her progress with a handful of children for whom standard care does not work reveals the promise of modern cancer drugs  an increasingly crowded pharmaceuticals field from which investors must try to select future winners  The new therapy using engineered white blood cells has shown anti tumor activity in the hardest to treat neuroblastoma patients   The beauty is that it is very specific in targeting the cancer cells  while leaving healthy tissue unharmed   Straathof told Reuters  after presenting her early findings at a science meeting in Chicago in April   It s an important step forward    Autolus   the small British biotech company developing the chimeric antigen receptor T cell or CAR T treatment   is equally excited  and is planning a potential IPO on Nasdaq  But Autolus is far from alone in pursuing CAR T therapy  In fact  CAR T treatment   part of the wider field of cancer immunotherapy   is one of the hottest areas of drug research today  with multiple firms piling in  The biotech dollars are flooding in not only in Europe and the United States but also in China which  with 162 clinical trials  now boasts more CAR T studies than the United States  according to a Reuters analysis of the latest data  With over 2 000 drugs in the cancer immunotherapy space  the competitive landscape has never been more crowded as each firm seeks its own proprietary version of often similar drugs  Overall  researchers are working on more than 5 200 cancer drugs  up 7 6 percent from a year ago  according to the Pharmaprojects database  The sheer number is stretching the ability of scientists to find enough patients to test them on  Cancer now makes up 34 1 percent of the total drug industry pipeline  up from 26 8 percent in 2010  as companies divert resources into a promising sector where new treatments can often fetch more than  100 000 a year    MORE CIRCUMSPECT   With the first two CAR T treatments from  Novartis   S NOVN  and Gilead Sciences  O GILD  winning U S  approval last year for rare blood cancers  the promise of such smart medicine is real and life changing   especially if it can be made to work in solid tumors  as Straathof s work suggests is possible  However  the wholesale rush by pharmaceutical and biotech companies into the cancer area poses a dilemma for investors   A flood of similar products makes it hard for investors to pick those companies that will achieve commercial success   More competition means you should be more circumspect   said Nooman Haque  head of life sciences at Silicon Valley Bank in London  which provides financing for start ups and venture capitalists   The traditional investment thesis in biotech is to have a differentiated medicine with not many competitors  which helps drive value  Here the problem is that even if there is a big patient benefit  there are questions as to how long your advantage lasts and what your commercial edge will be   Pharmaceutical executives are not blind to the issue  although each hopes to find a winning formula in immunotherapy   the fastest growing part of the  100 billion a year cancer drug market  with sales expected to top  25 billion by 2021  according to analyst forecasts compiled by Thomson Reuters  Roche  S ROG  CEO Severin Schwan  head of the world s top cancer company  says he expects  an enormous drop out   while Sanofi s  PA SASY  outgoing research head Elias Zerhouni warned analysts last week that duplication of effort would shrink the time available for drugmakers to recoup their R D investments   The cycle of innovation has been shortened significantly   agrees Aiman Shalabi  chief medical officer at the non profit Cancer Research Institute   There is no doubt we are seeing fast follow on and many identical agents hitting the same targets   The good news for society is that patients will find out much faster than in the past if new approaches work  But that means doctors can rapidly switch to alternatives  leading to increased product churn and uncertainty over future sales   COMBINATION STUDIES Twenty years ago  when Roche launched its state of the art cancer drugs Herceptin and Rituxan  it enjoyed years without rivals  Today  there are multiple versions of new drugs targeting molecular pathways with acronyms such as PD 1 L1  PARP and CDK  as well as CAR T   You re either first or you re best or you re nowhere because it has become such a race   said Paul Major  an investment manager at BB Healthcare Trust  L BBH   who is cautious about investing in cancer immunotherapy  Lydia Haueter at Pictet Asset Management is also wary  pointing out there are already five PD 1 L1 drugs on the market   from Merck  N MRK   Bristol Myers Squibb  N BMY   Roche  AstraZeneca  L AZN  and  Pfizer   N PFE    and more are coming   It seems everybody has a PD 1  so we especially don t go for those kind of cancer companies   she said  Some drugmakers like GlaxoSmithKline  L GSK  and Novartis that missed the initial PD 1 L1 wave are trying to make a virtue of looking ahead to the next phase of cancer immunotherapy  particularly drug combinations  Yet last month s failure of a combination study using a next generation drug from Incyte  O INCY  with Merck s PD 1 Keytruda shows that adding a new agent is no slam dunk for expanding the reach of immune boosting medicine  At Great Ormond Street  Straathof is less concerned about doubling up on research and more focused on getting effective  affordable cures   and she hopes automated processes will eventually bring down today s sky high drug prices   I m not too worried about duplication  It s important to not ask the same question in two trials but I think there are a lot of questions to be addressed because there is a lot of nuance in the system    
Cancer drug research and development   ",2018-05-02,Reuters,https://www.investing.com/news/general-news/too-many-cancer-drugs-crowded-market-gives-investors-pause-1426031,1426031
202814,424330,MRK,Esperion s Bempedoic Acid Succeeds In Phase II Diabetes Study,opinion,"Esperion Therapeutics   NASDAQ ESPR   announced that the phase II study evaluating a combination of pipeline candidate  bempedoic acid  and Merck s   NYSE MRK   Zetia  ezetimibe  met primary endpoints  The study was evaluating the regimen in patients with both hypercholesterolemia and type II diabetes and receiving diabetes medications but no statin therapy Data from the 12 week study showed that treatment with the combination regimen lowered LDL C  bad cholesterol  levels by 40  compared to placebo  The regimen also reduced high sensitivity C reactive protein  a measure of inflammation associated with cardiovascular disease  by 25   The results showed that the bempedoic acid Zetia combination led to improvement in multiple cardiovascular disease risk factors Shares of Esperion have decreased 20 5  so far this year against the  s rise of 5 1   We note that regulatory applications seeking approval for bempedoic acid as a monotherapy and in combination with Zetia as a treatment for elevated LDL C in patients receiving maximally tolerated statins or Zetia and having inadequate response are under review in the United States and Europe A decision from the FDA on the monotherapy regimen is expected by Feb 21  2020 while a decision on the combination therapy should come by Feb 26  2020 Esperion has successfully completed phase III studies evaluating bempedoic acid as a monotherapy and Zetia combination  Data from these studies have shown that the monotherapy regimen achieved addition 18  reduction in LDL C over levels achieved by maximally tolerated statin  The combination regimen reduced bad cholesterol by 35  compared with 24  for Zetia monotherapy  20  for bempedoic acid alone and 3  for placebo in similar patients These data along with the phase II data showed that bempedoic acid holds potential in patients independent of background statin therapy The targeted indications represent a significant opportunity for the company  It is estimated that 78 million people in the United States have high levels of LDL C along with 73 million people in Europe and 30 million people in Japan  Of these  an estimated 40 million patients in the United States are using statins  which is intolerable in 5  to 20  of this population  A potential approval will likely drive share price of the company higher  The company signed a deal with Daiichi Sankyo Europe in January for commercialization of the candidates in Europe  This deal has already boosted Esperion s cash resources Meanwhile  the company expects to complete enrollment in the CLEAR cardiovascular outcomes study by the end of September  The study is evaluating bempedoic acid for occurrence of major cardiovascular events in statin averse patients with or at high risk of cardiovascular disease Although there is significant opportunity for Esperion s pipeline candidate  the company s funds may prove inadequate for successful launch of the drugs  Moreover  Esperion s candidate will face significant competition from PCSK9 inhibitors   Sanofi   NASDAQ SNY   Regeneron s   NASDAQ REGN   Praluent and Amgen s Repatha   and several other classes of drugs already marketed for similar indications Esperion Therapeutics  Inc  Price
    Zacks RankEsperion currently has a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/esperions-bempedoic-acid-succeeds-in-phase-ii-diabetes-study-200460309,200460309
202815,424331,MRK,AstraZeneca s Lupus Drug Meets Primary Endpoint In Study,opinion,AstraZeneca PLC   NYSE AZN   announced positive top line results from the second phase III study on its human monoclonal antibody anifrolumab  currently under development for treating adult patients with moderate to severe systemic lupus erythematosus  SLE   The TULIP 2 study met the primary endpoint as treatment with anifrolumab showed a statistically significant and clinically meaningful reduction in disease activity compared to placebo with both arms receiving standard of care medicines The reduction was measured by the British Isles Lupus Assessment Group based Composite Lupus Assessment  BICLA  at week 52 of treatment This is the second phase III study on the candidate for SLE  Last August  the first study   TULIP 1   on anifrolumab failed to meet the primary endpoint of a statistically significant reduction in disease activity in patients with SLE per the SLE Responder Index 4  SRI4  measurement at 12 months AstraZeneca plans to present data from both TULIP 1 and TULIP 2 studies at an upcoming medical conference SLE is a chronic autoimmune disease with significant unmet need  Anifrolumab is a developmental monoclonal antibody that inhibits the activity of all type I interferons  IFN   which play a central role in lupus Further  anifrolumab is also being tested in a phase III long term extension study for SLE and a phase II study for lupus nephritis as part of the TULIP program Shares of AstraZeneca have rallied 19 5  so far this year against the  decrease of 1 7  We would like to remind investors that currently  there are a very few medicines approved for SLE with only one winning the nod in the last 60 years  GlaxoSmithKline s   NYSE GSK   human monoclonal antibody Benlysta  belimumab  is currently the only medicine specifically developed and approved for SLE A potential approval for anifrolumab upon review will help AstraZeneca gain access to the lucrative SLE patient population Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Merck   Co   Inc    NYSE MRK   and Novartis AG   NYSE NVS    both carrying a Zacks Rank  2  Buy   You can see  Merck s earnings estimates have moved 3 2  north for 2019 and 1 3  for 2020 over the past 60 days  The stock has gained 13 5  year to date Novartis  earnings estimates have been revised 2 8  upward for 2019 and 2 9  for 2020 over the past 60 days  The stock has inched up 5 5  year to date Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-lupus-drug-meets-primary-endpoint-in-study-200460355,200460355
202823,424339,MRK,U S  biotech companies Alnylam  Dicerna settle trade secrets case,news,"By Nate Raymond
BOSTON  Reuters    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it  25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene silencing technology used to develop drug treatments 
The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015  The accord came ahead of a jury trial that was set to begin on Monday in state court in Woburn  Massachusetts 
Under the agreement  Dicerna said it will pay Alnylam  2 million up front plus 983 208 shares of its common stock 
Cambridge  Massachusetts based Dicerna said it will also pay Alnylam another  13 million over the next four years  the timing of which is dependent on revenue Dicerna receives pursuant to future RNAi technology based partnerships under its GalXC brand 
Alnylam  also Cambridge based  in a statement said the deal would also place certain restrictions on Dicerna  Neither company admitted wrongdoing 
Dicerna s stock was trading at  13 20 midday on Friday  up 29 12 percent  Shares in Alnylam were trading at  97 59  up 1 46 percent 
Alnylam s lawsuit accused Dicerna of misappropriating confidential information related to RNAi technology Alnylam acquired when in 2014 when it bought a Merck  NYSE MRK    Co Inc subsidiary in a deal it valued in court papers at  325 million 
RNAi  or RNA interference  prevents a defective gene from making disease causing proteins 
The lawsuit said Dicerna  which unsuccessfully tried to acquire RNAi assets from Merck  used confidential information it reviewed while considering the potential transaction in violation of a confidentiality agreement 
Alnylam contended Dicerna also hired several Merck scientists who had been involved in developing the technologies its rival acquired as part of an intentional scheme to gain access to trade secrets and confidential information 
Alnylam in court papers filed in Middlesex County Superior Court said the scheme allowed Dicerna to develop  strikingly similar  technologies within a year and unjustly enriched the company by up to  325 million 
Dicerna denied the allegations  It filed a counterclaim alleging Alnylam was pursuing a frivolous lawsuit that improperly interfered with its funding sources and partnership opportunities in order to crush its smaller competitor 
Dicerna sought  42 2 million in damages  It also filed a related federal antitrust case against Alnylam  which is also being settled ",2018-04-20,Reuters,https://www.investing.com/news/stock-market-news/us-biotech-companies-alnylam-dicerna-settle-trade-secrets-case-1406258,1406258
202824,424340,MRK,Shire bid marks Takeda s latest   and biggest   push for global status,news,"By Sam Nussey TOKYO  Reuters    Takeda Pharmaceutical Co Ltd s  T 4502   64 billion bid for London listed rare disease specialist  Shire  Plc  L SHP  bolsters its credentials as Japan s most outward facing drugs firm  a mould breaking image that has been more than a decade in the making  Under chief executive Christophe Weber and his predecessor  Yasuchika Hasegawa  Takeda has cut its exposure to Japan  brought in expertise through overseas acquisitions and thrown open its leadership ranks to foreign talent  Some investors worry that Takeda  with only  4 3 billion in cash on hand for the Shire deal  may be overreaching  The company s shares dropped more than 7 percent on Wednesday after Shire said it was willing to recommend the offer to shareholders  and are down 18 percent since news of Takeda s interest in a deal became public in late March  But few argue that Takeda s management isn t ready to go global   Already only 30 percent of the company s drug sales come from Japan  and 70 percent of its workforce is based overseas  The Shire deal would radically accelerate that shift  adding more than  9 billion in U S  revenue   Takeda has been  is and will continue to be the truly international pharmaceutical company of Japanese origin   said Philippe Auvaro  Tokyo based president of rare disease specialist OrphanPacific Inc and a friend of Weber s  To get there  the company reshaped its corporate culture  along the way fending off a revolt against Hasegawa  who saw a focus on foreign business as the future  Takeda declined to make Weber or Hasegawa available for this story  Shire declined to comment   SHOCK TACTICS  Hasegawa was the architect of Takeda s shift  He took the company s reins from Kunio Takeda  the last member of the founding family to run the 237 year old drugmaker  Hasegawa was determined to look overseas for growth as well as leadership  His philosophy propelled the company onto its continent straddling path as it acquired U S  biotech business Millennium Pharmaceuticals in 2008 and Swiss drugmaker Nycomed in 2011  His pursuit of foreigners to fill Takeda s executive ranks cut against the grain of Japan s insular corporate world  The surprise decision to appoint Weber   then the company s chief operating officer   as his successor led to open revolt among some of Takeda s old guard  In 2014  more than 100 former executives and investors signed a letter of objection  calling Weber s appointment a  hijack by so called foreign capital    something that should never be allowed    But Hasegawa was unwavering  Acquisitions were essential if the drugmaker was to rebuild its pipeline as drugs lost patent protection  he told shareholders  Weber was the best choice to take Takeda s new products out into the world  he said   In the end  Weber s appointment sailed through the annual shareholders meeting  with more than 90 percent of the votes in favor   QUIET REVOLUTIONARY  At first glance  the mild mannered Weber might not seem the most likely choice to orchestrate the biggest overseas acquisition in Japanese history   But those who have worked with him praise his ability to convince others of the need for radical change  making him ideal for a company trying to expand globally   Peter Feldinger  who worked at Nycomed and Takeda before becoming a consultant  said the union of the two companies had stalled until Weber took charge   It was complicated to take an inherently old  conservative Japanese organization  and get it to understand the world had changed  he said   Brought up in the Alpine city of Annecy  the son of two doctors  Weber spent two decades at GlaxoSmithKline  L GSK   including a stint as head of its vaccines unit  He took over as chief executive in 2015 after joining Takeda a year earlier as chief operating officer  Hasegawa stayed on as chairman  using his position to act as a  shield  while Weber pushed through unpopular moves  said Tosh Nagate  formerly at Takeda and now chief executive of e Projection  a company that helps foreign drugmakers expand in Japan  Hasegawa stepped aside into an advisory role last year   One of the most difficult decisions was to reduce the number of research and development areas  The company also retrenched in two key sites  Boston and Shonan  southwest of Tokyo  Under Weber  Takeda s involvement in the Japanese market has continued to wane  The U S  now accounts for 35 percent of drug sales  but Takeda has promised to keep its headquarters in Japan  Weber has also been proactive in chasing down cross border deals  announcing the  5 20 billion purchase of U S  cancer drug maker Ariad Pharmaceuticals Inc last year and Belgian biotech group TiGenix NV in January as it tries to rebuild its drug pipeline  While questions remain over whether Takeda overpaid for its past acquisitions  drugs on the market as a result are feeding stronger recent results   nL4N1PR2AM   ESCAPE VELOCITY Acquiring Shire would transform Takeda s position in rare diseases  gastrointestinal disorders and neuroscience  where Shire is a leader in ADHD drugs   For now  many of its peers remain highly exposed to Japan  although a shrinking population and annual drug price revisions have encouraged them to consider overseas expansion plans of their own   Ono Pharmaceutical Co Ltd  T 4528   which co developed the blockbuster cancer drug Opdivo with Bristol Myers Squibb Co  N BMY   recently said it was looking to build its own sales network in the U S  and was considering acquisitions   Eisai Co Ltd  T 4523  favors a different approach  Last month it signed a deal to collaborate with Merck   Co Inc  N MRK  to develop and sell its cancer drug Lenvima  both alone and in combination with Merck s immunotherapy product  Keytruda   nL2N1QP262  Weber will be under pressure to prove his strategy is the right one   particularly as one of the best paid executives in Japan  His annual pay is more than 1 billion yen    Highly paid and saying he will stay on until 2025  it s possible he feels that he needs to do something big for his reputation as CEO   UBS analyst Atsushi Seki said   Complicating matters is that chief financial officer Costa Saroukos  who had overseen the finances of Takeda s Europe and Canada businesses  only started in his new role this month  
Takeda s previous CFO  James Kehoe  quit abruptly in March  citing Japan s high tax rates and a desire to return to the U S ",2018-04-25,Reuters,https://www.investing.com/news/stock-market-news/shire-bid-marks-takedas-latest--and-biggest--push-for-global-status-1412704,1412704
202825,424341,MRK,Pfizer s Xtandi Label Expansion Filing Gets Priority Review ,opinion,Pfizer  Inc    NYSE PFE   and partner Astellas announced that the FDA has accepted the supplemental New Drug Application  sNDA  looking for label expansion of cancer drug  Xtandi in men with metastatic hormone sensitive prostate cancer and granted priority review designation to it The sNDA was based on data from the phase III ARCHES study  data from which demonstrated that Xtandi in combination with androgen deprivation therapy   ADT   significantly reduced the risk of radiographic progression or death by 61  compared to ADT alone  The sNDA is also supported by data from an Astellas supported study  ENZAMET  which also met the primary endpoint of overall survival  With the FDA granting priority review designation to the sNDA  a decision is expected in the fourth quarter  A similar application is also under review in the EU and JapanPfizer s shares have declined 20 2  this year so far compared with a decline of 2 2  for the    Xtandi is already approved to treat metastatic and non metastatic castration resistant prostate cancer   If data from ARCHES is approved to be included in the label of Xtandi  it can treat a broader prostate cancer patient population Xtandi was added to Pfizer s portfolio with the acquisition of Medivation in September 2016  While Pfizer sells Xtandi in the United States in partnership with Astellas  the latter owns the marketing right outside the U S  markets  Pfizer recorded Xtandi alliance revenues of  369 million in the first half of 2019 Xtandi is also being evaluated in late stage studies for hormone sensitive prostate cancer as well as in mid stage studies for advanced breast cancer and hepatocellular carcinoma In a separate press release  Pfizer said it is investing half a billion dollars for expanding its state of the art gene therapy manufacturing facility in Sanford  NC  The  500 million investment will add more capacity at the Sanford plant  which makes gene therapies as well as Pfizer s popular vaccine Prevnar 13  It also has other vaccines in development Pfizer currently carries a Zacks Rank  5  Strong Sell   Some better ranked large cap pharma stocks are Roche Holding  SIX ROG  AG   OTC RHHBY    Sanofi   NASDAQ SNY   and Merck   NYSE MRK    While Roche sports a Zacks Rank  1  Strong Buy   Sanofi and Merck carry a Zacks Rank  2  Buy   You can see  Shares of Roche have gained 11 9  this year so far  Earnings estimates for 2019 have risen 0 8  while that for 2020 have increased 2  over the past 30 days Sanofi s earnings estimates have increased 0 3  and 0 9   respectively  for 2019 and 2020 over the past 30 days Merck s stock is up 13 7  this year so far  Its earnings estimates have risen almost 3 2  for 2019 and 1 1  for 2020 over the past 30 days It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise  Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/pfizers-xtandi-label-expansion-filing-gets-priority-review-200457600,200457600
202826,424342,MRK,Esperion s Drugs In Review Hold Potential  Funds A Concern,opinion,"We issued an updated research report on Esperion Therapeutics   NASDAQ ESPR   on Aug 23  Shares of the company have decreased 19 8  so far this year against the  s rise of 5   The company does not have any marketed drug in its portfolio  However  regulatory applications for its pipeline candidates   bempedoic acid as a monotherapy and in combination with Merck s   NYSE MRK   Zetia  ezetimibe    are under review in the United States as well as in Europe  The company is looking to the get the oral therapies approved for the treatment of elevated LDL C  bad cholesterol  in patients receiving maximally tolerated statins or Zetia and having inadequate response A decision from the FDA on the monotherapy regimen is expected by Feb 21  2020  while a decision on the combination therapy should come by Feb 26  2020  The FDA is currently not expected to hold an advisory committee meeting for discussing the new drug applications The regulatory applications were filed based on data from multiple pivotal studies evaluating bempedoic acid monotherapy and combination therapy Data from four phase III studies evaluating bempedoic acid monotherapy  presented previously  demonstrated that treatment with the therapy led to additional 18  reduction in LDL C over 31  LDL C reduction in statin treated patients on maximally tolerated statin Data from the phase III study evaluating bempedoic acid Zetia combination pill showed that the combination regimen reduced bad cholesterol by 35  compared with 24  for Zetia  20mg  monotherapy  20  for bempedoic acid and 3  for placebo in patients receiving maximally tolerated statins The targeted indications represent a significant opportunity for the company  It is estimated that 78 million people in the United States have high levels of LDL C along with 73 million people in Europe and 30 million people in Japan  Of these  an estimated 40 million patients in the United States are using statins  which is intolerable in 5  to 20  of this population  A potential approval will likely drive share price of the company higher  The company signed a deal with Daiichi Sankyo Europe in January for commercialization of the candidates in Europe  This deal has already boosted Esperion s cash resources Meanwhile  the company expects to complete enrollment in the CLEAR cardiovascular outcomes study by the end of September  The study is evaluating bempedoic acid for occurrence of major cardiovascular events in statin averse patients with or at high risk of cardiovascular disease However  any regulatory setback related to the company s pipeline candidates will be a major disappointment for the company Esperion had  300 million as of Jun 30  2019  sufficient to fund operations till operating cash flow remains positive  However  timely availability of fund is necessary for successful commercialization of the company s drugs  following a potential approval  In June  Esperion entered into a revenue interest purchase agreement of  200 million with an investor group to extend its resources  However  these funds may prove inadequate for successful launch of the drugs as the company s operating expenses remain significantly high Moreover  Esperion s candidates will face significant competition from PCSK9 inhibitors   Sanofi   NASDAQ SNY   Regeneron s   NASDAQ REGN   Praluent and Amgen s Repatha   already marketed for similar indications Esperion Therapeutics  Inc  Price
    Zacks RankEsperion currently has a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-25,Zacks Investment Research,https://www.investing.com/analysis/esperions-drugs-in-review-hold-potential-funds-a-concern-200458605,200458605
202827,424343,MRK,Bristol Myers  Empliciti Gets EMA Nod For Label Expansion,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the European Medicines Agency   EMA   has approved the label expansion of Empliciti in combination with Celgene s   NASDAQ CELG   Pomalyst  pomalidomide  and low dose dexamethasone  EPd  for the treatment of relapsed and refractory multiple myeloma  r rMM  in third or later line settings  Patients should have received at least two prior therapies including Revlimid and a proteasome inhibitor and demonstrated disease progression on the last therapy The approval was based on data from the phase II ELOQUENT 3 study  which showed that treatment with EPd combination reduced the risk of disease progression by 46  compared to dexamethasone alone  which is the current standard of care in Europe for r rMM  Updated data presented in June 2018 from an exploratory analysis of ELOQUENT 3 study showed that 67  were alive in EPd arm compared to 51  for the comparator arm A similar label expansion for Empliciti was approved by the FDA in November last year  Please note that Bristol Myers is developing the drug in collaboration with AbbVie   NYSE ABBV   while it is solely responsible for commercial activities related to the drug Shares of Bristol Myers have declined 2 1  year to date compared with the  s decrease of 7 8   Empliciti is also approved in combination with Celgene s Revlimid for treatment of r rMM in patients who have received one to three prior therapies  The company is developing this combination for first line multiple myeloma The drug generated sales of  174 million in the first half of 2019  Approval of the combination therapy will provide an important treatment option for European patients with relapsed refractory multiple myeloma whose disease has progressed after treatment with lenalidomide and a proteasome inhibitor Meanwhile  the company s blockbuster immuno oncology drug  Opdivo continues to perform well  driven by label expansions  However  the drug faces stiff competition globally from Merck s   NYSE MRK   PD L1 inhibitor  Keytruda Bristol Myers Squibb Company Price
    Zacks RankBristol Myers currently sports a Zacks Rank  1  Strong Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-empliciti-gets-ema-nod-for-label-expansion-200459465,200459465
202832,424348,MRK, Wall Street Sees Keytruda Cancer Drug Lifting Merck s Fortune  ,news,Investing com    Barclays   LON BARC  became the latest firm to upgrade Merck  NYSE MRK  because of its blockbuster cancer drug Keytruda  The firm gave Merck an overweight rating and raised its stock price target from  62 to 64   Morgan Stanley   NYSE MS  recently upped its price target from  60 to  63 while Leerick Partners upgraded Merck to outperform  Keytruda is expected to gain a larger share of the market treating non small cell lung cancers as it competes with Bristol Myers Squibb  Sales of Keytruda more than doubled in 2017 to  3 8 billion and are expected to reach  8 2 billion by their peak in 2020  The drug is already approved for lung  skin and several other cancers types and is being tested for still others Merck shares  however  are down 13  in the past 12 months ,2018-04-10,Investing.com,https://www.investing.com/news/stock-market-news/wall-street-sees-keytruda-cancer-drug-lifting-mercks-fortune-1387411,1387411
202833,424349,MRK,U S  Northeast carbon market creating jobs  revenue  study,news,"By Nichola Groom
 Reuters    Nine states in the U S  Northeast have slashed greenhouse gas pollution  created thousands of jobs in clean energy  and cut consumer power costs using a market based scheme to slash carbon emissions  according to a study released on Tuesday 
The report on the Regional Greenhouse Gas Initiative from Boston based consultancy Analysis Group comes as the Trump administration seeks to unwind federal efforts to fight climate change  arguing they would kill jobs and stifle growth 
The RGGI   a cap and trade scheme adopted in 2009   has provided its nine members  1 4 billion in net economic benefits since 2015  according to the study  It has generated more than 14 500 job years in the renewable energy and efficiency sectors  A job year is the equivalent of a full time job for a year 
Those benefits come in addition to a more than 50 percent cut in emissions of carbon dioxide in the region since the RGGI s inception   a trend aided by the retirement of aging fossil fuel power plants  cheap natural gas  and sluggish demand in the wake of the 2008 financial crisis 
 All of the states have benefited from an actual reduction in carbon emissions   Sue Tierney  a senior adviser with Analysis Group  said in an interview last week   From a monetary and economic point of view     consumers are a bit better off  
A report by the Congressional Research Service last year  however  said the RGGI program s direct impact on reducing global greenhouse gas emissions was  arguably negligible   in part because the region overall is responsible for just 7 percent of total U S  greenhouse gas emissions 
The RGGI system  which was meant as a model for other states and countries to join or replicate  seeks to encourage carbon cuts by requiring industries like power plants to acquire tradable permits to cover their emissions  Each year  fewer permits are made available by the states   creating an incentive for businesses to reduce carbon output 
The revenue from the permit sales has amounted to some  2 8 billion since 2009  The revenue goes to the member states  which then invest in programs that support energy efficiency  renewable energy and jobs training  according to the report 
Analysis Group said the permit costs had led some fossil fuel generators most affected to hike power prices  but that the states  investments in energy efficiency and renewables had more than compensated for that by reducing consumer demand  resulting in an overall decline in costs for electricity 
Wholesale power prices in New England averaged roughly  33 per megawatt hour in 2017  among the highest in the country  but still less than half the level in 2008 before RGGI was adopted  according to data from grid operator ISO New England 
The RGGI states include Connecticut  Delaware  Massachusetts  Maryland  Maine  New Hampshire  New York  Rhode Island and Vermont  New Jersey  an original member  is seeking to rejoin after withdrawing in 2011 
The Analysis Group s report was funded mainly by progressive and environmentalist foundations including the Barr Foundation  the Energy Foundation and the Merck  NYSE MRK  Family Fund ",2018-04-17,Reuters,https://www.investing.com/news/economy-news/us-northeast-carbon-market-creating-jobs-revenue-study-1397718,1397718
202834,424350,MRK,Moleculin Completes Enrollment In Early Stage Cancer Study,opinion,Moleculin Biotech  Inc    NASDAQ MBRX   announced that it has completed enrollment in the proof of concept clinical study evaluating its p STAT3 inhibitor candidate  WP1220  as a topical treatment of cutaneous T cell lymphoma   CTCL    a form of skin cancer The study site is currently in Poland and will evaluate WP1220 to observe the potential of the candidate in treating CTCL  The company states that immunotherapies  including checkpoint inhibitors like Bristol Myers    NYSE BMY   Opdivo and Merck s   NYSE MRK   Keytruda are the major players in the oncology market  However  the company believes there are certain non responsive tumors where checkpoint inhibitors have lower efficacy  It states that research has shown that a combination of a STAT3 inhibitor and a checkpoint inhibitor immunotherapy might result in better results in non responsive tumors Another company developing treatment for CTCL is Soligenix   NASDAQ SNGX    which is evaluating its pipeline candidate  SGX301  in a pivotal phase III study Apart from WP1220  the company has five other candidates in its pipeline in pre clinical or early stage development The company is developing its lead pipeline candidate  annamycin  as a potential treatment for relapsed refractory acute myeloid leukemia   AML   in phase I II studies  Interim data from the ascending dose study has shown no significant adverse events and the company is proceeding with the evaluation of a higher dose of the candidate In April this year  the FDA granted a Fast Track Designation to annamycin for treating relapsed or refractory AML  The candidate also enjoys an orphan drug status for addressing AML In March  Moleculin announced positive interim safety and efficacy results from the phase I II studies on annamycin for treating AML  conducted both in the United States and Europe Annamycin is also being evaluated in pre clinical studies for treating metastatic lung cancer  In April 2019  the company announced that annamycin significantly improved the survival rate in an aggressive form of triple negative breast cancer metastasized to the lungs in animal models Annamycin  an anthracycline  is currently being evaluated in two phase I II studies for treating relapsed refractory AML  On approval  the new patents will provide a protection of 20 years for annamycin  In July  the company filed for new patents  covering the production and reconstitution of annamycin Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/moleculin-completes-enrollment-in-earlystage-cancer-study-200455397,200455397
202835,424351,MRK,Roche Receives FDA Nod For Rozlytrek In ROS1 positive NSCLC ,opinion,Roche Holdings   OTC RHHBY   announced that the FDA has approved Rozlytrek  entrectinib  for the treatment of adults with ROS1 positive  metastatic non small cell lung cancer  NSCLC  The FDA has also granted accelerated approval to Rozlytrek for the treatment of adult and pediatric patients aged 12 years or older with solid tumors that have a neurotrophic tyrosine receptor kinase  NTRK  gene fusion The agency s accelerated approval program allows conditional approval of a drug that fills an unmet medical need for a serious or life threatening disease or condition  Continued approval may be contingent upon verification and description of clinical benefit in the confirmatory trial The FDA approval was based on results from the integrated analysis of the pivotal phase II STARTRK 2  phase I STARTRK 1 and phase I ALKA 372 001 trials  and data from the phase I II STARTRK NG study Per the company  Rozlytrek is the first FDA approved treatment that selectively targets both ROS1 and NTRK fusions  and showed responses in various cancer types that have spread to the brain Meanwhile  Roche is leveraging its expertise in developing personalized medicines and advanced diagnostics in conjunction with Foundation Medicine to help identify patients with ROS1 and NTRK gene fusions Foundation Medicine will submit Foundation One CDx to the FDA for approval as a companion diagnostic for Rozlytrek Rozlytrek was approved in June 2019 in Japan for the treatment of adult and pediatric patients with NTRK fusion positive  advanced recurrent solid tumors  The drug has also been granted Priority Medicines  PRIME  designation by the European Medicines Agency The approval of Rozlytrek in the United States will strengthen Roche s oncology franchise  The company currently has five approved drugs  Tarceva  Avastin and Tecentriq  among others  to treat certain kinds of lung cancer and more than 10 candidates in the pipeline to target the most common genetic drivers of lung cancer or boost the immune system to combat the disease Lung cancer is one of the most prevalent cancers and the leading cause of cancer related death across the world  More than one and a half million patients die as a result of this disease globally  equating to more than 4 000 deaths every day  NSCLC is the most common type of lung cancer and accounts for 85  of all lung cancer diagnoses Roche s stock has gained 11 2  in the year so far against the  s decline of 3 6   However  competition is stiff in the NSCLC market  Immuno oncology therapies like Merck s   NYSE MRK   Keytruda  AstraZeneca s   NYSE AZN   Imfinzi and Bristol Myers    NYSE BMY   Opdivo are approved for various types of NSCLC Roche currently carries a Zacks Rank  1  Strong Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/roche-receives-fda-nod-for-rozlytrek-in-ros1positive-nsclc-200455764,200455764
202836,424352,MRK,AstraZeneca Calquence Gets FDA s Breakthrough Status For CLL,opinion,AstraZeneca   NYSE AZN   announced that the FDA has granted Breakthrough Therapy Designation  BTD  to its leukemia drug Calquence for chronic lymphocytic leukemia  CLL  as a monotherapy treatment  The BTD status was based on positive interim data from two phase III studies   ELEVATE TN and ASCEND   on the BTK inhibitor  Data from the studies have shown that Calquence alone or as a combination therapy significantly increased the time patients lived without disease progression or death Calquence is presently marketed for the previously treated mantle cell lymphoma  MCL    It is being developed in phase III programs for larger CLL indication and the company expects to file regulatory applications based on data from the ASCEND and ELEVATE TN studies later this year to get an approval for CLL  If approved  this would definitely help AstraZeneca gain access to a broader patient population and boost sales of this promising drug Shares of AstraZeneca have rallied 16 3  this year so far against the  s decrease of 3 6    In a separate press release  AstraZeneca announced that the phase III study  PAOLA 1  evaluating its and Merck s   NYSE MRK   PARP inhibitor  Lynparza  for a broader advanced ovarian cancer patient population met the primary endpoint  The study evaluated Lynpazra as a first line maintenance treatment in combination with Roche s   OTC RHHBY   Avastin  bevacizumab  versus Avastin alone in women suffering advanced ovarian cancer with or without BRCA gene mutations  Data from the study showed that treatment with Lynparza plus Avastin led to a statistically significant and clinically meaningful improvement in progression free survival  PFS  in the intent to treat  ITT  population versus Avastin alone   Lynparza is presently approved as first line maintenance treatment for BRCAm advanced ovarian cancer following response to platinum based chemotherapy Lynparza  presently marketed for advanced ovarian cancer and breast cancer  is also in different studies for a range of tumor types including prostate  pancreatic and gastric cancers as well as earlier line settings for ovarian and breast cancers Both Calquence and Lynparza are part of AstraZeneca s strong oncology portfolio of drugs  Oncology sales now comprise around 35  of AstraZeneca s total product sales  surging 50  in 2018 and 58  in the first half of 2019  In the same period  while Lynparza generated sales of  520 million  up 93  year over year  Calquence recorded revenues of  64 million Zacks Rank   Stock to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  A better ranked large cap pharma stock is Novartis   NYSE NVS    Its earnings estimates for 2019 have inched up 2 8  while that for 2020 have been raised 2 3  over the past 30 days  Novartis stock has returned 3 3  so far in 2019 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-calquence-gets-fdas-breakthrough-status-for-cll-200455882,200455882
202844,424360,MRK,ImmunoGen s mirvetuximab soravtansine shows positive effect in Phase 1 2 ovarian cancer study  shares up 12  premarket,news,ImmunoGen   NASDAQ IMGN  is up 12  premarket on the heels of its announcement of positive results from a Phase 1 2 clinical trial  FORWARD II  evaluating mirvetuximab soravtansine  combined with Merck  NYSE MRK  s Keytruda  pembrolizumab   in patients with platinum resistant epithelial ovarian cancer  The data are being presented at the Society of Gynecologic Oncology Annual Meeting in New Orleans  LA In eight heavily pretreated patients with medium high folate receptor alpha expression levels  the confirmed overall response rate  ORR  was 63   n 5 8   with median progression free survival  PFS  of 8 6 months The company intends to enroll an additional 35 patients in an expansion cohort Mirvetuximab soravtansine is an antibody drug conjugate that targets folate receptor alpha Now read ,2018-03-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/immunogens-mirvetuximab-soravtansine-shows-positive-effect-in-phase-12-ovarian-cancer-study-shares-up-12-premarket-1361541,1361541
202845,424361,MRK,Merck s Keytruda helps lung cancer patients live longer in trial,news,"By Tamara Mathias  Reuters    Merck   Co s  N MRK  blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late stage trial  potentially cementing its position as the dominant player in the lucrative lung cancer market  Shares of the drugmaker were up 3 1 percent at  55 07  Merck is already considered the frontrunner in the space and Keytruda is expected to earn peak sales of over  10 billion in 2023  according to  Credit Suisse   SIX CSGN   Keytruda is already approved in the U S  to treat patients with non small cell lung cancer  NSCLC  who have not received prior therapies and whose tumors show PD L1 protein levels of 50 percent or greater  If the company can show that the new data benefits patients whose PD L1 expression is between 1 and 49 percent  it would expand Keytruda s market and raise the competitive benchmark for rivals Bristol Myers Squibb  N BMY  and AstraZeneca Plc  L AZN   BMO Capital Markets analyst Alex Arfaei said  An independent data monitoring committee determined the trial  which tested Keytruda as a monotherapy to treat NSCLC  extended the lives of patients significantly compared to chemotherapy  Additional data from Merck  as well as results from trials of competitors  could eventually determine which companies will snatch the largest slice of the pie for the lung cancer market   I think the market still believes that there could be other players in the lung cancer market  which would combat overall sales of Keytruda in this setting   Guggenheim Securities analyst Tony Butler told Reuters    Because we don t know the full data set we don t know the survival benefit here   Based on a recommendation from the committee  the trial will continue to evaluate a secondary goal on whether the treatment can delay the disease from progressing   While it is still unclear whether Keytruda and  Bristol Myers   Opdivo are truly different in some way  it is crystal clear that Merck has done a much better job designing trials and developing their drug  This will solidify their lead   said Brad Loncar  chief executive officer of Loncar Investments  which runs the Loncar Cancer Immunotherapy ETF   Keytruda  which is approved to treat several other forms of cancer including skin and blood cancer  racked up  3 81 billion in revenue in 2017   Lung cancer is the second most common cancer and is expected to kill over 154 000 people this year  the American Cancer Society says  NSCLC accounts for about 85 percent of all lung cancer cases  Merck said   
Shares of Bristol Myers fell 2 3 percent to  59 43 ",2018-04-09,Reuters,https://www.investing.com/news/stock-market-news/mercks-keytruda-meets-main-goal-in-pivotal-lung-cancer-trial-1384976,1384976
202846,424362,MRK,Endo  ENDP  Q2 Earnings   Revenues Beat Estimates  Down Y Y,opinion,Endo International plc   NASDAQ ENDP   reported better than expected results for second quarter 2019 However  investors were not much impressed by the results as the company did not raise guidance  The stock crashed 21  following the results  Notably  shares of Endo have lost 68 1  in the year so far against the  s 7 3  growth  The company s earnings of 52 cents in the reported quarter easily beat the Zacks Consensus Estimate of 47 cents  However  earnings declined from 76 cents in the year ago quarter Revenues came in at  699 7 million in the quarter  surpassing the Zacks Consensus Estimate of  697 million but decreasing 2  from the year ago quarter s figure  The decrease was primarily attributable to competitive pressure in the Generic Pharmaceuticals segment  the Established Products portfolio of the Branded Pharmaceuticals segment and the International segment  Nevertheless  strong growth in the Sterile Injectables segment and the Specialty Products portfolio of the Branded Pharmaceuticals segment partially offset the decline Quarterly HighlightsEndo has four reportable business segments   Branded Pharmaceuticals  Generic Pharmaceuticals  Sterile Injectables and International Pharmaceuticals Branded Pharmaceuticals revenues were  209 million  down from  213 million in the year ago quarter due to the ongoing generic competition in Established Products portfolio   Specialty Products revenues increased 17  to  124 million  driven by the continued strong performance of Xiaflex  Sales of Xiaflex increased 18  to  75 million  owing to higher demand in the Peyronie s Disease and the Dupuytren s Contracture indications  driven by continued commercial execution and investment in promotional activities The company is on track to submit a BLA for the collagenase clostridium histolyticum program for the treatment of cellulite in the second half of 2019 Generic Pharmaceuticals recorded sales of  218 million in the quarter  down 9 5  due to competitive pressure in the generic business  During the quarter under review  this segment launched three products Sterile Injectables revenues came in at  244 million  up 12  year over year  driven by strong growth of Adrenalin and Vasostrict   In July 2018  the segment launched the ertapenem injection  the authorized generic of Merck s   NYSE MRK   Invanz  which boosted sales International Pharmaceuticals revenues were  29 million  down from  43 million in the year ago quarter 2019 Outlook ReiteratedEndo expects revenues between  2 76 billion and  2 96 billion for 2019  The company expects Xiaflex s full year revenues to grow mid to high teens  The company anticipates earnings from continuing operations to be  2 00  2 25 per share Our TakeEndo reported better than expected results for the second quarter of 2019  wherein it beat on both earnings and sales  However  the decline in revenues due to competitive pressure in the generic pharmaceuticals segment is a concern  The company is looking to turn around its business  with focus on the Branded Pharmaceuticals segment in the United States Zacks Rank   Stocks to ConsiderEndo currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the healthcare sector are Galectin Therapeutics  Inc    NASDAQ GALT   and Portola Pharmaceuticals  Inc    NASDAQ PTLA    Both stocks carry a Zacks Rank  1  Strong Buy   You can see  Galectin s loss per share estimates have narrowed from 59 cents to 51 cents for 2019 in the past 60 days Portola s loss per share estimates have narrowed from  4 13 to  4 12 for 2019 in the past 60 days This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/endo-endp-q2-earnings--revenues-beat-estimates-down-yy-200452359,200452359
202851,424367,MRK,Kindred Healthcare beats by  0 02   revenue in line,news,Kindred Healthcare  NYSE KND   Q4 EPS of  0 20 beats by  0 02 Revenue of  1 48B   2 6  Y Y  in line Press ReleaseNow read ,2018-02-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/kindred-healthcare-beats-by-002--revenue-inline-1316953,1316953
202852,424368,MRK,Esperion s high cholesterol med bempedoic acid successful in late stage study,news,A Phase 3 clinical trial  Study 4  assessing Esperion s  NASDAQ ESPR  bempedoic acid in statin intolerant patients atherosclerotic cardiovascular disease  ASCVD  or at high risk of ASCVD with elevated low density lipoprotein cholesterol  LDL C  achieved the primary endpoint Patients receiving a daily 180 mg dose of bempedoic acid for 12 weeks experienced a statistically significant 28  lowering of LDL C compared to placebo  p 0 001  and 23  lower from baseline  Patients in the treatment group also experienced a 33  reduction in a cardiovascular disease inflammation related biomarker called C reactive protein compared to a 2  increase in the control group  p 0 001  On the safety front  bempedoic acid was well tolerated with no difference in the occurrence of adverse events compared to placebo Top line data from two Phase 3 studies  Study 1 and Study 2  in patients with ASCVD on maximum doses of statins should be available in May and September  respectively Top line data from another study in statin intolerant ASCVD patients  Study 3  should be available in May Top line data from another pivotal study  053 Study  assessing bempedoic acid combined with ezetimibe  Merck  NYSE MRK  s Zetia  in ASCVD patients on maximum statins should be available in August Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins  Once in the liver  it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase  ACL  which plays a key role in cholesterol and fatty acid synthesis Management will host a conference call this morning at 8 30 am ET to discuss the results Update  Shares are up 4  premarket Now read ,2018-03-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/esperions-high-cholesterol-med-bempedoic-acid-successful-in-latestage-study-1329293,1329293
202853,424369,MRK,Merck teams up with Eisai to commercialize cancer med Lenvima in deal valued as high as  5 76B,news,Eisai Co   OTCPK ESALF  inks a collaboration agreement with Merck  NYSE MRK  to co develop and co commercialize LENVIMA  lenvatinib mesylate   an orally available tyrosine kinase inhibitor  as monotherapy and in combination with KEYTRUDA  pembrolizumab  Under the terms of the deal  Eisai will book global sales and the two companies will equally share profits  Merck will pay Eisai  300M upfront  up to  650M for certain option rights through 2020   450M for R D reimbursement  up to  385M in clinical and development milestones and up to  3 97B in sales milestones LENVIMA is currently approved in over 50 countries to treat thyroid cancer and over 40 countries for kidney cancer  Marketing applications for liver cancer are under review in the U S   Europe  Japan  China and other countries A Phase 3 clinical trial sponsored by Eisai assessing the combination of LENVIMA and KEYTRUDA or LENVIMA   Novartis  AFINITOR  everolimus  versus chemotherapy in kidney cancer is on deck Now read ,2018-03-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-teams-up-with-eisai-to-commercialize-cancer-med-lenvima-in-deal-valued-as-high-as-576b-1331635,1331635
202854,424370,MRK,Cidara down 20  on  positive  mid stage data on rezafungin acetate,news,Thinly traded Cidara Therapeutics  CDTX  19 6   is down on over a 6x surge in volume following its release of Phase 2 data on lead antifungal candidate rezafungin acetate in patients with systemic Candida infection Shares initially spiked  20  premarket based on the company s statement that the study met all of its objectives  but then quickly reversed after investors apparently looked closely at the results Two points stand out  the comparative data against caspofungin  Merck  NYSE MRK  s Cancidas  were not statistically valid since STRIVE was not powered to demonstrate superiority or non inferiority and the incidence of treatment emergent adverse events was higher  88 6  and 94 4  for rezafungin versus 81 8  for caspofungin   The rates of severe adverse events  though  were lower in the rezafungin groups  37 1  and 27 8  vs  39 4   The company plans to advance rezafungin into Phase 3 development Previously  Cidara s lead drug successful in mid stage study  March 19 Now read ,2018-03-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/cidara-down-20-on-positive-midstage-data-on-rezafungin-acetate-1348244,1348244
202855,424371,MRK,Merck  MRK  To Report Q2 Earnings  What s In The Cards ,opinion,"Merck   Co   Inc    NYSE MRK   will report second quarter 2019 resultson Jul 30 before market open  In the last reported quarter  the company delivered a positive earnings surprise of 16 19  Merck s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise was 5 67  Merck   Co   Inc  Price and EPS Surprise
     
Merck s shares have risen 7 3  in the year so far against 1 3  decrease for the    Let s see how things are shaping up for this announcement Factors to ConsiderMerck s relatively newer products like cancer drug Keytruda  Gardasil vaccine and Bridion injection should continue to drive the top line this quarter driven by strong demand trends  Alliance revenues from Lynparza and Lenvima should also boost oncology sales However  loss of market exclusivity for several drugs including Zetia and Vytorin  pricing pressure  currency headwinds  softness in the diabetes  Januvia Janumet  franchise  and lower sales of key products like Zostavax and Zepatier due to competitive pressure may hurt sales Keytruda sales should once again be driven by the launch of new indications globally  Sales of the drug are gaining particularly from strong momentum in first line lung cancer indication both as monotherapy and with the rollout of the chemo combo in both non squamous and squamous NSCLC This year so far  Keytruda has gained several label expansion approvals  It was approved by the FDA as an adjuvant therapy for high risk stage III melanoma and for five new cancer line extensions in Japan in the first quarter  In April  the FDA gave approval to Keytruda in combination with Pfizer s   NYSE PFE   Inlyta for the first line treatment of advanced renal cell carcinoma as well as for an expanded first line lung cancer patient population  In June  Keytruda was approved by the FDA for first line treatment of recurrent or metastatic HNSCC and for previously treated advanced small cell lung cancer  All these label expansion approvals should drive sales of Keytruda in the soon to be reported quarter and through 2019 Strong demand in most markets is driving sales of Bridion  sugammadex  Injection   a trend we expect to see in the second quarter results as well  Meanwhile  commercial launch in China and strong growth in Europe should drive sales of Gardasil Gardasil 9 vaccine  However  sales of the vaccine declined in United States in the first quarter due to unfavorable public sector buying patterns  It remains to be seen if U S  sales trends of Gardasil improve in the second quarter Animal health franchise sales should improve from a relatively weaker performance in the first quarter Meanwhile adjusted gross margin is expected to be hurt by lower prices  royalty payments  currency fluctuations and the continued amortization of collaboration milestones Earnings WhispersOur proven model does not conclusively show that Merck will beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP is  0 22   The Zacks Consensus Estimate stands at  1 16 per share  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Merck s Zacks Rank  2 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to Consider Here are some large drug biotech stocks that have the right combination of elements to beat on earnings this time around AbbVie   NYSE ABBV   has an Earnings ESP of  0 12  and a Zacks Rank  2  The company is slated to release results on Jul 26  You can see  Bristol Myers Squibb Company   NYSE BMY   has an Earnings ESP of  0 28  and a Zacks Rank  3  The company is scheduled to release results on Jul 25 The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-to-report-q2-earnings-whats-in-the-cards-200443821,200443821
202856,424372,MRK,What To Expect From Sanofi s  SNY  Q2 Earnings ,opinion,"Sanofi   NASDAQ SNY   stock is down 1 8  in 2019 and has been volatile most of the year  Will this slight cumulative downtrend turn around after SNY reports Q2 earnings 
Overview
Sanofi is the fourth largest pharmaceutical company in the world by revenue  bringing in  40 9 billion last year  It is also the seventh largest by market share  with 4 11   Sanofi specializes in seven therapeutic areas  cardiovascular  central nervous system  diabetes  internal medicine  oncology  thrombosis  and vaccines  Its subsidiary  Sanofi Pasteur  is the largest dedicated vaccine producer in the world 
Sanofi s most popular medicines include Latnus  Placix and  Lovenox  Latnus is currently Sanofi s most successful drug  bringing about  4 9 billion in revenue last year  It is a drug that controls blood sugar in diabetics with a once daily injection  Lovenox and Placix are anti clotting and blood thinning drugs respectively 
Unknown to most  Sanofi also manufactures many popular over the counter brands  Products such as Gold Bond  Rolaids  Selsun Blue  and Allegra can all be found in drug stores across the country and are steady revenue streams for Sanofi 
On Wednesday  Sanofi acquired the OTC rights to popular flu medicine  Tamiflu  from competitor Roche  Sanofi is now attempting to get Tamiflu approved by the FDA for OTC sales  hoping to cash in on convenience  Roche  meanwhile  has another flu drug in the works called Zofluza  which the company says is faster acting and stronger than Tamiflu  Therefore  it looks like it will be a battle between the two companies to see if consumers will go through the extra hassle of getting a prescription for a stronger medicine  or just chose the quicker and easier access treatment 
Outlook
Our Zacks Consensus Estimate predicts Q2 revenue of  9 88 billion  a 1 24  bump over last year s Q2 sales  For each of the past four quarters  revenues have declined year over year by an average of 1 4   Hopefully  Sanofi can meet projections and have a positive quarter  which may boost SNY stock 
Although revenues have gone down the past few quarters  earnings have managed to stay in the black  Earnings have not been increasing greatly  however  with an average year over year jump of just 0 94  over the past 8 quarters  Earnings this quarter are projected to fall by 6 79  to  0 69  This estimate is  however  up from our  0 66 estimate 90 days ago 
Estimates for next quarter s EPS call for 5 61  growth to  1 13 a share  This would mark an all time high for the company  For all of 2019  estimates show just a 0 62  earnings increase from last year  Estimates also show 8 15  EPS growth for 2020  which would be the company s largest single year EPS growth since 2008 
Since the beginning of 2019  Sanofi s forward P E of 12 4x has dropped relative to its peer group  suggesting that it may currently be undervalued  Its peer group that includes Merck   NYSE MRK    GlaxoSmithKline   NYSE GSK    AbbVie   NYSE ABBV    Pfizer   NYSE PFE    and others has an average forward P E of 14 29 

Recent News
The FDA accepted an application for approval of Sanofi s relapsed refractory multiple myeloma drug  isatuximab  This drug has undergone successful phase III trials and is still in other clinical trials to possibly treat other types of hematologic malignancies and solid tumors 
Sanofi has a strong pipeline in addition to isatuximab  It includes several new biologics and vaccines in late stage development  A promising pipeline is always important for drug companies  as investors need to see how strong the future of the company looks after current patents inevitably run out 
Bottom Line
Sanofi currently holds a Zacks Rank  2  Buy   due to upward earnings estimate revisions for this fiscal year and next  Sanofi likely won t report stellar earnings when it releases its quarterly results before the market opens on Monday  July 29  But with a strong pipeline in development and possible OTC Tamiflu boosting future revenues  Sanofi has strong potential to raise earnings over the coming quarters and into 2020 
Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-sanofis-sny-q2-earnings-200444098,200444098
202857,424373,MRK,Will Opdivo   Eliquis Drive Bristol Myers  BMY  Q2 Earnings ,opinion,"Bristol Myers Squibb Company   NYSE BMY   is a global specialty biopharmaceutical company  Its key oncology products are Opdivo  Sprycel  Yervoy and Empliciti  Beyond oncology  the company focuses on immunology and cardiovascular drugs like Orencia and Eliquis 
Bristol Myers  immuno oncology drug  Opdivo  is approved for multiple indications and is the primary growth driver  The drug is expected to maintain momentum in the second quarter  It generated sales of  1 8 billion in the first quarter  increasing 19  year over year  The uptake of the drug continues to be strong  particularly in new indications of first line renal cell carcinoma and adjuvant melanoma  The trend should continue in the second quarter despite stiff competition from the likes of Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq 
However  investors will also focus on recent pipeline setbacks  The phase III CheckMate 498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6 methylguanine DNA methyltransferase  MGMT  unmethylated glioblastoma multiforme  GBM  did not meet its primary endpoint of overall survival  OS  at final analysis 
Moreover  CheckMate 459  a randomized phase III study evaluating Opdivo compared to Nexavar as a first line treatment in patients with unresectable hepatocellular carcinoma  HCC   also did not achieve statistical significance for its primary endpoint of OS 
Nevertheless  the performance of blood thinner drug  Eliquis  was strong in the first quarter  propelled by increased share in the novel oral anticoagulant  NOAC  market  and should boost sales in the second quarter   Oncology drug  Sprycel  should contribute positively to the top line  driven by recent label expansions 
Rheumatoid arthritis  RA  drug  Orencia  also contributes to the company s top line  The recent label expansion of the drug should further boost sales  Yervoy should also continue with its stellar performance in the second quarter 
The Zacks Consensus Estimate for second quarter sales and earnings is pegged at  6 03 billion and  1 06  respectively 
Apart from the quarterly results  investors will also focus on further updates on the company s impending acquisition of Celgene Corp    NASDAQ CELG    Bristol Myers needs to sell one of Celgene s blockbuster drugs  Otezla  to complete the impending merger on a timely basis  in light of concerns expressed by the U S  Federal Trade Commission  FTC  
Bristol Myers  shares have decreased 17 7  in the year so far compared with the  s decline of 1 3  

 
Bristol Myers currently carries a Zacks Rank  3  Hold   You can see  
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/will-opdivo--eliquis-drive-bristolmyers-bmy-q2-earnings-200443625,200443625
202858,424374,MRK,What To Expect From Sanofi s  SNY  Q2 Earnings  Revised ,opinion,"Sanofi   NASDAQ SNY   stock is down 1 8  in 2019 and has been volatile most of the year  Will this slight cumulative downtrend turn around after SNY reports Q2 earnings 
Overview
Sanofi is the fourth largest pharmaceutical company in the world by revenue  bringing in  40 9 billion last year  It is also the seventh largest by market share  with 4 11   Sanofi specializes in seven therapeutic areas  cardiovascular  central nervous system  diabetes  internal medicine  oncology  thrombosis  and vaccines  Its subsidiary  Sanofi Pasteur  is the largest dedicated vaccine producer in the world 
Sanofi s most popular medicines include Latnus  Placix and  Lovenox  Latnus is currently Sanofi s most successful drug  bringing about  4 9 billion in revenue last year  It is a drug that controls blood sugar in diabetics with a once daily injection  Lovenox and Placix are anti clotting and blood thinning drugs respectively 
Unknown to most  Sanofi also manufactures many popular over the counter brands  Products such as Gold Bond  Rolaids  Selsun Blue  and Allegra can all be found in drug stores across the country and are steady revenue streams for Sanofi 
On Wednesday  Sanofi acquired the OTC rights to popular flu medicine  Tamiflu  from competitor Roche  Sanofi is now attempting to get Tamiflu approved by the FDA for OTC sales  hoping to cash in on convenience  Roche  meanwhile  has another flu drug in the works called Xofluza  which the company says is faster acting and stronger than Tamiflu  Therefore  it looks like it will be a battle between the two companies to see if consumers will go through the extra hassle of getting a prescription for a stronger medicine  or just chose the quicker and easier access treatment 
Outlook
Our Zacks Consensus Estimate predicts Q2 revenue of  9 88 billion  a 1 24  bump over last year s Q2 sales  For each of the past four quarters  revenues have declined year over year by an average of 1 4   Hopefully  Sanofi can meet projections and have a positive quarter  which may boost SNY stock 
Although revenues have gone down the past few quarters  earnings have managed to stay in the black  Earnings have not been increasing greatly  however  with an average year over year jump of just 0 94  over the past 8 quarters  Earnings this quarter are projected to fall by 6 79  to  0 69  This estimate is  however  up from our  0 66 estimate 90 days ago 
Estimates for next quarter s EPS call for 5 61  growth to  1 13 a share  This would mark an all time high for the company  For all of 2019  estimates show just a 0 62  earnings increase from last year  Estimates also show 8 15  EPS growth for 2020  which would be the company s largest single year EPS growth since 2008 
Since the beginning of 2019  Sanofi s forward P E of 12 4x has dropped relative to its peer group  suggesting that it may currently be undervalued  Its peer group that includes Merck   NYSE MRK    GlaxoSmithKline   NYSE GSK    AbbVie   NYSE ABBV    Pfizer   NYSE PFE    and others has an average forward P E of 14 29 

Recent News
The FDA accepted an application for approval of Sanofi s relapsed refractory multiple myeloma drug  isatuximab  This drug has undergone successful phase III trials and is still in other clinical trials to possibly treat other types of hematologic malignancies and solid tumors 
Sanofi has a strong pipeline in addition to isatuximab  It includes several new biologics and vaccines in late stage development  A promising pipeline is always important for drug companies  as investors need to see how strong the future of the company looks after current patents inevitably run out 
Bottom Line
Sanofi currently holds a Zacks Rank  2  Buy   due to upward earnings estimate revisions for this fiscal year and next  Sanofi likely won t report stellar earnings when it releases its quarterly results before the market opens on Monday  July 29  But with a strong pipeline in development and possible OTC Tamiflu boosting future revenues  Sanofi has strong potential to raise earnings over the coming quarters and into 2020 
We are reissuing this article to correct a mistake  A previous version of this article refered to  Xofluza  as  Zofluza   The original article  issued July 24  2019  should no longer be relied upon 
Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-sanofis-sny-q2-earnings-revised-200444235,200444235
202859,424375,MRK,AstraZeneca  AZN  Q2 Earnings Top   19 Product Sales View Up,opinion,"AstraZeneca   NYSE AZN   beat the Zacks Consensus Estimate for both earnings and sales in the second quarter of 2019 and also raised its previously issued product sales growth guidance range for the year Earnings   Sales BeatSecond quarter 2019 core earnings of 37 cents per American Depositary Share beat the Zacks Consensus Estimate of 30 cents  Core earnings per share of 73 cents increased 1  year over year at constant exchange rates   CER    benefiting from higher product sales Total revenues were up 13   18  at CER  to  5 82 billion in the reported quarter driven by higher product sales  Revenues also beat the Zacks Consensus Estimate of  5 51 billion AstraZeneca s shares rose around 5  in pre market trading in response to the better than expected results  In fact  the stock has rallied 6 2  this year so far against the  s decrease of 0 8    All growth rates mentioned below are on a year over year basis and at CER Product Sales RiseProduct sales rose 19  at CER in the quarter to  5 72 billion  Higher sales of newer medicines  particularly cancer drugs  and higher sales in every sales region  offset lower sales of many other legacy medicines and drove product sales growth The Cambridge  U K  based drugmaker s newer medicines recorded sales of  2 39 billion in the second quarter  up 72  at CER as almost every product it has launched in recent years did well  In fact  AstraZeneca expects five of its newer medicine to reach blockbuster status this year  Collaboration revenues  formerly Externalization revenues  declined 12  from the year ago period to  105 million Among AstraZeneca s various therapeutic areas  Oncology was up 57   New Cardiovascular  Renal and Metabolism was up 13  and Respiratory rose 7   However  other medicines declined 6  Newer Products Drive SalesAmong the newer medicines  Lynparza sales rose 95  year over year and 19  sequentially to  283 million in the quarter on the back of expanded use in ovarian and breast cancer  Sales of the drug in the United States increased 72   following the successful launch in first line ovarian cancer setting in late 2018  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK   Tagrisso recorded sales of  784 million  up 92  year over year driven by continued underlying demand growth and rapid uptake in the first line setting Imfinzi generated sales of  338 million in the quarter  up 14 6  sequentially mainly driven by strong demand in lung cancer patients  Like previous quarters  the vast majority of Imfinzi s sales came from the United States and the lung cancer indication Calquence  which was launched in the United States in October 2017  generated sales of  35 million in the second quarter compared with  29 million in the previous quarter Brilinta Brilique sales were  389 million in the reported quarter  up 28  year over year driven by continued patient uptake in acute coronary syndrome and high risk post myocardial infarction indications New hyperkalemia drug Lokelma recorded sales of  2 million in the quarter  predominantly in the United States  where it was recently launched  The drug is expected to be launched in other markets soon Farxiga recorded sales of  377 million in the quarter  up 16  mainly driven by growth in emerging markets and Europe  U S  sales were flat as growth slowed due to increased competition and formulary plan changes for competitors  drugs  Sales in Europe were up 22   Emerging market sales increased 40   fueled by growth in China New asthma medicine  Fasenra recorded sales of  167 million in the quarter compared with  129 million in the previous quarter  AstraZeneca said Fasenra enjoys leadership position among novel biologic asthma medicines in the United States and European countries like Germany and Japan Bevespi  a LAMA LABA in a pressurized metered dose inhaler  recorded sales of  10 million in the quarter  similar to the previous quarter  amid slower than anticipated growth in LAMA LABA class Among other medicines  Iressa sales were down 13  to  118 million  Bydureon sales declined 8  to  141 million and Onglyza sales declined 4  to  116 million  Byetta sales declined 10  to  25 million and Movantik Moventig recorded sales of  22 million in the quarter  down 8  Older ProductsCrestor sales declined 3  to  310 million  U S  and Europe sales were weak as multiple generic versions of the drug entered the market Symbicort sales declined 9  in the quarter to  585 million due to lower sales in the United States  Japan and Europe  U S  sales were hurt by pricing pressure and the impact of managed market rebates  Pulmicort sales rose 23  to  333 million as higher sales in the emerging markets made up for weaker performance in Europe Nexium recorded sales of  393 million  down 7  due to lower sales in the United States and Europe  Sales of other legacy drugs including Faslodex  Zoladex  Arimdex  Casodex Seloken and Daliresp Daxas grew in the quarter while sales of others like Synagis  Duaklir and Atacand declined Regional PerformanceIn the United States  product sales were up 16  to  1 9 billion on the back of higher sales of newer products  European markets returned to growth in the second quarter witnessing an 8  increase in sales to  1 05 billion  Revenues from Emerging Markets were up 27  to  1 95 billion  primarily on the back of strong growth in China  up 44  to  1 17 billion  Importantly  AstraZeneca s chief executive officer  Pascal Soriot  in an interview to Bloomberg  said that sales growth in China could slow down in the second half due to government pressure on prices of older products In Established ROW market  comprising Japan  Canada and other markets   sales were up 21  to  847 million Profit DiscussionAstraZeneca s core gross margin was flat  at CER  at 82 1   Core selling  general and administrative  SG A  expenses rose 8  to  2 19 billion In the quarter  core research and development  R D  expenses rose 1  to  1 28 billion  Core operating profit rose 8  to  1 37 billion in the quarter  Operating margin  however  declined 2 percentage points to 23 4  in the quarter Ups 2019 Product Sales OutlookAstraZeneca raised its product sales guidance  following a strong performance in the first half of 2019  The company  however  maintained its earnings outlook for 2019 AstraZeneca maintained core EPS guidance for 2019 in the range of  3 50 to  3 70  The company expects product sales to grow by a low double digit percentage versus prior expectation of a high single digit percentage  Core operating profit is expected to grow in a mid teens percentage range in 2019 Currency movements are expected to unfavorably impact product sales and core earnings per share by a low single digit percentage Adjusted tax rate is expected to be in the range of 18  22  Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  4  Sell  AstraZeneca PLC Price  Consensus and EPS Surprise
    
 
Some better ranked large cap pharma stocks are Roche Holding  SIX ROG  AG   OTC RHHBY   and Sanofi   NASDAQ SNY    both with a Zacks Rank  2  Buy   You can see  Shares of Roche have gained 9 1  this year so far  Earnings estimates for 2019 have risen 2 9  while that for 2020 have increased 3 3  over the past 30 days Sanofi s earnings estimates have increased 0 3  and 1 1   respectively  for 2019 and 2020 over the past 30 days This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-azn-q2-earnings-top-19-product-sales-view-up-200445218,200445218
202860,424376,MRK,Bristol Myers  BMY  Beats On Q2 Earnings   Sales  Raises View,opinion,Bristol Myers Squibb Company   NYSE BMY   reported better than expected results for the second quarter of 2019 on the stellar performance of its blood thinner drug  Eliquis  However  results were overshadowed by the failure of the part 2 of the phase III Checkmate 227 study on Opdivo for the lucrative indication of first line non squamous non small cell lung cancer  NSCLC  Shares are down in pre market trading on the same  Bristol Myers  shares have decreased 16 8  in the year so far compared with the  s decline of 0 8   Second quarter 2019 earnings of  1 18 per share easily beat the Zacks Consensus Estimate of  1 06 and increased from the year ago quarter s earnings of  1 01 Total revenues of  6 27 billion comprehensively surpassed the Zacks Consensus Estimate of  6 04 billion and increased 10  from  5 7 billion in the year ago period  Continued strong sales of Opdivo  Eliquis and Orencia contributed to the company s top line in the reported quarter Quarterly DetailsRevenues were up 13  year over year  when adjusted for foreign exchange impact  Revenues increased 14  to  3 7 billion in the United States and 5  outside the country  Ex U S  revenues were up 12   when adjusted for foreign exchange impact Eliquis witnessed strong growth and became the top revenue generator for the company yet again  Sales of the drug rose 24  to  2 04 billion  We note that Bristol Myers has a collaboration agreement with Pfizer   NYSE PFE   for Eliquis  Opdivo  which is approved for multiple cancer indications  continued its impressive performance  with sales up 12  year over year to  1 8 billion  Sales of Opdivo and Eliquis rose 9  and 30   respectively  in the United States Leukemia drug  Sprycel  raked in sales of  544 million  up 2  year over year  Sales of rheumatoid arthritis drug  Orencia  were up 9  to  778 million  Melanoma drug  Yervoy  contributed  367 million to the top line  up 17  year over year Multiple myeloma drug  Empliciti  recorded sales of  91 million  up 42  year over year     However  performance of key drugs in the Virology unit disappointed  Sales of Baraclude declined 18  to  147 million  Sales of other brands  including Sustiva  Reyataz  Daklinza and all other products that have lost exclusivity in major markets  fell 23  year over year to  481 million Adjusted research and development  R D  expenses in the quarter were down 4 2  to  1 28 billion  Adjusted marketing  selling and administrative expenses decreased 5 1  to  1 1 billion Gross margin was 68 2  in the quarter compared with 71 5  in the year ago quarter Celgene Acquisition UpdateEarlier in the year  the company  that it will acquire biotech bigwig Celgene Corporation   NASDAQ CELG   for a whopping  74 billion  The acquisition was finally given a green signal a few months back after facing opposition from some of the shareholders  However  Bristol Myers needs to  one of Celgene s blockbuster drugs  Otezla  to complete the impending merger on a timely basis in light of concerns expressed by the U S  Federal Trade Commission  FTC   We remind investors that the company has a tyrosine kinase 2  TYK2  inhibitor  BMS 986165  in its pipeline  which is being evaluated in several autoimmune diseases  including psoriasis  The regulatory agency was concerned about a possible overlap between Otezla and BMS 986165 in the pipeline  Hence  Bristol Myers decided to sell Otezla Moreover  the company now expects to conclude the merger by the end of 2019 or beginning of 2020 Pipeline UpdateThe part 1a of the phase III Checkmate 227 study  evaluating Opdivo plus low dose Yervoy versus chemotherapy  met the co primary endpoint of overall survival in first line NSCLC patients  whose tumors express PD L1  1   However  part 2 of the study evaluating Opdivo plus chemotherapy versus chemotherapy alone did not meet its primary endpoint of overall survival in first line non squamous NSCLC patients  regardless of PD L1 status The phase III CheckMate 498 trial  evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6 methylguanine DNA methyltransferase  MGMT  unmethylated glioblastoma multiforme  GBM   did not meet its primary endpoint of overall survival at final analysis Business Development UpdateEarlier  Bristol Myers  Bayer  DE BAYGN  and Ono Pharmaceutical Co   Ltd  announced a clinical trial collaboration to evaluate Opdivo in combination with Bayer s Stivarga in patients with micro satellite stable metastatic colorectal cancer 2019 Guidance UpdatedBristol Myers updated its adjusted earnings expectation for 2019  The company projects earnings of  4 20  4 30 per share  previous guidance   4 10  4 20   The Zacks Consensus Estimate for earnings is pegged at  4 16 Our TakeWhile Bristol Myers  performance in the second quarter was encouraging  beating on both earnings and sales primarily on robust sales of Opdivo and Eliquis  pipeline setbacks were a concern  The failure of the part 2 of the Checkmate 227 study was disappointing  given the potential of the NSCLC market   Additionally  the approval of Merck s   NYSE MRK   Keytruda for first line NSCLC adds to Bristol Myers  woes Bristol Myers currently carries a Zacks Rank  3  Hold   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-beats-on-q2-earnings--sales-raises-view-200444919,200444919
202861,424377,MRK,Buy Merck   Co  MRK  Stock Ahead Of Q2 Earnings Report ,opinion,"Merck   Co   NYSE MRK   is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th  The large cap pharmaceutical company has been able to outpace its peers  gaining 7 6  year to date  While the broader drug and pharmaceutical market has struggled to stay in the green this year  MRK has been able to provide returns for its shareholders  MRK is a leading biopharmaceutical company known as MSD outside of the United States and Canada  The company prides itself on its ability to deliver innovative health solutions to consumers  Let s take a further look into the company and what to expect from them this earnings season 
Company Overview and Q1 Performance 
Merck is based in Kenilworth  NJ  and is a global research driven pharmaceutical products company  Back in 2009  the company acquired Schering Plough for  41 1 billion  Furthermore  Merck sold off its Consumer Care business in October 2014 to German pharmaceutical Bayer  DE BAYGN   In January 2015  the company acquired Cubist Pharmaceuticals and added four marketed products  including Cubicin and Zerbaxa  to its hospital acute care portfolio  MRK has demonstrated their commitment to increasing access to healthcare through far reaching policies  programs  and partnerships  Merck tries to keep itself at the forefront of research to advance prevention and treatments of diseases  Some of the diseases Merck manufactures drugs to treat are cancer  HIV  Ebola  and Alzheimer s 
In Q1 2019  Merck was able to bring in  10 8 billion in revenue and report earnings of  1 22  which beat our estimates by 16 2  and 4 8   respectively  The company was able to increase its net income by a whopping 286 2  with profits of  2 86 billion  Merck s oncology pharmaceutical sector leads the pack with  2 54 billion in revenue for a 56 5  year over year increase  Vaccines brought in  1 78 billion and its hospital acute care portfolio attributed  725 million for a 21 6  jump and 8 46  fall  respectively 
Q2 Outlook 
Our Consensus Estimates are currently calling for the pharmaceutical company s top line to make a jump of 4 29  with  10 91 billion in revenue  Earnings are expected to jump 9 43  to  1 16 per share  Merck has made a habit out of beating our Consensus Estimates  consecutively surpassing our estimates the past four quarters for an average EPS surprise of 5 67   The pharmaceutical giant s earnings revisions have ticked in the right direction as the four revisions have unanimously projected earnings to be higher 

Merck s new products like Keytruda  Lynparza  and Bridion are contributing significantly to the company s top line  Keytruda sales are gaining momentum with approval for additional indications  especially in the first line lung cancer setting  Animal health and vaccines are also performing well and remain core components to future growth  Merck is currently a Zacks Rank  2  Buy  and has a Style Score of B in Growth  Looking past Q2 to fiscal 2019 as a whole  Consensus Estimates are projecting for the company to see a 9 22  bottom line jump and predict revenue to reach  44 63 billion for a year over year increase of 5 51   In addition  MRK has been able to outperform some of its industry peers such as Bayer   OTC BAYRY    Sanofi   NASDAQ SNY    and AbbVie   NYSE ABBV   

This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-07-25,Zacks Investment Research,https://www.investing.com/analysis/buy-merck--co-mrk-stock-ahead-of-q2-earnings-report-200445363,200445363
202867,424383,MRK,Merck Q4 revenues up 3   non GAAP EPS up 10  updates guidance,news,Merck  MRK  1   Q4 results  Revenues   10 433M   3 1    Pharmaceutical   9 290M   4 3    Animal Health   981M   11 0    Other Revenues   162M   50 5   Net Loss    872M    46 8    Loss Per Share    0 32    45 5    Non GAAP EPS   0 98   10 1   Key Product Sales  JANUVIA   JANUMET   1 524M   1    KEYTRUDA   1 297M  ZETIA   VYTORIN   509M   42    ZEPATIER   296M   29    GARDASIL   GARDASIL 9   633M   17    PROQUAD  M M R II and VARIVAX   403M  ISENTRESS   ISENTRESS HD   308M   9    PNEUMOVAX 23   263M   11    SIMPONI   217M   17    BRIDION   209M   50   2018 Guidance  Revenues   41 2B   42 7B  GAAP EPS   2 97   3 12  Non GAAP EPS   4 08   4 23 Shares are up 2  premarket on light volume Now read ,2018-02-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-q4-revenues-up-3-nongaap-eps-up-10-updates-guidance-1187326,1187326
202868,424384,MRK,Exclusive  Merck s consumer health sale at risk as Nestle bows out   sources,news,"By Pamela Barbaglia  Patricia Weiss and Martinne Geller LONDON FRANKFURT  Reuters    The sale of Merck  NYSE MRK  KGaA s  DE MRCG  consumer health unit has been thrown off track after Nestle  S NESN  has pulled out  leaving the race to buy the maker of Seven Seas vitamins without its main contender  sources familiar with the matter told Reuters  Nestle has walked away from the process  led by JPMorgan  N JPM   after months of negotiations as the Swiss company was put off by Merck s price expectations of about 4 billion euros   4 99 billion   the sources said  Nestle and Merck declined to comment  A spokesman for Merck said that  the process of evaluating options for our consumer health business is well on track   Four sources familiar with the sale said that interest from other bidders  including British consumer goods giant  Reckitt Benckiser   L RB   was also waning as a rival consumer health auction  led by U S  drug giant  Pfizer   N PFE   was gaining momentum  Reckitt is now concentrating on buying the Pfizer unit which makes Advil painkillers  Centrum multivitamins and Chapstick lip balm and is worth about  20 billion  the sources said  Reckitt declined to comment  Germany s Merck said last year it was looking to sell its consumer healthcare business  which has annual sales of about  1 billion  to help to fund more research into prescription drugs  Nestle was initially seen as a natural buyer for the business  which also makes Bion nutritional supplements  after previous talks to set up a consumer joint venture with Merck fell through over the summer  Consumer health is a fragmented sector ranging from over the counter medicines and vitamins to sports nutrition products and condoms  It has proved fertile ground for deals in recent years  as aging populations and health conscious consumers drive demand  Nestle s CEO Mark Schneider is a healthcare veteran and wants a deeper focus on nutrition  health and wellness  Nestle made a non binding bid for the Merck s business in November and was then shortlisted to carry out due diligence and submit a final offer this year  But the Swiss food group could not reach an agreement on price as Merck was targeting a valuation as high as 20 times the unit s core earnings  according to one of the sources  Another source said mounting pressure from Dan Loeb s activist fund Third Point  which last year made a  3 5 billion investment in Nestle  also played a role in deciding against buying the Merck s business  Loeb has repeatedly asked Nestle to move faster to overhaul its strategy  He wants the Swiss company to boost its exposure in high growth areas such as coffee  pet care  bottled water and nutrition while selling  ill fitting businesses  more quickly  Schneider has so far taken positive steps including selling the U S  confectionery business to Italy s Ferrero for  2 8 billion but he wants to be disciplined on price  the sources said  Famous for his sharply worded letters to corporate chieftains  Loeb wrote on Jan  22 that he was concerned about Nestle pushing more deeply into consumer healthcare with the purchase of Canadian vitamin maker Atrium Innovations  and said he wants a better explanation of that move  
  1   0 8013 euros ",2018-02-02,Reuters,https://www.investing.com/news/stock-market-news/exclusive-mercks-consumer-health-sale-at-risk-as-nestle-bows-out--sources-1190093,1190093
202869,424385,MRK,Merck slips 1  premarket on positive BMY data in first line NSCLC,news,Merck  NYSE MRK  eases 1  premarket on light volume on the heels of positive data from a Phase 3 clinical trial evaluating Bristol Myers Squibb s Opdivo   Yervoy in first line non small cell lung cancer  NSCLC  Several weeks ago  Merck announced positive late stage results for KEYTRUDA  pembrolizumab  in first line NSCLC The companies are competing furiously for first mover dominance in the new indication  expected to be extremely lucrative Previously  Bristol Myers  Opdivo Yervoy combo successful in late stage lung cancer study  shares ahead 3  premarket  Feb  5 Previously  Merck s gain is Bristol Myers  pain  shares down 5  on Keytruda success in first line lung cancer  Jan  16 Now read ,2018-02-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-slips-1-premarket-on-positive-bmy-data-in-firstline-nsclc-1196758,1196758
202870,424386,MRK,Bristol Myers to pay  1 85 billion in cancer deal with Nektar,news,"By Bill Berkrot  Reuters    Bristol Myers Squibb Co will pay Nektar Therapeutics  1 85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug  the companies announced on Wednesday  In one of the largest single drug collaboration deals ever  Nektar will receive  1 billion in cash upfront and Bristol Myers will purchase about 8 28 million Nektar shares at  102 60 per share  or an equity stake of just under 5 percent of the company  Nektar shares closed at  75 66 on Nasdaq on Tuesday  The partnership is built around the Nektar drug  NKTR 214  which will be tested in combination with Bristol s immuno oncology  IO  drugs Opdivo and Opdivo and Yervoy in 20 cancer indications across nine different tumor types  including melanoma  kidney and lung cancers  following  very encouraging  early data from clinical trials   We ve been in a clinical collaboration with Nektar since 2016  This partnership was a natural next step   Paul Biondi  head of business development for Bristol Myers  said in a telephone interview  The combination therapies could become  potentially a new backbone in the IO space   he added  Early immunotherapy leader Bristol Myers has been viewed by investors as having fallen behind Merck  NYSE MRK    Co in the burgeoning field  especially in the most lucrative lung cancer space  NKTR 214  an interleukin 2  IL 2  agonist  is designed to increase the number and activation state of cancer fighting T cells in the tumor microenvironment  while limiting IL 2 toxicity  with the hope of improving and lengthening patient responses  Under the deal terms  Nektar is also eligible to receive an additional  1 78 billion in milestone payments  of which  1 43 billion are development and regulatory milestones and the remainder are sales milestones  Following approvals  Nektar will book revenue for worldwide sales of NKTR 214 and the companies will split the global profits  with Nektar receiving 65 percent and Bristol Myers 35 percent  they said  Bristol Myers will retain 100 percent of product revenues for its own medicines  
The transaction is expected to be completed in the second quarter of 2018  the companies said ",2018-02-14,Reuters,https://www.investing.com/news/stock-market-news/bristolmyers-to-pay-185-billion-in-cancer-deal-with-nektar-1244501,1244501
202871,424387,MRK,Merck s Antibiotic Recarbrio Gets FDA Nod For Infections,opinion,Merck   NYSE MRK   recently announced that the FDA has approved its new combination antibacterial injection  MK 7655A  which is a fixed combination of relebactam and imipenem cilastatin The medicine  to be marketed by the trade name of  Recarbrio  is approved for the treatment of adults with complicated urinary tract infections  cUTI   and complicated intra abdominal bacterial infections  cIAI  caused by certain susceptible gram negative bacteria Limited clinical safety and efficacy data led to the approval of the drug for the above mentioned indications  Recarbrio offers an additional treatment option for patients with cIAI and cUTI  who have limited and in some cases  no alternative therapeutic options Recarbrio received the FDA s Qualified Infectious Disease Product  QIDP  designation for the treatment of cUTI and cIAI  QIDP is a designation granted to antibacterial or antifungal drugs for human use  intended to treat serious or life threatening infections  This designation can boost the sales uptake of the drug  We remind investors that the new drug application  NDA  for Recarbrio received Priority Review designation from the FDA  Merck expects to launch the drug later this year Shares of the company have gained 8 2  so far this year compared with the  s growth of 2 3   Stock was slightly up in pre market trading following the news Last month  Merck also received FDA approval for the label expansion of its antibacterial medicine  Zerbaxa  in two types of pneumonia infections   hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  HABP VABP   Zerbaxa  a combination of ceftolozane and tazobactam  was initially marketed for some complicated urinary tract infections Merck   Co   Inc  Price    Zacks Rank and Other Stocks to ConsiderMerck currently has a Zacks Rank  2  Buy  Some other similar ranked stocks in the large cap pharmaceutical sector include Novartis AG   NYSE NVS    Sanofi   NASDAQ SNY   and Roche Holding  SIX ROG  AG   OTC RHHBY    You can see Novartis  earnings per share estimates increased from  5 00 to  5 01 for 2019 and from  5 54 to  5 60 for 2020 over the past 60 days  Share price of the company has increased 20 8  year to date     Sanofi s earnings per share estimates have moved up from  3 23 to  3 25 for 2019 and from  3 48 to  3 50 for 2020 in the past 60 days Roche s earnings per share estimates have moved up from  2 45 to  2 47 for 2019 and from  2 44 to  2 52 for 2020 in the past 60 days  Share price of the company has increased 10 5  year to date     Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/mercks-antibiotic-recarbrio-gets-fda-nod-for-infections-200440814,200440814
202880,424396,MRK,How Sanofi s setback could lead to better dengue vaccines,news,"By Julie Steenhuysen CHICAGO  Reuters    New dengue vaccines being developed by Takeda Pharmaceuticals Co Ltd and U S  government scientists are poised to provide a safer alternative to Sanofi s Dengvaxia  according to vaccine experts  because they already take into account some of the issues that sidelined the product last year  Sanofi  PA SASY  revealed in November that Dengvaxia   the world s first dengue vaccine   might increase the risk of severe disease in people who had never been exposed to the virus  The news prompted an uproar in the Philippines  where more than 800 000 school age children had been vaccinated  Next generation vaccines by Japan s Takeda and the U S  National Institutes of Health  in conjunction with Brazil s Butantan Institute  are now in late stage testing   They both differ significantly from Dengvaxia  which may increase the chances for a stronger  more durable immune response  according to more than a dozen dengue experts interviewed by Reuters   They expressed especially high hopes for the NIH vaccine  which protected 100 percent of volunteers who received it in a small study   Merck  NYSE MRK    Co Inc holds an exclusive license for the NIH vaccine in the United States  Canada  China  Japan and the European Union  and plans to begin its own trials in the first half of 2018  It s too early to say whether either candidate will ultimately succeed  and experts await data from large  late stage clinical trials  And while Sanofi s early safety troubles may delay licensing of new vaccines for a few years as global regulators seek assurances from longer term data  the increased scrutiny should result in a better  safer product  they said   We ve learned a tremendous amount about dengue from the Sanofi vaccine   said Dr  Anna Durbin  a researcher at the Johns Hopkins Bloomberg School of Public Health who helped develop the NIH vaccine   There is hope the two candidates coming down the pike can provide the benefit of a good dengue vaccine without the risk   LESSONS LEARNED Dengue is the world s fastest growing infectious disease  afflicting up to 100 million people worldwide  causing half a million life threatening infections and killing up to 25 000 people  mostly children  each year  An effective vaccine could be worth more than  1 billion globally  according to industry analysts   There are four distinct types of dengue  A first infection with any one of them can increase the chances of severe disease when exposed to a second   Experts say an effective vaccine must protect against all four types at once  A weak response to one of them could act like a first infection and leave a person vulnerable to severe disease when exposed a second time  That is what appears to have happened with Sanofi s Dengvaxia  according to vaccine experts   It wasn t a uniformly high level of response to all four subtypes  of dengue  simultaneously   Dr  Anthony Fauci  director of the NIH s National Institutes of Allergy and Infectious Diseases  said in an interview  Sanofi s late stage clinical trials  which were designed in 2009  only collected blood samples from 10 to 15 percent of study participants before they were vaccinated   As a result  it was impossible to know when the studies were published in 2015 whether risks were greater in children who had never been exposed to dengue  said Dr  Su Peing Ng  Sanofi s global medical head  in an interview  To answer this question  Sanofi developed a special test to re analyze its results  leading to the November 2017 disclosure    We ve been extremely transparent with our data   Ng said  adding that the company consulted with the field s leading experts as it was developing its vaccine  Clinical trials testing the two new vaccines both require blood samples for all participants before they are vaccinated so they can quickly identify any similar risks  Dr  Stephen Whitehead  who developed the NIH vaccine  said in a 2016 review that the long term follow up from Sanofi s studies  was instrumental in identifying safety concerns that are currently being investigated        IMMUNE RESPONSE Dengvaxia uses a widely effective yellow fever virus vaccine as its genetic backbone  To induce an immune response to dengue  certain yellow fever genes were swapped out for dengue genes   It seemed like a bright idea 20 years ago   said dengue expert Dr  Scott Halstead  an adjunct professor at the Uniformed Services University of the Health Sciences in Bethesda  Maryland  In hindsight  Halstead said  simply splicing select dengue genes into a yellow fever vaccine may not present enough of the virus to the immune system to induce full protection  Instead of yellow fever  Takeda s vaccine  TAK 003  is based on a weakened version of a live dengue 2 virus    We ve taken a dengue 2 virus backbone and inserted elements of dengue 1  3 and 4   said Dr  Rajeev Venkayya  president of Takeda s global vaccine business unit  That s important  Venkayya said   because it exposes an individual that is immunized to a broad range of proteins on the outside and the inside of the virus  which allows individuals to generate a broad immune response   Data published in November in Lancet Infectious Diseases showed Takeda s vaccine produced responses against all four virus types  regardless of previous dengue exposure  There were no safety concerns   Takeda s vaccine is being tested in 20 000 children aged 4 to 16 in Asia and Latin America  Initial data are expected in late 2018  Venkayya said the company s research has shown the vaccine  given in two doses  can produce both antibodies to dengue as well as a second type of response in which immune cells   known as CD8 positive T cells   recognize and kill virus infected cells  Several researchers suspect exposure to the full spectrum of dengue proteins is key to developing a fully protective vaccine   Johns Hopkins  Durbin said the presence of T cells triggered by non structural proteins in dengue 2 could help clear the virus before people become sick  But  like Sanofi s Dengvaxia  the Takeda vaccine appears to produce an unbalanced antibody response  with the highest protection offered against dengue 2   In a July 2017 paper published in Cold Spring Harbor Perspectives in Biology  Halstead said that it is also not clear whether Takeda s vaccine will provoke T cell immunity to the other three dengue viruses  clouding its potential to succeed  The NIH vaccine  called TV003 TV005  also features weakened versions of live dengue  but three of the four components   dengue 1  3 and 4   are based on whole dengue viruses  The fourth component is based on a dengue 4 backbone with dengue 2 genes spliced in   It has been shown to provoke a strong antibody response to all four types of dengue in a single shot  as well as producing T cell immunity   It appears to be a true  protective  one dose vaccine   Halstead said  Brazil s non profit Butantan Institute is testing the vaccine in some 17 000 participants in 14 areas with widespread dengue   
 Though you never  ever  definitively predict until after everything is completely over  everything we ve seen on the preliminary work on that looks pretty good   Fauci said ",2018-01-29,Reuters,https://www.investing.com/news/stock-market-news/how-sanofis-setback-could-lead-to-better-dengue-vaccines-1163376,1163376
202881,424397,MRK,Imprimis Pharma supplying two glaucoma drugs on FDA shortage list  shares ahead 51  premarket,news,Thinly traded nano cap Imprimis Pharmaceuticals  NASDAQ IMMY  is up 51  premarket on robust volume in response to its announcement that it is now making two glaucoma drugs listed on the FDA s Drug Shortage List The two preservative free products are dorzolamide and dorzolamide timolol  branded as Cosopt and Cosopt PF by Merck  NYSE MRK   According to IQVIA  the two topical meds were dispensed  4M times in 2017 Now read ,2018-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/imprimis-pharma-supplying-two-glaucoma-drugs-on-fda-shortage-list-shares-ahead-51-premarket-1170288,1170288
202882,424398,MRK,Updated data on Affimed s AFM13 shows 89  response rate in HL patients  shares up 28 ,news,Thinly traded nano cap Affimed N V   AFMD  28 3   is up on a 7x surge in volume on the heels of its announcement of updated data from two clinical trials evaluating lead candidate AFM13 in lymphoma patients Interim results from a Phase 1b study assessing the combination of AFM13 and Merck s  MRK  0 9   KEYTRUDA  pembrolizumab  in Hodgkin lymphoma  HL  showed an 89  overall response rate  ORR   n 8 9   including four complete metabolic responses  The other patient had stable disease  implying a disease control rate  DCR  of 100   The historical ORR for KEYTRUDA alone in HL is 58   63  In a Phase 1b 2a study evaluating AFM13 as monotherapy in patients with CD30 positive cutaneous lymphoma  the ORR was 66   n 2 3  with one patient showing stable disease  implying a DCR of 100  as well AFM13 is a bispecific antibody that binds to a protein expressed in a range of T cell and B cell lymphomas called CD30 and to a protein expressed on the immune system s natural killer cells called CD16A  both of which play key roles in the activation of the immune system to detect and kill cancer cells Previously  Affimed s lead candidate shows treatment benefit in early stage study  investors unimpressed  shares down 27   Dec  11  2017 Now read ,2018-02-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/updated-data-on-affimeds-afm13-shows-89-response-rate-in-hl-patients-shares-up-28-1182801,1182801
202883,424399,MRK,AstraZeneca s Imfinzi Gains Orphan Drug Status For SCLC,opinion,AstraZeneca PLC   NYSE AZN   announced that the FDA has granted an orphan drug designation to its PD L1 inhibitor  Imfinzi  durvalumab   for the treatment of patients with extensive stage small cell lung cancer  SCLC   the most aggressive type of the indication The orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200 000 people in the United States The prestigious status comes close on the heels of presentation of positive overall survival  OS  data from the phase III CASPIAN study  which evaluated Imfinzi for SCLC in June  The analysis met the primary endpoint as Imfinzi when combined with the standard of care medicine  etoposide and platinum based chemotherapy  demonstrated a statistically significant and clinically meaningful improvement in OS as compared to chemotherapy alone This is the first study that offers the flexibility of combining immunotherapy with different platinum based regimens in small cell lung cancer  thereby its expanding treatment options Shares of AstraZeneca have increased 6 5  so far this year  outperforming the rise of 2 8  Imfinzi is presently approved for unresectable  stage III NSCLC in second line setting across the United States  The company is evaluating the drug in several late stage programs for treating stage IV NSCLC  The drug also secured a nod for the treatment of bladder cancer Moreover  it is being developed under other SCLC studies  Currently  the medicine is being tested in the phase III ADRIATIC assessment following a concurrent chemoradiation therapy for the limited stage SCLC SCLC constitutes about 15  of all lung cancer diagnosis and is a difficult disease to address as only 6  of patients is able to survive after five years of treatment Other than lung cancer  key phase III probes are evaluating Imfinzi in combination with tremelimumab for hepatocellular carcinoma  metastatic urothelial cancer and head and neck squamous cell carcinoma However  Imfinzi is significantly lagging other approved PD L1 inhibitors  namely Bristol Myers    NYSE BMY   Opdivo and Merck s   NYSE MRK   Keytruda in terms of recognized indications and sales While Imfinzi recorded sales of  295 million in the first quarter of 2019  Opdivo and Keytruda generated  1 8 billion and  2 27 billion  respectively  in the period  Notably  Keytruda and Opdivo were launched much ahead of Imfinzi  Other PD L1 inhibitors in the market are Pfizer s   NYSE PFE   Bavencio and Roche s Tecentriq Zacks RankAstraZeneca currently carries a Zacks Rank  4  Sell  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-imfinzi-gains-orphan-drug-status-for-sclc-200439379,200439379
202884,424400,MRK,Mallinckrodt  MNK  Discontinues Sclerosis Study On Acthar Gel,opinion,Mallinckrodt plc   NYSE MNK   is permanently discontinuing its phase IIB study  PENNANT  designed to assess the efficacy and safety of Acthar Gel  repository corticotropin injection  as an investigational treatment for amyotrophic lateral sclerosis  ALS   Shares of the company fell 2 6  following the news  Shares of the company have plunged 48 1  year to date compared with the  s decline of 2 8  Mallinckrodt took the decision after considering a recent recommendation by the study s independent Data and Safety Monitoring Board  DSMB   The issue specified was a higher than expected rate of pneumonia in the treatment group compared to the placebo group  Another factor was the lack of a clear efficacy signal  The independent DSMB noted that there was not a great enough proportion of subjects who completed week 36 to provide a definitive determination of a treatment effect Enrollment in the study will stop immediately and patients already enrolled will be tapered off the drug before discontinuing use This action does not affect any other ongoing clinical studies on Acthar Gel We note that  Acthar Gel  which became part of the company s portfolio following the Questcor acquisition  is currently approved for 19 indications but marketed for only 9 with a 3  patient penetration rate  Hence  Mallinckrodt is working on boosting Acthar sales in the approved indications  including rheumatology and pulmonology as well as underserved patient populations  Performance of the drug has been impressive so far  propelled by solid demand for rheumatology  pulmonology  ophthalmology and nephrology  expanded access in more recently promoted indications such as lupus and sarcoidosis  and mature indications like infantile spasms and nephrotic syndrome   Mallinckrodt public limited company Price    Zacks Rank and Stocks to ConsiderMallinckrodt currently has a Zacks Rank  3  Hold  Some better ranked stocks in the large cap pharmaceutical sector include Novartis AG   NYSE NVS    Merck and Co   Inc    NYSE MRK   and Roche Holding  SIX ROG  AG   OTC RHHBY    All of them carry a Zacks Rank  2  Buy   You can see Novartis  earnings per share estimates increased from  5 00 to  5 01 for 2019 and from  5 54 to  5 60 for 2020 over the past 60 days  Share price of the company has increased 20 8  year to date     Merck s earnings per share estimates have moved up from  4 72 to  4 74 for 2019 and from  5 20 to  5 28 for 2020 in the past 60 days  Share price of the company has increased 8 2  year to date     Roche s earnings per share estimates have moved up from  2 45 to  2 47 for 2019 and from  2 44 to  2 52 for 2020 in the past 60 days  Share price of the company has increased 10 5  year to date     Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-discontinues-sclerosis-study-on-acthar-gel-200440818,200440818
202892,424408,MRK,Global business group  lit a flame  for long term U N  goals  chair,news,"By Alister Doyle
OSLO  Reuters    Many companies are looking past quarterly results to discover long term economic opportunities in U N  goals to end poverty and protect the planet  the head of an international business commission has said 
Mark Malloch Brown s Business and Sustainable Development Commission has contacted 1 500 CEOs over two years to persuade them that embracing development can boost their bottom line  and will wrap up its work at the Davos World Economic Forum on Tuesday 
 We feel we ve lit a flame here   said Malloch Brown  a British former U N  deputy secretary general who will now spearhead campaigning to keep Britain in the European Union 
His 37 strong group included leaders of firms such as  Unilever   LON ULVR   Merck  NYSE MRK   Mars   Alibaba   NYSE BABA   Safaricom and  Aviva   LON AV  as well as academics and civil society leaders  urging businesses to adopt U N  goals for 2030 such as ending poverty and hunger and to slow climate change 
In a report last year  the commission said companies could unlock at least  12 trillion in market opportunities by 2030 and create up to 380 million jobs by focusing on transport  energy  cities  agriculture  food and health 
Malloch Brown told Reuters the biggest barrier was CEOs  mindsets 
 CEOs are still terribly preoccupied by quarterly results   he said   The hardest argument is to persuade them to persuade their shareholders to let them think   at least in a portion of their business   in the long term  
Companies such as Unilever and Mars found it was much better to pay African farmers fair  stable prices for cocoa and focus on quality chocolate rather than risk putting farmers out of business with low prices  he said 
And insurer Aviva is developing benchmarks so that investors  can judge whether a company is having an impact  in terms of the sustainable development goals  he said 
Another initiative was to develop more  blended finance  for the global development goals involving both public and private sources 
Malloch Brown said construction firms could tap a vast market for low cost houses in cities such as Mumbai or Lagos rather than building a  few mansions in Weybridge   a prosperous English town 
Commission member Amy Jadesimi  managing director of Nigeria s Lagos Deep Offshore Logistics Base  said the opportunities in emerging economies were huge 
A 330 metre  1080 ft  long Floating Production  Storage and Offshore vessel built for Total will arrive in Nigeria this week from South Korea for completion work before deployment at Nigeria s 200 000 barrel per day Egina field 
 We re sending a signal to the world that you can do the most expensive industrial projects in the world here in Africa   Jadesimi said ",2018-01-22,Reuters,https://www.investing.com/news/stock-market-news/global-business-group-lit-a-flame-for-longterm-un-goals-chair-1132594,1132594
202893,424409,MRK,Glaxo s Two Drug HIV Pill Dovato On Par With Three Drug Pill,opinion,"GlaxoSmithKline plc s   NYSE GSK   HIV subsidiary  ViiV Healthcare  announced that the late stage study  evaluating its newly approved single tablet two drug HIV regimen of Dovato met the primary endpoint  The phase III TANGO study assessed the antiviral efficacy and safety of switching to Dovato in HIV 1 infected patients  who are virally suppressed and stable on a three drug tenofovir alafenamide fumarate TAF based regimen 
The 48 week data from the study showed that Dovato was non inferior in maintaining viral suppression in such patients compared with the TAF containing  three drug regimen  thereby achieving the study s primary goal  This suggests that such patients can maintain viral suppression if they change to the two drug regimen from the three drug  TAF containing regimen  thereby reducing their pill burden  The study also confirmed that no patients met virologic withdrawal criteria or developed any treatment resistance in the Tivicay plus Epivir arm 
Glaxo plans to present these results at the International AIDS Society Conference on HIV Science to be held later in July  ViiV Healthcare is majorly owned by Glaxo and Pfizer   NYSE PFE   
Shares of Glaxo have increased 6 6  so far this year  outperforming the rise of 1 9  

 
Dovato  a single tablet regimen ofGlaxo s HIV drugs   Tivicay  dolutegravir  50 mg    Epivir  lamivudine    for treatment na ve HIV patients  was approved in the United States during April this year and in the EU this month 
HIV is a key therapeutic area for Glaxo with successful dolutegravir based regimens  namely Tivicay  Triumeq and Juluca in its portfolio  HIV sales totaled  1 1 billion in the first quarter of 2019  The metric increased 4  at CER on the back of 7  growth in dolutegravir franchise  Triumeq and Tivicay and Juluca   which partly offset lower sales of the established HIV products 
Zacks Rank   Stocks to Consider
Glaxo currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Merck   Co   Inc    NYSE MRK   and Novartis AG   NYSE NVS    both carrying a Zacks Rank  2  Buy   You can see  
Merck s earnings estimates have been revised 0 4  upward for 2019 and 1  for 2020 in the past 60 days  The stock has rallied 11  so far this year
Novartis  earnings estimates have moved 0 6  north for 2019 and 1 5  for 2020 in the past 60 days  The stock has gained 6 1  so far this year 
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-07-10,Zacks Investment Research,https://www.investing.com/analysis/glaxos-twodrug-hiv-pill-dovato-on-par-with-threedrug-pill-200438647,200438647
202905,424421,MRK,Bayer Sets Up Special Committee To Tackle Glyphosate Lawsuits,opinion,Bayer AG  DE BAYGN    OTC BAYRY   announced its decision to create a special litigation committee of the supervisory board to help resolve a multi billion dollar glyphosate litigation issue  The company also said that it has hired high profile U S  lawyer John H  Beisner to fight its glyphosate litigationsand advise the supervisory board Meanwhile  activist investor  Elliott Advisors  UK  Limited  disclosed a 1 1 billion euro   1 3 billion  stake in Bayer The company is facing more than 13 000 lawsuits  claiming its glyphosate based products  including Roundup weedkillers  manufactured by its subsidiary Monsanto  NYSE MON  to cause cancer  Bayer has already lost threesuits in U S  courts  Year to date  the company s share price has declined 3  against the  s growth of 5 3   mainly due the ongoing litigation issues Elliott believes the creation of the supervisory board and the hiring of Beisner will provide Bayer relevant litigation expertise and resolve itsongoing glyphosate litigation  The stock rose more than 5  following the news Bayer has been stating that glyphosate based products are completely safe to use and do not cause cancer  The company has stated in the past that decades of scientific studies have shown the chemical to be safe for human use However  there have been debates by environmentalists  regulators  researchers and lawyers about whether Roundup causes cancer The newly established supervisory board committee will closely look into these issues  consult with management and make recommendations on the litigation strategy  Both management and the supervisory board have also hired Ken Feinberg as mediator  Feinberg has an outstanding track record as mediator in some of the most complex settlements  The company has taken up these measures to mitigate the litigation uncertainty s negative impact on its stock price movement  Bayer Aktiengesellschaft Price     Zacks Rank and Stocks to ConsiderBayer currently has a Zacks Rank  3  Hold  Some better ranked stocks in the large cap pharmaceutical sector include Novartis AG   NYSE NVS    Pfizer   NYSE PFE   and Merck and Co   Inc    NYSE MRK    All of them carry a Zacks Rank  2  Buy   You can see Novartis  earnings per share estimates increased from  4 98 to  5 01 for 2019 and from  5 48 to  5 56 for 2020 over the past 60 days  Share price of the company has increased 23 6  year to date     Pfizer s earnings per share estimates increased from  2 86 to  2 88 for 2019 over the past 60 days  Share price of the company has increased 0 2  year to date     Merck s earnings per share estimates have moved up from  4 65 to  4 74 for 2019 and from  5 19 to  5 28 for 2020 in the past 60 days  Share price of the company has increased 10 8  year to date     Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/bayer-sets-up-special-committee-to-tackle-glyphosate-lawsuits-200435257,200435257
202906,424422,MRK,AstraZeneca s Imfinzi Meets Endpoint In Lung Cancer Study  ,opinion,"AstraZeneca Plc   NYSE AZN   announced positive overall survival  OS  results from the phase III CASPIAN study evaluating Imfinzi  durvalumab  in first line extensive stage small cell lung cancer  SCLC   the most aggressive type of lung cancer 
Data from an interim analysis conducted by an Independent Data Monitoring Committee showed that the study met its primary endpoint  as Imfinzi combined with standard of care medicine  etoposide  and platinum based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS compared with chemotherapy alone 
This is the first study that offers the flexibility of combining immunotherapy with different platinum based regimens in small cell lung cancer  expanding treatment options 
Imfinzi  a PD L1 inhibitor  is presently approved for unresectable  stage III NSCLC in second line setting in the United States  The company is evaluating the drug in several late stage studies for treating stage IV NSCLC  The drug is also approved for the treatment of bladder cancer 
AstraZeneca s shares are up 10 3  so far this year compared with the  s growth of 4 3  

 
Imfinzi in being studied in other SCLC studies as well  It is being tested following concurrent chemoradiation therapy in limited stage SCLC in the phase III ADRIATIC study 
Meanwhile  other than SCLC  key phase III trials are evaluating Imfinzi in combination with tremelimumab for hepatocellular carcinoma  HCC  liver cancer   NSCLC  and head and neck squamous cell carcinoma 
However  the drug is significantly lagging other approved PD L1 inhibitors   Bristol Myers    NYSE BMY   Opdivo and Merck s   NYSE MRK   Keytruda   in terms of approved indications and sales  While Imfinzi recorded sales of  371 million in the first nine months of 2018  Opdivo and Keytruda generated  4 9 billion and  5 billion  respectively  Notably  Keytruda and Opdivo were launched much earlier than Imfinzi  Other PD L1 inhibitors in the market are Pfizer s   NYSE PFE   Bavencio and Roche s Tecentriq 
Earlier this month  Keytruda received FDA approval for metastatic SCLC in third  or later line setting  This approval marks the first label expansion for Keytruda in the SCLC indication AstraZeneca PLC Price

    
Zacks Rank
AstraZeneca carries a Zacks Rank  3  Hold   You can see  
Will you retire a millionaire  
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-28,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-imfinzi-meets-endpoint-in-lung-cancer-study-200435789,200435789
202907,424423,MRK,Pharma Stock Roundup  PFE s Regulatory Pipeline Updates  CHMP Nod For Several Drugs ,opinion,"This week  there were several pipeline and regulatory updates from Pfizer   NYSE PFE    Meanwhile  the Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency gave positive recommendations  granting marketing approval to several drugs this week  In other news  Sanofi   NASDAQ SNY   and Glaxo s   NYSE GSK   new drugs  skin cancer drug Libtayo and HIV medicine  Dovato  respectively  won approval in EU Recap of the Week s Most Important StoriesPfizer Presents Early Data on Gene Therapy for DMD  Wins FDA Nod for Avastin Biosimilar  Pfizer presented promising early data from a study on its investigational gene therapy  PF 06939926  for Duchenne muscular dystrophy  DMD   However   were observed in two participants in the study  While one of the six boys dosed with PF 06939926 was hospitalized for two days for severe nausea and vomiting  another developed a severe immune response  which led to renal complications  Pfizer has stopped further dosing in the study until specific additional safety monitoring has obtained all appropriate approvals Meanwhile  Pfizer announced   its biosimilar version of Roche s   OTC RHHBY   blockbuster cancer drug Avastin for five types of cancer  This is Pfizer s second oncology biosimilar to be approved in the United States  the first being  Trazimera  a biosimilar of Roche s breast cancer drug  Herceptin  which was approved by the FDA in March this year Pfizer also announced that a phase III study evaluating its pulmonary arterial hypertension drug  Revatio  sildenafil citrate  for the treatment of newborns with persistent pulmonary hypertension  PPHN  did not meet its primary efficacy endpoint  Presently  Revatio is not approved for the treatment of PPHN Pfizer also announced evaluating its crisaborole topical ointment  2   to treat mild to moderate eczema  or atopic dermatitis  in children aged 3 months to less than 24 months  The steroid free topical treatment  marketed as Eucrisa  is already approved to treat patients two years and older  The data from the study showed that Eucrisawas well tolerated in the said pediatric populationCHMP Nod to Several Drugs  The CHMP gave a positive opinion recommending approval of Roche s Tecentriq in combination with Celgene s Abraxane as an initial treatment of patients with PD L1 positive    The cancer immunotherapy regimen was approved for a similar indication in the United States in March this year  The CHMP also recommended changing the label of AstraZeneca s   NYSE AZN   SGLT2 inhibitor  Forxiga  to include data from the phase III cardiovascular outcomes study  The DECLARE TIMI 58 study evaluated the cardiovascular and renal effects of Farxiga  dapagliflozin  in adults with type II diabetes compared to placebo Meanwhile  AstraZeneca s Fasenra was also given a positive CHMP opinion for self administration option and a new delivery method   a pre filled  single use auto injector  the Fasenra pen   The CHMP also recommended expanding the European label of Sanofi s eczema drug Dupixent  dupilumab  12 to 17 years of age Sanofi s Libtayo and Glaxo s Dovato Win EU Approval  Sanofi and Regeneron Pharmaceuticals  Libtayo was granted  by the European Commission for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation  Libtayo was approved in the United States in September last year The regulatory agency also gave approval to Glaxo s once daily  single tablet two drug regimen  2DR   for the treatment of newly diagnosed adults with HIV 1 infection  Dovato is a fixed dose combination of Tivicay  dolutegravir   50 mg  in combination with lamivudine  300 mg  and was approved by the FDA in April  Dovato has been developed by Glaxo HIV subsidiary  ViiV Healthcare Glaxo Begins Late Stage Development of RA Candidate Otilimab  Glaxo began phase III studies on its anti GM CSF antibody  otilimab  in patients with rheumatoid arthritis  RA   This late stage program in RA will include head to head comparisons of otilimab with current treatments like Pfizer s Xeljanz  tofacitinib  and Regeneron Sanofi s Kevzara  sarilumab  and will include a broad range of difficult to treat patients The initiation of the phase III program was based on encouraging data from the phase II BAROQUE study  data from which showed encouraging clinical benefits in patients treated with otilimab The NYSE ARCA Pharmaceutical Index rose 2 6  in the last four trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
Here is how the seven major stocks performed in the last four trading sessions Last week  all the stocks were in the green with Merck   NYSE MRK   recording the highest increase  3 7   In the past six months  Merck has been the biggest gainer  11 9   while Bristol Myers   NYSE BMY   declined the most  3 8    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-07-04,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pfes-regulatorypipeline-updates-chmp-nod-for-several-drugs-200437291,200437291
202914,424430,MRK,Healthcare leads averages lower,news,The S P  Dow  and Nasdaq are all down about 0 25   but the healthcare sector  XLV  1   is lit up a brighter share of red Gilead is down 3 2   Bristol Myers 2 55   Eli Lillly 1 9   and Merck  NYSE MRK  1 4  Now read ,2017-12-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-leads-averages-lower-994393,994393
202915,424431,MRK,FDA OKs Merck s Steglatro for type 2 diabetics,news,The FDA has approved Merck s  NYSE MRK  STEGLATRO  ertugliflozin  for glycemic control in adults with type 2 diabetes  T2D   The product was jointly developed with  Pfizer   NYSE PFE  Under the companies  2013 agreement  Merck and Pfizer will shares revenues and certain costs on a 60 40 basis while Pfizer may be eligible for additional milestone payments  Merck will exclusively promote in the U S The FDA also approved STEGLUJAN  ertugliflozin and sitagliptin  for glycemic control in adults with T2D Previously  FDA OKs Merck s ertugliflozin sitagliptin for T2D  Dec  20 Now read ,2017-12-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-mercks-steglatro-for-type-2-diabetics-1023218,1023218
202916,424432,MRK,Sanofi Regeneron s Asthma Candidate Meets Goal In Study,opinion,Sanofi  PA SASY    NASDAQ SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that a phase II study evaluating their investigational IL 33 antibody REGN3500  SAR440340  in asthma met the primary endpoint Top line data from the phase II proof of concept study on the candidate showed that REGN3500  SAR440340  monotherapy significantly reduced loss of asthma control  primary endpoint  and improved lung function  secondary endpoint  compared to placebo The study had four treatment groups namely REGN3500 plus placebo  REGN3500 plus Dupixent  Dupixent plus placebo  and placebo  Dupixent is Sanofi Regeneron s successful new drug  which is marketed for atopic dermatitis as well as moderate to severe asthma Coming back to the phase II REGN3500 study  patients in the Dupixent monotherapy group   did numerically better than REGN3500 across all endpoints  Interestingly  the REGN3500 plus Dupixent group failed to demonstrate increased benefit compared to Dupixent monotherapy  The percentage of adverse events was 61 6  in the REGN3500 patient group  66 2  in the REGN3500 and Dupixent group  56 8  in Dupixent and 64 9  in the placebo patient group Sanofi and Regeneron are developing REGN3500 in phase II studies for atopic dermatitis  asthma and chronic obstructive pulmonary disease  COPD  Sanofi s stock has risen 1 2  this year so far  underperforming the rise of 4 2    Asthma was the second indication for which Dupixent was approved in the United States in October 2018  The asthma indication has been boosting sales of Dupixent since then  Dupixent was approved for the asthma indication in EU in May 2019 Dupixent is also being evaluated in phase III studies for other inflammatory disease like eosinophilic esophagitis and COPD and in phase II study for food and environmental allergies  It is under regulatory review for chronic rhinosinusitis with nasal polyps for which the FDA s decision is expected next week  We are optimistic about sales prospects of Dupixent  which could prove to be an important growth driver for the company Sanofi currently carries a Zacks Rank  3  Hold   You can see  Some better ranked large cap pharma stocks are AbbVie  Inc    NYSE ABBV   and Merck   Co   Inc    NYSE MRK    both with a Zacks Rank  2  Buy   You can see  Shares of Merck have gained 10 7  so far this year while estimates for 2019 and 2020 have risen 1 7  and 0 4   respectively  over the past 60 days  AbbVie s earnings estimates have increased 1 5  for 2019 and 1 4  for 2020 over the past 60 days Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year undefined undefined,2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/sanofiregenerons-asthma-candidate-meets-goal-in-study-200433648,200433648
202917,424433,MRK,Novo Nordisk s Haemophilia A Drug Esperoct Gets EU Approval,opinion,"Novo Nordisk  CSE NOVOb  A S   NYSE NVO   announced that the European Commission has granted marketing authorization for Esperoct for the treatment of adolescents   12 years of age  and adults with haemophilia A  The authorization covers all 28 European Union member states  Novo Nordisk expects to launch Esperoct in the first European countries during the second half of 2019 
Esperoct is the brand name for turoctocog alfa pegol  N8 GP  The efficacy and safety evaluation was based on the results from the largest pre registration clinical program conducted in haemophilia A  with inclusion of 270 previously treated people  PTPs  with severe haemophilia A and more than 5 years of clinical exposure 
Esperoct has been found effective in treating severe haemophilia A through a simple fixed dosing regimen of one injection every four days in adults and adolescents or every 3 4 days  twice weekly  in children  The drug is also found to be effective in controlling bleeding episodes and perioperative management with no acute safety concerns 
The marketing authorization for the use of Esperoct treads on the heels of the positive opinion given by the Committee for Medicinal Products for Human Use  CHMP  under the European Medicines Agency  EMA  in April 2019 
Shares of Novo Nordisk have increased 12 2  year to date compared with the  7 8  growth 

 
In February 2019  Novo Nordisk announced the FDA s approval of its biologics license application  BLA  for Esperoct to treat adults and children with haemophilia A  In the United States  Esperoct is indicated for use in adults and minors with haemophilia A   using routine prophylaxis   to reduce bleeding episode frequency as well as on demand for controlling bleeding episodes and the perioperative management of bleeding 
The marketing authorization for Esperoct in Europe will further lead to increased sales of the drug 
The company is making efforts to develop new treatments for diabetes  which is its core area of expertise  In January 2019  Novo Nordisk initiated a phase I study on LAIsema  the combination of once weekly insulin LAI287 and once weekly injectable GLP 1 semaglutide  The study will investigate single dose pharmacokinetics of LAIsema in a fixed ratio compared with LAI287 and semaglutide given separately to people with type II diabetes 
In November 2018  Novo Nordisk completed the extension phase of REAL 3  the phase II study with long acting recombinant growth hormone  somapacitan  NN8640  for treatment of growth hormone deficiency  GHD   The company is preparing for the pivotal phase III somapacitan programs in children with GHD and a phase II study in children born small for gestational age  SGA  Novo Nordisk A S Price

    
Zacks Rank and Stocks to Consider
Novo Nordisk currently has a Zacks Rank  3  Hold  
Some better ranked stocks in the large cap pharmaceutical sector include AbbVie Inc    NYSE ABBV    Novartis AG   NYSE NVS   and Merck and Co   Inc    NYSE MRK    each carrying a Zacks Rank  2  Buy   You can see 
AbbVie s earnings per share estimates increased from  8 68 to  8 81 for 2019 and from  9 25 to  9 38 for 2020 over the past 60 days  The company surpassed estimates in three of the trailing four quarters  with average positive surprise of 2 58           
Novartis  earnings per share estimates increased from  4 90 to  5 01 for 2019 and from  5 50 to  5 56 for 2020 over the past 60 days 
Merck s earnings per share estimates have moved up from  4 65 to  4 73 for 2019 and from  5 19 to  5 21 for 2020 in the past 60 days  The company beat estimates in the trailing four quarters  with the average being 5 67     
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-21,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-haemophilia-a-drug-esperoct-gets-eu-approval-200433742,200433742
202918,424434,MRK,Bristol Myers To Sell Otezla For Celgene Merger  Shares Down ,opinion,"Shares of Bristol Myers Squibb Company   NYSE BMY   declined 7 42  after it announced plans to divest one of Celgene Corporation s   NASDAQ CELG   blockbuster drugs  Otezla  to complete the impending merger  The company also announced dismal results from a liver cancer study 
Bristol Myers is planning to divest plaque psoriasis and psoriatic arthritis drug  Otezla  to be able to close the acquisition on a timely basis in light of concerns expressed by the U S  Federal Trade Commission  FTC  
We remind investors that the company has tyrosine kinase 2  TYK2  inhibitor  BMS 986165  in its pipeline  which is being evaluated in several autoimmune diseases  including psoriasis  The regulatory agency was concerned about a possible overlap between Otezla and BMS 986165 in the pipeline 
Hence  Bristol Myers decided to sell Otezla 
However  investors were clearly disappointed by the decision as Otezla raked in more than  1 6 billion of sales in 2018 and was one of the key growth drivers for Celgene  while BMS 986165 is still in development   Sales of the drug are expected to come in around  1 9 billion in 2019 and retaining the same would have enabled Bristol Myers to develop a strong inflammation portfolio along with its rheumatoid arthritis drug  Orencia 
Moreover  the impending acquisition will be delayed as the company now expects to complete the merger by the end of 2019 or beginning of 2020  assuming the FTC accepts the consent order and other customary closing conditions are satisfied 
The divestiture is subject to further review by the FTC and requires Bristol Myers to enter a consent decree with the commission  The proceeds of the divestiture will allow the company to accelerate its post closing deleveraging plans 
On the other hand  Bristol Myers might not be able to sell Otezla at a lucrative price  given the regulatory constraints 
Shares of the company have lost 12 2  in the year so far against the  s growth of 4 3  

 
We remind investors that in January 2019  Bristol Myers announced that it will acquire Celgene for  74 billion to boost its oncology portfolio  given the stiff competition for Opdivo from the likes Merck s   NYSE MRK   Keytruda  However  the acquisition has hit a few road blocks  with a few large shareholders of Bristol Myers opposing the merger 
The shareholders thought it to be risky and may add significant debt to the balance sheet  Moreover  Celgene s growth driving oncology drug  Revlimid  is expected to lose patent protection soon  The acquisition was finally given a green signal a couple of months back 
The divestiture of the drug also puts question mark on the targeted synergies and anticipated sales of the combined company  per Bristol Myers 
Concurrently  it announced that a randomized phase III study CheckMate 459  evaluating Opdivo versus Bayer s   OTC BAYRY   Nexavar as a first line treatment  in patients with unresectable hepatocellular carcinoma  HCC  failed  Nevertheless  Opdivo is being studied by the company across multiple settings and lines of therapy for HCC  including as monotherapy in the adjuvant setting and in combination with Yervoy  ipilimumab  for previously treated patients 
Zacks Rank
Bristol Myers currently carries a Zacks Rank  3  Hold    You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-to-sell-otezla-for-celgene-merger-shares-down-200434609,200434609
202924,424440,MRK,Merck announces increased quarterly dividend and  10B share repurchase authorization,news,Merck  NYSE MRK  declares  0 48 share quarterly dividend  2 1  increase from prior dividend of  0 47  Forward yield 3 50  Payable Jan 8  for shareholders of record Dec  15  ex div Dec  14  The Board also authorized an additional  10B of treasury stock purchases with no time limit for completion ,2017-11-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-announces-increased-quarterly-dividend-and-10b-share-repurchase-authorization-923628,923628
202925,424441,MRK,Nestle to buy vitamin maker Atrium Innovations for  2 3 billion,news,"By Martinne Geller LONDON  Reuters    Nestle is buying Canadian vitamin maker Atrium Innovations for  2 3 billion  expanding its presence in consumer healthcare as it seeks to offset weakness in packaged foods   The world s largest packaged food company said on Tuesday it will buy the maker of vitamins  probiotics and meal replacements from a group of investors led by Permira Funds   About 80 percent of Atrium s sales come from the United States  meaning there is still room to buy businesses elsewhere  such as the vitamins unit being sold by Germany s Merck  NYSE MRK   which has a large presence in emerging markets and is also being looked at by Nestle   We continue to look for opportunities in things that make sense in very disciplined fashion   said Greg Behar  head of Nestle Health Science  the division that will house Atrium Innovations   Nestle Health Science already sells nutritional products for people with specific medical conditions and has been at the forefront of Nestle s ambition to become a  nutrition  health and wellness  company as packaged food sales slow  amid changing tastes  Nestle  the maker of Gerber baby food  Purina pet food and Nescafe coffee came under pressure this year to improve returns from activist shareholder Third Point  It has since announced a share buyback  a margin target and three other small acquisitions   The purchase of Atrium  which will have  700 million in sales this year  will add to earnings immediately  Behar said  The deal reflects comments made earlier this year by Nestle s new chief executive  Mark Schneider  who identified consumer health as a strategic priority   They ve been trying to articulate a message around Nestle Health Science and health and wellness for some time   Liberum analyst Robert Waldschmidt said   In terms of nutrition  this makes sense   Atrium has seven factories in the United States  Canada  Europe and Argentina  Its biggest brand is Garden of Life supplements  This is Nestle s fourth purchase in recent months  It announced deals for Sweet Earth vegetarian foods and Blue Bottle coffee in September and Chameleon Cold Brew coffee in November   The purchase of Atrium is expected to close in the first quarter of 2018  
Atrium was advised by  Morgan Stanley   NYSE MS   RBC Capital Markets and William Hood   Co  a division of AXIA Capital Markets ",2017-12-05,Reuters,https://www.investing.com/news/stock-market-news/nestle-to-buy-vitamin-maker-atrium-innovations-for-23-billion-955264,955264
202926,424442,MRK,Perrigo to bid for German Merck s consumer health unit   Reuters,news,Reuters reports that Perrigo  PRGO  1 8   is preparing an offer for Merck  NYSE MRK  KGaA s  OTCPK MKGAF  OTCPK MKGAY  consumer health business  expected to fetch  US 4 8B Perrigo will be competing against Nestle and privately owned Strada for the business Merck advisor JPMorgan  NYSE JPM  wants a short list of suitors by month end Previously  Suitors preparing bids for Merck KgaA s consumer health unit  Dec  1 Now read ,2017-12-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/perrigo-to-bid-for-german-mercks-consumer-health-unit--reuters-993616,993616
202927,424443,MRK,AstraZeneca Merck s Lynparza Wins EU Nod For First Line Use,opinion,AstraZeneca plc    NYSE AZN   and partner Merck   NYSE MRK   announced that the European Commission  EC  has granted marketing approval to their PARP inhibitor Lynparza for first line maintenance treatment of BRCA mutated advanced ovarian cancer  It was approved in the United States for the indication in late 2018 With the latest approval  Lynparza can now be used as maintenance monotherapy for the treatment of advanced ovarian cancer patients with BRCA1 2 mutation who have achieved complete or partial response  following first line standard platinum based chemotherapy  The regulatory filing was based on data from the phase III SOLO 1 study  which showed that 60  of patients treated with Lynparza remained free of disease progressionafter three years versus 27  on placebo The approval was expected as in April the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a positive opinion recommending this label expansion of Lynparza  In April  Lynparza was also approved by EC for the breast cancer indication for which it was approved in the United States in early 2018 Lynparza is presently approved for multiple indications in advanced ovarian cancer and metastatic breast cancer  It is also being evaluated in different studies for a range of tumor types including prostate  pancreatic and gastric cancers as well as earlier line settings for ovarian cancer and breast cancer  A key phase III study  PAOLA 1 is evaluating Lynparza in combination with Roche s Avastin as a first line maintenance treatment for women with newly diagnosed  advanced ovarian cancer  regardless of the BRCA status Other PARP inhibitors available in the market are Tesaro s Zejula and Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  Tesaro is now part of GlaxoSmithKline   NYSE GSK    However  Lynparza is the only PARP inhibitor approved in the EU as a first line maintenance treatment for advanced ovarian cancer AstraZeneca s stock has rallied 5 2  this year so far  outperforming the rise of 2 1    AstraZeneca reported Lynparza sales of  237 million in the first quarter of 2019  up 13 4  sequentially at constant exchange rates on the back of expanded use for ovarian and breast cancer  U S  sales of the drug increased 80   following a strong launch in first line ovarian cancer setting in late 2018  The recent label expansion approvals in EU should boost sales further in the rest of the quarters of the year Lynpazra is a key drug in AstraZeneca s oncology portfolio together with Tagrisso and Imfinzi  Oncology sales now comprise almost 35  of total product sales for AstraZeneca and rose 59  in the first quarter of 2019 AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/astrazenecamercks-lynparza-wins-eu-nod-for-firstline-use-200432460,200432460
202928,424444,MRK,AstraZeneca s Triple Combo COPD Inhaler Gets Japan s Nod ,opinion,AstraZeneca plc    NYSE AZN   announced that its investigational triple combination therapy  PT010 has been approved by the Japanese regulatory authority to relieve symptoms of chronic obstructive pulmonary disease  COPD  PT010 is a combination of budesonide  an ICS with glycopyrronium  a long acting muscarinic antagonist  LAMA  and formoterol fumarate  a long acting beta agonists  LABA  therapy  PT010 can be delivered using AstraZeneca s Aerosphere Delivery Technology With the approval  PT010  to be marketed by the trade name of Breztri Aerospher  will be the only triple combination therapy in a pressurized metered dose inhaler device to be approved in Japan  This approval marks the first global regulatory approval for Breztri Aerospher while the candidate is under review in the United States and EU The approval is based on positive data from the KRONOS study  which compared PT010 to dual combination therapies   Bevespi Aerosphere  Symbicort Turbuhaler  and PT009   in COPD  The study demonstrated that PT010 led to a statistically significant improvement in trough forced expiratory volume in one second  FEV1   a measure of lung function and the primary endpoint for Japan  versus the dual combination therapies We remind investors that Glaxo   NYSE GSK   also markets a once daily  single inhaler triple combination therapy Trelegy Ellipta  for COPD  Trelegy Ellipta is a combination of fluticasone furoate   an ICS  umeclidinium   a LAMA and vilanterol   a LABA therapy  Trelegy Ellipta is delivered in Glaxo s Ellipta dry powder inhaler  Theravance Biopharma  Inc    NASDAQ TBPH   has an economic interest in Trelegy Ellipta and earns royalties on its sales Along with the approval for the triple combo inhaler  Japan s Ministry of Health  Labour and Welfare also granted approval to Bevespi Aerosphere  AstraZeneca s fixed dose dual  LABA LAMA  inhaler that is delivered in a pressurized metered dose inhaler  Bevespi Aerosphere is already approved in the United States  Europe Canada and Australia as a dual bronchodilator for the long term maintenance treatment of COPD AstraZeneca s stock has rallied 9 7  this year so far  outperforming the  rise of 3 3  AstraZeneca and partner Merck   NYSE MRK   also gained approval in Japan for their PARP inhibitor Lynparza for first line maintenance treatment of BRCA mutated advanced ovarian cancer  It was approved in the United States for the indication in late 2018 while the same in Europe came earlier this week With the latest approval  Lynparza can now be used in Japan as a maintenance treatment after first line chemotherapy in patients with BRCA mutated advanced ovarian cancer as detected by an approved companion diagnostic test AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-triplecombo-copd-inhaler-gets-japans-nod-200433368,200433368
202929,424445,MRK,Pharma Stock Roundup  PFE To Buy ARRY  RHHBY  MRK  AZN Drugs Get Regulatory Nod,opinion,"This week Pfizer   NYSE PFE   announced a definitive deal to buy Array BioPharma to strengthen its cancer portfolio  In other news  Merck s   NYSE MRK   blockbuster PD L1 inhibitor  Keytruda won approval for previously treated advanced small cell lung cancer  SCLC  while AstraZeneca   NYSE AZN   and Roche   OTC RHHBY   gained approval in Japan for their investigational medicines  Meanwhile  AstraZeneca and Merck s Lynparza was approved in EU and Japan for first line maintenance treatment of BRCA mutated advanced ovarian cancer Recap of the Week s Most Important StoriesPfizer to Buy Array BioPharma  In a bid to strengthen its cancer portfolio  Pfizer announced a for  48 per share in cash for a total enterprise value of approximately  11 4 billion  Array  which makes targeted small molecule drugs for treating cancer  launched its only commercial medicine  Braftovi plus Mektovi  as a treatment for BRAF mutant melanoma  last year  The combination medicine is also being evaluated in label expansion studies for other cancer types including metastatic colorectal cancer  mCRC  with BRAF mutation  The acquisition will bring to Pfizer a large portfolio of royalty generating out licensed medicines  The transaction has been approved by the boards of both the companies and is expected to close in the second half of the year FDA Approves Merck s Keytruda for SCLC  The FDA granted accelerated approval for label expansion of Keytruda as a monotherapy for  SCLC   The approval was based on clinical response data from SCLC cohorts of the phase Ib KEYNOTE 028 and phase II KEYNOTE 158 studies  While Keytruda already holds a strong position in the non small cell lung cancer market  this is the first approval for the drug in the SCLC indication  which accounts for 10  to 15  of all lung cancers Several Approvals for AstraZeneca s Drugs  AstraZeneca Merck s PARP inhibitor Lynparza was granted approval in EU and Japan for first line maintenance treatment of   It was approved in the United States for the indication in late 2018  With the latest approval  Lynparza can now be used as a maintenance monotherapy for the treatment of advanced ovarian cancer patients with BRCA1 2 mutation who have achieved complete or partial response  following first line standard platinum based chemotherapy  The regulatory filing was based on data from the phase III SOLO 1 study AstraZeneca also  for PT010  its investigational triple combo inhaler and Bevespi Aerosphere  its fixed dose LABA LAMA inhaler  both to treat COPD  PT010 will be marketed by the trade name of Breztri Aerospher  Japan marks the first global regulatory approval for Breztri Aerospher while the candidate is under review in the United States and EU Roche s Personalized Medicine Entrectinib Gets Approval in Japan  Japan s regulatory authority granted marketing approval to  for adult and pediatric patients with NTRK fusion positive advanced recurrent solid tumors  Japan became the first company to approve this tumor agnostic medicine  which will be marketed by the trade name of Rozlytrek  It is under priority review in the United States with the FDA s decision expected in August Novo Nordisk  CSE NOVOb  Gets EU Approval for Esperoct  The European Commission granted marketing approval to Novo Nordisk s   NYSE NVO   Esperoct for the treatment of haemophilia A in adult patients and children  The drug is indicated for prophylaxis and on demand treatment of bleeding as well as for surgical procedures in adolescents and adults with hemophilia  A  Esperoct is expected to be launched in the EU in the second half of 2019  The drug was approved in the United States in February Sanofi Regeneron s Asthma Candidate Succeeds in Study  Sanofi   NASDAQ SNY   and partner Regeneron Pharmaceuticals announced that a phase II study evaluating their investigational IL 33 antibody REGN3500  SAR440340  in asthma met the primary endpoint  Data from the study showed that REGN3500  SAR440340  monotherapy significantly reduced loss of asthma control  primary endpoint  and improved lung function compared to placebo  However  the REGN3500 plus Dupixent treatment arm failed to demonstrate increased benefit compared to Dupixent The NYSE ARCA Pharmaceutical Index rose 2 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last five trading sessions Last week  all the stocks were in the green with AstraZeneca recording the highest gain  4 3   In the past six months  Merck has been the biggest gainer  18 9   while Bristol Myers   NYSE BMY   has recorded the least gain  0 3    See the last pharma stock roundup here  What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pfe-to-buy-arry-rhhby-mrk-azn-drugs-get-regulatory-nod-200433811,200433811
202938,424454,MRK,Orexigen Contrave up 10  on Contrave distribution deal with Merck KGaA for Latin America,news,Orexigen Therapeutics   OREX  10 3   inks an agreement with Merck  NYSE MRK  KGaA  OTCPK MKGAF  for exclusive distribution rights for obesity med Contrave  naltrexone HCl bupropion HCl extended release  for Latin America  including Brazil and Mexico Under the terms of the contract  Merck will be responsible for all commercialization and regulatory activities in the territory  Orexigen will receive an upfront payment and regulatory  and sales  based milestones  Specific financial terms are not disclosed Now read ,2017-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/orexigen-contrave-up-10-on-contrave-distribution-deal-with-merck-kgaa-for-latin-america-851415,851415
202939,424455,MRK,Syndax Pharma reports study results that support treatment benefit of entinostat   investors unmoved after Nektar data  shares down 11 ,news,Thinly traded micro cap  Syndax Pharmaceuticals   SNDX  10 9   slumps on 50  higher volume  albeit on turnover of only 153K shares  on the heels of its announcement of results from an open label Phase 1b 2 study  ENCORE 601  evaluating the combination of entinostat and Merck s  MRK  0 4   KEYTRUDA  pembrolizumab  in patients with non small cell lung cancer  NSCLC   melanoma and colorectal cancer  CRC   The data were presented at the SITC Annual Meeting in National Harbor  MD The overall response rate in NSCLC patients who progressed after anti PD 1 or anti PD L1 therapy was 10  and 24  in NSCLC patients who had not been previously treated with a PD 1 or PD L1 inhibitor Across both cohorts  the responders with known PD  L 1 expression levels were either low  1 49   or negative   1   expressors The combination of  Nektar Therapeutics    NKTR  15 6   NKTR 214 and BMY s Opdivo  nivolumab  produced a 75   n 3 4  response rate in NSCLC patients who did not express PD L1 and had progressed after chemo The study is ongoing  A decision on advancing the colorectal cancer cohort into Phase 2 will be made in H1 2018  the lung cancer and melanoma cohorts have already been advanced  Entinostat is a small molecule that inhibits an enzyme class called histone deacetylases  HDACs   specifically Class 1 HDACs which play a key role in modulating immuno suppressive cells called myeloid derived suppressor cells  MDSCs  and regulatory T cells  The company says entinostat has therapeutic potential in a range of cancers when used in combination with immune checkpoint inhibitors  like Keytruda  Previously  Combination of Opdivo and Nektar s NKTR 214 show positive effect in advanced lung cancer in Phase 1 2 study  Nov  13 Previously  Nektar s gain Calithera s pain on Opdivo combo treatments  shares down 15   Nov  13 Now read ,2017-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/syndax-pharma-reports-study-results-that-support-treatment-benefit-of-entinostat--investors-unmoved-after-nektar-data-shares-down-11-851650,851650
202940,424456,MRK,Premarket Losers as of 9 05 am,news,SUNW  23  on Q3 earnings NTIP  20  PRQR  14  on announcing public offering of common shares HPJ  14  on Q3 earnings ZX  13  EKSO  10  ANTH  9  SWCH  8   on Q3 earnings SMI  7   on Q3 earnings TPRE  7  on announcing offering of 15M common shares by selling shareholders LOXO  6  on teaming up with Bayer  DE BAYGN  to develop and commercialize larotrectinib and LOXO 195 for TRK fusion cancers NVFY  6   Now read ,2017-11-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-losers-as-of-905-am-857202,857202
202941,424457,MRK,UK launches plan for industry as Brexit looms  wins Merck investment,news,"LONDON  Reuters    The British government launched a new strategy for industry on Monday  aiming to intervene in key sectors to tackle weak productivity and bolster businesses to counter any new problems caused by Brexit  Prime Minister Theresa May first flagged the plan in January  seven months after Britain voted to leave the European Union  adopting a hands on approach to business that had largely been abandoned by her predecessors from the time of Margaret Thatcher in the 1980s  The government said on Monday that it had secured a major investment from global healthcare company MSD  known as Merck   Co  N MRK  in the United States  ahead of the publication of the strategy  Life sciences is one of four sectors being targeted by the government  which will also focus on construction  artificial intelligence and the automotive industry  Business Minister Greg Clark said Britain has some of the world s best universities and research institutions  as well as leading companies in sectors ranging from advanced manufacturing to financial services  life sciences and creative industries   But any serious strategy should address the weaknesses that stop us achieving our potential  as well as our strengths  and this Industrial Strategy does that   he said   Britain s productivity performance has not been good enough and is holding back our earning power as a country   Last week Britain s budget forecasters cut the country s growth estimates for the next five years  largely because of reduced projections for productivity  the Achilles  heel of the economy since the financial crisis  Clark said the new industrial strategy would strengthen infrastructure and the business environment in an effort to improve productivity  MSD said it would open a state of the art life sciences discovery research facility in London by 2020  focusing on early bioscience discovery and entrepreneurial innovation   This new London location will enable us to build on our proud legacy of invention and be an important contributor to the vibrant and rapidly growing London life sciences community while providing access for more collaborations within the European life science ecosystem   said Roger M  Perlmutter  president of MSD Research Laboratories  MSD intends to create 150 new research roles and is evaluating locations in the London area  it said  The vote of confidence in Britain s life sciences sector was welcomed by the government after the news last week that the European Medicines Agency would move from London to Amsterdam when Britain leaves the EU in March 2019  Brexit remains the biggest concern for British companies and multinationals with operations in Britain  With only months to go before many businesses need to make decisions on future investment  they are eager for clarity on how Brexit will work  
However  talks with the European Union have made slow progress  and the government has only been able to reiterate its plan to seek a transition deal as soon as possible ",2017-11-26,Reuters,https://www.investing.com/news/stock-market-news/uk-launches-plan-for-industry-as-brexit-looms-wins-merck-investment-913053,913053
202942,424458,MRK,Novartis Reports Data On Cosentyx For Psoriatic Arthritis,opinion,"Novartis AG   NYSE NVS   announced new data from the FUTURE 5 study that showed no radiographic progression in almost 90  of psoriatic arthritis  PsA  patients treated with Cosentyx  secukinumab  300mg over two years 
The study evaluated the effect of Cosentyx on the signs and symptoms of PsA  in addition to inhibition of radiographic progression of the disease  These data demonstrate that 89 5   300mg   82 3   150mg  and 81 1   150mg no loading dose  LD   of PsA patients treated with Cosentyx found no radiographic progression at two years 
FUTURE 5 is a phase III  randomized  double blind  placebo controlled study evaluating the effect of Cosentyx on radiographic progression across two years in PsA patients  Data at two years demonstrated that more than 50  of adults with active PsA achieved American College of Rheumatology criteria  ACR50   and almost 50  achieved Psoriasis Area and Severity Index  PASI 100  response with Cosentyx 300mg 
The results show that Cosentyx can be a rapid and long lasting comprehensive treatment of spondyloarthritis and psoriatic disease  with more than 200 000 patients treated worldwide 
The company also announced new data from the MAXIMISE study evaluating the efficacy and safety of the drug in the management of axial manifestations of PsA  The ongoing 52 week phase IIIb study met its primary endpoint  with 63 1  of patients treated with Cosentyx 300 mg achieving rapid and significant improvements in the signs and symptoms of PsA with axial manifestations at week 12  The study also met the secondary endpoint  with 66 3  of patients treated with Cosentyx 150 mg achieving the same at week 12 
Shares of the company increased 19 4  year to date compared with the  s growth of 5 3  

 
Cosentyx is the first and only fully human biologic that directly inhibits interleukin 17A  IL 17A   a cornerstone cytokine involved in the inflammation and development of PsA  psoriasis  PsO  and ankylosing spondylitis  AS  Novartis AG Price
   Zacks Rank   Stocks to Consider
Novartis currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the healthcare sector include Bristol Myers Squibb Company   NYSE BMY    Pfizer Inc    NYSE PFE   and Merck and Co   Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Pfizer and Merck carry a Zacks Rank  2  Buy   You can see 
Bristol Myers  earnings per share estimates increased from  4 79 to  5 03 for 2020 over the past 60 days  Estimates for 2020 also increased 48 cents  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 11 85           
Pfizer s earnings per share estimates increased from  2 86 to  2 89 for 2019 over the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 5 65           
Merck s earnings per share estimates have moved up from  4 65 to  4 73 for 2019 and from  5 18 to  5 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 5 67     
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/novartis-reports-data-on-cosentyx-for-psoriatic-arthritis-200431081,200431081
202943,424459,MRK,3 Big Pharma Stocks To Buy Right Now,opinion,"AbbVie Inc    NYSE ABBV  
Zacks Rank   2  Buy 
AbbVie is a pharmaceutical researcher and producer based in Illinois  Abbvie currently holds an overall  A  VGM  Value  Growth  Momentum  score  ABBV s P E of 8 92 is significantly below the industry average of 15 3  Additionally  AbbVie is expected to have solid top and bottom line growth in the coming years  Zacks Consensus Estimates have fiscal 2019 earnings growth at 11 38   followed by an additional 6 4  in fiscal 2020  Earnings estimates for both fiscal 2019 and fiscal 2020 have also received 6 upward revisions over the past 60 days and no downward revisions over that same time frame  Over the past 12 months  the stock is down 19   But AbbVie s predicted earnings growth could help the stock to turnaround and improve its performance 

Bristol Myers Squibb   NYSE BMY  
Zacks Rank   1  Strong Buy 
Bristol Myers Squibb is a large pharmaceutical manufacturer headquartered in New York City  Bristol Myers Squibb boasts a Zacks Rank  1  Strong Buy   along with a  B  VGM score  Zacks Consensus Estimates call for solid growth in fiscal 2019  with 5 03  bottom line growth and 6 88  revenue growth  Looking forward into fiscal 2020  earnings for Bristol Myers Squibb are expected to grow significantly  Estimates currently put fiscal 2020 s earnings growth around 20  above 2019  Plus  there have been 4 upward revisions for 2020 earnings over the past 60 days  against no downward revisions  This means at least some analysts are confident in the company s ability to produce solid earnings growth in fiscal 2020  Similarly to AbbVie  BMY stock has been on a downward trend  Since reaching its 52 week high in September  the stock has tumbled over 25   That being said  given Bristol Myers Squibb s estimated earnings growth  the stock could be on the right track to recover from these losses 
Merck   Co    NYSE MRK  
Zacks Rank   2  Buy 
Merck   Co  is one of the largest pharmaceutical companies in the world  Based in New Jersey  it currently provides a large variety of drugs including name brands such as Keytruda  The company also developed the common MMR vaccine  Merck is expected to have healthy growth over the next couple of years  Zacks Consensus Estimates call for 8 99  earnings growth for fiscal 2019  fueled by 4 8  top line growth  Fiscal 2020 has even better expectations with top line growth of a further 5 5  expected to contribute to earnings growth of 10 3  on top of the fiscal 2019 growth  All this growth is expected to bring EPS to  5 21 in 2020  compared to just  4 34 in 2018  Additionally  the company has only received upward revisions for its earnings expectations for fiscal 2019 and 2020 over the past 60 days  Overall  this positive outlook could help MRK stock continue to climb 
Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-14,Zacks Investment Research,https://www.investing.com/analysis/3-big-pharma-stocks-to-buy-right-now-200431749,200431749
202947,424463,MRK,FDA OKs Merck s Prevymis for preventing CMV infection in HSCT patients,news,The FDA approves Merck s  NYSE MRK  PREVYMIS  letermovir  for the prevention of cytomegalovirus  CMV  infection in patients receiving an allogeneic hematopoietic stem cell transplant  HSCT  and for preventing CMV reactivation in CMV seropositive patients undergoing HSCT  Both oral and IV formulations were approved The product should be commercially available next month at a wholesale cost of  195 day for the tablets and  270 for the IV version  does not include potential discounts  Shares are up a fraction premarket on light volume Now read ,2017-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-mercks-prevymis-for-preventing-cmv-infection-in-hsct-patients-841157,841157
202948,424464,MRK,Aduro Stock Crashes After ASCO Updates On Cancer Candidate,opinion,"Aduro Biotech  Inc    NASDAQ ADRO   and its partner Novartis   NYSE NVS   presented data from the ongoing phase Ib data evaluating a combination of Aduro s lead candidate  ADU S100 and Novartis  PD 1 inhibitor  spartalizumab  in patients with advanced solid tumors or lymphomas  Data were presented at the annual meeting of the American Society of Clinical Oncology   ASCO   However  investors seemed far from being impressed and the company s shares crashed 40 3  on Jun 3  Aduro s shares are down 26 5  so far this year compared with the  s decline of 0 8  The phase Ib study is a dose escalation clinical study evaluating once weekly or once monthly 50   1 600  g dose of ADU S100 in combination with a fixed dose of 400 mg of spartalizumab once monthly  The company presented data from 83 enrolled patients  with 53 and 30 patients in the weekly group and monthly group  respectively Data showed that five patients out of eight patients in the weekly arm achieved confirmed responses  which included one complete response and two partial responses in anti PD 1 na ve patients with triple negative breast cancer   TNBC    The remaining two patients achieving partial response have melanoma and were previously treated with an immunotherapy Moreover  12 patients achieved stable disease with eight of them receiving prior treatment with immunotherapy   In the monthly arm  six patients achieved stable disease with five of them having received prior immunotherapy treatment The Investors were underwhelmed with response rates which led to plunge in share prices  Moreover  these are early data and more mature data is required for a clear future development path  Based on presented data  some investors also believe that the study may require additional time for completion Aduro is focused on developing its STING agonist  ADU S100  in combination with checkpoint inhibitor therapy as treatment for several cancer indications  Meanwhile  the company is currently enrolling patients in an early stage study evaluating ADU S100 in combination with Bristol Myers    NYSE BMY   Yervoy  ipilimumab  in relapsed refractory melanoma  Another study to evaluate ADU S100 in combination with Merck s   NYSE MRK   Keytruda  pembrolizumab  in first line head and neck cancer is expected to start in the second half of 2019 Aduro Biotech  Inc  Price
    Zacks RankAduro currently carries a Zacks Rank  4  Sell  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/aduro-stock-crashes-after-asco-updates-on-cancer-candidate-200428265,200428265
202952,424468,MRK,Merck withdraws European marketing application for Keytruda in first line NSCLC,news,Merck  NYSE MRK  shareholders now know the main reason behind today s selloff  After the close  it announced that it has withdrawn its marketing application in Europe seeking approval to use Keytruda  pembrolizumab   in combination with pemetrexed and carboplatin  for the first line treatment of nonsquamous non small cell lung cancer  NSCLC   a large potential market being hotly pursued by a list of competitors The company says it is  confident  in the clinical data supporting the application  generated in the KEYNOTE 021 study  Cohort G1  but apparently not overconfident considering the withdrawal Topline data from the KEYNOTE 189 study  also in first line NSCLC  is being anxiously awaited by investors Shares are off a fraction after hours on robust volume Previously  Merck announces follow up data with Merck s KEYTRUDA  June 3 Now read ,2017-10-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-withdraws-european-marketing-application-for-keytruda-in-firstline-nsclc-549582,549582
202953,424469,MRK,Cancer drug setback sends Merck shares down again,news,"By Lewis Krauskopf NEW YORK  Reuters    A setback for Merck   Co s  N MRK  key cancer drug sent the drugmaker s stock swooning on Monday for a second straight session  putting the shares on track for their biggest two day decline in more than eight years  Late on Friday  Merck withdrew an application for European use of its flagship drug Keytruda as an initial  or first line  treatment for advanced lung cancer in combination with chemotherapy  raising questions about future sales  The Keytruda chemo combination is already approved in the United States based on initial promising data  But the company determined that a similar European first line approval without more mature late stage data was unlikely  Lung cancer is by far the most lucrative oncology market with first line approval providing access to the most patients   In the wake of the news  at least three analysts cut their ratings on Merck s stock  a component of the blue chip Dow Jones Industrial Average  DJI   while other analysts lowered their target prices for the stock   We are downgrading MRK shares to Equal Weight from Overweight based on diminished upside potential from Keytruda  which is by far Merck s biggest value driver    Barclays   LON BARC  analyst Geoff Meacham said in his downgrade note  Aside from the European withdrawal  Meacham and other analysts also cited delays for another Keytruda study  revealed on Friday morning  Merck said a decision to make overall survival a main goal for a large  pivotal lung cancer trial of Keytruda plus chemotherapy would delay those results until February 2019  Merck shares fell 5 6 percent to  54 95 on Monday  touching their lowest point since May 2016  The stock had dropped 6 percent on Friday following the company s third quarter results   The drugmaker said that the cost of a June cyber attack that temporarily crippled manufacturing coupled with lower sales of off patent products caused its third quarter revenue to fall 2 percent to  10 33 billion  even as Keytruda sales topped  1 billion for the first time  The combined  roughly 11 percent two day decline for Merck shares would be the biggest since February 2009  Merck s setback boosted shares of Bristol Myers Squibb Co  N BMY   which sells a rival cancer therapy  Bristol Myers shares were up 1 6 percent  Pharmaceutical stocks have endured a rocky month so far as earnings results have poured in  The NYSE Arca Pharmaceutical index  DRG  is down 2 percent in October against a 2 1 percent rise for the overall S P 500  SPX   
Pharmaceutical heavyweight  Pfizer  Inc  N PFE  is set to report results on Tuesday    additional reporting by Bill Berkrot  Editing by Nick Zieminski ",2017-10-30,Reuters,https://www.investing.com/news/stock-market-news/cancerdrug-setback-sends-merck-shares-down-again-760240,760240
202954,424470,MRK,Bayer s Aliqopa Gets Breakthrough Therapy Status By FDA,opinion,Bayer  DE BAYGN  Aktiengesellschaft   OTC BAYRY   announced that the FDA granted Breakthrough Therapy designation to Aliqopa  copanlisib  for the treatment of adult patients with relapsed marginal zone lymphoma  MZL   who have received at least two prior therapies  MZL is an indolent form of non Hodgkin s lymphoma  iNHL  and accounts for about 10  of all non Hodgkin s lymphoma in the United States The Breakthrough Therapy designation is aimed at accelerating the development and review of drugs intended to treat serious or life threatening diseases Aliqopa is a pan PI3K inhibitor  with predominant activity against the PI3K alpha and PI3K delta isoforms expressed in malignant B cells  developed by Bayer The Breakthrough Therapy designation was based on data from the MZL subgroup of the pivotal phase II CHRONOS 1 study that led to accelerated approval of Aliqopa in the United States for the treatment of adult patients with relapsed follicular lymphoma  FL   who have received at least two prior systemic therapies  The data from the CHRONOS 1 study showed efficacy of the drug in patients with iNHL  who have received at least two prior therapies  including those with relapsed or refractory MZL Shares of Bayer have declined 10 8  year to date against the s growth of 0 9  Bayer is conducting two additional phase III studies   CHRONOS 3 and CHRONOS 4   to evaluate the efficacy and safety of Aliqopa in combination with other therapies in iNHL  including MZL  patients  who have relapsed following one or more prior therapies  We remind investors that recently  the FDA approved Celgene Corporation s   NASDAQ CELG   Revlimid  lenalidomide  in combination with a rituximab product  R   for the treatment of adult patients with previously treated FL or MZL  This is the first combination regimen for patients with these indolent forms of non Hodgkin lymphoma  NHL  that does not include chemotherapy Bayer Aktiengesellschaft Price    Zacks Rank   Stocks to ConsiderBayer currently carries a Zacks Rank  3  Hold  Some other better ranked stocks in the health care sector include Bristol Myers Squibb Company   NYSE BMY   and Merck and Co   Inc    NYSE MRK    While Bristol Myers carries a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see Bristol Myers  earnings per share estimates have moved up from  4 78 to  5 03 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 11 85           Merck s earnings per share estimates have moved up from  4 65 to  4 72 for 2019 and from  5 17 to  5 20 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 5 67           The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-05-30,Zacks Investment Research,https://www.investing.com/analysis/bayers-aliqopa-gets-breakthrough-therapy-status-by-fda-200426503,200426503
202955,424471,MRK,Roche Presents Positive Data On Xolair   Updates From ASCO,opinion,"Roche   OTC RHHBY   announced positive top line data from two phase III multicenter studies on allergic asthma drug  Xolair  omalizumab  The two studies  POLYP 1 and POLYP 2  were evaluating Xolair for the treatment of adults with chronic rhinosinusitis with nasal polyps  CRSwNP   who have not adequately responded to intranasal corticosteroids Both the studies met the co primary and key secondary endpoints  Xolair  omalizumab  significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies The results showed that Xolair  an injectable biologic medicine designed to target and block immunoglobulin E  IgE   was well tolerated  while safety profile was consistent with that observed in previous studies in patients with moderate to severe allergic asthma and chronic idiopathic urticaria  CIU   Roche will discuss the results with the FDA soon  CRSwNP impacts up to 4  of the global population and the prevalence of the disease increases with age  thereby underlying the demand for such drugs  The label expansion of the drug for this indication should boost sales  given the demand Roche is making efforts to expand its portfolio beyond oncology into immunology  Apart from Xolair  the company s immunology portfolio includes Actemra for rheumatoid arthritis  Rituxan for rheumatoid arthritis granulomatosis with polyangiitis and microscopic polyangiitis and for pemphigus vulgaris  PV   Pulmozyme for cystic fibrosis  and Esbriet for idiopathic pulmonary fibrosis  IPF    Roche has a collaboration agreement with Novartis   NYSE NVS   for Xolair The company s stock has gained 5 7  in the year so far against the  s 2 9  decline  Earlier  Roche announced positive additional results of a prespecified exploratory analysis from the phase III IMpower150 study at the American Society of Clinical Oncology  ASCO  annual meeting The results showed that the combination of Tecentriq  Avastin  carboplatin and paclitaxel  chemotherapy  provided patients suffering from chemotherapy na ve  metastatic non squamous non small cell lung cancer  NSCLC  an overall survival  OS  advantage in baseline liver metastases compared with the combination of Avastin and chemotherapy The combination was approved by the FDA in December 2018 for the first line treatment of adults with metastatic non squamous NSCLC with no EGFR or ALK genomic tumour aberrations  The European Commission approved the same in March 2019 The performance of immuno oncology drug  Tecentriq  has been strong  even though it faces stiff competition from Merck s   NYSE MRK   Keytruda and Bristol Myers Squibb Company s   NYSE BMY   Opdivo in the NSCLC space Zacks Rank
Roche currently carries a Zacks Rank  2  Buy   You can see  
Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/roche-presents-positive-data-on-xolair--updates-from-asco-200427787,200427787
202956,424472,MRK,AstraZeneca s Imfinzi Shows Long Term Benefits In Lung Cancer,opinion,"AstraZeneca   NYSE AZN   presented updated long term data from the follow up of phase III PACIFIC study  evaluating its PD L1 inhibitor  Imfinzi  in unresectable  stage III non small cell lung cancer   NSCLC   at the ongoing annual meeting of the American Society of Clinical Oncology   ASCO   Please note that in 2018  Imfinzi was approved for the above mentioned patient population based on PACIFIC study data in the United States  Europe and Japan The latest data shows that more than half of the unresectable  stage III NSCLC patient population treated with Imfinzi was alive following three years of treatment  The overall survival rate   OS   was 57  for patients treated with Imfinzi compared with 43 5  for placebo  However  median OS for the Imfinzi arm is yet to be reached while the same for the placebo is 29 1 months  Moreover  the drug is the only immunotherapy to demonstrate overall survival at three years in this patient population The primary analysis of the PACIFIC study data had shown that treatment with Imfinzi reduced the risk of death by 32  compared to placebo over two years in patients with unresectable  stage III NSCLC who had not progressed following concurrent chemoradiation therapy   CRT   Per the press release  previously 15  to 30  with unresectable  stage III NSCLC patients remained alive after five years of treatment  Notably  57  of the patients remaining alive after three years of treatment with Imfinzi raises the bar for treatments in this curative intent setting The follow up data shows that durable efficacy of Imfinzi treatment was nearly maintained in patients with 31  reduction in risk of death compared to placebo after an additional year following primary analysis  The safety and tolerability profile for Imfinzi also remained consistent with results reported at the time of the previous OS analysis AstraZeneca s shares have decreased 1 6  so far this year compared with the  s decline of 2 3  in that period Apart from the lung cancer indication  Imfinzi is also approved for second line advanced bladder cancer  The company is also developing Imfinzi as monotherapy as well as combination therapy for treatment of NSCLC in first line or adjuvant setting  The drug is also being developed for several other cancer indications including head and neck  gastric  pancreatic  hepatocellular and blood cancers Meanwhile  competition is increasing in the cancer market especially in the lung cancer segment  due to its large patient population  with several approved PD L1 inhibitors  Two key PD L1 inhibitors available for treating multiple cancer indications include Bristol Myers Squibb Company s   NYSE BMY   Opdivo and Merck   Co  s   NYSE MRK   Keytruda  Roche s   OTC RHHBY   PD L1 inhibitor  Tecentriq  is also making significant inroads into the cancer market AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-imfinzi-shows-longterm-benefits-in-lung-cancer-200427845,200427845
202957,424473,MRK,Novartis  NVS  Announces Various Data Presentations At ASCO ,opinion,"Novartis AG   NYSE NVS   announced few data presentations at the ASCO 2019 annual meeting The company announced statistically significant overall survival  OS  results for its breast cancer drug  Kisqali  in combination with endocrine therapy  The phase III MONALEESA 7 study evaluated Kisqali plus endocrine therapy as initial treatment compared to endocrine therapy alone in pre  and peri menopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer The data released showed survival rates of 70  inpre menopausal women with HR  HER2  advanced or metastatic breast cancer at 42 months after getting a combination of Kisqali and endocrine therapy  That compares with 46  who received only endocrine therapy  which at the time of the study was the standard of care Kisqali is the only CDK4 6 inhibitor to show superior OS in advanced breast cancer Results from subgroup analyses showed that Kisqali plus an aromatase inhibitor demonstrated a 30  reduced risk of death compared to an aromatase inhibitor alone  Also  Kisqali plus tamoxifen demonstrated a 20 9  reduced risk of death compared to tamoxifen alone Shares of the company increased 18 6  year to date compared with the  s growth of 1  Novartis also announced new data and clinical trial updates in non small cell lung cancer  NSCLC   The company announced primary efficacy results from the GEOMETRY mono 1 phase II study  The results demonstarted that investigational MET inhibitor capmatinib  INC280  showed promising efficacy in patients with locally advanced or metastatic NSCLC that harbor MET exon 14 skipping mutation  There are currently no approved targeted therapies to treat thisparticularly aggressive form of NSCLC Overall response rate among patients receiving capmatinib was 68  for treatment naive and 41  for previously treated patients  The median duration of response was also clinically meaningful irrespective of prior line of therapy Capmatinib  INC280  is an investigational  oral and selective MET inhibitor licensed to Novartis by Incyte Corporation   NASDAQ INCY   in 2009  Under the agreement  Incyte granted the company worldwide exclusive development and commercialization rights to capmatinib and certain back up compounds in all indications Further  Novartis also announced positive top line data from two phase III studies evaluating Xolair  omalizumab   The phase III POLYP 1 AND POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with nasal polyps  crswnp  with inadequate response to intranasal corticosteroids met both co primary endpoints and key secondary endpoints  In both studies  Xolair showed a safety profile consistent with previous FDA approved indications of chronic spontaneous urticaria and severe allergic asthma  CRSwNP impacts up to 4  of people worldwide  and the prevalence increases with age  Novartis AG Price
    Zacks Rank   Stocks to ConsiderNovartis currently carries a Zacks Rank  5   Strong Sell  Some other better ranked stocks in the healthcare sector include Bristol Myers Squibb Company   NYSE BMY   and Merck and Co   Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see Bristol Myers  earnings per share estimates have moved up from  4 78 to  5 03 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 11 85           Merck s earnings per share estimates have moved up from  4 72 to  4 73 for 2019 and from  5 17 to  5 21NVS for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  with average beat of 5 67     Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-announces-various-data-presentations-at-asco-200427903,200427903
202958,424474,MRK,Bristol Myers  BMY  Presents Multiple Data On Opdivo At ASCO,opinion,"Bristol Myers Squibb Company   NYSE BMY   made a series of presentations at the American Society of Clinical Oncology 2019  ASCO  annual meeting in Chicago The company announced encouraging updated results from studies evaluating lead immuno oncology drug  Opdivo  and Yervoy  alone or in combination  in patients with advanced or metastatic melanoma With a median follow up of 43 1 months in all patients  at four years or longer  overall survival  OS  rates were stable at 57  in a five year analysis of the phase I CA209 004 study  the longest follow up for the Opdivo plus Yervoy combination in patients with previously treated or untreated advanced melanoma to date The three year OS rate following discontinuation of therapy was 56   The study also showed long term survival outcomes with Opdivo plus Yervoy  regardless of BRAF or lactate dehydrogenase  LDH  status  with four year OS rates of 62  compared to 49  for patients with normal and elevated LDH  respectively  Data also showed four year OS rates of 54  and 61  for patients with wild type and mutant BRAF tumors  respectively  The overall safety of the combination was consistent with previously reported studies of these medicines in patients with advanced melanoma Separately  an analysis evaluating long term quality of life  QoL  and symptom burden in the phase 3 CheckMate  067 study showed that that QoL was maintained during the treatment free interval  TFI  in patients with previously untreated unresectable or metastatic melanoma  following discontinuation of therapy with Opdivo or the combination  Moreover  a four year analysis from the CheckMate 067 study of Opdivo and Yervoy  alone or in combination  in patients with previously untreated unresectable or metastatic melanoma  showed that patient reported QoL and symptoms were maintained from baseline during extended treatment The results reinforce the long term efficacy of the combination for the treatment of advanced melanoma Additionally  Bristol Myers announced first results from the Opdivo plus Yervoy cohort of the phase 1 2 CheckMate 040 study  The study is evaluating the combination in patients with advanced hepatocellular carcinoma  HCC   previously treated with Bayer s   OTC BAYRY   Nexavar  Opdivo plus Yervoy yielded objective response rate of 31  and median duration of response of 17 5 months   Meaningful responses were observed across treatment arms Bristol Myers  shares have lost 11 3  in the past six months compared with the  s decline of 5 1   Immuno oncology drug  Opdivo  is currently approved in several countries  including the United States  the EU and Japan for several cancer indications  Label expansion of the drug into additional indications will further boost sales  The performance of the drug has been impressive amid stiff competition from Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq Zacks Rank
Bristol Myers currently carries a Zacks Rank  1  Strong Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-presents-multiple-data-on-opdivo-at-asco-200428251,200428251
202959,424475,MRK,Merck s Antibiotic Zerbaxa Gets FDA Nod For New Indication,opinion,Merck   Co   Inc    NYSE MRK   gained FDA approval for a supplemental new drug application looking for label expansion of its antibacterial medicine  Zerbaxa for two types of pneumonia infections Zerbaxa  a combination of ceftolozane and tazobactam  is presently marketed for some complicated urinary tract infections With the latest FDA approval  Zerbaxa  3g dose  can now be prescribed for the treatment of patients 18 years and older with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  HABP VABP   The supplemental new drug application was filed based on data from a pivotal phase III study  which evaluated critically ill and ventilated patients with pneumonia  Results from the study demonstrated non inferiority of Zerbaxa to meropenem  the active comparator  thereby meeting the study s primary endpointMerck s shares have performed well this year so far  Merck s shares have risen 5  this year so far against the  s decrease of 2 2    Zerbaxa was added to Merck s portfolio with the 2015 acquisition of Cubist Pharmaceutical and is part of its hospital acute care portfolio  Other popular products in Merck s hospital acute care portfolio are Noxafil  Cubicin and Bridion Merck has another anti bacterial candidate  MK 7655A  whose NDA is under review with the FDA  MK 7655A is a fixed combination of relebactam with imipenem cilastatin  Merck is looking to get MK 7655A approved for the treatment of complicated urinary tract infections  cUTI  and complicated intra abdominal infections  cIAI  caused by certain susceptible Gram negative bacteria  The FDA action on MK 7655A is expected on Jul 16 Merck currently carries a Zacks Rank  2  Buy   You can see Other top ranked large drug stocks include AbbVie   NYSE ABBV    Bristol Myers Squibb Company   NYSE BMY   and Roche   OTC RHHBY    While Bristol Myers sports a Zacks Rank  1  AbbVie and Roche have a Zacks Rank  2 AbbVie s earnings estimates increased 1 5  for 2019 and 1 3  for 2020 over the last 60 days  The company delivered positive earnings surprise in three of the trailing four quarters  with the average beat being 2 58  Bristol Myers  earnings estimates increased 5 2  for 2020 over the last 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with the average being 11 85  Roche s earnings estimates increased 2 1  for 2019 and 1 3  for 2020 over the last 60 days  The company s shares have increased 9 4  this year so far Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/mercks-antibiotic-zerbaxa-gets-fda-nod-for-new-indication-200428276,200428276
202966,424482,MRK,Merck cyber attack may cost insurers  275 million  Verisk s PCS,news,"NEW YORK  Reuters    Insurers could pay  275 million to cover the insured portion of drugmaker Merck  NYSE MRK    Co s loss from a cyber attack in June  according to a forecast by Verisk Analytics Inc s Property Claim Services  PCS  unit  Merck  however  has not disclosed the magnitude of its uninsured losses from the  NotPetya  attack  which disrupted production of some Merck medicines and vaccines   The company was among dozens of firms worldwide hit in the June 27 attack  which began in Ukraine  then rapidly spread through corporate networks of multinationals with operations or suppliers in Eastern Europe   Merck has not yet fully quantified its losses  much less given any of its insurers an estimate of the total amount of those losses   Merck spokeswoman Claire Gillespie said in a statement  She reiterated that Merck has insurance that would cover some costs  but declined to elaborate or say how much Merck expects to have to pay on its own  The drugmaker said in July that it had suffered a worldwide disruption of its operations as a result of the malware  It was still in the process of restoring its manufacturing operations a month later  Merck said then that it was confident it would be able to maintain a continuous supply of its top selling and life saving drugs  but warned of temporary delays in delivering some other products  NotPetya is a destructive virus that spread quickly across computer networks  crippling computers by encrypting hard drives so that machines cannot run  The attacks caused massive disruptions to industrial networks that rely on computers because businesses must individually replace damaged drives  a labor intensive process  Cyber insurance can be expensive to buy and is not widely used outside the United States  with one insurer previously describing the cost as  100 000 for  10 million in data breach insurance    Policies typically cover expenses stemming from a data breach  such as forensics and data restoration  among other costs  Coverage also helps pay for business interruption expenses when a breach or malware attack shuts down a company s website  Some companies without cyber insurance have used their policies covering kidnap  ransom and extortion to recoup losses caused by ransomware viruses  
PCS provides estimates on a wide variety of insured losses  ranging from damages caused by hacks to hurricanes and wildfires ",2017-10-19,Reuters,https://www.investing.com/news/technology-news/merck-cyber-attack-may-cost-insurers-275-million-verisks-pcs-544383,544383
202967,424483,MRK,Merck to lay off 1 800 sales reps,news,STAT reports that Merck  MRK  will cut 1 800 jobs from its sales organization  expected to be completed in early January  The company notified employees yesterday FiercePharma reports that it is axing three sales teams and launching a new one focused on chronic care  A company spokesperson says   These changes are part of ongoing companywide efforts to sharpen Merck s focus on innovative R D that addresses significant unmet medical needs and on our best opportunities for growth  while reducing overall costs  Now read ,2017-10-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-to-lay-off-1800-sales-reps-545052,545052
202974,424490,MRK,4 Trade Ideas For Merck  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Merck  NYSE MRK    MRK  had a long move higher culminating in a top at the beginning of April  It pulled back hard and fast from there finding support at the 200 day SMA less than 3 weeks later  That was a drop of nearly 14   Since then it has recovered and moved up to the 50 day SMA  It stalled there and has been consolidating for the past 3 weeks 
Coming into the week it is curling up in consolidation with the Bollinger Bands  squeezed  It has a RSI on the verge of a move into the bullish zone with the MACD rising and about to cross to positive  There is resistance at 80 and 82 then 84  Support lower comes at 77 and 75 70 before 72 50  Short interest is low under 1   The dividend yield on the stock is nearly 2 8  and it started trading ex dividend last on March 14th  The company is expected to report earnings next on July 30th 
The May 31 Expiry options chain shows sizable open interest at the 80 call strike  Moving out to the June Expiry shows the biggest open interest at the 82 50 call followed by the 80 call and then the 75 put  In July the 82 50 call is also the largest open interest with 80 and 85 also big  Finally the August Expiry  the first to include the next earnings report  will be freshly opened this week 
Merck  Ticker   MRK

Trade Idea 1  Buy the stock on a move over 80 with a stop at 77 
Trade Idea 2  Buy the stock on a move over 80 and add a June 77 50 72 50 Put Spread   1 00  while selling the September 85 Call   1 00 credit  
Trade Idea 3  Buy the July September 82 50 Call Calendar   1 00  and sell the July 72 50 Puts  70 cent credit  
Trade Idea 4  Buy the July 72 50 80 82 50 Call Spread Risk Reversal for 20 cents 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which saw equities continued to experience some setbacks as the markets closed out May options expiration 
Elsewhere look for Gold to continue its pullback while Crude Oil resumes the uptrend  The US Dollar Index looks to drift higher while US Treasuries are also biased to the upside  The Shanghai Composite remains stuck in its pullback while Emerging Markets continue the downtrend 
Volatility looks to continue to moderate easing the pressure on the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts show intra week strength in the pullbacks of the SPY and QQQ with the IWM stuck in a range  All 3 look weaker on the daily charts  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2019-05-20,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-merck-bonus-idea-200422956,200422956
202980,424496,MRK,Refugees  health problems in Greece mostly unmet  medical charity,news,"By Karolina Tagaris  ATHENS  Reuters    Refugees and migrants in Greece receive little or no medical care for most health problems they face and fewer than half of those pregnant had access to maternal care  aid group Doctors of the World said on Tuesday  About 60 000 migrants and refugees are stranded in Greece  most in overcrowded camps with unsanitary conditions  More than half of this year s 20 000 arrivals were women and children  United Nations data shows   Doctors of the World interviewed over 14 000 women treated at its clinics in Greece over three years and found fewer than 47 percent had access to antenatal care before it intervened  It also found as many as 72 percent of the health problems refugees faced were treated  inadequately  or not at all   While most countries offer new arrivals some kind of medical screening  the quality was  questionable  and overlooked mental health problems  the charity said  Often  women did not seek medical care because they were unaware of their rights  they found the healthcare system too complex or they were afraid of being arrested or discriminated against  Limited resources and lack of access to services such as translators also posed practical obstacles   Every mother deserves good care before  during and post pregnancy  Their residential status should not affect this basic right   said Nikitas Kanakis  head of Doctors of the World Greece  The charity  together with Merck  NYSE MRK  Sharp   Dohme  MSD   is implementing a two year initiative aimed at providing maternal healthcare services to pregnant women and babies from vulnerable populations in Greece  Asylum seekers in Greece have free access to hospitals and medical care but the public health system  already battered by years of economic crisis  is struggling to cope with the numbers   Adult migrants without documents only have access to emergency care unless they are considered  vulnerable    Access to quality maternal healthcare can save lives  yet across Europe the most vulnerable pregnant women are still facing challenges in accessing this basic care   said Mary Ann Etiebet  director of MSD for Mothers   A lack of antenatal care to prevent and identify conditions that may harm the fetus or mother increases the risk of complications during childbirth or passing on diseases such as HIV or Hepatitis B  the World Health Organisation says  
 We must work together this address this issue before it escalates further   Etiebet said ",2017-10-03,Reuters,https://www.investing.com/news/world-news/refugees-health-problems-in-greece-mostly-unmet-medical-charity-536065,536065
202981,424497,MRK,What s In Store For Affimed  AFMD  This Earnings Season ,opinion,"Investors will likely focus on the progress of Affimed N V  s   NASDAQ AFMD   lead pipeline candidate  AFM13  on the company s first quarter earnings call In the last reported quarter  the company delivered a positive earnings surprise of 200 00   The company has a mixed track record  It beat estimates twice in the four trailing quarters while missing the same in one quarter and meeting once  delivering an average positive earnings surprise of 44 12  Notably  Affimed s shares have gained 13 9  so far this year compared with the  s increase of 3 3  Let s see how things are shaping up for this announcement Affimed is a Netherland based pharmaceutical company focused on developing novel therapies which engage the immune system to treat cancerous cells  The company has no marketed products and depends on collaboration for revenues The company is developing its immune cell engager  AFM13  as monotherapy or in combination with other agents for treating various types of lymphoma  A phase Ib IIa is evaluating AFM13 monotherapy for treating relapsed or refractory CD30 positive lymphoma  A phase Ib study is evaluating the candidate in combination with Merck s   NYSE MRK   Keytruda  pembrolizumab  as a treatment for Hodgkin lymphoma   HL   Apart from AFM13  the company is developing another immune cell engager  AFM11  in phase I studies  However  the studies are under clinical hold and Affimed has submitted data to the FDA in support of removal of the clinical hold  The company is also progressing with the investigational new drug application submission for the third immune cell engager  AFM24 Ongoing clinical studies on AFM 13 and regulatory response application for two other candidates will likely increase operating expense in the first quarter Affimed has a collaboration agreement with Genentech  a subsidiary of Roche   OTC RHHBY    for developing and commercializing NK cell engager based immunotherapeutics to treat multiple cancer indications  During the first quarter  the company achieved a certain preclinical milestone  triggering an undisclosed payment from Genentech  This may boost the top line in first quarter The company may provide update on the progress of pipeline candidates  especially AFM13  on the first quarter earnings call Earnings WhispersOur proven model does not conclusively show that Affimed is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Earnings ESP  Its Earnings ESP is 0 00   This is because the Most Accurate Estimate as well as the Zacks Consensus Estimate is pegged at a loss of 16 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Affimed s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings surprise Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing negative estimate revisions Affimed N V  Price and Consensus
    A Stock That Warrants a LookHere is a stock from the pharma segment that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat this quarter CannTrust Holdings Inc    NYSE CTST   is scheduled to release results on May 14  The company has an Earnings ESP of  6 25  and a Zacks Rank  3  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-05-12,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-affimed-afmd-this-earnings-season-200420760,200420760
202982,424498,MRK,Pfizer s Bavencio Inlyta Combo Gets FDA Nod For Kidney Cancer ,opinion,"Pfizer   NYSE PFE   and its German partner Merck KGaA announced that the FDA has approved their supplemental Biologics License Application  sBLA  for PD L1 inhibitor  Bavencio  avelumab   The sBLA was looking to get the label for Bavencio expanded for the first line treatment for advanced renal cell carcinoma   RCC    the most common form of kidney cancer  in combination with Pfizer s another cancer drug  Inlyta  axitinib  Please note that the decision came earlier than expected  It was originally expected in June  We remind investors that a similar label expansion regulatory application is  in Europe  It was validated for review by the European Medicines Agency in March Bavencio is presently approved for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma in patients whose disease progressed following chemotherapy while Inlyta is approved for second line treatment of advanced RCC Pfizer s stock has declined 6 9  so far this year compared with the  s decrease of 2 7  The approval was based on data from the phase III JAVELIN Renal 101 study  which evaluated the Bavencio Inlyta combination against Pfizer s older kidney cancer drug  Sutent  Data from the study  presented in the past  showed that the combination regimen led to statistically significant improvement in progression free survival in patients whose tumors had PD L1 expression greater than 1  as well as in the entire study population regardless of PD L1 tumor expression  The study is currently evaluating the regimen for improvement in overall survival While the RCC market holds immense potential  competition is stiff  Last month  the sBLA seeking approval for Merck s   NYSE MRK   Keytruda in combination with Inlyta for the first line treatment of patients with advanced RCC was approved by the FDA   Bristol Myers    NYSE BMY   Opdivo and Yervoy for the treatment of poor and intermediate risk first line RCC was also approved in the same month  Meanwhile  Exelixis    NASDAQ EXEL   Cabometyx is a dominant player in the market Currently  Bavencio is being developed for more than 15 types of tumors  including breast  gastric gastro esophageal junction  head and neck  Hodgkin s lymphoma  melanoma  mesothelioma  Merkel cell carcinoma  non small cell lung cancer  ovarian and urothelial carcinoma  These studies are part of the JAVELIN development program However  the drug failed in three ovarian cancer studies in the past year including the phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio with Pfizer s PARP inhibitor  Talzenna  talazoparib   which was  in March this year Pfizer Inc  Price
    Zacks RankPfizer currently carries a Zacks Rank  2  Buy   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-14,Zacks Investment Research,https://www.investing.com/analysis/pfizers-bavencioinlyta-combo-gets-fda-nod-for-kidney-cancer-200421645,200421645
202987,424503,MRK,FDA halts patient recruitment in three Opdivo combo studies in MM after safety signal observed related to Keytruda combo,news,Bristol Myers Squibb  NYSE BMY  announces that the FDA has placed a partial clinical hold suspending patient recruitment in three studies of Opdivo  nivolumab  combinations in multiple myeloma  CheckMate 602  CheckMate 039 and CA204142 The agency took action after determining that the risk of PD 1 PD L1 treatment  Merck s  NYSE MRK  KEYTRUDA  pembrolizumab    in combination with pomalidomide  Celgene  NASDAQ CELG  s POMALYST  or lenalidomide  Celgene s REVLIMID   and possibly PD 1 PD L1 treatment alone or with other combinations  may not be worth the risk The company says it plans to work with the FDA on the issue  Other studies assessing Opdivo in other indications will continue BMY is up 2  premarket on light volume on the successful outcome of CheckMate 214 Now read ,2017-09-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-halts-patient-recruitment-in-three-opdivo-combo-studies-in-mm-after-safety-signal-observed-related-to-keytruda-combo-526364,526364
202988,424504,MRK,FDA suspension of enrollment in PD 1 L1 studies ensnares Celgene s FUSION program,news,The FDA has instituted a partial clinical hold on five clinical trials in Celgene s  CELG  0 6   FUSION program assessing anti PD LI antibody IMFINZI  durvalumab  in a range of blood cancers  Partial clinical hold means that no new patients can be added to the studies  but those already enrolled can continue treatment  One trial has been placed on full clinical hold  meaning recruitment is suspended and treatment stopped for current participants The FDA took action after identifying risks in studies involving Merck  NYSE MRK  s PD 1 inhibitor KEYTRUDA  pembrolizumab  Celgene says it has not identified an imbalance in IMFINZI s risk profile Previously  FDA halts patient recruitment in three Opdivo combo studies in MM after safety signal observed related to Keytruda combo  Sept  7 Now read ,2017-09-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-suspension-of-enrollment-in-pd1l1-studies-ensnares-celgenes-fusion-program-526438,526438
202989,424505,MRK,Idera Pharma s IMO 2125 shows encouraging action in early stage melanoma study  shares ahead 15  premarket,news,"Idera Pharmaceuticals   NASDAQ IDRA  is up 15  premarket on increased volume in response to its announcement of positive data in a Phase 1 clinical trial assessing IMO 2125  combined with Bristol Myers Squibb s YERVOY  ipilimumab   in patients with treatment resistant melanoma  The data were presented at ESMO in Madrid 
The dose selection process involved 18 patients  17 of whom progressed after receiving Bristol Myers  OPDIVO  nivolumab  or Merck  NYSE MRK  s KEYTRUDA  pembrolizumab   Six of nine patients who received the recommended Phase 2 dose of 8 mg of IMO 2125 experienced disease control  including one complete responder and three partial responders 
The IMO 2125 YERVOY combination was tolerable at all doses studied 
The target number of patients has been expanded in the ongoing Phase 2 expansion to include patients who have received prior treatment with YERVOY 
A Phase 3 study in PD 1 refractory melanoma will commence in Q1 2018 
IMO 2125 is an agonist of endosomal Toll like receptor  TLR  9  a cell surface protein that plays a key role in pathogen recognition and innate immunity 
The company will host a webcast this morning at 9 00 am ET to discuss the results 
Previously  Idera s IMO 2125 an Orphan Drug in U S  for advanced melanoma  shares ahead 5  premarket  June 23 
Now read ",2017-09-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/idera-pharmas-imo2125-shows-encouraging-action-in-earlystage-melanoma-study-shares-ahead-15-premarket-527347,527347
202990,424506,MRK,Merck  MRK  Tops On Q1 Earnings   Sales  Stock Up,opinion,"New Jersey based Merck   Co  Inc    NYSE MRK   is a global research driven pharmaceutical products company  Well known products in Merck s portfolio include Remicade  Nasonex  Simponi  Vytorin and Zetia  Januvia and Janumet  Isentress  Emend  Keytruda  Cozaar Hyzaar  Zocor  ProQuad  Gardasil  Zostavax and others However  like many of its peers  Merck is facing headwinds in the form of generic competition for several key products Merck s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters is 3 13   Earnings estimates have increased slightly over the past 60 days Currently  Merck has a Zacks Rank  2  Buy   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Merck surpassed earnings expectations  The company reported EPS of  1 22 while our consensus called for EPS of  1 05  Earnings rose 16  year over year  up 18  excluding the impact of currency Revenues Beat  Revenues in the reported quarter also came above expectations  Merck posted revenues of  10 8 billion also above our consensus estimate of  10 32 billion Key Stats  The Pharmaceutical segment generated revenues of  9 66 billion  up 6   up 12  excluding Fx impact  year over year as higher sales in oncology and vaccines were offset by lower sales in virology Keytruda  the largest product in Merck s portfolio  brought sales of  2 27 billion in the quarter  up around 5 6  sequentially and 55  year over year 2019 Outlook  Merck raised earnings and sales guidance for 2019 Merck expects revenues to be in the range of  43 9 billion    45 1 billion  previously  43 2 billion    44 7 billion   The Zacks Consensus Estimate stood at  44 31 billion  Adjusted earnings are expected to be in the range of  4 67  4 79  previously  4 57  4 72   The Zacks Consensus Estimate stood at  4 65 per share  While revenue guidance includes slightly more than 1  negative impact of currency fluctuation  earnings guidance includes a slightly positive impact Stock Price Impact  Shares were up more than 2 2  in pre market trading Merck   Co   Inc  Price and EPS Surprise
    Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-30,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-tops-on-q1-earnings--sales-stock-up-200412815,200412815
202991,424507,MRK,ImmunoGen  IMGN  Misses On Earnings   Revenues In Q1,opinion,"ImmunoGen  Inc    NASDAQ IMGN   reported adjusted loss of 30 cents per share for the first quarter of 2019  wider than the Zacks Consensus Estimate of a loss of 28 cents  The bottom line remained flat year over year ImmunoGen s shares have significantly underperformed the  so far this year  The stock has declined 40  against the industry s increase of 11  RevenuesSince ImmunoGen has no approved product in its portfolio  the company earns revenues through royalties  license and milestone payments plus research and development  R D  support fees paid by its partners Revenues came in at  8 6 million in the quarter  missing the Zacks Consensus Estimate of  10 82 million  Revenues declined from the year ago quarter figure of  19 8 million as the first quarter of 2018 included  11 5 million in upfront and milestone payments  Revenues in the first quarter of 2019 included  9 7 million in non cash royalty revenues  Revenues from R D support and clinical materials were  0 4 million and  0 7 million  respectively Operating Expenses   Cash DetailsResearch and development expenses decreased almost 13 2  from the year ago level to  38 9 million due to lower costs related to clinical development of its lead pipeline candidate  mirvetuximab soravtansine  General and administrative  G A  expenses were up 8  to  10 8 million in the first quarter of 2019 ImmunoGen s cash and cash equivalents decreased to  270 4 million at the end of March 2019 compared with  262 3 million at the end of December 2018 Pipeline UpdateIn March  ImmunoGen faced a major setback as mirvetuximab soravtansine  in the late stage FORWARD I study  Data showed that treatment with the candidate did not achieve significant improvement in progression free survival  PFS  in the overall patient population as well FR alpha high patient subset Following the disappointing news  the company is analyzing data from the study for consistent efficacy signal across a range of parameters in the pre specified subset of ovarian cancer patients with high folate receptor alpha expression  The company plans to meet the FDA in the second quarter of 2019 to discuss the potential of registration for the candidateas a monotherapy ImmunoGen is currently enrolling patients in the phase Ib II FORWARD II study evaluating combination regimens with mirvetuximab soravtansine in ovarian cancer  The company has initiated enrollment in a study arm  which is evaluating the candidate in combination with Roche s   OTC RHHBY   Avastin for recurrent platinum resistant ovarian cancer in patients eligible for non platinum based regimen Previously  data showed that the candidate in combination with Merck s   NYSE MRK   Keytruda achieved encouraging anti tumor activity  especially in patients with medium or high FR  expression levels Apart from mirvetuximab soravtansine  ImmunoGen is working to develop a couple of other candidates in early stage studies including IMGN779  relapsed or refractory adult acute myeloid leukemia  and IMGN632  hematological malignancies including acute myeloidImmunoGen  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Key PickImmunoGen currently carries a Zacks Rank  2  Buy  Editas Medicine  Inc    NASDAQ EDIT   is another stock to consider from the pharmaceutical sector carrying a Zacks Rank  2  You can see  Editas  loss estimates have narrowed from  2 74 to  2 68 for 2019 and from  3 05 to  3 01 for 2020 over the past 60 days Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-05,Zacks Investment Research,https://www.investing.com/analysis/immunogen-imgn-misses-on-earnings--revenues-in-q1-200417508,200417508
203000,424516,MRK,FDA grants priority review for Genentech s Gazyva in previously untreated Follicular Lymphoma,news,Genentech  a member of the Roche Group  OTCQX RHHBY   announces that the FDA has       accepted the company s supplemental Biologics License Application  sBLA        and granted Priority Review for Gazyva  obinutuzumab  in       combination with chemotherapy followed by Gazyva alone for people with       previously untreated follicular lymphoma  The sBLA is based on results of the GALLIUM study  which is the first       Phase III study in previously untreated follicular lymphoma to show       superior progression free survival  NYSE PFS  over Rituxan  rituximab  based treatment  the current standard of care  Adverse       events  AEs  with either Gazyva or Rituxan were consistent with those       seen in previous studies  The FDA is expected to make a decision on approval under Priority Review       by December 23 Priority Review designation is granted to       medicines that the FDA has determined to have the potential to provide       significant improvements in the safety and effectiveness of the       treatment  prevention or diagnosis of a serious disease  Now read ,2017-08-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-grants-priority-review-for-genentechs-gazyva-in-previously-untreated-follicular-lymphoma-522963,522963
203001,424517,MRK,Clovis Focuses On Rubraca Label Expansion  Competition Stiff,opinion,"We issued an updated research report on Clovis Oncology  Inc    NASDAQ CLVS   on Apr 17  Shares of the company have increased 15 8  so far this year compared with the  s rise of 8 3  The commercial portfolio of Clovis consists of a single drug  Rubraca  which is approved as a maintenance treatment in recurrent ovarian cancer patients in second line setting  The drug is also approved for treating BRCA mutated ovarian cancer in third or later line setting  The company had in licensed Rubraca from Pfizer   NYSE PFE   in 2011 PARP inhibitor  Rubraca s sales increased sequentially in seven of the last eight reported quarters  The company s commercialization efforts including the awareness programs aided sales  Net revenues  entirely from Rubraca  were approximately  95 4 million for full year 2018  representing year over year growth of 71 8  Other PARP inhibitors approved for similar indications include Glaxo s   NYSE GSK   Zejula and Astrazeneca Merck s   NYSE MRK   Lynparza  Sales of these two drugs have been significantly higher than Rubraca in 2018  With strong balance sheet of these pharma bigwigs  competition is expected to rise as they can spend more on commercialization initiatives However  Clovis remains focused on label expansion of Rubraca and launch of the drug in newer countries to boost the prospect of the drug  The company has collaborated with Merck and Bristol Myers to develop Rubraca in combination with their PD 1  PDL1 inhibitors  Keytruda and Opdivo  respectively  Apart from ovarian cancer  Rubraca is also being evaluated as monotherapy or in combination for treating several cancer indications including prostate  breast and gastroesophageal cancers  among others Clovis is looking to file a regulatory application for label expansion in prostate cancer later this year  Please note that the expansion of Rubraca s label to include other cancer indications may also face stiff competition  In 2018  two PARP inhibitors were approved for treating breast cancer namely Lynparza and Pfizer s Talzenna  However  there are no approved PARP inhibitors for prostate cancer yet In April 2019  Clovis discontinued phase II ATLAS study evaluating Rubraca monotherapy for metastatic bladder cancer as preliminary data suggested that it was unlikely to provide a meaningful clinical benefit to patients  Such setbacks hurt the prospects of the company Apart from Rubraca  the company is developing another candidate  lucitanib  for treating breast and lung cancer We will have to wait and see if the sales recovery that started in the fourth quarter continues  Moreover  the rise in mergers and acquisitions so far this year may lead to a buyout offer from any large pharma companies looking to boost their oncology portfolio Clovis Oncology  Inc  Price
    Zacks RankClovis currently has a Zacks Rank  4  Sell  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/clovis-focuses-on-rubraca-label-expansion-competition-stiff-200408262,200408262
203008,424524,MRK,Gemphire s cholesterol med gemcabene successful in mid stage study but treatment effect less than previous trial  shares down 36  premarket,news,Thinly traded Gemphire Therapeutics  NASDAQ GEMP  craters 36  premarket  albeit on light volume  in response to its announcement of positive preliminary results from a Phase 2b clinical trial  ROYAL 1  assessing the ability of once daily oral gemcabene for lowering low density lipoprotein cholesterol  LDL C  in patients not adequately controlled with statins and or ezetimibe  Merck  NYSE MRK  s Zetia  Patients receiving 600 mg of gemcabene experienced an average reduction in LDL C of 17 2  compared to 5 5  for placebo  p 0 0057   achieving the primary endpoint Investors appear concerned  however  that the treatment effect  while positive  was less than COBALT 1  reported in June  In this study  patients receiving the same 600 mg dose experienced a mean LDL C reduction of 30   p 0 047  Previously  Gemphire s gemcabene successful in mid stage HoFH study  shares up 10  after hours  June 28 Now read ,2017-08-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/gemphires-cholesterol-med-gemcabene-successful-in-midstage-study-but-treatment-effect-less-than-previous-trial-shares-down-36-premarket-515302,515302
203009,424525,MRK,Esperion s bempedoic acid successful in mid stage study  shares ahead 16  premarket,news,Esperion Therapeutics  NASDAQ ESPR  is up 16  premarket on average volume in response to its announcement of positive results from a Phase 2 clinical trial evaluating bempedoic acid as a component of triplet oral therapy in patients with high cholesterol  hypercholesterolemia  The study met its primary endpoint of demonstrating a statistically valid treatment effect compared to placebo  Specifically  patients receiving the triplet therapy of bempedoic acid ezetimibe  Merck  NYSE MRK  s Zetia  plus atorvastatin   Pfizer   NYSE PFE  s Lipitor  experienced a 64  lowering of LDL C from baseline compared to control 90  of the treatment group achieved LDL C levels less than 70 mg dL  optimal range  100   129 mg dL  The combination was safe and well tolerated The company expects to file two NDAs for LDL C lowering indications for the bempedoic acid ezetimibe combo pill and bempedoic acid by Q1 2019 Now read ,2017-08-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/esperions-bempedoic-acid-successful-in-midstage-study-shares-ahead-16-premarket-515855,515855
203010,424526,MRK,Trump yields to pressure  calls neo Nazis and KKK criminals,news,"By Scott Malone and Jeff Mason CHARLOTTESVILLE  Va  WASHINGTON  Reuters    U S  President Donald Trump denounced neo Nazis and the Ku Klux Klan as criminals and thugs on Monday  bowing to mounting political pressure to condemn such groups explicitly after a white nationalist rally turned deadly in Virginia  Trump had been assailed from across the political spectrum for failing to respond more forcefully to Saturday s violence in Charlottesville  The head of one of the world s biggest drug companies quit a presidential business panel as a result  saying he was taking a stand against intolerance and extremism  Critics slammed Trump for waiting too long to address the bloodshed  and for initially denouncing hatred and violence  on many sides   rather than singling out the white supremacists widely seen as instigating the melee  Democrats said Trump s reaction belied a reluctance to alienate white nationalists and  alt right  political activists who occupy a loyal segment of Trump s political base  Several senators from his own Republican Party had harsh words for him  Some 48 hours into the biggest domestic challenge of his young presidency  Trump tried to correct course   Racism is evil  and those who cause violence in its name are criminals and thugs  including the KKK  neo Nazis  white supremacists and other hate groups that are repugnant to everything we hold dear as Americans   the president said in a statement to reporters at the White House on Monday   We condemn in the strongest possible terms this egregious display of hatred  bigotry and violence   he said  A 20 year old man said to have harbored Nazi sympathies was arrested on charges of plowing his car into protesters opposing the white nationalists  killing 32 year old paralegal Heather Heyer and injuring 19 other people  The accused  James Fields  was denied bail at a court hearing on Monday  Trump said anyone who engaged in criminal behavior at the rally would face justice  the Republican president said   I wish that he would have said those same words on Saturday   responded Democratic Senator Mark Warner of Virginia on MSNBC   I m disappointed it took him a couple of days   A group of local community leaders meeting in Charlottesville likewise said they were unimpressed by Trump s latest message   Why did it take criticism from his Republican buddies to move him     to adjust the moral compass that he does not possess   said Don Gathers  who serves as chairman for the city s commission on monuments and memorials   Trump lashed out at his critics again later on Monday on Twitter   Made additional remarks on Charlottesville and realize once again that the  Fake News Media will never be satisfied   truly bad people    As the chorus of outrage over Virginia grew louder on Sunday  Trump stayed silent on the matter while at his golf course in Bedminster  New Jersey  Early Monday  he took to Twitter   his preferred method of communication   to attack Democrats over trade deals and to endorse a political candidate in Alabama  but said nothing about white supremacists   In a strong rebuke to Trump early on Monday  the black chief executive of Merck  NYSE MRK    Co Inc  Kenneth Frazier  resigned from a business panel led by the president  saying expressions of hatred and bigotry must be rejected  Trump quickly hit back on Twitter  but made no reference to Frazier s reasons for quitting the panel  instead revisiting a longstanding gripe about expensive medicines  Frazier would now have more time to focus on lowering  ripoff  drug prices  Trump tweeted  GLOBAL REACTION  The jarring images of violence from Charlottesville and the heated public debate over racism resonated around the world  particularly in Europe where leaders are contending with a wave of xenophobia   German Chancellor Angela Merkel told local broadcaster Phoenix on Monday that clear and forceful action must be taken to counter right wing extremism  and that  we have quite a lot to do at home ourselves   About 130 people demonstrated outside the U S  Embassy in London  some with placards reading  Fascism is not to be debated  it is to be smashed   and  I am an ashamed American   The United Nations said there must be no place in today s societies for the violent racism  anti Semitism  xenophobia and discrimination on display in Charlottesville  About 200 protesters assembled in front of the White House for a  Reject White Supremacy  rally  then marched to Trump s hotel on Pennsylvania Avenue nearby  In Manhattan  thousands of demonstrators stood outside Trump Tower on Fifth Avenue shouting  No Trump  no KKK  no fascist USA   Saturday s disturbances broke out after white nationalists converged to protest at plans to remove a statue of Confederate General Robert E  Lee  Such monuments are viewed today by many Americans as symbols of racism  because of the Confederate defense of slavery during the Civil War  Asked on Monday whether one side was more responsible for the violence than another  Charlottesville police chief Al Thomas said   This was an alt right rally     using the term to describe a loose grouping that rejects mainstream politics and includes neo Nazis  white supremacists and anti Semites   Mounting anger over Trump s response to events in Charlottesville added to a litany of problems for the president   His inflammatory rhetoric toward North Korea s nuclear ambitions rattled Americans and U S  allies even as he publicly fumed at fellow Republicans in Congress over their failure to notch up any major legislative wins during his first six months in office  The mother of the woman killed on Saturday welcomed Trump s latest comments  In a statement cited by NBC News  Susan Bro thanked him for what she called  those words of comfort and for denouncing those who promote violence and hatred   Fields appeared in a Charlottesville court on Monday by video link from the jail where he was being held on a second degree murder charge  three counts of malicious wounding and a single count of leaving the scene of a fatal accident  His next court date was set for Aug  25  Several students who attended high school with Fields in Kentucky described him as an angry young man who passionately espoused white supremacist ideology  The U S  Justice Department was pressing its own federal investigation of the incident as a hate crime  Also on Monday  in what critics decried as an official endorsement of racism  Trump told Fox News he is considering pardoning Joe Arpaio  the former Arizona sheriff found guilty last month of criminal contempt for violating the terms of a 2011 court order in a racial profiling case  
Arpaio styled himself  America s toughest sheriff  for his tough treatment of inmates and crackdown on illegal immigrants ",2017-08-14,Reuters,https://www.investing.com/news/politics-news/trump-yields-to-pressure-calls-neonazis-and-kkk-criminals-518077,518077
203011,424527,MRK,Top 5 things to know in the market on Tuesday,news,"Investing com   Here are the top five things you need to know in financial markets on Tuesday  August 15 
1  Dollar continues to move higher as geopolitical tensions ease
Market sentiment improved after North Korea said on Tuesday it had delayed a decision on a plan to fire missiles at the U S  Pacific territory of Guam while it watches U S  actions a little longer 
At the same time  South Korean President Moon Jae in said there will be no military action upon the Korean peninsula without Seoul s consent and that the government would prevent war by all means 
Market participants were looking ahead to U S  retail sales data  to be released at 8 30 a m  ET  12 30 a m  GMT  for further indications on the strength of the economy after disappointing inflation figures on Friday dampened expectations for another rate hike by the Federal Reserve this year 
The greenback found some support after New York Fed President William Dudley said on Monday that he favored another interest rate hike this year if the economic conditions evolved in line with his expectations 
The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  was up 0 27  at 93 58  the highest since August 10  at 6 a m  ET  10 00 a m  GMT  
2  Oil prices stabilize after falling to fresh 3 week lows
Oil prices stabilized after plumbing fresh three week lows earlier as a stronger U S  dollar and concerns over a global supply glut continued to weigh 
Concerns over slowing demand from China  the world s second largest oil consumer  pressured prices lower  A report on Monday pointed to a drop in crude demand from Chinese refiners in July 
Oil prices remain vulnerable to bearish sentiment  with traders assessing supply and demand figures to determine how close the oil market is to rebalancing 
The American Petroleum Institute was to release its latest U S  inventories report later Tuesday  ahead of official storage figures from the U S  Energy Information Administration on Wednesday 
U S  crude oil Futures were at  47 48  while Brent oil was last at  50 61 
3  German economy grows less than expected
German gross domestic product rose 0 6  in the second quarter  Germany s Federal Statistical Office said  disappointing expectations for an increase of 0 7  
Year over year  Germany s economy grew 0 8  in the last quarter  less than the expected growth rate of 1 9  
The Statistical Office noted an increase in fixed capital formation in machinery and equipment  in construction and in other fixed assets compared with the first quarter of 2017 
The weak data fueled concerns over the strength of the euro zone s biggest economy and sent the euro lower  EUR USD was down 0 23  at 1 1753 at 6 a m  ET  10 00 a m  GMT  
4  Pound slumps as UK inflation holds steady in July
Sterling slumped to 5 week lows against the U S  dollar after data showing that Britain s annual inflation rate unexpectedly held steady in July underlined the case for the Bank of England to keep interest rates on hold 
GBP USD fell to lows of 1 2899  the weakest since July 13  while EUR GBP advanced 0 24  to 0 9110 
Consumer prices rose 2 6  compared with a year earlier  the Office for National Statistics said  slightly below economists  expectations for a 2 7  annual rise 
Falling motor fuel prices were offset by higher prices for clothes  utilities and food  the ONS said 
In its latest assessment of the economy released last week  the BoE said it expected inflation to peak at 3  in October 
5  Markets rebound from recent losses in risk on trade
European stocks opened higher on Tuesday  as tensions between the U S  and North Korea continued to subside  lending support to riskier assets 
 Danone  SA  PA DANO  was one of the top performers on France s CAC 40  following reports Corvex Management now owns a stake of about  400 million in the company and as rumors surfaced of a possible takeover 
At 6 a m  ET  10 00 a m  GMT   the EURO STOXX 50 was up 0 23   France s CAC 40 gained 0 44   while Germany s DAX 30 added 0 31  
In the U S   equity markets pointed to a higher open on Tuesday  The Dow Jones Industrial Average futures pointed to a 0 20  rise  S P 500 futures signaled a 0 16  gain  while the Nasdaq 100 futures indicated a 0 23  increase 
Merck  NYSE MRK    Co  was expected to be in focus  after CEO Ken Frazier made headlines on Monday when he resigned from the president s American Manufacturing Council  citing a  responsibility to take a stand against intolerance and extremism  
The move came after President Donald Trump was seen to equivocate about the violent protest by white supremacists in Charlottesville  Virginia  over the weekend that killed a 32 year old woman and injured 19 other people ",2017-08-15,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-know-in-the-market-on-tuesday-518597,518597
203012,424528,MRK,AstraZeneca Merck s Lynparza Wins EU Nod For Breast Cancer,opinion,AstraZeneca plc   NYSE AZN   and partner Merck   NYSE MRK   announced that the European Commission has approved their PARP inhibitor  Lynparza  olaparib  as a monotherapy  for a new patient population suffering germline BRCA mutated HER2 negative locally advanced metastatic breast cancer  previously treated with chemotherapy  The drug is already marketed in the United States for the breast cancer indication Lynparza is also presently marketed for advanced ovarian cancer in the United States  the EU and across several other countries  With this latest nod in the EU  Lynparza can now be used to treat breast cancer patients  previously treated with an anthracycline and a taxane or who have progressed after being treated with endocrine therapy or are considered unsuitable for endocrine therapy This nod makes Lynparza the first approved PARP inhibitor for treating metastatic breast cancer in Europe The approval was based on data from the phase III OlympiAD study  which evaluated Lynparza against chemotherapy  Results from the program showed that patients treated with Lynparza achieved an objective response rate  ORR  of 52  while the progression free survival  PFS  was 7 months compared with 23   ORR  and 4 2 months  PFS   attained by the chemotherapy arm  respectively  Moreover  Lynparza reduced the risk of disease progression or death by 42  as compared to chemotherapy Shares of AstraZeneca have increased 7 1  in the year so far  outperforming the  rise of 3 9  Other PARP inhibitors available in the market are Tesaro s Zejula and Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  Notably  Tesaro is now part of GlaxoSmithKline   NYSE GSK    However  both medicines are not approved for breast cancer Lynpazra is a key new product in AstraZeneca s oncology portfolio alongside Tagrisso and Imfinzi  The drug delivered sales of  647 million in 2018  up 116  at constant exchange rate on its expanded use for ovarian cancer and the label expansion in breast cancer The approval of Lynparza last December as a first line treatment of patients with BRCAm ovarian cancer in the United States and the drug s latest label expansion in the EU is expected to support its further widespread application in 2019 and drive sales higher Zacks Rank AstraZeneca currently carries a Zacks Rank  2  Buy   You can see Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/astrazenecamercks-lynparza-wins-eu-nod-for-breast-cancer-200405590,200405590
203023,424539,MRK,Merck profit beats as Keytruda sales soar  expenses drop,news," Reuters    Merck   Co Inc s  N MRK  quarterly profit blew past analysts  estimates on Friday as demand surged for its key immuno oncology drug  Keytruda  and the company reined in expenses  The company s shares were up 1 3 percent at  64 50 in premarket trading  Sales of Keytruda  which works by taking the brakes off the immune system  nearly tripled to  881 million in the second quarter  handily beating consensus estimates of  777 million  according to  Barclays   LON BARC   First approved in 2014 to treat melanoma  Keytruda has since won approvals to treat lung as well as head and neck cancer and is being tested against other cancers  The drugmaker s position as the market leader in previously untreated lung cancer was bolstered on Thursday after AstraZeneca Plc  L AZN  said its combination of two injectable immunotherapies failed to help patients as hoped in a closely watched advanced lung cancer trial  Merck said on Friday it does not yet know the magnitude of the impact of a hacking in June and was restoring its manufacturing operations  The drugmaker narrowed and raised its full year revenue forecast to a range of  39 4 billion to  40 4 billion  reflecting the company s efforts to restore operations   Merck also reduced its full year profit forecast to between  1 60 per share and  1 72 per share due to the inclusion of licensing expenses related to its deal with AstraZeneca  The company on Thursday agreed to pay AstraZeneca up to  8 5 billion under an oncology collaboration agreement to study cancer drug combinations using the British drugmaker s ovarian cancer drug  Lynparza  Merck maintained its full year adjusted profit forecast  Net income attributable to Merck rose to  1 95 billion  or 71 cents per share  in the second quarter  from  1 21 billion  or 43 cents per share  a year earlier  Research and development expenses fell about 19 percent to  1 75 billion  Excluding items  Merck earned  1 01 per share  above analysts  average estimate of 87 cents  according to Thomson Reuters I B E S  Sales inched up about 1 percent to  9 93 billion  largely due to loss of market exclusivity for several products and lower sales of its diabetes drugs   
Analysts on average had expected  9 75 billion ",2017-07-28,Reuters,https://www.investing.com/news/stock-market-news/merck-profit-soars-61.5-percent-as-keytruda-sales-surge-511584,511584
203024,424540,MRK,Fitch downgrades AstraZeneca to A  with negative outlook,news,Credit rater Fitch slaps AstraZeneca  AZN  0 4   with a downgrade to A  with a negative outlook citing increasing business risk as the pharmaceuticals group transitions to next generation drugs Source  BloombergPreviously  AstraZeneca down 15  premarket on failed late stage study on lung cancer candidate durvalumab  Merck  NYSE MRK  up 5  on improved prospects for Keytruda  July 27 Now read ,2017-08-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/fitch-downgrades-astrazeneca-to-a-with-negative-outlook-512972,512972
203025,424541,MRK,Advaxis Up On Positive Early Stage Immunotherapy Study Data,opinion,"Advaxis  Inc    NASDAQ ADXS   announced encouraging updated data from its ongoing phase I II study   KEYNOTE 046   evaluating its pipeline candidate  ADXS PSA  in combination with Merck s   NYSE MRK   stellar drug  Keytruda  in heavily pre treated patients with metastatic  castration resistant prostate cancer  mCRPC  Data showed that efficacy achieved by the combination therapy compares favorably with current standard of care and results from studies in patient populations with bone predominant disease  These factors support further evaluation of the combination therapy Data from the study was also presented at the American Association for Cancer Research   AACR   Annual Meeting Investors cheered the data as shares of the company rallied 10 2  on Apr 1  The company s shares have gained 128 5  so far this year compared with the  s increase of 12 5   The KEYNOTE 046 is an open label study  which is being conducted in two parts  one part evaluating ADXS PSA monotherapy and another evaluating it in combination with Keytruda  for safety  tolerability and dosing Median overall survival was 21 1 months in the combination arm at the data cut off date  Feb 1   Broader immune stimulation was observed in the combination arm compared to the monotherapy arm  T cell responses and antigen spreading was observed in 75  and 85  of patients in the study  respectively  Moreover  combination therapy was well tolerated in the patient population ADXS PSA is a Listeria monocytogenes  Lm  based immunotherapy  which delivers antigens to cancerous cells and generate immune response  On the other hand  Keytruda is an anti PD 1 therapy that inhibits cancer cells  ability to stop body s immune response  A combination of these therapies holds potential as it may generate better immune response and is likely to target and kill cancer cells more effectively  However  further evaluation in advanced stages of development will establish the efficacy and safety of the combination therapy   ADXS PSA plus Keytruda   which is likely to take a few more years Meanwhile  several other biotech pharma companies are developing their pipeline candidates  based on different mechanisms  for treating mCRPC  These include Clovis Oncology   NASDAQ CLVS   and AstraZeneca s   NYSE AZN   PARP inhibitors   Rubraca and Lynparza   respectively as well as Novartis  radioligand candidate  177Lu PSMA 617 Apart from ADXS PSA  Advaxis also has three other pipeline candidates  ADXS HPV for cervical cancer  ADXS NEO for multiple cancers  ADXS 503 for non small cell lung cancer  in different stages of clinical development Advaxis  Inc  Price
    Zacks RankAdvaxis currently sports a Zacks Rank  1  Strong Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/advaxis-up-on-positive-earlystage-immunotherapy-study-data-200403257,200403257
203026,424542,MRK,Exelixis  EXEL  Rallies 22 4  YTD  What To Expect Ahead ,opinion,"Shares of Exelixis  Inc    NASDAQ EXEL   have rallied 22 4  in the year so far  outperforming 14 6  growth registered by the  

 
The company received a major boost with the approval of a tablet formulation of cabozantinib  Cabometyx  which was approved in the United States in April 2016 for the treatment of patients with advanced renal cell carcinoma  RCC   who have received prior anti angiogenic therapy 
Since the drug is now approved for first line RCC as well  Exelixis can now target the entire patient population suffering from the disease in the United States  Cabometyx continues to maintain its market leading position in RCC  The drug held 34  market share at the end of the fourth quarter  driven by its broad label for advanced RCC and the recent NCCN update as the preferred TKI for the majority of both previously untreated and refractory RCC patients  The company experienced a 10  increase in Cabometyx s prescriber base compared with that in the third quarter 
Exelixis is evaluating cabozantinib in a broad development program  comprising more than 45 clinical studies across multiple indications  In January 2019  the FDA also approved Cabometyx for hepatocellular carcinoma  HCC   Per estimates  more than 40 000 patients are diagnosed with liver cancer  resulting in approximately 29 000 deaths each year in the United States  Sales should get a boost from this label expansion  given the market potential 
Exelixis also has collaboration agreements with Bristol Myers Squibb   NYSE BMY   and Roche   OTC RHHBY   to evaluate cabozantinib in combination with immunotherapy agents 
While the RCC market holds immense potential  competition is stiff  The approval of Opdivo and Yervoy for the treatment of poor and intermediate risk first line RCC has increased competition for Cabometyx 
The FDA recently granted priority review to Merck s   NYSE MRK   sBLA for Keytruda in combination with Inlyta for the first line treatment of patients with advanced RCC  based on the results of KEYNOTE 426  The agency has set a target action date of Jun 20  2019 
Hence  we expect investors to focus on Cabometyx s performance in 2019  which is expected to be backed by a broad label 
Zacks Rank
Exelixis currently carries a Zacks Rank  3  Hold   You can see  
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-05,Zacks Investment Research,https://www.investing.com/analysis/exelixis-exel-rallies-224-ytd-what-to-expect-ahead-200404432,200404432
203033,424549,MRK,Trump unveils companies   500 million U S  drug packaging project,news,"WASHINGTON  Reuters    President Donald Trump on Thursday announced a  500 million investment that Corning Inc is making with pharmaceutical giants Merck  NYSE MRK  and  Pfizer   NYSE PFE  to manufacture a new kind of glass for injectable drug vials  At a White House event  Trump said the effort will create nearly 1 000 jobs at facilities in New York and New Jersey and at a soon to be determined site in the southeastern United States  The deal could eventually result in a total investment of  4 billion and create around 4 000 jobs  Trump said  joined by the CEOs of Corning  Merck and Pfizer  The commitments were made as part of Trump s  Made in America  week  during which he has showcased American made products and made an impassioned defense of his  America First  policies  Corning said it developed the new type of glass in collaboration with the drugmakers   This initiative will bring a key industry to our shores that for too long has been dominated by foreign countries  We re moving more and more companies back into the United States   Trump said  
After the remarks  Trump tested the strength of the new Corning Valor Vial  Pressing down on an old vial in a vise like machine  he easily broke it but struggled to break one of the new vials despite putting far greater effort into it ",2017-07-21,Reuters,https://www.investing.com/news/politics-news/corning-vows-new-jobs-as-part-of-trump's-'made-in-america'-week-508072,508072
203034,424550,MRK,Merck launches RENFLEXIS  a biosimilar of Remicade in U S ,news,Merck  NYSE MRK  announces the U S  launch of RENFLEXIS  infliximab abda   a       biosimilar to J J s Remicade  infliximab         RENFLEXIS was approved by the FDA on       April 21 for all eligible indications RENFLEXIS is the first medicine       available in the U S  under a global biosimilars development and       commercialization agreement between Merck and Samsung  KS 005930  Bioepis Co   Ltd  RENFLEXIS will be introduced in the U S  at a list price of  753 39  a 35  discount to the       current list price of Remicade  Now read ,2017-07-24,Seeking Alpha,"https://www.investing.com/news/stock-market-news/merck-launches-renflexis,-a-biosimilar-of-remicade-in-u.s.-509068",509068
203035,424551,MRK,AcelRx Pharma poised to continue up move  shares ahead 7  premarket,news,Micro cap  AcelRx Pharmaceuticals   NASDAQ ACRX  is up 7  premarket on increased volume  Shares have almost doubled since early July  No particular company news accounts for the action  although Jefferies did its part by initiating coverage on the 14th with a Buy rating and  7 price target The company s U S  marketing application for pain med DSUVIA is currently under FDA review with an action date of October 12 It is due to report Q2 results after the close on Wednesday  August 2  Consensus view is a loss share of   0 28  on revenue of  2 3M Now read ,2017-07-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/acelrx-pharma-poised-to-continue-up-move;-shares-ahead-7-premarket-509623,509623
203036,424552,MRK,European stocks open higher  oil rally supports  Dax up 0 09 ,news,"Investing com   European stocks opened higher on Wednesday  helped by gains in the energy sector due to a rally in oil prices  while investors awaited the Federal Reserve s policy decision due later in the day 
During European morning trade  the EURO STOXX 50 rose 0 24   France s CAC 40 gained 0 45   while Germany s DAX 30 eased up 0 09  
Investors were hoping that the Fed s rate statement  due later Wednesday  will reveal more about policy plans for the second half of the year  with markets paying close attention to details of when and how the Fed will start reducing its  4 5 trillion balance sheet 
Investors also remained focused on the investigation into alleged links between U S  President Donald Trump s administration and Russia in last year s election 
A rally in oil prices pushed energy related stocks higher on Wednesday  Shares in French oil and gas major  Total  SA  PA TOTF  gained 0 31  and Italy s  ENI   MI ENI  advanced 0 83   while Spanish rival Repsol  MC REP  climbed 0 65  
Financial stocks were mixed  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  gained 0 51  and 0 63   while  Deutsche Bank   DE DBKGn  advanced 0 83  and Commerzbank  DE CBKG  slipped 0 14  in Germany 
Among peripheral lenders   Intesa Sanpaolo   MI ISP  rose 0 21  and Unicredit  MI CRDI  declined 0 59  in Italy  while Spanish banks  Banco Santander   MC SAN  and BBVA  MC BBVA  added 0 15  and 0 33  
Elsewhere  Merck  NYSE MRK    Company Inc  MU MRK  shares plummeted 2 21  after the drugmaker said Keytruda   a type of immuno oncology  IO  drug known as a checkpoint inhibitor   failed to extend survival in previously treated patients with advanced head and neck cancer compared to the standard treatment 
On the upside  Volkswagen  DE VOWG p  saw shares rally 1 99  despite news Oliver Schmidt  former head of US environmental compliance at tbe company  plans to plead guilty for his role in the carmaker s conspiracy to cheat on emissions tests 
In London  FTSE 100 climbed 0 45   boosted by  ITV   LON ITV   whose shares surged 2 50  even after the TV giant reported lower earnings for the first half of the year  weighed by a decline at the ITV Studios production arm and a drop in advertising revenue 
Mining stocks added to gains on the commodity heavy index  Shares in  Glencore   LON GLEN  rose 0 41  and BHP Billiton  LON BLT  climbed 0 63   while  Rio Tinto   LON RIO  advanced 0 88  
In the financial sector  stocks were mixed  The Royal Bank of Scotland  LON RBS  gained 0 66  and  Barclays   LON BARC  jumped 1 02   while  HSBC Holdings   LON HSBA  slipped 0 25  and Lloyds Banking  LON LLOY  dropped 0 81  
Meanwhile   Sage Group   LON SGE  saw shares dive 5 14  after the software company Sage Group agreed to purchase Intacct  a 19 year old accounting software company  for  850 million 
In the U S   equity markets pointed to a steady open  The Dow Jones Industrial Average futures pointed to a 0 06  gain  S P 500 futures signaled a 0 06  uptick  while the Nasdaq 100 futures indicated a flat open ",2017-07-26,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-open-higher,-oil-rally-supports;-dax-up-0.09-510035",510035
203037,424553,MRK,European stocks open mixed with earnings in focus  Dax down 0 22 ,news,"Investing com   European stocks opened mixed on Thursday  as investors were still digesting the Federal Reserve s latest policy decision amid a fresh batch of corporate earnings 
During European morning trade  the EURO STOXX 50 gained 0 42   France s CAC 40 advanced 0 45   while Germany s DAX 30 slipped 0 22  
At the conclusion of its two day policy meeting on Wednesday  the Fed left interest rates unchanged at 1 25  in a widely expected move 
The central bank also said it planned to start shrinking its balance sheet  relatively soon  and noted weakness in U S  inflation  sparking doubts over the possibility of a third rate hike this year 
Financial stocks were mixed  as French lenders  Societe Generale   PA SOGN  and  BNP Paribas   PA BNPP  lost 0 03  and 0 41   while  Deutsche Bank   DE DBKGn  plummeted 2 59  and Commerzbank  DE CBKG  rose 0 20  in Germany 
Deutsche Bank reported on Thursday an unexpected surge in profits for the second quarter of 2017  doubling its pre tax profit figure from last year  However  CEO Jon Cryan said revenues were  not as universally strong as we would have liked  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  and Unicredit  MI CRDI  gained 0 30  and 0 47  respectively  while Spanish banks  Banco Santander   MC SAN  and BBVA  MC BBVA  dropped 0 57  and 0 81  
Elsewhere   Bayer AG   DE BAYGN  lost 2 33  after reporting an 11  drop in net profit for the second quarter and lowering its guidance for the full year  The German drugmaker is currently in the process of taking over U S  firm  Monsanto   NYSE MON  
In London  FTSE 100 slipped 0 16   weighed by  Astrazeneca   LON AZN   whose shares dove 16 59  after the pharmaceutical company s crucial combination trial of durvalumab  Imfinzi  and tremelimumab failed the primary endpoint on progression free survival as a first line therapy for non small cell lung cancer 
Shortly after the news  the U K  group said it had signed a  8 4 billion development and commercialization partnership with Merck  NYSE MRK  for two promising drugs 
Financial stocks added to losses  as the Royal Bank of Scotland  LON RBS  slid 0 31  and  HSBC Holdings   LON HSBA  declined 0 40   while Lloyds Banking  LON LLOY  tumbled 1 35    Barclays   LON BARC  shares were flat 
Meanwhile   Diageo   LON DGE  Plc was one of the top performers on the index  with shares up 5 19  after the company posted higher than expected full year sales and profits  adding that productivity initiatives beat expectations 
Mining stocks were also broadly higher on the commodity heavy index  Shares in  Rio Tinto   LON RIO  climbed 0 43  and BHP Billiton  LON BLT  advanced 0 58   while  Randgold Resources   LON RRS  jumped 1 81  and  Anglo American   LON AAL  surged 3 10  
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 18  gain  S P 500 futures signaled a 0 25  rise  while the Nasdaq 100 futures indicated a 0 58  climb ",2017-07-27,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-open-mixed-with-earnings-in-focus;-dax-down-0.22-510723,510723
203038,424554,MRK,AstraZeneca s Lynparza deal with Merck stokes fellow PARP developer Clovis  shares ahead 6 ,news,Buying has ticked up in  Clovis Oncology   CLVS  6    Shares are up on modestly higher volume on the heels of AstraZeneca s deal with Merck  NYSE MRK  to develop and commercialize the combination of PARP inhibitor LYNPARZA  olaparib  and KEYTRUDA  pembrolizumab   Investors perceive the potential for expanding the clinical reach of AZN s product bodes well for Clovis s PARP inhibitor Rubraca  rucaparib  Celgene  NASDAQ CELG  has added credibility to the potential opportunity with its comments earlier today that it is interested in pursuing a PARP combo with its new PD 1 asset  BGB A317  licensed from  BeiGene   BGNE  2 8   Previously  AstraZeneca teams up with Merck to co develop co commercialize cancer med Lynparza  July 27 Previously  BeiGene initiates trial of PD 1 antibody BGB A317 in China in patients with UC  July 5 Previously  FDA OKs Clovis  rucaparib for ovarian cancer  shares up 15   Dec  19  2016 Now read ,2017-07-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/astrazeneca's-lynparza-deal-with-merck-stokes-fellow-parp-developer-clovis;-shares-ahead-6-511117,511117
203039,424555,MRK,Pfizer Merck KGaA End Bavencio Talzenna Ovarian Cancer Study,opinion,Pfizer  Inc    NYSE PFE   and partner Merck KGaA  announced the discontinuation of a late stage study evaluating a combination of its PD L1 inhibitor  Bavencio and its new PARP inhibitor  Talzenna  talazoparib  for first line ovarian cancer The phase III JAVELIN Ovarian PARP 100 study  n 998  evaluated Bavencio  avelumab    chemotherapy followed by a maintenance treatment of avelumab   Talzenna versus an active comparator for previously untreated advanced ovarian cancerThis is the third avelumab ovarian cancer study failure for Pfizer Merck KGaA in less than six months  In December  a phase III JAVELIN Ovarian 100 study  evaluating Bavencio in combination with and or following platinum based chemotherapy in previously untreated patients with advanced ovarian cancer  was discontinued  Data from a planned interim analysis showed that the study will not achieve superiority in the pre specified primary endpoint of progression free survival  PFS   In November  a late stage study  evaluating avelumab   chemotherapy in a difficult to treat advanced ovarian cancer patient population failed to meet the primary endpoints of showing superior overall survival  OS  and PFS The companies said several factors led to the decision to end the JAVELIN Ovarian PARP 100 study  which did not include safety reasons  First  the degree of benefit observed with avelumab in frontline ovarian cancer in the JAVELIN Ovarian 100 study did not support continuation of the JAVELIN Ovarian PARP 100 study  the companies said or for that matter evaluating an immunotherapy in ovarian cancer itself  Also  the approval of AstraZeneca Merck s PARP inhibitor  Lynparza in the first line maintenance setting for ovarian cancer in December last year has raised competitive pressure in the PARP inhibitor market  Lynparza is the first and only PARP inhibitor approved in the first line maintenance setting for ovarian cancer  This also induced Pfizer and Merck KGaA s decision to end the JAVELIN Ovarian PARP 100 study Other PARP inhibitors available in the market are Tesaro s  now a part of GlaxoSmithKline  Zejula and Clovis Oncology  Inc  s Rubraca  Zejula and Rubraca are also being evaluated in late stage studies in the first line maintenance setting in ovarian cancer patients Shares of Pfizer have declined 3 1  so far this year against the  s 3 7  increase   Bavencio is marketed for metastatic Merkel cell carcinoma in the United States  Europe and Japan and for the second line treatment of locally advanced or metastatic urothelial carcinoma in the United States  Though Bavencio is a relatively new drug in Pfizer s oncology portfolio and is currently approved for two relatively smaller indications  it might emerge as a key long term growth driver for Pfizer on future label expansion approvals The company is focusing on consistent growth and expansion of Bavencio into new indications and markets globally  Currently  Bavencio is being developed for more than 15 types of tumors  These studies are part of the JAVELIN development program Pfizer is also conducting avelumab double triple combination studies for chemotherapy and targeted therapies and has several avelumab combination therapies with immuno oncology agents under development However  several studies on Bavencio have failed in the past  In February 2018  a late stage study evaluating avelumab monotherapy in advanced non small cell lung cancer patients who were previously treated with platinum containing doublet therapy  failed to meet the primary endpoint of OS  In 2017  a late stage study evaluating avelumab for the treatment of gastric cancer in the third line setting also failed to meet the primary endpoint Failures like these significantly hurt the drug s prospects as it competes with successful  PD L1 inhibitors in the market like Merck s   NYSE MRK   Keytruda  Bristol Myers    NYSE BMY   Opdivo and Roche s Tecentriq Pfizer currently carries a Zacks Rank  4  Sell  You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-03-19,Zacks Investment Research,https://www.investing.com/analysis/pfizermerck-kgaa-end-bavenciotalzenna-ovarian-cancer-study-200399493,200399493
203040,424556,MRK,Bristol Myers  Celgene Buyout Still Uncertain Amid Opposition,opinion,Bristol Myers Squibb Company   NYSE BMY   is facing strong criticism from activist investors for the proposed acquisition of another large pharmaceutical company  Celgene Corporation   NASDAQ CELG    Bristol Myers investors have expressed multiple concerns related to growth of the company following the merger We remind investors that Bristol Myers  in January that it will acquire Celgene for an equity value of approximately  74 billion or more than  90 billion including debt  The deal is expected to close in the third quarter of 2019 Bristol Myers  stockholder  Starboard Value LP  has urged all shareholders to support its proposal to vote against the deal Starboard Value has posted a presentation on its website detailing the reasons for its opposition  In late February  the investment firm had informed all shareholders of Bristol Myers in a letter about its intention to oppose the mega acquisition  The investment firm has requested all shareholders to vote against the acquisition deal at the Special Meeting of Bristol Myers scheduled to be held on Apr 12  2019 Wellington Management Company  one of the top stakeholders  is also not supportive of the proposed acquisition and had informed the same to the board of Bristol Myers in February Bristol Myers  ExpectationsBristol Myers expects the combined entity to generate more than  45 billion in cash flow over the first three full years post closing and cost synergies of approximately  2 5 billion by 2022  Moreover  Bristol Myers expects the acquisition to be 40  accretive to the bottom line on a standalone basis in the first full year after closing The company expects the merged entity to have a market leading oncology portfolio in both solid tumors and hematologic malignancies led by Opdivo and Yervoy along with Revlimid and Pomalyst  The cardiovascular  immunology and inflammation franchise will be strengthened with the presence of Eliquis  Orencia and Otezla  respectively  Moreover  the entity will also have a deep pipeline including six expected near term product launches with potential sales of  15 billion Starboard s ArgumentStarboard Value believes that the deal is overpriced  The investment firm believes that the acquisition of Celgene will increase shareholders  risk significantly without generating enough rewards  It believes that initiatives for cost management within the standalone Bristol Myers will produce better returns than the proposed acquisition Starboard Value stated that Celgene has produced only three blockbuster products in 15 years  which raises concerns about Bristol Myers  assumption of significantly higher number of new blockbuster products in lesser time from Celgene s current pipeline  Moreover  Celgene s major revenue generator drug  Revlimid  will lose patent protection in 2026  which is likely to dent its sales The investment firm has also raised questions on Bristol Myers  current management as the company s share price has been on a decline over the past three years and it has underperformed other large pharmaceutical peers Starboard Value believes that the abovementioned factors along with several others stated in the presentation makes the deal look bad  It also believes that there can be better alternatives than the proposed acquisition to fuel growth at Bristol Myers Our TakeBristol Myers was on the lookout for an acquisition for quite some time now to bolster its portfolio  The company s top drug  Opdivo  has fallen behind Merck s   NYSE MRK   Keytruda in capturing market share in the anti PD 1 PD L1 category  Moreover  competition is rising in the category with the presence of Roche s   OTC RHHBY   Tecentriq  Both Keytruda and Tecentriq are approved for first line non small cell lung cancer   NSCLC    which has the largest patient population among all cancer indications Meanwhile  Opdivo is yet to gain approval for the same indication  which is denting its prospects  In January  Bristol Myers had withdrawn a label expansion application for Opdivo seeking its approval in combination with Yervoy in first line NSCLC However  sales of Opdivo grew substantially in 2018  Moreover  cardiovascular drug  Eliquis is witnessing strong growth  Sales growth of Celgene s Revlimid also remained impressive  While Revlimid generated global sales of  9 7 billion in 2018  Opdivo and Eliquis together recorded sales of  13 2 billion  Total product revenues of both the companies was  36 8 billion in 2018  The current product sales of both the companies and a strong growth rate of major drugs are positives that back the deal  However  successful development of pipeline into several blockbuster products will be necessary for long term growth Although the acquisition will enable Bristol Myers to diversify its portfolio and looks positive prima facie  any acquisition of this magnitude comes with its own set of integration risks  The deal will also add considerable debt to Bristol Myers  balance sheet With rising opposition from stakeholders the future of the deal is getting blurred  However  outcome of the Special Meeting is likely to provide a view of all shareholders  which will decide the future of the deal Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-20,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-celgene-buyout-still-uncertain-amid-opposition-200399870,200399870
203041,424557,MRK,Bristol Myers   BMY  Acquisition Of Celgene Looks Certain,opinion,"Bristol Myers Squibb Company s   NYSE BMY   acquisition offer for Celgene   NASDAQ CELG   received a fresh lease of life following endorsement from two major advisory firms  Institutional Shareholder Services   ISS   and Glass Lewis  The completion of acquisition will make the deal the largest in the history of the pharmaceutical industry Glass Lewis and ISS advise large institutional investors in matters related to vote on proxy proposals as well as corporate governance  Both the firms have endorsed the strategic deal  which may lead to several institutional investors voting in favor of the deal on Apr 12 Bristol Myers  shares have declined 8 2  so far this year against the  s gain of 4 9  We remind investors that Bristol Myers  in January that it will acquire Celgene for an equity value of approximately  74 billion or more than  90 billion including debt  The deal is expected to close in the third quarter of 2019  However  the deal  from two of its large shareholders  Wellington and Starboard Starboard had urged all shareholders to support its proposal to vote against the deal  However  it has decided to withdraw the campaign following ISS and Glass Lewis  support  Starboard  however  will go per its plans and vote against the deal as it believes the acquisition to be a loss making deal Per Starboard s argument  Bristol Myers  offer of one of its common stock and  50 for each Celgene s shares is overpriced  Starboard is also skeptical about the success of pipeline candidates as portrayed by Bristol Myers  Moreover  it raised questions on the performance of Bristol Myers  management Bristol Myers expects the acquisition to create synergies with market leading portfolio of oncology and cardiovascular drugs  The merged entity will have nine blockbuster drugs in its marketed portfolio and is likely to generate  45 billion in cash flow in first three years  Bristol Myers also expects to launch six products with blockbuster potential from the pipeline of the merged entity Bristol Myers  top drug  Opdivo  lags its competitors   Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq   which are already approved in the lucrative first line lung cancer  An acquisition  which can diversify its portfolio of marketed drugs and boost its pipeline  will change the course of the company s share price movement  The company s shares have been consistently declining for the past few years  However  the deal will add considerable debt to Bristol Myers  balance sheet We remain on the sidelines until the acquisition is complete and the synergies pan out as expected Bristol Myers Squibb Company Price
    Zacks RankBristol Myers currently has Zacks Rank  3  Hold  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-03-31,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-acquisition-of-celgene-looks-certain-200402727,200402727
203050,424566,MRK,Pfizer s  PFE  Kidney Cancer Drug Combo Gets EMA s Validation,opinion,"Pfizer  Inc    NYSE PFE   and partner Merck KGaA announced that the European Medicines Agency  EMA  has validated their type II variation application for PD L1 inhibitor  Bavencio  avelumab  in combination with Inlyta for the treatment of patients with advanced renal cell carcinoma  RCC  Per the regulatory agency  the application is complete and the EMA will now begin its review procedure The application was based on positive results from the phase III JAVELIN Renal 101 study  which showed that Bavencio and Inlyta significantly extended median progression free survival  PFS  by more than five months compared with Sutent  sunitinib  as a first line treatment for patients with advanced RCC We remind investors that the FDA has also accepted a supplemental Biologics License Application  sBLA  for Bavencio in combination with Inlyta for patients with advanced RCC for Priority Review  with a target action date in June 2019 Inlyta is already approved in Europe for use in adult patients with advanced RCC after failure of prior treatment with Sutent or cytokine  while Bavencio is approved for the treatment of adults and pediatric patients aged 12 years or older with metastatic Merkel cell carcinoma  mMCC  and metastatic urothelial carcinoma  mUC   Currently  avelumab is being developed for more than 15 types of tumors  including breast  gastric gastro esophageal junction  head and neck  Hodgkin s lymphoma  melanoma  mesothelioma  Merkel cell carcinoma  non small cell lung cancer  ovarian and urothelial carcinoma  These studies are part of the JAVELIN development program Pfizer s stock has lost 0 8  in the past six months against the  growth of 3  While the RCC market holds immense potential  competition is stiff   Last month  the FDA also granted priority review to Merck s   NYSE MRK   sBLA for Keytruda in combination with Inlyta for the first line treatment of patients with advanced RCC based on the results of KEYNOTE 426  and has set a target action date of Jun 20  2019 Exelixis    NASDAQ EXEL   Cabometyx is a dominant player in the market  The drug is approved for the treatment of patients with previously untreated advanced RCC and those with advanced RCC who have received prior anti angiogenic therapy   The drug continues to gain market share with its broad label Competition has further stiffened up with the approval of Bristol Myers    NYSE BMY   Opdivo and Yervoy for the treatment of poor and intermediate risk first line RCC Zacks Rank
Pfizer currently carries a Zacks Rank  4  Sell  
You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-11,Zacks Investment Research,https://www.investing.com/analysis/pfizers-pfe-kidney-cancer-drug-combo-gets-emas-validation-200396925,200396925
203051,424567,MRK,Canon drops to more than two month low after EU threatens huge fine,news,"TOKYO  July 7  Reuters    Canon Inc s stock fell to its lowest levels in more than two months on Friday after EU regulators said they may fine it up to 10 percent of annual revenue for jumping the gun in its acquisition of Toshiba Corp s medical unit  The EU Commission said it had reached a preliminary view that Canon breached rules by using a so called  warehousing  two step transaction structure involving an interim buyer to buy the company prior to obtaining relevant approvals  Ten percent of Canon s annual revenue would be roughly equivalent to  2 9 billion  The  6 billion deal  completed late last year  raised eyebrows at the time due to the unorthodox method which allowed Toshiba  which was struggling for cash after an accounting scandal  to book proceeds in time for the financial year end in March  Rival bidder Fujifilm Holdings Corp  had criticized it as a  mockery of the law    Canon said in statement that it would respond appropriately  but declined further comment before regulators make their final decision  Canon shares fell as much as 3 percent to its lowest level since May 1  The stock was the fifth most traded stock by turnover  EU regulators also accused General Electric  and German drugmaker Merck  NYSE MRK  KGaA  on Thursday of providing misleading information during separate merger deals   
Facebook Inc  was hit with a 110 million euro   125 million  fine in May for providing misleading information during the EU review of its messaging service WhatsApp purchase in 2014  Last month  EU antitrust regulators hit Alphabet s Google with a record 2 4 billion euro fine for favoring its own shopping service ",2017-07-06,Reuters,https://www.investing.com/news/stock-market-news/canon-drops-to-more-than-two-month-low-after-eu-threatens-huge-fine-503019,503019
203052,424568,MRK,T cell cancer therapy holds promise  longer term results await,news,"By Deena Beasley  Reuters    A novel cell treatment that saved the life of 9 year old Austin Schuetz was given the green light by U S  regulatory advisers on Wednesday and doctors hope it can save the lives of more children with the most common type of childhood cancer  An advisory committee to the U S  Food and Drug Administration voted unanimously to recommend approval of  Novartis  AG s  S NOVN  tisagenlecleucel for treating B cell acute lymphoblastic leukemia  ALL  in children and young adults who relapsed or failed chemotherapy  The FDA is not required to follow the recommendations of its advisers but typically does so  Austin Schuetz  who lives in Wisconsin  was treated in 2013 with the Novartis therapy as part of a clinical trial after leukemia cells were detected in his brain just two months after a bone marrow transplant from an anonymous donor    We knew it was risky     but it was the only option for us   said Kim Schuetz  Austin s mother  She said Austin  then age 6  suffered fever and severe headaches after the engineered T cells were administered  but today shows no signs of cancer  The new drug class  known as chimeric antigen receptor T cell or CAR T  involves a complicated process of extracting immune system T cells from an individual patient  altering the cell DNA to sharpen their ability to spot and kill cancer cells  and infusing them back into the patient   The majority of calls we are getting are from patients looking for immunotherapies   particularly CAR T therapies   said Dr  Gwen Nichols  chief medical officer at the Leukemia and Lymphoma Society   Novartis has lagged some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment  Companies including Merck   Co Inc  N MRK  and Bristol Myers Squibb Co  N BMY  are logging billions of dollars in annual sales of drugs known as  checkpoint inhibitors  that fight cancer by removing a brake on the body s immune system   The word is out there that this is different from traditional chemotherapy   Dr  Nichols said   Between 80 percent and 90 percent of children with ALL are cured with intense chemotherapy or bone marrow transplant  but there are few options for remaining patients   If your child is in that 10 to 20 percent  you are desperate   Dr  Nichols said  while cautioning that it is too early to tell whether CAR Ts offer lasting remissions for patients  In a clinical trial  79 percent of patients given the Novartis therapy were alive a year later  Patients with ALL who fail chemotherapy typically have only a 16 percent to 30 percent chance of survival   CAR Ts can also pose serious risks  including a potentially life threatening inflammatory condition  Austin Schuetz  one of a handful of CAR T patients to achieve multi year remission of his cancer  requires biweekly infusions of immunoglobulin to replace B cells wiped out by the engineered cancer killing T cells  Without B cells  his body would not be able to fight off common infections  If approved by the FDA  CAR T therapies could cost up to  500 000 and generate billions of dollars for their developers   As the cost of cancer drugs increases  health insurers have placed tighter restrictions on patient access   While CAR T is a promising new type of immunotherapy  it is not commercially available and we have yet to complete our evaluation   T J  Crawford  a spokesman for health insurer  Aetna Inc   N AET  said in a statement  About 6 000 people are diagnosed with ALL in the United States each year and about 60 percent are children  according to the American Cancer Society   The FDA s decision on the Novartis drug  expected by late September  has significant implications not only for the Switzerland based drugmaker but for companies making similar drugs  including  Kite Pharma  Inc  O KITE   Juno Therapeutics Inc  O JUNO  and  Bluebird bio Inc   O BLUE   The agency is expected to decide by Nov  29 whether to approve Kite s CAR T  axi cel  for treatment of adults with advanced and aggressive lymphoma  Kite has also reported data showing remission in 73 percent of 11 patients with relapsed ALL treated with axi cel  It plans to launch a Phase 2 trial in the fourth quarter  
Juno scrapped its initial CAR T candidate for ALL after five patient deaths  The company has since reported early trial results for a different CAR T showing that 66 percent of non Hodgkin lymphoma patients responded to the drug  and 18 percent suffered severe neurological side effects ",2017-07-13,Reuters,"https://www.investing.com/news/stock-market-news/t-cell-cancer-therapy-holds-promise,-longer-term-results-await-505181",505181
203053,424569,MRK,Merck s Keytruda Gets EU Approval For Difficult Lung Cancer,opinion,"Merck   Co   Inc    NYSE MRK   announced that the European Medicines Agency   EMA   has approved the label expansion of its blockbuster PD 1 inhibitor  Keytruda  pembrolizumab   The drug is now approved in combination with chemotherapy  carboplatin and either paclitaxel or nab paclitaxel  for the first line treatment of adult patients with metastatic squamous non small cell lung cancer   NSCLC     a difficult to treat lung cancer population   regardless of PD L1 expression The European approval was expected as the Committee for Medicinal Products for Human Use had recommended the same in February Following the recent approval  the Keytruda combo is now the first anti PD 1 therapy to be approved in the EU for adult patients affected by metastatic squamous NSCLC The approval was based on data from the phase III KEYNOTE 407 study  Data from the study showed that the combination of Keytruda plus chemotherapy led to a significant improvement in both overall survival   OS   and progression free survival rates compared with patients receiving only chemotherapy  Results presented from this study stole the limelight at the annual meeting of the American Society of Clinical Oncology last June In the United States  a similar label expansion was approved last October  This nod will help Merck gain access to a broader lung cancer patient population and boost sales of its blockbuster drug Please note that the drug is under review in the United States for label expansion as monotherapy for locally advanced or metastatic non squamous or squamous NSCLC patients with PD L1 expression  A decision is expected next month Shares of Merck have increased 6 6  so far this year  compared with the  s gain of 3 5  Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer  The company is also developing the drug as a treatment for several other oncology indications including different lung cancers in multiple settings Keytruda is the largest product in Merck s portfolio and has recorded impressive growth rate since its launch in 2014  The drug generated sales of  7 17 billion in 2018  reflecting a massive increase of 88  year over year  Sales were driven by the launch of the drug for new indications globally  Keytruda sales are particularly gaining from a strong momentum in first line lung cancer indication as it is the only anti PD 1 medicine approved in the first line setting Merck   Co   Inc  Price
    Zacks Rank   Stocks to ConsiderMerck currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY    AstraZeneca PLC   NYSE AZN   and Bayer  DE BAYGN  AG   OTC BAYRY    All the stocks carry a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings estimates have been revised 1  and 6 4  upward for 2019 and 2020  respectively  over the past 90 days AstraZeneca s earnings estimates have been revised 5 3  higher for 2019 over the past 60 days  The stock has increased 11 3  so far this year Bayer s earnings estimates have moved 1 6  north for 2019 over the past 60 days  The stock is up 8 5  so far this year Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-14,Zacks Investment Research,https://www.investing.com/analysis/mercks-keytruda-gets-eu-approval-for-difficult-lung-cancer-200398222,200398222
203054,424570,MRK,AstraZeneca Up This Year On New Drugs   Pipeline Progress,opinion,AstraZeneca plc  s   NYSE AZN   stock has rallied 11 9  this year so far  outperforming the rise of 3 7  The company s outperformance has been backed by quite a few positive developments on the regulatory and pipeline front  a strong performance of its relatively newer drugs as well as a bullish outlook for 2019 New Drugs Push Return to GrowthNewer drugs like Brilinta  cardiovascular   Lynparza  ovarian cancer   Farxiga Forxiga  type II diabetes  and Tagrisso  lung cancer  are driving top line growth  with AstraZeneca launching them in more markets and in an increased number of indications  AstraZeneca expects Tagrisso to become its biggest medicine in 2019  Brilinta and Farxiga achieved blockbuster status in 2017  exceeding  1 billion in sales  Imfinzi and Fasenra  launched in 2017 early 2018  are off to a strong start  given their highly competitive clinical profile   AstraZeneca is looking for further label expansions for these drugs The company returned to product sales growth in the second half of 2018 on the back of its newer drugs after patent expirations persistently hurt its product sales growth since 2010  Sales of AstraZeneca s newer medicines rose 81  in 2018 as almost every new product it has launched in recent years has done well  The company is confident of seeing a sustained uptick for several years driven by sales growth of its new medicines  namely Tagrisso  Imfinzi  Lynparza  Farxiga and Fasenra Positive Pipeline DevelopmentsAstraZeneca delivered well on its R D pipeline with meaningful data readouts and regulatory updates announced in 2018 Last year s new drug approvals included Lokelma  hyperkalemia  in the United States as well as the EU  Lumoxiti  third line hairy cell leukemia  in the United States and roxadustat for anaemia in chronic kidney disease patients on dialysis in China  Moreover  new asthma medicine  Fasenra  benralizumab   was approved in Japan and the EU  Fasenra got the FDA nod in November 2017 and is fast becoming a key contributor to the company s sales Key approvals for line extensions of new cancer drugs in 2018 included Imfinzi for an early stage lung cancer  Lynparza for breast cancer in the United States and Japan as well as in first line maintenance setting for ovarian cancer in the United States and Tagrisso in first line EGFR mutated NSCLC in both the United States and the EU  These label expansions significantly aided sales growth of these important cancer drugs in the second half of 2018 with the momentum likely to continue in 2019 as well  Notably  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK   Meanwhile  a new formulation of AstraZeneca s diabetes medicine  Bydureon  in an improved once weekly  single dose pre filled BCise device was also approved in the United States and the EU last year Several product introductions are underway for AstraZeneca across each of the therapeutic areas   Oncology  CV metabolism and Respiratory  AstraZeneca hopes to launch four respiratory medicines between 2017 and 2020 with Fasenra and Bavespi already launched  In oncology  AstraZeneca s target is to launch at least six new medicines between 2014 and 2020 with Lynparza  Tagrisso  Imfinzi and Calquence already hitting the market  An interesting candidate in the company s immuno oncology pipeline is Imfinzi  durvalumab   which is being evaluated for multiple cancers  either alone or in combination with other regimens Meanwhile  several pipeline and regulatory events are scheduled for 2019  This includes NDA filing for investigational triple combination therapy PT010 for COPD and for roxadustat in the United States apart from data readout on Calquence in first line chronic lymphocytic leukemia ConclusionAstraZeneca  which carries a Zacks Rank  2  Buy   has its share of challenges  These include generic competition for its core products  stiff competition in its diabetes franchise and pricing pressure on its respiratory franchise  However  we believe  the company s newer drugs  upcoming product launches  aggressive cost cutting efforts and a promising late stage pipeline should keep the stock afloat in 2019 Other better ranked large drug biotech stocks include Bayer  DE BAYGN  Aktiengesellschaft   OTC BAYRY   and Celgene Corporation   NASDAQ CELG    both sporting a Zacks Rank  1  Strong Buy   You can see  Celgene s earnings estimates have been inched 0 4  up for 2019 and 1 1  for 2020 over the past 30 days  The stock has surged 38  year to date Shares of Bayer have increased 8 7  year to date Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-up-this-year-on-new-drugs--pipeline-progress-200398599,200398599
203055,424571,MRK,Roche s Tecentriq Gets FDA Approval For Difficult Lung Cancer,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the FDA has approved its regulatory application  looking for approval of its cancer immunotherapy   Tecentriq   in combination with chemotherapy for the first line treatment of extensive stage small cell lung cancer  ES SCLC  With this FDA nod  Tecentriq   a PD L1 inhibitor   becomes the first cancer immunotherapy approved for the initial treatment of ES SCLC  which is a difficult to treat cancer with limited treatment options This sBLA was based on results from the phase III IMpower133 study that met its overall survival  OS  and progression free survival  PFS  co primary endpoints  per the study protocol  Results from the study showed that the initial treatment with the combination of Tecentriq and chemotherapy  carboplatin and etoposide  enabled patients with ES SCLC to live significantly longer as compared to chemotherapy alone  The combination also reduced the risk of disease worsening or death  PFS  in comparison to only chemotherapy Roche s stock has rallied 8 9  this year so far  outperforming the  rise of 3 7    Tecentriq is already approved for the treatment of patients with advanced bladder cancer  advanced lung cancer and in combination with Avastin and chemotherapy for the preliminary treatment of people with metastatic non squamous NSCLC Roche is working to expand the drug s label further  The company currently has nine phase III lung cancer studies  evaluating Tecentriq alone or combined with other drugs Tecentriq sales came in at CHF 772 million during 2018  up 59   A label expansion of the drug in the NSCLC market will further boost sales  given its potential However  competition is stiff in the first line NSCLC market  Merck s   NYSE MRK   PD L1 inhibitor  Keytruda commanded a strong place in first line NSCLC market  Bristol Myers Squibb Company s   NYSE BMY   PD L1 inhibitor  Opdivo is also in the race for the first line NSCLC treatment  However  the FDA extended its review period for the company s application by three months and set a target action date of May 20  2019  Other PD L1 inhibitors available in the market are AstraZeneca s   NYSE AZN   Imfinzi and Pfizer s Bavencio Roche carries a Zacks Rank  2  Buy   You can see   Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/roches-tecentriq-gets-fda-approval-for-difficult-lung-cancer-200399194,200399194
203063,424579,MRK,Merck s anacetrapib reduced incidence of major coronary events in high risk patients in large scale study  shares ahead 2  premarket,news,Merck  NYSE MRK  is up 2  premarket on increased volume in response to its announcement of positive results from a Phase 3 clinical trial  REVEAL  assessing anacetrapib for reducing the risk of major coronary events in patients at risk for cardiac events who are currently receiving a LDL C lowering regimen The study met its primary endpoint of reducing such events compared to placebo  median follow up of four years   The safety profile of anacetrapib was consistent with previous studies  including the accumulation of the drug in fat tissue The company intends to review the data with external experts and will consider global regulatory applications  Complete results will be presented at the European Society of Cardiology meeting on August 29 Anacetrapib inhibits a protein called cholesterol ester transfer protein  CETP   which is designed to elevate HDL cholesterol  the  good  cholesterol   CETP inhibitors were all the rage a few years ago over their potential to provide more cardioprotective benefits than lowering LDL cholesterol  the  bad  cholesterol   Big Pharma s efforts to push CETP inhibitors over the finish line hit fell flat due to toxicity and less than expected efficacy  Eli Lilly  Roche and  Pfizer   NYSE PFE  all abandoned their programs Now read ,2017-06-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck's-anacetrapib-reduced-incidence-of-major-coronary-events-in-high-risk-patients-in-large-scale-study;-shares-ahead-2-premarket-499598,499598
203064,424580,MRK,Merck confirms ransomware compromise,news,Merck  NYSE MRK  confirms on Twitter that the company was compromised by the new ransomware virus spreading through and beyond Europe                Merck tweets   We are investigating the matter and will provide additional information as we learn more    Now read ,2017-06-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-confirms-ransomware-compromise-499723,499723
203065,424581,MRK,Bayer to cut profit view on Brazil  consumer health setbacks,news,"By Ludwig Burger FRANKFURT  Reuters    Bayer  DE BAYGn  said on Friday it would cut its full year earnings forecast due to high inventories at crop protection distributors in Brazil and a weaker than expected consumer health business   At the end of the harvest season in Brazil  regular stock taking revealed an unexpectedly high channel inventory level of crop protection products   the company said in an unscheduled statement   This would result in a one time hit of 300 400 million euros   342  456 million  on full year earnings before interest  taxes  depreciation and amortisation  EBITDA   Bayer  in the midst of seeking regulatory approval for its  66 billion takeover of U S  seeds group  Monsanto   N MON   said it would adjust its business outlook when it publishes second quarter results  due on July 27  without providing details  The shares were down 4 3 percent to 113 euros at 0758 GMT  The company also cited unfavorable currency developments but added its pharmaceuticals division and chemicals business Covestro  DE 1COV  were still performing strongly  while business at its animal health unit was line with expectations  Bayer has been trying to overcome a weaker than expected performance of key consumer care brands Coppertone sun screen and Dr  Scholl s foot care products  acquired from Merck   Co  N MRK   
When asked about Bayer s plan to file for regulatory approval in Europe for the Monsanto deal this quarter  a spokesman said that remarks by Bayer CEO Werner Baumann last week  reaffirming that goal  were still valid ",2017-06-30,Reuters,"https://www.investing.com/news/stock-market-news/bayer-to-cut-profit-view-on-brazil,-consumer-health-setbacks-500881",500881
203066,424582,MRK,Esperion  ESPR  Reports Wider Than Expected Loss In Q4,opinion,"Esperion Therapeutics  Inc    NASDAQ ESPR   incurred a loss of  2 24 per share in the fourth quarter of 2018  wider than the Zacks Consensus Estimate of  1 33  The company s loss was  1 44 per share in the year ago period With no approved products in its portfolio  the company did not generate any revenues in the reported quarter  However  the company has filed regulatory applications seeking approval for its key candidates   bempedoic acid monotherapy and bempedoic acid   Merck s   NYSE MRK   Zetia  ezetimibe  combination pill Esperion s shares have lost significant value in the past year  falling 40 1  Quarter in DetailsResearch and development  R D  expenses surged 47 9  from the year ago period to  49 5 million  The rise was primarily due to higher cost needed to support development of bempedoic acid monotherapy and combination therapy  including five pivotal studies and one cardiovascular outcomes study General and administrative  G A  expenses more than doubled year over year to  11 2 million primarily driven by costs related to support pre commercialization activities for both the candidates As of Dec 31  2018  Esperion had cash  cash equivalents and investment securities of  136 3 million compared with  273 6 million as of Dec 31  2017 Full Year ResultsEsperion incurred a loss of  7 54 per share  wider than the year ago loss of  6 98 due to increase in operating expense to support the progress of its pipeline  The company generated no revenues during the period 2019 GuidanceEsperion provided guidance for collaborations revenues and operating expenses in 2019  The company expects income from collaboration and license agreement to be  150 million  R D expense is estimated between  115 million and  120 million while G A expense is expected in the range of  60  65 million Pipeline UpdateIn February 2019  Esperion submitted regulatory applications in the United States and EU seeking approval for bempedoic acid monotherapy as well as bempedoic acid Zetia combination tablet  The regulatory applications  seeking approval for cholesterol  LDL C  lowering indications  were filed based on data from several pivotal studies evaluating the candidates Data from four phase III studies evaluating bempedoic acid monotherapy  presented previously  demonstrated that treatment with the therapy led to additional 18  reduction in LDL C over 31  LDL C reduction in statin treated patients on maximally tolerated statin Data from the phase III study evaluating bempedoic acid Zetia combination pill showed that the combination regimen reduced bad cholesterol by 35  compared with 24  for Zetia  20mg  monotherapy  20  for bempedoic acid and 3  for placebo in patients receiving maximally tolerated statins In January 2019  Esperion announced an agreement with Daiichi Sankyo Europe  granting exclusive rights to the latter to commercialize bempedoic acid and the bempedoic acid Zetia combination pill in Europe and Switzerland  The company is eligible to receive up to  900 million in payments from Daiichi including an upfront payment of  150 million and additional future milestone and royalty payments Esperion Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderEsperion currently carries a Zacks Rank  4  Sell  Some better ranked stocks in the healthcare sector include Celgene Corporation   NASDAQ CELG   and Genomic Health  Inc    NASDAQ GHDX    While Celgene sports a Zacks Rank  1  Strong Buy   Genomic Health carries a Zacks Rank  2  Buy   You can see  Celgene s earnings estimates have been revised 5 3  upward for 2019 and 9 2  for 2020 over the past 60 days  The stock has rallied almost 29 7  so far this year Genomic Health s earnings estimates have moved north 17 9  for 2019 and 13 9  for 2020 over the past 60 days  The stock has gained 17 9  so far this year This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-02-28,Zacks Investment Research,https://www.investing.com/analysis/esperion-espr-reports-widerthanexpected-loss-in-q4-200393939,200393939
203067,424583,MRK,Endo  ENDP  Q4 Earnings   Revenues Beat Estimates  Shares Up,opinion,"Shares of Endo International plc   NASDAQ ENDP   increased 6 2  after the company reported better than expected results for fourth quarter 2018 
Endo s stock has lost 13 1  in the past three months Endo International plc Price  Consensus and EPS Surprise

   Earnings of 75 cents easily beat the Zacks Consensus Estimate of 59 cents  However  earnings declined from 77 cents recorded in the year ago quarter 
Revenues came in at  786 4 million in the quarter  surpassing the Zacks Consensus Estimate of  744 2 million and increasing 2  from the year ago quarter s figure  This increase was primarily attributable to continued strong growth in the U S  Branded   Sterile Injectables segment and the Specialty Products portfolio of our U S  Branded   Specialty   Established Pharmaceuticals segment 
Quarterly Highlights
Endo now has four reportable business segments   1  U S  Generic Pharmaceuticals   2  U S  Branded   Specialty   Established Pharmaceuticals   3  U S  Branded Sterile Injectables and  4  International Pharmaceuticals 
U S  Generic Pharmaceuticals recorded sales of  263 8 million in the quarter  down 13  due to competitive pressures in the generic business 
U S  Branded Pharmaceuticals  Specialty   Established Pharmaceuticals  sales were up 1  to  229 8 million  driven by continued strong growth of Specialty Products portfolio  offset by ongoing generic competition in Established Products portfolio  Specialty Products revenues increased 15  to  143 million  driven by the continued strong performance of Xiaflex  Sales of Xiaflex increased 30  to  80 million  owing to underlying volume growth in both Peyronie s Disease and Dupuytren s Contracture indications  and a benefit from the timing of shipments compared to prior year 
Earlier  Endo reported positive results from two phase III trials of collagenase clostridium histolyticum  CCH  for the treatment of cellulite in the buttocks  The results demonstrated that subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment  as measured by the trial s primary endpoint 
U S  Branded Sterile Injectables  sales of  259 1 million was up 32   driven by strong growth of Adrenalin and Vasostrict  In July  the segment launched ertapenem for injection  the authorized generic of Merck s   NYSE MRK   Invanz  which boosted sales 
Endo has decided to terminate its previously announced acquisition of Somerset Therapeutics  LLC  a New Jersey based specialty pharmaceutical company  and the business of its India based affiliate Wintac Limited  which operates as Somerset Therapeutics  contract developer and manufacturer  The decision was taken as certain regulatory approvals in India took longer than anticipated and the company lacks clarity on when those approvals could be received 
Earlier  Endo also entered into an exclusive licensing agreement with Nevakar  a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas  Both companies have collaborated for the development of five differentiated  sterile injectable products in the United States and Canada  While Nevakar will develop and seek FDA approval for these products  Endo s Par Pharmaceuticals Sterile Products division will launch and distribute them upon approval 
The International Pharmaceuticals division generated sales of  34 million  down from  41 million in the year ago quarter due to recent divestitures  Endo sold Mexican subsidiary  Somar to Advent International in October 2017  Endo also sold its South African subsidiary  Litha Healthcare Group in July 2017 
2018 Results
Endo s revenues came in at  2 9 billion  down 15  from 2017  but were in line with the Zacks Consensus Estimate  Earnings per share of  2 89 were down from  3 84 in 2017 and easily beat the Zacks Consensus Estimate of  2 73  
2019 Outlook
Endo expects revenues between  2 76 billion and  2 96 billion in 2019  The company expects Xiaflex s full year revenues to grow mid to high teens 
Branded Sterile Injectables revenues are now expected to grow high single to low double digits  U S  Generics revenues are projected to decline mid to high teens  International Pharmaceuticals  revenues are estimated to decline approximately 20  due to the impact of generic competition in the business in Canada 
The company anticipates earnings from continuing operations to be  2 00  2 25 per share 
Our Take
Endo s fourth quarter results were positive as the company beat on both earnings and sales  The last year was a transitional year for Endo as it transformed its legacy branded pharmaceutical business  which was primarily focused on pain management  into a highly focused branded specialty pharmaceutical business in the United States 
The company has divested its non core assets and businesses  and repositioned its generics business in the United States by executing a comprehensive product portfolio and manufacturing footprint rationalization initiative 
However  the guidance wasn t impressive as the company expects continued competitive pressure for the generic business  The huge level of debt is a concern   Moreover  response rates from the CCH trials did not impress the investors earlier 
Zacks Rank   Stocks to Consider
Endo currently carries a Zacks Rank  4  Sell  
A few better ranked stocks are Celgene Corp    NASDAQ CELG   and BioDelivery Sciences International  Inc    NASDAQ BDSI    Both the stocks carry a Zacks Rank  1  Strong Buy   You can see  
Celgene s earnings per share estimates have increased from  10 21 to  10 75 for 2019 and from  11 63 to  12 70 for 2020 in the past 60 days 
BioDelivery Sciences  loss per share estimates has narrowed from 25 cents to 22 cents for 2019 in the past 60 days 
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities 
These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-03-01,Zacks Investment Research,https://www.investing.com/analysis/endo-endp-q4-earnings--revenues-beat-estimates-shares-up-200394072,200394072
203068,424584,MRK,Immunogen Ovarian Cancer Drug Fails In Phase III  Stock Sinks,opinion,"Shares of ImmunoGen  Inc    NASDAQ IMGN   fell almost 47  after its ovarian cancer candidatefailed to meet the primary endpoint of progression free survival  PFS in a phase III study  The FORWARD 1 study evaluated the efficacy of mirvetuximab soravtansine as a single agent therapy compared to chemotherapy for the treatment of patients with platinum resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens 
The study did not meet the primary endpoint of PFS in the entire study population as well as the pre specified subset of patients with high FR  expression 
Shares of the company have declined 78 1  in the past year compared with the  s decline of 16 3  

Although the study did show that in the entire study population  the confirmed overall response rate was higher for mirvetuximab soravtansine than for chemotherapy  there was no significant difference in PFS 
The overall response rate for the company s treatment was higher than the study in which patients were treated with chemotherapy  However  there was no significant difference in overall survival rates  
The company will further assess data from the FORWARD I study to determine potential future steps with a monotherapy approach 
Further  the company said that mirvetuximab combination regimens will continue to be evaluated in ongoing studies as an independent path forward to support a registration in ovarian cancer  Combination regimens with mirvetuximab soravtansine in ovarian cancer are being evaluated in the phase Ib II FORWARD II study 
The FORWARD II study consists of cohorts assessing mirvetuximab soravtansine in combination with Roche s   OTC RHHBY   Avastin and Merck s   NYSE MRK   Keytruda  Preliminary data presented in October 2018 showed that mirvetuximab soravtansine in combination with Keytruda achieved encouraging anti tumor activity  especially in patients with medium or high FR  expression levels 
In June 2018  the FDA granted Fast Track designation to mirvetuximab soravtansine asa single agent therapy for the treatment of patients with platinum resistant ovarian cancer whose tumors express high or medium levels of FR  and who have received up to three prior treatment regimens  Mirvetuximab soravtansine enjoys Orphan Drug status in both the United States and EU for the treatment of ovarian cancer ImmunoGen  Inc  Price

    
Zacks Rank and Stocks to Consider
Immunogen currently carries a Zacks Rank 3  Hold  
A better ranked stock is Celgene Corp    NASDAQ CELG    carrying a Zacks Rank  1  Strong Buy   You can see  
Celgene s earnings per share estimates have increased from  10 21 to  10 75 for 2019 and from  11 63 to  12 70 for 2020 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  with average of 2 65  
Zacks  Top 10 Stocks for 2019 
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-03-04,Zacks Investment Research,https://www.investing.com/analysis/immunogen-ovarian-cancer-drug-fails-in-phase-iii-stock-sinks-200394563,200394563
203069,424585,MRK,Roche s  RHHBY  SNDA For Flu Candidate Accepted By The FDA ,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   member  Genentech announced that the FDA has accepted the supplemental new drug application  sNDA  for Xofluza  baloxavir marboxil  for the treatment of influenza in people at high risk of complications  The FDA is expected to make a decision on approval by Nov 4  2019 
The sNDA was supported by results from the phase III CAPSTONE 2 study evaluating a single dose of Xofluza compared with placebo or Tamiflu  oseltamivir  75 mg  twice daily for five days  in people aged 12 years or older who are at high risk of complications from the flu  In the study  baloxavir marboxil met the primary and secondary endpoints compared to placebo  Baloxavir marboxil significantly reduced the duration of flu symptoms by more than one day  It also considerably reduced the duration of fever by nearly a day and the levels of virus in the nose and throat from 24 hours through 120 hours 
Xofluza would be the first antiviral medicine approved specifically for the high risk population 
Xofluza will be further be evaluated in a phase III development program  including pediatric population  post exposure prophylaxis and severely ill hospitalized people with influenza  The program will also assess the potential of the candidate to reduce transmission in otherwise healthy people 
Shares of Roche have increased 19 9  in the past year  compared with the  s growth of 14  

We remind investors that in January 2019 the FDA approved the 0 5mL dose of Sanofi s   NASDAQ SNY   influenza vaccine  Fluzone Quadrivalent  for treating children falling within the six to 35 month age bracket  The 0 5 mL dosage is already approved for use in patients aged three years or older along with the lesser 0 25 mL dose  which is approved for kids in the six to 35 month age category  Both medicinal measures of the vaccine will be available for the upcoming 2019 2020 flu season 
Notably  in December 2018  the FDA approved Sanofi s pediatric vaccine  Vaxelis  which is developed for active immunization to prevent six different diseases in minor patients aged six weeks to four years  Vaxelis has been jointly developed by Sanofi  PA SASY  and Merck   NYSE MRK    Both the companies are working on its production  with a commercial launch expected not before 2020 
Also  in January 2018  GlaxoSmithKline plc   NYSE GSK   received approval from the FDA s Center for Biologics Evaluation and Research for the label expansion of influenza vaccine   Fluarix Quadrivalent  The vaccine has been approved for infants aged six months or older Roche Holding AG Price

   Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-06,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-snda-for-flu-candidate-accepted-by-the-fda-200395230,200395230
203070,424586,MRK,Roche s  RHHBY  Tecentriq Gets EC Nod For First Line NSCLC,opinion,"Swiss pharma company  Roche   OTC RHHBY   announced that the European Commission  EC  has approved and granted marketing authorization to immuno oncology drug  Tecentriq in combination with Avastin  paclitaxel and carboplatin for the first line treatment of adults with metastatic non squamous non small cell lung cancer  NSCLC  The approval includes EGFR mutant or ALK positive NSCLC after failure of a targeted therapy The EC approval was based on positive results from the phase III IMpower150 study  which showed that Tecentriq in combination with Avastin and chemotherapy enabled patients live significantly longer as compared to the combination of Avastin and chemotherapy  The safety profile of the Tecentriq combination was consistent with that observed in previous studies The label expansion of the drug should further boost sales  given the market potential for first line NSCLC  which accounts for 85  of all lung cancer cases in the world We remind investors that Tecentriq is already approved in the European Union and the United States for previously treated metastatic NSCLC and for certain types of untreated or previously treated metastatic urothelial carcinoma  mUC   The FDA recently approved Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with metastatic non squamous NSCLC Roche is working to expand the drug s label further  Nine phase III lung cancer studies are ongoing  evaluating Tecentriq alone or in combination with other medicines However  competition is stiff in the promising first line NSCLC market with the likes of Merck s   NYSE MRK   Keytruda Earlier  Roche announced that it submitted a supplemental New Drug Application  sNDA  for leukemia drug  Venclexta in combination with of Gazyva  The company is seeking label expansion of the drug for the treatment of previously untreated chronic lymphocytic leukemia  CLL  and co existing medical conditions The FDA is reviewing the application under the Real Time Oncology Review pilot program  which should speed up the process to ensure availability of safe and effective treatments for patients as early as possible We remind investors that the combination was earlier granted Breakthrough Therapy designation by the FDA  which should expedite the review process Roche has a collaboration agreement with AbbVie  Inc    NYSE ABBV   for Venclexta  Both the companies jointly commercialize the drug in the United States  while AbbVie commercializes it outside the United States Venclexta is already approved for the treatment of CLL in adults with or without 17p deletion who have received at least one prior treatment Roche s stock has gained 11 5  in the past six months compared with the  growth of 3 4   Approval of new drugs and label expansion of existing drugs bode well for the company as biosimilars pose stiff competition for some of its key drugs  Separately  Roche announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics  Inc    NASDAQ ONCE   at  114 50 per share  The acquisition will strengthen Roche s position in the hemophilia market Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-07,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-tecentriq-gets-ec-nod-for-firstline-nsclc-200395795,200395795
203078,424594,MRK,Merger benefits expected for Luxottica,news,Luxottica  NYSE LUX  ADRs are on watch after the luxury stock was upgraded by  Morgan Stanley   NYSE MS  to Overweight from Equal weight  The firm sees significant upside from Luxottica s merger with Essilor  OTC ESLOF  OTCPK ESLOY   upping its synergy estimate to  800M  In Milan trading  Luxottic is up 3 6   while Essilor is about 2 2  higher in Paris  Source  Bloomberg Now read ,2017-06-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/merger-benefits-expected-for-luxottica-494831,494831
203079,424595,MRK,Leap Therapeutics to explore the potential of DKN 01 Keytruda combo in treatment  resistant esophagogastric cancers  shares ahead 5 ,news,Leap Therapeutics  LPTX  5 4   inks a clinical trial collaboration agreement with Merck  MRK  0 9   to investigate the combination of DKN 01 and KEYTRUDA  pembrolizumab  for the treatment of relapsed refractory advanced esophagogastric cancers Leap VP  Clinical Development Cynthia Sirard  M D   says   This clinical collaboration with Merck is the first of the combination immunotherapy studies we plan to initiate in each of our two programs  DKN 01 and TRX518  Combining DKN 01 with KEYTRUDA has a strong scientific rationale and offers hope to patients with few treatment options  Additional terms of the partnership are not disclosed  but Merck is principally just supplying product  at least initially  DKN 01 is a humanized IgG4 monoclonal antibody that binds to Dickkopf 1  DKK1   a protein associated with a poor prognosis in a range of cancers  Specifically  it inhibits a pathway called canonical Wnt Beta catenin which plays a key role in embryonic development  cell proliferation and differentiation Pembrolizumab helps the immune system fight tumor cells by blocking the interaction between PD 1  a cell surface receptor expressed on T cells and pro B cells  and its ligands PD L1 and PD L2  PD 1 is an immune checkpoint which down regulates the immune system  Now read ,2017-06-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/leap-therapeutics-to-explore-the-potential-of-dkn-01-keytruda-combo-in-treatment--resistant-esophagogastric-cancers;-shares-ahead-5-497757,497757
203080,424596,MRK,AstraZeneca Merck s Lynparza Meets Endpoint In POLO Study,opinion,AstraZeneca plc   NYSE AZN   and partner Merck s   NYSE MRK   PARP inhibitor  Lynparza met the primary endpoint in a late stage study evaluating it as first line maintenance treatment in germline BRCA mutated metastatic pancreatic cancer  Data from the POLO study showed that treatment with Lynparza tablets  300mg twice daily  led to statistically significant and clinically meaningful improvement in the primary endpoint of progression free survival compared to placebo Lynparza is presently approved for multiple indications in advanced ovarian cancer and metastatic breast cancer  It became the first PARP inhibitor to show positive data in a study in germline BRCA mutated metastatic pancreatic cancer  Other PARP inhibitors available in the market are Tesaro s Zejula and Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  both are not approved in pancreatic cancer indications  Tesaro is now part of GlaxoSmithKline   NYSE GSK   Please note that the FDA has granted orphan drug designation  ODD  to Lynparza for the treatment of pancreatic cancer  Full data from the study is expected to be presented at a future medical meeting AstraZeneca reported Lynparza sales of  647 million in 2018  up 116  at constant exchange rates  on expanded use in ovarian cancer and label expansion in breast cancer  The approval of Lynparza in December last year as a first line treatment of patients with BRCAm ovarian cancer in the United States is expected to support further expanded use This year so far  AstraZeneca s shares have risen 10 5  Lynpazra is a key new drug in AstraZeneca s oncology portfolio together with Tagrisso and Imfinzi  Oncology sales now comprise almost 30  of total product sales for AstraZeneca and rose 49  in 2018 AstraZeneca currently carries a Zacks Rank  2  Buy   You can see Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/astrazenecamercks-lynparza-meets-endpoint-in-polo-study-200392958,200392958
203088,424604,MRK,Exclusive  McConnell expects bipartisan support for bill reauthorizing FDA user fees,news,"WASHINGTON  Reuters    U S  Senate Republican Leader Mitch McConnell told Reuters on Wednesday he expects bipartisan support for approval of a bill authorizing taxpayer and industry funding for the U S  Food and Drug Administration  The bill to reauthorize the Prescription Drug User Fee Act would let the FDA continue to collect hundreds of millions of dollars from drugmakers and medical device companies to partially cover the cost of reviewing new products  with U S  taxpayers funding the remainder   It s an extremely important bill that I think we ll be able to move on a bipartisan basis   McConnell said in an interview   L1N1IQ1CH  The FDA has been charging companies to review their products since 1992  On Tuesday  President Donald Trump proposed in his 2018 budget that the industry pay the full cost of drug and medical device reviews   The industry at present pays about 60 percent  That proposal is unlikely to be approved in this cycle  Reauthorization of the user fee bill is typically negotiated between the FDA and industry over a period of several years  Earlier this month  the bill was approved by a Senate panel by a 21 2 vote  It must be renegotiated every five years  
The FDA reviews drugs for approval or rejection for many companies  including major ones such as  Pfizer  Inc  NYSE PFE   Merck  NYSE MRK    Co Inc and Johnson and Johnson  Pharmaceutical companies based overseas  including Roche Holding  SIX ROG  AG and Novartis AG  also pay these fees for U S  approved drugs ",2017-05-24,Reuters,https://www.investing.com/news/politics-news/exclusive:-mcconnell-expects-bipartisan-support-for-bill-reauthorizing-fda-user-fees-488158,488158
203089,424605,MRK,Merck s Keytruda beats Bristol Myers  Yervoy in melanoma,news,Three year data from a Phase 3 clinical trial  KEYNOTE 006  showed the superiority of Merck s  NYSE MRK  KEYTRUDA  pembrolizumab  over Bristol Myers Squibb s  NYSE BMY  YERVOY  ipilimumab  in patients with advanced melanoma  The results will be presented on Sunday  June 4 at ASCO  Abstract  9504  A pooled analysis of two KEYTRUDA doses showed 50  of patients were alive almost three years  33 9 months  after starting treatment compared to 39  in the YERVOY group  Progression free survival  PFS  also favored KEYTRUDA  with 31  of patients alive at 33 9 months compared to 14  with YERVOY  KEYTRUDA came out ahead in terms of overall response rate ORR   42  vs  16   ASCONow read ,2017-06-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck's-keytruda-beats-bristol-myers'-yervoy-in-melanoma-491202,491202
203090,424606,MRK,NeoGenomics expands I O profiling test lineup,news,Adjusting for recent advances in immunotherapy  NeoGenomics  NEO  expands its Immuno Oncology profiling test menu  Specifically  its NeoTYPE cancer profiles now include Tumor Mutation Burden  TMB  and microsatellite instability  MSI  testing TMB is a new biomarker designed to predict response to PD 1 and PD L1 checkpoint inhibitors  e g   Merck  NYSE MRK  s KEYTRUDA and Bristol Myers Squibb s OPDIVO  MSI testing is being added after the FDA approved the use of KEYTRUDA in patients with MSI high or mismatch repair deficient  MMR  solid tumors Now read ,2017-06-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/neogenomics-expands-i-o-profiling-test-lineup-491253,491253
203091,424607,MRK,Pfizer SBLA For Kidney Cancer Drug Combo Gets Priority Review,opinion,"Pfizer   NYSE PFE   and its partner Merck KGaA  announced that the supplemental Biologics License Application  sBLA  for Bavencio  avelumab   in combination with Pfizer s another cancer drug Inlyta  axitinib  was granted priority review by the FDA  The sBLA is seeking approval of the drug combination as a treatment for advanced renal cell carcinoma   RCC    the most common form of kidney cancer  The FDA s decision is expected in June 2019 While Bavencio is approved for treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma in patients whose disease progressed following a chemotherapy  Inlyta is approved for second line treatment of advanced RCC The sBLA was filed based on interim data from the phase III JAVELIN Renal 101 study which evaluated the Bavencio Inlyta combination against Pfizer s older kidney cancer drug Sutent  Data from the study  presented in the past  showed that the combination regimen led to statistically significant improvement in progression free survival   PFS   in patients whose tumors had PD L1 expression greater than 1  as well as in the entire study population regardless of PD L1 tumor expression  The ongoing study is currently evaluating the regimen for improvement in overall survival   OS   We note that Pfizer is developing Bavencio in JAVELIN program  which consists of at least 30 clinical studies evaluating the drug in more than 15 different cancer indications  Although Bavencio is approved two small cancer indication  successful development in the ongoing studies will help its label to expand into major indications  The company considers Bavencio  an anti PD L1 antibody  as a key driver of its long term growth  It is mainly focusing on developing the drug in combination with its other targeted therapies  PD 1 PD L1 targeted therapies hold tremendous potential as evident from the growth of Merck s   NYSE MRK   Keytruda and Bristol Myers    NYSE BMY   Opdivo  which are PD 1 inhibitors Pfizer s stock has risen 2 1  in the past six months  in line with the i s increase in the same time frame In a separate press release  Pfizer announced that it will present data from the phase III ARCHES study evaluating Xtandi for treating metastatic hormone sensitive prostate cancer  mHSPC   The company stated that the drug in combination with androgen deprivation therapy   ADT   significantly reduced the risk of radiographic progression or death by 61  compared to ADT alone Pfizer Inc  Price
    Zacks RankPfizer currently carries a Zacks Rank  4  Sell  You can see  Zacks  Best Stock Picking StrategyIt s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ",2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/pfizer-sbla-for-kidney-cancer-drug-combo-gets-priority-review-200386973,200386973
203092,424608,MRK,Bristol Myers  Sprycel Gets European Nod For Label Expansion,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the European Commission  EC  has approved its oncology drug Sprycel  dasatinib  in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive  Ph   acute lymphoblastic leukemia  ALL   The approval includes both the tablet form of Sprycel and  the powder for oral suspension  PFOS  formulation of the drug in a first for pediatric patients with ALL in Europe 
The FDA approved Sprycel for the same indication in January 2019  This is the second pediatric leukemia indication for Sprycel in Europe  It received an approval in July 2018 by the EC for the treatment of pediatric patients with Ph  chronic myeloid leukemia  CML  in chronic phase  CP  
The approval came on the back of positive data from a phase II study  CA180 372  NCT01 460160   which evaluated Sprycel tablets in combination with chemotherapy in 78 pediatric patients with newly diagnosed B cell precursor Ph  ALL  Sprycel plus chemotherapy demonstrated a three year event free survival benefit 
We note that Sprycel is already approved in the United States for the treatment of adults with Ph  CML in CP  The drug also received the FDA approval for adults with Ph  acute lymphoblastic leukemia  ALL  who are resistant to or intolerant of prior therapy  The FDA also approved Sprycel for treatment of pediatric patients with Ph  CML CP in November 2017 
Approval of new drugs and label expansion of existing drugs bode well for Bristol Myers  The stock has decreased 18 4  in the past year  against the  growth of 9 6   

 
While its blockbuster drug  Opdivo continues to perform well and label expansion of the drug will further boost the top line  pricing concerns and stiff competition in the immuno oncology space are major concerns  In particular  Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq pose stiff competition  Hence  the label expansion of other drugs of the company should help maintain the top line momentum 
Another drug of Bristol Myers  Eliquis is also expected to drive growth  owing to increases in market share in the novel oral anticoagulant  NOAC  market 
In a separate release  Bristol Myersannounced new results from the phase III CheckMate 214 study  wherein therapy with Opdivo  nivolumab  plus low dose Yervoy  ipilimumab  continued to demonstrate long term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma  RCC  
With a minimum follow up of 30 months  intermediate  and poor risk patients randomized to Opdivo plus low dose Yervoy continued to show a significant overall survival  OS  benefit compared to those randomized to Pfizer s   NYSE PFE   Sutent  sunitinib  Bristol Myers Squibb Company Price

   Zacks Rank 
Bristol Myers carries a Zacks Rank  2   Buy  You can see  
Zacks  Best Stock Picking Strategy 
It s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year  How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ",2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-sprycel-gets-european-nod-for-label-expansion-200387108,200387108
203093,424609,MRK,AstraZeneca s  AZN  Q4 Earnings Beat  New Drugs Drive Sales,opinion,"AstraZeneca plc   NYSE AZN   beat the Zacks Consensus Estimate for both earnings and sales in the fourth quarter of 2018  Pascal Soriot  AstraZeneca s chief executive officer  said  AstraZeneca has returned to growth  as its product sales grew for two consecutive quarters  Per Soriot  2019 will be marked by successful pipeline progress and commercial initiatives  The stock rose 5 4  in pre market trading on Feb 14 This year so far  AstraZeneca s shares have declined 4 9  against the  s increase of 2 2  Fourth quarter 2018 core earnings of 79 cents per American Depositary Share   ADS   beat the Zacks Consensus Estimate of 73 cents  Core earnings per share of  1 58 increased 22  year over year at constant exchange rates   CER    benefiting from higher revenues and operating profit Total revenues were up 14  at CER to  6 4 billion in the reported quarter  Revenues also  beat the Zacks Consensus Estimate of  6 16 billion All growth rates mentioned below are on a year over year basis and at CER Product Sales RiseProduct sales rose 8  at CER in the quarter to  5 77 billion  Higher sales of newer medicines  particularly cancer drugs  and strong performance in emerging markets  mainly China  offset lower sales of many other legacy medicines and drove product sales growth Externalization revenues were up more than twofold from the  year ago period to  649  These revenues are generated from AstraZeneca s externalization agreements Among AstraZeneca s various therapeutic areas  Oncology was up 61   New Cardiovascular  Renal and Metabolism   CVRM   was up 11  and Respiratory rose 5   However  other medicines declined 21  Newer ProductsAmong the newer medicines  Lynparza sales rose 23 7  sequentially to  209 million in the quarter  AstraZeneca markets Lynparza in partnership with Merck   NYSE MRK    The ovarian cancer drug received label expansion to include breast cancer patients in the United States in 2018 Tagrisso recorded sales of  594 million  nearly doubling year over year  driven by increased rapid uptake in the first line setting  Tagrisso was approved in first line setting for advanced lung cancer in the United States in April  in EU in June and in Japan in August Imfinzi generated sales of  262 million in the quarter compared with  187 million in the third quarter  In February  Imfinzi was approved and immediately launched for the second indication in the United States   early stage lung cancer  NSCLC    which drove sales higher in 2018  Imfinzi was approved in the EU for early stage lung cancer indication in September Calquence  which was launched in the United States in October 2017  generated sales of  24 million in the fourth quarter compared with  18 million in the previous quarter Brilinta Brilique sales were  376 million in the reported quarter  up 29  year over year Farxiga recorded sales of  397 million in the quarter  up 24  driven by growth across all markets New asthma medicine  Fasenra recorded sales of  125 million in the quarter compared with  86 million in the previous quarter  AstraZeneca said Fasenra enjoy leadership position among novel biologic asthma medicines Bevespi  a LAMA LABA in a pressurized metered dose inhaler  recorded sales of  10 million in the quarter  similar to the previous quarter  amid slower than anticipated growth in LAMA LABA class Among other new medicines  Movantik Moventig recorded sales of  25 million in the quarter  down 17   Iressa sales declined 11  to  112 million  Bydureon sales decreased 5  to  138 million  Byetta sales were down 31  to  32 million and Onglyza sales fell 15  to  148 million Older ProductsCrestor sales declined 38  to  353 million  U S  and Europe sales were weak as multiple generic versions of the drug entered the market  Seroquel XR sales declined 64  to  56 million due to competition from generic launches Symbicort sales declined 13  in the quarter to  636 million due to pricing pressure in the United States and stiff competition in Europe  Pulmicort sales rose 9  to  389 million as higher sales in the emerging markets made up for weaker performance in the United States and Europe Nexium recorded sales of  390 million  down 6  due to lower sales in the United States and Europe  In October  AstraZeneca announced its decision to divest prescription medicine rights to Nexium in Europe Sales of other legacy drugs including Faslodex  Zoladex  Seloken  Synagis and Daliresp Daxas grew in the quarter while sales of others like Arimdex  Casodex and Atacand declined Regional PerformanceIn the United States  product sales were up 15  to  2 billion on the back of higher sales of newer products  However  European markets witnessed a 7  decline in sales to  1 17 billion  Revenues from Emerging Markets were up 16  to  1 77 billion  primarily on the back of strong growth in China  up 22  to  948 million   In Established ROW market  comprising Japan  Canada and other markets   sales were up a mere 1  to  792 million Profit DiscussionAstraZeneca s core gross margin declined one percentage point to 78 6   Core selling  general and administrative  SG A  expenses rose 15  to  2 44 billion In the quarter  core research and development  R D  expenses rose 3  to  1 47 billion  Operating margin increased 3 percentage points to 34 2  in the quarter due to higher revenues 2019 OutlookAstraZeneca provided its earnings and sales outlook for 2019  which looked encouraging compared to market expectations AstraZeneca expects core EPS for 2019 in the range of  1 75 to  1 85 per ADS  The Zacks Consensus Estimate is pegged at  1 70  The company expects product sales to grow in high single digit percentage  Total externalization revenues and other income is expected to decline Currency movements are expected to unfavorably impact product sales and core earnings per share by a low single digit percentage Adjusted tax rate is expected to be in the range of 18  22  compared with 11  for 2018 AstraZeneca PLC Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Some better ranked pharma stocks include GlaxoSmithKline plc   NYSE GSK   and Bristol Myers Squibb Company   NYSE BMY    While Glaxo sports a Zacks Rank  1  Bristol Myers carries a Zacks Rank  2  Buy  Glaxo s earnings estimates have risen from  2 86 to  2 95 for 2019 over the past 60 days Bristol Myers  earnings estimates have increased from  4 07 to  4 16 for 2019 over the past 60 days Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2019-02-13,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales-200387999,200387999
203097,424613,MRK,WHO confirms second Ebola case in Congo outbreak,news,"By Aaron Ross
KINSHASA  Reuters    The World Health Organization  WHO  confirmed on Sunday a second case of Ebola in Democratic Republic of Congo after an outbreak this week of 17 other suspected cases 
Health officials are trying to trace 125 people thought to be linked to the cases identified in the remote northeastern province of Bas Uele province in northeastern Congo near the border with Central African Republic  WHO s Congo spokesman Eugene Kabambi said 
Three people have so far died among the 19 suspected and confirmed cases  he added 
It was not immediately clear how the first victim  a deceased male  caught the virus  although past outbreaks have been linked to contact with infected bush meat such as apes 
The outbreak comes just a year after the end of an epidemic in West Africa killed more than 11 300 people mostly in Guinea  Sierra Leone and Liberia 
However  Congo  whose dense forests contain the River Ebola near where the disease was first detected in 1976  has experienced many outbreaks and has mostly succeeded in containing them without large scale loss of life 
The GAVI global vaccine alliance said on Friday some 300 000 emergency doses of an Ebola vaccine developed by Merck  N MRK  could be available in case of a large scale outbreak and that it stood ready to support the Congo government on the matter ",2017-05-14,Reuters,https://www.investing.com/news/stock-market-news/who-confirms-second-ebola-case-in-congo-outbreak-484065,484065
203098,424614,MRK,Syndax advances study of etinostat and Keytruda  shares ahead 12  premarket,news,Thinly traded micro cap  Syndax Pharmaceuticals   NASDAQ SNDX  is up 12  premarket on light volume in response to its announcement that the non small cell lung cancer  NSCLC  cohort in its ENCORE 601 study assessing the combination of etinostat and Merck  NYSE MRK  s Keytruda  pembrolizumab  has met its pre specified objective response threshold and will proceed into the second stage of the trial  Enrollment will re open immediately and should be completed in H1 2018 The cohort consisted of NSCLC patients who failed to respond to anti PD 1 or PD L1 therapy  To advance into the definitive stage of the Phase 2 study  at least 10   n 2 20  of the participants who failed to respond to PD 1 L1 therapy and at least 23   n 3 13  of treatment naive participants needed to demonstrate an objective response  partial or complete  to etinostat   Keytruda treatment Etinostat is an orally available small molecule drug that inhibits an enzyme called histone deacetylase  HDAC  which plays a key role in controlling cell survival  proliferation  angiogenesis  formation of new blood vessels  and immunity Now read ,2017-05-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/syndax-advances-study-of-etinostat-and-keytruda;-shares-ahead-12-premarket-485397,485397
203099,424615,MRK,European stocks open lower amid U S  political worries  DAX down 0 14 ,news,"Investing com   European stocks opened lower on Thursday  as recent political developments in the U S  continued to weigh heavily on market sentiment 
During European morning trade  the EURO STOXX 50 fell 0 15   France s CAC 40 edged down 0 15   while Germany s DAX 30 slipped 0 14  
Global equities tumbled following reports on Tuesday that U S  President Donald Trump asked former FBI Director James Comey to end the agency s investigation into ties between former White House national security adviser Michael Flynn and Russia 
Investors were already cautious after news that Trump shared sensitive intelligence with Russia s foreign minister in a meeting last week 
Former FBI Director Robert Mueller was appointed on Wednesday by the Justice Department as a special counsel to take over the probe into Russia s interference in the 2016 election 
Financial stocks were broadly higher  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  lost 0 15  and 1 08   while Germany s  Deutsche Bank   DE DBKGn  declined 0 61  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  slid 0 38   while Spanish banks BBVA  MC BBVA  and  Banco Santander   MC SAN  dropped 0 49  and 2 82  respectively 
Elsewhere  Merck  NYSE MRK  saw shares decline 0 45  even after the German drugmaker reported better than expected results for the first three months of the year 
In London  FTSE 100 fell 0 37   weighed by  Hargreaves  Lansdown  LON HRGV   whose shares plummeted 2 38  even as the company reported a 10  rise in assets under administration in the four months to 30 April 
Mining stocks were also broadly lower on the commodity heavy index  Shares in  Fresnillo   LON FRES  fell 0 25  and BHP Billiton  LON BLT  declined 0 62   while  Glencore   LON GLEN  dropped 0 76  
Thomas Cook Group Plc  LON TCG  saw shares ease 0 09  after the tour operator reported a rise in revenue for the first quarter  in line with expectations  The company added that it was expecting strong demand for a number of southern European destinations over the summer season 
Meanwhile  financial stocks were mixed as  Barclays   LON BARC  slumped 0 69  and  HSBC Holdings   LON HSBA  tumbled 1 45   while Lloyds Banking  LON LLOY  rose 0 27  and the Royal Bank of Scotland  LON RBS  gained 0 31  
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 09  rise  S P 500 futures showed a 0 21  gain  while the Nasdaq 100 futures indicated a 0 28  increase ",2017-05-18,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-open-lower-amid-u.s.-political-worries;-dax-down-0.14-485771,485771
203100,424616,MRK,Glaxo Inks Deal With Merck KGaA To Co Develop Cancer Candidate,opinion,"GlaxoSmithKline plc   NYSE GSK   announced that it has entered into a global strategic alliance with Germany based Merck KGaA  to co develop and co commercialize the latter s next generation immunotherapy candidate  M7824  bintrafusp alfa   which has potential in multiple difficult to treat cancers  The move is line with Glaxo s strategy to boost its oncology pipeline The deal has a potential value of  4 2 billion   3 7 billion   which Glaxo will be eligible to pay to Merck KGaA in upfront and milestone payments  Per the deal terms  Glaxo will make an upfront payment of  341 7 million   300 million  to Merck KGaA and  569 5 million   500 million  in potential milestone payments related to development of the candidate in its lung cancer program  Glaxo will be eligible to pay additional  3 3 billion   2 9 billion  for future approval and commercial milestones  Moreover  the companies will equally share the cost of global development and profits on worldwide sales related to M7824 In the past six months  Glaxo s shares have underperformed the   falling 4 8  against a 1 1  increase for the industry M7824 is a novel immunotherapy and the first of its kind as it simultaneously targets two immuno suppressive pathways   transforming growth factor    TGF    along with the currently favorite  anti programmed cell death ligand 1  PD L1   Targeting these two pathways  which are commonly used by cancerous tumors to spread  is expected to help the candidate in restoring and enhancing anti tumor responses  This may result in better efficacy compared to individual therapies or combinations of individual therapies  Successful development of this next generation immunotherapy may help Glaxo to gain lead in the market targeted by checkpoints inhibitors  which already generate several billion dollars in annual sales Merck KGaA has eight high priority immuno oncology clinical development studies on M7824  While some of these are ongoing  the rest will commence this year  The candidate has shown encouraging clinical anti tumor activity in phase I studies across several difficult to treat cancer indications  A phase II study is comparing the candidate against U S  based Merck s   NYSE MRK   blockbuster immunotherapy  Keytruda  as first line treatment for non small cell lung cancer   NSCLC  We remind investors that Glaxo sold its oncology assets to Novartis   NYSE NVS   in 2015 in exchange for the latter s Vaccine portfolio  In the following years  Glaxo has significantly benefited from strong growth in Vaccine sales  However  it missed the opportunity to tap into the lucrative cancer market  which also witnessed impressive growth over the past couple of years and is the most sought after segment for pharma companies Moreover  Glaxo s Consumer Healthcare segment is facing slowdown and pricing pressure as new entrants have increased competition in the segment  The company is also facing generic competition for key respiratory and HIV drugs in its Pharmaceuticals division The company is re prioritizing its strategies to make up for the lost opportunity in the cancer market as well as offset loss in sales due to slowdown and rising competition by focusing on its oncology portfolio Apart from the Merck KGaA deal  the company bought TESARO  Inc  adding an interesting cancer drug  Zejula The company is also looking to spin off its consumer healthcare business into a separate entity in the next three years  Glaxo s joint venture with Pfizer  NYSE PFE  announced in December will be the world s largest consumer healthcare business  In December 2018  it announced the sale of its Horlicks brand to London based consumer giant Unilever  LON ULVR   These steps were taken to enable the company focus on its pharma segment GlaxoSmithKline plc Price
    Zacks RankGlaxo currently carries a Zacks Rank  3  Hold   You can  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/glaxo-inks-deal-with-merck-kgaa-to-codevelop-cancer-candidate-200384286,200384286
203101,424617,MRK,ImmunoGen  IMGN  Beats On Earnings   Sales In Q4  Shares Up,opinion,"ImmunoGen  Inc    NASDAQ IMGN   reported adjusted loss of 28 cents per share for the fourth quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of 33 cents  However  the loss was wider than the year ago loss of 10 cents per shares due to lower revenues and higher costs ImmunoGen s shares were up 10 3  on Feb 8  presumably on beating estimates on both counts  However  shares of ImmunoGen have significantly underperformed the  in the past six months  The stock has declined 38  compared with the industry s decrease of 12 9  RevenuesSince ImmunoGen has no approved product in its portfolio  the company earns revenues through royalties  license and milestone payments plus research and development  R D  support fees paid by its partners Revenues came in at  13 8 million in the quarter  beating the Zacks Consensus Estimate of  12 million  Sales decreased 65 1  from the year ago figure of  39 4 million due to lower license and milestone fees  Revenues consist of  1 7 million in license and milestone fees and  9 7 million in non cash royalty revenues  Revenues from R D support and clinical materials were  0 2 million and  2 2 million  respectively Operating Expenses   Cash DetailsResearch and development expenses increased almost 8 2  from the year ago level to  47 1 million  General and administrative  G A  expenses were up 7 4  to  9 7 million in the fourth quarter of 2018 ImmunoGen s cash and cash equivalents decreased to  262 3 million at the end of December 2018 compared with  303 2 million at the end of September 2018 The company expects its current cash and estimated cash revenues from partners and collaborators to fund its operations atleast through the first half of 2020  which is a year after the anticipated announcement of top line data from the phase III FORWARD I study Full Year ResultsThe company s adjusted earnings per share were  1 17 per share for the full year  up 20 6  from the year ago period Full year revenues were down 53 4  to approximately  53 8 million  The company had recorded much higher license and milestone fees of  79 5 million in 2017  including  30 million received from Sanofi   NASDAQ SNY   related to an amended agreement and  29 5 million related to the sale of ImmunoGen s IMGN529 asset to Debiopharm Pipeline UpdateImmunoGen has been progressing well with its pipeline product  mirvetuximab soravtansine  In October  the company announced preliminary data from the phase Ib II FORWARD II study evaluating combination regimens with mirvetuximab soravtansine in ovarian cancer  Data showed that the candidate in combination with Merck s   NYSE MRK   Keytruda achieved encouraging anti tumor activity  especially in patients with medium or high FR  expression levels The company completed enrollment ahead of schedule in a cohort of the FORWARD II study which is evaluatingthe candidate in combination with Roche s   OTC RHHBY   Avastin and carboplatin in recurrent platinum resistant ovarian cancer The company expects top line data from the phase III study  FORWARD I  in first half of 2019  The study is evaluating mirvetuximab soravtansine as a single agent therapy for treating patients with platinum resistant ovarian cancer whose tumors express high or medium levels of FR alpha  The company anticipates filing regulatory applications for mirvetuximab soravtansine in the United States and Europe in the second half of 2019  assuming positive result from the study  The company has also validated and developed a commercial version of the candidate  which it expects to launch in 2020 The company also submitted a pre market approval application for a companion diagnostic test for the candidate Apart from mirvetuximab soravtansine  ImmunoGen is working to develop a couple of other candidates in early stage studies including IMGN779  relapsed or refractory adult acute myeloid leukemia  and IMGN632  hematological malignancies including acute myeloid leukemia  2019 ViewThe company expects 2019 revenues to be in the range of  40  45 million  The Zacks Consensus Estimate is pegged at  56 4 million The company expects to end 2019 with cash and cash equivalents between  135 million and  140 million ImmunoGen expects operating expenses for 2019 in the range of  265  270 million ImmunoGen  Inc  Price  Consensus and EPS Surprise
    Zacks RankImmunoGen currently carries a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-02-10,Zacks Investment Research,https://www.investing.com/analysis/immunogen-imgn-beats-on-earnings--sales-in-q4-shares-up-200386345,200386345
203102,424618,MRK,4 Trade Ideas For Merck,opinion,"Merck   Company Inc  NYSE MRK   ended a run higher in December  but only pulled back less than 38 2  of that move  In January it made a higher low and reversed to the current consolidation  It sits there with a RSI on the edge of retaking the bullish zone and the MACD rising and positive 
There is resistance at 77 75 and 79 then 80 25  Support lower comes at 76 25 and 74 50 then 72  Short interest is low at 1 6   The stock pays a 3 28  dividend and starts trading ex dividend March 14th  The company is expected to report earnings next on April 30th 
The February options chain shows big open interest at the 73 and 75 strikes on the put side  It is comparable at the 73 50  75 and 77 50 strikes on the call side but much bigger at the 80 strike  March options see open interest focused from 62 50 to 75 on the put side and bigger size from 75 to 80 on the call side 
April options are similar with put open interest focused from 65 to 75 and calls bigger at 75 and 80  June options are the first to cover the earnings report and show put open interest spread from 50 to 75  On the call side it is big at 65 but also 77 50 and 80 
Merck  Ticker   MRK

Trade Ideas For Merk
Buy the stock on a move over 77 75 with a stop at 75 50 
Buy the stock on a move over 77 50 and add a March 77 50 72 50 Put Spread   1 35  while selling a June 82 50 Covered Call   1 10  to pay for it 
Buy a March June 80 Call Calendar   1 50  
Buy a June 77 50 80 Call Spread   1 30  and sell the June 70 Put   1 10  
Elsewhere look for Gold to resume its uptrend while Crude Oil may be reversing lower  The U S  Dollar Index continues to mark time moving sideways in broad consolidation while U S  Treasuries are at resistance as they move higher  The Shanghai Composite reopens with a positive outlook and Emerging Markets are pausing in their move higher 
Volatility looks to remain at low levels making it easier for equities to advance  Their charts show digestion of the 6 week move higher in the shorter timeframe as the SPY  IWM and QQQ all held over their 20 day SMA s  The longer timeframe sees the uptrend intact but with some indecision in the short run  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2019-02-11,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-merck-bonus-idea-200386215,200386215
203112,424628,MRK,Merck higher after boosting full year guidance,news,Merck  NYSE MRK  raises full year guidance along with its Q1 earning beat  The drug company sees 2017 revenue of   39 1  40 3b vs   38 6  40 1B prior and  39 7B consensus  The view on full year EPS is narrowed to  3 76  3 87 vs   3 72  3 87 prior and  3 81 consensus  During Q1  Merck surprised by bringing in  532M in Gardasil revenue and  378M in Zepatier revenue  tha tallies for Simponi   184M  and Isentress   305M  were below expectations  Source for estimates  BloombergPreviously  Merck beats by  0 05  beats on revenue  May 2  MRK  1 62  premarket to  63 39  Now read  Merck  Strong Research And Bolt On Acquisitions,2017-05-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck-higher-after-boosting-full-year-guidance-479259,479259
203113,424629,MRK,Merck eyes key cancer drug growth as others lose patent protection,news,"By Bill Berkrot and Natalie Grover  Reuters    Merck   Co Inc  N MRK  on Tuesday reported better than expected profit in the first quarter as surprisingly strong demand for animal health products  vaccines and its hepatitis C treatment offset nearly  700 million in lower sales from drugs that lost patent protection  The U S  drugmaker said its fast growing immuno oncology drug Keytruda is gaining market share and sees future sales opportunities across multiple types of cancer  despite first quarter sales of  584 million falling just shy of analysts  estimates  The company said Keytruda has become  the most prescribed  product for previously untreated  or first line  lung cancer and it is looking to expand its use in second line lung therapy  Merck is awaiting a potential U S  approval next week for Keytruda in combination with chemotherapy   The approval could meaningfully boost sales of Keytruda given the size of the lung cancer market   said Edward Jones analyst Ashtyn Evans of by far the largest oncology market  Research chief Roger Perlmutter called the combination  a major opportunity to establish Keytruda further as a real preferred treatment therapy   Keytruda use is also growing in head and neck cancers  with 15 percent of U S  sales for that indication now compared with 40 percent from lung  Merck slightly raised its 2017 adjusted earnings forecast to a range of  3 76 to  3 88 per share from its prior view  3 72 to  3 87  due to a favorable foreign exchange environment  It now expects full year revenue of  39 1 billion to  40 3 billion  up from  38 6 billion  40 1 billion  Total revenue rose 1 3 percent to  9 43 billion in the quarter  beating analysts  average estimate of  9 25 billion  despite the loss of U S  patent exclusivity on cholesterol drug Zetia  antibiotic Cubicin  Nasonex nasal spray  and new competition for rheumatoid arthritis drug Remicade in Europe  Merck s blockbuster cholesterol drug Vytorin will also face competition from cheap generic rivals going forward   In addition to Keytruda  we ve got multiple other launches that are showing good growth and we ve got a strong portfolio of vaccines  to help offset loss of exclusivities  said Adam Schechter  Merck s head of global human health  Merck s hepatitis C treatment Zepatier had sales of  378 million  topping analysts  estimates of  269 million  while sales of  532 million for Gardasil vaccine against human papillomavirus also sailed past Wall Street forecasts  Animal health sales grew 13 percent to  939 million  The company cautioned that animal health growth would be  more measured in subsequent quarters    Excluding items  Merck earned 88 cents per share  beating analysts  average estimate by 5 cents  according to Thomson Reuters I B E S  
Merck shares were up 10 cents at  62 48 ",2017-05-02,Reuters,https://www.investing.com/news/stock-market-news/merck-profit-tops-estimates-as-margins-rise;-co-raises-2017-forecast-479264,479264
203114,424630,MRK,Merck s Keytruda wins EU approval,news,It s the first approval for Keytruda in a hematologic malignancy in the EU  says Merck  NYSE MRK   and allows marketing of the drug in all 28 EU member states plus Iceland  Lichtenstein  and Norway at the approved dose of 200 mg every three weeks The approval was based on data from 241 patients from the Keynote 087 and Keynote 013 trials Now read  Merck And A Curiously Effective Buyback,2017-05-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck's-keytruda-wins-eu-approval-480542,480542
203115,424631,MRK,Inovio s Early Mid Stage Vaccine Pipeline Exhibits Growth,opinion,"On Jan 25  we issued an updated research report on Inovio Pharmaceuticals  Inc    NASDAQ INO   
Inovio s most advanced candidate  VGX 3100 vaccine  has been progressing well alongside other promising pipeline candidates in its portfolio 
VGX 3100 is currently being evaluated in a phase III study  REVEAL 1  for the treatment of cervical dysplasia  caused by human papillomavirus  HPV   The company expects to complete enrollment in REVEAL 1 study by early 2019 and initiate the REVEAL 2 study thereafter  Another phase II study is examining the efficacy of VGX 3100 on women with vulvar dysplasia and anal dysplasia  This will be the third indication that VGX 3100 will be evaluated for 
Last August  Inovio announced a partnership with the AIDS Malignancy Consortium to evaluate VGX 3100 for treating HPV associated precancerous conditions in patients  who have tested positive for HIV 
Shares of Inovio have increased 5 2  in the past year against the  decrease of 23 9  

Inovio out licensed MEDI0457 to MedImmune  a subsidiary of AstraZeneca plc   NYSE AZN    MEDI0457 is a combination of VGX 3100 and its DNA based IL 12 cytokine 
Inovio is set to receive an undisclosed milestone payment from AstraZeneca as the latter dosed the first patient in a phase II study on T cell activating immunotherapy  MEDI0457  The program will evaluate MEDI0457 in combination with AstraZeneca s anti PD L1 checkpoint inhibitor  Imfinzi  for treating several HPV related cancers 
Apart from VGX 3100  Inovio has several vaccine candidates in its pipeline under early to mid stage development 
Earlier this month  Inovio initiated the first human study of its DNA encoded monoclonal antibody  dMAb  technology to prevent Zika virus infection in collaboration with The Wistar Institute and the University of Pennsylvania  The phase I dose escalation study on INO A002 demonstrated safety and tolerability  starting at lower level and then gradually increasing the doses 
Last week  Inovio announced that a second patient with HPV related head and neck cancer treated with INO 3112 in a phase I analysis achieved a sustained complete response after subsequent treatment with a PD 1 checkpoint inhibitor  The complete responder received Merck s   NYSE MRK   Keytruda  a PD 1 inhibitor  after being administered with INO 3112  The first complete responder received Bristol Myers Squibb s   NYSE BMY   Opdivo after the vaccine 
Inovio is developing a vaccine for Ebola virus  INO 4212   The vaccine provided 100  protection following a lethal dose in a preclinical study and prompted long term immune responses in monkeys 
Inovio s INO 4700 vaccine is being co developed by GeneOne Life Science Inc for MERS  Middle East Respiratory Syndrome   The company expects to begin a phase II probe on MERS vaccine in the Middle East during 2019  Inovio and GeneOne Life Science also dosed the first patient in a phase I investigation on its hepatitis C vaccine  GLS 6150  to boost immunity in patients 
Inovio is evaluating its HIV vaccine  Pennvax GP s  in a phase I II study and dosed the first patient with the same  The vaccine targets all major HIV strains with potential capacity to improve the human immune system and control HIV without antiretroviral therapy 
Inovio has collaboration with a few big pharma companies  which help it with constant funding for pipeline development  However  Inovio has no approved product in its portfolio  Hence  an excessive dependence on its partners for developing its pipeline candidates remains an overhang on the company 
Zacks Rank
Inovio currently carries a Zacks Rank  3  Hold   You can see  
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/inovios-earlymidstage-vaccine-pipeline-exhibits-growth-200380236,200380236
203116,424632,MRK,Merck s Pneumococcal Vaccine Gets Breakthrough Therapy Status,opinion,"Merck   Co   Inc    NYSE MRK   announced that the FDA has granted Breakthrough Therapy designation to its 15 valent pneumococcal conjugate vaccine candidate  V114  The candidate is being developed as a preventive treatment for invasive pneumococcal disease   IPD   in pediatric patients The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life threatening conditions  The FDA also indicated that the candidate can be eligible for Accelerated Approval and Priority Review depending upon certain criteria The designation was granted on the basis of positive immunogenicity data from two clinical studies   phase I II Study 005 and phase II Study 008   of the multivalent pneumococcal conjugate vaccine in children aged 6 weeks to 18 years  Data from the studies showed that the vaccine induced an immune response for two disease causing serotypes  22F and 33F   which are not provided by the currently available 13 valent pneumococcal conjugate vaccine  The candidate demonstrated non inferiority for the other serotypes contained in both the vaccines The candidate is also being developed for prevention of IPD in adult patients  V114 is also currently being evaluated in two phase III studies in patients aged 50 years and above or adult HIV patients We remind investors that Pfizer   NYSE PFE   is developing a 20 valent pneumococcal conjugate vaccine for a similar indication in a late stage study Merck s stock has outperformed the industry in the past six months  Merck s shares have risen 12  against the  s decrease of 1 7   Merckhas a strong vaccine portfolio led by its human papillomavirus   HPV   vaccine  Gardasil  Total vaccine portfolio generated sales of  2 2 billion in the third quarter of 2018  The company s approved pneumococcal vaccine  Pneumovax 23 alone generated sales of  214 million in the quarter  However  the portfolio is being unfavorably impacted by major decline in sales of shingles vaccine  Zostavax  which faces strong competition from Glaxo s   NYSE GSK   shingles vaccine  Shingrix Merck also has a strong vaccine pipeline  In December  the company received approval for its Hepatitis B vaccine  Vaxelis  which was developed in collaboration with Sanofi   NASDAQ SNY    Apart from this  the company has two late stage vaccine candidates for shingles and Ebola  These developments are likely to maintain the double digit growth rate for the vaccines portfolio Merck   Co   Inc  Price
    Zacks RankMerck currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-31,Zacks Investment Research,https://www.investing.com/analysis/mercks-pneumococcal-vaccine-gets-breakthrough-therapy-status-200382142,200382142
203123,424639,MRK,Aurinia completes out licensing deal with Merck Animal Health for VOS for canine dry eye syndrome  shares ahead 4  after hours,news,Aurinia Pharmaceuticals  NASDAQ AUPH  is up 4  after hours on robust volume in response to its announcement that it has inked a license agreement with Merck  NYSE MRK  Animal Health granting it global rights to develop and commercialize voclosporin ophthalmic solution  VOS  for the treatment of dogs with dry eye syndrome Under the terms of the agreement  Aurinia will receive an upfront payment  milestones and royalties on net sales  Merck Animal will be responsible for all remaining clinical development related to VOS in animal health  Aurinia retains all rights for human uses  Specific financial terms are not disclosed ,2017-04-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/aurinia-completes-out-licensing-deal-with-merck-animal-health-for-vos-for-canine-dry-eye-syndrome;-shares-ahead-4-after-hours-474809,474809
203124,424640,MRK,Glaxo submits marketing application in Japan for shingles vaccine,news,GlaxoSmithKline  GSK  1 4   has filed a New Drug Application in Japan seeking approval of its shingles vaccine  Shingrix  for the prevention of herpes zoster in people at least 50 years old The company filed its marketing application in the U S  in October 2016 and a month later in Canada and Europe In clinical studies  a two dose regimen of Shingrix showed 90  efficacy in participants at least 70 years old and was maintained in those aged 80 and above  significantly better than Merck  NYSE MRK  s ZOSTAVAX which is only 18  effective in people aged 80  Previously  Glaxo submits BLA for shingles vaccine in U S   Oct  24  2016 ,2017-04-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/glaxo-submits-marketing-application-in-japan-for-shingles-vaccine-475036,475036
203125,424641,MRK,PDL Biopharma settles keytruda patent infringement lawsuit with Merck,news,PDL BioPharma  NASDAQ PDLI  announces that it has entered into a settlement agreement with certain subsidiaries of Merck  NYSE MRK  to resolve their patent infringement lawsuit related to Keytruda  pembrolizumab  Under the terms of the agreement  Merck will pay PDLI  19 5M in exchange for a fully paid up  royalty free  non exclusive license to certain patent rights related to Keytruda while PDLI has agreed not to sue Merck for royalties  Both parties have agreed to dismiss all claims related to the litigation PDLI is up 4  premarket on light volume Now read  Merck Leads Rivals In Novel Drug Approvals,2017-04-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/pdl-biopharma-settles-keytruda-patent-infringement-lawsuit-with-merck-476678,476678
203126,424642,MRK,Fresenius snaps up Akorn  Merck KGaA s biosimilars in separate deals,news,"By Ludwig Burger FRANKFURT  Reuters    German healthcare conglomerate Fresenius SE   Co KGaA  DE FREG  revved up the pace of its deals by acquiring U S  generic drugmaker  Akorn  Inc  O AKRX  for  4 75 billion  4 37 billion euros   and in a separate agreement  the biosimilars unit of German peer Merck  NYSE MRK  KGaA   While in keeping with its focus on drugs that have lost patent protection  the deals mark a foray into new dosage forms  new therapeutic areas and into biotech drugs for Fresenius s Kabi unit  a maker of generic infusion drugs  tube feeding and blood transfusion equipment  Akorn will add products such as medical creams  ophthalmic drugs  oral liquids  ear drops  nasal sprays and respiratory drugs  where competition is relatively benign when compared with standard pills and tablets  The deal with Merck  in turn  marks the entry into biosimilar copies of complex biologic drugs made from living cells  which Fresenius has previously shunned    We ve always said the regulatory environment would have to clear up before we invest in biosimilars  A lot has been done in that area in the recent past   Fresenius Chief Executive Stephan Sturm told Reuters  Reuters earlier on Monday reported that Fresenius was close to acquiring Akorn  In a deal that has the backing of Akorn s management and its largest shareholder  Fresenius will pay  34 per share and take on Akorn s net debt of about  450 million for a total price tag of  4 75 billion  Fresenius said in a statement late on Monday  It will be financed by a broad mix of euro  and dollar denominated debt instruments  it added  In the separate agreement with Merck KGaA  Fresenius will pay an initial 170 million euros   185 million  and up to 500 million euros in future milestone payments tied to achievements of drug development targets as none of Merck s biosimilar drugs have been launched yet  Fresenius said it expects first revenues towards the end of 2019 and it is prepared to spend and invest an extra 1 4 billion euros to build up the business over the years through 2022  It will pay single digit percentage royalties to Merck based on sales  Fresenius  with a market capitalization of more than 40 billion euros  runs businesses in areas ranging from kidney dialysis and drug manufacturing to hospital management   Fresenius CEO Sturm  had signaled that acquisitions would be a hallmark of his leadership after he took over the top job in July last year  In September  the company made its biggest deal ever with the acquisition of Spain s private hospital chain Quironsalud for 5 8 billion euros to expand the international presence of its hospital business Helios  Group net debt as a multiple of core earnings will temporarily increase to about 3 3 after closing of both transactions but the ratio is expected to return to about 3 at the end of 2018  
Fresenius has for years enjoyed low borrowing costs because of its diversified businesses in an industry that is largely immune to swings in the business cycle ",2017-04-24,Reuters,"https://www.investing.com/news/stock-market-news/fresenius-snaps-up-akorn,-merck-kgaa's-biosimilars-in-separate-deals-476876",476876
203127,424643,MRK,FDA OKs Impax Labs  generic Vytorin  shares ahead 2  after hours,news,Impax Laboratories  NASDAQ IPXL  perks up 2  after hours on increased volume in response to its announcement that the FDA has approved its generic version of Merck  NYSE MRK  s cholesterol drug Vytorin  ezetimibe simvastatin   the first generic to be commercially available in the U S According to IMS Heath  the U S  market is   678M  Merck booked over  1 1B in sales for Vytorin in 2016 Now read  GlaxoSmithKline  Good News  2016 s Positive Momentum Continues,2017-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-impax-labs'-generic-vytorin;-shares-ahead-2-after-hours-477802,477802
203128,424644,MRK,Merck  MRK  Q4 Earnings Coming Up  What s In The Cards ,opinion,Merck   Co   Inc    NYSE MRK   will report fourth quarter and full year 2018 results on Feb 1 before market open  In the last reported quarter  the company delivered a positive earnings surprise of 2 59  Merck s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters is 3 96  Merck s shares have outperformed the  in the past year  It has risen 18 3  in the said time frame against a 6 6  decrease for the industry   Let s see how things are shaping up for this announcement Factors to ConsiderMerck s new products like cancer drug  Keytruda  Gardasil vaccine and Bridion injection should continue to drive the top line this quarter driven by strong demand trends  Alliance revenues from Lynparza and Lenvima should also boost oncology sales However  loss of market exclusivity for several drugs  softness in the diabetes  Januvia Janumet  franchise  and lower sales of key products like Zostavax and Zepatier due to competitive pressure may hurt sales Keytruda sales are likely to be driven by the launch of new indications globally  Keytruda sales are gaining particularly from strong momentum in the indication of first line lung cancer as it is the only anti PD 1 approved in the first line setting In October  Keytruda gained FDA and EU approval to include overall survival data from a key late stage lung cancer study  KEYNOTE 189 study on its label  It was also approved for metastatic merkel cell carcinoma  a rare form of skin cancer in the United States and for high risk stage III melanoma patients in the adjuvant setting in the EU in December  These label expansion approvals should drive sales of Keytruda in the future quarters Strong demand in most markets is driving sales of Bridion  sugammadex  Injection   a trend which is expected to be reflected in the fourth quarter results  Bridion was launched in China in the third quarter  which can bring in additional sales In the third quarter  Merck received FDA approval for Gardasil 9 in an expanded patient population  women and men ages 27 to 45   which can bring in additional sales of the vaccine in the fourth quarter However  rising competitive pressure is hurting sales of relatively newer drugs like Zostavax and Zepatier  Zepatier sales are going down sharply due to reduction in patient volume due to increasing competition  Zostavax sales will continue to be hurt by strong competition from Glaxo s   NYSE GSK   newly approved shingles vaccines  Shingrix  Among the older products  while continued pricing pressure is hurting sales of the diabetes franchise  Januvia Janumet   lower demand in the United States and competitive pricing pressure in Europe is hurting sales of Isentress Animal health franchise sales should remain strong in the fourth quarter Meanwhile  higher R D costs will hurt profits due to increased clinical development spending for Lynparza and Lenvima and investment in early drug development Earnings WhispersOur proven model does not conclusively show that Merck will beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP is 0 00  as both the Zacks Consensus Estimate and the Most Accurate Estimate is pegged at  1 03  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Merck s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderLarge pharma stocks that have both a positive ESP and a favorable Zacks Rank include AstraZeneca  plc   NYSE AZN   has an Earnings ESP of  8 00  and a Zacks Rank of 3  The company is scheduled to report fourth quarter earnings on Feb 14  You can see  Novo Nordisk  CO NOVOb  A S   NYSE NVO   has an Earnings ESP of  0 89  and a Zacks Rank  3  The company is slated to release results on Feb 1 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-q4-earnings-coming-up-whats-in-the-cards-200380136,200380136
203140,424656,MRK,European stocks steady to lower in more cautious trade  DAX dips 0 01 ,news,"Investing com   European stocks were steady to lower in more cautious trade on Thursday  as markets were still jittery after the terrorist attack perpetrated in London on Wednesday and as investors continued to focus on U S  president Donald Trump s policies 
During European morning trade  the EURO STOXX 50 fell 0 26   France s CAC 40 slipped 0 22   while Germany s DAX 30 dipped 0 01  
Market sentiment waned after five people  including a police officer and one man believed to be the attacker  were killed on Wednesday in an attack that London police are calling a  terrorist incident  
The suspect mowed down pedestrians in a vehicle on Westminster Bridge before fatally stabbing the officer outside the Houses of Parliament and being shot and killed 
Investors were also cautious ahead of a key vote on U S  President Donald Trump s healthcare bill later in the day 
Investors were especially concerned about Trump s ability to gather enough support for his healthcare bill   set to replace Obamacare and one of his key campaign pledges 
Financial stocks were mixed  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  fell 0 05  and 0 13   while Germany s  Deutsche Bank   DE DBKGn  edged down 0 13  and Commerzbank  DE CBKG  gained 0 72  
Among peripheral lenders   Intesa Sanpaolo   MI ISP  rallied 1 60  and Unicredit  MI CRDI  slipped 0 21  in Italy  while Spanish banks  Banco Santander   MC SAN  and BBVA  MC BBVA  gained 0 51  and 0 35  
Elsewhere  Merck   Company  NYSE MRK  Inc  SIX MRKUSD  shares rose 0 25  even as an appeals court in Philadelphia ruled on Wednesday that plaintiffs may proceed to trial in their lawsuit accusing the company of failing to provide adequate warning on the risk of thigh bone fractures associated with osteoporosis medicine Fosamax 
In London  FTSE 100 slipped 0 21   weighed by  Kingfisher   LON KGF   whose shares plummeted 2 29  after saying on Wednesday that falling sales at its French operations offset much of the benefit from the weaker pound and growth at its UK based chain Screwfix 
Meanwhile  financial stocks were mixed  Shares in Lloyds Banking  LON LLOY  dipped 0 06  and  Barclays   LON BARC  fell 0 23   while  HSBC Holdings   LON HSBA  edged up 0 08  and the Royal Bank of Scotland  LON RBS  rose 0 26  
Mining stocks were also mixed on the commodity heavy index  as  Rio Tinto   LON RIO  and BHP Billiton  LON BLT  slid 0 34  and 0 43  respectively  while  Glencore   LON GLEN  gained 0 80  and  Antofagasta   LON ANTO  rallied 1 01  
 Tesco   LON TSCO  was one of the top performers on the index  with shares up 1 21  after the supermarket chain refused to accept price increases from Heineken  which the brewer blamed on Brexit and the budget  and pulled Sol  Amstel and Tiger from its shelves 
In the U S   equity markets pointed to a steady open  The Dow Jones Industrial Average futures pointed to a 0 05  dip  S P 500 futures showed a 0 04  uptick  while the Nasdaq 100 futures indicated a 0 05  loss ",2017-03-23,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-steady-to-lower-in-more-cautious-trade;-dax-dips-0.01-468217,468217
203141,424657,MRK,European stocks mixed on U S  political jitters  E Z  data  DAX up 0 03 ,news,"Investing com   European stocks were mixed on Friday  as markets were still jittery ahead of a highly anticipated vote on U S  President Donald Trump s healthcare bill and as investors eyed the release of a string of euro zone manufacturing and service sector data 
During European morning trade  the EURO STOXX 50 edged down 0 18   France s CAC 40 slipped 0 21   while Germany s DAX 30 inched up 0 03  
Investors remained cautious after Trump warned House Republican lawmakers that he will leave Obamacare in place and move on to tax reform if they do not approve new healthcare legislation in a vote on Friday 
The healthcare vote is seen by investors as a test of his ability to implement key campaign promises such as tax reform and infrastructure spending 
Earlier Friday  data showed that German private sector growth hit its strongest level in nearly six years 
Financial stocks were broadly lower  as French lenders  Societe Generale   PA SOGN  and  BNP Paribas   PA BNPP  lost 0 07  and 0 51   while Germany s Commerzbank  DE CBKG  dipped 0 04  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  and Unicredit  MI CRDI  slipped 0 24  and 0 35  respectively  while Spanish banks  Banco Santander   MC SAN  and BBVA  MC BBVA  declined 0 40  and 0 51  
Elsewhere  Sanofi  PA SASY  SA slid 0 71  despite reports the French drugmaker struck a deal to buy Flexion and the pain drug it now has under review at the FDA 
On the upside  Merck   Company  NYSE MRK  Inc  SIX MRKUSD  saw shares jump 1 43  after it and  Pfizer   NYSE PFE  got their first FDA approval of the checkpoint inhibitor avelumab  making it the fourth drug in this category to make it to the market 
In London  FTSE 100 inched up 0 03   helped by  Smiths Group   LON SMIN   whose shares surged 4 31  after the company said its pretax profit more than doubled in the six months ended January 31  helped by a rise in sales and profit from a disposal 
 National Grid   LON NG  added to gains  with shares advancing 0 98  following reports International Public Partnership expects its investment in the company s gas distribution network to be completed in the next few weeks 
Last December  International Public Partnership said that it was part of a consortium to buy a 61  stake in National Grid s gas distribution network and that it will invest up to  275 million 
Mining stocks were also broadly higher on the commodity heavy index  Shares in BHP Billiton  LON BLT  climbed 0 44  and  Glencore   LON GLEN  advanced 0 68   while  Rio Tinto   LON RIO  jumped 0 93  
In the financial sector  stocks were mostly higher as Lloyds Banking  LON LLOY  eased up 0 06  and  HSBC Holdings   LON HSBA  gained 0 29   while  Barclays   LON BARC  rallied 1 05   The Royal Bank of Scotland  LON RBS  underperformed however  with shares down 0 54  
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 25  rise  S P 500 futures showed a 0 19  gain  while the Nasdaq 100 futures indicated a 0 26  increase ",2017-03-24,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-mixed-on-u.s.-political-jitters,-e.z.-data;-dax-up-0.03-468561",468561
203142,424658,MRK,New budget test puts UK on front line in global drug price fight,news,"By Ben Hirschler LONDON  Reuters    Can society afford modern medicines  It s a question facing governments worldwide and nowhere more so than in Britain  where a new budget test due to take effect on April 1 threatens to throw up another hurdle to patients getting the drugs  For the last 18 years Britain has led the way in measuring drug cost effectiveness in a rational and dispassionate way  using a model of economic benefits developed by the National Institute for Health and Care Excellence  NICE   NICE has inspired copycat agencies across Europe   and in countries as diverse as South Korea and Mexico   giving it an influence beyond Britain s 3 percent slice of global drug sales  Now  however  the original system is struggling and patient charities and drugmakers are alarmed  especially given the wider funding uncertainties facing the National Health Service  NHS   which offers free care at the point of delivery  The new rules mean drugs costing NHS England more than 20 million pounds   25 million  a year will no longer get automatic funding  even if they are cost effective   Instead  firms will have to haggle to get them used  resulting in a potential delay of three years  Peter Johnson  professor of medical oncology at the University of Southampton  fears his patients may lose out on a wave of costly new immunotherapy drugs that are starting to transform treatment   Just when we are seeing an increase in the pace of progress with these drugs  I m worried that this country is going to be unnecessarily slowed down by the new affordability cap   he told Reuters  Since immune system boosting drugs like Merck  NYSE MRK    Co s Keytruda  Bristol Myers Squibb s Opdivo and Roche s Tecentriq can be used against a wide range of cancers  their budget impact will be significant   Almost all these new cancer drugs will hit the 20 million pounds ceiling very quickly indeed  particularly when they are used for common cancers like lung cancer   said Johnson  who also acts as chief clinician for Cancer Research UK  Meeting rising demand from medical advances and aging populations is a universal problem  whether healthcare is funded by UK style general taxation  compulsory social insurance common in western Europe or private insurance as in the United States  But NICE is unusual in putting a clear number on the benefit it expects from new drugs  using quality adjusted life years  QALYs   where one QALY equals a year of perfect health or two years of middling health  Its basic cost effectiveness threshold is up to 30 000 pounds per QALY and in future it wants to incentivize drugmakers to come in below 10 000 pounds by offering rapid approval for  exceptional value  products  NICE data  however  shows only 10 to 15 percent of the drugs it approves currently meet this lower cost effectiveness hurdle  RESPONSIBLE PRICING Carole Longson  director of NICE s center for health technology evaluation  says the onus is on drugmakers to price medicines responsibly   Given the pace of technological innovation  the demands of people who need healthcare and the return on investments that shareholders wish for  the system is struggling   she said  In some cases that may mean phasing payments  rather than simply cutting prices  when treatments like cancer immunotherapy or gene therapy offer long lasting benefits   We need to find ways to structure the budget impact   she said in an interview  NICE s QALY thresholds have long provoked controversy and complaints among drugmakers whose products have fallen on the wrong side of the equation  yet the system has stood the test of time  albeit with tweaks such as looser requirements for end of life care  The new budget test  however  is  a kind of fudge   said Karl Claxton  a health economist at the University of York  who served on NICE s appraisal committee from 1999 to 2012   As a result of trying to put patches on all of this  we end up with a very confusing and rather arbitrary approach   he said  The upheaval comes at a tricky time for the government  which is about to trigger proceedings to leave the European Union but wants to encourage investment by pharmaceutical firms  which account for a fifth of all UK business R D spending  
 It s a disastrous signal to send to the rest of the world   said Mike Thompson  chief executive of the Association of the British Pharmaceutical Industry  who still hopes the government could change its mind before the end of the month ",2017-03-27,Reuters,https://www.investing.com/news/economy-news/new-budget-test-puts-uk-on-front-line-in-global-drug-price-fight-469072,469072
203143,424659,MRK,The cost of cancer  new drugs show success at a steep price,news,"By Deena Beasley  Reuters    Newer cancer drugs that enlist the body s immune system are improving the odds of survival  but competition between them is not reining in prices that can now top  250 000 a year  The drugs  success for patients is the result of big bets in cancer therapy made by Bristol Myers Squibb Co  Merck  NYSE MRK    Co Inc and Roche Holding  SIX ROG  AG  among others in big pharma  The industry s pipeline of cancer drugs expanded by 63 percent between 2005 and 2015  according to the QuintilesIMS Institute  and a good number are reaching the market  The global market for cancer immunotherapies alone is expected to grow more than fourfold globally to  75 8 billion by 2022 from  16 9 billion in 2015  according to research firm GlobalData  For a graphic  click   For cancer drugs in general     it is hard for us to drive down cost   said Steve Miller  chief medical officer at Express Scripts Holding Co  the nation s largest manager of drug benefit plans for employers and insurers   You don t want to be in the position of being told to use the second best cancer drug for your child   Lawmakers on both sides of the aisle  as well as President Donald Trump  have been grappling with how to restrain rising prescription drug costs  They have talked about solutions ranging from more price negotiation to faster approval of new drugs  often invoking increased competition between drugmakers   Competition is key to lowering drug prices   Trump told pharmaceutical executives at an Oval Office meeting in January  But that is not happening with new drugs called checkpoint inhibitors that work by releasing a molecular brake  allowing the immune system to recognize and attack cancer cells the same way it fights infections caused by bacteria or viruses   For cancers like melanoma  the treatments can mean long term survival for around 20 percent of patients  Bristol s Yervoy  first approved in 2011  targets a protein known as CTLA 4  Other immunotherapies  including Bristol s Opdivo  Keytruda from Merck  Roche s Tecentriq  and  Pfizer   NYSE PFE  Inc s Bavencio  involve a different protein called PD 1  Other targets are being explored  Some new data will be presented this week in Washington at the American Association for Cancer Research s annual meeting  Current checkpoint inhibitors each have a list price near  150 000 a year  A combination of Yervoy and Opdivo  approved by the Food and Drug Administration for advanced or inoperable melanoma  has a cost of  256 000 a year for patients who respond to the treatment  Similar immunotherapies are in development at companies like AstraZeneca Plc  Merck  which declined to comment on pricing plans  expects an FDA decision by May 10 on its combination of Keytruda and chemotherapy as an initial treatment for the most common form of lung cancer   by far the biggest market for cancer drugs  Pfizer said Bavencio  cleared by the FDA earlier this month to treat Merkel cell carcinoma  a rare type of skin cancer  has a price  comparable to other checkpoint inhibitors approved for different indications   The pharmaceutical industry holds that discussion of prescription drug prices has to take into account the major investment required for innovation and discovery of new lifesaving drugs   UNRESTRAINED PRICING POWER   Scientific progress  and pricing power  are driving pharmaceutical companies to emphasize oncology research    Most of the strategy on the part of pharmaceutical companies assumes unrestrained pricing power   said Dr  Peter Bach  director of Memorial Sloan Kettering s Center for Health Policy Outcomes in New York   We don t see evidence that companies are pursuing cost effective strategies   Health insurers have had success in demanding price concessions in some drug categories   like diabetes  where several companies sell similar products and insurers are able to negotiate price discounts or rebates in exchange for coverage  According to IMS  that tactic capped the overall rise in spending on diabetes medicines at 8 percent in 2015  compared with an increase of 30 percent in billed invoices  All of the invoice price growth for insulin was offset by price cuts  the institute said  But discounting is much less common for newer  innovative cancer drugs  mostly given by injection and approved for defined patient populations  Net price growth for branded oncology drugs averaged 4 8 percent in 2015  versus 6 4 percent for invoices  according to IMS  Express Scripts  Miller and others said makers of new cancer medications enjoy pricing power due to coverage requirements  insurance plan structure and a lack of head to head comparison studies   Cancer drugs don t compete on price   said Dr  Aaron Kesselheim  a researcher at Harvard Medical School and author of several studies of drug pricing   Drug companies have market exclusivity and we require payers to cover cancer drugs   Medicare has six protected classes  including cancer   Medicare  the federal government s healthcare plan for seniors and the disabled  covers most prescription drugs under its  Part D  pharmacy benefits  The plans are required to cover all drugs in six classes  cancer  HIV  antidepressants  antispychotics  seizure disorders like epilepsy  and immune system suppressants for people undergoing organ transplantation   Trump met recently with Representatives Elijah Cummings and Peter Welch  both Democrats  to discuss draft legislation allowing the government to negotiate Medicare drug prices   but the bill preserves the six protected classes  In addition  drugs given by injection  including many cancer therapies  are covered under Medicare s main medical benefit  Bristol disappointed investors when it did not pursue accelerated FDA review of the Opdivo Yervoy combination for newly diagnosed lung cancer   putting Merck ahead in the lucrative lung cancer market  
 All of the immunotherapies have similar price points   said Miller at Express Scripts   When you stack therapies  it means more expense for patients and  health  plan sponsors  ",2017-04-03,Reuters,https://www.investing.com/news/stock-market-news/the-cost-of-cancer:-new-drugs-show-success-at-a-steep-price-470922,470922
203144,424660,MRK,Mallinckrodt exits pharma trade group ahead of changes,news,The Pharmaceuticals Research and Manufacturers Association is mulling bylaw changes which could exclude companies not spending enough money on research and development of new drugs  A vote is scheduled for early May Ahead of maybe getting booted out   Mallinckrodt   MNK  1 5   decided to resign from the group  writes Joseph Walker in the WSJ The proposed changes at PhRMA suggests members   including the likes of  Pfizer   NYSE PFE  and Merck  NYSE MRK    are trying to break their association with the likes of companies like Mallinckrodt whose strategy is to acquire drugs developed elsewhere and then boost prices PhRMA spent nearly  20M in D C  lobbying efforts last year ,2017-04-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/mallinckrodt-exits-pharma-trade-group-ahead-of-changes-471773,471773
203145,424661,MRK, 5 Reasons Why Investors Should Buy Exelixis  EXEL  In 2019,opinion,"Exelixis Inc  s   NASDAQ EXEL   lead drug  Cabometyx continues to perform well  The company s efforts to develop cabozantinib for various other indications are encouraging You can see  
Here are five reasons to invest in the stock 
Favorable Rank  Rising Shares Price and Estimates  Exelixis has a Zacks Rank  2  Buy   Exelixis  shares have outperformed the Medical   Biomedical And Genetic industry in the past six months  The stock has returned 12 8  in the said timeframe compared with the  s rise of 13 7   The company s outperformance was backed by decent quarterly results and positive news flow 

 
Impressive Performance of Cabometyx  Exelixis  lead product  Cometriq  the capsule form of cabozantinib  was approved in the United States in 2012 for the treatment of progressive  metastatic medullary thyroid cancer  MTC   In April 2016  a tablet formulation of cabozantinib  Cabometyx was approved in the United States for the treatment of patients with advanced renal cell carcinoma  RCC  who have received prior anti angiogenic therapy 
The approval for first line RCC has increased the eligible patient population for Cabometyx in the United States by approximately 14 000 patients  Cabometyx is poised to grab market share from key drugs   Sutent and Afinitor   in the first line RCC market  Exelixis  European partner Ipsen also obtained approval for the drug in Europe for the first line treatment of adults with intermediate  or poor risk advanced RCC in the European Union  The approval will broaden the geographic reach of the drug as the market potential is significant for the first line treatment of kidney cancer 
Developing Cabozantinib for Additional Indications  Exelixis is developing cabozantinib in a broad development program  comprising more than 45 clinical studies across multiple indications  The FDA has accepted the company s supplemental New Drug Application  sNDA  for Cabometyx as a treatment for patients with previously treated advanced HCC  liver cancer  and is expected to provide a decision later today  A potential approval should further boost demand and diversify the franchise  given the huge market for liver cancer  The CHMP also gave a positive opinion on the same 
Separately  Exelixis has also initiated a phase Ib study  investigator sponsored  on cabozantinib  in combination with Bristol Myers Squibb s   NYSE BMY   Opdivo  nivolumab  or Opdivo plus Yervoy  in patients suffering from genitourinary tumors  including bladder cancer and RCC  The trial has established the preliminary safety and tolerability  and recommended dose for this combination  A phase II trial evaluating safety and preliminary activity of the cabozantinib Opdivo combination as compared to the cabozantinib  Opdivo and Yervoy combination in advance HCC completed enrollment earlier in 2018 
Collaborations with Leading Companies   Exelixis has collaborations with several leading pharmaceuticals such as Bristol Myers Squibb  Merck   NYSE MRK   and Daiichi Sankyo Company forvarious compounds and programs in its portfolio  These collaborations allow Exelixis to earn milestone payments and royalties that boost its top line  Exelixis also has an exclusive licensing agreement with Ipsen for the commercialization and further development of cabozantinib 
Exelixis recently announced encouraging results from the dose escalation stage of the phase Ib COSMIC 021 study of Cabometyx in combination with Roche s   OTC RHHBY   Tecentriq  in previously untreated advanced RCC  The combination was well tolerated and showed promising anti tumor activity  In October 2018  Exelixis initiated a phase III trial  COSMIC 311  of single agent cabozantinib in patients with radioiodine refractory differentiated thyroid cancer  DTC  who have progressed up to two prior vascular endothelial growth factor receptor  VEGFR  targeted therapies  
Exelixis and Ipsen announced the initiation of a pivotal phase III study   COSMIC 312   to evaluate a Cabometyx combination therapy in treatment na ve advanced HCC patients  Moreover  an exploratory arm will also evaluate Cabometyx monotherapy in the first line setting for similar patients 
Cotellic s Label Expansion to Boost Top Line  Another drug in Exelixis  portfolio  Cotellic  in combination with Zelboraf  vemurafenib   gained approval in the United States for the treatment of patients with BRAF V600 mutation positive advanced melanoma in November 2015  The drug was also approved in the EU for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation 
Cotellic is also being evaluated in combination with multiple agents for the treatment of various types of tumors  including an immunotherapy in several tumor types like non small cell lung cancer  colorectal cancer  triple negative breast cancer and melanoma 
The IMspire150  TRILOGY  trial  which evaluates the combination of Cotellic  Tecentriq  and Xelboraf in first line BRAF V600 mutation positive metastatic or unresectable locally advanced melanoma  has completed enrollment  The IMspire170 study  evaluating the combination of Cotellic and Tecentriq versus Merck s Keytruda in first line BRAF wild type metastatic or unresectable locally advanced melanoma  is ongoing
Exelixis faces its share of challenges in the form competition 
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-why-investors-should-buy-exelixis-exel-in-2019-200375407,200375407
203146,424662,MRK,Roche s SBLA For Tecentriq Abraxane Combo Accepted By FDA,opinion,"Swiss oncology major Roche   OTC RHHBY   announced that the FDA has accepted its supplemental Biologics License Application  sBLA  for immuno oncology drug  Tecentriq 
The sBLA seeks to get FDA approval for Tecentriq in combination with Celgene Corporation s   NASDAQ CELG   Abraxane and carboplatin for the initial  first line  treatment of patients suffering from metastatic non squamous non small cell lung cancer  NSCLC  who do not have EGFR or ALK genomic tumour aberrations 
A decision from the FDA is expected by Sep 2  2019 
The sBLA is based on positive results from the phase III IMpower130 study  which met its co primary endpoints of overall survival  OS  and progression free survival  PFS  in the first line treatment of metastatic non squamous NSCLC 
We remind investors that Tecentriq is already approved in the Unites States for the treatment of patients suffering from metastatic NSCLC who have disease progression during or following platinum containing chemotherapy   In December 2018  the FDA also approved Tecentriq in combination with Avastin  paclitaxel and carboplatin  chemotherapy  for the first line treatment of people with metastatic non squamous NSCLC with no EGFR or ALK genomic tumor aberrations 
The drug is also approved for certain types of untreated or previously treated metastatic urothelial carcinoma  mUC  
Shares of Roche have gained 10 9  in the past six months  outperforming the  growth of 4 5  

 
Roche is working to expand the drug s label further  The company currently has nine phase III studies evaluating Tecentriq alone or in combination with other drugs for lung cancer Tecentriq sales came in at CHF 524 million in the first nine months of 2018  up 49   A label expansion of the drug in the first line NSCLC market will further boost sales  given the potential of the market 
However  competition is stiff in the first line NSCLC market  Merck s   NYSE MRK   Keytruda is already approved for the first line treatment of NSCLC 
Bristol Myers Squibb Company s   NYSE BMY   Opdivo is also in the race for the first line NSCLC treatment  However  the FDA extended the review period of the company s application by three months and set a target action date of May 20  2019 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/roches-sbla-for-tecentriqabraxane-combo-accepted-by-fda-200376881,200376881
203147,424663,MRK,Aerie s  AERI  Eye Care Candidate To Enter Clinical Studies,opinion,Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced that the FDA has reviewed the Investigational New Drug  IND  application for AR 1105  dexamethasone intravitreal implant   The company will now initiate studies for AR 1105 for the treatment of macular edema due to retinal vein occlusion  RVO   Aerie plans to begin a phase II study later in the first quarter of 2019 Shares of Aerie have declined 26  in the past year compared with the  s decline of 19 6    AR 1105 is a bio erodible implant that is designed to release the steroid dexamethasone over a six month sustained period  It is commonly administered through intravitreal injection  The benefits of AR 1105 versus other steroid products are its six month duration of efficacy  improved administration owing to a smaller needle size and a better safety profile due to lower peak drug levels AR 1105 is the first IND stage candidate in Aerie s retina pipeline  The company also plans to file an IND for its second retina product for the treatment of wet age related macular degeneration and diabetic macular edema The advancements of these candidates will make Aerie reach its goal of being the next major ophthalmic pharmaceutical company We remind investors that another company Regeneron s   NASDAQ REGN   drug Eylea  which is co developed by HealthCare unit of Bayer  DE BAYGN  AG   OTC BAYRY    is approved in the United States  EU  Japan and other countries for the treatment of wet AMD  diabetic macular edema  DME   macular edema following retinal vein occlusion  which includes macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion Aerie Pharmaceuticals  Inc  Price    Zacks Rank and A Stock to ConsiderAerie currently carries a Zacks Rank  4  Sell  A better ranked stock from the same space is Merck   Co   Inc    NYSE MRK    which holds a Zacks Rank  2  Buy   You can see  Merck s earnings per share estimates have increased from  4 28 to  4 33 for 2018 and from  4 65 to  4 69 for 2019 over the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with the average being 3 96  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/aeries-aeri-eye-care-candidate-to-enter-clinical-studies-200377108,200377108
203148,424664,MRK,Merck s Partner Gets FDA Nod For Herceptin Biosimilar ,opinion,"Merck   Co Inc    NYSE MRK   announced that its partner  Samsung  KS 005930  Bioepis Co   Ltd received FDA approval for Ontruzant  a biosimilar to Roche Holding  SIX ROG  AG s   OTC RHHBY   breast cancer treatment  Herceptin  Ontruzant is approved for the treatment of patients with HER2 overexpressing breast cancer  metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease 
Ontruzant is Samsung Bioepis  first oncology biosimilar to receive FDA approval and will be marketed and distributed in the United States by Merck  Ontruzant was also approved by the European Commission  EC  in November 2017 
Shares of Merck have increased 27 7  in the past year compared with the  s growth of 2 5  

We remind investors that last month  the FDA approved Herzuma  which is another biosimilar of Herceptin for the treatment of patients with HER2 overexpressing breast cancer  Herzuma is co developed by Celltrion and Teva Pharmaceutical Industries   NYSE TEVA   
Merck is looking toward biosimilars to drive long term growth  The biosimilars market represents huge commercial opportunity  Merck has an agreement with Samsung Bioepis for the development and commercialization of several pre specified and undisclosed biosimilar candidates 
The companies received a tentative U S  approval for the biosimilar version of Sanofi s   NASDAQ SNY   Lantus  MK 1293  in July 2017  The Lantus biosimilar is already approved in the EU  Meanwhile  the companies launched a biosimilar version of blockbuster RA drug  Remicade in the United States in July 2017 Merck   Co   Inc  Price
 

   Zacks Rank 
Merck currently carries a Zacks Rank  2  Buy   You can see  
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year  Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity 
In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/mercks-partner-gets-fda-nod-for-herceptin-biosimilar-200377735,200377735
203155,424671,MRK,Snap extends losses as U S equities trickle lower,news,"Investing com   Snap sustained further losses on Tuesday  as investors continued to dump shares of the social media firm  after several analysts initiated a bearish view of the tech company 
Shares of  Snap Inc   NYSE SNAP   which closed below its opening price on Monday  lost more than 12  by 15 03 ET  as the initial euphoria surrounding the company s first few days of trade since its IPO appears to have faded 
On Monday  Wall Street analysts  initiated coverage on Snap with a rating of  sell  and warned that Snap s share price was overvalued 
Meanwhile  the Dow and S P are on track for their first two day losing streak since January 2  as investors considered the prospect of a March rate hike while healthcare stocks tumbled after a warning from President Donald Trump 
Healthcare stocks  started the session on the back foot  after President Donald Trump claimed on Tuesday that he will bring drug prices  way down  



Trump s tweet supported his earlier statement in January  when he claimed that pharmaceutical companies are  getting away with murder  in what they charge the government for medicine 
Merck   Company Inc  NYSE MRK    Pfizer  Inc  NYSE PFE  as well as a slew of European household pharmaceutical stocks sank lower 
Meanwhile  economic data had little impact on U S  equities  after data showed the U S  trade deficit grew in January to its widest monthly level in almost five years 
The commerce department said Tuesday  the trade gap widened by 9 6  to  48 5 billion in January  the highest level since March 2012  and in line with economists  forecasts 
The Dow Jones Industrial Average traded 0 14  lower at 20 924  The S P 500 shed 0 32  and the Nasdaq Composite traded 0 12  lower at 5 840 ",2017-03-07,Investing.com,https://www.investing.com/news/stock-market-news/snap-extends-loses-as-u.s-equities-trickle-lower-464428,464428
203156,424672,MRK,Asian shares weaker as China dollar trade figures awaited,news,"Investing com   Asia stocks were weaker on tensions in the Korean peninsula as China weighed in on North Korea s nuclear and missile tests and the U S  and South Korean responses 
In Japan  the Nikkei 225 fell 0 58  as the yen strengthened against the greenback on safe haven demand and the S P ASX 200 in Australia fell 0 14   with losses in its materials sub index  down 0 89 
The Shanghai composite slipped 0 06   while Hong Kong s Hang Seng index fell 0 17  
Earlier  China reported that exports rose 4 2  in February in yuan terms  while imports soared 44 7   Dollar denominated trade balance figures are pending 
Overnight  Wall Street closed lower on Tuesday  as investors considered the prospect of a March rate hike while healthcare stocks tumbled after a warning from President Donald Trump 
Healthcare stocks  started the session on the back foot  after President Donald Trump claimed on Tuesday that he will bring drug prices  way down  
Trump s tweet supported his earlier statement in January  when he claimed that pharmaceutical companies are  getting away with murder  in what they charge the government for medicine Merck   Company Inc  NYSE NYSE MRK    Pfizer  Inc  NYSE NYSE PFE  as well as a slew of European household pharmaceutical stocks sank lower 
Meanwhile  economic data had little impact on U S  equities  after data showed the U S  trade deficit grew in January to its widest monthly level in almost five years 
The commerce department said Tuesday  the trade gap widened by 9 6  to  48 5 billion in January  the highest level since March 2012  and in line with economists  forecasts 
The Dow Jones Industrial Average closed 0 15  lower at 20 922  The S P 500 shed 0 29  and the Nasdaq Composite lost 0 26  to close at 5 833  It was the first time since Jan 2  the Dow and S P closed lower for a second straight session ",2017-03-08,Investing.com,https://www.investing.com/news/stock-market-news/asian-shares-weaker-as-china-dollar-trade-figures-awaited-464506,464506
203157,424673,MRK,The Zacks Analyst Blog Highlights  Bristol Myers  Celgene  Merck  Pfizer And AbbVie,opinion,For Immediate ReleaseChicago  IL   January 7  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Bristol Myers   NYSE BMY    Celgene Corporation   NASDAQ CELG    Merck   NYSE MRK    Pfizer   NYSE PFE   and AbbVie   NYSE ABBV   Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  BMY CELG Deal   MoreThe pharma sector was relatively lying low this week with some news grabbing attention only towards the end  Top stories this week were Bristol Myers  offer to buy cancer giant Celgene Corporation in a cash and stock deal worth  74 billion and Merck s decision to exercise the option to in license a NASH candidate from partner NGM Biopharmaceuticals Recap of the Week s Most Important HeadlinesBristol Myers to Acquire Celgene for  74B  Bristol Myers began the year announcing one of the largest merger deals in the biotech pharma sector  The company is acquiring cancer drug specialist Celgene in a cash stock deal valued at  74 billion  Per the transaction  each Celgene shareholder will receive a consideration of  102 43  comprising one share of Bristol Myers  valued at  52 43 on Jan 2  2019  and  50 per share in cash  The deal makes strategic sense as the combination will create a premier innovative biopharma giant with leading franchises in oncology  immunology and inflammation and cardiovascular disease  The combined entity with have nine products generating more than  1 billion in sales and is expected to launch six products in the near term  Moreover  the consolidated company will have a deep and diverse early and late stage pipeline  Following the transaction  Bristol Myers is expected to realize cost synergies of approximately  2 5 billion by 2022  The company also separately issued adjusted earnings guidance for 2019 in the range of  4 10  4 20  While shares of Bristol Myers decline  that of Celgene were up on announcement of the news Meanwhile  Bristol Myers tyrosine kinase inhibitor   in combination with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia  Sprycel is also approved for Ph  chronic myeloid leukemia in chronic phase in pediatric patients Merck In Licenses NASH Candidate  Keytruda Gets 5 Approvals in Japan  Merck exercised its option to in license a NASH and type II diabetes candidate  NGM313  now renamed as MK 3655 from NGM Biopharmaceuticals  Inc  for  20 million  With this deal   to develop  manufacture and commercialize NGM313  a once monthly insulin sensitizer  Merck s one time option was triggered as NGM completed a phase Ib proof of concept study on the candidate  Data from the study presented last November showed that a single dose of the medicine led to a statistically significant reduction in liver fat content  LFC  and improvements in multiple metabolic parameters after five weeks of treatment  Merck plans to initiate a phase IIb study on the candidate while NGM Biopharmaceuticals retains the option to take a 50  cost and profit sharing partnership for NGM313 once the candidate enters late stage development Meanwhile  the company s PD 1 inhibitor Keytruda clinched five new label expansion approvals in Japan  These included three approvals as a first line treatment option for advanced non small cell lung cancer  NSCLC  and the other two as an adjuvant therapy for melanoma and in advanced microsatellite instability high  MSI H  tumors Pfizer Starts Pivotal Study on Alopecia Areata Candidate  Pfizer initiated a  on its oral JAK3 inhibitor candidate  PF 06651600  for the treatment of moderate to severe alopecia areata   Alopecia areata is a chronic autoimmune skin disease causing hair loss   often patchy   on the scalp  face or body  Top line data from a phase IIa study on PF 06651600 was presented in September 2018  The study met the primary endpoint of improving hair re growth on the scalp as compared to baseline over 24 weeks  regimen AbbVie Inks New Immunotherapy Deal  AbbVie signed a strategic collaboration with private cancer biotech  Tizona Therapeutics  to develop and commercialize immunotherapies targeting the CD39 enzyme including pre clinical candidate TTX 030  AbbVie plans to begin clinical studies on TTX 030 in the first quarter of 2019  The company made an upfront payment of  105 million to Tizona for the license to its CD39 program while also buying an equity stake in the company The NYSE ARCA Pharmaceutical Index declined 1 4  in the last four trading sessions Media ContactZacks Investment Research800 767 3771 ext  9339    Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-bristolmyers-celgene-merck-pfizer-and-abbvie-200373183,200373183
203158,424674,MRK,4 Trade Ideas For Merck,opinion,"Merck   Company Inc  NYSE MRK 
Merk has been a very strong stock  Rising from an April low  it paused over the summer and then kept going higher as the rest of the market rolled over  It finally made a top at the beginning of December and started moving lower  It did not even retrace 38 2  of the move higher though before it found support and reversed 
The reversal happened just under the 100 day SMA and with capitulation volume  It reversed and met resistance at the 20 day SMA  It has consolidated there for a week  A move over that resistance would give a target move back to the all time high  The RSI is rising back through the midline towards the bullish zone with the MACD crossing up and turning positive 
There is resistance at 76 60 and 79 10 before the top at 80 19  Support lower comes at 74 and 73 25 before 71 and 70 40  Short interest is low at 2 5   The company is expected to report earnings next on February 1st before the market opens  The stock began trading ex dividend on December 14th  It pays a 2 88  dividend 
The January options chain shows the biggest open interest is above at the 80 strike  and much bigger on the call side  The 75 strike would be the next largest  The February 1 Expiry  covering the earnings report  shows biggest open interest at the 76 call strike  and gives an estimated price range of about 72 to 80 50 for the stock at Expiry  The February monthly chain shows the biggest open interest centered at the 80 call strike 

Merk Trade Ideas
Buy the stock on a move over 76 60 with a stop at 74 
Buy the stock on a move over 76 60 and add February 1 Expiry 75 72 Put Spread   1 60  as protection while selling a February 80 Call  83 cents  
Buy the January February 77 50 Call Calendar   1 18  
Buy the February 70 77 50 80 Call Spread Risk Reversal  43 cents  
Elsewhere
Look for gold to continue in its uptrend while crude oil joins it moving higher  The U S  dollar index will continue to move sideways  while U S  Treasuries pause in their uptrend  The Shanghai Composite will continue to move lower while Emerging Markets may pause in their downtrend 
Volatility looks to continue to fall from elevated levels easing the pressure on the equity index ETF s SPY  IWM and QQQ  Their charts look ready for more upside after a strong week with the IWM leading the charge and the QQQ and SPY not far behind  Use this information as you prepare for the coming week and trade them well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2019-01-07,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-merck-bonus-idea-200373219,200373219
203159,424675,MRK,2 Reasons Merck Is A Compelling Defensive Play For Current Markets ,opinion,"As 2019 begins  it looks as if markets are picking up where they left off at the end of last year  when volatility reigned and high flying growth stocks started losing their luster  We believe volatility will continue and growth stocks will remain under pressure on increasing concerns the decade long US economic expansion could be coming to an end 
During times of market gyrations and increasing economic uncertainty  having a few income stocks in one s portfolio is a good defense  In fact  in 2018 defensive stocks outperformed the broader market  In this space  we strongly favor the global healthcare provider Merck  NYSE MRK  for two reasons its roster of top selling meds and the company s dependable dividend 
1  Strong Growth Momentum  Powerhouse Drugs

Over the past three years  Merck has consistently exceeded analysts expectations on earnings  This impressive winning streak powered its shares higher  Indeed  for 2018 it was the best performer among the 30 mega cap companies listed on the Dow Jones Industrial Average  gaining 30  for the year 
We don t expect that pace of growth to slow anytime soon either  Merck s cancer immunotherapy drug  Keytruda  continues to capture market share  In the first nine of months of 2018  Keytruda sales doubled  reaching a whopping  5 billion  The drug has become a core component of Merck s growth  particularly in the large and lucrative area of lung cancer 
Earlier this year the drug showed what medical experts called practice changing results when combined with chemotherapy  As well  just last month  Keytruda gained EU approval for use on adults who ve undergone surgery to remove melanomas  According to Merck  it s the first approval for the drug as an auxiliary treatment in the European Union 
Some analysts expect the majority of previously untreated patients will start taking the drug as well  According to EvaluatePharma projections  it could bring in  12 69 billion in annual sales by 2024  Helped by Keytruda s remarkable success  Merck plans to invest  16 billion on new capital projects through 2022  a 33  surge over what the company announced it would spend in early 2018 
While Merck s cancer treatment is grabbing much of the attention  the company s other drugs are also performing well  HPV vaccine Gardasil s sales were up 55  in the third quarter from the year ago period  while diabetes medications Januvia and Janumet brought in  1 49 billion in sales during the same period 
2  Reliable Payouts
One of the primary reasons to bet on a dividend paying stock is for its benefits during market highs and lows  Which means the focus should be on the company s history of reliably paying dividends 
With its forward dividend yield of about 3   Merck has made returning capital to investors a top priority  Since at least 1970  the company has never missed a quarterly payout  Merck s dividend has grown at an annualized rate of 5 5  since 2010 beating the rate of inflation  After delivering a 15  hike in October  Merck now pays  0 55 a share every three months 
The company has also been returning capital to stockholders in recent years via share buybacks  further boosting its total yield  In October  the company announced that it plans to buy back an additional  10 billion worth of outstanding shares 
Any future dividend growth will depend on both earnings and the company s payout ratio  Merck s current payout ratio is 66   suggesting it s in a comfortable position to continue the current dividend growth strategy 
Bottom Line
If you re looking to play it safe in 2019  Merck is worth considering  At its current  75 43 share price  with a dividend yield that s a bit higher than the pharmaceutical industry average  it s a good shelter for conservative  long term investors ",2019-01-08,Haris Anwar/Investing.com,https://www.investing.com/analysis/2-reasons-merck-200373488,200373488
203168,424684,MRK,Merck 2017 forecast reassuring  full speed ahead with Keytruda,news,"By Bill Berkrot  Reuters    Merck   Co Inc  N MRK   faced with patent expirations and increasing development costs for its high profile Keytruda cancer immunotherapy  reassured investors on Thursday with a 2017 profit forecast roughly in line with Wall Street expectations  Shares of Merck were up nearly 3 percent at  63 90 after the U S  drugmaker also reported fourth quarter earnings that matched analysts  expectations  Despite acknowledging a need to hold down costs  Merck said it was charging ahead with Keytruda development  with about 430 studies ongoing in a wide variety of cancers and combinations with other therapies  Merck forecast 2017 earnings of  3 72 to  3 87 per share  excluding special items  Analysts on average were expecting  3 85 per share  The company gave a revenue outlook of  38 6 billion to  40 1 billion  compared with analysts  expectations of  40 04 billion   We are actually implying EPS growth despite the headwinds of loss of exclusivity and  foreign exchange  and the other challenges that we face   Chief Executive Officer Ken Frazier told analysts on a conference call  Merck expects unfavorable foreign exchange rates to sap 2 percent from 2017 global sales  Frazier said Merck was in the market for deals to augment its early to mid stage drug development pipeline if the price is right  Such moves are not contingent on tax reform or changes to U S  healthcare laws being discussed by President Trump and Congress  he added   In 2017  Merck will face generic competition for cholesterol drugs Zetia and Vytorin  antibiotic Cubicin and its Nasonex nasal spray in the United States and for Remicade  its big selling arthritis drug  in Europe  But the U S  drugmaker is confident it can solidify its leading position for Keytruda in lung cancer  by far the largest oncology market  and that it has the potential to become a foundational therapy in other cancers as well  Last summer Merck leapfrogged Bristol Myers Squibb  N BMY  as the perceived leader in the market for potentially game changing drugs that spur the immune system to fight cancer  when Keytruda extended survival among previously untreated lung cancer patients  Bristol s rival drug  Opdivo  failed to do so  Keytruda is now approved as a first option treatment for non small cell lung cancer patients whose tumor cells display a high level of the PD L1 protein the drug targets  as well as for patients whose cancer has progressed after other treatments  Merck said there has been a significant acceleration of PD L1 testing  a clear indication of heightened interest in use of Keytruda in first line lung cancer  In May  Merck may also get U S  approval for Keytruda with chemotherapy in first line lung cancer  opening it up to many more potential patients  Edward Jones healthcare analyst Ashtyn Evans forecast annual Keytruda sales would reach  7 billion by 2020  She said there was relief that Merck s 2017 forecast was not lower  because they really need to put a significant amount of investment behind Keytruda    Fourth quarter Keytruda sales more than doubled from a year earlier to  483 million  with 40 percent coming from melanoma  its initial approval  and 30 percent from lung cancer  
Sales of diabetes drugs Januvia and Janumet grew 4 percent to  1 5 billion despite intensifying competition ",2017-02-02,Reuters,"https://www.investing.com/news/stock-market-news/merck-2017-forecast-eases-concerns-over-royalty-payments,-dollar-457458",457458
203169,424685,MRK,Lundbeck gives up on Alzheimer s drug  rival to Axovant pill,news,By Ben Hirschler  Reuters    Two remaining late stage clinical trials testing an experimental Alzheimer s drug from Denmark s Lundbeck have failed  scuppering hopes for the medicine and underscoring the difficulty of developing such treatments  Lundbeck s idalopirdine is a so called 5 HT6 antagonist and is similar to another pill  called intepirdine  being developed by U S  biotech firm Axovant Sciences  Unlike some higher profile Alzheimer s drugs from companies such as Eli Lilly and Merck  NYSE MRK    Co  idalopirdine was aimed at treating symptoms of the brain disorder  rather than halting progression of the underlying disease  The failure of Lundbeck s two latest Phase III trials is not a huge surprise  since the company and its Japanese partner Otsuka had already announced disappointing results from another late stage trial in September  Taken together  Lundbeck said on Wednesday  the trials  do not demonstrate efficacy to support a regulatory submission   The setback casts further doubt on the 5 HT6 antagonist approach to fighting Alzheimer s  following discontinuation of another 5 HT6 antagonist last year from  Pfizer   NYSE PFE  that had reached mid stage clinical testing  Shares in Lundbeck fell more than 4 percent after the company gave its update on idalopirdine alongside fourth quarter financial results  Drugs working to block 5 HT6 are designed to promote the release of acetylcholine  a neurotransmitter needed for normal cognition  The idea is to use them alongside the existing drug donepezil to help patients with mild to moderate Alzheimer s  Cholinesterase inhibitors  like donepezil  are currently among the few medical options for treating Alzheimer s patients  Looking ahead  drugmakers hope to use new types of medicines that target the build up of certain proteins in the brain that are thought to impair cognition   The failure of one such closely watched experimental drug from Eli Lilly in November dealt a blow to this concept but experts believe subtly different therapies could still work ,2017-02-08,Reuters,"https://www.investing.com/news/general-news/lundbeck-gives-up-on-alzheimer's-drug,-rival-to-axovant-pill-458650",458650
203170,424686,MRK,Horizon Pharma  HZNP  Up 28  On Business Expansion Strategy ,opinion,"Share price of Horizon Pharma Inc    NASDAQ HZNP   has increased 28 3  in the past year  against the  s decline of 24 6  

 
Horizon s strategy is to transform into a balanced  diversified  sustainable growth biopharmaceutical company  predominantly focused on rare disease medicines 
The company has been focused on expanding its orphan drug business  as evidenced by its long range plan  wherein the orphan business is expected to constitute approximately 60  of net sales in 2020  Meanwhile  the company has been quite active on the acquisition front  In May 2015  Horizon acquired Hyperion in a deal valued at about  1 1 billion and added a couple of UCD drugs like Ravicti and Buphenyl Ammonaps to its portfolio 
The FDA approved a supplemental new drug application  sNDA  for Ravicti to expand the age range  for chronic management of urea cycle disorders  UCD  in patients  to two months and older from two years and older  in April 2017  In December 2018  the FDA approved an sNDA to expand the age range for Ravicti Oral Liquid to include infants younger than two months  living with a UCD 
Also  in January 2016  Horizon acquired Crealta for approximately  540 million in cash  The acquisition added Krystexxa and Migergot to its portfolio  Krystexxa is the first and only FDA approved medicine for chronic refractory gout  Sales of Krystexxa increased 56  year over year in the first nine months of 2018  In addition  Krystexxa has a long patent life running through 2027 
Meanwhile  to evaluate the safety and efficacy related to the immunogenicity profile of Krystexxa  two investigator initiated studies    TRIPLE and RECIPE   are currently enrolling patients  Horizon initiated a new company sponsored immunomodulation MIRROR study with Krystexxa in September 2018 to continue exploring a broader clinical profile of the drug 
The study will evaluate the impact of adding methotrexate to Krystexxa to enhance the patient response rate  The company expects to begin enrolling patients into the adapted protocol in the second quarter of 2019 
Earlier in 2017  the company acquired River Vision  thereby adding the latter s biologic candidate teprotumumab in late stage development for Thyroid Eye Disease  TED   The company completed enrollment in phase III confirmatory clinical study  OPTIC  evaluating teprotumumab for the treatment of TED in September 2018 Top line data from the study is expected in the second quarter of 2019 
Horizon Pharma is pursuing two development programs   HZN 003 and PASylated uricase technology   for next generation biologics for uncontrolled gout  These programs are expected to support and sustain the company s market leadership in the said indication 
The company is also working to expand the label of Actimmune  which is approved for the treatment of chronic granulomatous disease  CGD  and severe malignant osteopetrosis  SMO    The company has collaborated with the Fox Chase Cancer Center to evaluate Actimmune in combination with Bristol Myers Squibb Company s   NYSE BMY   Opdivo in a phase I dosing study for the treatment of kidney and bladder cancer 
The National Cancer Institute is evaluating Actimmune in combination with Merck   Co s   NYSE MRK   Keytruda in phase II study to treat cutaneous t cell lymphoma patients  A dose ranging study is evaluating Actimmune in combination with Bristol Myers  Taxol  and Roche s   OTC RHHBY   Herceptin and Perjeta in a certain type of advanced breast cancer Horizon Pharma Public Limited Company Price
 

    
Zacks Rank
Horizon Pharma currently carries a Zacks Rank 3  Hold   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-02,Zacks Investment Research,https://www.investing.com/analysis/horizon-pharma-hznp-up-28-on-business-expansion-strategy-200372359,200372359
203171,424687,MRK,Bristol Myers To Acquire Leading Biotech Celgene For  74B,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that it will acquire Celgene Corporation   NASDAQ CELG   in a cash and stock transaction with an equity value of approximately  74 billion  The transaction has been approved by both the boards While shares of Bristol Myers lost 13 3  on news of what will be one of the biggest acquisitions in recent times  Celgene s shares gained 20 7  Financial Terms of the AgreementPer the terms  Celgene shareholders will receive 1 0 share of Bristol Myers and  50 00 in cash for each share held  In addition  shareholders will also receive one tradeable Contingent Value Right  CVR  for each share of Celgene whereby they will be entitled to receive a payment for the achievement of future regulatory milestones  The board of directors of both the companies have approved the combination The total value received by Celgene s shareholders will be  102 43 per Celgene share and one CVR based on the closing price of Bristol Myers stock of  52 43 on Jan 2  2019   The tradeable CVR will entitle its holder to receive a one time potential payment of  9 00 in cash upon FDA approval of three candidates   ozanimod  by Dec 31  2020   liso cel  JCAR017   by Dec 31  2020  and bb2121  by Mar 31  2021    in each case for a specified indication  The total consideration represents an approximately 51  premium to Celgene shareholders based on the 30 day volume weighted average closing stock price of Celgene prior to signing Upon completion  shareholders of Bristol Myers will own approximately 69  of the company  while Celgene shareholders are expected to own approximately 31  The acquisition is expected to be 40  accretive to the bottom line on a standalone basis in the first full year  following close of the transaction  The combined company is expected to generate more than  45 billion in cash flow over the first three full years post closing  Bristol Myers expects to realize cost synergies of approximately  2 5 billion by 2022  The acquisition is expected to close in the third quarter of 2019 Strategic Aspect of the TransactionThe merger will result in a specialty biopharma company with a strong oncology portfolio and diverse pipeline in the therapeutic areas of inflammatory  immunologic and cardiovascular diseases The combined entity will have a market leading oncology portfolio in both solid tumors and hematologic malignancies led by Opdivo and Yervoy along with Revlimid and Pomalyst  In addition  it will also have a strong immunology and inflammation franchise led by Orencia and Otezla and a leading cardiovascular franchise led by Eliquis  The combined company will have nine drugs with more than  1 billion in annual sales Moreover  the company will also have a deep pipeline that includes six expected near term product launches  two in immunology and inflammation  TYK2 and ozanimod  respectively  and four in hematology  luspatercept  liso cel  JCAR017   bb2121 and fedratinib   with potential sales of  15 billion  The early stage pipeline includes 50 high potential assets across solid tumors and hematologic malignancies  immunology and inflammation  cardiovascular disease and fibrotic disease  leveraging combined strengths in innovation Concurrently  Bristol Myers announced its earnings guidance for 2019  The company expects earnings per share of  4 10  4 20  The guidance excludes the impact of the Celgene acquisition  The company expects to execute an accelerated share repurchase program of approximately  5 billion Our TakeBristol Myers was in the lookout of an acquisition for quite some time now to bolster its portfolio  While its blockbuster immuno oncology drug  Opdivo continues to perform well on the back of label expansions  pricing concerns and stiff competition in the immuno oncology space have limited market share gains  In particular  Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq pose stiff competition in the promising first line non small cell lung cancer  NSCLC  space  The FDA extension of the PDUFA date for the company s application seeking approval of Opdivo Yervoy as a treatment for first line NSCLC with tumor mutational burden greater than 10 mutations megabase was disappointing  given the market potentialThe acquisition will enable Bristol Myers to diversify its portfolio  The combined company will have a dominant position in the oncology  immunology and inflammation spaces  Celgene expects total revenues of  19  20 billion by 2020 from its key growth driver  Revlimid While the acquisition looks positive prima facie  any acquisition of this magnitude comes with its own set of integration risks  While the prospects of Revlimid looks solid  the drug will lose patent protection shortly resulting in a dent in sales  Moreover  it might be expensive and will add considerable debt to Bristol Myers  balance sheet Bristol Myers  stock has decreased 25  in the past 12 months  against the  growth of 4 4  On the other hand  Celgene gets a reprieve from the acquisition  having faced a series of pipeline setbacks in recent times  A late stage study on its lead cancer drug  Revlimid  in combination with Rituxan failed  Consequently  shares took a hammering  A phase III trial  REVOLVE   CD 002  on pipeline candidate GED 0301 in Crohn s disease and the extension trial  SUSTAIN  CD 004  were discontinued  following a recommendation from the Data Monitoring Committee  which assessed overall benefit risk during a recent interim futility analysis  The company also suffered a setback in February 2018  when it received Refusal to File letter from the FDA regarding its New Drug Application   NDA   for multiple sclerosis candidate  ozanimod The company then acquired Juno Therapeutics and added JCAR017  lisocabtagene maraleucel  liso cel  to its lymphoma pipeline  JCAR017 is a best in class CD19 directed CAR T candidate  currently in a pivotal program for relapsed and or refractory diffuse large B cell lymphoma  However  two leading CAR T therapies  Kymriah and Yescarta are already in the market  Hence  JCAR017 will have a tough time grabbing market share  Hence  the acquisition bodes well from Celgene s point of view Quite a few large cap pharma companies are on the look out for strategic acquisitions  given the stiff competition looming on their high profile drugs from biosimilars and generics  Swiss pharma giant Novartis recently acquired Endocyte to strengthen its leadership in nuclear medicine and radioligand therapy for treating cancer Zacks Rank   Key Pick
Both Bristol Myers and Celgene carry a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-to-acquire-leading-biotech-celgene-for-74b-200372904,200372904
203177,424693,MRK,Second missing Pakistani blogger found  leaves country fearing for life  family,news,"By Mehreen Zahra Malik
ISLAMABAD  Reuters    Pakistani blogger Aasim Saeed who went missing earlier this month has been found but has quickly left the country fearing for his life  his family said on Sunday 
Saeed s father said his son was detained by  state agencies  while visiting Pakistan from Singapore  though he did not name which one 
Pakistan s government and Federal Investigation Agency have denied holding any of five liberal activists who went missing this month 
The military and other state agencies have declined to officially comment  The army s media wing did not reply to questions and phone calls on Sunday 
Saeed s recovery comes a day after poet and activist Salman Haider  who disappeared from the capital Islamabad on Jan  6  was recovered  according to his family 
Five liberal activists  some of whom have posted blogs criticizing the political influence of the military and speaking for the rights of religious minorities  had each gone missing separately since Jan  4 
Saeed  who is Singapore based and works in the IT department of the German Merck  NYSE MRK  Group  disappeared on Jan  4 while visiting the eastern city of Lahore 
 It was no one other than the state agencies who took him   Aasim Saeed s father  Ghulam Haider  told Reuters  referring to Pakistan s intelligence agencies 
He said Saeed was picked up over a social media post intelligence agencies deemed  objectionable  
 My son is not against any agency  he is not against the military or government and he is not against Islam   Haider said   The fact that he was set free means that he has been cleared of all charges  
 The only instruction Aasim got from the agencies was that he could not give any media interviews   Haider added 
The military s media wing did not return calls or text messages seeking comment 
Haider said Aasim returned to his house briefly on Saturday but then left quickly  and messaged the family on Sunday morning to inform them that he was safe and would call soon 
Haider said Saeed had either returned to Singapore or was in Germany 
It is not known how the five activists went missing  but some rights groups and newspapers have asked whether state or military agencies were in any way involved 
The Interior Ministry has repeatedly said it was doing all it could to recover the missing men 
Shortly after the activists  disappearances  blasphemy allegations against them appeared on social media and in a complaint to police 
Friends  family and supporters of all five men deny they have blasphemed and have denounced the campaign to press that charge  which could endanger their lives were they to reappear 
In Pakistan  conviction under the blasphemy laws can carry a death sentence ",2017-01-29,Reuters,"https://www.investing.com/news/world-news/second-missing-pakistani-blogger-found,-leaves-country-fearing-for-life:-family-456382",456382
203178,424694,MRK,U S  securities class actions soar to two decade high,news,"By Jonathan Stempel  Reuters    U S  securities class actions have soared to a two decade high  topping levels during the financial crisis  after a landmark January 2016 ruling meant to deter lawsuits in Delaware that accomplish nothing for shareholders sent many lawyers scurrying instead to federal courts  There were 270 shareholder lawsuits in 2016 accusing companies of making false or misleading statements or concealing bad news about their businesses or mergers  a study released on Tuesday by Cornerstone Research and Stanford Law School shows  The number rose from 188 in 2015  and was the highest since the Private Securities Litigation Reform Act  designed to curb frivolous lawsuits  took effect in 1995  A separate study last week from NERA Economic Consulting also noted a two decade high  Cornerstone attributed much of the increase to a surge in federal lawsuits challenging mergers  to 80 from 17  That trend could prove sustainable  It followed a series of Delaware state court decisions culminating in Chancellor Andre Bouchard s January 2016 rejection of a settlement arising from Zillow Group Inc s  O ZG  purchase of online real estate rival Trulia Inc  Chancery Court judges decided to no longer reflexively approve  disclosure only  settlements requiring companies merely to reveal more  often immaterial details about their mergers  Lawyers are not entitled to six  or seven figure paydays for winning that  the judges said  Roughly half of the Fortune 500 companies are incorporated in Delaware  long seen as having laws favorable to business  Cornerstone said the number of traditional securities class actions  often following revelations of weak financial results or regulatory probes  rose to 189 last year from 170 in 2015  It said the  maximum dollar loss   or largest sums that shareholders might claim in damages  rose to  823 billion from  371 billion  and topped even the  816 billion level from 2008  Eighty of the 270 lawsuits targeted biotechnology  healthcare and pharmaceutical companies  Thirty four targeted financial companies  NERA  meanwhile  said settlements also increased  to 113 last year from 109 in 2015  It said the average settlement was  72 million  topped by  HSBC Holdings  Plc s  L HSBA   1 575 billion accord over lending practices at Household International Inc  a consumer finance company it bought  and Merck   Co s  N MRK   1 06 billion accord over its marketing of the painkiller Vioxx  Those settlements were long in coming  The Household litigation began in 2002  and the Merck litigation in 2005  
A  7 2 billion settlement in 2006 over energy company Enron Corp s collapse remains the largest on record ",2017-01-31,Reuters,https://www.investing.com/news/stock-market-news/u.s.-securities-class-actions-soar-to-two-decade-high-456923,456923
203179,424695,MRK,Sanofi Wins FDA Nod For Pediatric Hexavalent Combo Vaccine,opinion,Sanofi  PA SASY    NYSE SNY   announced that the FDA has approved its pediatric vaccine Vaxelis  which has been developed for active immunization to prevent six different diseases in children aged six weeks to four years Vaxelis has been jointly developed by Sanofi and Merck   NYSE MRK    Both companies are working on the vaccine production with a commercial launch expected not before 2020 The hexavalent combination vaccine is indicated for immunizing children to prevent diphtheria  tetanus  pertussis  poliomyelitis  hepatitis B and invasive disease due to Haemophilus influenzae type b  Vaxelis is approved as a 3 dose series for pediatric children prior to their fifth birthday Sanofi possesses one of the world s leading vaccine operations  Apart from pediatric vaccines  the company s portfolio includes influenza vaccines  adult and adolescent booster vaccines  meningitis vaccines  travel and endemic vaccines  Sanofi also has a strong position in both seasonal and pre pandemic influenza vaccine spaces Notably  in November this year  the European Commission gave marketing authorization to Sanofi s dengue vaccine  Dengvaxia  The vaccine is already available across 20 countries for the prevention of dengue Total sales of its vaccine division  Sanofi Pasteur  in the first nine months of 2018 were 3 6 billion euros  which declined slightly at constant exchange rate  CER  Sanofi is focused on expanding its vaccine business further  At the end of October 2018  the company s pipeline included 40 pharmaceutical new molecular entities and vaccine candidates  which were in phase III studies or under a regulatory review Shares of Sanofi have dipped 1 3  year to date  comparing unfavorably with the  decline of 1 2  Zacks Rank   Stocks to ConsiderSanofi currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY   and Roche Holding  SIX ROG  AG   OTC RHHBY    both carrying a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings estimates have been revised 0 8  upward for 2018 and 2 7  for 2019 over the past 60 days Roche s earnings estimates have moved 0 4  north for 2018 and 2 6  for 2019 over the past 60 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-26,Zacks Investment Research,https://www.investing.com/analysis/sanofi-wins-fda-nod-for-pediatric-hexavalent-combo-vaccine-200371278,200371278
203180,424696,MRK,BioXcel Surges On Fast Track Designation To Agitation Drug ,opinion,"Shares of clinical stage biopharmaceutical company  BioXcel Therapeutics  Inc    NASDAQ BTAI   surged significantly after the FDA granted Fast Track designation to its experimental drug  BXCL501 
BXCL501  a proprietary sublingual film of dexmedetomidine  is being evaluated for the treatment of acute agitation resulting from neurological and psychiatric disorders 
The fast track program from the agency is designed to provide certain benefits for new drugs that treat serious or life threatening conditions and demonstrate the potential to address unmet medical needs 
The designation should facilitate anticipated registration trials for BXCL501 in 2019  upon completion of pharmacokinetic  bioavailability  and safety study 
The candidate is currently being evaluated in a phase I placebo controlled  single dose  dose escalation study  The study is expected to enroll up to 60 healthy adult volunteers across various dosing groups  The primary endpoints are pharmacokinetics and safety  with secondary endpoints including assessment of pharmacodynamics  PD  and the relationship between BXCL501 concentrations and PD endpoints 
Top line data from the study is expected in the first half of 2019 
A potential approval will boost prospects for the company  Approximately 5 0 million patients suffering from Alzheimer s disease  schizophrenia and bipolar disorder experience agitation in the United States  Approximately 1 1 million of these patients experience mild to moderate agitation and represent a potential patient population for treatment with BXCL501 
BioXcel s other candidate  BXCL701 is an immuno oncology agent designed for the treatment of a rare form of prostate cancer and also for pancreatic cancer 
In September 2018  the company entered an immuno oncology partnership with Nektar Therapeutics   NASDAQ NKTR   to develop a combination of BXCL701  Nektar Therapeutics  NKTR 214 and a checkpoint inhibitor as a potential treatment for pancreatic cancer  Around the same time  the company filed an IND application with the FDA for a phase Ib II study to evaluate BXCL701 in combination with Merck s   NYSE MRK   Keytruda in treatment emergent neuroendocrine prostate cancer  tNEPC  
In October  the company received notice from the FDA stating that it may proceed with its planned human clinical investigation  which is expected to be initiated prior to year end  Data from the pharmacokinetic safety and efficacy study of BXCL701 in tNEPC are expected to be available throughout 2019 
Zacks Rank   Stock to Consider
BioXcel currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Bristol Myers Squibb Co    NYSE BMY    which sports a Zacks Rank  2  Buy   You can see   
Bristol Myers  earnings per share estimates have increased from  3 84 to  3 87 for 2018 and  3 89 to  4 14 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 11 99  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-12-28,Zacks Investment Research,https://www.investing.com/analysis/bioxcel-surges-on-fast-track-designation-to-agitation-drug-200371678,200371678
203191,424707,MRK,European stocks move higher as sentiment improves  DAX up 0 46 ,news,"Investing com   European stocks moved higher on Friday  as sentiment mildly improved while markets digested recent remarks by U S  President elect Donald Trump and uncertainties surrounding his future policies 
During European morning trade  the EURO STOXX 50 advanced 0 45   France s CAC 40 climbed 0 53   while Germany s DAX 30 gained 0 46  
Market sentiment initially weakened after Donald Trump failed to offer details on his promises to boost fiscal spending and cut taxes at a highly anticipated news conference on Wednesday 
However  optimism over the U S  economy strengthened after Federal Reserve Chair Janet Yellen said the economy is doing well and faces no serious obstacles in the short term  with the labor market looking strong 
Ms  Yellen was speaking at a town hall meeting with educators  in Washington 
Financial stocks were broadly higher  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  rallied 1 19  and 1 22   while Germany s  Deutsche Bank   DE DBKGn  and Commerzbank  DE CBKG  gained 0 45  and 1 05  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  and Unicredit  MI CRDI  advanced 0 66  and 1 24  respectively  while Spanish banks  Banco Santander   MC SAN  and BBVA  MC BBVA  climbed 0 43  and 0 54  
Elsewhere  Fiat Chrysler Auto saw shares surge 5 54  even as the U S  Environmental Protection Agency accused the carmaker on Thursday of illegally using hidden software to allow excess diesel emissions 
Merck  NYSE MRK  added to gains  with shares up 0 94  after the German drugmaker announced plans to team up with U S  data and analysis software company  Palantir  to develop new drugs more quickly 
In London  FTSE 100 gained 0 39   led by  Travis Perkins   LON TPK   whose shares rallied 3 09  after analysts at Liberum Capital reiterated their  buy  rating on the stock 
Financial stocks were also on the upside  as  Barclays   LON BARC  rose 0 45  and  HSBC Holdings   LON HSBA  climbed 0 61   while Lloyds Banking  LON LLOY  and the Royal Bank of Scotland  LON RBS  advanced 0 77  and 0 87  respectively 
Meanwhile  mining stocks were broadly lower on the commodity heavy index  Shares in  Antofagasta   LON ANTO  declined 0 83  and  Randgold Resources   LON RRS  tumbled 0 96   while rival company  Fresnillo   LON FRES  plunged 3 02    Glencore   LON GLEN  overperformed  with shares up 0 70  
In the U S   equity markets pointed to a moderately higher open  The Dow Jones Industrial Average futures pointed to a 0 07  uptick  S P 500 futures showed a 0 10  rise  while the Nasdaq 100 futures indicated a 0 11  gain ",2017-01-13,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-move-higher-as-sentiment-improves;-dax-up-0.46-452947,452947
203192,424708,MRK,Businesses can unlock  12 trillion via key development goals  Davos study,news,"By Sujata Rao DAVOS  Switzerland  Reuters    Companies could unlock at least  12 trillion in market opportunities by 2030 and create up to 380 million jobs by implementing a few key development goals  according to a study by a group including global business and finance leaders  The report  released on Monday by the Business and Sustainable Development Commission  said pressure on business to become a  responsible social actor  was likely to grow   The group was launched at the Davos 2016 World Economic Forum to encourage businesses to take the lead in poverty reduction and sustainable development   Members include the chief executives of multinational firms such as Edelman   Pearson   LON PSON   Investec  Merck  NYSE MRK   Safaricom  Abraaj   Alibaba   NYSE BABA  and  Aviva   LON AV   alongside academics  environmentalists  trade union leaders and philanthropists  The study said businesses have a key role to play in achieving the United Nations  Sustainable Development Goals  SDG  to end poverty and protect the planet    Achieving the global goals opens up an economic prize of at least  12 trillion by 2030 for the private sector and potentially 2 3 times more   the study said  adding this could be achieved by action in just four areas   energy  cities  agriculture and health  The  12 trillion   made up of business savings and revenue gains   would be equal to a tenth of forecast global economic output while 90 percent of the new jobs would be in the developing world  the study said  Mark Malloch Brown  chair of the Commission  said the opportunities included measures to cut greenhouse gas emissions even though U S  President elect Donald Trump has sometimes dismissed man made climate change as a hoax   In many cases the horse has already left the stable   he told Reuters of a shift to a greener economy under way in many parts of the world  driven by concern over rising temperatures and by falling prices for renewable energies  Progress has been slow  however  and the study said businesses are still balking at longer term investments  preferring instead to sit on cash or return it to shareholders via buybacks and dividends  The 17 SDGs  adopted in September 2015  include targets on such issues as climate  clean water  gender equality and economic inequality  The last of these has grabbed attention in recent years  bringing to prominence populist and nationalist politicians  especially in the West  as anger has grown over stagnant wages  migration  high CEO salaries and corporate tax evasion    We anticipate much greater pressure on business to prove itself a responsible social actor  creating good  properly paid jobs in its supply chains as well as in its factories and offices   the report said  adding that paying taxes transparently was key to rebuilding social contract  Other steps it urged include pricing pollution via carbon trading and reducing food waste  a step that by itself could be worth up to  405 billion   The cost of achieving these goals by 2030 will likely require  2 4 trillion of additional annual investment  however  especially in infrastructure  the study found  
The group recommended  innovative financing  from public and private sector sources to raise this amount  adding   The global finance system needs to become much better at deploying the trillions of dollars of savings into the sustainable investments that     the world needs    with additional reporting by Alister Doyle in Oslo  Editing by Jeremy Gaunt ",2017-01-16,Reuters,https://www.investing.com/news/stock-market-news/businesses-can-unlock-$12-trillion-via-key-development-goals:-davos-study-453308,453308
203193,424709,MRK,Wall Street ends higher as Trump becomes president,news,"By Caroline Valetkevitch NEW YORK  Reuters    U S  stocks closed higher on Friday in a modest but broad based advance as Donald Trump was sworn in as U S  President  marking the first time in more than 50 years that a new commander in chief has been welcomed by a rising equity market on his first day in office  In his speech  Trump said U S  policy will be to buy American and hire American  reiterating what he had said many times during this campaign for the White House  Some investors said the comments reinforced concerns about potential protectionist trade policies  Indexes pared gains during his speech and ended off the highest levels of the day  However  the rally in stocks since the Nov  8 election had stalled in recent weeks as investors awaited clarity on his plans to boost the economy  All three major indexes ended with losses for the week   We re now trading off of reality rather than hope  and it s natural to be a bit more cautious when we make that transition   said Brad McMillan  chief investment officer for Commonwealth Financial in Waltham  Massachusetts  The S P 500 s 6 2 percent gain since the election is one of the best performances for the American stock market for any presidential transition period of the modern era  Former President Barack Obama s transition period  which came amid the throes of the 2008 financial crisis  overlapped a 15 5 percent fall for the S P 500 from his election to the day of his 2009 inauguration  Yet he presided over the second best run for the stock market under any president since Dwight Eisenhower  The Dow Jones Industrial Average  DJI  snapped a five session losing streak  closing up 94 85 points  or 0 48 percent  to 19 827 25  The S P 500  SPX  gained 7 62 points  or 0 3 percent  to 2 271 31 and the Nasdaq Composite  IXIC  added 15 25 points  or 0 28 percent  to 5 555 33  The last time when either the S P or Dow rose on the day a new president was inaugurated was Jan  20  1961  when John F  Kennedy was sworn in to succeed Eisenhower  The S P gained 0 32 percent and the Dow added 0 31 percent  the Nasdaq did not yet exist  The first day aside  the coming month might not be as rosy  The S P 500 has fallen by a median 2 7 percent in the month after each new president has taken the keys to the White House since Herbert Hoover in January 1929  according to a Reuters analysis  Trump also loomed on the earnings front  Shares of Kansas City Southern  N KSU  rose 4 percent even as it reported a lower quarterly net profit that missed Wall Street estimates  A historic drop in the Mexican peso  after Trump s election affected the regional U S  railroad s operations in Mexico   Among other gainers  Merck  N MRK  rose 3 6 percent to  62 53 after Bristol Myers  N BMY  said it would not seek accelerated U S  approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer  giving Merck an advantage in the lucrative market  Bristol Myers  stock fell 11 3 percent  About 6 6 billion shares changed hands on U S  exchanges  higher than the 6 1 billion daily average for the past 20 trading days  according to Thomson Reuters data  Advancing issues outnumbered declining ones on the NYSE by a 1 76 to 1 ratio  on Nasdaq  a 1 58 to 1 ratio favored advancers  
The S P 500 posted 19 new 52 week highs and seven new lows  the Nasdaq Composite recorded 85 new highs and 33 new lows ",2017-01-20,Reuters,https://www.investing.com/news/stock-market-news/futures-rise-ahead-of-trump's-inauguration-454599,454599
203194,424710,MRK,European stocks open higher  financials lead  DAX up 0 55 ,news,"Investing com   European stocks opened higher on Thursday  led by gains in the financial sector and boosted by the previous session s strong gains on Wall Street  although concerns over protectionist measures under the Trump administration continued to loom 
During European morning trade  the EURO STOXX 50 added 0 18   France s CAC 40 rose 0 33   while Germany s DAX 30 climbed 0 55  
Trump on Wednesday ordered construction of a U S  Mexican border wall and punishment for cities shielding illegal immigrants 
In addition  Trump was expected to sign an executive order in the coming days to block the entry of refugees from Syria and suspend the entry of any immigrants from Muslim majority Middle Eastern and African countries 
Markets were jittery after Donald Trump s inauguration last Friday amid concerns over a lack of clarity on his economic policies and fears that his protectionist trade stance could hit corporate profits and act as a drag on growth 
Financial stocks were broadly higher  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  rallied 1 31  and 2 02   while Germany s  Deutsche Bank   DE DBKGn  and Commerzbank  DE CBKG  surged 2 70  and 3 10  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  and Unicredit  MI CRDI  advanced 0 70  and 2 08  respectively  while Spanish banks BBVA  MC BBVA  and  Banco Santander   MC SAN  jumped 1 79  and 1 90  
Elsewhere  Merck  NYSE MRK  saw shares climb 1 43  following news that former Buffalo Bills quarterback Jim Kelly discussed his new partnership with the drugmaker to create  Your Cancer Game Plan  in an effort to help people with cancer stay informed during their fight against the disease 
In London  FTSE 100 edged up 0 08   boosted by  Diageo   LON DGE   whose shares surged 4 30  after the alcoholic beverages company reported a 28  increase in operating profit for the first half of its fiscal year and a hike in its dividend 
Financial stocks added to gains  as Lloyds Banking  LON LLOY  climbed 0 69  and  HSBC Holdings   LON HSBA  advanced 0 80   while  Barclays   LON BARC  and the Royal Bank of Scotland  LON RBS  rallied 1 04  and 1 63  respectively 
RBS seemed to ignore earlier reports that it could take another multi billion pound charge for mis selling 
Meanwhile  mining stocks were mixed on the commodity heavy index  Shares in Anglo America gained 0 55  and  Rio Tinto   LON RIO  advanced 0 78   while BHP Billiton  LON BLT  declined 0 75  and  Fresnillo   LON FRES  tumbled 1 62  
  Whitbread   LON WTB  was one of the worst performers on the index  with shares down 4 83  even as the hotel and coffee shop operator posted a 8 6  climb in total sales for the third quarter 
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 26  increase  S P 500 futures showed a 0 15  rise  while the Nasdaq 100 futures indicated a 0 36  gain ",2017-01-26,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-open-higher,-financials-lead;-dax-up-0.55-455788",455788
203195,424711,MRK,AstraZeneca s  AZN  Lynparza Gets FDA Nod In 1st Line Setting,opinion,"AstraZeneca Plc    NYSE AZN   and partner Merck   Co   Inc    NYSE MRK   announced that the FDA has approved a label expansion of its advanced ovarian cancer drug Lynparza  The FDA has approved Lynparza as a first line maintenance therapy for BRCA mutated advanced ovarian cancer  It is the first regulatory approval for a PARP inhibitor in first line maintenance setting 
We note that Lynparza is already marketed in the United States for platinum sensitive relapsed ovarian cancer  regardless of BRCA status and germline BRCAm HER2 negative metastatic breast cancer 
The approval in the first line setting  was based on data from the pivotal phase III SOLO 1 study  which demonstrated that Lynparza  olaparib  tablets led to a statistically significant and clinically meaningful improvement in progression free survival  PFS  compared to placebo in women with BRCA mutated  BRCAm  advanced ovarian cancer who were in complete or partial response following first line standard platinum based chemotherapy 
In the Lynparza arm  60  of the patients were progression free at 36 months compared with 27  in the placebo arm  Lynparza reduced the risk of disease progression or death by 70  compared to placebo  following response to platinum based chemotherapy 
With the approval for expanded use in the first line setting  sales of Lynparza can improve in the future quarters 
Other PARP inhibitors available in the market are Tesaro  Inc  s   NASDAQ TSRO   Zejula and Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  Zejula and Rubraca are also being evaluated in late stage studies in the first line maintenance setting for the treatment of ovarian cancer patients who have responded to platinum based chemotherapy 
This year so far  AstraZeneca s shares have risen 13 7  compared with the  s growth of 4 9  

In a separate press release  AstraZeneca and Merck announced positive results from phase III SOLO 3 study of Lynparza  which was conducted as a post approval commitment in agreement with the FDA  The results showed that BRCAm advanced ovarian cancer patients treated with Lynparza following two or more prior lines of chemotherapy experienced a statistically significant and clinically meaningful improvement in the primary endpoint of objective response rate  ORR  and the key secondary endpoint of progression free survival  PFS  compared to chemotherapy  This is the fourth phase III study to report positive results for Lynparza  The companies plan to discuss the results with the FDA 
Astrazenca also announced that two phase III studies OLYMPUS and ROCKIES  evaluating pipeline candidate roxadustat for the treatment of patients with anaemia in chronic kidney disease  CKD   met their primary efficacy endpoint 
The OLYMPUS study was conducted on non dialysis dependent CKD patients  while the ROCKIES study was conducted on dialysis dependent CKD patients 
While OLYMPUS demonstrated a statistically significant and clinically meaningful improvement in haemoglobin versus placebo  ROCKIES showed a similar improvement in haemoglobin versus epoetin alfa 
Roxadustat is a hypoxia inducible factor prolyl hydroxylase inhibitor  HIF PHI   which is being jointly developed and commercialized by AstraZeneca and FibroGen 
Data from the phase III OLYMPUS and ROCKIES trials together with the efficacy and pooled safety data from the global phase III program conducted by AstraZeneca  FibroGen and Astellas will be part of the regulatory submission package in the United States and other major countries 
We remind investors that roxadustat was approved in China  its first regulatory approval  for the treatment of anaemia in chronic kidney disease patients on dialysis  earlier this week AstraZeneca PLC Price

   Zacks Rank 
AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-azn-lynparza-gets-fda-nod-in-1st-line-setting-200370055,200370055
203212,424728,MRK,Novartis  Gilenya Approved In EU For Expanded Population,opinion,"Novartis AG   NYSE NVS   announced that the European Commission  EC  has approved a label expansion of multiple sclerosis  MS  drug Gilenya  fingolimod  
The drug is now approved in Europe for the treatment of children who are 10 17 years old with relapsing remitting forms of multiple sclerosis  RRMS   Following  the nod  the drug became the first and only oral disease modifying treatment for children and adolescents who experience more severe relapses than adults 
The approval was based on positive data from the phase III PARADIGMS study  Data from the study showed that Gilenya significantly reduced the relapse rates by 82  compared to interferon beta 1a  Moreover  85 7  of patients treated with Gilenya were relapse free for up to two years compared to interferon beta 1a  Additionally  patients experienced a 77  risk reduction of disability progression when treated with Gilenya versus patients treated with interferon beta 1a 
We note that Gilenya is already approved in the United States and Europe for treating relapsing forms of MS in patients aged 18 years or older   In May 2018  the drug was approved in the United States for the treatment of children aged 10 years or older with MS 
Shares of Novartis have gained 7  year to date compared with the  growth of 7 7  

 
We would like to remind investors that  in October 2018  Novartis announced encouraging top line results from another phase IIIb ASSESS study on Gilenya 
The study evaluated the safety and efficacy of oral  once daily Gilenya 0 5mg and 0 25mg compared with once daily subcutaneous injections of Teva Pharmaceuticals    NYSE TEVA   Copaxone  glatiramer acetate  20mg in patients with RRMS 
The safety of Gilenya across both doses was consistent with the known safety profile of the drug  Notably  more discontinuations due to adverse events and unsatisfactory treatment effects were reported in the Copaxone group  The data from the ASSESS study further reinforces efficacy of Gilenya in treating relapsing MS 
Novartis  MS portfolio comprises approved drugs like Gilenya and Extavia  Notably  Extavia is approved in the United States for the treatment of relapsing forms of MS  In Europe  the drug is approved to treat people with relapsing remitting MS and secondary progressive MS  SPMS  with active disease 
Zacks Rank   Stocks to Consider
Novartis currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the large cap pharma sector include Bristol Myers Squibb Co    NYSE BMY   and Merck   Co   Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings estimates have been revised 6 9  upward for 2018 and 6 8  for 2019 over the past 60 days  
Merck s earnings estimates have been raised 1 6  for 2018 and 1 7  for 2019 over the past 60 days  The stock has surged 37 2  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-30,Zacks Investment Research,https://www.investing.com/analysis/novartis-gilenya-approved-in-eu-for-expanded-population-200364100,200364100
203213,424729,MRK,AstraZeneca s Imfinzi Fails In Head And Neck Cancer Study,opinion,"AstraZeneca   NYSE AZN   announces that the phase III EAGLE study  evaluating Imfinzi  durvalumab  as monotherapy as well as a combination therapy with tremelimumab  failed to meet primary endpoint of improvement in overall survival   OS   in advanced head and neck squamous cell carcinoma patients compared to chemotherapy   HNSCC   The study compared Imfinzi monotherapy and combination therapy to standard of care  SoC  chemotherapy in HNSCC patients whose disease has progressed following a platinum based chemotherapy  regardless of their PD L1 tumor status Data from the study showed neither Imfinzi monotherapy nor Imfinzi combo achieved improvement in OS compared with SoC chemotherapy We remind investors that Imfinzi and Imfinzi  tremelimumab also failed in another late stage study evaluating the therapies in first line stage IV  metastatic  non small cell lung cancer   NSCLC   Imfinzi  a PD L1 inhibitor  is marketed for unresectable  stage III NSCLC and metastatic urothelial carcinoma in second line setting AstraZeneca s shares are up 12  so far this year compared with the  s increase of 9 1  Although the drug failed in this HNSCC study  the company remains committed to developing it for the indication  Another late stage study  KESTREL  is evaluating the same combination in HNSCC patients who have not received any prior chemotherapy  Data from this study is expected in the first half of 2019 Per the press release  globally 880 000 patients were diagnosed with HNSCC in 2018 and about two third of them are in advanced stages  This represents a significant opportunity for drugs that are being developed for this indication  However  with this failure of Imfinzi in second line HNSCC  AstraZeneca is set to miss an opportunity to grab a share in the market  Investors should remain focused on KESTREL study data for Imfinzi s prospects in this patient population Imfinzi is a key drug in AstraZeneca s immuno oncology   IO   pipeline  which is being evaluated for treating multiple cancers as monotherapy or in combination with other regimens including Incyte s   NASDAQ INCY   epacadostat  Key phase III trials are evaluating Imfinzi in combination with tremelimumab for hepatocellular carcinoma  HCC  liver cancer   NSCLC  small cell lung cancer  HNSCC and bladder cancer The company s PD L1 inhibitor is significantly lagging the other two approved PD L1 inhibitors   Bristol Myers    NYSE BMY   Opdivo and Merck s   NYSE MRK   Keytruda   in terms of approved indications as well as sales  While Imfinzi recorded sales of  371 million in the first nine months of 2018  Opdivo and Keytruda generated sales of  4 9 billion and  5 billion  respectively  Successful development of Imfinzi is necessary for AstraZeneca to grab the lucrative IO market AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-06,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-imfinzi-fails-in-head-and-neck-cancer-study-200366099,200366099
203214,424730,MRK,Novartis Presents Additional Data On Breast Cancer Candidate,opinion,Novartis AG   NYSE NVS   announced additional data from a phase III SOLAR 1 study  currently evaluating its pipeline candidate  BYL719  alpelisib   in combination with AstraZeneca s   NYSE AZN   Faslodex  fulvestrant  The test assessed the combo of BYL719  an investigational alpha specific PI3K inhibitor  and AstraZeneca s Faslodex compared with Faslodex alone in postmenopausal women and men suffering hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   PIK3CA mutant advanced or metastatic breast cancer that progressed on or following aromatase inhibitor  AI  treatment In the study  BYL719 plus Faslodex doubled the median progression free survival  PFS  in patients with the above mentioned disease  The proposed combined regime also consistently demonstrated a clinically meaningful treatment effect after progression on an AI or post receiving one additional therapy for addressing advanced breast cancer The updated results from the study were presented at the San Antonio Breast Cancer Symposium Patients who progressed within 12 months after receiving AI experienced a median PFS of 11 0 months after getting the combo therapy compared with the 6 8 month routine on fulvestrant only  Median PFS was also superior for patients administered with the combo therapy in comparison to those subject to an additional line of therapy Shares of Novartis have gained 6 1  year to date compared with the  s increase of 9 1  In August 2018  Novartis announced that the study met the primary endpoint as patients treated with BYL719 showed a positive response in terms of PFS The study will continue to analyze data for secondary endpoints  The company expects to initiate discussions with regulatory authorities worldwide The favorable top line results from the program increases the likelihood of success and a subsequent approval of the candidate Novartis already has Kisqali in its portfolio for treating breast cancer  The drug is approved in the United States for the treatment of women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer Zacks Rank   Stocks to ConsiderNovartis currently carries a Zacks Rank  3  Hold   Better ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY   and Merck   Co   Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings estimates have been revised 6 6  upward for 2018 and 4 1  for 2019 over the past 60 days Merck s earnings estimates have been inched 1 4  up for 2018 and 0 9  for 2019 over the past 60 days  The stock has surged 39 2  year to date Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-06,Zacks Investment Research,https://www.investing.com/analysis/novartis-presents-additional-data-on-breast-cancer-candidate-200366170,200366170
203225,424741,MRK,Northwest Bio initiates mid stage study of DCVax Keytruda combo in advanced colorectal cancer,news,Northwest Biotherapeutics  NWBO  12 8   teams up with the University Medical Center of the Johannes Gutenbury University Mainz in Germany in a Phase 2 clinical trial assessing the combination of DCVax L and Merck s  MRK  0 4   PD 1 inhibitor Keytruda  pembrolizumab  in patients with colorectal cancer with liver metastases After receiving the necessary regulatory approvals  the study will treat patients for up to six months with the combination followed by a long term follow up period to assess survival ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/northwest-bio-initiates-mid-stage-study-of-dcvax-keytruda-combo-in-advanced-colorectal-cancer-441811,441811
203226,424742,MRK,Astrazeneca s Fasenra Gets Orphan Drug For Autoimmune Disease,opinion,"AstraZeneca  plc s   NYSE AZN   new asthma drug  Fasenra  benralizumab   was granted orphan drug designation by the FDA for the treatment of eosinophilic granulomatosis with polyangiitis   EGPA    The company is developing the drug for treating EGPA in a phase II study Notably  the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200 000 people in the United States  The status makes Fasenra eligible for seven years of marketing exclusivity in the United States if approved for the given indication  The designation also makes the company entitled to certain other benefits including tax credits related to clinical trial expenses and exemption from FDA user fee Fasenra is marketed in Europe and the United States as an add on maintenance treatment in patients with severe eosinophilic asthma  Fasenra is given as a fixed dose subcutaneous injection via a prefilled syringe  once in every eight weeks  making it the first respiratory biologic medicine to be approved in the United States and the EU with a convenient 8 week maintenance dosing schedule  GlaxoSmithKline s   NYSE GSK   Nucala and Teva Pharmaceutical Industries    NYSE TEVA   Cinqair are presently marketed for the same indication but administered once every four weeks AstraZeneca s shares have risen 15 5  so far this year compared with the  s increase of 6 7  Eosinophilic granulomatosis with polyangiitis  formerly known as Churg Strauss Syndrome  is a rare autoimmune disease  which is caused by inflammation of blood vessels and the presence of elevated levels of eosinophils in blood  The disease may lead to damage of multiple organs  including lungs  skin  heart  gastrointestinal tract and nerves The company is also developing the drug for treating severe nasal polyposis in a late stage study Fasenra s sales have done well so far in 2018 on the back of strong demand in both the United States and Europe  Successful label expansion of the drug in additional indications is likely to drive sales further However  in May  AstraZeneca announced that Fasenra has failed to meet primary endpoint of reduction in exacerbations of statistical significance compared to placebo in the phase III study  GALATHEA  The study was evaluating Fasenra as an add on to dual or triple inhaled therapy in patients with moderate to very severe chronic obstructive pulmonary disease AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  A better ranked large cap pharma stock is Merck   Co   Inc    NYSE MRK   with a Zacks Rank  2  Buy   The company s earnings estimates have increased from  4 27 to  4 34 for 2018 and from  4 63 to  4 71 for 2019 over the past 60 days The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-26,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-fasenra-gets-orphan-drug-for-autoimmune-disease-200362707,200362707
203237,424753,MRK,Buyers clubs for cheaper drugs help fight hepatitis and HIV,news,By Ben Hirschler LONDON  Reuters    Frustrated by the high price of antiviral drugs  thousands of patients from London to Moscow to Sydney are turning to a new wave of online  buyers clubs  to get cheap generic medicines to cure hepatitis C and protect against HIV infection  While regulators warn that buying drugs online is risky  scientific data presented at a recent medical conference suggest that treatment arranged through buyers club can be just as effective as through conventional channels   Will Nutland  who supports a drug buying network in London and takes Indian made generic drugs that are not available through the health service to prevent HIV infection  thinks the latest research will build confidence in such schemes   This new data shows that so far we ve got it right   the HIV activist said   It gives us a boost in confidence in the types of drugs that are available online   The buyers clubs  websites act as middlemen by providing details of trusted online pharmacies and drug manufacturers  exploiting a loophole in World Trade Organization patent rules that allows small scale imports of medicines for personal use  Like Ron Woodroof  the 1980s AIDS patient in the movie  Dallas Buyers Club   the sponsors of today s drug clubs aim to help patients who can t get the drugs they want through local healthcare systems by bringing in medicines from abroad  But while Woodroof had to smuggle drugs in bulk across the Mexican border  users of modern day clubs can  in many countries  tap orders into their computers quite legally  Savings can be huge  A month s generic supply of the pre exposure prophylaxis  PrEP  HIV drugs emtricitabine and tenofovir costs about 45 pounds   56  online in Britain  around a tenth of Gilead Sciences  branded version Truvada  A Indian made course of treatment for the liver destroying disease hepatitis C  meanwhile  can be had for around 1 000 pounds against a list price for branded drugs of around 35 000  Gilead is also a leading producer of patented hepatitis C drugs  along with Merck  NYSE MRK  and AbbVie  BRAVE ENOUGH TO TRY  Resorting to a buyers club is clearly not conventional medicine but it is something some people have been brave enough to try and it seems to be working   said Andrew Hill of London s Chelsea and Westminster Hospital  Data presented at the Oct  23 26 HIV Glasgow conference showed generic drugs bought via buyers clubs in Australia  Britain  Russia and South East Asia by a total of 900 patients delivered hepatitis C cure rates of around 95 percent  That is similar to outcomes in clinical trials using the original brands  Another piece of research involving more than 200 gay men in London taking generic PrEP bought through a buyers club found that their drugs  mostly made by India s Cipla  were both safe and effective at preventing HIV infection   Such observational studies do not have the rigor of full scale clinical trials but they do provide reassurance   What this sort of data does is give doctors and patients some faith that this isn t an act of complete lunacy that is going to cause patient harm   said James Freeman  a Tasmanian doctor behind a hepatitis C drug buying club  For Freeman and other critics of the pharmaceuticals industry  the advent of today s buyers clubs is just the latest chapter in an ongoing war over drug prices  with parallels to the battle over getting cheap HIV drugs into Africa  In the 1990s  HIV drugs costing more than  10 000 per patient a year were simply out of reach for millions of people in the developing world  Today  thanks to cheap generics  the cost for the poor has been slashed to around  100  Still  there are obstacles  In a number of European countries  including Germany  medicines cannot be sent in the post  prompting some people to collect supplies from friends in countries like Britain where it is permitted  Some online pharmacies demand a doctor s prescription to fulfil an order  although many do not  and people using buyers clubs still require blood tests to ensure the drugs they are on are working properly  without serious side effects  The need for those laboratory tests is controversial  since it costs money to test people taking medicines that were not prescribed by the official healthcare system in the first place   But Nneka Nwokolo  who presented the data on PrEP in Glasgow  believes it makes sense  given the proven efficacy of PrEP in several clinical trials  She works at a National Health Service  NHS  sexual health clinic in London s Soho that has been offering blood tests for generic PrEP users since February    HIV rates among gay men are not going down  despite all our interventions  including promoting condom use  But we know PrEP works and it has been shown to make a significant difference to HIV acquisition   she said  Clinical trials have shown PrEP cuts the risk of catching the virus during sex by more than 90 percent  PATCHY ACCESS Across Europe and around the world access to PrEP remains patchy  In Britain  routine use is stalled by a funding row  as well as doubts over cost effectiveness  based on the high price of branded Truvada  Access to hepatitis C drugs faces similar budget constraints in many countries  given the high cost of brand name products  Gilead s Sovaldi initially cost  1 000 a pill in the United States  although competition has since pushed prices down  Gilead said in a statement that it worked  to ensure broad access to its medicines through dialogue and efforts with payers and other stakeholders  including governments   But HIV activist Nutland  who is also a research fellow at the London School of Hygiene and Tropical Medicine  believes drugmakers must do more to make their products affordable   It s an absolute scandal that the prices are so high that even wealthy national services are saying they cannot afford the costs of these drugs  ,2016-11-06,Reuters,https://www.investing.com/news/technology-news/buyers-clubs-for-cheaper-drugs-help-fight-hepatitis-and-hiv-438062,438062
203238,424754,MRK,Intec Pharma cuts sample size in late stage study of lead product candidate by almost 30   shares up 11 ,news,Thinly traded nano cap  Intec Pharma Ltd    NTEC  11 1   heads north  albeit on very light volume  in response to its announcement that it has amended the protocol in its Phase 3 clinical trial assessing the Accordion Pill Carbidopa Levodopa  AP CD LD  for the treatment of symptoms of Parkinson s disease  PD  in advanced PD patients The change  which does not alter the endpoints or statistical power  has reduced the sample size from 460 to 328  The double blind  double dummy  active controlled study will randomize participants to receive either AP CD LD or Merck s  MRK  2 1   SINEMET IR  carbidopa levodopa   an immediate release medication The primary endpoint is the percentage of daily  OFF   time during waking hours from baseline  Week 6  to the end of the study  Week 26   According to ClinicalTrials gov  the estimated final data collection date for the primary endpoint is September 2017 and the estimated study completion date is December 2017  but both are based on the larger sample size  The end dates should move up with fewer subjects Intec develops drugs based on its proprietary Accordion Pill platform technology  an oral drug delivery system that is designed to improve the efficacy and safety of existing medicines by increasing the time they are retained in the stomach  This has the potential to significantly improve the performance of drugs that have a narrow absorption window  poor solubility  act locally in the stomach upper GI tract or present adverse effects when reaching the distal parts of the GI tract ,2016-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/intec-pharma-cuts-sample-size-in-late-stage-study-of-lead-product-candidate-by-almost-30;-shares-up-11-438413,438413
203239,424755,MRK,OncoSec Medical s ImmunoPulse IL 12 shows positive effect in PD L1 inhibitor resistant melanoma patients  shares up 7 ,news,Thinly traded nano cap OncoSec Medical  ONCS  6 9   jumps out of the blocks this morning on increased volume in response to its announcement of positive interim results in a mid stage study assessing ImmunoPulse IL 12 and Merck s  MRK  0 5   KEYTRUDA  pembrolizumab  in patients with unresectable metastatic melanoma  The data will be presented on November 11 at the Society for Immunotherapy of Cancer Annual Meeting in National Harbor  MD In 15 patients determined to be unlikely to respond to a PD 1 inhibitor alone  40   n 6 15  responded to treatment with ImmunoPulse Il 12 and KEYTRUDA  The group included four complete responders and two partial responders ImmunoPulse IL 12 delivers a pulsed electric field to cells via a hand held applicator which temporarily increases the porosity of the cell membranes  electroporation   DNA IL 12 is then delivered to the electroporated cells which triggers each cell to produce and secrete IL 12 protein which then identifies and eliminates cancer cells as part of a natural immune response Pembrolizumab helps the immune system fight tumor cells by blocking the interaction between PD 1  a cell surface receptor expressed on T cells and pro B cells  and its ligands PD L1 and PD L2  PD 1 is an immune checkpoint which down regulates the immune system  Blocking its action activates the immune system to attack cancer cells ,2016-11-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/oncosec-medical's-immunopulse-il-12-shows-positive-effect-in-pd-l1-inhibitor-resistant-melanoma-patients;-shares-up-7-438734,438734
203240,424756,MRK,Bristol Myers and Infinity Pharma pair up in solid tumors study,news,Bristol Myers Squibb  NYSE BMY  and  Infinity Pharmaceuticals   NASDAQ INFI  will collaborate in a clinical program assessing the combination of Opdivo  nivolumab  and Infinity s IPI 549 in patients with advanced solid tumors  The dose escalation phase exploring the combination should begin shortly IPI 549 is an orally available inhibitor of phosphoinositide 3 kinase  PI3K  gamma  Opdivo is an programmed death receptor 1  PD 1  immune checkpoint inhibitor that activates the immune system s T cells to detect and attack cancer cells Preclinical data suggest that IPI 549 may enhance the effects of immune checkpoint inhibitors by altering the immune suppressive microenvironment A Phase 1 dose escalation study assessing IPI 549 as monotherapy and in combination with Merck s  NYSE MRK  Keytruda  pembrolizumab  is currently recruiting participants ,2016-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/bristol-myers-and-infinity-pharma-pair-up-in-solid-tumors-study-439113,439113
203241,424757,MRK,AstraZeneca s Imfinzi Fails In Lung Cancer Study  Stock Down,opinion,"AstraZeneca s   NYSE AZN   Imfinzi  durvalumab  monotherapy as well as in combination with tremelimumab failed to meet overall survival   OS   endpoint in phase III MYSTIC study evaluating it in first line stage IV  metastatic  non small cell lung cancer   NSCLC   Imfinzi  a PD L1 inhibitor  is approved for unresectable  stage III NSCLC in second line setting in the United States and the company is evaluating the drug in several late stage studies for treating stage IV NSCLC  The drug is also approved for treating bladder cancer Shares of the company were down 1 8  on Nov 16 following the news  AstraZeneca s shares are up 17 2  so far this year compared with the  s increase of 8 2  The MYSTIC study was evaluating Imfinzi monotherapy  and combination of Imfinzi and tremelimumab  an anti CTLA4 antibody  compared with standard of care platinum based chemotherapy in NSCLC patients who did not receive any previous treatment  The patients who were selected for analysis had their tumors expressing PD L1 on 25  or more of their cancer cells Data from the study showed neither Imfinzi monotherapy nor Imfinzi combo achieved improvement in OS of statistical significance compared with chemotherapy In fact  data from the study last year indicated that Imfinzi as monotherapy or in combination with tremelimumab had failed to improve progression free survival  Moreover  the OS data was expected in the first half of 2018 but a delay in the data readout was announced in March Imfinzi is a key drug in AstraZeneca s immuno oncology   IO   pipeline which is being evaluated for treating multiple cancers as monotherapy or in combination with other regimens including Incyte s   NASDAQ INCY   epacadostat  Key phase III trials are valuating Imfinzi in combination with tremelimumab for hepatocellular carcinoma  HCC  liver cancer   NSCLC  small cell lung cancer and head and neck squamous cell carcinoma   HNSCC   among others are under way Successful completion of the MYSTIC study and approval for the first line indication could have helped AstraZeneca in bolstering the sales of the drug significantly as first line lung cancer is a lucrative market  However  three other phase III studies   PEARL  NEPTUNE and POSEIDON   are evaluating the drug alone or in combination with tremelimumab in first line NSCLC Meanwhile  the company s PD L1 inhibitor is significantly lagging the other two approved PD L1 inhibitors   Bristol Myers    NYSE BMY   Opdivo and Merck s   NYSE MRK   Keytruda   in terms of approved indications as well as sales  While Imfinzi recorded a sales of  371 million in the first nine months of 2018  Opdivo and Keytruda generated sales of  4 9 billion and  5 billion  respectively Although  Imfinzi s development did not progress well in 2018  there are several data readouts scheduled in 2019  Positive data should boost the prospects of the drug and help it achieve the potential it holds as a PD L1 inhibitor AstraZeneca PLC Price
    Zacks RankAstraZeneca carries a Zacks Rank  3  Hold  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-18,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-imfinzi-fails-in-lung-cancer-study-stock-down-200360621,200360621
203244,424760,MRK,Merck Q3 EPS  1 07 vs estimate  0 99  sales climb 5   ,news,Investing com   Merck s third quarter earnings and revenues beat estimates Merck  NYSE MRK  Q3 non GAAP EPS  1 07 vs  estimate  0 99  year earlier  0 96 Revenues rose 5  yoy to  10 54 bn vs  estimate of  10 08 bn Pharmaceutical guidance for full year non GAAP EPS of  3 71  3 78 Full year revenue guidance raised to  39 7 bn   40 2 bn Merck shares up 1 25  at  61 50 in pre market trade ,2016-10-25,Investing.com,https://www.investing.com/news/stock-market-news/merck-q3-eps-$1.07-vs-estimate-$0.99;-sales-climb-5-434555,434555
203245,424761,MRK,AstraZeneca s Lynparza Gets Priority Review In 1st Line Use,opinion,"AstraZeneca plc   NYSE AZN   and partner Merck s   NYSE MRK   supplemental new drug application  sNDA  looking for label expansion of their PARP inhibitor Lynparza as a first line maintenance treatment for advanced ovarian cancer was accepted by the FDA  With the FDA granting priority review  a decision is expected in the first quarter of 2019 
Lynparza is already marketed in the United States for platinum sensitive relapsed ovarian cancer regardless of BRCA status and germline BRCAm HER2 negative metastatic breast cancer 
The sNDA filing was based on data from the pivotal phase III SOLO 1 study  which demonstrated that Lynparza  olaparib  tablets led to a statistically significant and clinically meaningful improvement in progression free survival  PFS  compared to placebo in women with BRCA mutated  BRCAm  advanced ovarian cancer who were in complete or partial response following first line standard platinum based chemotherapy  In the Lynparza arm  60  of the patients were progression free at 36 months compared with 27  of women in the placebo arm 
This year so far  AstraZeneca s shares have risen 17 9  compared with the  s increase of 8 3  
 

 
AstraZeneca reported Lynparza sales of  438 million in the first half of 2018  up 118  at constant exchange rates  on expanded use in ovarian cancer and label expansion in breast cancer  If approved for expanded use in the first line setting  sales of Lynparza can improve in the future quarters 
Other PARP inhibitors available in the market are Tesaro  Inc  s   NASDAQ TSRO   Zejula and Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  Zejula and Rubraca are also being evaluated in late stage studies in the first line maintenance setting in ovarian cancer patients who have responded to platinum chemotherapy 
AstraZeneca also announced presentation of detailed data from a phase III cardiovascular outcomes study  DECLARE   TIMI 58  on type II diabetes drug Farxiga at the annual session of the American Heart Association 
In September  AstraZeneca had already announced that Farxiga led to statistical significant reduction in hospitalization for heart failure  hHF  or CV death in the study  thereby meeting one of the two primary efficacy endpoints  Along with the latest release  AstraZeneca said that Farxiga significantly reduced the combined risk of hHF or CV death by 17  versus placebo  Meanwhile  for the other endpoint  though fewer major adverse cardiovascular events  MACE  were observed in the Farxiga arm  this did not reach statistical significance  8 8  for Farxiga vs  9 4  for placebo  
The DECLARE   TIMI 58 cardiovascular outcomes study was carried out in type II diabetes who have multiple CV risk factors or established CV disease  The study compared the effect of Farxiga versus placebo in reducing the risk of MACE in such patients 
AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-lynparza-gets-priority-review-in-1st-line-use-200358844,200358844
203246,424762,MRK,Tesaro  Clovis Rally On FDA Priority Review For Lynparza SNDA ,opinion,"Shares of TESARO  Inc    NASDAQ TSRO   and Clovis Oncology   NASDAQ CLVS   were up on Tuesday  after AstraZeneca plc   NYSE AZN   and partner Merck   NYSE MRK   announced that the FDA has granted priority review to their regulatory application looking for label expansion of its PARP inhibitor  Lynparza  in the first line setting for advanced ovarian cancer Notably  TESARO and Clovis market PARP inhibitors  Zejula and Rubraca  respectively  Both these companies are also developing the respective drugs  Zejula and Rubraca  as a first line maintenance treatment for advanced ovarian cancer While TESARO gained 8 4   Clovis was up 5 4  on Nov 13  However  so far this year  shares of TESARO and Clovis  have lost 64 7  and 77 6   respectively  compared with the biotech  s 19 4  decline The supplemental new drug application  sNDA  is looking for approval of Lynparza  as maintenance treatment in newly diagnosed advanced ovarian cancer patients with BRCA mutation who have achieved complete or partial response  following first line standard platinum based chemotherapy  A decision from FDA is expected in the first quarter of 2019 In fact  Lynparza s sNDA is the first regulatory application in the PARP inhibitor segment seeking label expansion in first line maintenance setting   The three approved PARP inhibitors at present compete in the second line maintenance setting for ovarian cancer  irrespective of BRCA mutation and third or later line setting in BRCA mutated ovarian cancer Successful development of these drugs in first line setting is likely to improve sales for each  This is because first line setting represents the largest addressable ovarian cancer patient population and only three drugs compete in the PARP inhibitor segment  Moreover  data from AstraZeneca s phase III SOLO 1 study  which evaluated Lynparza in ovarian cancer as first line maintenance  showed that duration of progression free survival in first line is significantly higher than in recurrence setting  This suggest better acceptance of PARP inhibitors in first line setting Meanwhile  on their third quarter earnings call  TESARO has stated that market share of PARP inhibitors  in the ovarian cancer market has stagnated  Thus  label expansion in first line setting might be a way to boost market share in the highly crowded advanced ovarian cancer market A phase III study   PRIMA   is evaluating Zejula monotherapy for treating advanced ovarian cancer in first line maintenance setting  In the second quarter  TESARO has completed enrolment in the study and the top line data is expected in 2019  A phase III study  ATHENA  is currently enrolling patients and evaluating Rubraca in combination with Bristol Myers  Opdivo in similar indication  Both these studies evaluate the therapies in ovarian cancer irrespective of BRCA mutation  which represents a larger patient population than BRCA mutant ovarian cancer patients in Lynparza s SOLO 1 study AstraZeneca PLC Price
    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/tesaro-clovis-rally-on-fda-priority-review-for-lynparza-snda-200359185,200359185
203250,424766,MRK,Doctors grapple with best use of potent new cancer drugs,news,"By Ben Hirschler COPENHAGEN  Reuters    Evelyn O Flynn still has lung cancer  But after going straight on to a new immune system boosting drug more than a year ago  rather than traditional hard to tolerate chemotherapy  she is feeling great   It s like a miracle   said the 72 year old ex smoker  who is about to become a great grandmother  As a patient being treated with Merck  NYSE MRK    Co s immunotherapy drug Keytruda  O Flynn is one of the lucky ones   Data presented at the European Society for Medical Oncology  ESMO  congress suggest her early treatment with immunotherapy  as part of a clinical trial in Britain  will become standard for a growing number of patients  But there is a catch  it doesn t work for all  Giving immunotherapy on its own only seems to work better than chemotherapy in previously untreated lung cancer patients who have high levels of a protein called PD L1  which makes them more receptive to immunotherapy  From now on  oncologists in Copenhagen have been told  lung cancer patients should be routinely tested for this biomarker  However  only a quarter to a third of non small cell lung cancer patients have tumors with at least 50 percent of cells producing PD L1  leaving the majority unserved and around 70 percent of the market still up for grabs  The inability to treat everyone with monotherapy using one single drug is a blow for Bristol  which tried to make treatment with its Opdivo drug work across the board  only to fail comprehensively in a major clinical trial   But it has opened up the field to rivals like Merck  Roche and AstraZeneca  which own what could be among the biggest selling drugs of all time  and all companies are now racing to find smart ways to combine treatments  Oncologists poring over immunotherapy trial results at Europe s biggest cancer meeting have learnt one thing  finding optimal treatments for different patient groups will take more research   I think the future of immunotherapy will be defined over the next 10 or 15 years   said lung cancer specialist Solange Peters from Lausanne University Hospital  one of the organizers of the Copenhagen meeting  Despite immunotherapy successes and the prospect of a potential market worth up to  40 billion in sales  veteran cancer experts urge caution   In oncology  we see these kind of waves from cosmic pessimism to over optimism  so we have to be cautious   ESMO President Fortunato Ciardiello said   Investors  though  were quick to position themselves as shares in Bristol fell 10 percent in early trade on Monday  while Merck hit its highest level since 2001  FIGHTING BACK By taking the brakes off the immune system and allowing the body s natural killer cells to home in on tumors  immunotherapy offers a different approach to toxic chemotherapy treatment  which causes collateral damage to healthy tissue  It is not without side effects but it is a kinder option  which also promises much longer lasting efficacy  Bristol  Merck and Roche have U S  approval for immunotherapies  while Bristol and Merck also sell their drugs in Europe  China  however  has yet to license them  Lung cancer  the world s biggest cancer killer with an annual death toll of 1 6 million  will account for by far the largest portion of future prescriptions  although immunotherapy is used additionally in melanoma  Hodgkin lymphoma and cancers of the bladder  kidney  head and neck  With Merck set to sweep the board in lung cancer monotherapy  doctors are looking to the next phase of the story and there is a growing consensus that combination treatments are the future for remaining patients with lower PD L1 levels   Clearly  the race is on   said Jean Charles Soria  a professor of medicine at France s Institut Gustave Roussy  of the looming battle for dominance in the combination market  In theory  researchers believe  it should be possible to get more people to respond by adding other drugs to the mix in order to coax the immune system to fight back against cancer cells  Most attention so far has been on combining two immunotherapies  although this raises questions over cost  with each medicine typically priced at  100 000 to  150 000 a year  The strategy creates an opportunity for AstraZeneca  which has lagged rivals so far but hopes to jump ahead with a drug cocktail that should report clinical results early next year  Bristol is chasing the same idea  although its double immunotherapy trial is not expected to have results until 2018  But the ESMO meeting has also raised the prospect of another approach    successfully combining immunotherapy and chemotherapy  A lot of scientists have been sceptical of this idea in the past  and there are still questions over whether patients will have a long lasting response  but positive data from a mid stage study at ESMO suggests the concept has real promise  Roche and Merck are both enthusiastic  Steering a path through all these permutations is going to be a challenge and ESMO s Ciardiello says the cancer community must await more clinical trial results over the next few years   I think we live in great times for rendering cancer a curable disease but it will take time because the more we learn  the more we understand that it is hugely complex   he told Reuters   30 40 BILLION SALES While nobody yet knows what the  gold standard  treatment regimen is going to be  it is already clear this new generation of drugs is going to be big   Every time we come back to the immunotherapy market we are amazed at just how large the opportunity is   said Leerink analyst Seamus Fernandez  who sees combined annual sales of  30 billion to  40 billion for drugs like Keytruda and Opdivo  as well as rivals from Roche  AstraZeneca and  Pfizer   NYSE PFE    How the market will ultimately divide between companies is still unclear but Merck certainly emerges from the past weekend in Copenhagen as the main winner  That underscores a shift in expectations that has been evident since August  when Bristol first revealed its monotherapy trial had failed  British patient O Flynn  whose tumors shrunk dramatically  is just glad she has a chance to try something new  
 My brother had cancer and he had chemotherapy  which was very gruelling  But I haven t experienced any real side effects  apart from a bit of tiredness  ",2016-10-10,Reuters,https://www.investing.com/news/world-news/doctors-grapple-with-best-use-of-potent-new-cancer-drugs-431428,431428
203251,424767,MRK,Bristol lung cancer setback puts rival Merck drug in driver seat,news,"By Ransdell Pierson and Bill Berkrot  Reuters    New data is likely to prompt doctors to abandon Bristol Myers Squibb s immunotherapy Opdivo in favor of Merck  NYSE MRK    Co s rival Keytruda in a large segment of the lucrative lung cancer market  analysts said on Monday  The results of a closely watched clinical trial sent Bristol s shares plunging 10 percent  The data  presented at a medical meeting on Sunday  showed that lung cancer patients fared worse on Opdivo than those on chemotherapy  Merck shares rose nearly 2 percent on strong benefits shown by Keytruda in a similar late stage lung cancer study   Both trials tested the drugs that help the immune system to recognize and fight cancer as an initial treatment for advanced lung cancer  They are already approved for patients whose disease had progressed following chemotherapy  but approval as a so called first line therapy could greatly increase the number of patients taking them  Opdivo had been considered the leader among the new class of medicines  It generated  840 million of sales in the second quarter  more than double those of Keytruda  The view of the rival drugs began to change in August  with the surprise announcement by Bristol Myers that Opdivo had failed to best older chemotherapies in the Phase III trial  Details of the trial unveiled at the European Society for Medical Oncology meeting in Copenhagen only heightened those concerns  Patients on Opdivo went 4 2 months before their disease worsened versus 5 9 months for those on chemo  although the difference was not deemed statistically significant   This data represented a worst case scenario for Opdivo   Sanford Bernstein analyst Tim Anderson said in a research note   The Opdivo trial enrolled patients regardless of their tumor s level of PD L1 expression  a protein targeted by the drug whose presence may help identify those most likely to benefit from treatment with the new medicines  Meanwhile  researchers reported that Keytruda halved the risk of disease progression in previously untreated patients  and cut overall deaths by 40 percent compared to chemotherapy  Patients in the Merck trial were only enrolled if they were shown to have high levels of PD L1  a narrower segment of the lung cancer population than those in the Bristol Myers study   Merck will completely  own  the segment of first line lung cancer patients who have high PD L1 expression levels  and Bristol Myers will capture nothing really   Anderson said  Doctors are allowed to prescribe medicines for not yet approved uses  but analysts said they expect current off label prescribing of Opdivo in first line lung cancer to dry up now  In addition  competition in second line lung cancer is soon expected to intensify with the anticipated approval of Roche s immunotherapy Tecentriq  which is now approved to treat bladder cancer  Both Keytruda and Tecentriq are given every three weeks  while Opdivo is administered every two weeks  which is seen as a convenience disadvantage    The nearly inexplicable failure of  Opdivo  at every level of PD L1 expression     puts Merck in the driver s seat in first line lung cancer for at least the next 12 18 months   said Leerink Partners analyst Seamus Fernandez  Calling the Keytruda data  stunning   Fernandez said   We fully expect Merck to retain a significant place at the table long term    Bristol shares  which had already lost one quarter of their value since the initial trial data was disclosed in August  fell 10 percent  49 85  while Merck shares were up 1 7 percent at  63 84 after earlier rising more than 3 percent to a near 15 year high  
Opdivo is also approved for advanced melanoma  kidney cancer and a type of Hodgkin lymphoma  while Keytruda is also approved for advanced melanoma  plus head and neck cancer  But lung cancer is considered by far the biggest market for cancer drugs ",2016-10-10,Reuters,"https://www.investing.com/news/stock-market-news/bristol-plunges,-merck-jumps,-on-contrasting-lung-cancer-data-431443",431443
203252,424768,MRK,Agenus  AGEN  Q3 Loss Wider Than Expected  Pipeline In Focus,opinion,"Shares of Agenus Inc    NASDAQ AGEN   gained 10 1   following the company s third quarter results  The company reported third quarter 2018 loss of 29 cents per share  wider than the Zacks Consensus Estimate of loss of 25 cents but narrower than the year ago loss of 37 cents 
The company generated revenues of  13 million  which include milestone achievements and non cash royalties earned  compared with  3 3 million in the year ago quarter  Revenues beat the Zacks Consensus Estimate of  11 million 
So far this year  shares of Agenus have declined 35 9  compared with the  s decrease of 13 5  

 
Quarterly Highlights
Research and development  R D  expenses increased 15 7  to  29 8 million  General and administrative expenses increased 14 3  to  9 2 million 
Pipeline Update
Agenus is a clinical stage immuno oncology company with a comprehensive portfolio  consisting of antibody based therapeutics  adjuvants and cancer vaccine platforms 
Lead clinical stage antibodies  CTLA 4 and PD 1 antibodies are progressing well  PD 1 agent  AGEN2034 showed a clinical benefit of 68  in evaluable patients with metastatic or locally advanced solid tumors  The company recently reported that out of the 130 patients treated with CTLA 4 and PD 1 antibodies  more than 60  have shown clinical benefit  The company targets a biologics license application  BLA  filing as early as 2020 
In September 2018  the company announced the closing of its non dilutive royalty transaction with XOMA Corp    NASDAQ XOMA    whereby the latter purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte   NASDAQ INCY   and Merck   NYSE MRK   
Earlier  Agenus received a cash milestone from Incyte for the initiation of a phase I trial of INCAGN2385  an anti LAG 3 antibody discovered by Agenus  Per the terms  Agenus received a  5 million payment and is eligible to receive up to an additional  505 million in potential development  regulatory and commercial milestones from Incyte 
In August 2018  Agenus received a  4 million milestone payment from Merck for the initiation of a phase I trial on an undisclosed antibody candidate 
The company filed four investigational new drugs  INDs  in 2018  Two additional INDs will be filed by the end of the year 
Zacks Rank
Agenus currently has a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/agenus-agen-q3-loss-wider-than-expected-pipeline-in-focus-200357197,200357197
203256,424772,MRK,EU court says Lundbeck pay for delay deals anti competitive,news,"By Francois Aulner
LUXEMBOURG  Reuters    Danish drugmaker Lundbeck s  CO LUN  deals with smaller rivals to delay cheaper generic copies of its blockbuster citalopram anti depressant from entering the market were anti competitive  a European Union court said on Thursday 
The ruling followed an appeal by Lundbeck and five other generic drugmakers against a 2013 decision by the European Commission that their  pay for delay  deals breached EU rules 
The companies were fined a combined 146 million euros   165 million   93 7 million euros of which was from Lundbeck 
The General Court of the European Union said in its ruling that it dismissed the action brought by Lundbeck in its entirety  It said that the agreements had restricted potential competition 
Lundbeck s case  among several before the EU courts  has been closely watched by the pharmaceutical industry seeking to preserve a longstanding business practice opposed by regulators on both sides of the Atlantic 
The pharmaceutical industry says pay for delay deals prevent costly and lengthy litigation  Other companies appealing the EU decision were Merck  NYSE MRK  KGaA  Generics  UK   Arrow Group  Sun Pharmaceutical Industries  NS SUN   Xellia Pharmaceuticals and Alpharma 
The Commission s cases came in the wake of an inquiry into the sector in 2008 2009  Israeli drugmaker Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA  and France s Servier have also challenged the EU decisions and fines in separate but similar cases 
The cases are T 472 13 Lundbeck v Commission  T 471 13  T 471 13  T 469 13  T 467 13 and T 467 13 
  1   0 8845 euros ",2016-09-08,Reuters,https://www.investing.com/news/stock-market-news/eu-court-says-lundbeck-pay-for-delay-deals-anti-competitive-425058,425058
203261,424777,MRK,ImmunoGen  IMGN  Beats On Earnings In Q3  Lowers Guidance,opinion,"ImmunoGen  Inc    NASDAQ IMGN   reported adjusted loss of 31 cents per share for the third quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of 34 cents  The adjusted loss excludes restructuring charges  Moreover  the reported loss of 32 cents was narrower than the year ago loss of 61 cents per share on higher revenues ImmunoGen s shares were down 4 6  on Nov 2  presumably on sales miss and reduced revenue guidance for 2018  Moreover  shares of ImmunoGen have significantly underperformed the  in the past six months  The stock has declined 44 4  compared with the industry s decrease of 2 5  RevenuesSince ImmunoGen has no approved product in its portfolio  the company earns revenues through royalties  license and milestone payments plus research and development  R D  support fees paid by its partners Revenues came in at  10 9 million in the quarter  missing the Zacks Consensus Estimate of  12 million  However  sales increased by 28 9  from the year ago figure of  8 5 million  The revenue consists of  0 7 million in license and milestone fees and  8 4 million in non cash royalty revenue  Revenues from R D support and clinical materials were  0 4 million and  1 4 million  respectively  License and milestone fees included milestone payment of  0 5 million from privately held Fusion Pharma Operating Expenses   Cash DetailsResearch and development expenses increased almost by 50  from the year ago level to  47 2 million  mainly on additional manufacturing costs to support commercial validation of mirvetuximab soravtansine and higher costs to support phase Ib II FORWARD II study  Selling  general and administrative  SG A  expenses were up 5 1  to  8 3 million in the third quarter of 2018 The company recorded net proceeds of  162 5 million from the sale of its common stock in June ImmunoGen s cash and cash equivalents decreased to  303 2 million at the end of September 2018 compared with  345 1 million at the end of June 2018  The company expects its current cash and estimated cash to fund its operations atleast through the first half of 2020  which is a year after the anticipated announcement of top line data from the phase III FORWARD I study Pipeline UpdateImmunoGen has been progressing well with its pipeline product  mirvetuximab soravtansine  In October  the company announced preliminary data from the phase Ib II FORWARD II study evaluating combination regimens with mirvetuximab soravtansine in ovarian cancer  Data showed that the candidate in combination with Merck s   NYSE MRK   Keytruda achieved encouraging anti tumor activity  especially in patients with medium or high FR  expression levels The company anticipates to initiate an expansion cohort in the study to evaluate the candidate in combination with Roche s   OTC RHHBY   Avastin in recurrent ovarian cancer in the first quarter of 2019 The company continues to expect top line data from the phase III study  FORWARD I  in first half of 2019  The study is evaluating mirvetuximab soravtansine as a single agent therapy for treating patients with platinum resistant ovarian cancer  whose tumors express high or medium levels of FR alpha Apart from mirvetuximab soravtansine  ImmunoGen is working to develop a couple of other candidates in early stage studies including IMGN779  relapsed or refractory adult acute myeloid leukemia  and IMGN632  hematological malignancies including acute myeloid leukemia   IMGN632 was granted orphan drug designation for acute myeloid leukemia during the quarter The company s most advanced partner program using its ADC platform is Roche s Kadcyla  trastuzumab emtansine   In October  Roche announced that Kadcyla is superior to Herceptin as an adjuvant treatment in reducing risk of disease recurrence or death in HER2 positive early breast cancer 2018 Outlook DowngradedThe company decreased its revenues guidance to a range of  50  55 million for 2018 from  60  65 million  expected previosuly  The Zacks Consensus Estimate for the metric is pegged at  56 14 million The company also reduced its expectation for cash and cash equivalents to the range of  250 million to  255 million from the previous expectation of  265 million to  270 million ImmunoGen however maintained its operating expenses guidance for 2018 in the range of  215  220 million ImmunoGen  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderImmunoGen currently carries a Zacks Rank  3  Hold  A better ranked stock from the same space is CRISPR Therapeutics   NASDAQ CRSP    sporting a Zacks Rank  1  Strong Buy   You can see  CRISPR Therapeutics  loss per share estimates have narrowed from  2 95 to  2 92 for 2018 over the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 19 50   Share price of the company has increased 56 8  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/immunogen-imgn-beats-on-earnings-in-q3-lowers-guidance-200354817,200354817
203262,424778,MRK,Endo  ENDP  To Report Q3 Earnings  What s In The Cards ,opinion,"Endo International plc   NASDAQ ENDP   is expected to report third quarter 2018 results on Nov 8  before the opening bell 
Last quarter  the company delivered a positive earnings surprise of 38 2   In fact  it pulled off a positive surprise in each of the trailing four quarters  recording average positive surprise of 29 1  
Shares of Endo s have gained 116 4  year to date  against the  decline of 4 1  

 
Let s see how things are shaping up for this quarter 
Factors Influencing This Quarter
Propelled by strong results in the first half  Endo raised its guidance along with its second quarter results   Endo now expects revenues between  2 75 billion and  2 85 billion in 2018  earlier estimate   2 6 billion and  2 8 billion  
The company is in the process of redefining its business  given the persistent decline in the Generic business  which is expected to face challenges  The focus now is on sterile injectables and Xiaflex   Xiaflex s performance was outstanding in the first half  propelled by strong volume growth for the indication of Dupuytren s Contracture and Peyronie s Disease 
We expect the drug s momentum to continue in the third quarter as well  The company expects Xiaflex s full year revenue growth to be in the high teens percentage range versus its previous guidance of low  to mid teens growth 
U S  Branded Sterile Injectables revenues are now expected to grow in the high teens percentage range   The company anticipates earnings from continuing operations to be  2 50  2 60 per share  earlier estimate   2 15  2 55  
While the turnaround might take time  the company seems to be on the right track  Endo advanced its cellulite treatment development program  The company initiated two phase III clinical trials of collagenase clostridium histolyticum   CCH   for the treatment of cellulite  Recruitment has been accelerated in both the trials and top line results from these trials are now expected in the fourth quarter of 2018 
Revenues from sterile injectable business are being driven by continued growth of Adrenalin  The business is poised to become Endo s core business   In April  Endo entered into definitive agreements to acquire Somerset Therapeutics  LLC  a specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U S  market  and the business of its affiliate Wintac Limited  which operates as Somerset Therapeutics  contract developer and manufacturer  The acquisition will be closed by the end of 2018  
During the last reported quarter  Endo launched glycopyrrolate injection  the generic version of Robinul  as Somerset Therapeutics  exclusive distributor  In July  the segment launched ertapenem for injection  the authorized generic of Merck s   NYSE MRK   Invanz  New launches should propel growth 
During the third quarter earnings call  investors are expected to focus on the company s performance and pipeline updates Endo International plc Price  Consensus and EPS Surprise

   Earnings Whispers
Our proven model does not conclusively show an earnings beat for Endo this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is  3 63   This is because the Most Accurate Estimate is 57 cents  while the Zacks Consensus Estimate is pegged higher at 59 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Endo currently carries a Zacks Rank  3  which is favourable  However  the negative ESP makes surprise prediction difficult 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision 
Stocks to Consider
Here are some health care stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
CRISPR Therapeutic   NASDAQ CRSP   has an Earnings ESP of  3 53  and a Zacks Rank  1   The company is expected to release third quarter results on Nov 14  You can see  
Horizon Pharma   NASDAQ HZNP   has an Earnings ESP of  2 41  and a Zacks Rank  3  The company is expected to release third quarter results on Nov 7 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/endo-endp-to-report-q3-earnings-whats-in-the-cards-200355062,200355062
203269,424785,MRK,Exclusive  Global firms beef up investigations of Indian mica suppliers after expos  on child deaths,news,By Nita Bhalla and Rina Chandran DELHI MUMBAI  India  Thomson Reuters Foundation    Major global companies buying the mineral mica from India vowed on Thursday to beef up inspections of their suppliers for child labor after a Thomson Reuters Foundation investigation revealed children were dying in illegal mines  A three month investigation in the mica producing states of Bihar  Jharkhand  Rajasthan and Andhra Pradesh found at least seven children have been killed since June mining for mica  the valued mineral that puts a sparkle in make up and car paint  These deaths  feared to be just the tip of the iceberg  have gone unreported as victims  impoverished families and mine operators do not want to end the illegal mining in abandoned mines and protected forests   often their only source of income  While officials in Jharkhand and Rajasthan vowed to investigate child deaths following the expose  major companies buying from India said they would examine suppliers   and could stop buying from India without more efforts to end child labor   We have immediately started investigations with our direct suppliers   said a spokesman from German car manufacturer Volkswagen  DE VOWG p   adding that a meeting with suppliers was now scheduled for later this month   Based on the outcome of the results of our investigations we will take corresponding actions based on our internal processes   BMW said it did not tolerate child labor   If the allegations are substantiated  we will do everything to ensure that the supplier involved is no longer part of our supply chain in the future   a company spokesman said  Other big car makers in India   Maruti Suzuki  Hyundai  Honda  Audi  Mercedes Benz   Renault   PA RENA   Mahindra and Tata Motors   did not respond to requests for comments  BOYCOTTS AND ALTERNATIVES Indian law forbids children below the age of 18 working in mines and other hazardous industries but many families living in extreme poverty rely on children to boost household income  India is one of the world s largest producers of mica  a silver coloured  crystalline mineral  that has gained prominence in recent years as an environmentally friendly material  used in the car and building sectors  electronics and  natural  make up  This surge in demand has revived a flagging industry in India which closed most of its 700 mines employing over 20 000 workers in the 1980s following stricter laws to limit deforestation and the discovery of substitutes for natural mica  In 2013 14 India produced 19 000 tonnes of mica  according to the Bureau of Mines  but exported 128 000 tonnes  with the biggest buyers China  Japan  and the United States  It is estimated up to 70 percent of India s mica is produced in illegal mines falling into disrepair  Activists have called for more funding to provide schooling and alternative livelihoods in mica areas which are some of the poorest regions  Rajesh Malhotra  spokesman for the Ministry of Power  Coal and Renewable Energy  said the government has dedicated funds for the welfare of local people in mining areas which will generate  1 billion annually to support various programs  He listed water  health  education  training  child welfare and sustainable livelihoods as priorities  Some companies are supporting these community initiatives  Major buyer  Chinese pigment manufacturer Fujian Kuncai Material Technology Co Ltd  said changes were  urgently needed  and called on all parties involved in the supply chain to act  Mike Tijdink  general manager of Kuncai Europe  said the manufacturer was setting up its own company in India this month to source directly from mines  working with NGO Terre des Hommes to help communities  and had started making synthetic mica   If we are not able to create a child labor free and legal mica industry in India  the industry could consider the switch toward an undisputed product like synthetic mica   he said  German drugmaker Merck  NYSE MRK  KGaA  which cut some suppliers after it discovered children collecting mica at some mines in 2008  reiterated its condemnation of child labor  While some companies invest in communities  others say they cannot guarantee supplies are child labor free so have stopped using mica  10 percent of which goes into cosmetics  British cosmetics company Lush  which prides itself on its handmade products and ethical trading  switched from natural to synthetic mica in 2014 due to concerns about child labor and described revelations of child deaths in mines as  atrocious    No industry should result in the loss of life  let alone that of children   Lush s head of ethical buying  Simon Constantine  told the Thomson Reuters Foundation   We continue to choose a boycott of natural mica until greater transparency and assurances can be given on ethical supply     We only hope that other companies see this reporting and are as shocked into action as we have been   A spokeswoman from L Oreal said the company was only buying from a  limited number of trusted suppliers who have committed to sourcing only from legal gated mines where working conditions are closely monitored and human rights are respected   Estee Lauder did not respond to requests for comment ,2016-08-04,Reuters,https://www.investing.com/news/world-news/exclusive:-global-firms-beef-up-investigations-of-indian-mica-suppliers-after-expos-on-child-deaths-418563,418563
203270,424786,MRK,AstraZeneca hits 2014 Pfizer bid price  helped by Bristol s woes,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca  L AZN  shares hit a record high on Friday  breaching for the first time the 55 pounds a share level offered by  Pfizer   N PFE  in 2014 during the U S  group s abortive  100 billion attempt to buy the drugmaker  The British firm s stock has been on a roll recently  helped by a falling pound and speculation that Switzerland s  Novartis   S NOVN  might be next to launch a bid  However  the shares were lifted to a high of 55 05 pounds by the misfortunes of Bristol Myers Squibb  N BMY   The failure of Bristol s immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer as hoped was seen by investors as good news for rivals Merck   Co  N MRK  and AstraZeneca  Analysts at Leerink  Jefferies and  Deutsche Bank   DE DBKGn  said the negative result with Opdivo increased the potential market opportunity for AstraZeneca s keenly watched combination of durvalumab and tremelimumab  Crucial clinical trial results with durvalumab  both on its own and in combination with tremelimumab  are due next year  Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer drugs that bolster the immune system  And its ability to carve out billions of dollars in potential sales hinges not only on the effectiveness of its own products but on the competitive profile of rivals  
Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again  with speculation turning last week to Novartis as a bidder ",2016-08-05,Reuters,"https://www.investing.com/news/stock-market-news/astrazeneca-hits-2014-pfizer-bid-price,-helped-by-bristol's-woes-418755",418755
203271,424787,MRK,Payrolls power Wall Street to record high,news,"By Chuck Mikolajczak NEW YORK  Reuters    U S  stocks notched their best day in a month on Friday  with the S P 500 and Nasdaq closing at record highs after a second straight month of robust labor market data boosted optimism that economic growth is accelerating  The U S  Labor Department report showed that nonfarm payrolls rose by 255 000 in July  far outpacing expectations for a gain of 180 000   While the unemployment rate remained unchanged at 4 9 percent  it held below the 5 percent mark associated with full employment  The S P 500 ended at 2 182 87  its eighth closing high of the year  powered by a 1 9 percent gain in financials  SPSY   which would be primed for a profit boost should the Federal Reserve raise interest rates   JPMorgan Chase  N JPM  shares gained 2 7 percent to  66 30 and the financial index closed at its highest level of the year    This is a flat out strong report  there don t appear to be any holes whatsoever   said Tom Porcelli  chief U S  economist at RBC Capital Markets in New York    But we need to temper enthusiasm  with two straight positive payroll reports everyone is going to shift to the other side of the boat   first the boat was sinking and now everyone is going to think the boat is going to take off   Employment numbers were weak in April and May  and a surprisingly strong reading in June left investors unsure of the state of the economy  The June employment number was revised to 292 000 from 287 000  The Fed may still wait for gross domestic product growth to improve and inflation to move closer to its 2 percent target before pulling the trigger on a rate hike   The probability of a hike doubled to 18 percent for September after the jobs report and rose to about 46 percent for December  according to CME Group s FedWatch tool  The Dow Jones industrial average  DJI  rose 191 21 points  or 1 04 percent  to 18 543 26  the S P 500  SPX  gained 18 57 points  or 0 86 percent  to 2 182 82 and the Nasdaq Composite  IXIC  added 54 87 points  or 1 06 percent  to 5 221 12  The Nasdaq surpassed a record set in July 2015   For the week  the Dow rose 0 6 percent  the S P 500 gained 0 4 percent and the Nasdaq advanced 1 1 percent   Bristol Myers  N BMY  plunged 16 percent after its lung cancer drug failed in a late stage study while Merck  N MRK   which makes a rival drug  rose 10 4 percent  Bristol Myers was the biggest drag on the S P 500  while Merck gave the benchmark index its biggest boost  Advancing issues outnumbered declining ones on the NYSE by a 2 64 to 1 ratio  on Nasdaq  a 2 57 to 1 ratio favored advancers  The S P 500 posted 29 new 52 week highs and no new lows  the Nasdaq Composite recorded 126 new highs and 21 new lows   
About 6 77 billion shares changed hands in U S  exchanges  compared with the 6 58 billion daily average over the last 20 sessions   Additonal reporting by Karen Brettell  Editing by Meredith Mazzilli ",2016-08-05,Reuters,https://www.investing.com/news/stock-market-news/futures-rise-ahead-of-crucial-jobs-report-418726,418726
203272,424788,MRK,U S  stocks soar  as job gains push NASDAQ  S P to record closing highs,news,"Investing com    U S  stocks rose considerably on Friday  as stronger than expected jobs data in July helped bolster the financial sector  propelling the NASDAQ Composite index and the S P 500 to all time record closing highs 
Last month  U S  nonfarm payrolls surged by 255 000  the Labor Department said on Friday  topping the high end of analysts  expectations by 70 000 and erasing lingering concerns that June s robust report may have been a fluke  The Labor Department also upwardly revised June gains by 5 000 to 292 000  helping erase some negative sentiments from a disappointing report in May when the labor market added only 24 000 jobs  The solid figures could compel the Federal Reserve to consider raising interest rates when the Federal Open Market Committee  FOMC  meets again in September 
As a result  stocks on Wall Street turned in one of their strongest one day performances since early July  placing a temporary halt to a two week period of range bound  sideways trading  The Dow Jones Industrial Average gained 191 48 or 1 04  to 18 543 53  while the NASDAQ added 54 87 or 1 06  to 5 221 12  soaring to a fresh record close for the first time in more than a year  The gains were fueled by major tech stocks such as Apple Inc  NASDAQ AAPL  and Micron Technology Inc  NASDAQ MU   which posted sharp gains in Friday s session  The NASDAQ last closed at a record high on July 20  2015 when it ended the session at 5 210 14 
The S P 500  meanwhile  added 18 62 or 0 86  to 2 182 87  moving back into record territory  On the S P 500  eight of 10 sectors closed in the green as stocks in the Financials and Technology industries led  Stocks in the interest rate sensitive Utility sector lagged  falling by 1 31  for the session 
The top performer on the Dow was Merck   Company Inc  NYSE MRK   which gained 6 02 or 10 41  to 63 86  Merck  NYSE MRK  shares received a boost after rival BMY reported disappointing results with a late stage clinical trial for treating advanced non small cell lung cancer  On Friday shortly before markets opened  Bristol Myers announced that its drug Opdivo failed to significantly outperform chemotherapy treatment in a study of newly diagnosed lung cancer patients  The results could jeopardize Bristol Myers chances of gaining regulatory approval by the U S  Food and Drug Administration  FDA  for the usage  while paving the way for Merck to capitalize with sales of its drug Keytrada  The worst performer was  VZ Holding AG   SIX VZN   which fell 0 29 or 0 54  to 53 64 
The biggest gainer on the NASDAQ was Symantec Corporation  NASDAQ SYMC   which added 0 86 or 4 07  to 21 89  Earlier  the cybersecurity firm reported earnings of  135 million and revenue of  884 million for its first quarter of 2017  slightly beating analysts  forecasts of  878 1 million  The worst performer was Liberty Interactive Corp A  NASDAQ QVCA   which tumbled 5 69 or 21 63  to 20 61  While Liberty Interactive reported earnings growth of 13  last quarter  CEO Greg Maffei warned that the company could be moving into a  choppy retail environment   marred by weakening consumer demand  At one point on Friday  shares in the Colorado based media holdings company hit a 52 week low at  19 92 
On the New York Stock Exchange  advancing issues outnumbered declining ones by a 2 133 824 margin ",2016-08-05,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-soar,-as-job-gains-push-nasdaq,-s-p-to-record-closing-highs-418826",418826
203273,424789,MRK,Wall Street takes tiny step back from record highs,news,"By Noel Randewich  Reuters    Wall Street receded from record highs on Monday as a drop in healthcare stocks offset gains caused by higher oil prices and a strong jobs report  A rally to several all time highs since late June has left the S P 500 up nearly 7 percent in 2016  with many investors concerned about stretched valuations   This is a natural pause for reflection by the markets  Everyone is sitting there saying  Holy cow  what did we do     said Brad McMillan  chief investment officer at Commonwealth Financial Network    Momentum is a big part of it  People are afraid of missing out   Pressured by losses in Bristol Myers  Merck  NYSE MRK  and Allergan  NYSE AGN pa   the S P 500 healthcare index dipped 0 9 percent while the Nasdaq biotech index dropped 1 1 percent  Oil prices rose more than 2 percent after a report last week indicated some OPEC members had called for a freeze in production   O R  Investors fretted about growing signs that S P 500 aggregate earnings could decline for a sixth straight quarter   Analysts polled by Reuters expect third quarter earnings to fall 0 2 percent  as of Monday  They had estimated a 0 2 percent rise on Aug  3  The S P 500 opened at a record high before turning modestly negative and closing down 0 09 percent at 2 180 89   The Dow Jones industrial average edged down 0 08 percent to end at 18 529 29  The Nasdaq Composite dropped 0 15 percent to 5 213 14  It was one of the year s slowest sessions  About 5 86 billion shares changed hands in U S  exchanges  compared with the 6 56 billion daily average over the last 20 sessions  Seven of the 10 major S P 500 indexes fell  with the healthcare group losing the most  The energy index gained 1 22 percent  with  Exxon Mobil   NYSE XOM  up 1 18 percent and Schlumberger climbing 1 6 percent   Bristol Myers fell for the second straight day  shedding 4 71 percent after it said on Friday its lung cancer drug failed a key late stage study  It was the strongest contributor to the S P 500 s loss  Merck  which makes a rival drug  fell 1 57 percent  The stock had rallied 10 percent on Friday   Allergan lost 2 18 percent after it slashed its full year revenue forecast and said it was not looking to use its surplus cash to fund any deals  Advancing issues outnumbered declining ones on the NYSE by a 1 35 to 1 ratio  on Nasdaq  a 1 10 to 1 ratio favored decliners  
The S P 500 posted 30 new 52 week highs and no new lows  the Nasdaq Composite recorded 96 new highs and 18 new lows ",2016-08-08,Reuters,https://www.investing.com/news/stock-market-news/futures-rise-as-jobs-data-boosts-investor-sentiment-419076,419076
203281,424797,MRK,The Post ASCO IO Pecking Order ,opinion,"What it means for smaller biotech companies
Immunotherapy has become one of the most relevant areas at the American Society of Clinical Oncology  ASCO  Annual Meeting and the leaders have emerged  Immunotherapies for cancer include a number of technologies such as immune checkpoint inhibitors  ICIs   T cell based therapies  oncolytic viruses or cancer vaccines  Several ICIs have been approved across the world for a number of cancer types  Still  a significant number of patients do not benefit from ICI therapies  so combinations with other agents have become increasingly popular  In 2017  469 clinical trials with such combinations were initiated  This year clinical data in lung cancer were of special relevance  setting a new standard of care in first line advanced squamous lung cancer and exposing the gaps in improved combinations 
Harness the immune system to fight disease
The field of immunotherapy for cancer has experienced significant growth over the last few years  ICIs target molecules that inhibit the immune system  releasing the brakes on the immune system to fight cancer  In particular  antibodies targeting CTLA 4 and PD 1 L1 from Merck  NYSE MRK   Bristol Myers Squibb  NYSE BMY  and Roche have been approved and are on the market  However  some patients do not respond to current immunotherapies and subgroups  according to biomarkers  and combinations are being investigated extensively to find the best therapeutic options for patients  Additionally  chimeric antigen receptor T cell  CAR T  therapies from Novartis and Gilead gained regulatory approval in 2017  and are now commercialised for acute lymphoblastic leukaemia  ALL  and diffuse large B cell lymphoma  DLBCL  
To read the entire report Please click on the pdf File Below ",2018-06-27,Edison,https://www.investing.com/analysis/the-postasco-io-pecking-order-200328021,200328021
203282,424798,MRK,Clovis  CLVS  Q3 Earnings   Sales Lag  Rubraca Disappoints,opinion,"Clovis Oncology  Inc    NASDAQ CLVS   incurred an adjusted loss of  1 71 per share in the third quarter of 2018  wider than the Zacks Consensus Estimate of a loss of  1 60 and the year ago loss of  1 24 per share Net revenues  entirely from Clovis  only marketed drug  Rubraca  were approximately  22 8 million in the quarter  down 4 2  sequentially  due to challenges in adoption in earlier line setting  Revenues missed the Zacks Consensus Estimate of  30 12 million  The company had recorded total revenues of  16 8 million entirely from Rubraca sales in the year ago quarter Clovis stated that Rubraca is failing to capture significant share in the second line maintenance ovarian cancer market as it has to compete with PARP inhibitors as well as other approved therapies  This is hurting sales of Rubraca  The company expects Rubraca sales to be similar or slightly higher than  22 8 million in the fourth quarter  The Zacks Consensus Estimate for the fourth quarter is pegged at  40 24 million Shares of the company declined almost 19 7  in pre market trading   on lower than expected sales of Rubraca and the disappointing guidance  Moreover  Clovis has underperformed the  in the past six months  The stock has lost 63 2  compared with the industry s decline of 8 7  Operating Expenses   Cash DetailsDuring the third quarter  research   development expenses increased 64 3  year over year to  63 9 million primarily due to increased expenses for clinical studies on Rubraca  Selling  general and administrative  SG A  expenses escalated 21 4  year over year to  42 5 million  reflecting increased activities to support commercialization of Rubraca in the United States as well as Europe Cash used in operating activities in the quarter was  72 5 million  higher than  45 8 million in the year ago quarter Clovis ended the quarter with  604 4 million of cash equivalents and available for sale securities compared with  682 2 million as of Jun 30  2018 Update on RubracaIn July 2018  the European Medicines Agency   EMA   accepted the regulatory application for the label expansion of Rubraca to include maintenance treatment in recurrent ovarian cancer  A European approval for maintenance setting is expected in early 2019  The drug was launched for a similar indication in the United States in April  The EMA approved the drug for ovarian cancer patients with BRCA mutation in third  or later line setting in May The company is actively working on expanding the label of Rubraca in and beyond ovarian cancer  The company is evaluating Rubraca as monotherapy or in combination with immunotherapies   Bristol Myers    NYSE BMY   Opdivo or Merck s   NYSE MRK   Tecentriq   in multiple clinical studies in additional indications including first line ovarian cancer  prostate and breast cancer  In August  a phase III study was initiated to evaluate Rubraca   Opdivo combo in advanced ovarian cancer In October  the company presented encouraging initial data from phase II TRITON2 study evaluating Rubraca in metastatic castration resistant prostate cancer Apart from Rubraca  Clovis is also developing lucitanib for treating breast and lung cancer  Clovis now owns global  excluding China  development rights for lucitanib  as its partner returned the ex U S  rights during the quarter Our TakeThe adoption of Rubraca in manitenance setting in the United States was dismal  The company is facing challenges for the expansion in early line of therapy and the PARP inhibitor market has stagnated  The company may also face similar challenges in Europe if Rubraca gets approval in maintenance setting  Rubraca competes with Tesaro  Inc  s   NASDAQ TSRO   Zejula and AstraZeneca s Lynparza in its approved indications Operating expenses are expected to rise in 2018 as the company will incur higher investments to support Rubraca s launch in Europe and expanded indication in the United States Clovis Oncology  Inc  Price  Consensus and EPS Surprise
    Zacks Rank Clovis currently has a Zacks Rank  4  Sell  You can see  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/clovis-clvs-q3-earnings--sales-lag-rubraca-disappoints-200352493,200352493
203289,424805,MRK,AstraZeneca helped by new drugs as cholesterol pill fades,news,"By Ben Hirschler LONDON  Reuters    Generic competition to cholesterol buster Crestor in the U S  market pushed second quarter core earnings down by nearly a third at drugmaker AstraZeneca  which is now banking on new cancer medicines to revive its fortunes  The profit drop had been expected  however  and investors took heart from encouraging early sales of newer products  lifting the shares 2 percent on Thursday  Analysts predict falling group sales and profits this year and next before a return to growth in 2018  when the impact of patent expiries will lessen and sales of newer medicines should have picked up speed  Its new lung cancer drug Tagrisso achieved stronger than expected quarterly sales of  92 million  Heart drug Brilinta and Farxiga for diabetes also did well  Quarterly core earnings per share  which exclude some items  fell 31 percent to 83 cents as revenue slid 11 percent to  5 60 billion  following the arrival of the first copies of Crestor in the United States in May  Industry analysts had on average forecast quarterly revenue of  5 58 billion and earnings of 84 cents a share  according to Thomson Reuters  The British company said it continued to expect a low to mid single digit percentage decline in both revenue and core earnings at constant exchange rates for the full year  In addition to falling sales of Crestor and other older drugs like Nexium  AstraZeneca also has to deal with a slump in U S  revenue this year from its nasal spray flu vaccine Flumist  after health officials decided it was not worth using  IMMUNO ONCOLOGY Chief Executive Pascal Soriot  who saw off a takeover attempt by  Pfizer   NYSE PFE  in 2014  is looking beyond current problems and believes AstraZeneca can become a major player in cancer treatment by developing drugs that bolster the immune system and others that disrupt DNA repair mechanisms used by tumor cells  He said he was particularly encouraged by rapid patient recruitment in immuno oncology combination drug trials  which are expected to produce make or break clinical results in the first half of next year   Over the next 12 months the profile of this company will change   Soriot told reporters   We will start getting very serious proof points and hopefully people will see that our plan is working    Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again  with speculation focused on Novartis  Soriot declined to comment  AstraZeneca faces formidable competition from others with new cancer medicines that are already on the market  including Roche  Bristol Myers Squibb and Merck  NYSE MRK    Co  To free resources for investment in new products  AstraZeneca has been selling off rights to non core drugs and such  externalization  deals helped to boost revenue by  134 million in the second quarter  The company said externalization revenue would increase in the second half of the year  
Soriot says he can build a business with annual sales of at least  45 billion by 2023  up from  24 7 billion in 2015  though many analysts question this target  which was first set out during the takeover battle with Pfizer ",2016-07-28,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-earnings-hit-by-waning-cholesterol-drug-sales-417054,417054
203290,424806,MRK,Pfizer in  486 million settlement of Celebrex  Bextra litigation,news,"By Jonathan Stempel NEW YORK  Reuters     Pfizer  Inc  N PFE  on Tuesday said it has reached a  486 million settlement of litigation accusing it of causing big losses for shareholders by concealing safety risks associated with its Celebrex and Bextra pain relieving drugs  The accord is subject to negotiation of a final settlement agreement with the plaintiff shareholders  and would end more than 11 years of litigation against the drugmaker and several officials  including former Chief Executive Henry McKinnell  It was reached nearly seven years after Pfizer agreed in September 2009 to pay  2 3 billion to settle a U S  government probe into the marketing of Bextra and other drugs   Pfizer said it has set aside reserves to cover the entire shareholder settlement  which requires court approval  All defendants denied wrongdoing   This resolution reflects a desire by the company to avoid the distraction of continued litigation and focus on the needs of patients and prescribers   Pfizer said in a statement  Gregory Joseph  a lawyer for shareholders including the Teachers  Retirement System of Louisiana  declined to comment  The lawsuit covered shareholders who bought Pfizer stock between Oct  31  2000 and Oct  19  2005  Pfizer s market value fell by roughly  70 billion from early October 2004 until the day after the class period ended  Shareholders accused Pfizer of having concealed tests that began in 1998 and which suggested health risks associated with Celebrex and Bextra  Safety concerns mounted in late 2004 when rival Merck   Co  N MRK  withdrew its Vioxx drug because of associated cardiovascular risks  Pfizer pulled Bextra from the U S  market the following April  
The shareholder litigation had been dismissed in July 2014  but was revived on April 12 by the 2nd U S  Circuit Court of Appeals in Manhattan  which cited errors by the lower court judge ",2016-08-02,Reuters,"https://www.investing.com/news/stock-market-news/pfizer-in-$486-million-settlement-of-celebrex,-bextra-litigation-418009",418009
203296,424812,MRK,Bristol Myers Posts Data On Empliciti  China Approves Opdivo,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced positive results from the phase II study  ELOQUENT 3  on oncology drug  Empliciti 
The study is evaluating the addition of Empliciti to Pomalyst and low dose dexamethasone  EPd  in patients with relapsed refractory multiple myeloma  RRMM   The international study is evaluating Pomalyst based triplet combination in patients with RRMM  who received at least two prior therapies  including Revlimid and a proteasome inhibitor 
The study achieved its primary endpoint as the results show a statistically significant and clinically meaningful improvement in progression free survival  PFS  for patients treated with EPd compared with only Pomalyst and dexamethasone  Pd  
The data were also presented at the 23rd Congress of the European Hematology Association 
Data from the study showed that patients randomized to EPd experienced a 46  reduction in risk of disease progression compared with patients randomized to Pd alone  with median PFS of 10 3 months compared with 4 7 months in Pd patients 
Additionally  the PFS benefit experienced among patients randomized to EPd was consistent among patients who had received two to three prior lines of therapy and four or more prior lines of therapy 
The combination therapy  if approved  can provide an important treatment option for patients with relapsed refractory multiple myeloma whose disease has progressed after treatment with lenalidomide and a proteasome inhibitor 
Bristol Myers is co developing Empliciti with AbbVie   NYSE ABBV   

 
Bristol Myers  shares have declined 9 4  year to date compared with the  s decline of 1 8  
Earlier  the company announced that the China National Drug Administration has approved its blockbuster immuno oncology drug Opdivo  for the treatment of locally advanced or metastatic non small cell lung cancer  NSCLC  after prior platinum based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations 
Per the company  this is the first and only PD 1 inhibitor approved in China  The approval was based on data from the pivotal phase III study  CheckMate 078 trial  in which 90  of the patients enrolled were from China 
We note that Opdivo became the first PD 1 immune checkpoint inhibitor to gain regulatory approval  It is currently approved in several countries including the United States  the EU and Japan for several cancer indications 
Opdivo became the first PD 1 inhibitor to be approved for a hematological malignancy   classical Hodgkin lymphoma   in both the United States  May 2016  and the EU  November 2016    The drug has been performing impressively  due to demand resulting from the rapid commercial acceptance for several indications  including melanoma  renal cell carcinoma and second line NSCLC 
Label expansion into additional indications would give the product access to a higher patient population and increase the commercial potential of the drug significantly 
However  Opdivo faces stiff competition from Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq which can limit market share gains 
Zacks Rank   Another Stock to Consider
Bristol Myers carries a Zacks Rank  3  Hold    You can see   
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-posts-data-on-empliciti-china-approves-opdivo-200325954,200325954
203297,424813,MRK,ImmunoGen s Lead Candidate Gets Fast Track For Ovarian Cancer,opinion,"ImmunoGen  Inc    NASDAQ IMGN   announced that the FDA has granted Fast Track designation to its lead candidate  mirvetuximab soravtansine  a first in class antibody drug conjugate targeting folate receptor   FR   alpha  The designation is for the development of the candidate in platinum resistant ovarian cancer patients with medium to high FR alpha positive The patients must have received at least one but no more than three prior systemic treatment regimens and single agent chemotherapy is the appropriate next line of therapy With the FDA granting fast track designation  the candidate s development and review are expected to accelerate  The designation is granted to candidates  which treat serious and unmet medical conditions  With this designation  a candidate is expected to be granted a priority review once it files a new drug application ImmunoGen s shares were up almost 5 8  including after hours trading on Jun 18  Shares of the company have rallied 61 2  compared with the  s rise of 4 6   so far this year  The company is evaluating mirvetuximab soravtansine in a phase III study   FORWARD I   for the treatment of platinum resistant ovarian cancer expressing medium or high levels of FR alpha against a single agent chemotherapy  The primary endpoint of the study is progression free survival  Enrollment in the study was completed ahead of schedule in April and top line data is expected in the first half of 2019 A phase Ib II FORWARD II study is evaluating the candidate in combination with Roche s   OTC RHHBY   Avastin or Merck s   NYSE MRK   anti PD L1 therapy  Keytruda  in platinum sensitive ovarian cancer expressing FR alpha  The study is also evaluating a triplet combination   mirvetuximab plus carboplatin and Avastin With no approved product in its portfolio  the progress of its lead candidate is driving the stock  Investors should remain focused on further updates on mirvetuximab ImmunoGen  Inc  Price
    Zacks Rank   Stocks to ConsiderImmunoGen currently carries a Zacks Rank  3  Hold  Aeglea BioTherapeutics  Inc    NASDAQ AGLE   is a better ranked stock in the pharma sector carrying a Zacks Rank  2  Buy   You can see  Aeglea s loss estimates narrowed from  1 93 to  1 67 for 2018 and from  3 86 to  3 57 for 2019 over the last 60 days  The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19 32   Its share price has increased 101 3  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/immunogens-lead-candidate-gets-fast-track-for-ovarian-cancer-200326051,200326051
203298,424814,MRK,Myriad Genetics Wins FDA SPMA Nod For BRACAnalysis CDx,opinion,Myriad Genetics  Inc    NASDAQ MYGN   has moved one step forward in acquiring the FDA approval for the company s BRACAnalysis CDx test to be used as a companion diagnostic with Pfizer s   NYSE PFE   PARP inhibitor  talazoparib  The company noted that the FDA has accepted its supplementary premarket approval  sPMA  application for BRACAnalysis CDx  which can help identifying the best responders to talazoparib It is also encouraging to know that talazoparib is currently holding the status of New Drug Application  NDA  priority review from the FDA with a target date set for December 2018 Both Myriad Genetics and Pfizer submitted their respective sPMA and NDA proposals to the FDA  based on results from the Pfizer sponsored EMBRACA trial  which evaluated talazoparib compared with chemotherapy in patients with germline  inherited  BRCA mutated  gBRCAm   HER2 negative locally advanced or metastatic breast cancer  MBC   Last December  the primary results of the study were presented  The data showed that patients with gBRCA  locally advanced and or metastatic breast cancer  MBC  demonstrated superior progression free survival  PFS  when treated with talazoparib in comparison to those having received physician s choice standard of care chemotherapy  Recent Developments in BRACAnalysisMyriad Genetics has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx  In this regard  the system got manufacturing and marketing approval from the Japanese Ministry of Health  Labour and Welfare  earlier in April this year  The system can now be used as a companion diagnostic with the PARP inhibitor  Lynparza Notably  in January  the FDA approved BRACAnalysis CDx test for usage as a companion diagnostic with AstraZeneca   NYSE AZN   and Merck s   NYSE MRK   PARP inhibitor  Lynparza  olaparib  on patients with HER2 negative metastatic breast cancer  MBC  and germline BRCA mutation Market PotentialPer Myriad Genetics  about 40 000 patients with metastatic disease are currently eligible for BRACAnalysis testing in Japan  Moreover  approximately 15 000 new cases of HER2 negative breast cancer are diagnosed every year  This promising data indicates what a timely and strategic role the latest approval is likely to play in favor of the company Share Price Performance  Myriad Genetics has been gaining investors  confidence from consistently positive results  Over the past three months  shares of the company have significantly outperformed the broader   The stock has surged 36 6  against the broader industry s 5 2  fall Myriad Genetics currently carries a Zacks Rank  3  Hold  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/myriad-genetics-wins-fda-spma-nod-for-bracanalysis-cdx-200326165,200326165
203299,424815,MRK,TESARO  TSRO  Stock Up On Rumors Of Buyout Offer From Roche,opinion,"TESARO  Inc  s   NASDAQ TSRO   shares rallied 16 3  on Jun 20 on rumors of a potential acquisition offer from Roche   OTC RHHBY    as reported by intereconomia com  The article on the website states that Roche may announce an offer soon Roche is looking to strengthen its oncology portfolio through acquisitions Roche has recently offered to buy the remaining stake in molecular information company  Foundation Medicine   NASDAQ FMI   for  2 4 billion  which will help Roche to develop personalized cancer drugs using Foundation Medicine s genomic profiling expertise Why Roche May be Interested in TESARO Tesaro has long been considered an attractive acquisition target by the investment community TESARO received a major boost with the approval of its PARP inhibitor  Zejula  in the United States in March last year  The drug is available as maintenance therapy for ovarian cancer treated with platinum based chemotherapy  The drug has shown potential with commendable sales growth and has gained a majority share in the PARP inhibitor segment  The drug was also approved in Europe in November 2017 Furthermore  TESARO is developing Zejula for the treatment of ovarian cancer in first line setting  The company is also focused on developing the drug as monotherapy or in combination with PD L1 antibodies beyond ovarian cancer in breast cancer  non small cell lung cancer and bladder cancer The company has collaborations with Roche and Merck   NYSE MRK   for developing Zejula in combination with Tecentriq and Keytruda  respectively  Moreover  TESARO is also developing its own anti PD 1 antibody  TSR 042  in several cancer indications The performance of Zejula in its approved indication and ongoing clinical studies in prospective indications makes TESARO an attractive acquisition target for Roche However  several large pharma companies now have ample cash in hand  following the tax overhaul  This increases the probability of other companies rivaling a potential bid from Roche TESARO  Inc  Price
    TESARO currently carries a Zacks Rank  3  Hold   You can see  A look at TESARO s share price movement so far this year shows that the company has underperformed the   While the stock fell 43 9   the industry declined 5 4  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-06-20,Zacks Investment Research,https://www.investing.com/analysis/tesaro-tsro-stock-up-on-rumors-of-buyout-offer-from-roche-200326796,200326796
203300,424816,MRK,Bristol Myers  BLA For Opdivo Label Expansion Accepted By FDA,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the FDA accepted its supplemental Biologics License Application  sBLA  for the label expansion of its blockbuster immuno oncology drug Opdivo for the indication first line advanced non small cell lung cancer  NSCLC  in patients with tumor mutational burden  TMB   10 mutations per megabase  mut Mb   The FDA set an action date of Feb 20  2019 
The filing was based on the phase III CheckMate  227 study  evaluating Opdivo based regimens versus platinum doublet chemotherapy in patients with first line advanced non small cell lung cancer across squamous and non squamous tumor histologies  There are two co primary endpoints in Part 1 for Opdivo plus low dose Yervoy versus chemotherapy  overall survival  OS  in patients whose tumors express PD L1 and progression free survival  PFS  in patients with TMB  10 mut Mb across the PD L1 spectrum  The primary endpoint in Part 2 is OS  and the study is ongoing 
Shares of the company declined 11 9  year to date compared with the  s decline of 5 0  

 
We note that Opdivo became the first PD 1 immune checkpoint inhibitor to gain regulatory approval  It is currently approved in several countries including the United States  the EU and Japan  for several cancer indications 
Opdivo became the first PD 1 inhibitor to be approved for a hematological malignancy   classical Hodgkin s lymphoma   in both the United States  May 2016  and the EU  November 2016   The drug has been performing impressively  due to demand resulting from the rapid commercial acceptance for several indications  including melanoma  renal cell carcinoma and second line NSCLC 
Non small cell lung cancer occurs in 85  of patients with a lung cancer condition  the leading cause of cancer deaths worldwide  Notably  About 25  to 30  of all lung cancers are squamous cell carcinomas  and non squamous NSCLC accounts for approximately 50  to 65  of all lung cancer diagnoses 
Moreover  despite a significant progress made in this space  the disease is associated with low survival rates  Hence  the label expansion into additional indications would give the product access to a higher patient population and increase the commercial potential of the drug significantly 
We remind investors that  Opdivo faces stiff competition from  Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  which is approved in the first line lung cancer setting  We also note that in March 2018  Roche   OTC RHHBY   presented data on Tecentriq in novel combinations across a broad range of tumors including lung cancer Bristol Myers Squibb Company Price

   Zacks Rank   Stocks to Consider
Bristol Myers has a Zacks Rank  3  Hold  
A better ranked stock from the same space is Aeglea BioTherapeutics  Inc    NASDAQ AGLE   carrying a Zacks Rank  2  Buy   You can see  
Aeglea s loss per share estimates have narrowed from  1 93 to  1 67 for 2018 and from  3 86 to  3 57 for 2019 over the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 19 32   The stock has rallied 101 3  so far this year 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-22,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bla-for-opdivo-label-expansion-accepted-by-fda-200327234,200327234
203313,424829,MRK,U S  regulator says too many drugmakers chasing same cancer strategy,news," This June 10 story corrects reference to AstraZeneca drug to PD L1 instead of PD 1  paragraph 10  By Deena Beasley CHICAGO  Reuters    A new type of cancer drug that takes the brakes off the body s immune system has given drugmakers some remarkable wins against the deadly disease  but a top U S  regulator says too many companies are focused on the same approach  Dr  Richard Pazdur  head of the Food and Drug Administration s office of oncology products  was referring to therapies designed to disable the PD 1 protein that tumors use to evade the immune system   The FDA has approved such treatments from Merck   Co  N MRK   Bristol Myers Squibb Co  N BMY  and Roche Holding AG  S ROG   each of which have list prices of  150 000 per year  At least five other drugmakers are developing similar medicines    People should ask themselves     would we be better off spending those resources into looking at more novel drugs   Pazdur told Reuters during the annual American Society of Clinical Oncology  ASCO  meeting in Chicago this week   Pazdur acknowledged that the success of a few drugmakers in the worldwide  110 billion market for cancer treatments makes it attractive for rivals to continue developing similar therapies rather than invest heavily in unproven approaches    As with everything in drug development  it is about reduction of risk   he said  But the number of similar drugs in development at the same time is a first in the oncology field  and latecomers to the PD 1 market will likely be relegated to  niche  indications  he added  Drug company executives disputed Pazdur s critique  In interviews with Reuters  they argued that the science around cancer is advancing rapidly  with a focus on how to best combine therapies to attack multiple mechanisms of the disease  determine which patients are most likely to respond to them and how long patients will need to be treated   Bristol Myers and Merck are widely viewed as leaders in the immunotherapy race  with treatments defying the odds to help patients fight off some of the deadliest cancers  Merck s Keytruda was shown to help a significant number of patients with advanced melanoma live at least three years  while Bristol Myers  Opdivo prolonged life for some lung cancer patients by two years  according to data presented at the ASCO meeting   In practice  doctors say  around 20 percent of advanced cancer patients respond to the new drugs and a subset of those patients can have lasting remissions  AstraZeneca PLC s  L AZN  PD L1 drug  which similarly prevents tumors from evading detection  received  breakthrough  status from the FDA to expedite review for treating a type of bladder cancer  Other companies in earlier stages of development include  Pfizer  Inc  N PFE   in partnership with Germany s Merck KGaA  DE MRCG    Novartis  AG  S NOVN   Regeneron Pharmaceuticals Inc  O REGN  and China s  BeiGene   O BGNE    Our reason to go into PD 1s is not just to have a  me too  drug   said Israel Lowy  head of translational science and oncology at Regeneron  which has a PD 1 in early stage trials   Most people think that the future is in combinations     Having our own PD 1 that is active and useful gives us enormous flexibility in how we do clinical trials    ENOUGH PROFIT FOR EVERYONE   Industry executives say they are investing in additional  potentially complementary  approaches to PD 1 treatment that can eventually be used against many types and stages of cancer    We don t look at ourselves as  latecomers   We are leading in multiple areas with combination therapies   said Bahija Jallal  executive vice president at AstraZeneca s MedImmune unit  which is testing its PD 1 candidate with a range of other experimental drugs   The question is  how can we really follow the science   Jallal said   At the ASCO meeting  for example  Pfizer presented early stage data from a trial showing that its experimental agent 4 1BB  which aims to increase T cells  was safe when combined with Merck s Keytruda  but only two of 23 patients achieved complete remissions for a year   Somebody may emerge with a surprise new mechanism   said Leerink Partners pharmaceutical analyst Seamus Fernandez  He said drugs from Bristol Myers and Merck will most likely become the standard of care for many patients   Pazdur and other experts agreed that the biggest opportunity for cancer immunotherapies will be their use earlier on in treatment  Fernandez said Bristol Myers could  win the war   if it succeeds with a combination of Opdivo and its other immunotherapy Yervoy as an initial treatment for advanced non small cell lung cancer  Merck and Roche are testing their PD 1s combined with chemotherapy for the same purpose   In the end  patients may benefit from lower costs if Merck and Bristol Myers face more rivals in the marketplace  Both Keytruda and Opdivo have a U S  list price of about  150 000 per year   If combinations of expensive therapies become the norm  drugmakers could theoretically keep prices lower by mixing their own treatments rather than seeking permission from a rival   
 The profits on oncology drugs are so high that  me too  drugs will be developed   said Joel Hay  professor of pharmaceutical economics and policy at the University of Southern California   They will ultimately reduce the profits in that class  That s how competition is supposed to work  ",2016-06-14,Reuters,https://www.investing.com/news/general-news/regulator-says-too-many-drugmakers-chasing-same-cancer-strategy-407688,407688
203314,424830,MRK,Wall Street rebounds  snaps five day losing streak,news,"By Lewis Krauskopf  Reuters    Wall Street closed higher on Thursday as investors digested the implications of a British lawmaker s death on the country s impending referendum on whether to leave the European Union  The benchmark S P 500 index snapped a five day losing streak  after erasing sharp losses earlier in the session  A British Member of Parliament was shot dead in the street in northern England  causing the temporary suspension of campaigning for next week s referendum on EU membership  The lawmaker  Jo Cox  had been a vocal supporter of Britain remaining in the European Union  The prospect of Britain s voting to leave in the June 23 referendum has been rattling markets    We re seeing a move in the pound rallying off its lows  the Treasuries coming off of their highs and the stocks coming off of their lows because of that   said Lou Brien  market strategist at DRW Trading in Chicago   People are anticipating that this could be one of those things that turns a vote back in favor of remain   The Dow Jones industrial average  DJI  rose 92 93 points  or 0 53 percent  to 17 733 1  the S P 500  SPX  gained 6 49 points  or 0 31 percent  to 2 077 99 and the Nasdaq Composite  IXIC  added 9 98 points  or 0 21 percent  to 4 844 92  Traders also said covering of short bets after several days of selling could be helping stock prices  Nine of 10 S P sectors finished higher  Global stocks have been under duress for a week amid looming uncertainty about the British vote and a focus on central bank policy    I believe there is a lot of positioning going on ahead of that event to try to hedge the risk of a negative outcome  and a negative outcome for the markets would be a vote to leave   said Walter Todd  chief investment officer at Greenwood Capital Associates in Greenwood  South Carolina  The Federal Reserve on Wednesday left interest rates unchanged but signaled it still planned two hikes this year  Fed Chair Janet Yellen acknowledged the need to see clear signs of economic strength before lifting rates  The S P is up more than 1 percent for the year  rebounding since mid February with help from higher oil prices  However  on Thursday energy shares  SPNY  were the lone declining sector  falling 0 2 percent  as oil slumped to one month lows  The CBOE Volatility index  VIX   the most notable gauge of Wall Street anxiety  shot up to a 4 month high  After weeks of calm  the index has risen significantly this week  Merck  N MRK  shares rose 2 5 percent  propping up the Dow and the S P  after positive clinical trial results for cancer drug Keytruda  Shares of  Cavium   O CAVM  fell 17 5 percent after the chipmaker said it would buy network equipment maker QLogic  O QLGC  for about  1 36 billion  QLogic shares rose 9 3 percent  About 7 3 billion shares changed hands on U S  exchanges  above the 6 8 billion average over the past 20 trading days  according to Thomson Reuters data  NYSE declining issues outnumbered advancers by a 1 05 to 1 ratio  on the Nasdaq  a 1 17 to 1 ratio favored decliners  
The S P 500 posted 17 new 52 week highs and 4 new lows  the Nasdaq recorded 30 new highs and 59 new lows ",2016-06-16,Reuters,"https://www.investing.com/news/stock-market-news/futures-lower-as-fed-comments,-brexit-vote-spook-investors-408798",408798
203317,424833,MRK,3 Stocks Raising Hopes In Troubled Large Cap Pharma Industry,opinion,In spite of a strong start in 2018  the pharma biotech industry is struggling currently  presumably due to a shift in focus to lowering of high drug prices and faster approval of generics  Moreover  quite a few negative pipeline and regulatory updates announced this year so far have probably had an unfavorable impact on the industry However  we expect the industry to turn around as the year progresses  Demand for drugs is rising worldwide due to increasing ailing and elderly population  frequent approval of new drugs as well as line extensions of already marketed drugs  and increased healthcare spending Moreover  reduction in tax and one time low tax window for cash repatriation has boosted the cash position of large pharma companies  This has led to an increase in merger   acquisition activity and may boost innovation and capital building in the biotech industry  With the  62 billion price tag  the proposed acquisition of Shire plc   NASDAQ SHPG   by Japanese firm Takeda is the biggest deal in the industry  Earlier in the year  we have seen Sanofi   NYSE SNY   and Celgene Corporation   NASDAQ CELG   acquiring smaller biotech companies  Impax Laboratories merged with Amneal  Other large pharma companies are also on the lookout for acquisition targets Why Large Caps Given the current dampening mood  we focus on some large cap companies to lower portfolio risk Putting your money in large cap companies reduces risk due to their diversified portfolio and a large cash base  Moreover  the companies  stability and dividend payments provide a safety cushion to one s portfolio  Moreover  in a flat or downtrend market  it is better to focus on specific stocks  Large caps also give high returns and are less risky than small and mid caps However  the large cap pharma  is down 4 5  so far this year while the S P 500 has risen 2 3   But the large cap industry ranks among the top half of the 255 Zacks industry list The below mentioned stocks have risen this year so far  outperforming the large cap pharma industry  Let s discuss the factors driving these stocks and why one should add them to their portfolio AstraZeneca   NYSE AZN   shares have gained 6  so far this year on the back of several regulatory approvals and successful study results this year The company s Lynparza became the first PARP inhibitor to be approved beyond ovarian cancer as the FDA approved its label expansion in   Another cancer drug  Imfinzi s label was  to include advanced non small cell lung cancer   NSCLC   indication  Tagrisso s eligible patient population was expanded recently as it is now approved for treating first line  with EGFR mutations Apart from cancer drugs  AstraZeneca s asthma drug    received approval in Europe for severe eosinophilic asthma  Moreover  the company added a new drug to its portfolio with the approval of   formerly known as ZS 9  for hyperkalemiaAstraZeneca s triple combination therapy    for the treatment of chronic obstructive pulmonary disease   COPD   significantly improved several lung functions compared with dual combination therapies   per data from a late stage KRONOS study These approvals for new drugs as well as line extensions are likely to boost the company s top line in the future quarters  In addition  a regulatory application seeking label expansion of Forxiga as an oral adjunct treatment to insulin in adults with type 1 diabetes was  for review in March in Europe  Thus  we expect the stock s momentum to continue  However  negative regulatory updates or data readouts may impact the stock unfavorably  key among them being the final overall survival data from MYSTIC study  which has already been delayed Merck   Co   Inc    NYSE MRK   stock has gained 7 6  so far this year backed by encouraging data from several clinical studies evaluating Keytruda as well label expansions of the drug Keytruda received  for treating urothelial carcinoma in Japan  Moreover  label expansion in advanced cervical cancer is  in the United States  Several other regulatory decisions are pending in the United States as well as Europe The drug has shown encouraging development in clinical studies  Keytruda significantly improved recurrence free survival   RFS   in  patients and overall survival   OS   in  patients as monotherapy  In combination with Eli Lilly s Alimta  Keytruda  overall survival   OS   and progression free survival   PFS   in first line NSCLC  These positive data readouts increase the probability of Keytruda s label expansion  Moreover  data readouts from a few clinical studies evaluating Keytruda  including two pivotal lung cancer studies  presented at the annual meeting of the American Society of Clinical Oncology  ASCO  in Chicago were also encouraging Apart from Keytruda  Merck s anti cancer drug    was approved in Japan for label expansion in first line hepatocellular carcinoma   HCC    a type of liver cancer  Moreover  label expansion of AstraZeneca s Lynparza in breast cancer will also boost Merck s revenues as the latter shares development and commercialization costs as well as sales with AstraZeneca Meanwhile  Merck s immunotherapy pipeline for cancer treatment is expected to get a boost with the completion of the  of Australian Firm  Viralytics Limited  in the second quarter  We expect growth of new drugs to continue  which will offset the loss of sales of certain products due to loss of market exclusivity  This should drive the company s shares higher going forward GlaxoSmithKline plc s   NYSE GSK   influenza vaccine   FluarixQuadrivalent   got  for label expansion in infants six months or older in the United States and Europe  HIV treatment    was approved in Europe   Moreover  the company s shingles vaccine nears approval in Europe as in January the Committee for Medicinal Products for Human Use  a positive opinion for the marketing authorization application  In May  the FDA approved the label expansion of asthma therapy  Arnuity Ellipta  as a maintenance treatment in pediatric patients aged five years and older Moreover  the approval of three new products   Trelegy Ellipta  Shingrix and Juluca   in quick succession in the United States and Europe last year early this year boosted the company s top line as the drugs  uptake was encouraging In addition  the agreement to  Novartis    NYSE NVS   stake in the Consumer Healthcare JV is likely to strengthen its competitive position The stock has rallied 14 9  so far this year AstraZeneca  Merck and Glaxo are all Zacks Rank  3  Hold  stocks  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-03,Zacks Investment Research,https://www.investing.com/analysis/3-stocks-raising-hopes-in-troubled-largecap-pharma-industry-200321933,200321933
203318,424834,MRK,Is Merck   Co   MRK  Outperforming Other Medical Stocks This Year ,opinion,"The Medical group has plenty of great stocks  but investors should always be looking for companies that are outperforming their peers  Has Merck   Co   NYSE MRK  been one of those stocks this year  Let s take a closer look at the stock s year to date performance to find out 
Merck   Co  is one of 763 individual stocks in the Medical sector  Collectively  these companies sit at  11 in the Zacks Sector Rank  The Zacks Sector Rank considers 16 different sector groups  The average Zacks Rank of the individual stocks within the groups is measured  and the sectors are listed from best to worst 
The Zacks Rank is a successful stock picking model that emphasizes earnings estimates and estimate revisions  The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months  MRK is currently sporting a Zacks Rank of  2  Buy  
Over the past 90 days  the Zacks Consensus Estimate for MRK s full year earnings has moved 1 65  higher  This signals that analyst sentiment is improving and the stock s earnings outlook is more positive 
Based on the most recent data  MRK has returned 10 06  so far this year  At the same time  Medical stocks have gained an average of 1 09   This means that Merck   Co  is outperforming the sector as a whole this year 
Looking more specifically  MRK belongs to the Large Cap Pharmaceuticals industry  which includes 14 individual stocks and currently sits at  108 in the Zacks Industry Rank  Stocks in this group have lost about 2 06  so far this year  so MRK is performing better this group in terms of year to date returns 
MRK will likely be looking to continue its solid performance  so investors interested Medical stocks should continue to pay close attention to the company ",2018-06-06,Zacks Investment Research,https://www.investing.com/analysis/is-merck--co-mrk-outperforming-other-medical-stocks-this-year-200322939,200322939
203324,424840,MRK,Eisai And Merck Announce Update On Lenvatinib SNDA Review,opinion,"Eisai Inc   a subsidiary of Japan based Eisai Co    OTC ESALY   and partner Merck   NYSE MRK   announced that the FDA has extended the review period of its supplemental New Drug Application  sNDA  for its cancer drug  lenvatinib  by three months to Aug 24  2018  Currently  the company is looking to get lenvatinib approved for first line treatment of patients with unresectable hepatocellular carcinoma   HCC    commonly known as liver cancer The FDA had accepted the sNDA in September last year  The regulatory body has now extended the review period as it requires additional time for review of the application  Eisai being the marketing authorization holder is working with the FDA to support the continuation of the review process The drug received its first approval for this indication in Japan in March Lenvima is approved as a single agent for treating differentiated thyroid cancer and in combination with Novartis    NYSE NVS   chemo drug  Afinitor  everolimus   for advanced renal cell carcinoma following one prior anti angiogenic therapy Eisai s shares are up 27 1  so far this year  which compares favorably with an increase of 1  registered by the  during this period The sNDA includes data from a phase III study  which compared lenvatinib with Bayer s   OTC BAYRY   chemo drug  Nexavar  sorafenib   The candidate demonstrated non inferiority in overall survival in treating liver cancer patients who have not received any prior treatment  The drug also achieved statistically significant and clinically meaningful improvements in progression free survival  time to progression and objective response rate Eisai entered into a strategic collaboration with Merck in March to develop lenvatinib as single agent and in combination with Merck s anti PD 1 therapy  Keytruda  as well Eisai Co  Price
    Eisai currently carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/eisai-and-merck-announce-update-on-lenvatinib-snda-review-200319460,200319460
203325,424841,MRK,AstraZeneca s Imfinzi Improves Survival In Lung Cancer Study,opinion,AstraZeneca PLC    NYSE AZN   announced that a phase III PACIFIC study evaluating its oncology candidate  Imfinzi  durvalumab   for an early stage lung cancer indication met its second primary endpoint of overall survival  OS   The study was conducted on patients with locally advanced  unresectable  stage III  non small cell lung cancer  NSCLC   whose disease has not progressed following platinum based chemotherapy concurrent with radiation therapy  CRT   Please note that Imfinzi was approved in the United States for this indication in February this year based on positive progression free survival dataA planned interim analysis showed that patients receiving Imfinzi experienced statistically significant OS benefit with clinically meaningful improvement compared to placebo  The OS data will be added to the label of Imfinzi which can drive sales of the drug higher Imfinzi is also marketed in the United States for second line advanced bladder cancer Interim data from the study  presented in September last year  showed that Imfinzi led to superior progression free survival to standard of care in the above mentioned patients  Treatment with Imfinzi improved PFS by more than 11 months in comparison to standard of care  Imfinzi also led to significant reductions in the risk of deterioration of health or death per data from the study  Astrazeneca s shares have outperformed the  so far this year  Shares of the company have gained 6 7   while the industry declined 4 9   AstraZeneca is also developing Imfinzi as monotherapy as well as combination therapy for treatment of NSCLC in first line or adjuvant setting  The drug is also being developed for several other cancer indications including head and neck  gastric  pancreatic  hepatocellular and blood cancers However  lung cancer is a competitive segment as it attracts several players due to the huge market opportunity  Novartis   NYSE NVS   and Roche   OTC RHHBY   received approval for their respective drugs  Zykadia and Alecensa  in 2017 for treating metastatic NSCLC in first line setting Other immunotherapies for treating various cancer indications include Bristol Myers Squibb Company s   NYSE BMY   Opdivo and Merck  NYSE MRK    Co  s Keytruda Zacks RankAstraZeneca carries a Zacks Rank  4  Sell  You can see   AstraZeneca PLC Price    5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-05-27,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-imfinzi-improves-survival-in-lung-cancer-study-200319902,200319902
203326,424842,MRK,Why Is Aduro  ADRO  Up 18 6  Since Its Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Aduro Biotech  Inc    NASDAQ ADRO    Shares have added about 18 6  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is ADRO due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Aduro Q1 Loss Narrower Than Expected  Revenues BeatAduro incurred first quarter 2018 loss of 28 cents per share  narrower than both the Zacks Consensus Estimate of a loss of 30 cents and the year ago loss of 32 cents Quarterly revenues soared substantially 73 7  year over year to  6 6 million  This upside can mainly be attributed to a receipt of  3 million milestone payment from Merck  NYSE MRK  under Aduro s worldwide licensing agreement with the company for initiation of a phase I study  evaluating its own anti CD27 antibody  The top line also surpassed the Zacks Consensus Estimate of  4 million Research and development expenses slightly dipped 2 4  in the reported quarter to  20 1 million  mainly owing to lower contract manufacturing expense of  3 1 million  This is primarily related to the company s pipeline candidate  BION 1301   However  this was offset by an increase in costs related to manufacturing of B select antibodies and the company s personalized neoantigen based immunotherapy General and administrative expenses were  9 million  up 8 4  year over year on higher stock based compensation expense and legal fees 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision higher for the current quarter compared to two lower Aduro Biotech  Inc  Price and Consensus
    VGM Scores
At this time  ADRO has a subpar Growth Score of D  however its Momentum is doing a lot better with a B  The stock was allocated a grade of F on the value side  putting it in the fifth quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
The company s stock is suitable solely for momentum based on our styles scores 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  ADRO has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-31,Zacks Investment Research,https://www.investing.com/analysis/why-is-aduro-adro-up-186-since-its-last-earnings-report-200321462,200321462
203331,424847,MRK,Agenus   AGEN  Q1 Loss Wider Than Expected  Shares Down,opinion,"Agenus Inc    NASDAQ AGEN   reported first quarter 2018 adjusted  loss of 42 cents per share  excluding loss on early extinguishment of debt of 11 cents per share   wider than both the Zacks Consensus Estimate of a loss of 28 cents and the year ago loss of 18 cents  The higher net loss was due to several one time items as well as non cash charges 
The company did not generate any revenues in the quarter  The Zacks Consensus Estimate was  16 million  However  the company reported revenues of  27 million in the prior year period 
Shares of the company fell about 9 8  following the earnings release  So far this year  shares of Agenus have gained 1 8  as against the  s decline of 11 9  

Quarterly Highlights
Agenus  first quarter research and development  R D  expenses declined 9 8  to  29 4 million  General and administrative expenses decreased by 8 1  to  10 7 million 
Pipeline Update
Agenus is progressing well with various pipeline candidates  During the quarter under review  the company launched combination trials of CTLA 4 antibody  AGEN1884 and PD 1 targeting antibody AGEN2034 including trials in second line cervical cancer 
The company has shifted its strategy for first approval from first line non small cell lung cancerto second line cervical cancer  The reasons for the strategy shift includes increasingly crowded lung cancer opportunities and Merck s   NYSE MRK   recent data with Keytruda in combination with chemotherapy in first line non small cell lung cancer  which has set the bar higher for any future approvals 
The company remainson track to file six investigational new drugs  INDs  in 2018 and an additional two INDs in the first half of 2019  Amongst that  is the company s next gen CTLA 4  designed to deplete cancer prone Tregs and improve T cell priming  
 Zacks Rank   Stocks to Consider
Agenus has a Zacks Rank  3  Hold  
A few better ranked stocks from the same space worth considering are Ligand Pharmaceuticals   NASDAQ LGND   and Protagonist Therapeutics   NASDAQ PTGX   both sporting a Zacks Rank  1  Strong Buy   You can see  
Ligand s earnings per share estimates have moved up from  4 24 to  4 43 for 2018 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 15  year to date 
Protagonist s loss estimates narrowed from  1 30 to 66 cents for 2018 and from  1 99 to  1 26 for 2019  over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 95  Agenus Inc  Price  Consensus and EPS Surprise

   Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-08,Zacks Investment Research,https://www.investing.com/analysis/agenus-agen-q1-loss-wider-than-expected-shares-down-200314359,200314359
203337,424853,MRK,Merck gives cautious 2016 outlook as sales of top medicines lag,news,"By Ransdell Pierson  Reuters    Merck   Co Inc  N MRK  issued cautious 2016 revenue and earnings forecasts after disappointing fourth quarter demand for its Januvia diabetes treatment and its Remicade arthritis drug   Sales of Januvia and a related drug called Janumet  the company s biggest franchise  fell 12 percent to  1 45 billion  Merck said their tumble was due in large part to timing of customer purchases in the third quarter  Competition from a growing number of other oral diabetes treatments also hurt sales   Remicade  which is facing competition outside the United States from cheaper generics  suffered a 29 percent sales decline to  396 million   Shares of Merck fell 1 5 percent to  49 65 in premarket trading   Merck is counting on Keytruda  a recently approved immuno oncology treatment for melanoma and lung cancer  to boost its earnings for years to come  The medicine  which takes the brakes off the immune system  is competing with Bristol Myers Squibb Co s  N BMY  similar Opdivo treatment  which is picking up sales faster   Keytruda sales rose to  214 million in the fourth quarter  about half Opdivo s  475 million in revenue in that period    Our initial read on the earnings and guidance reaffirms our neutral stance on  Merck  as pressure on key products such as Januvia and Remicade will likely limit near term  earnings  growth    Credit Suisse   VX CSGN  analyst Vamil Divan said in a research note   Merck  the second biggest U S  drugmaker behind  Pfizer  Inc  N PFE   forecast full year earnings of  3 60 to  3 75 per share  excluding special items  The analysts  average estimate was  3 72  according to Thomson Reuters I B E S  Merck said it expected 2016 revenue of  38 7 billion to  40 2 billion  Wall Street had forecast  40 25 billion  Fourth quarter revenue fell 3 percent to  10 22 billion  below analysts  expectations of  10 35 billion  Sales would have risen 4 percent if not for the stronger dollar  Merck said  Net income attributable to the company fell to  976 million from  7 32 billion  Excluding acquisition related costs and other special items  the company earned 93 cents per share  topping Wall Street forecasts of 91 cents  Sanford Bernstein analyst Tim Anderson attributed the earnings beat largely to a lower tax rate  
Also grappling with the stronger dollar  Pfizer on Tuesday forecast 2016 revenue and earnings below analysts  estimates ",2016-02-03,Reuters,https://www.investing.com/news/stock-market-news/merck-revenue-falls-as-dollar-strengthens-383056,383056
203338,424854,MRK,Aduro  ADRO  Q1 Loss Narrower Than Expected  Revenues Beat,opinion,Aduro Biotech  Inc    NASDAQ ADRO   incurred first quarter 2018 loss of 28 cents per share  narrower than both the Zacks Consensus Estimate of a loss of 30 cents and the year ago loss of 32 cents Quarterly revenues soared substantially 73 7  year over year to  6 6 million  This upside can mainly be attributed to a receipt of  3 million milestone payment from Merck   NYSE MRK   under Aduro s worldwide licensing agreement with the company for initiation of a phase I study  evaluating its own anti CD27 antibody in combination with Merck s Keytruda  pembrolizumab for treatment of adults with advanced solid tumors  The top line also surpassed the Zacks Consensus Estimate of  4 million Shares of Aduro increased more than 3  on May 2 in after hours trading following the earnings release  However  the stock has underperformed the industry in a year s time  having declined 26 1  compared with the  s decrease of 14 3   Research and development expenses slightly dipped 2 4  in the reported quarter to  20 1 million  mainly owing to lower contract manufacturing expense of  3 1 million  This is primarily related to the company s pipeline candidate  BION 1301  currently under development for treating adults with relapsed or refractory multiple myeloma  However  this was offset by an increase in costs related to manufacturing of B select antibodies and the company s personalized neoantigen based immunotherapy General and administrative expenses were  9 million  up 8 4  year over year on higher stock based compensation expense and legal fees Pipeline UpdateAduro has a broad pipeline of novel immunotherapies  developed for treating a variety of cancers The company evaluates its STING pathway activator  ADU S100  in combination with Novartis AG s   NYSE NVS   PD 1 checkpoint inhibitor  PDR001  in a phase Ib trial for treating solid tumors and lymphomas  Additionally  the candidate is being evaluated in a phase I trial as a monotherapy in patients with cutaneous accessible metastatic solid tumors or lymphomas  Top line data from the program is expected soon Meanwhile  in December 2017  Aduro initiated a phase I II dose escalation study  examining its pipeline candidate  BION 1301  for the treatment of adults with relapsed or refractory multiple myeloma Aduro Biotech  Inc  Price  Consensus and EPS Surprise    Zacks Rank   Key PicksAduro carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Ligand Pharmaceuticals Incorporated   NASDAQ LGND    which sports a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved north from  4 20 to  4 43 for 2018 in the last 30 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has surged 36 9  over a year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-05-03,Zacks Investment Research,https://www.investing.com/analysis/aduro-adro-q1-loss-narrower-than-expected-revenues-beat-200313260,200313260
203339,424855,MRK,Has Merck  MRK  Outpaced Other Medical Stocks This Year ,opinion,"For those looking to find strong Medical stocks  it is prudent to search for companies in the group that are outperforming their peers  Is Merck   Co   NYSE MRK  one of those stocks right now  By taking a look at the stock s year to date performance in comparison to its Medical peers  we might be able to answer that question 
Merck   Co  is one of 764 individual stocks in the Medical sector  Collectively  these companies sit at  8 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions  highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months  MRK is currently sporting a Zacks Rank of  2  Buy  
Over the past 90 days  the Zacks Consensus Estimate for MRK s full year earnings has moved 1 96  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Our latest available data shows that MRK has returned about 1 97  since the start of the calendar year  At the same time  Medical stocks have lost an average of 3 18   As we can see  Merck   Co  is performing better than its sector in the calendar year 
To break things down more  MRK belongs to the Large Cap Pharmaceuticals industry  a group that includes 14 individual companies and currently sits at  94 in the Zacks Industry Rank  This group has lost an average of 4 10  so far this year  so MRK is performing better in this area 
Investors with an interest in Medical stocks should continue to track MRK  The stock will be looking to continue its solid performance ",2018-05-07,Zacks Investment Research,https://www.investing.com/analysis/has-merck-mrk-outpaced-other-medical-stocks-this-year-200314121,200314121
203347,424863,MRK,Former President Jimmy Carter says cancer gone from brain,news,"By Colleen Jenkins  Reuters    Former U S  President Jimmy Carter delivered an unexpected message on Sunday to the several hundred people gathered at a Baptist church in Georgia for his Bible lesson   his latest brain scan showed no sign of cancer  Carter  91  started treatment in August for melanoma that had spread from his liver to his brain  A previous MRI test showed the four spots of cancer that had developed on his brain were responding to treatment  he said    When I went this week  they didn t find any cancer at all  so I have good news   Carter told the crowd at Maranatha Baptist Church in his hometown of Plains  Georgia  according to a video from NBC News  The former Democratic president  known for his unassuming style  offered a quick smile as people who had come for the Sunday School class he teaches gasped and clapped  In a brief written statement afterward  Carter confirmed his most recent brain scan  did not reveal any signs of the original cancer spots nor any new ones   He said he would continue to receive regular doses of pembrolizumab  a new treatment that is part of a promising class of drugs that harness the body s immune system to fight cancer  The immunotherapy is manufactured by Merck  N MRK    Co under the brand name Keytruda  While about 30 percent of patients treated with the drug experience significant shrinkage of their cancer  only approximately 5 percent experience complete remission  said Dr  Marc Ernstoff  director of the melanoma program at the Cleveland Clinic s Taussig Cancer Institute in Ohio  On average  the immunotherapy treatment extends a recipient s life expectancy by a year and a half   But people that are in complete remission tend to live significantly longer   said Ernstoff  who is not involved in Carter s care  Carter  who said after his diagnosis last summer that his fate was  in the hands of God   has defied expectations before  Critics derided his 1977 1981 presidency as a failure  although he played a key role in negotiation of the 1978 Camp David peace accord between Israel and Egypt  He lost his 1980 re election bid to Republican Ronald Reagan  But the former peanut farmer built one of the most successful post White House legacies  winning a Nobel Peace Prize in 2002 and remaining active into his  90s in causes such as fighting disease in Africa and building homes for the poor  He said in August that his cancer treatment  which has included radiation  would require him to cut back dramatically on his public schedule  
But Carter has continued to teach Sunday School classes and participated in at least one Habitat for Humanity home building event this autumn  In October  he announced he was also working with the Rev  Martin Luther King Jr  s heirs to help mediate their dispute over whether to sell their father s 1964 Nobel Peace Prize medal and the Bible he carried during the civil rights movement ",2015-12-06,Reuters,https://www.investing.com/news/politics-news/jimmy-carter-says-cancer-gone:-newspaper-report-374705,374705
203348,424864,MRK,Lufthansa plays down report about new chairman,news,"FRANKFURT  Reuters    German airline Lufthansa played down a report that it could get a new chairman after Merck  N MRK  KGaA Chief Executive Karl Ludwig Kley was quoted as saying he would take the job if it was offered to him  Kley is to step down as chief executive of pharmaceutical company Merck in April  He is a former finance chief at Lufthansa and a current member of the supervisory board of an airline which has been hit by a series of strikes    Were I to be asked  it would be my honor to say yes   Manager Magazin cites Kley as saying in an excerpt of an article to be published on Friday  made available to Reuters on Thursday  In response to the report  Lufthansa said in a written statement that Wolfgang Mayrhuber had been elected chairman until 2018   There are no intentions to change anything about that  Therefore there is no need to speculate about succession   Manager Magazin cited Lufthansa sources as saying Mayrhuber will remain in office at least until 2017  though adding that there had previously been signals he might step down earlier for personal reasons  Merck declined to comment   Germany s largest airline is facing tough competition from Gulf operators including Emirates  Etihad and Qatar and low cost carriers such as Ryanair and EasyJet  That has resulted in drawn out labor disputes with pilots and cabin crew over cost cutting measures  
The magazine cited Kley as saying he was fully aware that  to strengthen this icon of the German economy constitutes a tremendous task  ",2015-12-17,Reuters,https://www.investing.com/news/stock-market-news/merck-kgaa-ceo-interested-in-becoming-lufthansa-chairman--report-376531,376531
203349,424865,MRK,Can Jafaki Help Incyte  INCY  Beat Earnings Estimates In Q1 ,opinion,Incyte Corporation   NASDAQ INCY   is scheduled to report first quarter 2018 results on May 1  before the market opens In the last reported quarter  the company beat estimates by 103 85  Incyte s earnings track record has been decent so far  Over last four quarters  the company s earnings surpassed expectations thrice  while missing in one  Incyte delivered an average positive earnings surprise of 67 05  in the said time frame   Incyte s stock has lost 46 2  in the last six months  worse than the  s decline of 8 5  Let s see  how things are shaping up for this quarter Why a Likely Positive Surprise Our proven model shows that Incyte is likely to beat on earnings this quarter because it has the right combination of the two key ingredients  A stock needs to have both a positive   and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP   Incyte has an Earnings ESP of  92 00   as the Most Accurate estimate is pegged at earnings of 16 cents per share while the Zacks Consensus Estimate stands at an earnings of 8 cents  A positive ESP hints at an earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank   Incyte has a Zacks Rank  3  which increases the predictive power of ESP  Further  combined with a positive ESP  chances of an earnings beat are usually pegged higher We caution against all Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Factors Driving the GrowthIncyte s lead drug  Jakafi  ruxolitinib   is a first in class JAK1 JAK2 inhibitor  approved for the treatment of patients with polycythemia vera   PV    patients with intermediate or high risk myelofibrosis   MF    including primary MF  post PV MF  and post essential thrombocythemia MF  While Incyte markets the drug in the United States  it is marketed by Novartis   NYSE NVS   as Jakavi outside the country Incyte continues to gain traction by Jakafi s performance   Incyte s Jakafi performance was strong in 2017 driven by patient demand  The sales guidance for 2018 was also impressive  In October 2017  the FDA approved a label update of the drug to include the addition of new patient reported outcome data from the COMFORT I study  as well as updating the warning related to progressive multifocal leukoencephalopathy  The pivotal REACH1 trial evaluating Jakafi in patients with steroid refractory acute graft versus host disease   GVHD   has completed enrollment and results are expected in the first half of 2018 Assuming successful results  Incyte expects to submit an sNDA seeking approval of Jakafi for this indication  Jakafi sales are expected to get a boost from the updated labels  Incyte expects Jakafi revenues in the range of  1 35  1 4 billion in 2018  more than 20  growth over 2017 We remind investors that while Jakafi sales and royalties are a key component of Incyte s revenue growth  Iclusig sales and Olumiant royalties are also contributing to the top line Iclusig revenues are expected in the range of  80  85 million R D expenses are expected in the range of  1 077 1 172 million  SG A expenses are expected in the range of  465  480 million We also expect investors to focus on pipeline updates since Incyte suffered a few setbacks this month  Incyte and partner Merck   NYSE MRK   announced the failure of a combination therapy   Incyte s epacadostat and Merck s Keytruda   in achieving improved progression free survival over Keytruda alone in phase III study ECHO 301 KEYNOTE 252  The study was evaluating the combination drugs for the treatment of unresectable or metastatic melanoma  An external data monitoring committee recommended the termination of the study following the review of the data from the pivotal study Moreover  the FDA s Arthritis Advisory Committee has recommended an approval of the 2 mg dose of baricitinib  a once daily oral medication for the treatment of moderately to severely active rheumatoid arthritis for adult patients who have had an inadequate response or intolerance to methotrexate  However  the advisory committee did not recommend approval of the 4 mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit risk profiles  While the FDA is generally not required to follow the Advisory Committee s recommendation  but it will consider the same during its review of the NDA for baricitinib  The FDA had earlier issued a Complete Response Letter for the same A Stock to ConsiderHere is one other health care stock worth considering with the right combination of elements to beat on earnings GW Pharmaceuticals plc   NASDAQ GWPH   is expected to report earnings on May 8  The company has an Earnings ESP of  8 11  and a Zacks Rank  2    You can see see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/can-jafaki-help-incyte-incy-beat-earnings-estimates-in-q1-200310189,200310189
203350,424866,MRK,Sanofi s  SNY  Earnings Beat Estimates In Q1  Sales Miss Mark,opinion,Sanofi  PA SASY    NYSE SNY   reported first quarter 2018 earnings of 79 cents per American depositary share  which beat the Zacks Consensus Estimate of 74 cents  Earnings grew 6 8  on a reported basis  At constant currency rates  CER   earnings grew 1 4  First quarter net sales grew 5 9  on a reported basis to almost  9 71 billion   7 89 billion   Sales however missed the Zacks Consensus Estimate of  9 96 billion  Unfavorable exchange rate movements hurt sales by 8 3   At CER  sales dipped 0 4  year over year           Sales declined 8 2  at CER in the United States  However  sales rose 8 3  in Emerging Markets  0 5  in Europe but declined 3 4  in the Rest of the World  Japan  South Korea  Canada  Australia  New Zealand and Puerto Rico  Sanofi announced the successful completion of its acquisition of Bioverativ  which was consolidated in the company s financial statements from Mar 9  2018  All growth rates mentioned below are on a year on year basis and at CER Segmental PerformancePharmaceuticals sales  including emerging markets  dipped 0 9  to  5 9 billion  However  at CER  Pharmaceuticals sales fell 0 9  Sanofi reports through five Global Business Units  GBUs    Sanofi Genzyme  Specialty Care   Diabetes   Cardiovascular  General Medicines   Emerging Markets  Consumer Healthcare and Sanofi Pasteur  Vaccines  Sanofi Genzyme Specialty Care GBU sales  including emerging markets  increased 16 2  to  1 46 billion  driven by contribution from new immunology drugs   Dupixent and Kevzara   along with higher sales of multiple sclerosis and rare disease drugs Sales of MS drugs Aubagio rose 11 6  to  371 million while sales of Lemtrada fell  8 8  to  105 million Meanwhile  sales of rare disease drugs like Myozyme Lumizyme improved 11 1  to  196  million while Fabrazyme sales were  170 million  up 6 8   Cerdelga sales came in at  36 million  up 25 8  while Cerezyme sales rose 10 2  to  175 million Oncology sales declined 5 6  to  358 million  Jevtana sales were up 10 3  to  99 million while Thymoglobulin recorded sales of  70  was up 8 3   Taxotere sales fell 2 1  to  43 million  Eloxatin sales were up 6 7  to  44 million Sanofi and Regeneron s   NASDAQ REGN   rheumatoid arthritis drug Kevzara  sarilumab  was launched in the United States in June 2017 and in United Kingdom  the Netherlands and Germany in Europe in the second half   Kevzara recorded sales of  10 million in the quarter compared with  8 million in the previous quarter Meanwhile  Dupixent dupilumab for treating atopic dermatitis was launched in the United States in March and approved in the EU in September 2017  In December 2017  Sanofi launched Dupixent in Germany  Dupixent generated sales of  107 million in the first quarter compared with  118 million in the previous quarter  Kevzara and Dupixent generated total immunology sales of  117 million in the first quarter  lower than  126 million recorded in the previous quarter Diabetes and Cardiovascular GBU  including emerging markets  declined 8 7  to  1 48 billion  The Diabetes franchise  including emerging markets  declined 10  to  1 36 billion due to lower sales of key drug Lantus and Toujeo in the United States Sales of diabetes drugs in the United States declined 26 6  to  534 million due to the previously announced changes in coverage in the Part D business and a persistent decline in average U S  glargine net prices  Sales of diabetes drugs in Emerging Markets were up 17 7  while in Europe it fell 0 9  Lantus sales declined 17 7  to  911 million in the quarter  Lantus sales declined 31  in the United States due to lower average net price the change in coverage in Sanofi s Part D business while in Europe sales declined 9  due to biosimilar competition and patient switching to Toujeo Toujeo generated sales of  197 million in the reported quarter  up 13 8   However  sales were down 14 8  sequentially in the United States Soliqua  a once daily titratable fixed ratio combination of Lantus and Lyxumia  was launched in the United States in January 2017 and in some European countries  trade name   Suliqua  in 2017  Soliqua Suliqua generated sales of  9 million in the quarter compared flat sequentially In the cardiovascular franchise  Sanofi s anti PCSK9 therapy  Praluent garnered worldwide sales of  49 million in the reported quarter  up 55 9  General Medicines   Emerging Markets GBU sales came in at  3 4 billion  down 1 5   Sales of Established products were  2 32 billion  down 6 4  as strong performance in emerging markets was offset by lower sales in Europe and generic competition for Renvela Renagel in the United States Sales of Generics rose 0 9  to  435 million sustained by Emerging Markets sales Consumer Healthcare GBU sales were  1 24 billion  up 2  driven Emerging Markets especially Latin America First quarter consolidated Sanofi Pasteur  Vaccines  sales fell 0 9  to  711 million  Vaccines sales reflect the termination of the Sanofi Pasteur MSD joint venture with Merck   NYSE MRK   in Europe from December 2016  Vaccines sales were was impacted by the constrained supply of Pentaxim in China and low sales of Dengvaxia following the announced label update in November 2017 Costs RiseSelling general and administrative expenses  SG A  increased 1  at CER in the quarter  reflecting investments in immunology  additional expenses in China and consolidation of Bioverativ s operating expenses  R D expenses were up 4 5  at CER  reflecting increased spend on immuno oncology programs and medical investment behind the immunology franchise 2018 OutlookSanofi reiterated its guidance for 2018 and expects  business earnings to grow between 2  and 5  at CER Share BuybackThe company announced a  1 5 billion share buyback program during the quarter which is expected to be completed in mid 2019 Our TakeSanofi s first quarter 2018 results beat earnings but missed sales expectations  However  Sanofi s 2018 outlook looks upbeat as it expects to return to growth this year on the back of the Bioverativ and Ablynx deals  a strong pipeline and lower tax rates under the new tax laws  The company continues to execute on its business priorities and position the company for a new period of growth which is expected to begin in the second half of 2018 Year to date  Sanofi s shares have lost 6 1   compared with the 2 3  decline for the   Zacks Rank   Stocks to ConsiderSanofi carries a Zacks Rank  3  Hold  Another top ranked stock from the same space is Ligand Pharmaceuticals   NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy  You can see  Ligand s earnings per share estimates have moved up  4 15 to  4 43 for 2018 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 15 8  year to date  Sanofi Price  Consensus and EPS Surprise     Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/sanofis-sny-earnings-beat-estimates-in-q1-sales-miss-mark-200310244,200310244
203357,424873,MRK,Exclusive   Transatlantic divide  how U S  pays three times more for drugs,news,"By Ben Hirschler LONDON  Reuters    U S  prices for the world s 20 top selling medicines are  on average  three times higher than in Britain  according to an analysis carried out for Reuters  The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such as Democratic presidential candidate Hillary Clinton  The 20 medicines  which together accounted for 15 percent of global pharmaceuticals spending in 2014  are a major source of profits for companies including AbbVie  N ABBV   AstraZeneca  L AZN   Merck  N MRK    Pfizer   N PFE  and Roche  VX ROG   Researchers from Britain s University of Liverpool also found U S  prices were consistently higher than in other European markets  Elsewhere  U S  prices were six times higher than in Brazil and 16 times higher than the average in the lowest price country  which was usually India  The United States  which leaves pricing to market competition  has higher drug prices than other countries where governments directly or indirectly control medicine costs   That makes it by far the most profitable market for pharmaceutical companies  leading to complaints that Americans are effectively subsidizing health systems elsewhere  Manufacturers say decent returns are needed to reward high risk research and prices reflect the economic value provided by medicines  They also point to higher U S  survival rates for diseases such as cancer and the availability of industry backed access schemes for poorer citizens   In recent years  the price differential has been exacerbated by above inflation annual increases in U S  drug prices at a time when governments in Europe have capped costs or even pushed prices down  In fact  U S  prices for top brand name drugs jumped 127 percent between 2008 and 2014  compared with an 11 percent rise in a basket of common household goods  according to Express Scripts  O ESRX   the largest U S  manager of drug plans  In Europe  meanwhile  the impact of austerity on health budgets since the financial crisis has led industry executives to complain of single digit percentage annual price declines  PRICE DISCOUNTS The U S  Pharmaceutical Research and Manufacturers of America  PhRMA  says international comparisons are misleading because list prices do not take into account discounts available as a result of  aggressive negotiation  by U S  insurers  These discounts can drive down the actual price paid by U S  insurance companies substantially  However  similar confidential discounts are also offered to big European buyers such as Britain s National Health Service   The U S  has a competitive marketplace that works to control costs while encouraging the development of new treatments and cures   Holly Campbell  PhRMA s director of communications  said in a statement  PhRMA also argues that while Americans may pay more for drugs when they first come out  they pay less as drugs get older  since nearly 90 percent of all medicines prescribed to U S  patients are now cheap generics  In Britain  generics account for just over three quarters of prescriptions and that level is lower in other parts of Europe  Still  the United States is slower to see the arrival of generic competition to some top selling drugs  which explains some of the differences in pricing for certain medicines on the top 20 list  Overall  the analysis found that price differentials were slightly smaller for complex antibody based drugs  which are used to treat conditions like cancer and rheumatoid arthritis   Many of the biggest differences were evident for older drugs  reflecting the fact that prices are typically hiked each year in the United States  said University of Liverpool drug pricing expert Andrew Hill   It shows the U S  drug pricing situation isn t just a matter of isolated cases like Turing Pharmaceuticals   he said  The latest furor over U S  drug costs was prompted by the decision by unlisted Turing to hike the cost of an old drug against a parasitic infection to  750 a pill from  13 50  It has since promised to roll back the increase  The same medicine is sold in Britain by GlaxoSmithKline  L GSK  for 43 pence  66 cents   
 Transatlantic drug price divide graphic  ",2015-10-12,Reuters,https://www.investing.com/news/stock-market-news/exclusive---transatlantic-divide:-how-u.s.-pays-three-times-more-for-drugs-365696,365696
203359,424875,MRK,E therapeutics  A Matter Of Time Until Prime Time ,opinion,"With the refocusing of the business and the new CEO s strategic review now implemented  E Therapeutics Plc  LON ETXP  finds itself with the NDD platform and at least two lead preclinical small molecule immuno oncology  I O  assets at a time when big pharma partners are clamouring for those assets  This is because Merck  NYSE MRK  and BMS s marketed anti PD 1 antibodies need synergistic mechanisms to broaden and extend the number and duration of their responses  ETX s first partnership announcement will be a value inflection point 

FY18 results demonstrate prudent stewardship
Last year s focus on ETX s costs demonstrated the company s commitment to containing costs  The operating loss in H218 was 16  below the first half s  3 7m  As impressive was the 58  reduction  to  6 8m  in the full year operating loss over FY17 while at the same time preparing two network driven drug discovery  NDD  assets for licensing  Cash at the year end to 31 January 2018 was  9 6m and  outside of business development activities  options are available to extend the cash runway into 2020  Our model now includes slight changes to correct our previous estimates of R D expense and share based transactions to the reported values 
To read the entire report Please click on the PDF File Below ",2018-04-23,Edison,https://www.investing.com/analysis/etherapeutics-a-matter-of-time-until-prime-time-200307781,200307781
203368,424884,MRK,Beating parasites wins three scientists Nobel prize for medicine,news,"By Simon Johnson and Ben Hirschler STOCKHOLM LONDON  Reuters    Three scientists from Japan  China and Ireland whose discoveries led to the development of potent new drugs against parasitic diseases including malaria and elephantiasis won the Nobel Prize for Medicine on Monday  Irish born William Campbell and Japan s Satoshi Omura won half of the prize for discovering avermectin  a derivative of which has been used to treat hundreds of millions of people with river blindness and lymphatic filariasis  or elephantiasis  China s Tu Youyou was awarded the other half of the prize for discovering artemisinin  a drug that has slashed malaria deaths and has become the mainstay of fighting the mosquito borne disease  She is China s first Nobel laureate in medicine  Some 3 4 billion people  most of them living in poor countries  are at risk of contracting the three parasitic diseases    These two discoveries have provided humankind with powerful new means to combat these debilitating diseases that affect hundreds of millions of people annually   the Nobel Assembly at Sweden s Karolinska Institute said   The consequences in terms of improved human health and reduced suffering are immeasurable   Today  the medicine ivermectin  a derivative of avermectin made by Merck  NYSE MRK    Co  is used worldwide to fight roundworm parasites  while artemisinin based drugs from firms including Novartis and Sanofi  PARIS SASY  are the main weapons against malaria  Omura and Campbell made their breakthrough in fighting parasitic worms  or helminths  after studying compounds from soil bacteria  That led to the discovery of avermectin  which was then further modified into ivermectin  The treatment is so successful that river blindness and lymphatic filariasis are now on the verge of being eradicated  Omura  80  said the real credit for the achievement should go to the ingenuity of the Streptomyces bacteria  whose naturally occurring chemicals were so effective at killing off parasites   I really wonder if I deserve this   he said after learning he had won the prize   I have done all my work depending on microbes and learning from them  so I think the microbes might almost deserve it more than I do   Omura is professor emeritus at Kitasato University in Japan  while Campbell is research fellow emeritus at Drew University in Madison  New Jersey   This was the work of a team of researchers so it is by no means my work  it s our work   said Campbell  85  who learned of his prize in a pre dawn phone call from Reuters that woke him at his home in North Andover  Massachusetts    In the first decade  there were 70 authors that I co authored papers with  That gives you some idea of the number of people involved   he said  TRADITIONAL CHINESE MEDICINE Tu  meanwhile  turned to a traditional Chinese herbal medicine in her hunt for a better malaria treatment  following the declining success of the older drugs chloroquine and quinine  She found that an extract from the plant Artemisia annua was sometimes effective but the results were inconsistent  so she went back to ancient literature  including a recipe from AD 350  in the search for clues  This eventually led to the isolation of artemisinin  a new class of anti malaria drug  which was available in China before it reached the West  Tu  84  has worked at the China Academy of Traditional Chinese Medicine since 1965  World Health Organization spokesman Gregory Hartl said the award of a Nobel prize for the discovery was a great tribute to the contribution of Chinese science in fighting malaria   We now have drugs that kill these parasites very early in their life cycle   said Juleen Zierath  chair of the Nobel Committee   They not only kill these parasites but they stop these infections from spreading    Death rates from malaria have plunged 60 percent in the past 15 years  although the disease still kills around half a million people a year  the vast majority of them babies and young children in the poorest parts of Africa  The 8 million Swedish crowns   960 000  medicine prize is the first of the Nobel prizes awarded each year  Prizes for achievements in science  literature and peace were first awarded in 1901 in accordance with the will of dynamite inventor and businessman Alfred Nobel  
Last year  the medicine prize went to three scientists who discovered the brain s inner navigation system ",2015-10-05,Reuters,"https://www.investing.com/news/general-news/japanese,-chinese,-irish-scientists-win-2015-nobel-medicine-prize-364609",364609
203369,424885,MRK,Nobel discoveries on DNA repair now fueling cancer drug research,news,"By Julie Steenhuysen CHICAGO  Reuters    Cancer researchers are just beginning to understand the ramifications of the fundamental discoveries behind the 2015 Nobel Prizes in Chemistry  which were awarded on Wednesday to three scientists for explaining how cells repair mistakes in DNA that occur when cells divide  When deoxyribonucleic acid  DNA  repair mechanisms fail  they predispose people to cancer  That is especially true of individuals with mismatch repair defects  a mechanism discovered by Paul Modrich of Duke University and the Howard Hughes Medical Institute  Modrich  Tomas Lindahl and Aziz Sancar won the prize for  mechanistic studies of DNA repair   Their work mapped how cells repair DNA to prevent damaging errors from appearing in genetic information  Subsequent work by Dr  Bert Vogelstein of the Johns Hopkins Kimmel Cancer Center and Richard Kolodner  then at Harvard Medical School and currently at the University of California  San Diego  showed mismatch repair defects are the chief cause of the most common inherited form of colorectal cancer  affecting 15 percent of colon cancer patients  These defects may now help predict which patients are most likely to benefit from immunotherapies  promising new drugs that enlist the immune system to fight cancers  A small study published earlier this year in the New England Journal of Medicine showed that 92 percent of patients with advanced colon and rectal cancers who had mismatch repair defects responded to Merck  NYSE MRK    Co s immunotherapy drug Keytruda  That compared to a response of 16 percent in patients with the same cancers who did not carry the defect  The findings could also be applicable to patients with other cancers who have the same DNA repair defects  and possibly to those with defects in other DNA repair mechanisms as well  Vogelstein said   Mismatch repair defects are found not only in hereditary colorectal cancers  They are found in about 2 percent of cancer patients overall   he said in a telephone interview  Vogelstein also said mismatch repair is a marker for response to anti PD 1 inhibitor drugs such as Keytruda because patients with mismatch repair defects have tumors teeming with mutations   far more than cancer patients with functioning DNA repair genes  Since the immune system is trained to recognize foreign invaders  Hopkins researchers believe immune boosting drugs such as Keytruda or Bristol Myers Squibb s Opdivo  will perform better in mutation loaded tumors   So far  the findings  while strong  are preliminary  Vogelstein said if this same strategy extends to other cancer types   it could provide a very useful therapy for as many as one in 50 patients with cancer worldwide   Dr  Roger Perlmutter  president of Merck Research Laboratories  said  every company that s interested in making drugs that enhance the ability of the immune system to recognize cancer is interested  in exploring DNA repair mechanisms   In colorectal cancer  it s unambiguous  Administration of Keytruda is much  much more effective in those people who have DNA repair mutations   he said  The company is conducting a larger clinical trial in hopes getting FDA approval for the drug in colorectal cancers  Keytruda is already approved in melanoma  and in some forms of advanced lung cancer  Other drugs targeting DNA repair defects include AstraZeneca s Lynparza  a so called PARP inhibitor approved for women with advanced ovarian cancer associated with defective BRCA genes  The drug kills cancer cells by exploiting defects in a tumor DNA repair pathway  In a blog post earlier this year  Dr  Francis Collins  director of the National Institutes of Health  noted that most of the original work on DNA repair mechanisms was done in bacteria   with no expectation of medical relevance   
Vogelstein said the latest findings in cancer immunotherapies are  a beautiful demonstration of how basic science can have practical value which no one could have seen in the beginning  ",2015-10-07,Reuters,https://www.investing.com/news/general-news/nobel-discoveries-on-dna-repair-now-fueling-cancer-drug-research-365132,365132
203370,424886,MRK,Bristol Myers  Opdivo Gets Priority Review For Lung Cancer,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application  sBLA  for the label expansion of Opdivo  nivolumab  to treat patients with small cell lung cancer   SCLC   whose disease has progressed after two or more prior lines of therapy  The FDA set an action date of Aug 16  2018 
The submission was based on safety and efficacy data from the SCLC cohort of the phase I II CheckMate 032 trial evaluating Opdivo monotherapy or Opdivo plus Yervoy  ipilimumab  in advanced or metastatic solid tumors  including SCLC  The primary goal was to ascertain the objective response rate as assessed by a blinded independent central review  Secondary objectives included safety  overall survival  progression free survival and duration of response 
Shares of the company have declined 0 5  over a year  underperforming the  s gain of 11 2  

 
We note that  Opdivo  became the first PD 1 immune checkpoint inhibitor to gain regulatory approval in July 2014  It is currently approved in several countries including the United States  the EU and Japan for several cancer indications  Opdivo became the first PD 1 inhibitor to be approved for a hematological malignancy   classical Hodgkin lymphoma in both the United States  May 2016  and the EU  November 2016  
In November 2016  Opdivo gained FDA approval for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy  Opdivo continues to be launched globally on approvals and label expansions  The drug has been performing impressively due to demand resulting from the rapid commercial acceptance for several indications including melanoma  renal cell carcinoma  and second line NSCLC  The FDA also approved Opdivo for intravenous use for patients with hepatocellular carcinoma   HCC   who have been previously treated with Nexavar and Opdivo has rapidly penetrated the second line HCC market 
Label expansion into additional indications would give the product access to a higher patient population and increase the commercial potential of the drug significantly 
However  Opdivo faces stiff competition from Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq Bristol Myers Squibb Company Price

   Zacks Rank   Another Stock to Consider
Bristol Myers carries a Zacks Rank  3  Hold  
Another top ranked stocks from the same space worth considering is Ligand Pharmaceuticals   NASDAQ LGND   sporting a Zacks Rank  1  Strong Buy   You can see  
Ligand s earnings per share estimates have moved up  3 78 to  4 40 from  4 75 to  5 32 for 2018 and 2019  respectively  over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 62 1  over a year 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivo-gets-priority-review-for-lung-cancer-200307079,200307079
203378,424894,MRK,U S  stocks close lower  as Dow ends August down more than 1 000 points,news,"Investing com    U S  stocks fell broadly capping a volatile month of trading in August  as heightened concerns of a September interest rate hike by the Federal Reserve offset a sharp rally in crude prices amid further indications of declining production 
Following a roller coaster  topsy turvy week of trading last week  the Dow Jones Industrial Average fell substantially on Monday to close August down more than 1 000 points  It marked the worst month for the Dow in more than five years since May  2010  The NASDAQ Composite index and the S P 500 Composite index also dropped considerably on Monday to end a disappointing month in which both plunged by more than 6   The S P 500 suffered its worst month since May  2012  when it plummeted by 6 3   After setting an all time high in May  the S P 500 has lost nearly 13  in value  
The Dow fell 114 98 or 0 69  on Monday to close at 16 528 03  while the NASDAQ lost 51 82 or 1 07  to end the month at 4 776 51  The S P 500  meanwhile  dipped 16 69 or 0 84  to 1 972 18  as nine of 10 sectors closed in the red  Stocks in the Utilities and Health Care industries lagged  each losing more than 1 5   while energy stocks led after gaining more than 1  
Shares in PSX rose by more than 2 35  during Monday s session after Warren Buffett s company Berkshire Hathaway  NYSE BRKa  disclosed a  4 48 billion stake in the oil refinery  TWTR shares also gained more than 3 5  to 27 78  after analysts from SunTrust Robinson raised its rating in the social media network from a neutral rating to a buy 

The top performer on the Dow was CVX  which gained 0 56 or 0 70  to 80 99 on Monday  Only six of the 30 components on the Dow closed in the green  The worst performer was MRK  after a study on its Type 2 Diabetes drug indicated that it did not reduce hospitalization rates in relation to major cardiovascular events at a significantly higher percentage in comparison with its placebo  Shares in Merck  NYSE MRK  fell 1 52 or 2 75  to 53 85 at Monday s close 
The biggest gainer on the NASDAQ was GMCR  which surged 2 49 or 4 60  to 56 60  Shares in Keurig Green Mountain  NASDAQ GMCR   one of the world s largest coffee makers  are still down approximately 60  on the year  The worst performer was VRTX  which fell 6 53 or 4 87  to 127 52 
The top performer on the S P 500 was CNX  which rose 0 84 or 5 84  to 15 50 during Monday s session  U S  crude futures jumped more than 8  on Monday  after the U S  Energy Information  EIA  lowered its crude production estimates for June and OPEC said it will consider meeting with producers to discuss the prolonged downturn in crude oil prices  Over the last three days  WTI crude futures have soared by more than 25  after falling to fresh six and a half year lows last week  VRTX was also the worst performer on the S P 500  just below CELG which fell 5 96 or 4 80  to 118 08  after receiving a downgrade from analysts at Morningstar 
On the New York Stock Exchange  declining issues outnumbered advancing ones by a 1 763 to 1 370 margin ",2015-08-31,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-close-lower,-as-dow-ends-august-down-more-than-1,000-points-359394",359394
203379,424895,MRK,Scientists turn to aspirin to turbo charge cancer immunotherapy,news,By Ben Hirschler LONDON  Reuters    Giving cheap aspirin to cancer patients may turbo charge the effectiveness of expensive new medicines that help their immune systems fight tumors  experiments on mice suggest  Immunotherapy promises to revolutionize cancer care by offering a better  longer lasting response with fewer adverse side effects than conventional treatment  but the new drugs do not work well in all cases  One reason is that cancer cells often produce large amounts of the molecule prostaglandin E2  PGE2   which turns down the immune system s normal attack response to tumor cells  according to scientists at London s new Francis Crick Institute  Aspirin blocks PGE2 production and the researchers found that adding it to an immunotherapy treatment called anti PD 1 substantially slowed the growth of bowel and melanoma cancers in mice when compared with treatment by immunotherapy alone  There is already some evidence that the findings in mice will apply to human tissue but there is still a long way to go before this is proven  Still  the research adds to aspirin s reputation as a  wonder drug   First synthesized by a chemist at Bayer more than a century ago  the medicine is already used to prevent heart attacks and has previously been reported to reduce the risk of bowel and other cancers  Caetano Reis e Sousa  senior group leader at the London institute  hopes that adding aspirin or other so called COX inhibitor drugs will one day make a big difference to the benefits the patients get from immunotherapy   What we would like to do next is set up a clinical trial   he told Reuters   We will need to persuade a company to sponsor that and we have had some preliminary conversations    Merck  NYSE MRK  and Bristol Myers Squibb both have recently approved anti PD 1 drugs  while competing anti PD L1 medicines are in development at rival companies including Roche and AstraZeneca  In the experiments on mice  details of which were published in the journal Cell on Thursday  researchers used a mouse specific anti PD 1  but Reis e Sousa said he expected the aspirin effect to be similar with human medicines blocking PD 1  PD L1 and another class of drugs targeting CTLA 4  With future immunotherapy use widely expected to involve multi drug combinations  adding aspirin to the mix would be one way to help keep a lid on soaring costs ,2015-09-03,Reuters,https://www.investing.com/news/general-news/scientists-turn-to-aspirin-to-turbo-charge-cancer-immunotherapy-359982,359982
203380,424896,MRK,NewLink Shares Plunge After Incyte   Merck s Study Fails,opinion,"Shares of NewLink Genetics Corp    NASDAQ NLNK   plunged about 43  after it announced that it conducting a review of studies evaluating its IDO pathway inhibitor  indoximod in combination with anti PD 1 PD L1 agents in several cancer indications including melanoma  Shares of the company have also declined 77  over a year compared with the  s decline of 11 5  

 
NewLink s decision came in response to the Incyte Corp  s   NASDAQ INCY    and partner Merck   NYSE MRK   announcement of the failure of a key melanoma combination study on Friday Incyte and Merck said that a combination of Incyte s epacadostat and Merck s Keutruda failed in achieving improved progression free survival over Keytruda alone in phase III study ECHO 301 KEYNOTE 252  The study was evaluating the combination drugs for the treatment unresectable or metastatic melanoma 
An external data monitoring committee recommended the termination of the study following the review of the data from the pivotal study 
Data from the phase III study demonstrated that a combination of IDO1 inhibitor and PD 1 antagonists may not hold potential in treatment of melanoma which obviously raised doubts over the potential success of indoximod combination studies with anti PD 1 PD L1 agent 
Newlink will provide an update when the review is complete  Newlinkclaims that indoximod has a differentiated mechanism of action  MOA  and it has demonstrated that it can improve the outcomes for patients with cancer in combination studies 
The results of the ECHO 301 study also affected several companies like Bristol Myers Squibb s   NYSE BMY   which are developing combination immunotherapies for the treatment of cancer NewLink Genetics Corporation Price

   Zacks Rank NewLink carries a Zacks Rank  3  Hold   You can see  
Zacks Editor in Chief Goes  All In  on This Stock 
Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2018-04-09,Zacks Investment Research,https://www.investing.com/analysis/newlink-shares-plunge-after-incyte--mercks-study-fails-200304196,200304196
203381,424897,MRK,Pfizer s Kidney Cancer Drug Misses Endpoint In Phase III,opinion,Pfizer Inc    NYSE PFE   announced that a late stage study on its kidney cancer drug Inlyta  axitinib  failed to demonstrate a clear improvement in the primary endpoint of extending disease free survival  DFS   Accordingly  an independent Data Monitoring Committee recommended the study be stopped at a planned interim analysis  Detailed data from the study will be presented at a future medical meeting The phase III ATLAS study was evaluating Inlyta versus placebo as an adjuvant therapy for patients with high risk of recurrent renal cell carcinoma  RCC   a type of kidney cancer  following surgical removal of one or both kidneys Shares of Pfizer have risen 0 2  so far this year  comparing favorably with a 2 3  decrease for the  Inlyta is presently marketed for the second line treatment of patients with advanced RCC  If the ATLAS study was successful  then Inlyta would be able to cater to an expanded patient population   kidney cancer patients who are in the earlier stage of this disease Inlyta generated sales of  339 million in 2017  a decline of 15  from 2016 Meanwhile  Inlyta is being evaluated in two independent global phase III studies in combination with Merck s   NYSE MRK   PD L1 inhibitor Keytruda and its own PD L1 inhibitor Bavencio  avelumab   respectively   each compared with Sutent in first line advanced RCC  These studies continue to be unmodified Bavencio is currently approved in metastatic MCC  a rare and aggressive skin cancer  in the United States  Europe and Japan and for the second line treatment of locally advanced or metastatic urothelial carcinoma  accelerated approval  in the United States Pfizer has developed Bavencio in partnership with the German company  Merck KGaA   Meanwhile  avelumab is being developed for different types of cancer  The avelumab PD L1 program has several studies ongoing  both as monotherapy and in combination with other portfolio assets Zacks Rank   Key PickPfizer carries a Zacks Rank  2  Buy  You can see  Another top ranked large cap pharma stock is GlaxoSmithKline   NYSE GSK   with the same Zacks Rank as Pfizer Shares of Glaxo have returned 17 5  this year so far  Estimates for 2018 and 2019 have increased by 3 9  and 4 8   respectively  over the past 60 days 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenues and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/pfizers-kidney-cancer-drug-misses-endpoint-in-phase-iii-200304787,200304787
203382,424898,MRK,Bionomics  Novel Mechanisms In Drug Discovery  ,opinion,"We are re initiating coverage on Bionomics Ltd  AX BNO   a pharmaceutical company developing drugs for neuropsychiatric indications and oncology  It has leveraged its ionX and MultiCore development platforms to identify BNC210  a drug with a novel anxiolytic mechanism currently in Phase IIb for post traumatic stress disorder  PTSD   It has also leveraged this platform with partner Merck  NYSE MRK  to target cognitive dysfunction associated with Alzheimer s disease  in a deal worth US 506m in milestones plus royalties  We re initiate with a valuation of A 418 7m or A 0 87 per share 

Finding new targets to reduce anxiety
BNC210 is a negative allosteric modulator of the  7 nicotinic acetylcholine receptor  a protein in the brain implicated in the response to stress that has been previously unexplored for its therapeutic potential  In earlier exploratory studies the compound supressed activation of regions of the brain associated with anxiety and reduced the intensity of panic  suggesting a novel anxiolytic activity  It is currently being investigated for PTSD in a Phase IIb study expected to have data in H218 
To read the entire report Please click on the pdf File Below ",2018-04-11,Edison,https://www.investing.com/analysis/bionomics-novel-mechanisms-in-drug-discovery-200304559,200304559
203383,424899,MRK,Nektar Starts Phase I II Combo For Advanced Solid Tumors,opinion,Nektar Therapeutics   NASDAQ NKTR   has announced initiation of dosing in a phase I II study  evaluating the combination of its two novel immuno oncology agents  NKTR 262 and NKTR 214  on patients with advanced solid tumors While NKTR 262 is a toll like receptor agonist designed to invite an innate immune response to fight the cancer  NKTR 214 is an immuno stimulatory CD122 biased agonist Shares of Nektar have soared 72 1  so far this year  substantially outperforming the  s decrease of 2 2   The phase I II REVEAL study is an open label  multicenter dose escalation program  designed to evaluate the NKTR 262 NKTR 214 combination regimen  administered as an initial intratumoral  directly into the tumor  injection of NKTR 262 followed by an intravenous  IV  infusion of NKTR 214  The company believes that this combination therapy will enable it to provide an alternative treatment option to its patients Moreover  the company also plans to assess this NKTR 262 NKTR 214 combination with Bristol Myers    NYSE BMY   Opdivo  nivolumab  in the given patient population We remind investors that in September 2016  Nektar entered into a clinical collaboration agreement with Bristol Myers under which  Nektar s NKTR 214 will be examined in combination with the latter s Opdivo across nine tumor types including melanoma  kidney  colorectal  bladder and non small cell lung cancer plus 20 potential indications in phase I II trials Meanwhile  in September 2017  the company announced initiation of phase I II PROPEL study to evaluate the efficacy and safety of NKTR 214 in combination with Roche s   OTC RHHBY   Tecentriq  atezolizumab  and Merck s   NYSE MRK   Keytruda  pembrolizumab  It is also important to note that Nektar is developing several other candidates across important therapeutic areas including oncology  pain  anti infectives and immunology aong others  The company has made a significant progress with its lead candidate Onzeald  formerly known as NKTR 102   currently under accelerated assessment in the EU for treating adults with advanced breast cancer as well as brain metastases  A response is anticipated within the first half of 2018 A couple of other interesting candidates is NKTR 181 and NKTR 358  While NKTR 181 is being analyzed in a phase III program for treatment of chronic pain  the company initiated a phase I clinical study on NKTR 358 to treat a wide range of auto immune diseases and inflammatory disorders Nektar Therapeutics Price    Zacks RankNektar carries a Zacks Rank  4  Sell  You can see Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-11,Zacks Investment Research,https://www.investing.com/analysis/nektar-starts-phase-iii-combo-for-advanced-solid-tumors-200305177,200305177
203384,424900,MRK,Pharma Stock Roundup  NVS To Buy AveXis  PFE   ABBV s Drugs Succeed In Phase III,opinion,"The last week has been an eventful one for pharma stocks with Novartis   NYSE NVS   announcing that it is acquiring gene therapy company AveXis while Merck   NYSE MRK   and AbbVie   NYSE ABBV   announced successful study results  In other news  Pfizer s   NYSE PFE   kidney cancer drug  Inlyta missed primary endpoint in a phase III study 
Recap of the Week s Most Important Stories
Novartis to Buy AveXis for  8 7 Billion  The big news early in the week was Novartis   8 7 billion deal to buy AveXis whose lead product candidate AVXS 101 is a one time gene replacement therapy for spinal muscular atrophy  SMA   A regulatory filing for AVXS 101 in the United States is expected in the second half of this year  AVXS 101 has the potential to generate millions of dollars for Novartis  if approved  The company agreed to pay  218 for each share of AveXis  representing a whooping premium of 88  to AveXis  closing price on Friday 
With boards of both the companies having approved the deal  the buyout is anticipated to close in the second half of the year   Read More   
Merck s Keytruda Succeeds in Another Key Lung Cancer Study  A pivotal lung cancer study  KEYNOTE 042  on Merck s blockbuster PD 1 inhibitor  Keytruda met the primary endpoint  The KEYNOTE 042 study evaluated patients with locally advanced or metastatic nonsquamous or squamous non small cell lung cancer  NSCLC  whose tumors express PD L1 protein levels of 1 percent or greater   TPS of  1 percent   In such patients  Keytruda showed a significant survival benefit compared with platinum based chemotherapy 
Notably  Keytruda monotherapy is already marketed for the first line treatment of patients with metastatic NSCLC whose tumors express PD L1 protein levels of 50 percent or greater  TPS of  50 percent  
If the OS data from KEYNOTE 042 study are approved to be included in Keytruda s label  the drug can be prescribed to treat an expanded lung cancer patient population  further reinforcing its position in the lung cancer market   Read More   
AbbVie s 4th Late Stage Upadacitinib Study Succeeds  AbbVie s oral JAK 1 selective inhibitor  upadacitinib  met all primary as well as secondary endpoints in the 4th phase III study from its SELECT program  The phase III study  SELECT COMPARE  evaluated the candidate for moderate to severe rheumatoid arthritis in patients who are on a stable background of methotrexate and elicited an inadequate response 
After 12 weeks of treatment  the ACR20 response   the first primary endpoint   was achieved in 71  of the patients receiving the 15 mg dose of upadacitinib versus 36  for placebo  The second primary endpoint of clinical remission was achieved by 29  of the patients in the upadacitinib arm versus only 6  in the placebo arm   Read More   
Meanwhile  the FDA has extended the review period for AbbVie s pipeline candidate elagolix by three months  The FDA s decision  previously expected in the second quarter  will now come in the third quarter   Read More   
Pfizer s Inlyta Misses Primary Endpoint in Phase III Study  Pfizer s kidney cancer drug Inlyta  axitinib  failed to demonstrate a clear improvement in the primary endpoint of extending disease free survival  DFS  compared with placebo in the phase III ATLAS study  Accordingly  an independent Data Monitoring Committee recommended the study be stopped at a planned interim analysis   Read More   
Pfizer also announced initiation of dosing in an early stage study evaluating its mini dystrophin gene therapy candidate  PF 06939926  for the treatment of boys with Duchenne muscular dystrophy  DMD   the most common type of muscular dystrophy  Early data from the study is expected in the first half of 2019 
Pacira s Exparel Gets FDA Nod for Expanded Label  Pacira Pharmaceuticals  Inc  s   NASDAQ PCRX   supplemental new drug application  sNDA  for label expansion of Exparel in the nerve block setting for patients undergoing upper extremity surgeries got the FDA nod  The FDA s approval came as a surprise after an FDA Committee voted six to four against approval of the expanded indication in February   Read More   
Exparel generated sales of  282 9 million in 2017  representing an increase of 6  from 2016  With the latest label expansion  sales are expected to go up 
Glaxo to Divest Rare Disease Gene Therapy Drugs to Private Biotech  Glaxo   NYSE GSK   is divesting its rare disease gene therapy portfolio to private biotech Orchard Therapeutics in exchange for a 19 9  stake in the company as well as a seat on its board  The divesture is part of the strategic review that Glaxo announced in July last year to divest some preclinical clinical programs and allocate 80  of capital to priority programs in two current areas  Respiratory and HIV infectious  and two potential areas  Oncology and Immuno inflammation   Read More   
The NYSE ARCA Pharmaceutical Index rose 0 7  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 


 Here is how the seven major stocks performed in the last five trading sessions 

All stocks recorded a gain except Bristol Myers   NYSE BMY   and J J  Merck and AstraZeneca were the biggest gainers rising 4 0  and 2 8   respectively while Bristol Myers declined 5 6  
In the last six months  AstraZeneca has been the biggest gainer  7 8    while Merck declined the most  8 9   
 See the last pharma stock roundup here  Pharma Stock Roundup  
What s Next in the Pharma World 
Watch out for J J s and Novartis  first quarter 2018 earnings results and other pipeline and regulatory updates 
Will You Make a Fortune on the Shift to Electric Cars
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-04-13,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-nvs-to-buy-avexis-pfe--abbvs-drugs-succeed-in-phase-iii-200305499,200305499
203393,424909,MRK,Vaccine success holds hope for end to deadly scourge of Ebola,news,"By Kate Kelland and Tom Miles LONDON GENEVA  Reuters    The world is on the verge of being able to protect humans against Ebola  the World Health Organization said on Friday  as a trial in Guinea found a vaccine to have been 100 percent effective      Initial results from the trial  which tested Merck  N MRK  and  NewLink Genetics    O NLNK  VSV ZEBOV vaccine on some 4 000 people who had been in close contact with a confirmed Ebola case  showed complete protection after 10 days       The results were described as  remarkable  and  game changing  by global health specialists       We believe that the world is on the verge of an efficacious Ebola vaccine   WHO vaccine expert Marie Paule Kieny told reporters in a briefing from Geneva      The vaccine could now be used to help end the worst recorded outbreak of Ebola  which has killed more than 11 200 people in West Africa since it began in December 2013      WHO Director General Margaret Chan said the results  published online in the medical journal The Lancet  would  change the management of the current Ebola outbreak and future outbreaks   The Gavi Alliance  which buys vaccines in bulk for poor countries who struggle to afford them  immediately said it would back an Ebola shot once it is approved   These communities need an effective vaccine sooner rather than later   Gavi s chief executive Seth Berkley said   We need to be ready to act wherever the virus is a threat       This and other vaccine trials were fast tracked with huge international effort as researchers raced to test potential therapies and vaccines while the virus was still circulating       It was a race against time and the trial had to be implemented under the most challenging circumstances   said John Arne R ttingen of Norway s Institute of Public Health  chair of the trial s steering group            RING VACCINATION  The Guinea trial began on March 23 to evaluate the effectiveness and safety of a single dose of VSV ZEBOV using a so called  ring vaccination  strategy  where close contacts of a person diagnosed with Ebola are immunized   either immediately  or at a later date       As data began to emerge showing the very high protection rates in those vaccinated immediately  however  researchers decided on July 26 that they would no longer use the  delayed  strategy  since it was becoming clear that making people wait involved unethical and unnecessary risk      The trial is now being continued  with all participants receiving the vaccine immediately  and will be extended to include 13  to 17 year olds and possibly also 6  to 12 year old children  the WHO said      Jeremy Farrar  a leading infectious disease specialist and director of the Wellcome Trust  said the trial  dared to use a highly innovative and pragmatic design  which allowed the team in Guinea to assess this vaccine in the middle of an epidemic    Our hope is that this vaccine will now help bring this epidemic to an end and be available for the inevitable future Ebola epidemics   his statement said      The medical charity Doctors without Borders  MSF   which has led the fight against Ebola in West Africa  called for VSV ZEBOV to be rolled out to the other centers of the outbreak  Liberia and Sierra Leone  where it says it could break chains of transmission and protect front line health workers  VSV ZEBOV was originally developed by Canada s public health agency before being licensed to NewLink Genetics  which then signed a deal handing Merck the responsibility to research  develop  manufacture and distribute it  The success of the Guinea trial is a big relief for researchers  many of whom feared a sharp decline in cases this year would scupper their hopes of proving a vaccine could work  
    Another major trial in Liberia  which had aimed to recruit some 28 000 subjects  had to stop enrolling after only reaching its mid stage target of 1 500 participants  Plans for testing in Sierra Leone were also scaled back  That left the study in Guinea  where Ebola is still infecting new victims  as the only real hope for demonstrating the efficacy of a vaccine ",2015-07-31,Reuters,https://www.investing.com/news/stock-market-news/vaccine-success-holds-hope-for-end-to-deadly-scourge-of-ebola-353852,353852
203394,424910,MRK,Sanofi Inks Immuno Oncology Deal,news,"By   

Pharmaceutical giant Sanofi  PARIS SASY  is partnering with two biotech companies    Evotec AG in Hamburg  Germany and Apeiron Biologics AG in Vienna  Austria   in its latest effort to develop a drug that will harness the body s own immune system in the fight against cancer  The focus of the new collaboration will be on a first in class treatment that takes aim at tumors and cancers of the blood by boosting the function of white blood cells known as lymphocytes 
This strategy  known as immuno oncology  turns the body s own immune system against cancer cells and represents an emerging area of drug development  Already  major pharmaceutical companies including Merck  NYSE MRK   Roche and Bristol Myers Squibb have devoted hundreds of millions of dollars to the idea and launched several treatments known as PD 1 inhibitors that work in this manner  Others  such as Sanofi  are eager to get in the game 
 Immuno oncology has emerged as a particularly promising field to create potentially curative treatment options for many cancer patients   Victoria Richon  a vice president and head of cancer research for Sanofi  said in a statement   Our partnership with experts at Evotec and Apeiron Biologics will help us take the next step toward realizing the full value of these innovative treatments  
As part of the new agreement  Sanofi will pay the two biotech companies up to 200 million euros  or  219 million  each over two years to research  develop and commercialize treatments  plus additional royalties once these drugs hit the market 
The announcement comes on the heels of Sanofi s  2 billion deal with Regeneron Pharmaceuticals Inc  NASDAQ REGN   that pays Regeneron to develop an immuno oncology treatment that is already in its pipeline  In that deal  the companies will split the profits of any drugs that debut from the collaboration ",2015-08-10,International Business Times,https://www.investing.com/news/stock-market-news/sanofi-inks-immuno-oncology-deal-355301,355301
203395,424911,MRK,Roche buys  superbug  diagnostics firm for up to  425 million ,news, Reuters    Roche  VX ROG  is buying U S  diagnostics firm GeneWEAVE BioSciences for up to  425 million  expanding the Swiss group s commitment to fighting so called  superbugs  as the threat from drug resistant microbes grows  Roche said on Thursday it would pay shareholders in the privately held Californian company  190 million upfront and up to a further  235 million depending on the future success of its products  The deal gives Roche access to GeneWEAVE s  Smarticles  technology  which allows for the rapid identification of multi drug resistant organisms direct from clinical samples  without the need for traditional preparation processes  Better testing is seen as central to fighting drug resistant bacteria  It should allow doctors to make faster and more accurate diagnoses and give patients the appropriate drug to kill their particular infection  Many antibiotics used today are broad spectrum products  which can kill a wide range of bugs but are also responsible for breeding resistance because they damage gut flora  creating an environment for new infections to flourish   Roche has been building up its presence in antibacterial research since buying Switzerland s Polyphor  a developer of new medicines for resistant bacteria  in November 2013  Although Roche pioneered some of the more modern antibiotics  like many large drugmakers it wound down its research at the end of the 1990s  given the poor returns in the field compared to other therapy areas such as cancer  Several large pharmaceutical companies are looking again at antibiotics  given increased emphasis by governments on the resistance problem  with Merck  N MRK  agreeing a major deal to buy Cubist for more than  8 billion in December 2014 ,2015-08-13,Reuters,https://www.investing.com/news/stock-market-news/roche-buys-'superbug'-diagnostics-firm-for-up-to-$425-million-355790,355790
203397,424913,MRK,Immutep  Merck Collaboration Opens New Opportunities ,opinion,"Immutep Ltd ADR  NASDAQ IMMP  has entered a clinical trial collaboration and supply agreement with Merk   Co  MSD  for a Phase II study to evaluate eftilagimod alpha  IMP321  plus Keytruda in lung  head and neck and ovarian cancers  It is positive to see Immutep collaborating with a leading immunotherapy company  with three new indications added to its ongoing studies in breast cancer and melanoma  It has raised A 6 9m through a placement and has opened a share purchase plan to raise up to A 10m  We increase our valuation to A 439m  vs A 272m  or A 0 14 share  vs A 0 12 share  

Phase II in collaboration with Merck  NYSE MRK  to begin H218
Immutep and Merck will collaborate in the TACTI 002 Phase II study of IMP321 plus Keytruda in up to 120 patients with non small cell lung cancer  NSCLC   head and neck cancer or ovarian cancer  In clinical studies IMP321 has been shown to stimulate the immune system and turn  cold  tumours  hot   There is good potential for response rates in these three cancers to be increased by combining the immune activation activity of IMP321 with an immune checkpoint inhibitor such as Keytruda  particularly in patients with low levels of PDL1 expression in tumours 
To read the entire report Please click on the pdf File Below ",2018-03-29,Edison,https://www.investing.com/analysis/immutep-merck-collaboration-opens-new-opportunities-200301733,200301733
203398,424914,MRK,Aeglea Initiates Lung Cancer Combination Study With Keytruda,opinion,"Aeglea BioTherapeutics  Inc    NASDAQ AGLE   announced that it has initiated dosing of patients in two studies evaluating its lung cancer candidate  pegzilarginase  in small cell lung cancer   SCLC   A cohort expansion phase I study is evaluating pegzilarginase as monotherapy in SCLC patients  The other one is phase I II study evaluating the candidate in combination with Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  in a similar indication Top line data from the studies are expected in the fourth quarter of 2018 Aeglea s shares have risen 77 8  so far this year  against the  s loss of 4 9  during the period The SCLC expansion cohort is one of the three arms of the phase I study  which is evaluating pegzilarginase in cancer tumors that stop producing a certain amino acid  arginine  Depletion in arginine levels in the tumors causes cell death and promotes anti tumor immune responses The phase I II study is evaluating combination of pegzilarginase and Keytruda for overall response rate in patients with extensive disease SCLC whose disease has relapsed or progressed after receiving platinum based chemotherapy Per the press release  only 6  of SCLC patients survive after five years of treatment  showing a significant unmet need Several pharma companies are developing therapies for treating SCLC  AstraZeneca   NYSE AZN   is developing a combination of its PARP inhibitor  Lynparza  and chemotherapy  Temodar  in a phase I II study  AbbVie   NYSE ABBV   and Bristol Myers have collaborated to develop rovalpituzumab tesirine in combination with Opdivo and Yervoy in a phase I study  G1 Therapeutics is also developing therapies in combination with chemotherapy for SCLC Apart from SCLC  Aeglea is also developing pegzilarginase in a phase I II study in patients with Arginase 1 deficiency  a rare genetic disease  The company reported positive preliminary data from the study earlier this month Aeglea BioTherapeutics  Inc  Price
    Zacks RankAeglea currently has a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-04-03,Zacks Investment Research,https://www.investing.com/analysis/aeglea-initiates-lung-cancer-combination-study-with-keytruda-200302739,200302739
203399,424915,MRK,Pfizer s Lung Cancer Candidate Gets FDA s Priority Review,opinion,Pfizer   NYSE PFE   has announced that the regulatory applications for its pipeline candidate  dacomitinib  have been accepted for review in both the United States and the EU  The company is looking to get the drug approved for the first line treatment of locally advanced or metastatic non small cell lung cancer  NSCLC  in patients with EGFR activating mutations  Notably  the FDA granted a priority review to dacomitinib with a response expected in September 2018 The regulatory submissions for dacomitinib were based on positive data from a global head to head phase III ARCHER 1050 study  evaluating dacomitinib  n 227  versus AstraZeneca s   NYSE AZN   lung cancer drug  Iressa  gefitinib   among patients with NSCLC  Data from the study demonstrated a median progression free survival  PFS  of 14 7 months on treatment with dacomitinib compared with 9 2 months with Iressa  reflecting a reduction in the risk of disease progression by 41  However  10  of patients treated with dacomitinib discontinued the study due to adverse events compared with 7  treated with Iressa  The company stated that a final assessment of overall survival from ARCHER 1050 study will be presented at a medical meeting later in 2018 Shares of Pfizer were up almost 1 3  following the news  However  the stock has gained 5 9  in the past year  underperforming the  s increase of 6 5   Importantly  Pfizer s regulatory application for another candidate  which has recently received acceptance in the United States is lorlatinib  for the second line treatment of patients with NSCLC  A response from the FDA is awaited in August 2018 Non small cell lung cancer occurs in 85  of patients with a lung cancer condition  the leading cause of cancer deaths worldwide  Notably  EGFR mutations leading to growth in cancer cells occur in 10 35  of NSCLC tumors globally  Moreover  despite a significant progress made in this space  the disease is associated with low survival rates  Hence  approval of the candidate will provide the company with access to a huge patient population base in need of an additional treatment to apprehend the disease We remind investors that  Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  is approved in the first line lung cancer setting  We also note that last month Roche   OTC RHHBY   has presented data on Tecentriq in novel combinations across a broad range of tumors including lung cancer Blockbuster drugs like Bristol Myers  Opdivo is approved for treating NSCLC among others Pfizer Inc  Price    Zacks RankPfizer carries a Zacks Rank  2  Buy   You can  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-04,Zacks Investment Research,https://www.investing.com/analysis/pfizers-lung-cancer-candidate-gets-fdas-priority-review-200303545,200303545
203410,424926,MRK,Chinese firms pour money into U S  R D in shift to innovation,news,"By Jason Lange WASHINGTON Reuters    Surging investment by Chinese companies in U S  research labs is yielding a fast growing trove of patents  part of a push to mine America for ideas to help China shift from being the world s factory floor to a driver of innovation   Largely absent from American research hubs a decade ago  Chinese firms including Huawei Technologies  and ZTE Corp  SZ 000063  are now using U S  researchers to create patents ranging from new software to internet infrastructure  according to an analysis of Thomson Reuters  global intellectual property database  The rapid growth in China s U S  investments will be a key topic at economic and security talks on Tuesday and Wednesday between top U S  and Chinese officials in Washington  They are negotiating a bilateral investment treaty that could deepen ties between the world s two largest economies even amid tensions over China s military assertiveness  Even without a treaty  China is pouring capital into U S  research as well as buying other assets  While its firms are still newcomers to investing in America and few work on the technological frontier  the Thomson Reuters data offers a glimpse of the advanced economy China aspires to build   Patented inventions by Chinese firms that involved at least one U S  researcher roughly doubled worldwide in each of the last three years  reaching 910 in 2014   We have established a beachhead   said Vincent Xiang  who heads international investment at  Humanwell  Healthcare Group  SS 600079   a Chinese drug company that has put over  50 million into a New Jersey subsidiary that employs dozens of U S  researchers   Rather than compete with powerhouses like U S  drug maker Merck  N MRK  to invent blockbuster medicines  Humanwell s U S  researchers are making smaller refinements such as figuring out how to administer some drugs as pills rather than injections  Humanwell s New Jersey researchers have won approval on four patents so far in the United States and European Union  Xiang said  There are advantages to setting up labs in the U S   where there are over 800 000 people with research doctoral degrees in science  engineering  and health   Without access to innovation  it is hard to win in the domestic market   said Xiang  A SMALL BUT GROWING PLAYER  And yet  direct investment between the United States and China is remarkably low considering the size of their economies  and the fruits of China s U S  R D are similarly modest compared with the vast quantities of patents that emerge from America every year  The cumulative stock of foreign direct investment in China from the United States makes up just over 1 percent of the FDI sunk into Chinese businesses by all nations  according to U S  government data  Most FDI in China comes from other Asian countries  China s share of America s FDI stock is even smaller  but it has been growing rapidly in recent years as Beijing has eased restrictions on outward investment   That is helping Chinese companies sink more money into a range of advanced economies  The Thomson Reuters data also shows a sharp increase in recent years in patents by Chinese firms using German and Japanese researchers  This is a change in China s economic development model   said Thilo Hanemann  who helps maintain a database on Chinese FDI at the Rhodium Group  a New York consultancy   They want to move from an economy driven by domestic investment and exports to one driven by consumption  technology and services   Annual flows of Chinese FDI into the United States have gone from tens or hundreds of millions of dollars per year between 2000 and 2009 to  14 3 billion in 2013 and  11 9 billion in 2014  according to Rhodium Group figures  which are widely cited because they track China s investments made via third countries such as Singapore  That is now approaching the annual flows from America s traditional sources of FDI  advanced countries such as Germany and Canada who continue to mine much more knowledge from Americans than does China  German companies extracted 1 416 patents last year using U S  researchers   China already publishes more patent applications than any other country  although development economists note that its state mandated patent targets often lead to lower quality patents  particularly those taken out only in China   However  the Thomson Reuters data  which brings together information from patent offices in dozens of countries  points to many high quality inventions using U S  researchers   For example  Huawei  the top Chinese company with patents fueled by U S  research  has a U S  patent for processing fiber optic signals that was cited by 101 later inventions   The recent Chinese National Patent Development Strategy highlights the country s plans through 2020  including seven strategic industries positioned for growth  biotechnology  alternative energy  clean energy vehicles  energy conservation  high end equipment manufacturing  broadband infrastructure and high end semiconductors  It also includes an increase in research and development expenditures as a proportion of economic output from 1 75 percent in 2010 to 2 2 per cent this year  One Chinese concern likely to be aired at the U S  China meetings this week is that Beijing feels its companies  investments are singled out in U S  security reviews  Huawei is a world leader in producing telecommunications equipment and has six U S  research centers  but is a bit player in America s telecom infrastructure market  U S  national security concerns have helped scuttle several attempts by Huawei to expand its U S  presence   Huawei has occasionally found itself caught in the middle  of geopolitical tensions between Washington and Beijing  said company spokesman William Plummer  Most Chinese FDI happens when investors snap up established U S  companies  such as when auto parts maker Wanxiang Group  SZ 000559  bought California based electric carmaker Fisker Automotive   and its patents   at a bankruptcy auction last year   The Chinese are also starting new ventures and have invested  3 billion in these  greenfield  projects over the last three years  according to Rhodium   America s state and local governments have set up dozens of offices to compete with one another to attract this capital  which could flow more freely under a U S  China investment treaty  Officials offer potential investors tax incentives and introduce them to potential local partners and to legal and accounting firms   State officials understand there are no go areas given tensions between Washington and Beijing on security matters  Washington reviews more potential investments from China for security concerns than any other country   
 China being China we don t do aerospace or defense   said Bradley Gillenwater  the Maryland state government s point person for attracting Asian investment   But biotech is a big deal  ",2015-06-21,Reuters,https://www.investing.com/news/technology-news/chinese-firms-pour-money-into-u.s.-r-amp;d-in-shift-to-innovation-347506,347506
203412,424928,MRK,Merck KGaA s Tepotinib Gets Fast Track Designation In Japan,opinion,"Merck KGaA  announced that the Japanese Ministry of Health  Labour and Welfare  MHLW  has granted SAKIGAKE  fast track  designation to its pipeline candidate  tepotinib  The company is developing the candidate for the treatment of advanced non small cell lung cancer   NSCLC   The SAKIGAKE designation is granted to expedite a candidate s development and review in Japan and focuses on new or unmet areas and regenerative medicines Merck KGaA s shares have underperformed the  so far this year  The stock has lost 14 8  compared with the industry s decline of 4 6  in that period The designation was granted to tepotinib based on data from a phase II study evaluating it in NSCLC patients with MET exon 14 skipping mutations  There is no approved treatment for this indication Data from the study will be presented at a future medical congress Apart from tepotinib  Merck KGaA s oncology pipeline includes M7824  which is a bifunctional immunotherapy as it simultaneously blocks 2 immuno inhibitory pathways that are commonly used by cancer cells  The company is evaluating the candidate in several tumors  However  the most advanced candidate in oncology pipeline  avelumab  is being developed in collaboration with Pfizer   NYSE PFE   in several indications  including lung  gastric  ovarian and kidney cancer Per the press release  lung cancer is the most common cancer globally  NSCLC occurs in 80  to 85  of lung cancer patients  However  tepotinib targets only 2  to 3  of NSCLC patients  who have MET exon 14 skipping mutations However  several big pharma companies are already marketing their drugs to treat NSCLC  These include Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  Pfizer s Xalkori and Bristol Myers    NYSE BMY   PD 1 immune checkpoint inhibitor  Opdivo Merck KGaA Price
    Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-03-27,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaas-tepotinib-gets-fast-track-designation-in-japan-200301461,200301461
203419,424935,MRK,Merck KGaA  Threshold win fast track for pancreatic cancer drug,news,FRANKFURT  Reuters    Germany s Merck  NYSE MRK  KGaA said that experimental cancer drug evofosfamide  which it is jointly developing with Threshold Pharmaceuticals  won fast track status for the treatment of advanced pancreatic cancer from the U S  Food and Drug Administration  Merck had licensed in evofosfamide  previously known as TH 302  from Threshold in 2012   The drug attacks body tissue that is short of oxygen supply  a typical characteristic of many tumors because cancerous cells often grow without connecting to the blood vessels around them  The drug  currently being tested in the third and last phase required for regulatory approval  already has the FDA s fast track designation for treatment of soft tissue sarcoma  Fast track status means data from clinical trials can be submitted to the FDA on a rolling basis as it becomes available rather than waiting until pivotal studies are completed ,2015-05-12,Reuters,"https://www.investing.com/news/general-news/merck-kgaa,-threshold-win-fast-track-for-pancreatic-cancer-drug-341390",341390
203420,424936,MRK,Merck KGaA  MKGAF  Q4 Earnings Flat Y Y  Sales Up,opinion,"Merck  NYSE MRK  KGaA  is a science and technology company specializing in the fields of healthcare  life science and performance materials  The company s portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools  specialty chemicals and high tech materials The company is focused on oncology  multiple sclerosis  infertility  growth disorders  selected cardiovascular and metabolic diseases  women s and children s health  cough and cold as well as everyday health protection The company reports its results in three business sectors   Healthcare  Life Science and Performance Materials We have highlighted some of the key stats from this just revealed announcement below Earnings  The company s fourth quarter 2017 earnings per American Depositary Receipt  ADR  remained flat year over year at  1 54 Revenue  The company posted revenues of  4 5 billion in the reported quarter  up 9 6  including favorable currency movement  The Healthcare and Life Science segment drove the company s organic growth Key Stats  The company has proposed a dividend of  1 25  increasing the payout by  0 05 maintaining the trend of rising dividend since 2009 2018 Guidance  For 2018  the company expects its net sales to grow moderately  The company expects currency movements to have an unfavourable impact of 4  to 6  on EBIDTA Merck KGaA Price and EPS Surprise
    The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaa-mkgaf-q4-earnings-flat-yy-sales-up-200296636,200296636
203421,424937,MRK,Should Value Investors Pick Merck   Co   MRK  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Merck   Co   Inc    NYSE MRK   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Merck   Co  has a trailing twelve months PE ratio of 13 9  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 21 3  If we focus on the long term PE trend  Merck   Co  s current PE level puts it below its midpoint over the past five years  Moreover  the current level is fairly below the highs for this stock  suggesting it might be a good entry point Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 15 8  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Merck   Co  has a forward PE ratio  price relative to this year s earnings  of just 13 1  so it is fair to say that a slightly more value oriented path may be ahead for Merck   Co  stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Merck   Co  has a P S ratio of about 3 7  This is marginally higher than the S P 500 average  which comes in at 3 4 right now  Nonetheless  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  MRK is toward the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Merck   Co  currently has a Zacks Value Style Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Merck   Co  a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  its P CF ratio  another great indicator of value  comes in at 9 6  which is far better than the industry average of 12 3  Clearly  MRK is a solid choice on the value front from multiple angles What About the Stock Overall Though Merck   Co  might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of C and a Momentum score of B  This gives MRK a Zacks VGM score or its overarching fundamental grade of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been encouraging  The current quarter has seen no estimate revisions in the past sixty days  while the full year estimate has seen nine upward and zero downward revisions in the same time period As a result  the current quarter consensus estimate has risen by 8 8  in the past two months  while the full year estimate has increased 2 2   You can see the consensus estimate trend and recent price action for the stock in the chart below Merck   Company  Inc  Price and Consensus    Even though Merck   Co  has a better estimates trend  the stock has just a Zacks Rank  3  Hold   That is why we are looking for in line performance from the company in the near term Bottom LineMerck   Co  is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Furthermore  a robust industry rank  among the Top 18   should boost investor confidence However over the past two years  the industry has underperformed the broader market  as you can see below Despite the poor past performance of the industry  a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future  Add to this the positive estimate revisions and robust value metrics  and we believe that we have a strong value contender in Merck   Co The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-merck--co-mrk-stock-now-200298685,200298685
203422,424938,MRK,Agenus  AGEN  Q4 Loss Wider Than Expected  Revenues Miss,opinion,Agenus Inc    NASDAQ AGEN   has incurred fourth quarter 2017 loss of 35 cents per share  wider than both the Zacks Consensus Estimate of a loss of 28 cents and the year ago loss of 30 cents Revenues of  8 4 million missed the Zacks Consensus Estimate of  16 million  However  the top line was up from  5 6 million in the prior year period So far this year  shares of Agenus have surged 32 9  against the  s decline of 4 5  Quarterly HighlightsAgenus  fourth quarter research and development  R D  expenses were up 22 7  to  31 9 million  General and administrative expenses were slightly up by 12 9  to  9 8 million Pipeline UpdateAgenus is progressing well with various candidates in its pipeline  During the quarter under review  the company commenced its phase II combination trials on its CTLA 4 antibody  AGEN1884 in combination with Merck s   NYSE MRK   PD 1 antibody  Keytruda among patients with first line non small cell lung cancer  NSCLC   Agenus has already completed the dose escalation clinical trials of its CTLA 4 and PD 1 compounds  It also launched a phase II combination study of the PD 1 proprietary agents in second line cervical cancer  This combo regimen assessment may also support a BLA filing as soon as 2020 The company made a significant advancement with five novel immuno oncology antibodies  discovered and developed in 2017  It expects to file investigational new drug  IND  applications for at least three of these antibodies by 2018  In fact  the first IND filing will be for its next generation CTLA 4  designed to deplete cancer prone Tregs and improve T cell priming  The company also reported safety and immunogenicity of its first synthetic neoantigen vaccine  AutoSynVax  ASV   Combination studies of ASV with the company s own checkpoint antibodies are planned for 2018 2017 ResultsThe company reported a loss of  1 23 in 2017  narrower than  1 46 of loss in 2016  The figure was however  wider than the Zacks Consensus Estimate of a loss of  1 16 Revenues in 2017 came in at  42 9 million  up 89 9  year over year  However  the top line missed the Zacks Consensus Estimate of  50 1 million  Agenus Inc  Price  Consensus and EPS Surprise    Zacks Rank   Key PicksAgenus has a Zacks Rank  3  Hold   Two better ranked stocks from the same space are Regeneron   NASDAQ REGN   and Ligand Pharmaceuticals   NASDAQ LGND    While Regeneron sports a Zacks Rank  1  Strong Buy   Ligand carries a Zacks Rank  2  Buy   You can see  Regeneron s earnings per share estimates have moved up from  18 65 to  18 68 for 2018 in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  the average beat being 9 15  Ligand s earnings per share estimates rose from  3 78 to  4 20 and from  4 75 to  5 32 for 2018 and 2019  respectively  over the last 30 days  The company delivered positive surprises in three of the trailing four quarters with an average beat of 24 88   Share price of the company has soared 63 9  in a year s time The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/agenus-agen-q4-loss-wider-than-expected-revenues-miss-200298718,200298718
203428,424944,MRK,Earnings Buzz  Pfizer  Merck  Bristol Myers Squibb,news,"By   
  Pfizer  Inc   NYSE PFE  shares edged up 0 5 percent Tuesday  despite cutting its full year 2015 earnings forecast due to a stronger U S  dollar  Meanwhile  Merck   Co  Inc   NYSE MRK  shares jumped nearly 5 percent after beating Wall Street estimates  while Bristol Myers Squibb Co   NYSE BMY  shares dropped 2 percent  despite topping quarterly profit and revenue forecasts   title    Reuters Andrew Kelly  Pfizer Inc   NYSE PFE  shares edged up 0 5 percent Tuesday  despite cutting its full year 2015 earnings forecast due to a stronger U S  dollar  Meanwhile  Merck   Co  Inc   NYSE MRK  shares jumped nearly 5 percent after beating Wall Street estimates  while Bristol Myers Squibb Co   NYSE BMY  shares dropped 2 percent  despite topping quarterly profit and revenue forecasts   rel  external image  
Earnings season continues in full swing this week as pharmaceutical giants Pfizer Inc   Merck   Co  Inc  and  Bristol Myers Squibb Co  are among 40 Standard   Poor s 500 companies reporting quarterly results Tuesday   Of the S P 500 companies that have already released results this earnings season  around 77 percent have beaten profit projections  while 49 percent have topped revenue estimates  Bloomberg data show  
Here s a deeper look into  pharmaceutical companies reporting Tuesday  
Pfizer  
Shares of Pfizer NYSE PFE  edged up 0 5 percent to  34 77 in morning trading Monday after the New York company posted a 4 percent drop in quarterly revenue and cut its full year forecast due to a stronger U S  dollar  However  the drugmaker  which has a market capitalization of  217 billion  topped Wall Street   s earnings expectations  driven by demand for its vaccines and cancer drugs 
The drugmaker reported first quarter net income of  2 38 billion  or earnings per share of 38 cents  on revenue of  10 86 billion  compared with a profit of  2 33 billion  or earnings per share of 36 cents  on sales of  11 3 billion a year ago  Wall Street had expected Pfizer to report first quarter net income of  2 32 billion  or earnings per share of 46 cents  on revenue of  10 7 billion  analysts polled by Thomson Reuters said 
Pfizer now expects full year earnings in the range of  1 95 to  2 05 per share  with revenue in the range of  44 billion to  46 billion 
Shares of Pfizer have gained more than 10 percent this year  and are up 14 percent in the last 12 months 
Merck 
Shares of Merck NYSE MRK jumped nearly 5 percent Tuesday to  59 90 after the drugmaker reported stronger than expected quarterly earnings and revenue  helped by sales of its Januvia diabetes drug and its animal health products 
Merck  which has a market value of  163 billion  saw sales of Januvia rise 4 percent to  1 4 billion last quarter from  1 3 billion a year earlier  after recording a 1 8 percent decline in sales in 2014  Meanwhile  sales of its animal health products rose 2 percent to  829 million from  813 million during the same period a year ago 
The Kenilworth  New Jersey  company turned in first quarter net income of  953 million  or earnings per share of 33 cents  on revenue of  9 43 billion  compared with a profit of  1 71 billion  or earnings per share of 57 cents  on sales of  10 3 billion a year ago  Analysts had expected Merck to report first quarter net income of  834 7 million  or earnings per share of 29 cents  on revenue of  9 1 billion 
Shares of Merck have dipped 0 16 percent this year  and have lost nearly 1 percent in the last 12 months 
Bristol Myers Squibb
Shares of the biopharmaceutical company  Bristol Myers Squibb NYSE BMY dropped 2 percent to  63 90 in morning trading  despite beating Wall Street   s quarterly profit and revenue estimates  Sales last quarter were boosted by higher estimates of royalties owed the company from sales of its Abilify schizophrenia treatment and sales from Orencia  a biologic drug approved for the treatment of moderate to severe rheumatoid arthritis 
Sales of Abilify rose 3 percent to  554 million from a year earlier  while revenue from Orencia jumped 10 percent to  400 million  The New York company   s strong earnings come just days after it announced its experimental drug cured hepatitis C in more than 90 percent of patients in a late stage study 
Bristol Myers Squibb  which has a market cap of  108 billion  reported first quarter net income of  1 19 billion  or earnings per share of 71 cents  on revenue of  4 04 billion  compared with a profit of  937 million  or earnings per share of 56 cents  on sales of  3 8 billion a year ago   Meanwhile  Bristol Myers boosted its outlook this year after the company s quarterly revenue rose 6 percent  boosted on strength from its cancer immunotherapy drug Yervoy  whose sales 20 percent to  325 million from a year ago  
Shares of Bristol Myers Squibb have gained more than 9 percent this year  and have soared nearly 31 percent in the last 12 months  ",2015-04-28,International Business Times,"https://www.investing.com/news/stock-market-news/earnings-buzz:-pfizer,-merck,-bristol-myers-squibb-339273",339273
203431,424947,MRK,Nektar  NKTR  Q4 Loss Narrower Than Expected  Sales Soar Y Y,opinion,Nektar Therapeutics   NASDAQ NKTR   reported a loss of 14 cents per share in the fourth quarter of 2017  substantially narrower than both the Zacks Consensus Estimate of a loss of 38 cents and the year ago figure of 28 cents Shares of Nektar have significantly outperformed the  in a year s time  The stock has skyrocketed 471 6  while the industry has decreased 2 6  Quarterly revenues substantially soared 154 7  to  95 5 million from the year ago period  This upside can mainly be attributed to a massive rise in license and collaboration revenues  The top line also significantly beat the Zacks Consensus Estimate of  31 million Quarter in DetailThe top line comprised product sales  royalty revenues  non cash royalty revenues besides license  collaboration and other revenues In the fourth quarter  product sales tumbled 43 1  to  7 8 million from  13 7 million a year ago   However  non cash royalty revenues increased 17 9  to  9 2 million The company reported royalty revenues of  9 6 million in the quarter under review  registering a huge improvement of 50  from  6 4 million a year ago  This uptrend was mainly on the back of royalty revenues received under a license agreement with AstraZeneca for Movantik and Shire plc for Adynovate License  collaboration and other revenues came in at  68 9 million compared with  9 6 million in the prior year  This upside was mainly due to a receipt of  60 million in non recurring revenues related to a new sublicense agreement Research and development  R D  expenses mounted 62 2  to  81 4 million  primarily due to investments in pipeline including key candidates NKTR 358  NKTR 214 and NKTR 181 General and administrative  G A  expenses were down 3 9  to  12 3 million in the reported quarter 2017 ResultsFull year sales jumped 86  year over year to  307 7 million  Sales outpaced the consensus mark of  243 7 million as well as the previously guided range of  250  255 million The 2017 loss of 35 cents per share was narrower than both the Zacks Consensus Estimate of 78 cents and the year earlier figure of 80 cents Pipeline UpdateThe most advanced candidate in the company s portfolio is Onzeald  currently under evaluation in a phase III  ATTAIN  study for treatment of adults with advanced breast cancer  having brain metastases Apart from Onzeald  another candidate in the company s immuno oncology portfolio is NKTR 214  Last year in September  Nektar announced initiation of phase I II PROPEL study to evaluate the efficacy and safety of NKTR 214 in combination with Roche s   OTC RHHBY   Tecentriq  atezolizumab  and Merck s   NYSE MRK   Keytruda  pembrolizumab   Data from the trial is expected in the second half of 2018 A phase I II study evaluating NKTR 214 as a potential combination treatment regimen with Bristol Myers Squibb s   NYSE BMY   Opdivo is also underway  The candidate is being examined across nine tumor types including melanoma  renal cell carcinoma  non small cell lung cancer  bladder and triple negative breast cancer  The combo therapy will also be evaluated in more than 20 potential indications Another candidate  NKTR 181  is being evaluated in a phase III program for chronic pain management  Last July  the company reported positive top line results from an oral human abuse potential study  evaluating NKTR 181  to assess the opioid abuse potential compared with oxycodone  The company is planning to submit a new drug application  NDA  for the candidate by April 2018 2018 OutlookNektar estimates revenues in the range of  100  110 million excluding payments from the collaboration with Bristol Myers  entered last month  Per the agreement  both companies will jointly develop and commercialize the lead immuno oncology candidate  NKTR 214  of the former in combination with the latter s Opdivo and Opdivo plus Yervoy  ipilimumab  Nektar anticipates cash of approximately  1 9  1 925 billion at year end 2018 including upfront payments from the collaboration with Bristol Myers Notably  cash and investments in marketable securities as of Dec 31  2017 were  353 2 million in comparison to  389 1 million as of Dec 31  2016 Nektar Therapeutics Price  Consensus and EPS Surprise   Zacks RankNektar carries a Zacks Rank  3  Hold   You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/nektar-nktr-q4-loss-narrower-than-expected-sales-soar-yy-200295641,200295641
203432,424948,MRK,What s In The Cards For Merck KGaA  MKGAF  In Q4 Earnings ,opinion,"Merck  NYSE MRK  KGaA  is scheduled to report fourth quarter 2017 results on Mar 8 Merck s shares have declined 12 8  in the past year against the  s gain of 0 2   The company reports financial numbers under three business sectors   Healthcare  Life Science and Performance Materials Merck s revenues were driven by sales growth in its Healthcare and Life Science segments in the third quarter  We expect this positive trend to continue in the upcoming quarterly results  Meanwhile  the company is streamlining Healthcare business to focus on its pipeline of innovative medicines During the first half of 2017  the company received an approval for Bavencio for treatment of metastatic Merkel cell carcinoma  mMCC  and advanced bladder cancer in the United States  Moreover  the drug was approved in the EU and Japan for treating mMCC in September 2017 During the period to be   Merck s multiple sclerosis drug  Mavenclad  was approved in Australia and Canada following its approval in Europe in the third quarter The company continues to develop Bavencio in partnership with Pfizer Inc    NYSE PFE   for several cancer indications  However  the drug failed in a phase III study  conducted to evaluate it for the treatment of gastric cancer in the third line setting Sales of three key drugs   Rebif  Erbitux and Gonal f   are expected to be lower in fourth quarter 2017 results  This downside is likely to be caused by persistent competitive pressure and price reduction  Moreover  unfavorable currency movement is anticipated to dent the top line Additionally  operating expenses increased during the first nine months of 2017 due to product launches and higher pipeline development cost  Expenses are estimated to rise as the company focuses on developing an innovative pipeline  the launch of Bavencio in new geographies as well as Mavenclad We expect management to shed light on progress and commercialization plans for Bavencio on the earnings call  The company is likely to provide updates on its strategic plans Merck KGaA Price and EPS Surprise
     Stocks that Warrant a LookHere are a couple of healthcare stocks that you may want to consider  as our model shows that these have the right combination of elements   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to deliver an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Gemphire Therapeutics Inc    NASDAQ GEMP   is expected to release results on Mar 21  The company has an Earnings ESP of  24 74  and a Zacks Rank  2  You can see  Celldex Therapeutics  Inc    NASDAQ CLDX   is scheduled to release results on Mar 7  The Zacks  3 Ranked company has an Earnings ESP of  18 28  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-04,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-merck-kgaa-mkgaf-in-q4-earnings-200295898,200295898
203433,424949,MRK,Zacks Industry Outlook Highlights  Sanofi  Celgene  Bioverativ  Juno And Merck,opinion,For Immediate ReleaseChicago  IL   March 8  2018   Today  Zacks Equity Research discusses the Ecommerce  including Sanofi   NYSE SNY    Celgene   NASDAQ CELG    Bioverativ   NASDAQ BIVV    Juno Therapeutics  Inc    and Merck   NYSE MRK   Industry  Pharma  Part 1Link  The year 2017 was rewarding for pharma and biotech stocks  with the sector witnessing some positive developments that led to a much awaited recovery The NYSE ARCA Pharmaceutical Index gained 11 8   while the Nasdaq Biotechnology Index was up 18 7  in 2017  This is in sharp contrast to 2016  which was tough for pharma and biotech stocks following criticisms about rising drug prices A key reason for the sector s improved performance was the willingness of investors to look beyond the drug pricing controversy and focus on fundamentals instead  Although the drug pricing controversy will remain a headline risk  investors seem more comfortable with the issue Moreover  a significantly higher number of FDA approvals in 2017 restored investor confidence in the sector  The approval of the first gene cell therapy last year was a major breakthrough Though the sector was off to a strong start in 2018  it has been struggling recently with the NYSE ARCA Pharmaceutical Index and Nasdaq Biotechnology Index down 1 8  and 2 8  year to date  respectively  probably on broader market correction  Also  the mention of high drug prices by President Trump in his State of the Union address dampened investor sentiment  However  the sector is largely expected to rebound as the year progresses New product sales ramp up with rising demand  successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals  continued strong performance from key products  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending are some of the factors that should keep the sector on track in 2018  A faster drug approval process and the proposed removal of outdated regulations that push up costs and slow down innovation should also provide benefits Hopes of more mergers and acquisitions  M As  have also gone up with the tax reform in place and big players on the lookout for companies with innovative pipelines technology  There has already been quite a bit of M A buzz this year about potential deals  Sanofi and Celgene have already announced two deals each However  headwinds include drug pricing scrutiny  pricing pressure  increasing competition  the growing presence of biosimilars  generic competition  a slowdown in the growth of legacy products  concerns regarding Amazon s interest in entering the healthcare arena and major pipeline setbacks We are discussing some factors in details here Mergers and Acquisitions  M As  on the RiseThe year started off with expectations that M A activity would pick up  The new tax law  which cuts corporate tax rate from 35  to 21  and encourages companies to bring back huge cash held overseas at a one time tax rate of 10   is expected to spur merger activity this year This was held true with biotech pharma M A activity already starting to gather steam  Sanofi  earlier this year  announced deals to buy Belgian biotech company  Ablynx and haemophilia focused biotech  Bioverativ  Celgene also announced deals to buy Juno Therapeutics  Inc   which focuses on the development of CAR T therapies and Impact Biomedicines  which will add a late stage JAK2 kinase inhibitor  to Celgene s pipeline Merck recently announced that it has proposed to buy Australian oncolytic immunotherapies maker Viralytics Ltd  to strengthen its presence in the fast growing immuno oncology market In fact  most big pharma CEOs believe the tax cuts will place American companies on a level playing field as they can compete better with their foreign counterparts  which operate in better tax environments Meanwhile  in licensing deals continue to be popular with several big companies tying up with smaller and mid sized players with promising mid to late stage pipeline candidates or interesting technology  These deals make sense for both sides    the larger companies are able to boost their pipelines with promising candidates while the smaller ones gain access to a non dilutive source of funds that allows them to continue investing in those pipelines Some companies that often find themselves on the acquisition radar include Exelixis  Incyte  BioMarin and TESARO  among others Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/zacks-industry-outlook-highlights-sanofi-celgene-bioverativ-juno-and-merck-200296632,200296632
203439,424955,MRK,Scientists unveil map of  epigenome   a second genetic code,news,By Sharon Begley NEW YORK  Reuters    Scientists for the first time have mapped out the molecular  switches  that can turn on or silence individual genes in the DNA in more than 100 types of human cells  an accomplishment that reveals the complexity of genetic information and the challenges of interpreting it  Researchers unveiled the map of the  epigenome  in the journal Nature on Wednesday  alongside nearly two dozen related papers  The mapping effort is being carried out under a 10 year   240 million U S  government research program  the Roadmap Epigenomics Program  which was launched in 2008   The human genome is the blueprint for building an individual person  The epigenome can be thought of as the cross outs and underlinings of that blueprint  if someone s genome contains DNA associated with cancer but that DNA is  crossed out  by molecules in the epigenome  for instance  the DNA is unlikely to lead to cancer  As sequencing individuals  genomes to infer the risk of disease becomes more common  it will become all the more important to figure out how the epigenome is influencing that risk as well as other aspects of health  Sequencing genomes is the centerpiece of the  precision medicine  initiative that U S  President Barack Obama announced this month   The only way you can deliver on the promise of precision medicine is by including the epigenome   said Manolis Kellis of the Massachusetts Institute of Technology  who led the mapping that involved scientists in labs from Croatia to Canada and the United States  Drug makers including Merck  NYSE MRK    Co Inc   the Genentech unit of Roche Holding and GlaxoSmithKline Plc are conducting epigenetics research related to cancer  said Joseph Costello of the University of California  San Francisco  director of one of four main labs that contributed data to the epigenome map  Epigenetic differences are one reason identical twins  who have identical DNA  do not always develop the same genetic diseases  including cancer  But incorporating the epigenome in precision medicine is daunting   A lifetime of environmental factors and lifestyle factors  influence the epigenome  including smoking  exercising  diet  exposure to toxic chemicals and even parental nurturing  Kellis said in an interview  Not only will scientists have to decipher how the epigenome affects genes  they will also have to determine how the lives people lead affect their epigenome  BOOK OF LIFE The human genome is the sequence of all the DNA on chromosomes  The DNA is identical in every cell  from neurons to hearts to skin  It falls to the epigenome to differentiate the cells  as a result of epigenetic marks  heart muscle cells do not make brain chemicals  for instance  and neurons do not make muscle fibers  The epigenome map published on Wednesday shows how each of 127 tissue and cell types differs from every other at the level of DNA  Because scientists involved in the Roadmap project have been depositing their findings in a public database as they went along  other researchers have been analyzing the information before the map was formally published   One of the resulting studies show  for instance  that brain cells from people who died with Alzheimer s disease had epigenetic changes in DNA involved in immune response  Alzheimer s has never been seen as an immune system disorder  so the discovery opens up another possible avenue to understand and treat it  Other researchers found that because the epigenetic signature of different kinds of cells is unique  they could predict with nearly 90 percent accuracy where metastatic cancer originated  something that is unknown in 2 percent to 5 percent of patients  As a result  epigenetic information might offer a life saving clue for oncologists trying to determine treatment  said co senior author Shamil Sunyaev  a research geneticist at Brigham and Women s Hospital in Boston  There is much more to come  Instead of the epigenome map being the end  said Kellis   I very much see  it  as beginning a decade of epigenomics  ,2015-02-18,Reuters,"https://www.investing.com/news/general-news/scientists-unveil-map-of-'epigenome,'-a-second-genetic-code-328547",328547
203440,424956,MRK,Bavarian Nordic vaccine helps prolong life in prostate cancer trial,news,By Ransdell Pierson  Reuters    An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer  according to results of a small early stage trial conducted by the U S  National Cancer Institute   Shares of Bavarian Nordic closed up almost 12 percent in Copenhagen after the company released the data on Tuesday  The study involved 30 patients with prostate cancer that had failed to benefit from standard treatments that reduce levels of testosterone  the male hormone that fuels the cancer   Patients were treated with the company s Prostvac vaccine  in addition to escalating doses of Bristol Myers Squibb Co s Yervoy  an approved injectable treatment for advanced melanoma that works by taking the brakes off the body s immune system  On average  patients taking both drugs survived 31 3 months  compared with a predicted survival period of 18 5 months that had been based on historical survival data for older chemotherapy treatments  Among the 15 patients who received the highest 10 milligram dose of Yervoy in combination with Prostvac  20 percent remained alive at 80 months  Data from the combination trial were especially impressive  considering that Yervoy had previously failed in Bristol Myers  own trials to prolong survival in patients with advanced prostate cancer  Yervoy and an emerging group of immuno oncology drugs called PD 1 inhibitors from Bristol Myers  Merck  NYSE MRK    Co and other drugmakers are expected to have greatest effectiveness when used in combination  The PD1 inhibitors make cancer cells more visible to the immune system  removing their natural camouflage   Complete data from the Prostvac study are slated to be presented on Thursday at the Genitourinary Cancers Symposium in Orlando  The vaccine is designed to trigger an immune system response against prostate cancer cells ,2015-02-24,Reuters,https://www.investing.com/news/general-news/bavarian-nordic-vaccine-helps-prolong-life-in-prostate-cancer-trial-329452,329452
203441,424957,MRK,European stocks edge higher after Spanish  German data  Dax up 0 23 ,news,"Investing com   European stocks edged higher on Tuesday  supported by upbeat Spanish and German economic reports although investors remained cautious ahead of the European Central Bank s next policy meeting 
During European morning trade  the EURO STOXX 50 edged up 0 14   France s CAC 40 rose 0 19   while Germany s DAX 30 added 0 23  
Spain s Employment Ministry reported that the number of unemployed people declined by 13 500 last month  compared to expectations for an increase of 10 500  The number of unemployed people rose by 78 000 in January 
Earlier Tuesday  data showed that German retail sales jumped 2 9  in January  easily outstripping forecasts for a 0 4  increase 
Investors remained cautious however ahead of the upcoming ECB meeting on Thursday  when it was expected to announce details of its quantitative easing program 
Financial stocks were broadly lower  as French lenders BNP Paribas  PARIS BNPP  and Societe Generale  PARIS SOGN  slipped 0 29  and 0 20   while Germany s Deutsche Bank  XETRA DBKGn  and Commerzbank  XETRA CBKG  declined 0 38  and 0 42  
Among peripheral lenders  Italy s Unicredit  MILAN CRDI  and Intesa Sanpaolo  MILAN ISP  edged down 0 10  and 0 13   while Spanish banks BBVA  MADRID BBVA  and Banco Santander  MADRID SAN  fell 0 20  and 0 31  
Elsewhere  Merck  NYSE MRK  KGAA O N   XETRA MRCG  jumped 1 19  after the German drugmaker reported an increase in fourth quarter profit that exceeded analysts  estimates 
Also in earnings news  Evonik Industries AG  XETRA EVKn  saw shares rally 1 51  after the German chemical manufacturer forecast an increase in 2015 profit and sales and reported quarterly earnings above analysts  projections 
In London  commodity heavy FTSE 100 rose 0 26   supported by gains in the energy sector 
Shares in oil and gas major BP Plc  LONDON BP  advanced 0 48   while rival company Tullow Oil Plc  LONDON TLW  led gains on the index  with shares surging 2 46  
Meanwhile  mining stocks were broadly lower  Shares in Rio Tinto  LONDON RIO  and Bhp Billiton  LONDON BLT  dropped 0 49  and 0 75  respectively  while Fresnillo  LONDON FRES  tumbled 2 03  and Glencore Xstrata  LONDON GLEN  plunged 3 12  
In the financial sector  stocks were also mostly on the downside  Lloyds Banking  LONDON LLOY  slipped 0 16  and the Royal Bank of Scotland  LONDON RBS  declined 0 48   while Barclays  LONDON BARC  saw shares plummet 2 33  following reports the lender set aside an additional  750 million for the settlement of a currency manipulation probe 
HSBC Holdings  LONDON HSBA  overperformed on the other hand  with shares gaining 0 38  
In the U S   equity markets pointed to a steady to lower open  The Dow Jones Industrial Average futures pointed to a 0 04  dip  S P 500 futures signaled a 0 09  loss  while the Nasdaq 100 futures indicated a 0 06  downtick ",2015-03-03,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-edge-higher-after-spanish,-german-data;-dax-up-0.23-330555",330555
203445,424961,MRK,Incyte  INCY  Beats On Q4 Revenues On Strong Jakafi Sales,opinion,"Incyte Corporation   NASDAQ INCY   reported a net loss of 71 cents compared to a net income of 5 cents in the year ago quarter  The fourth quarter saw a significant surge in R D expenses  Excluding one time charges and stock based compensation expenses  earnings per share was  0 02 
The Zacks Consensus Estimate was a loss of 52 cents Incyte Corporation Price  Consensus and EPS Surprise
 

   Quarterly revenues were  444 1 million  up 36 1  year over year and beat the Zacks Consensus Estimate of  418 4 million  The top line was driven by higher sales of Jakafi in the United States and Iclusig in Europe as well as royalties from sales of Jakavi and Olumiant outside the United States 

 
Incyte s stock lost 29 6  over the past year  compared with the  s  1 9  decline 
Quarter in Detail
Jakafi sales grew 26 9   year over year to  302 million driven by strong patient demand for both indications  Net product revenues of Iclusig amounted to  19 5 million  up from  12 9 million in the year ago quarter  Product royalty revenues from Novartis AG   NYSE NVS   for the commercialization of Jakafi in ex U S  markets grew 57 4  to  52 3 million 
R D expenses were up to  447 million from  161 6 million in the year ago quarter  SG A expenses amounted to  98 million  up 1 8  year over year 
2018 Outlook
The company expects Jakafi revenues in the range of  1 350  1 400 million  Iclusig revenues are expected in the range of  80  85 million 
R D expenses are expected in the range of  1 077 1 172 million  SG A expenses are still expected in the range of  465  480 million 
Pipeline Update
The phase II trial  REACH1 trial evaluating Jakafi in patients with steroid refractory acute graft versus host disease   GVHD   has completed enrolment and results are expected in the first half of 2018  Assuming the success of the trial  Incyte expects to submit sNDA seeking approval of Jakafi for this indication 
The phase III trial  ECHO 301  evaluating epacadostat plus Keytruda in patients with unresectable or metastatic melanoma is now fully recruited and initial data are expected in the first half of 2018 
Incyte has also opened eight new pivotal trials of epacadostat plus PD 1 antagonists in collaboration with Merck   Co    NYSE MRK   and Bristol Myers Squibb   NYSE BMY   
In December 2017  the New Drug Application  NDA  for baricitinib was resubmitted to the FDA  This was classified as a Class II resubmission  which began a new six month review cycle  A pivotal trial of baricitinib in patients with moderate to severe atopic dermatitis has also been initiated 
The European Commission has already approved baricitinib as Olumiant in February 2017 for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease modifying anti rheumatic drugs 
Our Take
Incyte beat on sales in the fourth quarter on strong Jakafi performance  Jakafi sales were driven by patient demand  The sales guidance for 2018 was also impressive 
The label expansion of Jakafi for GVHD will further boost sales  Meanwhile  the NDA for Olumiant was resubmitted and a potential approval will further boost the top line 
Zacks Rank
Incyte currently carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-15,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-beats-on-q4-revenues-on-strong-jakafi-sales-200291075,200291075
203446,424962,MRK,Bayer  BAYRY  Q4 Earnings Beat Estimates  Sales Down Y Y,opinion,Bayer AG  DE BAYGN  s   OTC BAYRY   fourth quarter 2017 core earnings per share from continuing operations were 42 cents per American Depository Receipt   ADR    which topped the Zacks Consensus Estimate of 31 cents On Sep 20  2017  Bayer performed an ADR ratio change  With the new ratio  four Bayer ADRs correspond to one Bayer ordinary share  The fourth quarter 2017 core earnings per share incorporate the effect of ADR ratio change  Earnings were down 40  year over year from 30 cents per ADR Total sales in the quarter were approximately  10 14 billion  down 6 4  year over year  While the company registered growth in sales and earnings at Pharmaceuticals  business declined at Consumer Health and Crop Science  Animal Health improved as well All growth rates mentioned below are on a year over year basis and after adjusting for currency and portfolio changes Fourth Quarter and Full Year HighlightsThe Bayer Group lost de facto control over the Covestro Group at the end of September 2017  As of Sep 30  2017   there are four reporting segments   Pharmaceuticals  Consumer Health  Crop Science and Animal Health  As such  total figures for the four Life Science segments will no longer be presented separately Revenues at the Pharmaceuticals segment decreased 1 4  to  4 215 million in the fourth quarter but increased 2 6  to  16 847 million in 2017  The growth for full year was backed by a persistently strong performance of the key products like Xarelto  Eylea  Xofigo  Stivarga and Adempas  However  this division experienced a considerable decline in Kogenate s sales  mainly because of a distribution partner placing a lower volume of orders for the active ingredient However  Consumer Health sales were down 9 1  to  1 399 million in the fourth quarter and declined 2 9  to  5 862 million in 2017   The decline was due to decline in revenues in North America  particularly in the United States  owing to the challenging market environment  Further  the Chinese authorities unexpectedly changed the legal status of two of Bayer s medicated skincare brands from OTC to prescription  which led to sales declines in the fourth quarter of 2017  However  business expanded slightly in Europe Middle East Africa  while sales in Latin America came in at the prior year level In the reported quarter  Crop Science sales were  2 263 million  down 5 9  year over year while sales for full year 2017 declined 3 4  to  9 577 million  Sales in the agriculture business declined due to the situation in the Brazilian crop protection business  where volumes were held back by unexpectedly high inventories in the marketThe Seeds business and Environmental Science registered gains  However  there was a decline at the Crop Protection business Sales of the Animal Health segment came in at  322 million  down 2 1  in the fourth quarter but increased 2 2  to  1 571 million in 2017  Sales improved positively in the regions of North America  besides progressing well in Asia Pacific region  The development in North American region was on the back of price increases  lower selling expenses and the revenues generated by the Cydectin product portfolio  which the company acquired from Boehringer Ingelheim Vetmedica  Inc in January 2017 2017 ResultsCore earnings per share from continued operations were  1 9 per share compared with  1 8 in 2016  Earnings missed the Zacks Consensus Estimate of  2 21 Revenues in 2017 were  39 6 billion  compared with 38 8 billion in 2016  Tjis missed the Zacks Consensus Estimate of  42 3 billion Discontinued OperationsBayer took a big step in 2017 toward its goal of achieving full separation from Covestro in the medium term by selling approximately 36   of the interest in that company for  4 7 billion  Bayer ceded de facto control of Covestro and deconsolidated the company at the end of September 2017  In sync with this  Covestro ceased to be a reportable segment in the third quarter and is now presented as a discontinued operation Bayer s direct interest in Covestro currently amounts to 14 2    Another 8 9  is held by Bayer Pension Trust Acquisitions and DivestmentOn Oct 13  2017  Bayer signed an agreement to sell selected Crop Science businesses to BASF for  5 9 billion  in light of the planned acquisition of Monsanto Company   NYSE MON    In the reported quarterthe Brazilian antitrust authorities approved the acquisition   The company also committed to divest its entire vegetable seed business  Certain additional business activities of Bayer and Monsanto may also be sold or out licensed The transaction is subject to regulatory approval as well as the successful closing of Bayer s acquisition of Monsanto  Meanwhile  Bayer will continue to own  operate and maintain these businesses until the closing of this divestiture We note that Bayer has made several acquisitions and entered into a number of deals to boost its portfolio in the past few quarters  In September 2014  it acquired Merck s   NYSE MRK   consumer care business for  14 2 billion   10 4 billion   Besides category expansion  the addition of Merck s consumer care business expanded Bayer s geographic reach In addition  Bayer has a license and collaboration agreement with Regeneron   NASDAQ REGN   for the global development and commercialization of Eylea in ex U S  markets 2018 OutlookFor 2018  Bayer expects sales to be in about  35 billion  Bayer expects sales to increase by a low  to mid single digit percentage on a currency  and portfolio adjusted basis Through the expected acquisition of Monsanto in the second quarter of 2018  Bayer anticipates a significant increase in sales and earnings before interest  tax  depreciation and amortization  EBITDA  before special itemsThe Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/bayer-bayry-q4-earnings-beat-estimates-sales-down-yy-200295319,200295319
203447,424963,MRK,Horizon Pharma  HZNP  Tops Q4 Earnings  Provides 2018 View,opinion,"Horizon Pharma plc   NASDAQ HZNP   reported better than expected results for the fourth quarter of 2017   Following the news  the company s shares went up 1 4   However  Horizon Pharma s stock has declined 8 2  year to date  against the  s fall of 6 9  The company reported fourth quarter earnings of 29 cents per share which beat the Zacks Consensus Estimate of 22 cents but were down from 64 cents in the year ago quarter Sales in the fourth quarter were down 12  year over year to  274 2 million but beat the Zacks Consensus Estimate of  267 58 million Quarter in DetailThe Orphan unit recorded revenues of  116 6 million  up 32  from the year ago period  The strong performance was backed by solid net sales of Ravicti  which generated  51 9 million in the quarter  up 57  year over year  driven by continued conversion from older generation nitrogen scavenger therapies as well as the addition of treatment na ve patients due to the recent label expansion  In April 2017  Ravicti s label was expanded by including patients aging from two months to two years and older Additionally  Procysbi contributed to the performance with its net sales of  33 2 million  up 31  year over year  Actimmune sales in the reported quarter were  26 8 million  up 11  year over year The Rheumatology unit generated  61 4 million from sales  up 48  year over year  Also  Krystexxa sales in the quarter were strong and came in at  43 8 million  up 48  year over year  driven by strong and continued year over year vial demand Primary Care garnered revenues of  96 2 million  down 47  year over year  The decline in net sales was due to the implementation of a new contracting model  in order to secure broader inclusion of the company s primary care medicines on formularies In the reported quarter  net sales of Pennsaid2   Duexix and Vimovo were  50 million   28 2 million and  16 6 million  respectively Research and development  R D  expenses increased 28 8  to  15 3 million while selling  general and administrative expense was  126 5 million  down 16 6  year over year 2017 PerformanceRevenues for the full year were up 7 7  to  1 1 billion  However  the company reported earnings of  1 18 per share  down 45 4  year over year The Orphan unit recorded revenues of  116 6 million  up 32  from the year ago period  driven by 445  growth in sales of Procysbi to  137 7 million  Procysbi was acquired in October 2016  The sales of Rheumatology unit also grew 50  mainly driven by sales of Krystexxa at  156 5 million  up 72  year over year  However  Primary Care unit sales were down 38  to  375 4 million The full year s R D expense increased 270 6  to  225 million while selling  general and administrative expense was  677 4 million  11 4  higher year over year 2018 GuidanceHorizon Pharma provided its outlook for 2018  It expects sales in the range of  1 15  1 18 billion  mainly driven by expected strong growth to continue in its orphan and rheumatology business units The company continues to invest in the expansion of Krystexxa into nephrology indication and expects sales growth of more than 50  in 2018   The guidance includes an assumption of lower net average and net realized price  beginning in the second half  primarily resulting from the U S  Government s Health Resource and Services Administration s Final Rule on 340B drug ceiling price implementation scheduled for July 2018 Horizon Pharma is significantly increasing investments in one of its key growth drivers  Krystexxa  and expects net sales for it to grow more than 50   The company expects higher R D and SG A expenses in the first half of 2018 Other UpdatesIn February 2018  the company filed a supplemental New Drug Application to expand the age range in the label of Raviciti from two months of age and older to birth and older In December 2017  a regulatory application  seeking label expansion of Procysbi to include children of one year and older living with nephropathic cystinosis  was filed with the FDA In October 2017  the company announced that the first patient was enrolled and infused in phase III confirmatory clinical trial evaluating teprotumumab for the treatment of thyroid eye disease or TED  We remind investors that the company acquired River Vision earlier and added its biologic candidate teprotumumab to its pipeline Meanwhile  the company is working on expanding Actimmune s label   An investigator initiated study at the Moffitt Cancer Center is underway and enrolling patients  The study is evaluating Actimmune in combination with Roche Holdings    OTC RHHBY   Herceptin  Perjeta and Taxol in certain advanced breast cancer patients  A phase I study will evaluate Actimmune in combination with a Bristol Myers Squibb Company s   NYSE BMY   Opdivo in kidney and bladder cancer  Actimmune is also being evaluated in combination with Merck   Co s   NYSE MRK   Keytruda to treat cutaneous t cell lymphoma patients in phase II study The company also has plans to develop two next generation uncontrolled gout development programs to maintain its market leadership Our TakeHorizon Pharma s fourth quarter results were impressive with the company beating on both the top  and bottom line estimates  Moreover  the sales guidance for 2018 was encouraging as well  We expect Krystexxa  Ravicti and Actimmune to drive further growth The acquisition of teprotumumab has diversified the company s portfolio Horizon Pharma PLC Price  Consensus and EPS Surprise
    Zacks RankHorizon Pharma currently has a Zacks Rank  3  Hold  You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/horizon-pharma-hznp-tops-q4-earnings-provides-2018-view-200295561,200295561
203454,424970,MRK,Nektar  Bristol Myers Tie Up For Cancer Combos Drives Stock,opinion,Nektar Therapeutics    NASDAQ NKTR   shares increased more than 11  on Feb 14 after the company announced a global strategic collaboration agreement with Bristol Myers Squibb   NYSE BMY    Per the agreement  both companies will jointly develop and commercialize the lead immuno oncology candidate  NKTR 214  of the former in combination with the latter s Opdivo  nivolumab  and Opdivo plus Yervoy  ipilimumab  Pursuant to the contract  Nektar is entitled to receive an upfront payment of  1 85 billion  which includes a payment of  1 billion in cash and an equity investment of  850 million  Nektar will also get an additional  1 78 billion potential payment on achievement of certain developmental and sale based milestones Both Nektar and Bristol Myers will share profits in the respective ratios of 65  and 35  from the potential sales of NKTR 214  worldwide On a positive note  Nektar not only retains its ownership of the candidate but can also continue to collaborate with other companies for its further development  While Nektar will jointly commercialize NKTR 214 Opdivo combinations in the United States as well as major markets in the EU and Japan  Bristol Myers is entitled to solely commercialize the combinations in the other global markets We remind investors that Nektar is already evaluating NKTR 214 Opdivo in phase I II PIVOT studies across five tumor types  melanoma  kidney  colorectal  bladder and non small cell lung cancer  and eight potential indications  With this latest deal with Bristol Myers  it has been agreed upon by both companies to evaluate NKTR 214 Opdivo and NKTR 214 Opdivo plus Yervoy combinations in more than 20 cancer indications across nine tumor types In November 2017  the two companies reported a positive interim data from dose escalation part of the study  evaluating the safety and efficacy of the combo therapy on patients with melanoma  renal cell carcinoma and non small cell lung cancers Nektar s shares have significantly outperformed the  in a year s time  The stock has skyrocketed 513 2  compared with the industry s 0 4  increase  Importantly  Nektar is also conducting a phase I II PROPEL study to evaluate the efficacy and safety of NKTR 214 in combination with Roche s   OTC RHHBY   Tecentriq  atezolizumab  and Merck s   NYSE MRK   Keytruda  pembrolizumab   Notably  this PROPEL study complements the company s ongoing PIVOT trial Additionally  in May 2017  Nektar had entered into a research collaboration with Takeda Pharmaceuticals to explore the combination of NKTR 214 with five oncology compounds from Takeda s cancer portfolio Nektar Therapeutics Price    Zacks RankNektar carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-14,Zacks Investment Research,https://www.investing.com/analysis/nektar-bristolmyers-tieup-for-cancer-combos-drives-stock-200291085,200291085
203461,424977,MRK,Pfizer dampens Astra bid hopes with German Merck cancer deal,news,"By Ludwig Burger and Ben Hirschler FRANKFURT LONDON  Reuters    Pfizer  N PFE  dampened investors  expectations of a renewed bid for AstraZeneca  L AZN  on Monday by signing a major cancer drug deal with Germany s Merck KGaA  DE MRCG   reducing the U S  firm s need for Astra s products 
Merck will get an upfront payment of  850 million from the U S  drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer  It is also eligible for up to  2 billion in payments based on the medicine s future success 
Merck s MSB0010718C is part of a class of drugs known as anti PD L1 therapies  which work by blocking a tumor s ability to evade the immune system s defense 
The exclusive nature of the deal means Pfizer and Merck cannot collaborate with any other drugmaker in the PD LI or related PD 1 area  unless they jointly agree to do so 
Such immune boosting medicines represent the hottest area of cancer research and are also a major focus for AstraZeneca  which has a rival anti PD L1 product in development called MEDI4736 
Winning access to AstraZeneca s cancer pipeline has been viewed as a major goal for Pfizer  which was unsuccessful with a  118 billion bid for the British group in May  It has a chance to renew its approach under British takeover rules from Nov  26 
Shares in Merck jumped 2 4 percent on the news  while AstraZeneca slid 2 2 percent by 0510 ET  The British company s stock had already fallen on Friday after several people familiar with the matter said Pfizer seemed unlikely to renew its approach 
Pfizer said immuno oncology was  a top priority  for the firm but a spokeswoman said British rules did not allow it to make any comment on its intentions toward AstraZeneca 
HIGH PRICE
As a result of the cost of the deal  Pfizer said it now expected its 2014 reported diluted earnings per share to be between  1 40 and  1 49  compared with  1 50 1 59 indicated previously 
The drugmaker is paying a high price for a medicine that has yet to prove itself in full scale clinical tests  reflecting intense competition among firms wanting to do a deal  according to Belen Garijo  who will head Merck s healthcare business from next year 
Merck said in September it in talks about a partnership deal for the drug  which is being investigated as a treatment for lung and ovarian cancer  as well as the rare skin cancer Merkel cell carcinoma 
Pfizer and Merck will develop the German company s treatment as a single therapy as well as in combinations with Pfizer s and Merck s portfolio of approved and experimental drug candidates 
Up to 20 high clinical development programs are expected to begin in 2015  including as many as six Phase II or III trials that could be used to seek regulatory approval 
Merck s drug is some way behind rivals from Bristol Myers Squibb  N BMY   Roche  VX ROG   AstraZeneca and U S  namesake Merck   Co  N MRK   so advancing it quickly in clinical tests with a deep pocketed partner such as Pfizer makes good sense  according to analysts at Berenberg Bank 

Pfizer and Merck will jointly fund all development and marketing costs  and will share all revenues  They also agreed to co promote Pfizer s Xalkori cancer drug in the United States and other markets 
 Editing by Louise Heavens  editing by David Stamp ",2014-11-17,Reuters,"https://www.investing.com/news/stock-market-news/german-merck,-pfizer-in-cancer-immunotherapy-deal-316997",316997
203462,424978,MRK,Merck to take on superbugs with Cubist Pharma buy,news,"By Vidya L Nathan and Ben Hirschler   Reuters    Merck   Co Inc  N MRK  said it would buy Cubist Pharmaceuticals Inc  O CBST  for  8 4 billion plus assumption of debt  giving the major drugmaker an entry into the market for drugs that combat so called superbugs   The deal is the latest sign that large pharmaceutical companies are turning their attention back to antibiotics after decades of low investment   The spread of superbugs that evade even the most powerful antibiotics threatens modern medicine  the World Health Organization said in April  warning of  a post antibiotic era  in which common infections were killers once again   The U S  Centers for Disease Control and Prevention estimated last year that more than 2 million people in the United States are sickened every year by superbug infections  with at least 23 000 dying as a result      Merck said on Monday that the deal  which will give it access to Cubist s antibiotic Cubicin  is expected to add more than  1 billion to revenue in 2015 after closing in the first quarter  but will be neutral to non GAAP earnings per share until 2016   Cubist s third quarter sales rose 16 percent  driven by strong sales of Cubicin   Cubist may lose patent protection for Cubicin earlier than expected  after a Friday federal court ruling that invalidated four of its patents  If the ruling stands  it will allow Hospira Inc to launch a generic version of the drug in 2016   Merck could not immediately be reached for comment on the ruling   Cubist s lead drug in development  Ceftolozane Tazobactam  is widely expected to win marketing approval from the U S  Food and Drug Administration later this month as a treatment for complicated urinary tract infections   Merck will pay  102 per share for Cubist  a premium of 37 percent to the Lexington  Massachussetts based company s closing share price of  74 36 on Friday   The deal includes assumption of  1 1 billion in debt    Cubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late stage pipeline medicines   Merck CEO Kenneth Frazier said in a statement    Combining this expertise with Merck s strong capabilities and global reach will enable us to create a stronger position in hospital acute care while addressing critical areas of unmet medical need  such as antibiotic resistance    Merck has said it is focusing on acute care within hospitals   considered a hotbed for superbug infections such as bacterial pneumonia   as a top priority   Many drugmakers have cut investment in the past because antibiotics are typically low priced and used for only short periods  generating poor returns  That has fueled demands for a rethink of the antibiotic market model   It has also left Cubist as a leading investor in the field  with an annual research budget for antibiotics of  400 million   More recently  however  there have been signs of a revival  with Roche Holding AG  VX ROG   GlaxoSmithKline Plc  L GSK  and Sanofi SA  PA SASY  all investing in new approaches to fight superbugs   Cubist shares were trading at  101 04 premarket  Merck shares were unchanged from Friday s close at  61 50   The New York Times  citing people briefed on the matter  first reported the deal on Friday   The Cubist deal is Merck s second big acquisition this year  The company bought Idenix Pharmaceuticals for  3 85 billion in June to boost its hepatitis C drug portfolio   
 Top pharmaceutical deals       Editing by Ted Kerr ",2014-12-08,Reuters,https://www.investing.com/news/economy-news/merck-to-take-on-superbugs-with-cubist-pharma-buy-319450,319450
203463,424979,MRK,Merck says still plans to buy Cubist  despite patent setback,news," Reuters    Merck   Co Inc  N MRK  said on Tuesday it will proceed with its planned  8 4 billion purchase of Cubist Pharmaceuticals Inc  O CBST  and still expects the deal to boost its long term earnings  despite a court ruling that could speed the arrival of generic forms of Cubist s top selling product   Merck shares fell 3 7 percent to  59 55 in early trading  Cubist slid nearly 3 percent to  97 60   Late Friday  Merck said it planned to buy Cubist  whose flagship product is the widely used antibiotic Cubicin for skin infections  The deal would give Merck  the No  2 U S  drugmaker  entry into the market for drugs that fight so called superbugs   U S  District Judge Gregory Sleet in Delaware invalidated four Cubicin patents on Monday and ruled that Hospira Inc  N HSP  can launch a generic version of Cubicin as soon as 2016  two years sooner than Wall Street expected   Merck  in a release on Tuesday  said it still expects to complete its purchase of Cubist in the first quarter of 2015  and noted that Sleet s decision  is subject to appeal     The combined strength of both companies will provide both incremental and long term value  and Merck expects the transaction to add more than  1 billion of revenue to its 2015 base  with strong growth potential thereafter   Merck said   Leerink Partners analyst Seamus Fernandez said late Monday he expected several less expensive generic forms of Cubicin to be introduced in the United States by late 2016  given Sleet s ruling   
Fernandez said lost Cubicin sales from the generics suggested the price Merck will pay for Cubist  looks  2 billion to  3 billion high     This is a very tough start to a relatively sound strategic deal      Reporting by Ransdell Pierson  Editing by Jeffrey Benkoe ",2014-12-09,Reuters,"https://www.investing.com/news/stock-market-news/merck-says-still-plans-cubist-purchase,-despite-patent-setback-319569",319569
203472,424988,MRK,Merck beats by  0 02  misses on revenue,news,"Investing com   U S  pharmaceutical giant Merck   Company Inc  NYSE MRK  reported better than expected third quarter earnings ahead of Monday s opening bell  despite missing on revenue figures 
Merck said adjusted earnings came in at  0 90 per share in the three months ending September 30  beating expectations for earnings of  0 88 per share 
The company s third quarter revenue totaled  10 56 billion  below estimates for revenue of  10 65 billion 
The pharmaceutical company lowered its 2014 revenue forecast to a range between  42 4 billion and  42 8 billion and said it expected full year earnings per share in a range between  3 46 to  3 50 
 We delivered solid third quarter results and are making steady progress in our transformation  including divesting non core assets  reducing our expense base and investing in our promising new product launches and pipeline    said Kenneth C  Frazier  chairman and chief executive officer  Merck 
Following the release of the report  Merck  NYSE MRK  saw shares rise 0 7  in pre market trade 
Meanwhile  the outlook for U S  equity markets was downbeat  The Dow futures indicated a loss of 0 05  at the open  the S P 500 futures pointed to a decline of 0 15   while Nasdaq 100 futures shed 0 05  ",2014-10-27,Investing.com,"https://www.investing.com/news/stock-market-news/merck-beats-by-$0.02,-misses-on-revenue-314348",314348
203476,424992,MRK,Is A Beat In The Cards For AbbVie  ABBV  In Q4 Earnings ,opinion,We expect AbbVie Inc    NYSE ABBV   to beat expectations when it reports fourth quarter 2017 results on Jan 26 before the market opens  Last quarter  the company delivered a positive earnings surprise of 1 44  AbbVie s shares have soared 73 9  in a year s time  ahead of the  s rally of 24 6   Notably  AbbVie s earnings history is quite impressive with the pharmaceuticals company outpacing estimates in three of the last four quarters and meeting the same in one  Overall  AbbVie has an average beat of 1 12  Let s see  how things are shaping up for the company this quarter Factors to ConsiderAbbVie expects fourth quarter 2017 earnings in the range of  1 42  1 44 per share  Revenues are estimated to grow approximately 10  on an operational basis  Foreign exchange is anticipated to have a 2  favorable impact on sales in the period to be reported The company s key drug  Humira  is likely to remain the growth driver in the fourth quarter  backed by strong demand trends for the drug  AbbVie expects Humira full year sales growth in the mid to high teens range while internationally  the metric is projected in a mid single digit range on an operational basis  The Zacks Consensus Estimate for Humira is  4 8 billion for the to be reported quarter Significantly  on fourth quarter conference call  investors  focus will also be on the performance and label expansion updates of AbbVie s another cancer drug  Imbruvica  The drug has been recording strong sales since the past few quarters  a trend that we expect to continue even in the quarter to be reported  The Zacks Consensus Estimate for Imbruvica is  704 million for the period Other drugs like Duopa and Creon are also likely to continue to perform well in the soon to be reported quarter However  AbbVie s Hepatitis C virus  HCV  treatment  Viekira  will continue to see declining sales impacted by an intense pricing and competitive pressure in the HCV market Notably  AbbVie s eight week  pan genotypic  ribavirin free  once daily HCV treatment  Mavyret  gained approval in the United States  EU  Canada and Japan in third quarter 2017  Mavyret recorded  100 million global sales in the quarter  The initial uptake of the drug has been impressive and we expect its higher sales in the fourth quarter Earnings WhispersOur proven model shows that the stock is likely to beat on earnings this quarter as it has the right combination of the two key ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for this to happen Zacks ESP  AbbViehas an Earnings ESP of  1 30   representing the difference between the Most Accurate estimate   1 46 per share  and the Zacks Consensus Estimate   1 44   Moreover  a positive ESP indicates a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AbbVie has a Zacks Rank  3  which increases the predictive power of ESP and together with a positive ESP  chances of beating estimates in the stock s upcoming release are always pegged higher We caution against all Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions AbbVie Inc  Price and EPS Surprise    Other Stocks That Warrant a LookHere are some other health care stocks worth considering as per our model  these comprise the right combination of elements to beat on earnings this time around Pfizer  Inc    NYSE PFE   is scheduled to release results on Jan 30  The company has an Earnings ESP of  0 30  and a Zacks Rank  2  You can see  Merck   Co   Inc    NYSE MRK   has an Earnings ESP of  1 06  and a Zacks Rank of 3  The company is scheduled to report earnings numbers on Feb 2 Astrazeneca  LON AZN  PLC   NYSE AZN   is slated to announce financial figures on Feb 2  The company has an Earnings ESP of  6 82  and is a Zacks  3 Ranked player The Hottest Tech Mega Trend of All  Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-23,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-abbvie-abbv-in-q4-earnings-200283054,200283054
203480,424996,MRK,Pfizer wins dismissal of U S  investor class action ahead of trial,news,"By Nate Raymond NEW YORK  Reuters    Pfizer Inc  N PFE  won the dismissal Tuesday of a long running shareholder class action accusing the company of misleading investors about the safety of its Celebrex and Bextra pain relieving drugs 
The ruling by U S  District Judge Laura Taylor Swain in New York came ahead of a Sept  9 trial in the case  which investors launched in 2004 and followed an earlier ruling precluding testimony by the plaintiffs  damages expert 
A lawyer for the plaintiffs  James Sabella  had acknowledged at a hearing after that May ruling that  without a damages expert a securities fraud trial can t be tried  
They sought to amend a report issued by their expert  Daniel Fischel  a former dean of the law school at the University of Chicago whose methodology for calculating damages Swain had found to be flawed 
Swain  however  said the plaintiffs did not deserve a second chance and agreed with Pfizer the case should be dismissed 
 Plaintiffs  failure to proffer admissible loss causation and damages evidence is fatal to plaintiffs  claims   Swain wrote 
Pfizer in a statement said it was pleased with the ruling  adding it  has always believed the evidence in this case demonstrates that the company s historical statements about Celebrex and Bextra were accurate  
Sabella  a partner at law firm Grant   Eisenhofer who represented lead plaintiff Teachers  Retirement System of Louisiana  did not immediately respond to a request for comment 
The class action  which Swain had previously certified  covered investors who bought Pfizer stock between October 31  2000  and October 19  2005 
Concerns about the safety of Celebrex and Bextra began to mount following the release of medical studies in late 2004  when rival Merck   Co Inc  N MRK  withdrew its own Vioxx drug from the market because of associated cardiovascular risks 
The lawsuit contended before fall of 2004  Pfizer and its executives hid material results of tests conducted starting in 1998 regarding the safety of Celebrex and Bextra that indicated similar risks 
Revenues from Celebrex and Bextra fell by over  2 billion in the first nine months of 2005 after the safety concerns were made public  the lawsuit said 
The company s market capitalization meanwhile dropped by  68 4 billion between October 2004 and October 2005  the lawsuit said 
Pfizer pulled Bextra from the U S  market in April 2005 at the recommendation of the U S  Food and Drug Administration 

In September 2009  Pfizer agreed to pay  2 3 billion to settle a U S  Department of Justice probe into the marketing of drugs including Bextra 
The case is In re  Pfizer Inc Securities Litigation  U S  District Court  Southern District of New York  No  05 md 01688 
 Reporting by Nate Raymond in New York  Editing by Cynthia Osterman ",2014-07-08,Reuters,https://www.investing.com/news/stock-market-news/pfizer-wins-dismissal-of-u.s.-investor-class-action-ahead-of-trial-293813,293813
203481,424997,MRK,Merck Q2 adjusted EPS  0 85  vs   0 81 estimate,news,"Investing com   U S  pharmaceutical giant Merck   Company  NYSE MRK  reported better than expected second quarter earnings and revenue figures ahead of Tuesday s opening bell  sending its shares modestly higher in pre market trade 
Merck said adjusted earnings came in at  0 85 per share in the second quarter  beating expectations for earnings of  0 81 per share 
The company s second quarter revenue totaled  10 93 billion  above estimates for revenue of  10 61 billion 
The pharmaceutical company reaffirmed its 2014 revenue forecast and said it expected full year earnings per share in a range between  3 43 to  3 53 
 We delivered a strong first half of the year  making progress in transforming our operating model  fueling innovation and managing costs  while focusing on our best opportunities   said Kenneth C  Frazier  chairman and chief executive officer  Merck 
Following the release of the report  Merck  NYSE MRK  saw shares rise 0 1  in pre market trade 
Meanwhile  the outlook for U S  equity markets was higher  The Dow indicated a gain of 0 2  at the open  the S P 500 pointed to an increase of 0 15   while Nasdaq 100 added 0 2  ",2014-07-29,Investing.com,"https://www.investing.com/news/stock-market-news/merck-q2-adjusted-eps-$0.85,-vs.-$0.81-estimate-298623",298623
203482,424998,MRK,Pfizer leaves investors guessing on intentions for Astra,news,"By Ransdell Pierson   Reuters    Pfizer Inc  N PFE   which in May abandoned its  118 billion bid for AstraZeneca Plc  L AZN   on Tuesday left investors guessing whether it would renew its pursuit of its British rival  but said it was considering other deals   The largest U S  drugmaker reported higher than expected second quarter revenue  helped by growing demand for its cancer medicines  But overall sales fell on competition with newer rival drugs and cheaper generics  trends that have quickened Pfizer s efforts to buy companies and drugs that can fortify its medicine chest   Under UK takeover rules  AstraZeneca can attempt to re engage with Pfizer in August  and Pfizer can make another run at AstraZeneca in November   Pfizer officials on Tuesday gave no hints of whether they would do so  although Chief Executive Ian Read said Pfizer is not currently  doing any work on AstraZeneca  because of a six month quiet period imposed by U K  regulators    I think it s best to remain silent   Read said on an investor conference call  citing the takeover rules   Pfizer officially gave up its six month quest to buy AstraZeneca after its final bid was rejected on May 26  It had hoped to locate the combined company in Britain  which has lower taxes than the United States  a maneuver called tax inversion   Read said Pfizer was also looking at other potential deals and that taxes would be one of three major considerations   Other factors are whether a potential acquisition is undervalued  and whether cost savings from a deal would offset a premium price for shares of the target company   Read said Pfizer shareholders appreciated the company s limiting the final Astra offer to 55 pounds a share  rather than the minimum bid of 59 pounds that the British company had wanted   While 4 pounds might not seem a major chasm  Chief Financial Officer Frank D Amelio quickly interjected in an interview   Every pound was  2 billion    Pfizer shares have been flat this year due to declining revenue  while the drug sector as a whole has seen shares rise 11 percent   In the next four years  generic rivals will challenge well known Pfizer products such as the Celebrex painkiller  Lyrica nerve pain treatment and anti impotence drug Viagra  putting pressure on Pfizer to acquire new products   JP Morgan analyst Chris Schott speculated Pfizer may seek other tax inversion opportunities if it is unable to reach a friendly deal with AstraZeneca   In the meantime  Pfizer is developing new drugs  including a promising treatment for breast cancer called Palbociclib that could be approved next year   Pfizer s research chief  Mikael Dolsten  said new uses for its Prevnar vaccine against pneumococcal bacteria and Xeljanz arthritis treatment could also bolster Pfizer  New vaccines against staph aureus and c  difficile bacteria could prove to be hidden gems in the Pfizer pipeline  he added   Pfizer earned  2 91 billion  or 45 cents per share  in the second quarter  That compared with  14 1 billion  or  1 98 per share  a year earlier  when it received more than  10 billion in proceeds from the spinoff of its animal health business  creating Zoetis  N ZTS    Excluding special items  Pfizer earned 58 cents per share  Analysts on average expected 57 cents  according to Thomson Reuters I B E S   Sales fell 2 percent to  12 77 billion but exceeded Wall Street expectations of  12 46 billion   Sales of oncology medicines rose 16 percent to  570 million  but generic medicines that Pfizer calls established products and sells in emerging markets had lower sales   Pfizer stuck to its prior earnings forecast of  2 20 to  2 30 per share for the full year   Merck   Co  N MRK   the second biggest U S  drugmaker  also reported higher than expected quarterly results on Tuesday   
Pfizer shares closed down 1 2 percent to  29 73     Reporting by Ransdell Pierson  Editing by Lisa Von Ahn and David Gregorio ",2014-07-29,Reuters,https://www.investing.com/news/stock-market-news/pfizer-beats-forecasts-as-oncology-drugs-grow-298689,298689
203486,425002,MRK,Bristol Myers  BMY  Reports Data From CheckMate 142 Study,opinion,Bristol Myers Squibb Company   NYSE BMY   announced new data from a cohort of the phase II CheckMate  142 study on Opdivo CheckMate 142 study is an ongoing study evaluating Opdivo  nivolumab  and Yervoy  ipilimumab  for previously treated patients with DNA mismatch repair deficient  dMMR  or microsatellite instability high  MSI H  metastatic colorectal cancer  Results from the study showed that the primary endpoint of objective response rate per investigator assessment was 55   with a median follow up of 13 4 months  The overall survival rate at one year was 85   and median OS was not yet reached   The results showed that Opdivo plus Yervoy provide durable clinical benefit in patients with dMMR or MSI H metastatic colorectal cancer The data showed statistically significant and clinically meaningful improvements in key patient reported outcomes  including symptoms  functioning and quality of life Bristol Myers  shares have rallied 24 5  in the past one year compared with the  gain of 23 9    We note that Opdivo is already approved for a number of indications  These include classical Hodgkin lymphoma  recurrent or metastatic squamous cell carcinoma of the head and neck  SCCHN  with disease progression on or after platinum based therapy  Additionally  it is approved as a monotherapy for the treatment of SCCHN in adults progressing on or after platinum based therapy Opdivo is also approved for intravenous use for patients with hepatocellular carcinoma  who have been previously treated with Nexavar  The drug received approval for liver and colorectal cancers as well Meanwhile  the company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  Label expansion of the drug into additional indications would give the product an access to a higher patient population and increase the its commercial potential significantly However  Opdivo is facing competitive challenges in the United States  With the FDA approving Merck s   NYSE MRK   Keytruda  for the first line treatment of metastatic non squamous non small cell lung cancer  NSCLC   the company is expected to suffer further loss of market share  Bristol Myers Squibb Company Price     Zacks Rank   Stocks to ConsiderBristol Myers carries a Zacks Rank  3  Hold   A few better ranked stocks from the health care space are Exelixis  Inc    NASDAQ EXEL   and XOMA Corporation   NASDAQ XOMA    While XOMA sports a Zacks Rank  1  Strong Buy   Exelixis carries a Zacks Rank  2  Buy  You can see  Exelixis  earnings per share estimates have moved up from 72 cents to 73 cents for 2018 in the last 60 days  The company delivered a positive earnings surprise in all the last four quarters  with an average of 572 92   Share price of the company surged 53 1  in 2017 XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 in the last 60 days  The company posted a positive earnings surprise in one of the last four quarters  with an average beat of 47 92   Share price of the company skyrocketed 656 3  in 2017 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-bmy-reports-data-from-checkmate142-study-200282351,200282351
203496,425012,MRK,Bayer Paying  14 2B For Merck s Consumer Care Business,news,"By    Bayer AG NA  XETRA BAYGN  said Tuesday it will pay  14 2 billion for the consumer care business of Merck   Co  Inc   NYSE MRK   giving the giant German chemical and pharmaceutical company global trademark and prescription rights to such well known brands as Claritin allergy medicine  Coppertone suntan lotion and Dr  Scholl s foot care products 
Merck  which is based near Philadelphia  said it expects after tax proceeds of between  8 billion and  9 billion from the sale  which is expected to close later this year  The U S  company will use the proceeds to fund development of such medicines as MK 3475  a prospective melanoma cancer drug 

In addition  the two companies announced a worldwide clinical development collaboration to market and develop drugs for cardioavscular disease  including hypertension drug Adempas ",2014-05-06,International Business Times,https://www.investing.com/news/stock-market-news/bayer-paying-$14.2b-for-merck's-consumer-care-business-282066,282066
203499,425015,MRK,Novo Nordisk s Ozempic Gets Canadian Approval For Diabetes,opinion,Novo Nordisk  CO NOVOb    NYSE NVO   announced that Health Canada has approved Ozempic  semaglutide injection  to improve glycemic control in adults with type II diabetes mellitus  when metformin is not tolerated or contraindicated  Ozempic  a once weekly glucagon like peptide 1  GLP 1  receptor agonist  can also be used together with other antidiabetic drugs when diet and exercise do not achieve adequate glycemic control Shares of the company have rallied 52 4  compared with the  s gain of 16 8  in the past year The approval of Ozempic was based on results from the phase III SUSTAIN study  The results showed that people with type II diabetes  who are treated with once weekly semaglutide  experienced statistically significant and sustained blood glucose control compared with Merck s   NYSE MRK   Januvia  sitagliptin   Astrazeneca s   NYSE AZN   once weekly Bydureon  exenatide extended release   Sanofi s   NYSE SNY   Lantus  insulin glargine  and placebo In December 2017  the FDA approved Ozempic once daily pre filled pen to improve glycaemic control in type II diabetes patients  European regulatory authorities also adopted a positive opinion  recommending marketing authorization for Ozempicon Dec 15 Additionally  Novo Nordisk is making efforts to develop new treatments for diabetes  which is its core area of expertise  In September 2017  the company received approval for its fast acting insulin aspart  Fiasp  Other than semaglutide  its key pipeline candidate includes nonacog beta pegol  The approval of the drug will give a boost to the company s revenues Novo Nordisk A S Price    Zacks RankNovo Nordisk carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-01-09,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-ozempic-gets-canadian-approval-for-diabetes-200279153,200279153
203506,425022,MRK,Merck Q1 adjusted EPS  0 88  vs   0 79 estimate  stock up 3 2 ,news,"Investing com   U S  pharmaceutical giant Merck reported better than expected first quarter earnings ahead of Tuesday s opening bell  sending its shares higher in pre market trade 
Merck said adjusted earnings came in at  0 88 per share in the three months ended March 31  beating expectations for earnings of  0 79 per share 
The firm s first quarter revenue totaled  10 3 billion  missing estimates for revenue of  10 44 billion 
The pharmaceutical company reaffirmed its 2014 revenue forecast and said it expected full year earnings per share in a range between  3 35 to  3 53 
Following the release of the report  Merck  NYSE MRK  saw shares rise 3 2  in pre market trade 
Meanwhile  the outlook for U S  equity markets was higher  The Dow indicated a gain of 0 4  at the open  S P 500 futures pointed to an increase of 0 45   while Nasdaq 100 added 0 55  ",2014-04-29,Investing.com,"https://www.investing.com/news/stock-market-news/merck-q1-adjusted-eps-$0.88,-vs.-$0.79-estimate;-stock-up-3.2-280254",280254
203507,425023,MRK,U S  stocks rise ahead of consumer confidence data  Dow Jones up 0 48 ,news,"Investing com   U S  stocks opened higher on Tuesday  as investors eyed the release of upcoming U S  consumer confidence data  as well as the Federal Reserve s monthly policy statement due on Wednesday 
During early U S  trade  the Dow 30 gained 0 48   the S P 500 climbed 0 45   while the NASDAQ Composite advanced 0 48  
Earlier Tuesday  Standard   Poor s with Case Shiller said its house price index rose at an annualized rate of 12 9  in February from a year earlier  compared to forecasts for a 13  gain and following a rise of 13 2  in January 
Month on month  U S  home prices were little changed in February after dipping 0 1  in the preceding month 
In the telecom sector  mobile phone carrier AT T  NYSE T  jumped 0 97  after saying it is preparing to introduce 4G LTE wireless Internet access to commercial flights 
On the downside  LinkedIn  NYSE LNKD  plummeted 1 27  following reports the company s Chief Executive Officer Jeff Weiner s total compensation rose more than 40 fold to  49 1 million last year 
The news came after the stock dropped over 6  on Monday  amid reports investors are questioning whether Web companies can keep up revenue expansion  as some show signs of slowing gains in the number of users 
Pfizer  NYSE PFE  added to losses  down 0 12   as the drugmaker was said to be considering reducing its tax bill by moving its legal address outside the U S  The U S  company made headlines last week after confirming its willingness to acquire London based Astrazeneca  AZN LONDON  for about  58 8 billion 
In earnings news  Merck   Company  NYSE MRK  posted quarterly results that exceeded analysts  estimates  but said revenue fell just under expectations  Shares jumped 1 64  at the open of the U S  trading session 
Sprint  NYSE S  suged 2 15  after the wireless carrier reported a smaller than expected loss in the first quarter 
Other stocks likely to be in focus included Bristol Myers Squibb  NYSE BMY   Twitter  NYSE TWTR   eBay  NASDAQ EBAY  and Dreamworks Animation  NASDAQ DWA   scheduled to report quarterly results throughout the day 
Across the Atlantic  European stock markets were sharply higher  The DJ Euro Stoxx 50 jumped 1 17   France s CAC 40 gained 0 64   Germany s DAX rallied 1 21   while Britain s FTSE 100 advanced 0 69  
During the Asian trading session  Hong Kong s Hang Seng jumped 1 45   while Japan s Nikkei 225 remained closed for a national holiday 
Later in the day  the U S  was to publish a report compiled by the Conference Board on consumer confidence ",2014-04-29,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-rise-ahead-of-consumer-confidence-data;-dow-jones-up-0.48-280371,280371
203510,425026,MRK,5 Healthcare Mutual Funds To Buy In 2018,opinion,Last year was quite an eventful one for the U S  healthcare sector in particular  The economy witnessed the Republican tax reform becoming law and three rate hikes by the Fed  Thanks to both  healthcare was one of the top performers of 2017  The Health Care Select Sector SPDR ETF  NYSE XLV  rallied 19 5  year  This momentum is slated continue in 2018 Moreover  investors no longer have to deal with fears related to over pricing of drugs  with political voices on this issue mostly absent in recent times  Moreover  a higher number of FDA approvals and continued strong performance from legacy products have been instrumental in boosting gains  Considering all these factors  this might be the right time to bet on healthcare mutual funds Tax Reforms Likely to Boost Healthcare StocksThe much awaited tax cuts Bill was finally signed by President Trump on Dec 22  2017 in the Oval office  The Bill permanently slashes corporate tax rates from 35  to 21   In his comments  Trump pointed out that markets will benefit greatly from this legislation and that  corporations are literally going wild  following the Bill s passage A major aspect of these tax reforms relates to repatriation of trillions of dollars held as cash reserves overseas by companies with global operations at a one time rate of 8   This could improve the overall financial health of big drug companies  Analysts have estimated that companies such as Pfizer Inc   NYSE PFE  and Merck  NYSE MRK    Co   with close to  100 billion in earnings overseas  would be major winners of such a policy Moreover  lower domestic rates would leave such corporations with more cash  This is likely to lead to a surge in mergers and acquisitions in 2018  Moreover  there has been a surge in the number of FDA approvals of late  This means that more cash reserves would lead to a higher number of drug trials in 2018 and consequently  development of newer products Finally  domestically focused companies that provide only healthcare services would also benefit from a low tax rate  Companies from the sector with limited international exposure and significant capital expenditures would likely enjoy positive cash flows in 2018 End to Drug Pricing Woes Healthcare was hit hard before the presidential election after allegedly exorbitant drug prices were highly criticized by Hillary Clinton  Clinton had tweeted about  price gouging  and framed a proposal to combat skyrocketing drug prices Not to be left behind  President Donald Trump s tweet last year on March 7 relating to increasing competition and lowering drug prices sent fresh shockwaves across the industry  Trump had tweeted that his team was working on a  new system  which would involve  competition in the Drug Industry   Since this tweet  Trump has never commented publicly about drug pricing  Moreover  it is highly unlikely that the issue would resurface in 2018 Also  Trump s pledges to reduce FDA regulations  remove taxes and fees on pharmaceutical and medical device manufacturers  and successful clinical trials for new drugs may prove to be a boon for the space  Meanwhile  some other factors that should continue having a positive impact on pharma and biotech stocks are a new product sales ramp up  R D success and innovation  strong results  a higher number of FDA approvals  and continued strong performance from legacy products    Why Invest In Mutual Funds The question here is why should investors consider mutual funds  Reduced transaction costs and diversification of portfolios without several commission charges that are associated with stock purchases are the primary reasons why one should be parking their money in mutual funds  read more    5 Best Performing Healthcare Mutual FundsWe have highlighted five healthcare mutual funds sporting a Zacks Mutual Fund Rank  1  Strong Buy  or 2  Buy   Moreover  these funds have encouraging third quarter and YTD returns  Additionally  the minimum initial investment is within  5000 and net assets are above  50 million With a drastic reduction in domestic tax rates  the healthcare sector is poised to gain significantly  Further  there has been a significant increase in the number ofFDA approvals which also resulted in the development of newer products  This makes it the right time to invest in healthcare mutual funds We expect these funds to outperform their peers in the future  Remember  the goal of the Zacks Mutual Fund Rank is to guide investors to identify potential winners and losers  Unlike most of the fund rating systems  the Zacks Mutual Fund Rank is not just focused on past performance  but also on the likely future success of the fund Fidelity Select Biotechnology  invests the majority of its assets in securities of companies principally engaged in the research  development  manufacture  and distribution of various biotechnological products  The fund invests in domestic and foreign issuers and has a Zacks Rank  1 FBIOX has an annual expense ratio of 0 74   which is below the category average of 1 32   The fund has three year and YTD returns of 3 2  and 27 9  Hartford Healthcare HLS Fund IA  invests the lion s share of its assets in equity securities of companies engaged in the healthcare industry  These companies are located in different nations including the United States  HIAHX may invest in securities issued by companies of any market capitalization  The fund seeks appreciation of capital for the long run  It has a Zacks Rank  2 HIAHX has an annual expense ratio of 0 89   which is below the category average of 1 32   The fund has three year and YTD returns of 7 9  and 22 3   respectively Janus Henderson Global Life Sciences Fund T  invests in securities of companies that have a life science orientation  JAGLX invests a minimum of one fourth of its assets in securities issued by companies that are categorized in the  life sciences  sector  The fund seeks capital appreciation for the long run  It has a Zacks Rank  2 JAGLX has an annual expense ratio of 0 93   which is below the category average of 1 32   The fund has three year and YTD returns of 4 8  and 22 5   respectively T  Rowe Price Health Sciences  invests a major portion of its net assets in common stocks of companies involved in research  development  production  or distribution of products or services related to health care and life sciences  PRHSX may invest in companies of any size  however  the majority of its assets is invested in large and mid capitalization companies  It has a Zacks Rank  2 PRHSX has an annual expense ratio of 0 77   which is below the category average of 1 32   The fund has three year and YTD returns of 8 6  and 28   respectively Fidelity Select Health Care Svcs Fund  seeks capital appreciation  FSHCX normally invests at least 80  of assets in common stocks of companies principally engaged in the ownership or management of hospitals  nursing homes  health maintenance organizations  and other companies specializing in the delivery of healthcare services  It has a Zacks Rank  1 FSHCX has an annual expense ratio of 0 78   which is below the category average of 1 32   The fund has three year and YTD returns of 10 3  and 24 3   respectively Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2018-01-02,Zacks Investment Research,https://www.investing.com/analysis/5-healthcare-mutual-funds-to-buy-in-2018-200277342,200277342
203516,425032,MRK,US STOCKS Markets head into sixth day of losses,news,"  Bernanke offers no hint on easy monetary policy
   Futures down  Dow 59 pts  S P 6 3 pts  Nasdaq 16 75 pts
   For up to the minute market news see  STXNEWS US 
   Updates market activity 
 By Edward Krudy
 NEW YORK  June 8  Reuters    U S  stock index futures fell
on Wednesday  pointing to a sixth day of losses in an enduring
downtrend as investors worry about the bleak economic outlook
and technical market indicators point to more weakness ahead 
 Stocks reversed tentative gains late in the last session
after Federal Reserve Chairman Ben Bernanke acknowledged the
economy has slowed but offered no hint the U S  central bank is
considering any more stimulus to accelerate growth 
 ID nN07142566 
 Oliver Pursche  president of Gary Goldberg Financial
Services in Suffern  New York  said the market was likely
hoping for some hint of action from the Fed after its second
round of bond buying expires at the end of the month  He said
the market will sell off past the end of the second phase of
quantitative easing  known as QE2  into July 
  The catalyst for a reversal of this is going to be a
realization by the market that the end of asset purchases as
defined by QE2 is a far  far cry from the end of easy monetary
policy   he said   We are being opportunistic and adding to
positions we really like as they sell off  
 The S P 500 has taken out successive lows in the recent
downdraft  falling almost 6 percent since a peak in early May 
with some technical analysts looking for a pullback to the
March lows in the index at around 1 250  around 3 percent below
its close on Tuesday  A fall of 10 percent would be considered
a correction 
 S P 500 futures  fell 6 3 points and were below fair
value  a formula that evaluates pricing by taking into account
interest rates  dividends and time to expiration on the
contract  Dow Jones industrial average futures  fell 59
points  and Nasdaq 100 futures  fell 16 75 points 
 The S P 500 is now up just over 2 percent for the year so
far  Pursche said he  would not be entirely surprised  to see
the index return to support at 1 250 
 OPEC oil producers were split on whether to back a
Saudi led plan to increase supply and try to cap inflated world
crude prices as they meet in Vienna  A decision to increase
production could hit crude prices   ID nLDE75704C 
 U S  light crude fell by more than  1 as investors awaited
the outcome of the OPEC meeting to see whether production
quotas would be increased 
 European shares  fell 1 2 percent on Wednesday on
weaker mining companies  while the Nikkei average 
finished slightly higher  holding above key support near the
bottom of its post earthquake range as foreign investors were
lured by cheap valuations 
 U S  drugmaker Merck   Co  will discontinue a major
trial of a key vaccine from Intercell  designed to
protect against serious hospital infections  the Austrian
biotech firm said on Wednesday   ID nLDE757026 
 The Fed issues its Beige Book  a summary of economic
conditions in the 12 Federal Reserve districts  at 14 00  1800
GMT  
 Covidien Plc  is looking to sell its pharmaceuticals
unit for as much as  4 billion  a source familiar with the
situation said on Tuesday   ID nN07161340 
   Editing by Padraic Cassidy ",2011-06-08,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-markets-head-into-sixth-day-of-losses-216777,216777
203517,425033,MRK,Merck Q3 adjusted EPS USD0 92  vs  USD0 87 estimate  shares up 1 3 ,news,Investing com   U S  pharmaceutical giant Merck reported better than expected third quarter earnings ahead of Monday s opening bell  sending its shares higher in pre market trade Earlier in the day  in its third quarter earnings report  Merck said adjusted earnings per share came in at USD0 92  beating expectations for USD0 87 per share The firm s third quarter revenue totaled USD11 03 billion  missing estimates for revenue of USD11 13 billion The pharmaceutical company reaffirmed its 2013 revenue forecast and said it expected full year earnings per share in a range between USD3 48 to USD3 52  compared with expectations for USD3 47 per share Following the release of the report  Merck saw shares rise 1 3  in pre market trade Meanwhile  the outlook for U S  equity markets was higher  The Dow Jones Industrial Average futures indicated a gain of 0 15  at the open  S P 500 futures pointed to an increase of 0 1   while Nasdaq 100 futures added 0 25  ,2013-10-28,Investing.com,"https://www.investing.com/news/stock-market-news/merck-q3-adjusted-eps-usd0.92,-vs.-usd0.87-estimate;-shares-up-1.3-254373",254373
203518,425034,MRK,Novartis Acquires US Cancer Researcher CoStim,news,"By    Swiss drug maker Novartis  NYSE NVS  said in a statement on Monday that it will acquire CoStim Pharmaceuticals  a privately held Massachusetts based biotechnology company  to broaden its cancer immunotherapy research program 
CoStim s main field of research  which focuses on producing antibody agents that prevent immune blocking signals from cancer  is expected to reach annual sales of  35 billion  according to a news report by Bloomberg  The terms of the acquisition were not disclosed 
 Therapy for many types of cancers are expected to increasingly rely upon rational combinations of agents   Mark Fishman  president of Novartis Institutes for BioMedical Research  said in a statement 

This acquisition will add to several programs that Novartis has for cancer therapies including a chimeric antigen receptor or CAR technology being developed in collaboration with the University of Pennsylvania  With this deal  Novartis is targeting PD 1  which is reportedly the next big target for cancer 
Immunotherapy involves coaxing patients  immune cells to recognize and attack their tumors  This technology is reportedly the latest frontier of cancer research following tried and tested methods such as chemotherapy  radiation and surgery 
Companies like Bristol Myers Squibb  NYSE BMY   Merck  NYSE MRK  and Roche  OTCMKTS RHHBY  are working to use the human immune system to coordinate a powerful attack on cancer  And  for Novartis  the deal with CoStim will strengthen the company s hold over cancer immunotherapy discovery and will add to its CAR technology 
 Immunotherapy agents provide additional arrows in our quiver for such combinations  They complement our extensive portfolio of drugs that hit genetically defined cancer causing pathways  and also may be relevant to expansion of CAR therapies   Fishman said ",2014-02-17,International Business Times,https://www.investing.com/news/stock-market-news/novartis-acquires-us-cancer-researcher-costim-266692,266692
203522,425038,MRK,What s Happening In Advanced Renal Cell Carcinoma Space ,opinion,"The recent FDA approval of Exelixis  Inc  s   NASDAQ EXEL   Cabometyx for the treatment previously untreated advanced renal cell carcinoma has put the spotlight in this space RCC is the most common form of kidney cancer in adults  Per statistics  approximately 30 000 patients in the United States and 68 000 around the world need a first line treatment for advanced kidney cancer  As many as 14 000 patients need the same annually in the United States The approval comes two months ahead of schedule  We note that Cabometyx  cabozantinib   a tyrosine kinase inhibitor  or TKI  was already approved for the treatment of RCC in patients who have already received anti angiogenic therapy  Cabozantinib inhibits the activity of tyrosine kinases  including MET  AXL  VEGF receptors  and RET   The approval came on the back of results from the randomized phase II  trial CABOSUN  The results demonstrated statistically significant and clinically meaningful improvement in progression free survival  PFS  versus the current standard of care  Pfizer Inc  s   NYSE PFE   Sutent  Importantly  Cabometyx demonstrated a clinically meaningful and statistically significant 52  reduction in the rate of disease progression or death  Median PFS for Cabometyx was 8 6 months versus 5 3 months for Sutent corresponding to a 3 3 month  62   improvement Sutent is widely used as a first line treatment for RCC along with Novartis AG   NYSE NVS   Votrient  However  the FDA approval of Cabometyx on excellent rates of PFS might weigh on Sutent going forward though Pfizer too is striving hard to retain the drug s leadership  In November 2017  the FDA approved a label expansion for Sutent  The drug was approved for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy  surgical removal of the cancerous kidney   The approval was based on results from the S TRAC trial that demonstrated a significant reduction in the risk of a disease free survival event  defined as the interval between randomization and tumor recurrence  or secondary primary cancer or death from any cause  for patients at high risk of RCC recurrence who received Sutent compared to placebo in the adjuvant setting Meanwhile  Pfizer s another drug  Inlyta  a TKI  is also approved for RCC  Bavencio  avelumab   a monoclonal antibody that inhibits PD L1  in combination with Inlyta is being developed for the first line treatment of advanced RCC  in collaboration with Merck KGaA  Sector Total Return  
    On the other hand  immunotherapies are gearing up too for place in this space  In September 2017  Bristol Myers Squibb Company   NYSE BMY   announced that a phase III study is evaluating Opdivo plus Yervoy combination in patients with previously untreated advanced or metastatic RCC met its co primary endpoint  The combination demonstrated superior overall survival  OS  compared to Sutent in intermediate  and poor risk patients  The combination also met a secondary endpoint of improved OS versus Sutent in randomized patients   Consequently  an independent Data Monitoring Committee has recommended that the trial be stopped early based on a planned interim analysis   Last week  the FDA accepted Bristol Myers  supplemental Biologics License Application for priority review of Opdivo plus Yervoy  ipilimumab  to treat intermediate  and poor risk patients with advanced RCC with an action date of April 16  2018  The FDA had previously granted Breakthrough Therapy Designation for this application which should expedite the review Additionally  a variety of combination therapies being developed for RCC  including Roche s   OTC RHHBY   Avastin and Tecentriq  Earlier in the month  Roche announced that the phase III IMmotion151 study met its co primary endpoint of investigator assessed PFS and demonstrated that the combination of Tecentriq and Avastin provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death in patients whose disease expressed the PD L1  programmed death ligand 1  Expression  1   protein compared with Sutent for the first line treatment of people who have advanced or metastatic renal cell carcinoma  mRCC   Top line results from the co primary endpoint of OS are not mature Eisai Inc  and Merck   NYSE MRK   are also evaluating the combination of the former s Lenvima a multiple receptor tyrosine kinase inhibitor  including fibroblast growth factor receptors  FGFR  1   4   in combination with the latter s anti PD 1 therapy Keytruda for treatment na ve and previously treated patients with metastatic clear cell RCC  The combination is being evaluated for first line use of the combination in the ongoing phase III study  CLEAR  The combination reported encouraging interim results in September 2017 Hence  we expect investors to keep their focus in this space in 2018 given the stiff competition brewing up Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/whats-happening-in-advanced-renal-cell-carcinoma-space-200275126,200275126
203523,425039,MRK,Roche s Perjeta Gets FDA Nod For Post Surgery Breast Cancer,opinion,Roche Holding  SIX ROG  AG s   OTC RHHBY   announced that the FDA has approved Perjeta  pertuzumab   in combination with Herceptin and chemotherapy  the Perjeta based regimen   for adjuvant  after surgery  treatment of HER2 positive early breast cancer  EBC  at high risk of recurrence   Patients should receive the adjuvant Perjeta based regimen for one year  18 cycles  Perjeta in combination with Herceptin and docetaxel is already approved for use in patients who have HER2 positive breast cancer that has spread to different parts of the body  metastatic  and who have not received anti HER2 therapy or chemotherapy for metastatic breast cancer Coming back to the release  the approval for the indication was based on results of the phase III APHINITY study  The study showed that Perjeta  Herceptin and chemotherapy significantly reduced the risk of invasive breast cancer recurrence or death by 18  compared to Herceptin and chemotherapy alone   The combination wasalso granted a Priority Review by the FDA in October While  invasive disease free survival  DFS  served as the primary endpoint  secondary endpoints included overall and cardiac safety  DFS and health related quality of life In addition  the FDA granted full approval to use of that same regimen for neoadjuvant treatment of HER 2 positive  locally advanced  inflammatory or early stage breast cancer  Until now  the neoadjuvant indication had been allowed under accelerated approval  Roche s stock has rallied 8  year to date compared with  s gain of 16 1  The company has a strong presence in the oncology market  It dominates the breast cancer space with strong demand for its HER2 franchise drugs like Herceptin  Perjeta and Kadcyla   Herceptin s growth is g driven by improved demand in both the United States and Europe due to longer treatment duration  Moreover  the subcutaneous formulation of Herceptin is being increasingly adopted across Europe  Meanwhile  sales of Perjeta have been strong in Europe largely due to uptake in the neo adjuvant setting and persistent growth in the metastatic setting  Kadcyla sales are being driven by increasing demand in both the Europe and internationally  Apart from its strong breast cancer franchise  Roche s oncology portfolio also boasts drugs like Avastin and Tarceva for lung cancer However  we note that Roche is facing stiff competition from the likes of Merck   Co   Inc  s   NYSE MRK   Keytruda and Bristol Myers Squibb Company s   NYSE BMY   Opdivo in the immuno oncology space Roche Holding AG Price   Zacks Rank   Stock to ConsiderRoche carries a Zacks Rank  4  Sell  A better ranked stock in the same space is Sucampo Pharmaceuticals   NASDAQ SCMP   carrying a Zacks Rank  2  Buy   You can see  Sucampo s earnings per share estimates have moved up from 31 cents to  1 12 for 2017 and from  1 15 to  1 19 for 2018  over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 15 63   The share price of the company has increased 23 2  year to date Zacks  Best Private Investment Ideas While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/roches-perjeta-gets-fda-nod-for-post-surgery-breast-cancer-200275072,200275072
203524,425040,MRK,3 Drugs That Could Shake Up Diabetes Space In 2018,opinion,"2018 could be an incredible year for patients in the diabetes space  A number of fresh treatments have either picked up approval at the end of this year  and  in turn  are due to launch early next year  or will be subject to late stage investigation and seeking approval during 2018 and each of these fresh entrants has the potential to turn the current standard of care  SOC  regimens  which  in diabetes  are notoriously unpleasant  on their heads 
Here s a look at three drugs that fall into the above categories 
First up  Semaglutide 
This one picked up approval from the FDA in the US back on December 5 and is a Novo Nordisk  CO NOVOb  drug  For those not familiar with the current state of the diabetes treatment space  there are basically two types of therapy 
One is direct insulin therapy  which involves  normally  intramuscular injection of insulin into the body  with the goal being to top up insulin levels ahead of times at which glucose levels are likely to peak  mealtimes  for example   The insulin gets to work reducing glucose levels and returning the patient s blood sugar to normal 
The other is rooted in what s called GLP 1  which is a hormone that stimulates insulin production and  at the same time  induces the feeling of satiation in individuals that take it  It s into this category that Semaglutide fits 
Semaglutide is an agonist of the GLP 1 receptor  meaning  essentially  it makes it work harder than it would otherwise without stimulation  and  in turn  increases the rate of GLP 1 that the body produces 
So  the FDA approved the drug based on what amounted to some very solid late stage data  across more than 8 000 patients  that showed not only can it help lower blood glucose levels but that it can also induce weight loss when used as an adjunct to diet and exercise and   and here s an important point   it s a once weekly administration 
Compare this to the three or four times daily administration of insulin that patients have to undergo right now and it s clear why this one could be a game changer for the patient population 
Next up  ertugliflozin 
Ertugliflozin is the generic name for what Merck   Co   NYSE MRK   the company behind it  intends to call Steglujan commercially  This one literally just picked up approval and  just like Semaglutide is due to hit the shelves in the US at some point during the late first quarter or the early second quarter of next year 
Unlike Semaglutide  however  Steglujan is what s called a sodium glucose co transporter 2  SGLT2  inhibitor  This one s a pretty novel approach to treatment  Basically  SGLT2 is what s responsible for glucose reabsorption in the kidney  The idea behind Steglujan  then  is that by stopping  or at least lowering the level of  glucose that gets reabsorbed in the kidney  you can lower the levels of glucose that end up in the bloodstream at times of peak glucose   meal times  etc 
To put this another way  the drug makes patients extract glucose in their urine instead of absorbing it into the bloodstream  The commercial asset also includes ertugliflozin as an adjuvant type asset  which is what s called a DPP 4  dipeptidyl peptidase 4  inhibitor  These drugs reduce glucagon and blood glucose levels by increasing incretin levels 
Essentially  then  it s a two pronged approach and it allows Merck to go head to head with a blockbuster drug called Glyxambi  which has a more rigorous dosing regimen  giving Merck s asset the advantage 
Finally  ORMD 0801 
This one is the development stage addition to this list  The company that s developing the drug is called Oramed Pharmaceuticals Inc   NASDAQ ORMP  and it s trying to bring ORMD 0801 to market as an oral administration alternative to the current SOC assets in this space 
Oral insulin has long been just out of reach for the diabetes population and   to date   no company has figured out how to get the incredibly fragile insulin through the GI tract and to the liver without it being broken down and   in turn   rendered unusable 
Oramed has developed a proprietary capsule type technology that uses protease inhibitors to block the effect of the enzymes in the body that would normally break down the drug before it reached its destination 
The drug scored some pretty strong data in a wide reaching phase II trial last year and the FDA just gave Oramed the green light to kick off a phase III trial  which is slated to start any day now 
If the company can prove that its drug can help contribute to lowering blood glucose then it could serve as both a boost to current SOC and  at the same time  a sort of bridge drug that physicians can prescribe to pre diabetics ahead of the injectable SOC options ",2017-12-21,Samuel Rae,https://www.investing.com/analysis/here-are-three-drugs-that-could-shake-up-the-diabetes-space-in-2018-200275140,200275140
203525,425041,MRK,4 Reasons To Include Celldex  CLDX  Stock In Your Portfolio,opinion,Hampton  NJ based Celldex Therapeutics  Inc    NASDAQ CLDX   is a biopharmaceutical company developing immunotherapy technologies and other cancer targeting biologics  The company is still in development stage and does not have any marketed product in its portfolio  The company is developing its most advanced candidate  glembatumumab vedotin  in triple negative breast cancer and metastatic melanoma The stock carries a Zacks Rank  2  Buy  and looks like a good investment now  You can see  Let s see the reasons why this stock can prove to be a valuable addition to your portfolio in 2018 Favorable Share Price Movement  Shares of Celldex have risen 11  in the past six months while the  registered a loss of 2 9   Moreover  the company is trading at cheaper price book ratio of 1 66 compared with the industry s 4 07  The company is also in a better position to pay its obligations as its current ratio is 5 91  Rising Estimates  In fact  Celldex s earnings performance has been pretty impressive  with the company exceeding expectations in three of the past four quarters and meeting the same once  The average positive earnings surprise over the last four quarters is 15 36   Moreover  loss estimates for 2018 have narrowed 6 25  in the past 60 days  Revenues are expected to grow 28 4  in 2018 from 2017 Pipeline Progress  Celldex s most advanced pipeline candidate glembatumumab vedotin is being investigated in a phase IIb study for triple negative breast cancer and in a separate phase II study for metastatic melanoma  The data from the breast cancer study is expected in the second quarter of 2018 Moreover  Celldex is also evaluating glembatumumab in combination with varlilumab or a checkpoint inhibitor arm  including either Bristol Myers Squibb Company s   NYSE BMY   Opdivo or Merck   Co  Inc  s   NYSE MRK   Keytruda   In the melanoma study  glembatumumab performed well in the single agent setting Apart from glembatumumab vedotin  Celldex has several promising candidates in its pipeline  including varlilumab  being evaluated in phase II in combination with Opdivo for various cancers   CDX 1401 CDX 301  phase II multiple solid tumors  in collaboration with CITN  and CDX 014  phase I advanced renal cell carcinoma  among others Acquisitions   Collaborations  Celldex has a collaboration agreement with Bristol Myers  which provides the company a strong partner with expertise in the field of immuno oncology and strong financials  Also  the acquisition of privately held development stage company  Kolltan Pharmaceuticals strengthened its immuno oncology pipeline by adding a unique platform of antibodies targeting receptor tyrosine kinases ConclusionAlthough Celldex is developing its candidates in several cancer indications  the oncology market is highly competitive  With immuno oncology attracting a lot of interest  companies like Juno Therapeutics  Inc    NASDAQ JUNO    bluebird and others are all involved in the development of immuno oncology treatments Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-01,Zacks Investment Research,https://www.investing.com/analysis/4-reasons-to-include-celldex-cldx-stock-in-your-portfolio-200276989,200276989
203533,425049,MRK,Merck takeover of Schering Plough wins EU approval,news,"BRUSSELS  Oct 23  Reuters    U S  drugmaker Merck   Co Inc s
 41 1 billion takeover of smaller rival Schering Plough Corp won
approval from European Union antitrust regulators on Friday 
 The takeover  structured by Merck as a reverse merger 
followed a long standing joint venture between Merck and
Schering Plough that sells the cholesterol fighters Vytorin and
Zetia 
  The proposed transaction would not significantly impede
effective competition in the European economic area or any
substantial part of it   the European Commission said in a
statement 
  Reporting by Foo Yun Chee  Editing by Dale Hudson ",2009-10-23,Reuters,https://www.investing.com/news/equities-news/merck-takeover-of-schering-plough-wins-eu-approval-96937,96937
203534,425050,MRK,UPDATE 1 Merck takeover of Schering Plough wins EU approval,news,"  EU s executive arm sees no competition concerns
   Merger pegged at  41 billion when announced in March
 
  Adds background 
 BRUSSELS  Oct 23  Reuters    U S  drugmaker Merck   Co Inc s
  41 1 billion takeover of smaller rival Schering Plough
Corp  won approval from European Union antitrust
regulators on Friday 
 The takeover  structured by Merck as a reverse merger 
followed a long standing joint venture between Merck and
Schering Plough that sells the cholesterol fighters Vytorin and
Zetia 
  The proposed transaction would not significantly impede
effective competition in the European economic area or any
substantial part of it   the European Commission  executive arm
of the 27 country EU  said in a statement 
 Merck has agreed to sell its half of the Merial animal
health business to Sanofi Aventis   its French partner
in that joint venture  for  4 billion in order to meet antitrust
requirements for the Schering Plough takeover 
 Merck has said it hopes cost cuts from the merger and a
number of promising products from Schering Plough will improve
its profit outlook 
 The merged companies will cut 15 percent of their combined
workforce  with most job losses to take place outside the United
States 
  Reporting by Foo Yun Chee  Editing by Dale Hudson ",2009-10-23,Reuters,https://www.investing.com/news/equities-news/update-1-merck-takeover-of-schering-plough-wins-eu-approval-96952,96952
203535,425051,MRK,UPDATE 2 Swine flu gives Glaxo a shot in the arm,news,"  Q3 earnings of 28 5p shr  just under 28 7p consensus
   Sales 6 76 bln pounds vs 6 81 bln consensus
   Glaxo set for big H1N1 vaccine boost in Q4
  Shares down 1 percent in London market down 1 8 percent
 
  Adds CEO comments  analyst reaction  latest shares  details 
 By Ben Hirschler
 LONDON  Oct 28  Reuters    Sharply higher sales of flu drug
Relenza buoyed GlaxoSmithKline s quarterly sales  and the
British group said it was in line for a booster from its swine
flu vaccine in the last three months of the year 
 Third quarter earnings per share growth of 13 percent 
flattered by a weak pound  was just shy of expectations  while
group revenue rose 15 percent  helped by recent diversification 
the world s second biggest drugmaker said on Wednesday  
 Glaxo has lost plenty of business this year to cheap
generics  as patents on its older medicines expire  resulting in
a 12 percent fall in U S  sales in the period 
 But windfall sales of drugs and vaccines due to H1N1 are
softening the blow 
 As with many of its rivals  2009 is turning out better than
initially feared  and Chief Executive Andrew Witty said he
expected further growth in the fourth quarter of the year 
 including significant sales of influenza products  
 Glaxo said previously it had taken orders for 440 million
doses of its H1N1 vaccine Pandemrix  and analysts say it could
book around 1 billion pounds   1 64 billion  of this business in
the fourth quarter as immunisation campaigns get underway 
 Witty told reporters that market expectations for sales of
the vaccine were  pretty close to being right   adding Glaxo had
booked further orders and still had capacity for more 
 European drugmakers Glaxo  Sanofi Aventis  Novartis and
AstraZeneca are set to win the bulk of the business for mass
swine flu vaccination programmes launched by governments around
the world 
 Glaxo also gains from having the inhaled flu drug Relenza 
which registered sales of 182 million pounds in the third
quarter  against just 12 million pounds a year earlier 
 Roche has seen a similar sharp jump in sales of its rival
flu drug Tamiflu 
 Glaxo s pretax profit totalled 2 07 billion pounds in the
third quarter  equivalent to earnings per share before major
restructuring of 28 5 pence  on sales of 6 76 billion 
 The mean consensus forecast had been for earnings of 28 7p
and sales of 6 81 billion pounds  according to Thomson Reuters
I B E S 
 Sanford Bernstein analyst Tim Anderson said the results were
broadly in line  helped substantially by currencies 
  GSK has a decent revenue and EPS profile through 2015  but
its valuation seems to reflect this already   he added  as
shares in the group traded 1 percent lower in a London market
down 1 8 percent at 1400 GMT 
 
 MOVING ON FROM  WHITE PILLS 
 While H1N1 may be a one off  Witty said his strategy of
diversifying away from reliance on  white pills in Western
markets  would mean more predictable long term growth  as
emerging market and consumer products sales increase 
 Less than 30 percent of third quarter sales were generated
from traditional pharmaceuticals and markets  compared with 38
percent last year 
  What we ve begun to show very clearly in these results is
the change in dynamics in our business and particularly the good
progress we are making towards diversifying our portfolio   he
said 
 Witty added he would continue to look actively for bolt on
acquisitions  but only if the price was right  He has eschewed
large scale acquisitions of the kind pursued this year by Pfizer
 and Merck   Co 
 Progress on the research front included encouraging results
with experimental heart drug darapladib  which Witty said was
now six months ahead of schedule in late stage clinical trials 
 Glaxo trades at about 10 4 times forecast 2010 earnings  a
premium to AstraZeneca and Sanofi  which report on Thursday and
Friday respectively  but a discount to Swiss rivals Roche and
Novartis 
  Additional reporting by Kate Kelland  editing by Will
Waterman 
   1  6107 Pound ",2009-10-28,Reuters,https://www.investing.com/news/equities-news/update-2-swine-flu-gives-glaxo-a-shot-in-the-arm-98256,98256
203537,425053,MRK,Bristol Myers  Opdivo Yervoy SBLA For RCC Accepted By FDA ,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the FDA has accepted its supplemental Biologics License Application  sBLA  for priority review of Opdivo plus Yervoy  ipilimumab  for the treatment of intermediate  and poor risk patients with advanced renal cell carcinoma  RCC  
We note that the FDA had granted Breakthrough Therapy Designation for this application which will expedite the development and review of the same 
The FDA will make a decision by Apr 16  2018 
The application is based on data from the phase III study  Checkmate  214 study  The study was stopped ahead of schedule based on the recommendation of an independent Data Monitoring Committee following a planned interim analysis of overall survival  The study evaluated the combination of Opdivo plus Yervoy versus Sutent for previously untreated advanced or metastatic RCC 
The study met the co primary endpoints of improved overall survival and objective response rate compared to Sutent in intermediate  and poor risk patients  Although the combination demonstrated an improvement in progression free survival relative to Sutent  another co primary endpoint  it did not reach statistical significance 

 
So far this year  Bristol Myers  shares have rallied 9 2  compared with the  gain of 20 2  
We note that Opdivo is already approved for a number of indications  These include classical Hodgkin lymphoma  recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy  Additionally  it is approved as a monotherapy for the treatment of squamous cell carcinoma of the head and neck  in adults progressing on or after platinum based therapy 
Opdivo is also approved for intravenous use for patients with hepatocellular carcinoma  who have been previously treated with Nexavar  The drug received approval for liver and colorectal cancers 
Meanwhile  the company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  Label expansion of the drug into additional indications will give the product an access to a higher patient population and increase its commercial potential 
However  Opdivo is facing competitive challenges in the United States  With the FDA approving Merck s   NYSE MRK   Keytruda  for the first line treatment of metastatic non squamous NSCLC  the company is expected to suffer further loss of market share 
The virology business is also under pressure  The company is also looking to counter generic threat for key drugs through deals and acquisitions  The company recently entered into a deal with AbbVie  Inc    NYSE ABBV   and Halozyme Therapeutics  Inc    NASDAQ HALO   
Zacks Rank   Stock to Consider
Bristol Myers currently carries a Zacks Rank  3  Hold   You can see  
Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivoyervoy-sbla-for-rcc-accepted-by-fda-200273726,200273726
203538,425054,MRK,Bristol Myers Yervoy Gets Positive CHMP Opinion For Melanoma,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency has recommended the approval of Yervoy for pediatric patients of 12 years and older with unresectable or metastatic melanoma We note that the European Commission will take the CHMP recommendation into account while considering the application but is not bound by it The FDA had approved the drug for the same indication in July 2017 We remind investors that Yervoy 3 mg  kg monotherapy was approved in 2011   So far this year  Bristol Myers  shares have rallied 9 6  compared with the  s gain of 20 9  Last week  the company announced that the FDA has accepted its supplemental Biologics License Application for priority review of Opdivo plus Yervoy for the treatment of intermediate  and poor risk patients with advanced renal cell carcinoma  RCC   The application is based on data from the phase III study  Checkmate 214  The study was stopped ahead of schedule based on the recommendation of an independent Data Monitoring Committee following a planned interim analysis of overall survival  The study evaluated the combination of Opdivo plus Yervoy versus Sutent for previously untreated advanced or metastatic RCC  The FDA will make a decision by Apr 16  2018 Meanwhile  the company continues to evaluate its blockbuster immune oncology drug Opdivo alone or in combination therapies with Yervoy and other anti cancer agents  Label expansion of the combination into additional indications will give the product an access to a higher patient population and increase its commercial potential However  Opdivo is facing competitive challenges in the United States  With the FDA approving Merck s   NYSE MRK   Keytruda  for the first line treatment of metastatic non squamous NSCLC  the company is expected to suffer further loss of market share The virology business is also under pressure  The company is also looking to counter generic threat for key drugs through deals and acquisitions  The company recently entered into a deal with AbbVie  Inc    NYSE ABBV   and Halozyme Therapeutics  Inc    NASDAQ HALO   Zacks Rank Bristol Myers currently carries a Zacks Rank  3  Hold   You can see  Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-18,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-yervoy-gets-positive-chmp-opinion-for-melanoma-200274364,200274364
203546,425062,MRK,NEWSMAKER Severin Schwan finds his feet as Roche CEO,news,"  Filling big shoes of former CEO
   Gained confidence after  47 billion Genentech buy out
   Reinforced Roche s position at top of sector
   Greater biotech focus
   Now has new  younger management team
 
 By Sam Cage
 BASEL  Switzerland  Sept 8  Reuters    Severin Schwan has a
tough act to follow running top performing Swiss drugmaker Roche
  but is quickly finding his feet    and now he has a new 
younger management team to help 
 In 18 months in the job  Schwan has sealed the largest
acquisition in Roche s history  overseen impressive performance
in the teeth of a recession and reinforced the company s
position as the most richly valued large drugmaker in the world 
  He is increasingly fitting into those big shoes   said
Andrew Weiss  analyst at Swiss bank Vontobel   I think he s
rather pleased with himself that the Genentech deal has gone
through  
 Schwan  initially shy and reserved as chief executive 
gained confidence from sealing Roche s  47 billion buy out of
U S  biotech partner Genentech and as senior figures chairman
Franz Humer and drugs chief William Burns step out of the
limelight 
 The 1967 born Schwan  an Austrian  took charge last year
just before the bid to buy the remaining 44 percent of
Genentech  a protracted process complicated by a growing global
financial crisis that cast doubts on Roche s ability to raise
the required debt 
 In the end  Roche raised the money with ease and the
acquisition was judged a better deal than two other pharma
megadeals this year  Pfizer s offer for Wyeth and Merck   Co s
Schering Plough buy 
 Schwan s growing reputation has since been burnished by
Roche s strong business performance  helped by strong sales of
cancer drugs and antiviral Tamiflu  boosted by the spread of
H1N1 swine flu 
 
 INCREASINGLY  A BIOTECH COMPANY
 Schwan s one big change is Genentech s influence over Roche 
especially in the United States    a chance to shake up a key
unit that had been underperforming and improve drug development 
 That was underlined on Tuesday when Roche announced a revamp
of top management  naming new heads of its two business units 
drugs and diagnostics 
 Genentech developed many of Roche s big revenue drivers like
cancer drugs Avastin and Herceptin  and the Swiss group now dubs
itself a biotech company  stressing good science at a time when
Big Pharma is struggling to develop big selling medicines 
 Significantly  Schwan has decided to throw in his lot with
the specialist Biotechnology Industry Organisation trade group 
rather than with the pharmaceutical industry lobby 
 While Roche s stock performance has not significantly
outshone other drugmakers since Schwan took over  that is
largely due to the fact it was already trading at a hefty
premium to its Big Pharma peers 
 Shares have regained more than 10 percent since sealing the
Genentech deal and the premium  which had been cut down towards
parity with some peers  has expanded again 
 Roche now trades at about 12 times forecast 2010 earnings  a
premium of some 20 percent over closest European rivals
GlaxoSmithKline and Novartis and even further ahead of U S 
majors Pfizer  Merck   Co and Eli Lilly 
  I think there are some difficult and risky patches on the
horizon but they have a rich pipeline of their own now   said
Nick Draeger  a former healthcare fund manager who now manages
business advisors Cederberg   Roche is the best pharma company
out there  
 In July  investors  analysts and journalists saw the result
   raised financial forecasts and a relaxed and confident Schwan
expounding on Roche s transformation into what he called the
world s biggest biotech company 
  The Genentech takeover was not just an acquisition  but has
transformed Roche into a pharma biotech organisation which can
ensure earnings growth in the short term through synergies  and
long term thanks to a high  industry leading R D innovation  
said ZKB analyst Michael Nawrath 
 
 RAPID RISE
 It could have been a poisoned chalice for the softspoken
Schwan  whose dark hair is now scattered with hints of grey 
after he rose rapidly through the Roche ranks from trainee
finance officer to diagnostics chief and CEO in just 15 years 
 He took over after a management team of ex CEO Humer and
Burns guided Roche from the sick man of the sector to that with
the most enviable pipeline of new drugs 
 Even then Humer  now as chairman  Burns and Chief Financial
Officer Erich Hunziker dominated the Genentech transaction 
handling media and investor events  Burns is now retiring   
though he will remain on the board    and Humer is rarely
spotted at Roche events since the deal was sewn up 
 Company watchers say that while Schwan s performance has
been solid  he has not been signficantly tested yet 
  People think he  Schwan  is a good pair of hands  But the
real proof will be when the inevitable problems arise   said
Draeger  who is a former employee of Roche 
  Additional reporting by Paul Arnold  Editing by Ben Hirschler
and Sitaraman Shankar ",2009-09-08,Reuters,https://www.investing.com/news/equities-news/newsmaker-severin-schwan-finds-his-feet-as-roche-ceo-84809,84809
203547,425063,MRK,Addex lead drug shows potential in Parkinson s,news,"  Reduced dyskinesia in study with primates
   Shares rise more than 5 percent
 
 ZURICH  Sept 14  Reuters    Swiss biotech Addex s lead drug
candidate showed potential to treat a complication of
Parkinson s disease in a study with non human primates  news of
which boosted the group s shares 
 Two different doses of ADX10059 significantly reduced
dyskinesia  the sudden  uncontrollable and often chaotic
movements of limbs  face  tongue and body that are induced by
extended use of standard therapy levodopa  
 Addex  which does not yet have a drug on the market  said
ADX10059 will soon complete Phase IIb clinical testing in
gastroesophageal reflux disease  GERD  and migraine prevention 
  We welcome today s news flow as it provides strong
supportive evidence that ADX10059 has the potential to lower
side effects from levodopa treatment of mid  to late stage
Parkinson s disease patients   said Olav Zilian  analyst at
Swiss brokerage Helvea 
  The development programme on AD10059 is the main driver of
our valuation and contributes some 85 percent to our fair value
of Addex   said Zilian  who has a  buy  recommendation and price
target of 59 Swiss francs on the stock 
 Addex shares rose 5 3 percent to 31 95 francs by 1130 GMT 
versus a slightly lower overall DJ Stoxx European healthcare
index 
 The group has two partnering deals with Merck   Co Inc in
schizoprenia and Parkinson s disease  A third agreement  with
Johnson   Johnson  focuses on developing drugs to treat anxiety
and schizophrenia 
 A second Swiss biotech company  Santhera  last month struck
a deal with Canada s Biovail over a drug to treat dyskinesia in
Parkinson s disease 
  Reporting by Sam Cage  Editing by Jon Loades Carter ",2009-09-14,Reuters,https://www.investing.com/news/equities-news/addex-lead-drug-shows-potential-in-parkinson's-86363,86363
203548,425064,MRK,INTERVIEW Merck CEO  rivals may wait before any new MA,news,"  Some drug companies may sit on side line  Merck CEO says
   Industry seen watching how recent mega mergers work out
 
 By Ben Hirschler
 LONDON  Sept 17  Reuters    Rival drugmakers are likely to
wait and see how this year s mega mergers turn out before
considering another round of big ticket acquisitions  according
to Merck   Co s chief executive 
 Richard Clark  whose company agreed to buy Schering Plough
for  41 billion in March  said the industry was looking for
proof that deals could provide more than just cost savings 
  I would suspect some companies may sit on the side line
just to see how well these activities are taking place   Clark
told Reuters during a visit to London to unveil a vaccine joint
venture with the Wellcome Trust medical charity 
 Other large deals struck in the first quarter of 2009
include Pfizer s bid for Wyeth  worth  68 billion when it was
announced in January  and Roche s  47 billion buyout of the
remainder of Genentech 
 Many industry analysts see these deals as designed to take
out capacity and cut costs at a time when the global
pharmaceuticals industry faces a wave of patent expirations 
 But Clark said he aimed to deliver more than that 
  If the view is this is a cost synergy and you are going to
kick this can down the alley and it doesn t increase research
productivity  then at the time when you catch up with that can
again you are going to have to kick it again   he said 
  What Merck is trying to do is put a different model
together that says we are going to do research differently  
 If Merck gets it right and shows it can increase revenue
growth and the flow of new drugs from its laboratories  then
senior executives at other big drugmakers could change their
views on deal making 
 Credit Suisse analyst Catherine Arnold said in a report on
Thursday that the next wave of deals by major pharmaceutical
companies would emphasise revenue augmentation over cost
savings 
 She also predicted a divergence of activity between U S  and
European drugmakers  given new European chief executives  stated
disinterest in large deals 
  Editing by Jon Loades Carter ",2009-09-17,Reuters,https://www.investing.com/news/equities-news/interview-merck-ceo:-rivals-may-wait-before-any-new-m-a-87689,87689
203549,425065,MRK,US STOCKS SNAPSHOT Wall St cuts losses  defensives offset data,news,"NEW YORK  Sept 25  Reuters    The Dow briefly turned
positive and the S P 500 trimmed losses as gains by companies
which fare better in an uncertain economy offset disappointing
data 
   Defensive stocks lending support included Coca Cola  up
1 62 percent and Merck   Co up 1 4 percent 
   The Nasdaq remained in negative territory  but off its
worst levels  following Research In Motion s lackluster results
and outlook 
   The Dow Jones industrial average  dropped 7 78 points  or
0 08 percent  to 9 699 66  The Standard   Poor s 500 Index
dropped 2 40 points  or 0 23 percent  to 1 048 38  The Nasdaq
Composite Index dropped 9 98 points  or 0 47 percent  to
2 097 63 
  Reporting by Ellis Mnyandu  Editing by Kenneth Barry ",2009-09-25,Reuters,https://www.investing.com/news/equities-news/us-stocks-snapshot-wall-st-cuts-losses;-defensives-offset-data-90060,90060
203550,425066,MRK,UPDATE 3 Novartis sees faster growth  swine flu boost in Q4,news,"  Novartis Q3 net profit  2 1 bln  matching forecast
   Sees  400 700 million H1N1 vaccine sales in Q4
   Ups full year guidance excluding swine flu vaccine
   Shares up 0 5 percent  outperform sector
 
  Adds analyst comment  shares  H1N1 detail 
 By Sam Cage
 ZURICH  Oct 22  Reuters    Swiss drugmaker Novartis said
sales would grow faster than expected this year  even without a
shot in the arm of up to  700 million from its H1N1 swine flu
pandemic vaccine 
 Third quarter net profit at Novartis  which joined other
major drugmakers in reporting strong trading conditions  nudged
up 1 percent to  2 1 billion  in line with forecasts  the firm
said on Thursday 
  A surprisingly strong set of operating figures   said DZ
Bank analyst Thomas Maul   Management guidance  especially the
outlook for the pharmaceuticals division  is amazingly bullish  
 Novartis shares rose 0 5 percent to 52 75 Swiss francs by
0736 GMT  versus a 0 6 percent drop in the DJ Stoxx European
healthcare sector 
 This year is turning out to be better than initially feared
for Novartis and other major pharmaceutical companies  thanks to
hefty price increases and windfall sales arising from the H1N1
outbreak  though long term problems like increasing competition
from makers of generic drugs have not gone away 
 Both Pfizer  the world s biggest drugmaker  and Eli Lilly
topped earnings forecasts this week and investors will look to
U S  rivals Merck   Co and Bristol Myers Squibb  both due to
report later on Thursday  for more clues on the health of the
sector 
 Novartis  which faces loss of exclusivity on its top selling
blood pressure drug Diovan in 2012  was hit by one off charges
of  189 million from rival Roche s acquisition of Genentech and
discontinuing of a drug by Alcon 
 It has a 33 percent stake in Roche and holds 25 percent of
eye care company Alcon  It made no comment on an agreement with
Nestle to acquire a majority of Alcon 
 The world s biggest food group  which on Thursday reported
nine month sales that met forecasts and kept its 2009 outlook
unchanged  also gave no comment on Alcon in its trading
statement 
 
 SWINE FLU BOOSTER
 Swine flu is set to provide a significant boost to European
drugmakers this year and in the early part of 2010  though the
one off nature of these sales means investors may not set too
much store on the resulting profit boost 
 Roche reported a sharp jump in sales of its Tamiflu drug for
flu last week and analysts expect GlaxoSmithKline s Relenza will
also see strong sales in the third quarter 
 On the vaccine front  Glaxo  Sanofi Aventis and AstraZeneca
 are all expected to highlight an expected jump in
fourth quarter sales due to swine flu when they unveil results
next week 
 Novartis now expects group sales to grow at a high
single digit rate  even excluding H1N1 pandemic flu vaccine
sales  and sees drugs sales growth at a double digit rate  
 It had previously expected group sales to grow at a
mid single digit rate in 2009 and drug sales to rise at a
minimum high single digit rate  both in local currencies 
 It added currency related losses could significantly reduce
growth this year 
 The H1N1 flu vaccine is expected to contribute about
 400 700 million of sales in the fourth quarter 
 Novartis trades at about 13 times forecast 2010 earnings  a
premium to some of Europe s other big drugmakers like
AstraZeneca  Glaxo and Sanofi but a discount to Swiss rival
Roche  which has less exposure to generic competition 
 It had been expected to post third quarter net profit of
 2 1 billion  according to a Reuters poll 
 Additional reporting by Ben Hirschler in London  editing by
John Stonestreet ",2009-10-22,Reuters,"https://www.investing.com/news/forex-news/update-3-novartis-sees-faster-growth,-swine-flu-boost-in-q4-96451",96451
203554,425070,MRK,Daily Market Analysis   7 12 2017,opinion,"Market Summary
Asian markets ended in a sea of red on Wednesday as the rout in technology continued  sending many markets down significantly  Hong Kong s Hang Seng was hardest hit  falling 2 1   but the Nikkei in Japan was close behind with a 2  loss  and its worst one day performance in over eight months  The Nikkei was pressured not only by the selloff in tech  but also by a firmer Yen against the U S  dollar  which hurts Japanese exporter shares  Both Taiwan and South Korea saw their benchmark indices sliding 1 6  and 1 4  respectively  Australia didn t avoid the downdraft as weak commodity prices sent shares of Australian mining companies spiraling lower  even though the banking sector provided some support for the market  Mainland China also saw declines due to falling commodity prices  although it was the smallest loss in the region at just 0 3  
European markets edged lower on Wednesday  despite a weaker Euro  as technology shares continued their retreat on investor worries that the Senate version of the U S  tax reform bill would be passed  The Senate version of the bill keeps the corporate Alternative Minimum Tax  and some investors fear that this would negatively impact technology firms  more so than other types of companies  Losses were broad based  but modest across the region  as a softer Euro helped prop markets up to some extent  London s FTSE bucked the falling trend  adding 0 3  as the Pound softened further against the U S  dollar amid no signs of any progress in Brexit negotiations  The Pound also softened against the Euro  providing more fuel for British equities 
U S  markets struggled for direction on Wednesday as gains from the tech sector were offset by losses from the energy sector  By the close of trade the major indices were mixed  with the S P500 basically flat as it edged lower by 0 01   Even so  the small loss was the fourth consecutive declining session for the index and its longest losing streak since March  The Nasdaq gained 0 2  on the back of the rally in technology  which was likely a result of investors buying the dip after several sessions of declines for technology stocks  The Dow Industrials fell 0 16  as 18 of the 30 Dow components ended the day lower  Surprisingly given the weakness in energy  Merck  NYSE MRK  was the biggest loser ass it fell 2 6   followed by Disney  which fell 1 6  
Today s Assets
Cryptocurrencies
It was another stunning day for Bitcoin as the cryptocurrency began the day in Asia by topping the  12 000 level  then soon after was trading above the  13 000 level  It wasn t finished though  and by the late afternoon in New York Bitcoin was over  14 000  although it pulled back right after hitting that milestone and by early evening was a few hundred dollars off its daily high  Today was different however  as most of the other major cryptocurrencies didn t participate in the Bitcoin rally  declining instead by 1 5  to 3 8   One has to wonder if all the buying is from institutional investors preparing for the launch of Bitcoin futures on the CBOE December 10  and then on the CME December 18 
AUD USD
The pair is reaching a critical support level that if broken could lead to a decline of at least 200 pips  Currently trading right around the 0 7550 level  the pair sees long term support from here down to the 0 7500 level  The pair hasn t been able to break that support over the past few weeks  but with the U S  dollar picking up steam now could be the time we see a break of this level finally  There is mid term support from March April 2015  but also a longer term support on the monthly chart from the 1989 1991 timeframe  A break of this support could see the pair trading to the 0 7100 level in the coming weeks ",2017-12-07,AvaTrade,https://www.investing.com/analysis/daily-market-analysis--7122017-200271261,200271261
203565,425081,MRK,UPDATE 1 WHO clears Glaxo s Cervarix for developing world,news,"  WHO green light prerequisite for use in poor countries
   Financing issues for vaccine yet to be resolved
  Adds details  background  
 LONDON  July 9  Reuters    GlaxoSmithKline s cervical cancer
vaccine Cervarix has won a green light from the World Health
Organisation  WHO  for use in developing countries  although how
the shot will be paid for has yet to be resolved 
 WHO  prequalification  is necessary for UN agencies and the
non profit GAVI Alliance to purchase the vaccine  and Glaxo said
on Thursday it hoped the move would help speed access to
Cervarix globally 
 Jean Stephenne  head of vaccines  said the drugmaker planned
to work with GAVI  other agencies and governments to identify
financing mechanisms 
  We re exploring a variety of distribution partnerships to
ensure Cervarix will protect women and girls around the globe  
he said 
 Vaccines like Cervarix and Merck   Co s rival product
Gardasil could be particularly valuable in the developing world 
since 80 percent of the 280 000 cervical cancer deaths a year
occur in poor countries 
 But because they are more expensive than standard childhood
vaccines  ensuring widespread use will require concessionary
pricing by drugmakers and smart financing from donors 
 Both Cervarix and Gardasil protect against the sexually
transmitted human papillomavirus  HPV  that causes cervical
cancer 
  Reporting by Ben Hirschler  Editing by Hans Peters ",2009-07-09,Reuters,https://www.investing.com/news/equities-news/update-1-who-clears-glaxo's-cervarix-for-developing-world-70103,70103
203566,425082,MRK,US STOCKS Caterpillar  Merck results boost futures,news,"  Caterpillar shares rise 9 percent before the bell
   Retail sales up 0 5 pct in latest week
   Testimony from Fed s Bernanke on tap
  Recasts  updates prices  adds quote  byline 
 By Rodrigo Campos
 NEW YORK  July 21  Reuters    U S  stock index futures rose
on Tuesday  a day after the S P 500 hit its highest closing
level in eight months  after Caterpillar Inc posted
stronger than expected quarterly results 
 Shares of Caterpillar  a Dow component  rose 9 percent in
early trade after the machinery maker reported second quarter
earnings and raised its full year outlook 
 The better than forecast results from Caterpillar followed
similar upbeat postings from chemicals company DuPont Co and
drug maker Merck   Co  which investors took as a sign that a
recent stock rally had a healthy footing 
 The market is looking for incremental news to hold on to
recent gains  according to Art Hogan  chief market analyst at
Jefferies   Co in Boston 
 Investors will also closely watch testimony on the economic
outlook and monetary policy from Federal Reserve chairman Ben
Bernanke  expected at 10 a m   1400 GMT  
  Everyone knows we need to exit the monetary policy that
we re currently using before  rampant  inflation comes upon us 
but we don t want to think that is going to happen before we ve
actually gotten a stimulated economy   Jefferies  Hogan said 
  It s going to be a balancing act today for Bernanke  
 On the economic front  U S  chain store sales rose 0 5
percent last week compared with the previous week as tracked by
the ICSC and Goldman Sachs 
 Redbook is set to release its Retail Sales Index for July
versus June at 8 55 a m   1255 GMT  
 S P 500 futures were up 3 5 points and were above fair
value  a formula that evaluates pricing by taking into account
interest rates  dividends and time to expiration on the
contract  Dow Jones industrial average futures rose 41 points
and Nasdaq 100 futures gained 3 points 
 After the closing bell on Monday  chipmaker Texas
Instruments Inc posted a stronger than expected operating
second quarter profit  but its stock slipped 1 1 percent to
 23 35 
 U S  stocks jumped Monday  driving the Standard   Poor s
500 Index to an eight month closing high  The Dow Jones
industrial average shot up 104 21 points  or 1 2 percent  the
S P gained 10 75 points  or 1 1 percent and the Nasdaq
Composite Index rose 22 68 points  or 1 2 percent ",2009-07-21,Reuters,"https://www.investing.com/news/equities-news/us-stocks-caterpillar,-merck-results-boost-futures-73308",73308
203567,425083,MRK,UPDATE 2 Merck profit falls  but beats forecasts,news,"  EPS  excluding items   0 83  forecast  0 77
   Tax settlements  lower marketing costs bolster results
   Shares up 3 8 percent in premarket trade
  Adds stock gains  product sales  analyst quote  byline 
 By Ransdell Pierson
 NEW YORK  July 21  Reuters    Merck   Co  said
second quarter earnings fell  hurt by lower sales of its
cholesterol drugs  but income from partnerships and a rebound
in sales of asthma drug Singulair helped the drugmaker beat
profit forecasts 
 Merck  whose shares rose 3 8 percent in premarket trading
on Tuesday  earned  1 59 billion  or 74 cents per share  That
compares with  1 77 billion  or 82 cents per share  in the
year earlier period 
 Merck  which plans to acquire Schering Plough Corp 
in coming months  said it earned 83 cents per share  excluding
special items  Analysts on average expected 77 cents  according
to Reuters Estimates 
 Revenue fell 3 percent to  5 90 billion but came in  70
million above the Reuters Estimate forecast  Sales would have
risen 3 percent if not for the strong dollar  which undermines
the value of overseas sales 
 Sanford Bernstein analyst Tim Anderson said Merck s equity
income of  587 million from joint ventures  including its
cholesterol partnership with Schering Plough  was 15 percent
higher than his forecast and helped drive the earnings beat 
 Results were helped by a 10 percent decline in marketing
and administrative expenses  Moreover  the drugmaker s
effective tax rate  excluding special charges and
merger related costs  was 20 4 percent  a benefit of about 5
percentage points due to favorable tax settlements 
 A bright spot in the earnings report was Singulair  Merck s
asthma drug whose sales have steadily declined in the past year
due to safety concerns  Its quarterly sales jumped 16 percent
to  1 3 billion 
 Sales of Januvia  a relatively new diabetes treatment  rose
38 percent to  462 million 
 But combined sales of cholesterol fighters Zetia and
Vytorin  sold in partnership with Schering Plough  fell 10
percent to  1 billion  The drugs have lost favor with many
doctors following a pair of clinical trials that cast doubt on
their effectiveness 
 Results were also hampered by Gardasil  Merck s vaccine
against the virus that causes cervical cancer  Gardasil sales
fell 18 percent to  268 million    hurt by rival vaccine made
by GlaxoSmithKline Plc  
 Merck stuck with its full year 2009 profit forecast of
 3 15 to  3 30 per share excluding special items  and its
full year revenue forecast of  23 2 billion to  23 7 billion 
 The company expects its acquisition of Schering Plough to
close in the fourth quarter 
 Merck shares were up  1 06 at  29 00 
  Reporting by Ransdell Pierson  editing by John Wallace and
Derek Caney ",2009-07-21,Reuters,"https://www.investing.com/news/equities-news/update-2-merck-profit-falls,-but-beats-forecasts-73315",73315
203568,425084,MRK,Cancer Space Update  Label Expansion For Three Major Drugs,opinion,"With a busy earnings season almost coming to an end after an impressive run  we are again focused on latest cancer updates happening every week  The week gone by saw three cancer drugs receiving FDA approval for new indications   Roche Holding  SIX ROG  AG s   OTC RHHBY   Gazyva  Pfizer Inc  s   NYSE PFE   Sutent and AstraZeneca PLC s   NYSE AZN   Faslodex  However  an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck   NYSE MRK   are working on  Merck has provided a fund of  200 million to develop the vaccine in combination with its anti PD 1 therapy  Keytruda  in return for a right to half of the potential sales  The vaccine will be personalized and Moderna has just developed one for its first enrolled patient  Top line data is expected in September 2019  AVEO Pharmaceuticals  Inc  s   NASDAQ AVEO   also announced the launch of its first drug  Fotivda  which was approved in Europe for treating kidney cancer in August 2017 Recap of the Week s Most Important StoriesAstraZeneca s Faslodex Approved for Combination Use  The FDA approved a new indication for breast cancer drug  Faslodex  on Nov 15  The label of Faslodex will now be expanded to include combination use with Eli Lilly s  LLY  new CDK4 6 inhibitor Verzenio to treat women with HR   HER2  advanced or metastatic breast cancer whose disease has progressed after endocrine therapy   Read more  Astrazeneca  LON AZN  PLC Price and Consensus
    Pfizer s Sutent Approved as Adjuvant Treatment for Kidney Cancer  The FDA approved label expansion of cancer drug Sutent  sunitinib malate   With the latest FDA approval  Sutent s label has been expanded to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma   RCC    This approval marks the first and only adjuvant treatment for recurrent RCC  Sutent is presently marketed for the first line treatment of advanced RCC and has been the standard of care for this indication since its approval a decade ago An application for use in the same patient population is also under review in the EU Pfizer  Inc  Price and Consensus
    Roche s Gazyva Approved in First line Setting for Blood Cancer  Roche obtained FDA approval for Gazyva in combination with chemotherapy for previously untreated advanced follicular lymphoma  stage II bulky  III or IV   The patients who respond to the combination therapy will continue to be treated with Gazyva alone  The approval was based on superior progression free survival achieved by the drug compared to Rituxan in phase III GALLIUM study The drug is already approved for use in combination with chlorambucil to treat chronic lymphocytic leukemia   CLL   in adults who have not had previous CLL treatment Roche Holding AG Price and Consensus
    AVEO Adds First Drug to its Commercial Portfolio  AVEO and its partner EUSA Pharma announced the launch of its kidney cancer drug  Fotivda in the European Union  The company expects to initiate selling in Europe starting with Germany  The drug received approval in August as first line treatment of advanced RCC in adult patients  The drug is also approved in patients who are not treated with VEGFR and mTOR pathway inhibitor therapy  following disease progression after a cytokine based therapy  The approval and launch was a major milestone for AVEO as Fotivda is the first and only marketed drug in the company s portfolio  While the acceptance of the drug is yet to be seen  it cuts AVEO s dependence on funds from collaboration to some extent AVEO Pharmaceuticals  Inc  Price and Consensus
    Apart from these label expansions and drug launches  the buzzword of the immuno oncology segment  CAR T therapy  grabbed the headlines  In a major boost to Celgene Corporation   NASDAQ CELG   and Bluebird Bio  Inc    NASDAQ BLUE    the FDA granted breakthrough therapy designation to their CAR T therapy candidate  bb2121  The candidate also received access to PRIority Medicines in Europe  bb2121 is being developed for previously treated patients with multiple myeloma  With these regulatory designations  the development is expected to expedite Meanwhile  Bayer  DE BAYGN  signed a collaboration agreement with a small U S  based company  Loxo Oncology  which gives it access to the latter s pipeline candidate  LOXO 195  With this  Bayer gets an entry into the field of cancer treatment where the drug attacks cancer based on genetics rather than attacking the organ of origin  Moreover  Celsion submitted its phase I II clinical study protocol to the FDA  which will evaluate its DNA based immunotherapy  GEN 1  as localized treatment of ovarian cancer Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-16,Zacks Investment Research,https://www.investing.com/analysis/cancer-space-update-label-expansion-for-three-major-drugs-200266330,200266330
203569,425085,MRK,TESARO  TSRO  Ovarian Cancer Drug Zejula Gets Approval In EU,opinion,"TESARO  Inc    NASDAQ TSRO   announced that the European Commission has granted marketing authorization to its PARP inhibitor  Zejula  as monotherapy for the maintenance treatment of women with recurrent ovarian cancer  The drug is the first approved PARP inhibitor in Europe  which does not require BRCA mutation or other biomarker testing The marketing approval in EU has boosted prospects of Zejula  which is already marketed in the United States  The approval in EU was expected as the drug was recommended by the Committee for Medicinal Products for Human Use in September A look at TESARO s share price movement so far this year shows that the company has underperformed the   While the stock fell 37 9   the industry registered a gain of 1 4  The approval was based on data from an international phase III study  ENGOT OV16 NOVA  which showed clinically meaningful increase in progression free survival    The study evaluated the drug in recurrent ovarian cancer patients who had achieved either a partial response or complete response to their most recent platinum based chemotherapy TESARO is planning to launch the drug in Germany and UK by the end of this year and in other European countries next year PARP inhibitors have bright prospects  given their tremendous demand  However  Zejula will face competition from other approved PARP inhibitors  which include AstraZeneca   NYSE AZN    Merck s   NYSE MRK   Lynparza and Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  However  Rubraca is under review in Europe TESARO claims that Zejula is the most frequently prescribed PARP inhibitor for treating ovarian cancer since its launch in the United States  The sales numbers show better performance by Zejula Zejula has generated sales of more than  65 million in the first six months of its launch in the United States  whereas Lynparza s U S  sales were  60 million in that period  Also  Rubraca s sales were  31 5 million Similar adoption of the drug in Europe will aid the company Approximately 45 000 women are diagnosed with ovarian cancer each year in Europe and more than 22 000 women are diagnosed annually in Europe  Ovarian cancer is the sixth most common form of cancer and the fifth most frequent cause of cancer death However  Lynparza s recent approval in the second line setting can hurt Zejula s sales TESARO  Inc  Price
    TESARO carries a Zacks Rank  3  Hold   You can see  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-11-20,Zacks Investment Research,https://www.investing.com/analysis/tesaro-tsro-ovarian-cancer-drug-zejula-gets-approval-in-eu-200267236,200267236
203576,425092,MRK,US STOCKS Nasdaq lower as techs sell off  defensives gain,news,"  Big cap tech shares weigh on Nasdaq
   Defensive stocks shine after mixed economic data
   Indexes off  S P 500 0 5 pct  Dow 0 3  Nasdaq 1 2
  Updates to late morning 
 By Edward Krudy
 NEW YORK  June 12  Reuters    Technology shares fell on
Friday after disappointing results from National Semiconductor 
but a rise in defensive stocks  like healthcare  cushioned
losses in the Dow and S P 500 
 The Nasdaq took the brunt of the selling  led by
bellwethers such as Qualcomm Inc  which was down 1 percent to
 45 50  and Apple Inc  off 2 3 percent to  136 67 
 Chipmaker National Semiconductor Corp reported a quarterly
loss late Thursday  but offered a sales forecast that beat
expectations  Shares slid 7 3 percent to  13 41  The PHLX
semiconductor index fell 3 2 percent 
 The Dow Jones industrial average dropped 23 36 points  or
0 27 percent  to 8 747 92  The Standard   Poor s 500 Index fell
4 92 points  or 0 52 percent  to 939 97  The Nasdaq Composite
Index lost 23 06 points  or 1 24 percent  to 1 839 31 
  Defensives appear to be doing a little bit better today
    and the stock sectors performing especially well since the
March 9 bottoms are the ones underperforming  So you are just
seeing an intraday move in sector rotation   said Michael
Koskuba  portfolio manager and analyst at Victory Capital
Management in New York 
  Stocks are trading on what the underlying commodities are
doing  so it stands to reason that energy and materials stocks
would sell off a little bit  
 Stocks tumbled early after a sharp retreat in commodity
prices  but buying in shares of companies seen as better able
to withstand an uncertain economy helped trim losses 
  The Reuters University of Michigan Surveys of Consumers
showing consumers were worried about inflation and labor market
uncertainty added to the early stumble 
  Stocks such as Merck   Co Inc and Pfizer Inc rose as
investors rotated money out the recent market winners 
including healthcare  energy and technology  Merck was up 2 3
percent to  26 80  while Pfizer Inc rose 2 percent to  14 92 ",2009-06-12,Reuters,https://www.investing.com/news/equities-news/us-stocks-nasdaq-lower-as-techs-sell-off;-defensives-gain-62303,62303
203577,425093,MRK,US STOCKS Wall St rises on upbeat data  financials lead,news,"  Claims data  Philly Fed add to recovery hopes
   Financials lead S P 500 higher
   Dow up 0 8 pct  S P up 0 9 pct  Nasdaq dips 0 03 pct
   For up to the minute market news click  STXNEWS US 
  Updates to midday  changes byline 
 By Rodrigo Campos
 NEW YORK  June 18  Reuters    The Dow and the S P 500 rose
on Thursday following three days of losses as economic data
pointing to stabilization in the job market and improving
regional business conditions lifted investor sentiment 
 Financial shares commanded gains  with Lincoln National up
7 1 percent at  15 96 following an upgrade from Credit Suisse
and the KBW insurance index rose 2 2 percent 
 Discover Financial Services added 6 3 percent to  9 47
after posting a smaller than expected quarterly operating loss
on cost cutting and as growth in bad loans cooled 
 The S P financial index rose 2 1 percent  also reversing
three days of losses 
  Financials are strong and I still think the market
revolves around financials   said Joe Saluzzi  co manager of
trading at Themis Trading in Chatham  New Jersey 
 Government data showed that though initial claims for
jobless benefits exceeded expectations  continued claims
posted their first drop since January  to 6 69 million from a
revised 6 84 million the previous week  and marked the largest
one week drop in that series since November 2001 
 The Philadelphia Federal Reserve s business activity index
for the Mid Atlantic region in June was still negative  but
was much better than economists  expectations and the survey s
May reading 
  We ve got some decent economic news so that s the story
today   Saluzzi added 
 The Nasdaq inched lower  reversing Wednesday s gains 
weighed by shares of Microsoft  which fell 1 percent to  23 45
and erased most of their weekly gains 
 The Dow Jones industrial average rose 66 06 points  or
0 78 percent  to 8 563 24  The Standard   Poor s 500 Index
gained 7 89 points  or 0 87 percent  to 918 60  The Nasdaq
Composite Index dipped 0 49 of a point  or 0 03 percent  to
1 807 57 
 Friday marks the end of the two day quadruple witching
period referring to the expiration and settlement of June
stock and index futures and options  which may increase
volatility  At midday  the CBOE Volatility Index was slightly
above the psychologically important level of 30  although it
was down 4 4 percent for the day 
 Shares of healthcare companies and other defensive names
   deemed better positioned to withstand a still uncertain
economy    also supported the stock market  Merck   Co Inc
jumped 4 2 percent to  25 80  while McDonald s Corp gained 2 2
percent to  58 64 
  Editing by Jan Paschal ",2009-06-18,Reuters,https://www.investing.com/news/equities-news/us-stocks-wall-st-rises-on-upbeat-data;-financials-lead-64117,64117
203580,425096,MRK,Nektar Bristol Myers  Combo Trial Positive In Phase I II,opinion,"Nektar Therapeutics   NASDAQ NKTR   along with partner Bristol Myers Squibb   NYSE BMY   announced positive interim data from dose escalation part of a phase I II study  evaluating the safety and efficacy of the combination of its lead candidate  NKTR 214  with Bristol Myers  Opdivo  nivolumab   The combination therapy is being evaluated for treatment of patients with melanoma  renal cell carcinoma and non small cell lung cancers  NSCLC  
Data from the study was presented at the 2017 annual meeting of Society for Immunotherapy of Cancer  SITC  
Notably in September last year  Nektar had entered into a clinical collaboration agreement with Bristol Myers for evaluating the Opdivo NKTR 214 combination therapy across five tumor types  melanoma  kidney  colorectal  bladder and non small cell lung cancer  and eight potential indications in phase I II studies  While both companies share cost of the combination studies equally  Nektar retains the global commercial rights to NKTR 214 
Nektar s shares have significantly outperformed the  so far this year  The stock has skyrocketed 164 9  while the industry has increased 0 9  

The PIVOT 02 phase I II study was conducted on a total of 38 patients across a number of dose cohorts  Data from the trial demonstrated positive response rates across all three tumor types in both PD L1 positive and PD L1 negative patients The company reported no treatment discontinuation due to adverse events 
Importantly  NKTR 214 is a CD122 biased agonist  while Opdivo is a PD 1 immune checkpoint inhibitor  The two different and complementary mechanisms  which comprise the combination regimen  could provide new treatment options for cancer patients 
We remind investors that Nektar is also conducting a phase I II PROPEL study to evaluate the efficacy and safety of NKTR 214 in combination with Roche s   OTC RHHBY   Tecentriq  atezolizumab  and Merck s   NYSE MRK   Keytruda  pembrolizumab   The PROPEL study complements Nektar s ongoing PIVOT trial 
Earlier in May  Nektar had entered into a research collaboration with Takeda Pharmaceuticals to explore the combination of NKTR 214 with five oncology compounds from Takeda s cancer portfolio Nektar Therapeutics Price

   Zacks Rank
Nektar carries a Zacks Rank  3  Hold   You can see  
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/nektarbristolmyers-combo-trial-positive-in-phase-iii-200264694,200264694
203590,425106,MRK,Exelixis  EXEL  Beats Q3 Earnings On Solid Cabometyx Sales,opinion,"Exelixis  Inc    NASDAQ EXEL   reported impressive results for third quarter 2017 on the back of increased Cabometyx sales  The company posted third quarter 2017 earnings of 26 cents  beating the Zacks Consensus Estimate of 8 cents  Notably  the company reported a loss of 4 cents per share in the year ago quarter Exelixis  Inc  Price and EPS Surprise
    Net revenue came in at  152 5 million  significantly up from  62 2 million in the year ago quarter  Revenues also surpassed the Zacks Consensus Estimate of  104 4 millionRevenues were boosted by increased Cabometyx sales  The FDA approved a tablet formulation of cabozantinib   distinct from the capsule form  under the brand name Cabometyx in April 2016 for the treatment of advanced renal cell carcinoma  RCC  in patients who have received prior anti angiogenic therapy  Exelixis  share price has increased 62 5  year to date compared with the  gain of 4 1  Quarter in DetailTotal product revenues were  96 4 million  up from  42 7 million in the year ago quarter  Cabometyx generated  90 4 million in net product revenues  up 11 6  sequentially driven by 9  growth in demand which was attributable to new patient starts  refills for patients already on therapy and continued expansion of the prescriber base  Cometriq  cabozantinib  capsules for the treatment of medullary thyroid cancer generated  6 1 million in net product revenues Total collaboration revenues were  56 1 million compared with  19 5 million in the year ago quarter In the reported quarter  research and development expenses increased 40 4  to  28 5 million primarily as a result of increases in personnel expenses  clinical trial costs and consulting and outside services  Selling  general and administrative expenses were  38 1 million  up 17 2  driven by increases in consulting and outside services to support the company s marketing activities resulting primarily from an increase in general and administrative headcount to support the company s commercial and research and development organizations Pipeline UpdateThe company continues to focus on the commercialization of Cabometyx in the United States  Exelixis filed a supplemental New Drug Application  sNDA  for cabozantinib as a treatment for previously untreated patients with advanced RCC in August 2017   The FDA had accepted the sNDA and granted Priority Review  assigning a Prescription Drug User Fee Act  PDUFA  action date of Feb 15  2018 In March 2017  the FDA granted cabozantinib orphan drug designation for the treatment of advanced hepatocellular carcinoma  HCC   In October  Exelixis announced that the CELESTIAL trial met its primary endpoint of overall survival  OS  with cabozantinib providing a statistically significant and clinically meaningful improvement in OS compared to placebo in patients with advanced HCC  The independent data monitoring committee for the study recommended that the trial should be stopped for efficacy following review of the second planned interim analysis  Exelixis plans to submit an sNDA to the FDA in the first quarter of 2018 During the first quarter  Exelixis inked agreements with Bristol Myers Squibb Company   NYSE BMY   and Roche Holding  SIX ROG  AG   OTC RHHBY   to develope cabozantinib in combination with immunotherapy agents  Exelixis and Bristol Myers initiated a phase III trial  CheckMate 9ER  in July 2017 Meanwhile  Exelixis and Roche have agreed to revise the revenue and cost sharing arrangement for commercialization of the other drug in the former s portfolio  Cotellic in the United Sates The IMspire150  TRILOGY  trial  which evaluates the combination of Cotellic  Tecentriq  and Xelboraf in first line BRAF V600 mutation positive metastatic or unresectable locally advanced melanoma is underway while IMspire170  the trial evaluating the combination of Cotellic and Tecentriq versus Merck   Co   Inc  s   NYSE MRK   Keytruda in first line BRAF wild type metastatic or unresectable locally advanced melanoma  is open for enrolment 2017 GuidanceExelixis expects total costs and operating expenses for 2017 in the range of  285  295 million 
Our Take
Exelixis  third quarter results were strong wherein both earnings and sales beat estimates driven by solid Cabometyx sales  The sequential increase in Cabometyx sales is a positive for the company thereby underlying the increasing demand for the drug  New patient market share in the second line plus setting increased to 38   Going forward  we expect investors focus to remain on further label expansion of cabozantinib and Cotellic  A potential label expansion in first line RCC and advanced HCC will significantly boost the growth prospects of the company 
Zacks Rank   Key Pick
Exelixis currently carries a Zacks Rank  2  Buy   You can see 
Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/exelixis-exel-beats-q3-earnings-on-solid-cabometyx-sales-200257933,200257933
203591,425107,MRK,What s In The Cards For Merck KGaA  MKGAF  In Q3 Earnings ,opinion,"Merck  NYSE MRK  KGaA  is scheduled to report third quarter 2017 earnings results on Nov 9 
Merck KGaA s share price has increased 1 2  year to date  while the  gained 2 4  

The company reports results under three business sectors   Healthcare  Life Science and Performance Materials 
Merck s revenues were driven by sales growth in its Healthcare and Life Science segment in the first half of the year  We expect the positive trend to continue this quarter  Meanwhile  the company is streamlining its Healthcare business to focus on its pipeline of innovative medicines 
During the first half of 2017  the company received approval for Bavencio in metastatic Merkel cell carcinoma  mMCC  and advanced bladder cancer in the United States  Moreover  the drug was approved in the EU and Japan for treating mMCC in late September  However  Bavencio hasn t generated any meaningful sales as reported by Merck s partner  Pfizer Inc    NYSE PFE    Merck s multiple sclerosis drug  Mavenclad  was also approved in Europe this quarter 
The company continues to develop Bavencio in partnership with Pfizer for several cancer indications 
However  we expect sales of three key drugs  Rebif  Erbitux and Gonal f to be lower this quarter due to continued competitive pressure and price reduction  However  favorable currency movement is expected to positively impact the top line in the third quarter 
Moreover  operating expenses increased during the first half due to new launches and higher pipeline development cost  With the company focusing on the development of an innovative pipeline and launch of Bavencio in new indications and geographies  costs are expected to be higher in the third quarter 
In September  Merck completed the divestment of its Biosimilars business to Fresenius as part of its strategy to become a leading science and technology company  The company is planning to focus on developing its pipeline in oncology  immuno oncology and immunology  Meanwhile  Merck announced that it is also planning a partial or full sale of its consumer health business  which includes a number of leading products in over the counter  OTC  categories 
We expect management to shed light on progress and commercialization plans for Bavencio on the earnings call  It may also provide updates on its strategic plans Merck KGaA Price and Consensus
 

   Stocks that Warrant a Look
Here are a couple of health care stocks that you may want to consider  as our model shows that these have the right combination of elements   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to post an earnings beat this quarter  You can uncover the best stocks to buy or sell before they re reported with our  
Inovio Pharmaceuticals  Inc    NASDAQ INO   is scheduled to release results on Nov 8  The company has an Earnings ESP of  41 79  and carries a Zacks Rank  3  You can see  
Pieris Pharmaceuticals  Inc    NASDAQ PIRS   is scheduled to release results on Nov 9  The Zacks  3 Ranked company has an Earnings ESP of  2 44  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-merck-kgaa-mkgaf-in-q3-earnings-200263347,200263347
203592,425108,MRK,Here s What The Takeda Deal Means For the Healthcare,opinion,"Takeda Pharmaceutical  T 4502  just announced that it has teamed up with privately held Portal Instruments  Markets are relatively flat on the news  which isn t overly surprising given the early stage of the program that s at the heart of the collaboration  but the long term potential of the deal could be a real upside driver for Takeda if it materializes as the company hopes it will 
With this in mind  here s a look at the deal  what it means for Takeda and Portal and what to look out for going forward as indicative of successful maturation 
First  a quick introduction to the two companies  For most  Takeda likely doesn t need to be introduced  The company is a circa  45 billion biotechnology and healthcare behemoth headquartered in Osaka  Japan  Its portfolio of products is expansive and is broken down into three broad categories for the purposes of operational reporting   prescription drug  consumer and other 
Portal Instruments  on the other hand  is far less well known 
The company is a Cambridge  Massachusetts startup that has developed a handheld device that injects biologic medicines through a pressurized liquid rather than a needle  The needle was initially developed by a professor at MIT called Ian Hunter  who then founded the company on the back of this single invention and now serves as a board member 
This injection technology remains the company s primary asset and   unsurprisingly   it s the asset that underpins the collaboration between it and Takeda 
So what s involved 
Takeda wants to find out if it can use the technology that Portal has created to enhance the experience for patients that need to receive injections of  or  in some cases  self inject  some of the biologics that the Japanese behemoth has in its portfolio 
The justification for this sort of alternative delivery is pretty simple  For many  having needles in the home is not desirable  Aside from the associated stigma around needle use  concerns include an innate dislike of needles  the inconvenience of disposing of needles and  safety around needle use which is especially worrisome when children live in the home  Some people also suffer from needle phobia and even those that don t generally experience some degree of elevated stress associated with needle based administration 
If Portal can show that its device can achieve the same delivery goals as a needle  it has the potential to totally change the way certain biologics are delivered  Of course  Portal is privately held  so there s no direct exposure available to the technology right now 
And that s where Takeda comes into the equation 
The company could set itself aside from its peers in the self injectable biologics space   we re talking versus companies like Merck  NYSE MRK   Astrazeneca  NYSE AZN  and Bristol Myers Squibb  NYSE BMY    if it can show that the device works  Whether there s any exclusivity associated with the arrangement isn t clear  but at a glance  it looks like there isn t  Takeda has paid an undisclosed upfront sum for rights to use the asset with its own portfolio and Portal is eligible to receive up to  100 million in future milestone payments if and when the injection technology proves viable with Takeda s biologics 
Going needle free has long been a goal of the healthcare space but   as yet   the viscosity of certain biologics has made it difficult to achieve  With this MIT born technology  Takeda and Portal could be taking the first steps towards a major shift in the global healthcare space ",2017-11-08,Samuel Rae,https://www.investing.com/analysis/heres-what-the-latest-takeda-deal-means-for-the-healthcare-space-200263560,200263560
203593,425109,MRK,Merck KGaA  MKGAF  Q3 Earnings Down Y Y  Sales Flat,opinion,"Merck  NYSE MRK  KGaA  is a science and technology company specializing in the fields of healthcare  life science and performance materials  The company s portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools  specialty chemicals and high tech materials The company is focused on oncology  multiple sclerosis  infertility  growth disorders  selected cardiovascular and metabolic diseases  women s and children s health  cough and cold as well as everyday health protection The company reports its results in three business sectors   Healthcare  Life Science and Performance Materials At its 2016 Capital Market Day  the company provided an update on its objectives up to 2018   Beginning 2017  the company aims to gain approval of one medicine or new indication every year We have highlighted some of the key stats from this just revealed announcement below Earnings  The company s third quarter 2017 earnings per American Depositary Receipt  ADR  came in at  1 77  compared to the year ago figure of  1 90 Revenue  The company posted revenues of  4 35 billion in the reported quarter  The Healthcare and Life Science segment drove the company s organic growth Key Stats  The company s multiple sclerosis therapy  Mavenclad  received recommendation from NICE for approval in UK  Bavencio received approval in the EU and Japan for treating metastatic Merkel cell carcinoma in late September  Moreover  Merck completed the divestment of its Biosimilars business to Fresenius as a part of its strategy to become a leading science and technology company Guidance Reiterated  For 2017  the company maintained its net sales forecast in the range of  15 3 billion    15 7 billion  The company expects net sales to be at the lower end of the expected range due to appreciating Euro  The company reiterated its earnings per share forecast in the range of  6 15    6 50 Merck KGaA Price and EPS Surprise
    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaa-mkgaf-q3-earnings-down-yy-sales-flat-200263814,200263814
203601,425117,MRK,What s In The Cards For Immune Design  IMDZ  In Q3 Earnings ,opinion,Immune Design Corp    NASDAQ IMDZ   is scheduled to report third quarter 2017 results on Nov 1 Last quarter  the company pulled off a positive earnings surprise of 16 92   In fact  it outpaced the Zacks Consensus Estimate in each of the trailing four quarters  with an average earnings beat 12 94  However  Immune Design s shares have lost 25 5  year to date compared with the  decline of 2 2  Let s see how things are shaping up for this announcement Factors at PlayBeing a development stage biopharmaceutical company  Immune Design has not generated any product revenues yet  Notably  it earns revenues from collaboration and licensing agreements  and product sales Furthermore  investors remain focused on the company s progress based on its pipeline candidates  Evidently  Immune Design is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   for the treatment of various types of cancers  The company s key pipeline candidates include CMB305  solid tumor  and G100  merkel cell carcinoma  MCC   CMB305 has been designed under a prime boost approach  involving the sequential dosing of two complementary agents   LV305 and G305 Currently  this candidate is being evaluated in soft tissue sarcoma  STS  patients both as monotherapy  phase I  and in combination with Roche Holding s   OTC RHHBY   Tecentriq  phase II   In August 2017  Immune Design announced positive data from its interim analysis of the ongoing phase II study evaluating CMB305 in combination with Tecentriq or Tecentriq alone in 88 soft tissue sarcoma patients Meanwhile  G100  developed on the GLAAS platform  completed enrolment in a phase I study in patients with MCC in combination with radiation  Therefore  Immune Design is collaborating with Merck  NYSE MRK  to evaluate G100 in combination with its anti PD 1 agent Keytruda for the treatment of patients with non Hodgkin s lymphoma  NHL  Markedly  the company completed a phase I study on G100 in patients with MCC  Also  it has initiated a randomized phase II study evaluating the safety and efficacy of G100  in combination with low dose local radiation and Keytruda  in patients with follicular non Hodgkin s lymphoma  NHL   Data from the evaluation are expected in 2017   During the earnings call  we expect Immune Design to shed light on its progress with these ongoing trials What Our Model IndicatesOur proven model does not conclusively show an earnings beat for Immune Design this quarter  This is because a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to be able to beat estimates  However  that is not the case here as you will see below Zacks ESP  Immune Design has an Earnings ESP of  10 32   This is because the Most Accurate estimate is 70 cents and the Zacks Consensus Estimate is pegged at a loss of 63 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Immune Design has a Zacks Rank  3  which increases the predictive power of ESP  However  the company s negative ESP makes surprise prediction difficult for the quarter Conversely  we caution against Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Immune Design Corp  Price and EPS Surprise    Stocks to ConsiderHere are healthcare companies that you may consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter Clovis Oncology  Inc    NASDAQ CLVS   is scheduled to release results on Nov 1  after market close  The company has an Earnings ESP of  2 01  and a Zacks Rank  2  You can see  Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  8 11  and a Zacks Rank  2  The company is scheduled to release results on Nov 7 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-immune-design-imdz-in-q3-earnings-200257103,200257103
203602,425118,MRK,iFOREX Daily Analysis   October 31 2017,opinion,"The US Dollar Index  USDX  which measures the performance of the US Dollar was down on Monday by 0 43  after strong economic data from Europe and retracing from its 3 months high it reached last Friday 
Gold traded slightly up amidst a stronger US Dollar and falling US treasury yields  Oil remained stable and could hold on to the gains from last week as Russia  Saudi Arabia and OPEC are consistently pushing for an extension of production cuts beyond March next year 
US equities with the exception of the NASDAQ  US Tech 100   which again reached record highs  retraced amidst some disappointing company results news and the rumors that the Trump administration would cut business taxes only gradually 
Bitcoin retraced from its high close to  6 300 but was at the time of this report comfortably trading about the  6 000 level which took some time to reach  A report by the Wall Street Journal last Friday indicated that a hedge fund managed by Bill Miller by now has Bitcoin comprising 30  of its assets as the fund bought it at a much lower level  Bitcoin and other major cryptocurrencies such as Ethereum and Ripple are showing currently gains of around 5  over the course of a week  The first major fork of Bitcoin this year  Bitcoin Cash recently surged up and shows a performance of 40  plus within a week 
Tuesday in the Asian trading session Japan publishes unemployment  industrial production  retail sales and household spending data  followed by an interest rate decision by the Bank of Japan  France  Italy and the EU publish their inflation data with the EU also releasing GDP and unemployment figures  In the American trading session Canada releases GDP data and the US business PMI  employment cost  house price and consumer confidence data 
EUR USD
The EUR USD rose from its 3 months low from last week as positive economic data from the European Union and profit taking from the recent Dollar surge strengthened the Euro again  Polls from the Spanish region of Catalonia over the weekend indicated that regional parties fighting for independence would lose their majority in the December election  which strengthened the common currency 
On Tuesday France  Italy and the European Union  EU  release their inflation data and France and the EU also releasing GDP data  From the US we will see consumer and business confidence figures as well as the S P Case Shiller House Price Index and Employment Cost Index  On Wednesday the Federal Reserve could make a decision regarding the interest rate 

Pivot  1 157Support  1 157 1 152 1 148Resistance  1 17 1 1735 1 1785
Scenario 1  long positions above 1 1570 with targets at 1 1700   1 1735 in extension Scenario 2  below 1 1570 look for further downside with 1 1520   1 1480 as targetsComment  the RSI advocates for further advance 
Gold
Gold started the week with small gains as the US Dollar declined from its previous high and US Treasury rates were also down  supporting the non interest rate bearing precious metal  The decision by Donald Trump who to appoint as Federal Reserve Chair as well as the interest rate decision by the US central bank on Wednesday could give fresh impulses to gold 
The consumer confidence and Employment Cost Index statistics published in the US ahead of the rate decision by the FED could further move the Dollar market and with it influence gold 

Pivot  1268 5Support  1268 5 1265 1260Resistance  1279 1283 1288
Scenario 1  long positions above 1268 50 with targets at 1279 00   1283 00 in extension Scenario 2  below 1268 50 look for further downside with 1265 00   1260 00 as targets Comment  the RSI is supported by a rising trend line 
WTI Oil
Oil traded almost unchanged with small upside holding onto the gains of last week  Oil remains strong as key producers Saudi Arabia and Russia are continuing public support for extended production cuts  while market participants now strongly believe that an agreement beyond March 2018 will be reached  While US oil production positive  inventories are at the lowest level since beginning of 2016 
On Tuesday the American Petroleum Institute  API  will release oil stockpile figures  followed by the Energy Information Administration  EIA  on Wednesday 

Pivot  53 35Support  53 35 52 85 52 5Resistance  54 5 54 75 55
Scenario 1  long positions above 53 35 with targets at 54 50   54 75 in extension Scenario 2  below 53 35 look for further downside with 52 85   52 50 as targets Comment  the RSI is mixed to bullish 
US 500
US equity indices traded lower with the exception of the NASDAQ  US Tech 100  which traded for another day at record high  While economic data such as personal income and PCE price index was at the expected levels and the consumer spending even surpassed expectations  The rumors that the Trump administration plans to implement corporate tax cuts only gradually over a prolonged period of time made market participants curb their enthusiasm about the proposed tax reform 
The energy sector  US Energy ETF  NYSE XLE   was up 0 64  and the best performing sector  Bigger losses were seen in the banking sector with the US Banks ETF falling 1 13  on Monday  Pharmaceutical company Merck  NYSE MRK  lost 5 94  value as a much anticipated anti cancer drug suffered a setback 
On Friday the Employment Cost Index and Chicago PMI Business Barometer could move market sentiment  while traders are expecting Donald Trump soon to name the next Federal Reserve chair 

Pivot  2576Support  2565 2561 2556Resistance  2576 2580 75 2586
Scenario 1  short positions below 2576 00 with targets at 2565 00   2561 00 in extension Scenario 2  above 2576 00 look for further upside with 2580 75   2586 00 as targets Comment  the RSI is bearish and calls for further decline ",2017-10-31,iFOREX,https://www.investing.com/analysis/iforex-daily-analysis--october-312017-200257216,200257216
203603,425119,MRK,Merck s Keytruda Failure Dims Prospects,opinion,"The last few days have been a disaster for pharmaceutical giant Merck  NYSE MRK  in the aftermath of the company s earnings report and news about its key wonder drug   reported that Merck suffered on Friday and Monday its  biggest 2 day selloff since February 2009   The company lost 11 5 percent of its value in those two days before hovering around  55 for most of Tuesday  If that was not bad enough  Merck has lost 6 6 percent of its value year to date while the Dow Jones Industrial Average has risen by 18 percent 
Merck s recent fall is the product of a disappointing earnings report as well as delays in the testing of its key lung cancer drug Keytruda  In addition  Merck withdrew its application to market Keytruda in Europe  signaling that regulators there are not comfortable with the drug 
Merck is a large drug company  and these delays regarding Keytruda could just be short term prudence which will pay off in the long run  But buyers should look elsewhere for now  Merck has questions it must answer regarding Keytruda and other facets of its business before it can be viewed as an opportunity  
The Keytruda Problem
Understanding Merck s current problems and long term potential requires understanding Keytruda s problems  As noted above  Keytruda is a lung cancer drug which is supposed to work in conjunction with chemotherapy to help patients  and is the only FDA approved immunotherapy drug on the market  albeit only for certain groups and not the general public  A  last Friday noted that lung cancer is the most lucrative oncology market by far  and Keytruda s sales in the United States eclipsed  1 billion last quarter for the first time  However  Merck s de
cision to withdraw its European application and its U S  testing delays is a major blow towards Keytruda s growth prospects 
Investors still expect Keytruda s value to grow despite these setbacks  For example  Benzinga reports that a    0Barclays   investors which recently downgraded its valuation of Merck still holds that Keytruda sales will hit  5 4 billion in 2018 and  6 6 billion in 2019  But this is about 10 percent lower than the estimates before the announcement 
Furthermore  delays in Keytruda s general approval allows other medical firms more time to catch up with Merck and finish developing their lung cancer immunotherapy drugs  Merck had solidly beaten competitors Bristol Myers Squibb Company  NYSE BMY  and Roche Holding AG Participation  SIX ROG  in cancer drug tests earlier this year  but both of those companies could come out with further lung cancer drug data later this year or in early 2018  While neither of those companies are likely to surpass Merck  Merck could find itself as just another competitor in the lung drug oncology market instead of having a solid lead like investors had anticipated 
Optimistic investors interested in business capital could interpret Merck s delays as the company taking the time to make sure that its drugs work  and thus sacrificing short term benefits to ensure the long term efficiency of such an important drug  But the reality is that the Keytruda news is a major setback for a firm which could ill afford further bad news  
Further Bad News
While the Keytruda failure is disappointing  it is not the only concern which investors should have about Merck  After all  the company s stock had not performed well over the year even before these announcements 
The major reasons why investors have been so fixated on Keytruda is that it represents Merck s best chance to get out of its growth slump as shown in its earnings report  In that report  Merck s 3Q 2017 sales declined by 2 percent compared to the same quarter 12 months ago and pharmaceutical sales declined by 3 percent 
Merck states that the sales decline is due to losses from a June cyberattack which shut down production  reduced sales  and forced them to borrow drugs from the United States government and thus wants to claim that the decline is a temporary factor  But even if that is the case  they still need to discuss future growth prospects beyond Keytruda as well as a foray into animal health   Merck could perhaps increase revenue through acquisitions such as Cubist Pharmaceuticals and it will be okay as long as it has a steady supply of drugs  But okay does not mean great or growing  
Long Term Potential   Maybe
Despite the stock collapse and Merck s various issues  investors holding Merck stock should have some reason for optimism  The stock will likely rebound somewhat soon and Keytruda will still be successful even if expectations have dropped 
But until Merck can show that it will grow again  particularly through further Keytruda sales  expecting a real bounce back in the near future is not realistic  especially as Merck has been struggling since the beginning of the year  Analysts are right to slash their forecasts  and this is a stock probably not worth picking up for now  Only consider it if you plan to hold it for an extremely long time  and have confidence that Keytruda s success will make the eventual struggles worthwhile ",2017-11-01,Alex Newman,https://www.investing.com/analysis/mercks-keytruda-failure-dims-prospects-200257701,200257701
203617,425133,MRK,Can AbbVie  ABBV  Spring A Surprise This Earnings Season ,opinion,AbbVie Inc    NYSE ABBV   is scheduled to release third quarter 2017 earnings on Oct 27  before the opening bell AbbVie s shares have soared 47 8  so far this year  while the  has recorded an increase of 20 2  Last quarter  the company delivered a positive surprise of 1 43   Notably  AbbVie s earnings history is a mixed bag as the pharmaceuticals company beat estimates in two of the last four quarters and recorded in line earnings in the other two  The four quarter average beat is 0 76  AbbVie Inc  Price and EPS Surprise   Let s see how things are shaping up for the company this quarter Factors to ConsiderAbbVie expects third quarter 2017 earnings in the range of  1 36  1 38 per share  Revenues are estimated to grow approximately 9  on an operational basis  Foreign exchange is not expected impact the sales in the third quarter The company s key drug  Humira  is likely to remain the main growth driver in the third quarter  backed by higher demand  This quarter  AbbVie expects Humira sales to rise in the high teens range while internationally  sales are estimated to increase in a mid single digit range on an operational basis  The Zacks Consensus Estimates for Humira is  4 6 billion for the third quarter Significantly  cancer drug Imbruvica recorded strong sales since the past few quarters  a trend that we expect to continue  In the quarter to be reported  Imbruvica was approved by the FDA for treating adult patients with chronic graft versus host disease  cGVHD  disease after failure of one or more lines of systemic therapy  Imbruvica s expanded label should also contribute to its sales growth  The company expects the drug s U S  sales growth to approach 30  in the third quarter  The Zacks Consensus Estimate for Imbruvica is  676 million for this quarter Other drugs like Duopa and Creon are also expected to continue to perform well in the soon to be reported quarter However  Abbvie s Hepatitis C virus  HCV  treatment  Viekira  will continue to be adversely impacted by an intense pricing and competitive pressure in the HCV market Notably  AbbVie s eight week  pan genotypic  ribavirin free  once daily HCV treatment  Mavyret Maviret  gained approval in the United States  EU and Canada earlier in July August The company believes that Maviret has potential to rejuvenate growth in the HCV franchiseas compared to the competitive dynamics in the HCV market  We expect management to update on commercialization plans of Maviret at the conference call Maviret is expected to contribute considerably to revenues only from 2018 onward The company has made significant progress with its pipeline during the quarter  which will be another focus for investors to keep tabs on  AbbVie and partner Roche   OTC RHHBY   announced positive data from a phase III MURANO study of Venclexta plus Rituxan in September to expand the label to address the broader relapsed refractory CLL  chronic lymphocytic leukemia  patient population  Label expansion for this indication should increase the patient population for Venclexta significantly and boost its commercial potential  Also  in the same month  the company announced that its oral JAK 1 selective inhibitor  upadacitinib  ABT 494   met primary endpoints in a phase III study for treatment of RA  rheumatoid arthritis  Additionally  AbbVie and partner Neurocrine Biosciences announced that the new drug application  NDA  for elagolix has been submitted to the FDA in September  AbbVie is looking to get elagolix approved as an oral medicine for pain management associated with endometriosis Earnings WhispersOur proven model does not conclusively show that AbbVie is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a bullish Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here  as you will see below Zacks ESP  AbbVie has an Earnings ESP of 0 00  as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 39 per share  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Though AbbVie s Zacks Rank  3 increases the predictive power of ESP  its 0 00  Earnings ESP makes the surprise prediction difficult We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider as per our model  these have the right combination of elements to beat on earnings this quarter Merck   Company  Inc    NYSE MRK   is scheduled to release results on Oct 27  This Zacks  3 Ranked company has an Earnings ESP of  0 61   You can see  Pfizer  Inc    NYSE PFE   is scheduled to release results on Oct 31  The company has an Earnings ESP of  0 94  and also carries a Zacks Rank of 3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-23,Zacks Investment Research,https://www.investing.com/analysis/can-abbvie-abbv-spring-a-surprise-this-earnings-season-200220720,200220720
203627,425143,MRK,AstraZeneca s SNDA For Two Cancer Drugs Gets Priority Review,opinion,AstraZeneca  plc   NYSE AZN   and partner Merck   NYSE MRK   announced that the FDA has granted priority review to its supplemental New Drug Application  sNDA  for Lynparza  With this sNDA  AstraZeneca and Merck are looking to expand the label of Lynparza  presently marketed for advanced ovarian cancer  to an advanced breast cancer indication The sNDA  looking to get the drug approved for previously treated  chemotherapy  patients with HER2 negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations  was based on data from the phase III OlympiAD study  With the FDA granting priority review  the FDA is expected to give its decision in the first quarter of 2018 The sNDA is also the first regulatory application of this PARP inhibitor beyond ovarian cancerLynparza is in different studies for a range of tumor types including breast  prostate and pancreatic cancers as well as earlier line settings for ovarian cancer Competition in the PARP inhibitor market has become fierce with Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  launched in December 2016  doing well and Tesaro  Inc    NASDAQ TSRO   launching Zejula  niraparib   in April In a separate press release  AstraZeneca announced that the FDA has also granted priority review to its sNDA for key cancer drug  Imfinzi for an earlier stage of lung cancer disease  The sNDA was based on data from the phase III PACIFIC study  Interim data from the study  presented in September  showed that Imfinzi led to superior progression free survival compared to standard of care in patients with locally advanced  unresectable non small cell lung cancer  NSCLC  who have not progressed following chemoradiation Imfinzi was launched in the United States for the first indication   second line advanced bladder cancer   in May  Imfinzi is being evaluated for multiple cancers  either alone or in combination with other regimens   including phase III trials in combination with tremelimumab in first line urothelial cancer  NSCLC  small cell lung cancer and head and neck squamous cell carcinoma  HNSCC  among others Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-snda-for-two-cancer-drugs-gets-priority-review-200219819,200219819
203628,425144,MRK,Is A Beat In Store For Bristol Myers  BMY  In Q3 Earnings ,opinion,"We expect Bristol Myers Squibb Company   NYSE BMY   to beat expectations when it reports third quarter 2017 results on Oct 26  before the market opens Year to date  Bristol Myers  shares have increased 10 2  while the  has recorded an increase of 20 5  Bristol Myers  track record has been positive so far  The company delivered positive earnings surprise in three of the last four quarters and missed expectations in one  The average positive earnings surprise in the last four quarters is 7 99   In the last reported quarter  Bristol Myers came up with a positive surprise of 1 37  Let s see how things are shaping up for this quarter Factors at PlayBristol Myers  high profile immuno oncology drug  Opdivo is expected to be the primary sales driver in the third quarter  The drug is already approved in multiple cancer indications  During this quarter  the FDA approved the drug for two additional indications   hepatocellular carcinoma and metastatic colorectal cancer   in patients who have received prior treatment  Although  these label expansions are not expected to have much impact on the top line  these when combined with the two label expansions in the second quarter will certainly boost sales Although the second quarter saw some stability in the second line lung cancer setting  FDA s approval of Merck s   NYSE MRK   Keytruda in May for the first line treatment of metastatic nonsquamous NSCLC will increase competition and may impact sales unfavorably  The Zacks Consensus Estimates indicates the drug sales to increase 31  from the year ago quarter to  1 2 billion In July  the FDA also approved the label expansion of Yervoy injection in pediatric patients 12 years of age and older with unresectable or metastatic melanoma  The Zacks Consensus Estimate for the drug this quarter is  323 million Meanwhile  rheumatoid arthritis drug  Orencia  received approval for treating psoriatic arthritis in the United States as well as in Europe in July  Moreover  in June  Bristol Myers announced the availability of subcutaneous administration option for Orencia in patients with moderately to severely active polyarticular juvenile idiopathic arthritis  The label expansion and new administration option is expected to fuel growth of the drug  The drug  which registered growth of 10  in the previous quarter  is expected to generate sales of  635 million this quarter  per the Zacks Consensus Estimate On the other hand  the decline in the Hepatitis C franchise is expected to continue due to intense competition from multiple drugs including Epclusa whose label was expanded to include HIV co infection in August  Moreover  the HIV business continues to face competitive pressure  Recent launches by other companies in the same space are expected to further impact the Sustiva franchise  The Zacks Consensus Estimate for Hepatitis C franchise sales is pegged at  108 million this quarter  down 71 5  from year ago quarter The company is developing its key drug  Opdivo as monotherapy as well as combination therapy for several tumor types in multiple studies  with two label expansion applications under review in the United States  We expect investor focus on updates related to Opdivo in the conference call  Why a Likely Positive Surprise Our proven model indicates that Bristol Myers is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate  earnings of 77 cents  and the Zacks Consensus Estimate  earnings of 76 cents   stands at  0 79   This is a leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Bristol Myers currently has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Bristol Myers Squibb Company Price and EPS Surprise
    Other Stocks That Warrant a LookHere are some biotech stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Clovis Oncology  Inc    NASDAQ CLVS   is expected to release its results on Nov 2  The company has an Earnings ESP of  2 01  and a Zacks Rank  2  You can see  Celgene Corp    NASDAQ CELG   is scheduled to release its results on Oct 26  The company has an Earnings ESP of  0 08  and a Zacks Rank  3 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-10-22,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-bristolmyers-bmy-in-q3-earnings-200220418,200220418
203633,425149,MRK,Bristol Myers Gets Priority Review For Opdivo Label Expansion ,opinion,Bristol Myers Squibb Company   NYSE BMY   announced that that the FDA has granted priority review to the supplemental Biologics License Application  sBLA  for the label expansion of Opdivo The company is looking to get the drug approved for treating patients with melanoma  who are at high risk of disease recurrence following complete surgical resection  However  the drug is already approved for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma Generally  Priority Review designation from the FDA is granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment  prevention or diagnosis of a serious disease  The FDA also previously granted Breakthrough Therapy Designation for this application which is the seventh indication for which Opdivo has received this designation The supplemental Biologics License Application is based on data from the ongoing phase III CheckMate  238 study  Bristol Myers announced encouraging results from CheckMate 238 study  on Opdivo CheckMate 238 is a randomized double blind study of Opdivo versus Yervoy in patients  who have undergone complete resection of stage IIIb c or stage IV melanoma  Results from the study showed that Opdivo 3 mg kg led to a significant improvement in recurrence free survival  RFS  compared to Yervoy 10 mg kg in patients with stage IIIb c or stage IV melanoma following complete surgical resection  The results from the planned interim analysis showed that Opdivo met its primary endpoint  with a statistically significant improvement of 35  in RFS compared to Yervoy  In July 2017  the company reported positive results from the same study So far this year  Bristol Myers  stock has rallied 8 9  compared with the  s 18 2  gain  In fact  Opdivo became the first PD 1 immune checkpoint inhibitor to gain regulatory approval anywhere in the world in July 2014  Notably  the drug became the first PD 1 inhibitor to be approved for a hematological malignancy   classic Hodgkin lymphoma   in both the United States  May 2016  and the EU  November 2016  In November 2016  Opdivo gained the FDA approval for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy Opdivo continues to be launched globally on approvals and label expansions   It also received approvals for several indications including melanoma  head and neck  lung  kidney and blood cancer  In fact  the Opdivo Yervoy regimen is approved in multiple markets for the treatment of melanoma The drug has been performing impressively due to demand resulting from the rapid commercial acceptance for several indications  Opdivo generated revenues of  1 19 billion in the second quarter of 2017  up 42  from the year ago period Meanwhile  the FDA has put a partial clinical hold on three clinical trials  CA209602  CheckMate 602   CA209039  CheckMate 039  and CA204142  These trials are investigating Opdivo based combinations in patients with relapsed or refractory multiple myeloma  Also  concerns from AstraZeneca s   NYSE AZN   failed study on lung cancer drug  Imfinzi  loom large on the company s CheckMate 227 study on Opdivo Currently  Opdivo is facing competitive challenges in the United States  With the FDA approving Merck   Co  s   NYSE MRK   Keytruda for the first line treatment of metastatic nonsquamous NSCLC  Bristol Myers is expected to suffer further loss of market share Bristol Myers Squibb Company Price    Zacks Rank   Stocks to ConsiderBristol Myers carries a Zacks Rank  3  Hold   Another better ranked stocks in health care sector includes Novo Nordisk  CO NOVOb  A S   NYSE NVO   holding a Zacks Rank  2  Buy   You can see  Novo Nordisk s earnings per share estimates have moved up  2 37 to  2 38 for 2017 and from  2 51 to  2 53 for 2018  The company pulled off positive earnings surprises in three of the trailing four quarters  with an average beat of 3 63   The share price of the company has increased 37 6  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-gets-priority-review-for-opdivo-label-expansion-200219348,200219348
203643,425159,MRK,Company News For Oct 11  2017,opinion,Shares Barracuda Networks  Inc    NYSE CUDA   gained 0 04  after posting second quarter 2018 revenues of  94 million  surpassing the Zacks Consensus Estimate of  93 millionMerck   Co   Inc  s   NYSE MRK   shares gained 0 2  after the company purchased a 9 9  stake in KalVista Pharmaceuticals Inc    NASDAQ KALV   at a price of  8 50 per shareAnaptysBio  Inc  s   NASDAQ ANAB   shares rallied 101 2  after the company announced positive results and proof of concept data from Phase 2a trial of it drug ANB020 In used for the treatment atopic dermatitisShares of Hudson Technologies Inc    NASDAQ HDSN   declined 0 8  after the company lowered its third quarter 2017 earnings guidance to  0 03  0 05 a share from  0 10 per share earlier,2017-10-10,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-oct-11-2017-200218202,200218202
203653,425169,MRK,Agenus  AGEN  Remains Focused On Drug Development Programs,opinion,We issued an updated research report on Agenus Inc    NASDAQ AGEN   on Sep 26  2017 Notably  Agenus is an immuno oncology company focused on the discovery and development of checkpoint modulators  vaccines and adjuvants for the treatment of cancer In fact  the company has collaboration agreements with a number of companies  which not only provide it with funds in the form of upfront and milestone payments and future royalties but also validate the company s proprietary product platform  Agenus has formed collaborations with Merck   Co   Inc    NYSE MRK   and Incyte Corporation   NASDAQ INCY   to discover and develop multiple checkpoint antibodies In February 2017  Agneus and Incyte amended the agreement  The amended agreement converts the ongoing GITR and OX40 antibody programs from co funded development and profit sharing arrangements to royalty bearing programs Per the agreement  Incyte will be responsible for funding and conducting global development and commercialization  When any of the two candidates from either of these two programs are approved  Agenus would be entitled to receive 15  royalties on global net sales of each approved product Following the amended agreement  Agenus received accelerated milestone payments of  20 million from Incyte related to the clinical development of INCAGN1876  anti GITR agonist  and INCAGN1949  anti OX40 agonist   Across all programs in the collaboration  Agenus will be eligible to receive up to a total of  510 million for future potential development  regulatory and commercial milestones The company s collaboration agreements with players like Incyte and Merck not only validate its technology platforms but also provide the company with funds In fact  we note that the company s QS 21 Stimulon adjuvant is partnered with GlaxoSmithKline   NYSE GSK   and is a key component in multiple GSK vaccine programs that target prophylactic or therapeutic impact in a variety of infectious diseases and cancer Moreover  Agenus  efforts in developing Prophage vaccine for glioblastoma multiforme are encouraging  It is also exploring different options to advance the Prophage vaccine into a phase III study in newly diagnosed GBM either alone or in collaboration with a third party  Also  the company is looking for partners to fund studies with plans of retaining commercialization rights in the United States The company announced its strategic decision to spin off its cell therapy businesses as a separate unit  Also  it has made this decision so that it can make smaller teams that can entirely focus on getting the products approved  We expect the combined value of the separate companies will far exceed the perceived value under one roof  going forward   However  Agenus has no approved product in its portfolio  With only a few candidates in mid stages of development  including Prophage Series vaccine and a number of QS 21 Stimulon containing vaccine candidates  the company is still a few years away from bringing a product to market  Any hiccup in the development process of these candidates may weigh heavily on the stock  Agenus is highly dependent on its partners for the development of its candidates More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2017-09-27,Zacks Investment Research,https://www.investing.com/analysis/agenus-agen-remains-focused-on-drug-development-programs-200215970,200215970
203665,425181,MRK,Cancer Space Update  Mixed Week For Pfizer  Roche Falters,opinion,"While last week was eventful with European Society for Medical Oncology   ESMO   congress taking place  this week saw the approval of Pfizer Inc  s   NYSE PFE   Bavencio in Europe  On the one hand  TESARO  Inc  s   NASDAQ TSRO   Zejula received positive CHMP opinion in the EU  while on the other  Pfizer s Sutent got a mixed view from an FDA advisory committee for a label expansion application In a setback for Roche   OTC RHHBY    two early stage studies on Tecentriq were put on partial hold  A smaller biotech company  Karyopharm Therapeutics Inc    NASDAQ KPTI   announced that its oral selective inhibitor  selinexor  was superior to placebo in reducing risk of progression or death in dedifferentiated liposarcoma patients Recap of the Week s Most Important StoriesTESARO s Zejula Nears Approval in Europe for Ovarian Cancer  TESARO announced that the Committee for Medicinal Products for Human Use   CHMP   has recommended marketing approval of Zejula  The company is seeking approval for Zejula as monotherapy for the maintenance treatment of women suffering from recurrent epithelial ovarian  fallopian tube  or primary peritoneal cancer who are in a complete or partial response  CR or PR  to platinum based chemotherapy  The drug was approved in the United States in March   Read more   TESARO  Inc  Price and Consensus
    Pfizer s Bavencio Approved in Europe  Mixed View on Sutent  Pfizer s Bavencio received a boost with approval in Europe for treating metastatic Merkel cell carcinoma  With this approval  Bavencio became the first immunotherapy available in Europe for this indication  A launch is expected by October 2017  The drug is already approved in the United States  However  a label expansion application for Sutent as adjuvant treatment for recurrent renal cell carcinoma   RCC   received a mixed opinion from the FDA advisory committee  A decision from the FDA is expected in January 2018  The drug is currently approved as first line treatment for RCC   Read more   Pfizer  Inc  Price and Consensus
    Disappointment Continues for Roche  After last week s approval of Amgen s biosimilar of Roche s cancer drug  Avastin  the FDA  this week  put a  on two early stage studies on latter s Tecentriq  which were evaluating the drug in multiple myeloma and follicular lymphoma patients  The partial hold was implemented due to safety issues found in studies evaluating Merck   Co s   NYSE MRK   Keytruda in combination with Celgene  NASDAQ CELG  s Revlimid and Pomalyst in blood cancer  Meanwhile  data announced from the phase III MURANO study conducted by Roche  showed that Venclexta in combination with Rituxan achieved a statistically significant improvement in progression free survival in chronic lymphocytic leukemia patients compared to Teva Pharmaceutical Industries Limited s   NYSE TEVA   Treanda plus Rituxan   Read more   Roche Holding  SIX ROG  AG Price and Consensus
    5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-09-22,Zacks Investment Research,https://www.investing.com/analysis/cancer-space-update-mixed-week-for-pfizer-roche-falters-200214875,200214875
203666,425182,MRK,Roche  RHHBY  Gets Approval For Label Expansion Of Tecentriq ,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the European Commission  EC  has approved immunotherapy drug Tecentriq as a monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer after they have been previously treated with chemotherapy regardless of PD L1 status The EC also granted marketing authorisation of the drug as a monotherapy for the treatment of people with locally advanced or metastatic urothelial carcinoma who have been previously treated with a platinum containing chemotherapy or who are considered ineligible for cisplatin chemotherapy  regardless of PD L1 status We note that the drug is already approved in the United States for these indications Approval in other geographies will further boost sales  Per estimates  1 59 million patients die every year due to lung cancer Earlier in the month  the FDA has put a partial clinical hold on a phase Ib and phase I II b trials evaluating Tecentriq  due to safety issues  A partial hold was put due to emerging safety data from clinical trials evaluating Merck   Co  s   NYSE MRK   Keytruda in combination with Celgene Corporation s   NASDAQ CELG   Revlimid and Pomalyst Roche also announced that the EC has approved a label expansion of Gazyvaro  The drug has been approved in combination with chemotherapy  followed by Gazyvaro maintenance in patients achieving a response  as a new treatment for previously untreated advanced follicular lymphoma The approval was based on results from the the phase III GALLIUM study which showed show superior progression free survival over MabThera We note that the drug was approved in combination with chlorambucil  for patients with previously untreated chronic lymphocytic leukaemia with comorbidities that make them unsuitable for full dose fludarabine based therapy in 2014  Gazyvaro was also approved in combination with bendamustine  followed by Gazyvaro maintenance  in patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera or a MabThera containing regimen In addition  the EC approved Actemra RoActemra  tocilizumab  for the treatment of giant cell arteritis  GCA  making it the first therapy approved for the treatment of GCA in Europe as per Roche  The drug was also approved in the Unites States for this indication in May 2017  Actemra is approved for the treatment of adult patients with moderate to severe active rheumatoid arthritis  Roche s stock has gained 15 2  year to date compared with  s gain of 20 1  Roche has a strong presence in the oncology market  The company dominates the breast cancer space due to the strong demand for its HER2 franchise drugs like Herceptin  Perjeta and Kadcyla However  sales of Avastin and Tarceva continue to decline  Generic competition for Xeloda continues to hurt sales  Competition from biosimilars looms large on Roche s key drugs like Herceptin  Avastin and Rituxan  The FDA has accepted Novartis AG s   NYSE NVS   Biologics License Application for a proposed biosimilar version of Rituxan  Hence  approval of new drugs and label expansion of existing drugs will bode well for Roche 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana   Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-09-24,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-gets-approval-for-label-expansion-of-tecentriq-200215226,200215226
203678,425194,MRK,DAX 30 Rose By 0 23  On Wednesday,opinion,"DAX 30 rose by 0 23  on Wednesday  The biggest growth was recorded by companies from the food industry  the chemical sector and the services sector  Of the winners  Merck  NYSE MRK     1 97   and the losers E ON   1 54   were separated 
The volatility index that records the sentiment of the investor regarding the expected volatility in the future period has decreased by 2 95  and is at 12 91 points ",2017-09-14,SGT Markets,https://www.investing.com/analysis/dax30-rose-by-023-on-wednesday-200213223,200213223
203679,425195,MRK,Oncology Space In Focus This Week On ESMO Presentations,opinion,Cancer  capable of striking fear in even the strongest of hearts  is a malignancy characterized by uncontrolled growth of abnormal cells  which  if not treated  can lead to death  According to the American Cancer Society  there are more than 100 types of cancers  the deadliest among them being breast cancer  skin cancer  lung cancer  colon cancer  prostate cancer  and blood cancer Presentations at the European Society for Medical Oncology   ESMO   2017 Congress held between Sep 8 and 12 in Madrid  Spain dominated headlines in the cancer space this week  Major presentations included Bristol Myers Squibb Company   NYSE BMY   and AstraZeneca  plc s   NYSE AZN   positive results from ongoing phase III study in melanoma and lung cancer patients  respectively  and Pfizer  Inc  s   NYSE PFE   disappointing data for its lung cancer candidate Recap of the Week s Most Important StoriesAstraZeneca s Imfinzi Positive in Phase III Lung Cancer Study  AstraZeneca announced promising lung cancer data from a late stage study on its new cancer drug  Imfinzi  Interim data from the phase III study   PACIFIC   demonstrated that Imfinzi achieved an improvement of 11 months in  progression free survival over standard of care in patients with locally advanced  unresectable non small cell lung cancer  NSCLC  who have not progressed following chemoradiation  Data from a separate phase III FLAURA study on another lung cancer drug  Tagrisso  showed that the drug reduced the risk of progression or death by more than half compared with other commonly used EGFR inhibitors   Read more   Bristol Myers  Opdivo Superior to Yervoy in Melanoma Patients  Bristol Myers announced data from a phase III study  CheckMate  238  comparing Opdivo to Yervoy for treating patients with stage IIIb c or stage IV melanoma who have undergone complete resection  Interim data from the study showed that Opdivo is superior to Yervoy  Opdivo achieved a statistically significant improvement of 35  in recurrence free survival compared to Yervoy   Read more   Pfizer s Xalkori Fails Lung Cancer Study Xtandi Positive in Prostate Cancer Study  Pfizer s ongoing phase III study  PROFILE 1014   evaluating Xalkori for the first line treatment of ALK positive NSCLC  did not meet its secondary endpoint of significant improvement in overall survival  OS  rates  After a median follow up of 46 months  the median OS for patients treated with Xalkori was 45 8 months while it was 47 5 months for patients randomized to chemotherapy  However  Pfizer s prostate cancer candidate  Xtandi achieved a statistically significant improvement in metastasis free survival  The drug is being evaluated in combination with androgen deprivation therapy in a phase III study  PROSPER  for a potential label expansion to include early stage prostate cancer patients  Read more   Disappointing Week for Roche  The FDA accepted Sandoz s  the generics arm of Novartis  biologics license application for a biosimilar version of Roche s   OTC RHHBY   leukemia treatment Rituxan  rituximab   Novartis has received approval for Rituxan s biosimilar in Europe in June 2017  Rituxan had recorded sales of almost  3 9 billion in the first half of 2017  In another setback  the FDA approved Amgen Allergan s biosimilar version of another key drug  Avastin  for treating multiple cancer indications including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer  The biosimilar will be marketed by the trade name of Mvasi   Read more   Other UpdatesApart from the abovementioned news  there were a few other updates in the cancer space  The FDA accepted two New Drug Applications  NDAs  of Array BioPharma seeking approval for the combination of  to treat patients with BRAF mutant advanced  unresectable or metastatic melanoma  The regulatory body also accepted a supplemental NDA for Teva Pharmaceutical Industries Ltd  s   NYSE TEVA    seeking label expansion of the drug to include treatment na ve acute promyelocytic leukemia patients  Nektar Therapeutics  the initiation of dosing in a phase I II study  which evaluates the efficacy and safety of its lead immuno oncology candidate  NKTR 214  in combination with Roche s Tecentriq and Merck s   NYSE MRK   Keytruda Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-09-14,Zacks Investment Research,https://www.investing.com/analysis/oncology-space-in-focus-this-week-on-esmo-presentations-200213604,200213604
203680,425196,MRK,Roche s  RHHBY  Tecentriq Studies Put On Partial Hold By FDA,opinion,"Roche Holdings AG   OTC RHHBY   announced that the FDA has put a partial clinical hold on a phase Ib and phase I II b trials evaluating Tecentriq  due to safety issues 
A partial hold was put due to emerging safety data from clinical trials evaluating Merck   Co   NYSE MRK   Keytruda in combination with Celgene Corporation s   NASDAQ CELG   Revlimid and Pomalyst  We note that the FDA had put a hold on several trials in the FUSION program by Celgene 
The FDA is currently evaluating all ongoing blood cancer trials investigating an anti PD1 PDL1 drug in combination with an immunomodulatory drug in order determine if it is a class wide  anti PD1 PDL1  concern in multiple myeloma blood cancers or a specific concern with certain combinations with immunomodulatory drugs 
The two studies include cohorts evaluating Tecentriq in combination with an immunomodulatory medicine  IMiDs  in relapsed refractory multiple myeloma and relapsed refractory follicular lymphoma 
As a result of the partial clinical hold  patients who are currently enroled in these trials and are deriving clinical benefit may continue to receive treatment  but no additional patients will be enroled 
We note that the FDA granted accelerated approval to immuno oncology drug  Tecentriq in May 2016 for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  Initial uptake of the drug has been encouraging  In October 2016  Tecentriq became the first and only anti PDL1 cancer immunotherapy to be approved by the FDA for the treatment of metastatic NSCLC 
The FDA recently granted accelerated approval to Tecentriq for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  mUC  who are not eligible for cisplatin chemotherapy  The drug was previously approved for patients suffering from locally advanced or mUC who have disease progression during or following any platinum containing chemotherapy  or within 12 months of receiving chemotherapy before surgery  neoadjuvant  or after surgery  adjuvant  
The news comes as a disappointment as label expansion of the drug will boost sales  Roche s stock has gained 14 1  against the  s gain of 19 4  in the year so far 

 
Earlier  the FDA also put a partial clinical hold on Bristol Myers Squibb Company s   NYSE BMY   three clinical trials   CA209602  CheckMate 602   CA209039  CheckMate 039  and CA204142 for the same reason  The trials are investigating Opdivo based combinations in patients with relapsed or refractory multiple myeloma 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  
New Report  An Investor s Guide to Cybersecurity
Cyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020  The cybersecurity industry is expanding quickly in response to these threats  In fact  a projected  170 billion per year will be spent to protect consumer and corporate assets  Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits which reveals 4 promising investment candidates ",2017-09-18,Zacks Investment Research,https://www.investing.com/analysis/roches-rhhby-tecentriq-studies-put-on-partial-hold-by-fda-200213988,200213988
203681,425197,MRK,Roche  RHHBY  Announces Positive Data On Leukemia Drug ,opinion,"Roche Holdings AG   OTC RHHBY   announced positive results from the phase III study  MURANO 
The study evaluated Venclexta in combination with Rituxan in patients suffering from relapsed or refractory chronic lymphocytic leukemia  CLL   Data showed that the study met its primary endpoint as the results depicted a statistically significant improvement in the time patients lived without their disease progressing or progression free survival  PFS   when treated with Venclexta plus Rituxan compared to Treanda plus Rituxan 
We note that Roche is developing Venclexta in collaboration with AbbVie  Inc   NYSE ABBV    Both the companies are commercializing the drug in the United States while AbbVie will commercialize outside the country 
We remind investors that the FDA approved Venclexta in April 2016 for the treatment of people with CLL  who have received at least one prior therapy  with 17p deletion  as detected by an FDA approved test  The FDA also granted Breakthrough Therapy Designation to Venclexta in combination with Rituxan for the treatment of relapsed or refractory CLL based on promising results from the phase Ib M13 365 study 
The company is conducting MURANO study to convert the current accelerated approval of Venclexta to a full approval  Data from this study will be presented at an upcoming medical meeting and submitted to global health authorities 
As per estimates  there will be more than 20 000 new cases of CLL diagnosed in the United States in 2017  CLL is the most common type of adult leukemia  Hence  a potential approval for this indication will boost sales potential 
Roche s hematology portfolio includes approved drugs like MabThera Rituxan  Gazyva  Tecentriq  and Venclexta along with pipeline candidates  polatuzumab vedotin RG7596  and a small molecule antagonist of MDM2  idasanutlin RG7388  
Last week  the FDA placed a partial clinical hold on a phase Ib and phase I II b trials evaluating immuno oncology drug  Tecentriq due to safety issues  A partial hold was put due to emerging safety data from clinical trials evaluating Merck   Co    NYSE MRK   Keytruda in combination with Celgene Corp  s   NASDAQ CELG   Revlimid and Pomalyst  We note that the FDA had put a hold on several trials in the FUSION program by Celgene 

 
Roche s stock has gained 13 6  compared with the  s gain of 19 4  in the year so far 
Roche has a strong presence in the oncology market  The company dominates the breast cancer space due to the strong demand for its HER2 franchise drugs like Herceptin  Perjeta and Kadcyla  However  sales of Avastin and Tarceva continue to decline  Generic competition for Xeloda continues to hurt sales  Competition from biosimilars looms large on Roche s key drugs like Herceptin  Avastin and Rituxan 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold   You can see  
4 Promising Stock Picks to Keep an Eye On
With news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question 
This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-19,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-announces-positive-data-on-leukemia-drug-200214220,200214220
203682,425198,MRK,Pfizer Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval,opinion,Pfizer Inc    NYSE PFE   and German partner Merck KGaA announced that their anti PD L1 monoclonal antibody  Bavencio  avelumab   has been granted marketing authorization in the EU as a monotherapy for treating adult patients with metastatic Merkel cell carcinoma  mMCC   a rare and aggressive skin cancer  The company expects to make the drug commercially available in the EU along with Germany and the U K  within the next month Notably  with this approval  the drug will now be marketed in the 28 countries of the EU including Norway  Liechtenstein and Iceland  It is the first approved immunotherapy in the EU for the given indication Bavencio received the FDA approval for mMCC in March  With the approval  the drug became the first immunotherapy option for the said cancer treatment  In May  Bavencio received the FDA approval for a second indication  The drug was approved for urothelial carcinoma  an aggressive disease with a high rate of recurrence  Also  earlier this month  the drug was granted with an approval in Switzerland for treatment of mMCC Pfizer s shares are up 10 7  so far this year  comparing unfavorably with the 16 6  rally of the  during the period The approval was supported by positive data from the phase II study  JAVELIN Merkel 200 We remind investors that the approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA   recommending approval of Bavencio for mMCC in July Pfizer will focus on Bavencio  continuously growing and expanding into new indications and markets globally Also  Bavencio is being evaluated in collaboration with Merck KGaA for different types of cancers including late stage studies for renal cell carcinoma  lung cancer  ovarian cancer  plus head and neck cancer Although Pfizer is a major player in immunotherapy  there are several other big and small companies  looking to develop and introduce immunotherapy treatments to the market As a matter of fact  Merck   Co   Inc    NYSE MRK   is conducting numerous studies to evaluate its anti PD 1 therapy  Keytruda  for more than 30 types of cancer in more than 550 studies  including more than 300 combination studies  AstraZeneca plc s   NYSE AZN   recently approved immuno oncology drug Imfinzi  durvalumab  is being assessed for multiple cancers  either alone or in combination with other regimens  and has bright long term prospects Smaller biotechs are also working to bring innovative immuno oncology treatments to the market  Kite Pharma s   NASDAQ KITE   lead drug axicabtagene ciloleucel is currently under priority review in the United States for treating aggressive non Hodgkin lymphoma  NHL  with an FDA decision expected on Nov 29 However  we believe  Bavencio can give these drugs a tough run for their money as there is ample scope for growth in the immuno oncology space Pfizer  Inc  Price   Zacks RankPfizer currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-09-21,Zacks Investment Research,https://www.investing.com/analysis/pfizermerck-kgaa-skin-cancer-drug-bavencio-gets-eu-approval-200214962,200214962
203695,425211,MRK,Why Is Immune Design  IMDZ  Down 6 8  Since The Last Earnings Report ,opinion,"More than a month has gone by since the last earnings report for Immune Design Corp    NASDAQ IMDZ    Shares have lost about 6 8  in that time frame  outperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts Immune Design Posts Narrower than Expected Loss in Q2Immune Design incurred second quarter 2017 loss of 54 cents per share  narrower than the Zacks Consensus Estimate of a loss of 65 cents and also a  year ago loss of 71 cents Quarter in DetailImmune Design s total revenue for the second quarter was  0 7 million  down from  1 1 million in the year ago quarter  The revenue was primarily due to  0 7 million collaboration revenue received from partner Sanofi  PA SASY  for G103  HSV2 therapeutic vaccine   Quarterly revenues were below the Zacks Consensus Estimate of  2 million Research and development  R D  expenses were down 4 6  to  10 9 million in the quarter  The decrease was due to the timing differences of manufacturing activities  which were offset by increased clinical costs attributable to continued advancement of Immune Design s phase I and phase II studies  and an increase in personnel related expenses that are needed to support the company s pipeline General and administrative expenses also decreased 1 5  to  3 9 million Pipeline UpdateImmune Design is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   in the field of immuno oncology  Its key pipeline candidates include CMB305 and G100 Presently  CMB305 is being evaluated in soft tissue sarcoma  STS  patients both as monotherapy and in combination with an anti PD L1 antibody  The company presented CMB305 monotherapy data pat ASCO from 25 STS patients with recurrent disease  The data showed that observed median overall survival  mOS  has not yet been reached in these patients  with an overall survival rate at 12 and 18 months of 83  and 76   respectively Furthermore  G100  which is developed on the GLAAS platform  is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study in patients with low grade follicular non Hodgkin lymphoma  NHL   The data from the phase I dose escalation monotherapy study presented at ASCO demonstrated 100  disease control rate  DCR   with over a third of patients achieving a partial response  PR  using WHO criteria  at least a 50  tumor reduction   with PRs at all three dose levels tested  50  of evaluable patients experienced shrinkage of untreated distal  abscopal  lesions in association with presence of T cell infiltrates Notably  Immune Design  completed patient enrolment in the phase II study comparing G100 and low dose radiation  XRT   versus G100 and XRT with the systemic administration of Merck  NYSE MRK    Co   Inc  s anti PD 1 agent  Keytruda  The company intends to submit data from all 24 patients in the randomized phase II study comparing G100 and XRT versus G100 and XRT with pembrolizumab in Dec 2017  Furthermore  it also plans to submit follow up data from all patients treated with G100 monotherapy in the phase I dose escalation portion of this study 2017 Outlook
Immune Design continues to anticipate cash to fund operations into the second half of 2018 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has one revision lower for the current quarter 
Immune Design Corp  Price and Consensus    VGM Scores
At this time  Immune Design s stock has a nice Growth Score of B  a grade with the same score on the momentum front  The stock was allocated a grade of F on the value side  putting it in the fifth quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
The company s stock is suitable for growth and momentum investors based on our style scores 
Outlook
Estimates have been broadly trending downward for the stock  The magnitude of this revision also indicates a downward shift  Notably  the stock has a Zacks Rank  3  Hold   We expect in line returns from the stock in the next few months ",2017-09-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-immune-design-imdz-down-68-since-the-last-earnings-report-200212216,200212216
203704,425220,MRK,DAX 30  Tuesday s Winners And Losers,opinion,At around 15 15  the German index is growing  DAX 30 is about 12172 points  or 0 58  in the green  This morning  the indicators  expectations  of economic activity  composite and service sectors  in Germany were slightly above expectations for August  Before the end of trading in Frankfurt  Merck  NYSE MRK     2 4   and Volkswagen  DE VOWG p     2 05   are among the winners  while Komercni Banka  SG BKOM    1 35   and Doj e Bank   1 22   are among the losers ,2017-09-05,SGT Markets,https://www.investing.com/analysis/afternoon-analysis-dax30-200211554,200211554
203705,425221,MRK,DAX 30 Morning Analysis,opinion,DAX rose 0 18  on Tuesday  The winner of the day was Merck  NYSE MRK  s share that grew 2 37   This morning  the factory purchases in Germany showed a level much lower than expected ,2017-09-06,SGT Markets,https://www.investing.com/analysis/dax30-morning-analysis-200211713,200211713
203713,425229,MRK,Can Pfizer Bank On New Immunotherapy Bavencio For Growth ,opinion,As demand for immuno oncology drugs and their combinations rises  Pfizer  Inc  s   NYSE PFE   newly approved immunotherapy  Bavencio  is being considered a significant top line driver for this New York based pharma giant Pfizer s shares are up 5 8  so far this year  comparing unfavorably with an increase of 13 3  for the  Bavencio  previously avelumab  received FDA approval for metastatic Merkel cell carcinoma  MCC   a rare and aggressive skin cancer  in Mar 2017  With the FDA approval  Bavencio became the first immunotherapy option for the treatment of metastatic MCC  In May  Bavencio received FDA approval for a second indication  The drug was approved for urothelial carcinoma  an aggressive disease with a high rate of recurrence  Meanwhile  Bavencio is under review in the EU for MCC with a decision expected in the third quarter of 2017  Last month  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  granted a positive opinion recommending approval of Bavencio for MCC Pfizer will focus on continuously growing and expanding Bavencio into new indications and markets globally Meanwhile  Bavencio is being studied in different types of cancers   including late stage studies for renal cell carcinoma  lung cancer  ovarian cancer  head and neck cancer   in collaboration with Merck KGaA  Pfizer has also initiated avelumab double triple combination studies for chemotherapy and targeted therapies and has 11 avelumab combination therapies with immuno oncology agents under development Immuno oncology or immunotherapy is a new class of cancer therapy that utilizes certain parts of the immune system to fight the disease  This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body   Immuno oncology drugs and their combinations are in great demandAlthough Pfizer is among the major players in immunotherapy  there are several other companies  big as well as small  looking to develop and bring immunotherapy treatments to market Merck   Co   Inc    NYSE MRK   is conducting numerous studies to evaluate its anti PD 1 therapy  Keytruda for more than 30 types of cancer in more than 550 studies  including more than 300 combination studies  AstraZeneca plc s   NYSE AZN   recently approved immuno oncology drug Imfinzi  durvalumab  is being evaluated for multiple cancers  either alone or in combination with other regimens  and has bright long term prospects Meanwhile  smaller biotechs are also working to bring innovative immuno oncology treatments to market  Kite Pharma s lead drug axicabtagene ciloleucel is currently under priority review in the U S  for treating aggressive non Hodgkin lymphoma  NHL  with a FDA decision expected on Nov 29  Juno Therapeutics and Novartis AG   NYSE NVS   are developing JCAR017 and CTL019  respectively utilizing the CAR T cell technology However  we believe that Bavencio can give these drugs a tough run as there is ample scope for growth in the immuno oncology space Pfizer carries a Zacks Rank  3  Hold   You can see  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/can-pfizer-bank-on-new-immunotherapy-bavencio-for-growth-200207936,200207936
203714,425230,MRK,AstraZeneca Merck s Lynparza Gets FDA Nod For Label Expansion,opinion,AstraZeneca  plc   NYSE AZN   and partner Merck   Co   Inc    NYSE MRK   announced that the FDA has approved a new tablet formulation for ovarian cancer drug  Lynparza while also broadening its U S  label AstraZeneca s shares are up 11 5  so far this year  comparing unfavorably with an increase of 13 7  for the   The FDA has approved expansion of Lynparza s  tablets  label to include maintenance treatment of patients suffering from platinum sensitive recurrent ovarian cancer regardless of BRCA mutation status Meanwhile  the FDA also approved a new tablet formulation  2 tablets twice daily  of the PARP inhibitor as opposed to capsules  8 capsules twice daily   which should improve patient convenience Lynparza s accelerated approval for BRCA mutated ovarian cancer beyond the third line setting was also converted to a regular approval  We remind investors that Lynparza was first approved by the FDA on an accelerated approval basis in Dec 2014  as a capsule formulation The label expansion strengthens Lynparza s position in the PARP inhibitor market where competition has become fierce with Clovis Oncology  Inc  s   NASDAQ CLVS   Rubraca  launched in Dec 2016  and Tesaro  Inc  s   NASDAQ TSRO   Zejula  niraparib   available from Apr 2017  Shares of both these small biotechs were down on Thursday following the news Lynparza is also being evaluated in different studies for a range of tumor types including breast  prostate and pancreatic cancers as well as earlier line settings for ovarian cancer AstraZeneca announced an oncology collaboration with Merck last month to commercialize and develop Lynparza  both as monotherapy and in combination studies for multiple cancer types  The companies will share development and marketing costs equally and also the profits from Lynparza AstraZeneca carries a Zacks Rank  3  Hold   You can see  4 Surprising Tech Stocks to Keep an Eye on Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-17,Zacks Investment Research,https://www.investing.com/analysis/astrazenecamercks-lynparza-gets-fda-nod-for-label-expansion-200208159,200208159
203715,425231,MRK,BioLineRx Moves A Regulatory Submission For BL 8040 Trial,opinion,"BioLineRx Ltd   NASDAQ BLRX   announced a regulatory submission for commencement of a phase III study  evaluating the lead pipeline candidate  BL 8040  a CXCR4 antagonist   in combination with granulocyte colony stimulating factor  G CSF  
Notably  BL 8040 is a short peptide indicated to mobilize the hematopoietic stem cells for autologous transplantation in patients with multiple myeloma 
BioLineRx s shares have significantly outperformed the  so far this year  The stock has rallied 19 6  versus the broader industry s decrease of 4  

The randomized  controlled phase III  GENESIS  study is designed to evaluate the safety  tolerability and efficacy of the combination therapy as compared to the combination of placebo and G CSF  The study will be conducted in two parts 
The first part of the study will evaluate the efficacy and safety of treatment with BL 8040 and G CSF to be conducted on 10 30 patients  This part will be followed by a randomized  placebo controlled  multi center study to be conducted on approximately 180 patients 
We remind investors that in September 2016  BioLineRx had entered into a collaboration agreement with Genentech  a member of Roche Holding  SIX ROG  AG   OTC RHHBY    to support several phase Ib studies  investigating BioLineRx s BL 8040 combined with Tecentriq  atezolizumab  
It s significant to note that the collaboration is part of Roche s novel cancer immunotherapy development platform MORPHEUS  a phase Ib II adaptive platform to assess the efficacy and safety of combination cancer immunotherapies 
Importantly  BL 8040 is BioLineRx s one of the leading therapeutic candidates  having successfully completed a phase IIa study for relapsed refractory AML and is amid a phase IIb study as an AML consolidation treatment 
In July  BioLineRx had announced that its partner Genentech  has initiated a phase Ib II trial  evaluating BL 8040 in combination with Roche s Tecentriq for treatment of patients with metastatic pancreatic ductal adenocarcinoma 
In September 2016  BioLineRx had announced initiation of the first phase IIa COMBAT study for evaluating the efficacy of BL 8040 in combination with Merck s   NYSE MRK   Keytruda on patients with pancreatic cancer  Subsequently  in January  BioLineRx announced onset of the second phase IIa study on the given combination 
Per the American Cancer Society provided data  more than 50 000 patients will be diagnosed with pancreatic cancer in the United Stated in 2017  Pancreatic cancer accounts for about 3  of all cancers across the country and about 7  of all cancer deaths  with pancreatic adenocarcinoma accounting for about 95  of the cases  This indicates a huge market potential for this combination therapy BioLineRx Ltd  Price

   Zacks Rank   Key Picks
BioLineRx currently carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is Aduro Biotech  Inc    NASDAQ ADRO    carrying a Zacks Rank  2  Buy   You can see  
Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
Zacks  10 Minute Stock Picking Secret
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars 
But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-22,Zacks Investment Research,https://www.investing.com/analysis/biolinerx-moves-a-regulatory-submission-for-bl8040-trial-200208860,200208860
203716,425232,MRK,Celldex Ends Phase II Enrollment For Breast Cancer Candidate ,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   announced completion of enrollment in a phase IIb study   METRIC   evaluating lead pipeline candidate glembatumumab vedotin for treating patients with metastatic triple negative breast cancers 
Shares of Celldex have underperformed the  year to date  The stock has massively plunged 34 4  versus the industry s 6 9  gain during the period 

METRIC is a randomized phase IIb study which enrolled a total of 327 patients with the given indication  Patients in this trial are randomized 2 to 1 to either glembatumumab vedotin or to Roche Holding  SIX ROG  AG s   OTC RHHBY   breast cancer drug  Xeloda  capecitabine  
The primary endpoint of the study is progression free survival  PFS   Top line data from the study is expected in second quarter 2018 
We remind investors that another phase II study on glembatumumab vedotin is currently underway on patients with metastatic melanoma as a single agent  Data from the study was presented in June  at the annual meeting of the American Society of Clinical Oncology  ASCO  
Glembatumumab vedotin performed well in the single agent setting with 11  response rate  a 52  disease control rate and a median duration of response of six months in patients  having failed three or four prior lines of therapy  The study also includes two new cohorts  a glembatumumab plus varlilumab arm and a glembatumumab plus checkpoint inhibitor arm  including either Bristol Myers Squibb Company s   NYSE BMY   Opdivo or Merck   Co  Inc  s   NYSE MRK   Keytruda 
Besides glembatumumab vedotin  Celldex s pipeline comprises another important candidate  varlilumab  It is being evaluated in several phase I II combination studies across multiple types of cancer Celldex Therapeutics  Inc  Price

   Zacks Rank
Celldex currently carries a Zacks Rank  3  Hold   You can see  
One Simple Trading Idea
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars 
This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/celldex-ends-phase-ii-enrollment-for-breast-cancer-candidate-200209433,200209433
203723,425239,MRK,Here s How Takeda Pharmaceutical Is Trying To Dominate Immuno Oncology,opinion,"Takeda Pharmaceutical  OTC TKPYY   TKPYY   one of the biggest healthcare companies in the world and arguably the most well known and most respected of the Japanese pharmaceutical giants  just announced the signing of an agreement that will see it team up with a company called Shattuck Labs in the oncology space  The latter is a privately held company based out of Austin  Texas and is the latest in a line of tiny healthcare entities with which Takeda has struck an alliance 
With Shattuck being a relatively small entity  there is limited information available as to the technology that underpins the collaboration between it and Takeda  As such  the implications for Takeda and its shareholders as far as how this deal might play out are concerned are a little bit murky  With that said  however  a bit of digging can offer some clarity  especially as regards to the concept that Takeda is hoping will provide it with the next generation of cancer therapies 
With this in mind  here is a look at the science that underpins Takeda and Shattuck s latest collaboration with an attempt to figure out what it might mean for shareholders if and when it plays out successfully or otherwise going forward 
The easiest way to tackle this is from the top down  so let s start with a look at immunotherapy  Cancer immunotherapy aims to harness the immune system of the patient in an attempt to stimulate the body  or more accurately  the body s natural response to pathogens  to attack  kill and remove cancer cells  There are many different approaches to doing this  but they generally involve one of three high level concepts  The first is rooted in teaching the immune system to recognize cancer cells through some sort of antibody based engineering  The second is through the removal of a cancer cell s natural ability to hide itself from the immune system  The third is the stimulation of the immune system to such a degree that  regardless of the ability of the cancer cell to hide itself  the cells in question are overpowered and destroyed as appropriate 
Most immunotherapy types harness one of these high level concepts 
Shattuck has developed a technology that it calls its Agonist Redirected Checkpoint  ARC  platform and the latest collaboration is rooted in certain assets that are born out of this platform  The way it works is by combining two binding domains to create fusion proteins that potentially restore and enhance immune system function in a single construct  In other words  the platform is able to create immunotherapy assets that combine two or more of the three high level concepts outlined above and   in doing so   develop a treatment that should theoretically be more effective than a single asset on its own 
And there is evidence to suggest that this is the case   redirects to a healthcare conference at Boston back in May this year  at which Taylor Schreiber  CSO of Shattuck  gave an example of how the technology works and a real life application  Specifically  he discussed a drug that simultaneously blocks signaling through PD 1 and activates signaling through OX40  For those not familiar with these two treatment approaches  PD 1 is rooted in a cancer s ability to hide itself from the immune system  Blocking signaling through PD 1 reveals the cancer cells to our natural attack cells  T cells  etc   
OX40 is rooted in the signaling of the immune system to come and attack cancer cells  Through the upregulation of OX40  the immune system should be able to overwhelm cancerous cells and remove them from the body far more efficiently than might otherwise be the case 
As mentioned  normal drugs would only use one of these approaches  With Shattuck s ARC technology  the idea is to use both at the same time and provide a sort of 360  therapy 
So where does Takeda to come into this 
The collaboration sees Takeda team up with Shattuck on two pre clinical and four discovery stage programs  The Japanese pharma giant will provide funding for pre clinical and clinical development and will have the option to take an exclusive license to further develop and commercialize up to four ARC molecules resulting from the collaboration 
The idea  then  is that Takeda is trying to harness this technology in an attempt to get a jump on some of its healthcare giant competitors in the space 
Immunotherapy  as things stand  is dominated by companies like AstraZeneca PLC  AZN  and Merck   Co   Inc   NYSE MRK   The majority of the treatments offered by these two companies  however  and this includes those in their respective development pipelines  are single approach immunotherapy assets  If Takeda can use Shattuck s ARC technology to demonstrate that a double pronged approach is more effective than a single  then it could become a front runner in oncology very quickly 
Of course  these are early stage assets and there is no guarantee that they will ever reach the clinic  never mind commercialization  With that said  however  we were saying the same thing about immune oncology as little as a decade ago ",2017-08-15,Samuel Rae,https://www.investing.com/analysis/heres-how-takeda-pharmaceutical-is-trying-to-dominate-immunooncology-200207263,200207263
203724,425240,MRK,Bristol Myers Opdivo Fails Kidney Cancer Trial CheckMate 214,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced disappointing top line results from the CheckMate 214 trial  The study investigated immuno oncology drug Opdivo  nivolumab  in combination with Yervoy  ipilimumab  versus Pfizer Inc  s  NYSE PFE  Sutent in intermediate and poor risk patients previously untreated advanced or metastatic renal cell carcinoma Although the combination showed an improvement in progression free survival  PFS   it did not reach statistical significance as the median PFS was 11 56 months for the Opdivo and Yervoy combination versus 8 38 months for Sutent  Hence  the trial did not meet its primary endpoint  Nevertheless  the combination met the co primary endpoint of objective response rate  ORR  and achieved a 41 6  ORR versus 26 5  for Sutent However  the company has decided to continue with the study as planned to allow the third co primary endpoint of overall survival to mature  The tolerability profile observed in CheckMate 214 was consistent with that observed in previously reported studies of this dosing schedule   We note that renal cell carcinoma  RCC  is the most common type of kidney cancer in adults and accounts for more than 100 000 deaths worldwide each year  Among these  clear cell RCC is the most prevalent type of RCC and constitutes 80 90  of all cases thereby underlying the demand for the same Bristol Myers received a huge boost when its high profile immuno oncology drug  Opdivo  became the first PD 1 immune checkpoint inhibitor to gain regulatory approval anywhere in the world in Jul 2014  It is currently approved in several countries including the U S   the EU and Japan for several cancer indications However  the company has had its share of pipeline and regulatory setbacks  In Oct 2016  Bristol Myers announced the final primary analysis of CheckMate 026  a phase III study that evaluated the use of Opdivo monotherapy as a first line treatment of patients with advanced non small cell lung cancer  NSCLC  whose tumors expressed PD L1 greater than or equal to 1  In Jan 2017  the company announced not to pursue accelerated regulatory pathway for the regimen of Opdivo plus Yervoy in first line lung cancer in the United States  based on a review of available data  Bristol Myers  failed efforts to expand Opdivo s label to include first line treatment of lung cancer adversely impacted shares  Bristol Myers  stock has declined 1  in the year so far  against the  s 10 7  gain Opdivo faces stiff competition from Merck  Co s   NYSE MRK   Keytruda and Roche Holding s   OTC RHHBY   Tecentriq  The recent FDA approval of Merck s Keytruda for the first line treatment of metastatic nonsquamous NSCLC will further impact sales Moreover  with the failure of AstraZeneca s   NYSE AZN   Mystic study on Imfinzi in NSCLC  investors are worried about the outcome of the CheckMate 227 study on Opdivo for first line NSCLC given the similarity of trials  While management has played down the uncertainty regarding the trial  concerns remain 
Zacks Rank 
Bristol Myers currently carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-08-15,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivo-fails-kidney-cancer-trial-checkmate214-200207638,200207638
203736,425252,MRK,Exelixis  EXEL  Q2 Earnings  Sales Beat On Cabometyx Sales,opinion,"Exelixis  Inc    NASDAQ EXEL   reported impressive results for the second quarter on the back of increased Cabometyx sales  The company posted second quarter 2017 earnings of 8 cents  beating the Zacks Consensus Estimate of 3 cents  Notably  the company had reported a loss of 15 cents per share in the year ago quarter Exelixis  Inc  Price and EPS Surprise
 

   Net revenue came in at  99 0 million  significantly up from  36 2 million in the year ago quarter  Revenues also surpassed the Zacks Consensus Estimate of  84 6 million  Revenues were boosted by the FDA approval of a tablet formulation of cabozantinib   distinct from the capsule form  under the brand name Cabometyx in Apr 2016 for the treatment of advanced renal cell carcinoma  RCC  in patients who have received prior anti angiogenic therapy 

Exelixis  share price has increased 78 6  year to date compared with the  gain of 9 9  
Quarter in Detail
Total product revenue was  88 0 million  up from  31 6 million in the year ago quarter  Cabometyx generated  80 9 million in net product revenue  up 29 6  sequentially driven by 25  growth in demand which was attributable to new patient starts  refills for patients already on therapy and continued expansion of the prescriber base  Cometriq  cabozantinib  capsules for the treatment of medullary thyroid cancer generated  7 1 million in net product revenue 
Total collaboration revenue was  11 0 million compared with  4 6 million in the year ago quarter 
In the reported quarter  research and development expenses declined 22 7  to  28 2 million primarily a result of increases in clinical trial costs  costs related to CABOSUN  start up costs associated with CheckMate 9ER and with phase Ib trial of cabozantinib and Tecentriq in locally advanced or metastatic solid tumors and were partially offset by a decrease in costs related to METEOR  and personnel expenses 
Selling  general and administrative expenses were  40 7 million  up 13 7  driven by an increase in headcount connected with the build out and support of the commercial organization in the U S  an increase in legal costs  and an increase in consulting and outside services to support marketing activities 
Pipeline Update
The company continues to focus on the commercialization of Cabometyx in the U S  Exelixis plans to file a supplemental New Drug Application  sNDA  for cabozantinib as a treatment for previously untreated patients with advanced RCC in third quarter 2017 based on the positive data from the randomized phase II trial  CABOSUN  An independent radiology review committee has confirmed the primary efficacy endpoint results of investigator assessed progression free survival  PFS  in the CABOSUN trial  As per the analysis from the committee  Cabometyx demonstrated a clinically meaningful and statistically significant reduction in the rate of disease progression or death as measured by PFS 
During the first quarter  Exelixis inked agreements with The Bristol Myers Squibb Company   NYSE BMY   and Roche Holding  SIX ROG  AG   OTC RHHBY   to collaborate on the development of cabozantinib in combination with immunotherapy agents  Exelixis and Bristol Myers initiated a phase III trial  CheckMate 9ER  in Jul 2017 
Exelixis has also initiated the dose escalation stage of a phase Ib trial of cabozantinib in combination with Tecentriq  The drug will be evaluated in patients suffering from locally advanced or metastatic urothelial carcinoma  UC  or RCC 
In Mar 2017  the FDA granted cabozantinib orphan drug designation for the treatment of HCC  A phase III trial  CELESTIAL is currently ongoing in patients with advanced HCC  The company now expects completing the second intermin analysis at 75  of the events in the second half of 2017 
Meanwhile  Exelixis and Roche have agreed to revise the revenue and cost sharing arrangement for commercialization of the other drug in the former s portfolio  Cotellic in the U S 
Roche also announced that IMspire150 TRILOGY  which evaluates the combination of Cotellic  Tecentriq  and Xelboraf in first line BRAF V600 mutation positive metastatic or unresectable locally advanced melanoma  enrolled its first patient in Jan 2017 while IMspire170  the trial evaluating the combination of Cotellic and Tecentriq versus Merck   Co   Inc  s   NYSE MRK   Keytruda in first line BRAF wild type metastatic or unresectable locally advanced melanoma  is likely to enroll its first patient in the third quarter of this year 
2017 Guidance
Exelixis expects total costs and operating expenses for 2017 in the range of  290  310 million  This guidance includes about  25 million of non cash costs and expenses related primarily to stock based compensation expense  R D expense is projected to increase in the second half of 2017 due to initiation of combination studies 
Our Take
Exelixis  second quarter results were impressive where in both earnings and sales beat estimates  The sequential increase in Cabometyx sales is a positive for the company thereby underlying the increasing demand for the drug  Going forward  we expect investor on further label expansion of cabozantinib and Cotellic  A potential label expansion in first line RCC will significantly boost the growth prospects 
Zacks Rank   Key Pick
Exelixis currently carries a Zacks Rank  2  Buy   You can see 
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without 
Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future  Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/exelixis-exel-q2-earnings-sales-beat-on-cabometyx-sales-200205183,200205183
203737,425253,MRK,Horizon Pharma  HZNP  Q2 Earnings   Sales Top  Raises View,opinion,"Horizon Pharma plc   NASDAQ HZNP   topped both earnings and sales estimate in second quarter 2017  The company also raised its sales guidance for 2017  The company s shares moved up 4 72  on better than expected second quarter results and increased guidance However  Horizon Pharma s stock is down 17 8  year to date against the  gain of 8 8  The company reported second quarter 2017 earnings of 26 cents per share which beat the Zacks Consensus Estimate of 12 cents  including stock based compensation expense but excluding one time items  but were down from 42 cents in the year ago quarter  Excluding stock based compensation expense  the company reported EPS of 41 cents Sales in the second quarter were up 12  year over year to  289 5 million fueled by solid growth across its orphan and rheumatology business units  Reported sales also beat the Zacks Consensus Estimate of  235 million Horizon Pharma PLC Price  Consensus and EPS Surprise
    Quarter in DetailThe Orphan unit recorded revenues of  120 4 million  up 64  from the year ago period  The strong performance was backed by solid net sales of Ravicti  which generated sales of  47 2 million in the quarter  up 20  year over year driven by continued conversion from older generation nitrogen scavenger therapies  as well as the addition of treatment na ve patients due to the recent label expansion  On Apr 28  the FDA approved a supplemental New Drug Application for Ravicti to expand the age range for chronic management of urea cycle disorders in patients to two months and older from two years and older Additionally  Procysbi contributed to the performance with its net sales of  36 7 million  Actimmune sales in the reported quarter were  28 8 million  down 4  year over year The Rheumatology unit generated sales of  51 7 million  up 56  year over year  Also  Krystexxa sales in the quarter were strong and came in at  38 3 million  up 93  year over year  driven by continued strong year over year vial demand Primary Care garnered revenues of  117 4 million  down 22  year over year  The decline in net sales was due to the implementation of a new contracting model  in order to secure broader inclusion of the company s primary care medicines on formularies  Net sales of Pennsaid2   Duexix and Vimovo were  51 2 million   43 6 million and  21 1 million  respectively  in the reported quarter 2017 GuidanceThe company raised its outlook for 2017 and now expects sales in the range of  1 010  1 045 billion  compared to the earlier estimate of  985  1 020 billion Horizon Pharma is significantly increasing investments in one its key growth drivers  Krystexxa and expects net sales for Krystexxa around  400 million in 2017 driven by higher demand  The guidance includes assumption of lower net average net realized price beginning in the second half primarily resulting from the U S  Government s Health Resource and Services Administration s Final Rule on 340B drug ceiling price implementation scheduled for Oct 1   The company expects continued double digit net sales growth for Ravicti in 2017  with room for additional uptake due to the recent label expansion  The drug is also expected to be launched in Europe in the second half  Sales of Procysbi will decline to the divestiture of European rights  Sales of Actimmune are projected to grow in low single digits driven by a year over year growth in the second half  Other UpdatesDuring the quarter  the company acquired River Vision thereby adding its biologic candidate teprotumumab in late stage development for Thyroid Eye Disease  A confirmatory phase III trial is slated to being by year end  The company expects that annual net sales for teprotumumab in the U S  could exceed  250 million In Jun 2017  Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe  the Middle East and Africa regions to Chiesi Farmaceutici S p A  as the company focuses on higher return businesses Meanwhile  the company is working on expanding Actimmune s label  The company has collaborated with the Fox Chase Cancer Center to evaluate Actimmune in combination with a Bristol Myers Squibb Company s   NYSE BMY   Opdivo in a phase I dosing study for the treatment of kidney and bladder cancer   The National Cancer Institute has plans to evaluate Actimmune in combination with Merck   Co   NYSE MRK   Keytruda to treat cutaneous t cell lymphoma patients  This phase II study remains on track to begin later this year Our TakeHorizon Pharma s second quarter results were impressive with the company beating on both the top and bottom line estimates  Moreover  the increase in sales guidance for 2017 was encouraging as well  Net sales for rare diseases drug increased 70   We expect Krystexxa  Ravicti and Actimmune to drive growth in the second half The acquisition of teprotumumab has further diversified the company s portfolio  However  key drugs Duexis and Vimovo face competition from Pfizer Inc  s   NYSE PFE   Celebrex and its generics  and other branded non steroidal anti inflammatory drugs  NSAIDs  and cheaper generic versions of NSAID Zacks Rank
Horizon Pharma currently has a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/horizon-pharma-hznp-q2-earnings--sales-top-raises-view-200206081,200206081
203738,425254,MRK,Impax Laboratories  IPXL  Q2 Earnings Beat  Revenues Up Y Y,opinion,"Impax Laboratories Inc  s   NASDAQ IPXL   shares have risen almost 10  since it announced robust results on Aug 9  The company reported second quarter 2017 adjusted earnings of 18 cents per share  beating the Zacks Consensus Estimate of 14 cents  However  earnings were down 14 3  from 21 cents in the year ago period due to higher costs Total revenue increased 17 1  year over year to  202 1 million on growth in Generic division sales Revenues also surpassed the Zacks Consensus Estimate of  196 14 million in the reported quarter In fact  year to date  Impax shares are up 37 4   while the  declined 17 3  Quarter in DetailDuring the reported quarter  Impax Generic division revenues increased 24  from the year ago quarter to  150 8 million  The increase in revenues was due to higher sales of epinephrine auto injector  oxymorphone ER and products acquired from Teva Pharmaceuticals Industries Ltd    NYSE TEVA   and launch of generic version of Merck   Co   Inc s   NYSE MRK   Vytorin this quarter The Impax Specialty Pharma division recorded revenues of  51 2 million  up 26 7  year over year  largely due to higher sales of Rytary  However  Zomig sales were down 7  to  12 3 million Adjusted research and development  R D  expenses grew 6 2  to  22 1 million in the reported quarter Adjusted selling  general and administrative expenses  SG A  increased 17 9  to  51 2 million Other DetailsSubsequent to the quarter  in July  the company received approval for generic versions of Focalin XR  25 and 35 mg  and Concerta  18  27  36 and 54 mg  from the FDA  The approval of generic Focalin XR complemented its portfolio of generic Focalin XR  which included 5  10  15  20 and 30 mg capsules  These are already marketed In April  Impax announced it that it has received final FDA approval for a generic version of Vytorin  ezetimibe simvastatin tablets   10 10  10 20  10 40 and 10 80 mg  and immediately initiated commercialization activities of this first to market opportunity Toward the end of March  the company had announced that the U S  District Court  District of Delaware ruled in favor of it and AstraZeneca plc   NYSE AZN   in a patent infringement case regarding the generic version of Zomig 2017 Outlook UpdatedThe company expects its full year adjusted earnings to be in the range of 55 cents to 70 cents per share The company expects adjusted gross margin in the range of 47  to 49  Adjusted research and development expenses  including patent litigation expenses  across the generic and brand divisions are forecast to be in the range of  93 million to  97 million  previously  90 million to  95 million  Adjusted selling  general and administrative expenses are expected to be in the range of  190 million to  195 million Our TakeIn its first quarter release  Impax had discussed its cost saving initiatives  which included several processes to improve efficiencies and margins  and focus on growth opportunities  Savings in annualized costs to the tune of  85 million is expected  with limited savings in 2017 and a projection to save a total of  130 million by the end of 2019  However  the headwinds in the generic segment are likely to continue through 2017  which may impact the top line in the upcoming quarters Impax Laboratories  Inc  Price  Consensus and EPS Surprise
    Zacks RankImpax currently carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-08-10,Zacks Investment Research,https://www.investing.com/analysis/impax-laboratories-ipxl-q2-earnings-beat-revenues-up-yy-200206761,200206761
203747,425263,MRK,Weighing The Week Ahead  Is This The Time For A Congressional Vacation  ,opinion,"Once again  the calendar includes most of the important economic news in a single week  Competing with the data will be the ongoing discussion of important policy issues  Most significant are the debt ceiling and tax policy  Congress will start a five week recess  I expect pundits to be wondering 
Is this really the time for a Congressional vacation 
Last Week Recap
The Fed announcement  according to   was a  snoozefest   He sees an early move toward reducing the balance sheet 
The Story in One Chart
I always start my personal review of the week by looking at this  via Jill Mislinski 

Doug has a special knack for pulling together all the relevant information  His charts save more than a thousand words  Read the entire post for several more charts providing long term perspective  including the size and frequency of drawdowns 
Personal Note
I ll be back from vacation tomorrow  It was a refreshing trip  and I have some interesting new ideas for posts  Toronto is a great city with a vibrant community 
The News
The economic news has continued in the mildly positive trend  New home sales and consumer confidence showed strength last week  Most important has been the earnings news 
Earnings season has continued strong with energy living up to its great expectations for the most part  while the three largest S P sectors by market capitalization  Technology   20    Financials   16    and Healthcare   15 00   are reporting strong earnings growth 
As Brian Gilmartin at Fundamentalis explains in his article last week    the largest sectors reporting the best earnings growth often makes for bull markets  Over half of S P 500 constituents  57   have reported actual results for Q2 so far  and of those about three quarters are reporting EPS above estimates compared to a five year average  Actual sales reports show similar above estimate results for about three quarters of companies reporting 
The Week Ahead
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react 
The Calendar
The calendar is a busy one this week  with numerous important data points coming in such as Employment  ISM Manufacturing and Non Manufacturing PMI  as well as Auto Sales reporting 
 has a good U S  economic calendar for the week  Here are the main US releases 

Next Week s Theme
There is plenty to talk about  with employment taking center stage  The big economic weeks have not led to much volatility this year  and this will probably not be different 
There is an interesting counter theme  The Congressional recess  There is plenty of work undone  most urgently the debt limit   asked Congress to deal with the debt limit before the recess  While he has found extraordinary measures to keep the government going through September  it comes with a cost 
I expect this subject and stories about meetings with constituents will raise the question 
Is this really an appropriate time for a Congressional vacation 
As usual  I ll have more in my Final Thought 
Quant Corner
We follow some regular featured sources and the best other quant news from the week 
Risk Analysis 
I have a rule for my investment clients  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot

Watch Out
 on two vastly different views of Universal Display  NASDAQ OLED  are examined  Heavily endorsed by Jim Cramer as the company which will dominate the organic light emitting diode space for year to come  UDC s recent success stems both from such promotion  as well as from OLEDs having become the new  it  material for electronic displays 
As notable short seller Manuel Asensio mentions  however  UDC s key patents expire in December 2017  and their OLEDs based on the rare earth iridium can t display blue light nearly as efficiently as the potential touted for OLED technology  According to Sensio UDC faces stiff competition for this lucrative market  and is likely to lose its dominant position by the end of 2018 as large industry players like Merck  NYSE MRK   Panasonic  and LG bring new OLED technology to bear as well as compete in UDC s iridium home field  To say Cramer and Asensio have differing opinions on UDC s management would be an understatement 
Final Thoughts
What worries me 
China  Russia  and North Korea  Even more given the latest missile test  There has been no progress on this dangerous matter 
 and what doesn t
Continuing political turmoil  Beyond specific policies  cooperation and compromise will result in better outcomes for investors  This will only happen when the necessity becomes obvious to all ",2017-07-31,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead-a-congressional-vacation-200204474,200204474
203748,425264,MRK,The Zacks Analyst Blog Highlights  Merck  Citigroup  AstraZeneca  HSBC And Sprint,opinion,For Immediate ReleaseChicago  IL   August 03  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Merck  NYSE   NYSE MRK        Citigroup  NYSE   NYSE C        AstraZeneca  NYSE   NYSE AZN        HSBC  NYSE   NYSE C       and Sprint  NYSE   NYSE S       Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Wednesday s Analyst Blog  Top Research Reports for Merck  Citigroup and AstraZenecaThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Merck  NYSE       Citigroup  NYSE      and AstraZeneca  NYSE       These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Merck shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the last year  gaining  10 6  versus the industry s  1 9  decline  This momentum reflects the progress it has made with product pipeline  Merck beat estimates for both earnings and sales in the second quarter  backed primarily by strong sales of PD 1 inhibitor  Keytruda While generic competition for several drugs and pricing pressures as are material in the Merck story as they are for many of its peers  the Zacks analyst points out that the company s new products like Keytruda and Zepatier hold great potential  Also  Merck will continue to focus on cost cutting initiatives to drive the bottom line However  generic competition for several drugs and pricing pressure will continue to overhang on the top line  The Zacks analyst discusses all of these issues in the updated research report issued today  You can  Shares of Citigroup shares have outperformed the Zacks Major Banks industry over the last six months  gaining  20 4  vs  5   The company s second quarter 2017 earnings outpaced expectations riding on higher revenues  However  expenses and costs of credit escalated  The Fed s recent approval to the company s 2017 capital plan also remains encouraging Moreover  the recently approved Financial Choice Act will act as a tailwind for the company in coming quarters  However  several issues including Citigroup s litigation pressures are cause for concern  Moreover  in spite of rising rates  margin is under pressure  due to persistent decline in the company s legacy holdings portfolio The Zacks analyst likes the company s restructuring and streamlining efforts  strategic investments in core business and expense management  which should support profitability  going forward  You can  AstraZeneca s shares have gained  10 3  year to date  underperforming the Zacks Large Cap Pharmaceuticals sector which has gained  10 5  over the same period  Despite doing well this year  the stock plunged sharply after the company announced the failure of a pivotal first line lung cancer study  MYSTIC  on Imfinzi  AstraZeneca s second quarter results were mixed with earnings beating estimates but sales remaining in line Core products like Nexium and Crestor are facing generic competition  which is hurting sales growth  However  AstraZeneca s newer drugs like Tagrisso and Brilinta should keep contributing to the top line  Meanwhile  cost cutting initiatives should drive the bottom line AstraZeneca also has a promising late stage pipeline that includes immuno oncology candidates  Imfinzi s approval in May 2017 for bladder cancer was encouraging  The Zacks analyst is enthused by the fact that the company expects a lot of activity on the regulatory and pipeline front in the second half of 2017  You can  Other noteworthy reports we are featuring today include HSBC  NYSE      and Sprint  NYSE      Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth  Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-08-02,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-merck-citigroup-astrazeneca-hsbc-and-sprint-200205022,200205022
203749,425265,MRK,Immune Design  IMDZ  Posts Narrower than Expected Loss In Q2,opinion,Immune Design Corp    NASDAQ IMDZ   incurred second quarter 2017 loss of 54 cents per share  narrower than the Zacks Consensus Estimate of a loss of 65 cents and also a  year ago loss of 71 cents Immune Design s share price has increased 100  year to date  compared with the Zacks classified  gain of 1 7  Quarter in DetailImmune Design s total revenue for the second quarter was  0 7 million  down from  1 1 million in the year ago quarter  The revenue was primarily due to  0 7 million collaboration revenue received from partner Sanofi   NYSE SNY   for G103  HSV2 therapeutic vaccine   Quarterly revenues were below the Zacks Consensus Estimate of  2 million Research and development  R D  expenses were down 4 6  to  10 9 million in the quarter  The decrease was due to the timing differences of manufacturing activities  which were offset by increased clinical costs attributable to continued advancement of Immune Design s phase I and phase II studies  and an increase in personnel related expenses that are needed to support the company s pipeline General and administrative expenses also decreased 1 5  to  3 9 million Pipeline UpdateImmune Design is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   in the field of immuno oncology  Its key pipeline candidates include CMB305 and G100 Presently  CMB305 is being evaluated in soft tissue sarcoma  STS  patients both as monotherapy and in combination with an anti PD L1 antibody  The company presented CMB305 monotherapy data pat ASCO from 25 STS patients with recurrent disease  The data showed that observed median overall survival  mOS  has not yet been reached in these patients  with an overall survival rate at 12 and 18 months of 83  and 76   respectively In Sep 2017   the company will present early data from the phase II study comparing CMB305 plus Roche Holding  SIX ROG  AG s   OTC RHHBY   Tecentriq with Tecentriq alone Furthermore  G100  which is developed on the GLAAS platform  is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study in patients with low grade follicular non Hodgkin lymphoma  NHL   The data from the phase I dose escalation monotherapy study presented at ASCO demonstrated 100  disease control rate  DCR   with over a third of patients achieving a partial response  PR  using WHO criteria  at least a 50  tumor reduction   with PRs at all three dose levels tested  50  of evaluable patients experienced shrinkage of untreated distal  abscopal  lesions in association with presence of T cell infiltrates Notably  Immune Design  completed patient enrolment in the phase II study comparing G100 and low dose radiation  XRT   versus G100 and XRT with the systemic administration of Merck   Co   Inc  s   NYSE MRK   anti PD 1 agent  Keytruda  The company intends to submit data from all 24 patients in the randomized phase II study comparing G100 and XRT versus G100 and XRT with pembrolizumab in Dec 2017  Furthermore  it also plans to submit follow up data from all patients treated with G100 monotherapy in the phase I dose escalation portion of this study 2017 OutlookImmune Design continues to anticipate cash to fund operations into the second half of 2018  Immune Design Corp  Price  Consensus and EPS Surprise    Zacks RankImmune Design currently holds a Zacks Rank  2  Buy   You can see  More Stock News  Tech Opportunity Worth  386 Billion in 2017 From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ,2017-08-02,Zacks Investment Research,https://www.investing.com/analysis/immune-design-imdz-posts-narrowerthanexpected-loss-in-q2-200205151,200205151
203750,425266,MRK,Aduro  ADRO  Q2 Loss Narrower Than Expected  Revenues Top,opinion,"Aduro BioTech  Inc    NASDAQ ADRO   reported second quarter 2017 loss of 27 cents per share  narrower than the Zacks Consensus Estimate of a loss of 36 cents  However  the company reported earnings of 3 cents per share a year ago 
Quarterly revenues plunged 84 9  year over year to  5 9 million  This top line deterioration was mainly due to the recognition of a milestone payment of  35 million in the second quarter of 2016  pursuant to an agreement with Novartis   NYSE NVS   for development of ADU S100 in combination with anti PD1 checkpoint inhibitor 
However  the decrease was partially offset by a recognition of  2 million milestone payment under collaboration with Merck   Co   NYSE MRK   with a view to investigate CRS 207 combined with Merck s anti PD 1 therapy  Keytruda  for treating gastric cancer  Revenues surpassed the Zacks Consensus Estimate of  4 million 
Aduro  shares have outperformed the industry so far this year  Shares of the company have rallied 10 5  while the  has registered an increase of 9 9  

Research and development expenses showed a substantial decline of 20 4  in the quarter to  21 4 million  mainly due to a decrease in expenses related to the manufacturing of GVAX pancreas and pancreatic cancer clinical study expense  incurred in the second quarter of 2016 
General and administrative expenses were  8 2 million  down 4 6  year over year due to lower consulting and professional fees 
Pipeline Update
Aduro has a broad pipeline of novel immunotherapies under development for treatment of a variety of cancers 
The most advanced programs from the LADD platform is a combination of CRS 207   Aduro s LADD  live  attenuated double deleted  based immunotherapy  GVAX Pancreas and Bristol Myers Squibb Company s   NYSE BMY   Opdivo  anti PD1 checkpoint inhibitor    that is currently under evaluation in the phase II STELLAR study on patients with metastatic pancreatic cancer 
Aduro has also completed enrollment in the initial cohort of the phase Ib study  evaluating the combination of CRS 207 and standard of care chemotherapy on patients with unresectable malignant pleural mesothelioma  In Jun 2017  Aduro Biotech announced initiation of a phase II study to evaluate a combination therapy of CRS 207 with Merck s Keytruda for treating patients previously nursed for malignant pleural mesothelioma  MPM  
During the same month  Aduro announced that the FDA has cleared the Investigational new drug application  IND  for ADU S100  MIW815   Combined with Novartis  investigational anti PD 1 checkpoint inhibitor PDR00  the candidate is developed for treating advanced metastatic solid tumors or lymphomas Aduro Biotech  Inc  Price  Consensus and EPS Surprise

   Zacks Rank
Aduro currently carries a Zacks Rank  3  Hold   You can see  
More Stock News  Tech Opportunity Worth  386 Billion in 2017                 
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/aduro-adro-q2-loss-narrower-than-expected-revenues-top-200205186,200205186
203756,425272,MRK,E Therapeutics   Strategic Review Complete  Focus On Deal Making  ,opinion,"New CEO Dr Ray Barlow  who joined E Therapeutics  LON ETXP  in April  has undertaken a business and strategic review  assisted by an independent industry wide expert panel 
The portfolio has been rationalised from six to two preclinical immuno oncology programmes  two programmes are available for out licensing  while data will be published on two others to showcase and validate the proprietary network pharmacology discovery platform  This will secure ETX  cash runway comfortably to the end of 2019  free capacity to add new programmes in H217 and enable further investment in the platform  The management team is now focused on external collaborations and partnerships to provide validation and generate revenue  ETX s attendance at industry conferences  including one in Boston this week  will help to raise its profile 

Expert panel confirms utility of ETX s approach
Dr Barlow s significant business development experience is driving the ongoing transformation at ETX  His  root and branch  review of the company included the views of an independent panel of industry experts with scientific commercial backgrounds at Astrazeneca  NYSE AZN   Pfizer  NYSE PFE   Merck  NYSE MRK   and biotechs  It confirmed the productivity of the network driven discovery  NDD  approach and its potential advantages in terms of time  nine months or less from concept to hits vs  24 months by standard methods   cost  and number quality of output molecules 
To read the entire report Please click on the pdf File Below ",2017-07-27,Edison,https://www.investing.com/analysis/e-therapeutics---strategic-review-complete:-focus-on-deal-making-200203840,200203840
203757,425273,MRK,Roche s  RHHBY  Sales Grow Y Y In 1H17 On New Drug Launches,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   reported sales of CHF26 3 billion in the first half of 2017  up 5  from the year ago period Core earnings came in at CHF8 23 per share  up 6  from the first half of 2016 Shares of Roche have performed better than the Zacks classified  in the year so far  In fact  the stock gained 10 8  over this time frame  compared with a gain of 9 9  for the industry The company reports results under two divisions  Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates Sales at the Pharmaceuticals division increased 5  driven by strong growth in Tecentriq  Ocrevus and Perjeta which was partially offset by lower sales of Tarceva  Tamiflu and Pegasys  Diagnostics division sales climbed 5  primarily on the back of strong immunodiagnostic business First Half in DetailHerceptin sales improved 3  due to increasing demand in the U S  and Brazil along with additional reimbursement approvals and broader use in China  Perjeta sales grew 17  following increased demand in the neoadjuvant and metastatic settings in Europe  the U S  and international markets   Sales of Kadcyla   9   were driven by increasing demand in the international markets Meanwhile  sales of Avastin were strong in the international region   11    especially China where sales grew due to broader market penetration in the lung and colorectal cancer setting   However  sales in the U S  dropped 3  due to the increased use of new immunotherapy agents in the lung cancer setting  Overall  sales declined 1  Sales of Rituxan MabThera   3   contributed to the top line growth in the oncology as well as in the immunology segments  Growth in Gazyva Gazyvaro   44   was witnessed in the U S  and Europe despite increasing competition in chronic lymphocytic leukemia Recently launched drugs  Tecentriq for bladder cancer and Alecensa for lung cancer are off for an encouraging start  Initial uptake in the U S  has been strong  Tecentriq  Ocrevus and Alecensa contributed CHF 0 5 billion of new sales  contributing to half of the division s growth Performance of the immunology franchise was driven by increased sales of Actemra RoActemra  13    and strong uptake of Esbriet  16   and Xolair  17    Increasing use of Actemra RoActemra as a single agent and in the subcutaneous formulation were the key growth drivers globally However  sales of Tarceva declined   17   due to growing use of other therapeutic options  Sales of Xeloda   1   continue to be hit by generic competition  Sales of Tamiflu also declined 12  Revenues at the Diagnostics division climbed 5  on the back of solid performance of the Centralised and Point of Care Solutions  8   unit  which was in turn  propelled by Immunodiagnostics  13    Tissue Diagnostics  13   and Molecular Diagnostics  1   also performed impressively  However  Diabetes Care sales declined 4  as sales continue to be impacted by challenging market conditions  particularly in North America 2017 Outlook RaisedRoche now expect sales to grow in mid single digits  prior guidance  low to mid single digits   The company expects core earnings to grow in tandem with sales  The company intends to further increase its dividend in 2017 in local currency Roche Holding AG Revenue  TTM 
    Pipeline ProgressRoche continues to expand cancer immunotherapy drug Tecentriq  bladder and lung cancer  s label  Tecentriq received accelerated approval from the FDA for the treatment of people with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy in Apr 2017  Lucentis was approved by the FDA for the monthly treatment of all forms of diabetic retinopathy  Actemra RoActemra subcutaneous injection was approved by the FDA for the treatment of giant cell arteritis in May 2017 The FDA further approved Rituxan Hycela  rituximab and hyaluronidase human  for subcutaneous injection  for the treatment of adults with specific forms of blood cancer  On the other hand  a new tablet formulation of Esbriet was approved by the European Commission for the treatment of mild to moderate idiopathic pulmonary fibrosis  IPF   The FDA has already approved the same in early 2017 Roche also presented positive results on emicizumab in patients suffering from haemophilia A from the phase III study  HAVEN  Meanwhile  studies showed that Roche s Ocrevus significantly reduced the risk of both relapsing and primary progressive multiple sclerosis  RMS and PPMS  patients requiring mobility aids versus comparators However  the phase III study  IMvigor211  which evaluated Tecentriq in patients with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with a platinum based chemotherapy  previously treated   did not meet its primary endpoint of overall survival compared to chemotherapy Our TakeRoche s results for the first half of 2017 were impressive with sales being boosted by new product launches Tecentriq and Ocrevus   Sales of Tecentriq were mainly driven by strong uptake in the U S  in metastatic bladder cancer and in metastatic non small cell lung cancer  NSCLC   The label expansion of the drug is expected to boost sales further  The successful launch of Ocrevus for the treatment of two forms of multiple sclerosis has also boosted the topline   Based on a strong performance in the first half  the company also raised its sales guidance However  sales of Avastin and Tarceva continue to decline  Generic competition for Xeloda also continues to hurt sales We note that competition from biosimilars loom large on Roche s key drugs like Herceptin  Avastin and Rituxan  The first biosimilars for MabThera are already in the market  The company expect biosimilars for Herceptin towards 2017 end early 2018  We note that Novartis AG   NYSE NVS   has already launched its bisomilar version of Rituxan  MabThera in Europe  Moreover  Roche is facing stiff competition from the likes of Merck   Co   Inc    NYSE MRK   Keytruda and Bristol Myers Squibb Company   NYSE BMY   Opdivo in the immuno oncology space 
Zacks Rank
Roche currently carries a Zacks Rank  3  Hold  
You can see   
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaries   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-27,Zacks Investment Research,https://www.investing.com/analysis/roche's-(rhhby)-sales-grow-y-y-in-1h17-on-new-drug-launches-200204274,200204274
203774,425290,MRK,Stalking The Institutional Trade Level,opinion,"In the trading business there is always something to find  discover and learn  Very often when traders struggle to find an investment they should just simply learn to read the charts 
At this time  I m watching the stock chart of Merck  NYSE MRK  very closely  This stock has been trading around the daily chart 200 day moving average  Should this stock fail to recapture the  64 50 level over the next week or so it will be signaling that another decline is near  Should MRK stock decline then the next major chart support level will be around the  60 90 area  This is where the stock broke out in January 2017  Traders should watch this level closely as it should be defended by the institutional money when it is retested 
It is important to note that Merck   Co  Inc  NYSE MRK  will report earnings on July 28  2017 before the opening bell ",2017-07-18,Nicholas Santiago,https://www.investing.com/analysis/stalking-the-institutional-trade-level-200201668,200201668
203775,425291,MRK,Transgene  Building A Strong Immunotherapy Portfolio ,opinion,"Combinations with immunotherapies are key to Transgene s  PA TRNG  strategy  The company is focused on combining its main assets  TG4010  cancer vaccine  and Pexa Vec  oncolytic virus   with immune checkpoint inhibitors  ICIs   ipilimumab  Yervoy  and nivolumab  Opdivo   ICIs as monotherapies have proven successful in patients  however  positive efficacy has been limited to certain cancers and long term responses remain difficult  Combinations with other immunotherapies may improve both addressable population and long term efficacy  To this end  Transgene is conducting Phase I and II trials in collaboration with academic institutions and pharmaceutical companies  The first read outs are expected later this year  Our updated valuation is  208m 

Combination trials underway and planned
Lead assets TG4010 and Pexa Vec are in two ongoing trials with nivolumab  second line non small cell lung cancer  NSCLC  in collaboration with Bristol Myers Squibb  BMS  and UC Davis  and ipilimumab  solid tumours  respectively  with both expected to read out by year end  A Phase II trial of TG4010  in combination with nivolumab and chemotherapy  in collaboration with BMS   in first line NSCLC patients with low or undetectable PD L1 levels is due to start by end 2017 and read out in 2018  Pexa Vec plus nivolumab will shortly start patient enrolment in a Phase II trial for patients with first line hepatocellular carcinoma  HCC   A Phase I II trial of TG4001 in combination with avelumab  PD L1 ICI  in HPV positive head and neck cancer  HNSCC  in collaboration with Merck  NYSE MRK  and Pfizer  NYSE PFE  will commence in H217 
To read the entire report Please click on the pdf File Below ",2017-07-18,Edison,https://www.investing.com/analysis/transgene---building-a-strong-immunotherapy-portfolio-200201724,200201724
203783,425299,MRK,NetScientific  PDS Collaborates With Merck ,opinion,"One of NetScientific s portfolio companies  PDS Biotechnology  17 4  stake  14 5  fully diluted   announced on 10 July 2017 that it has entered into a collaboration agreement with Merck  NYSE MRK  to investigate the combination of the cancer vaccine PDS0101 with the PD 1 inhibitor Keytruda  PDS will be initiating a Phase IIb clinical study of the combination for the treatment of human papilloma virus 16 mediated forms of recurrent and metastatic head and neck cancer 

A smart combo for next gen immunotherapy
The premise of PD 1 inhibition is that it enables the body to leverage a natural T cell mediated immune response against cancer cells  However  only 16  of patients with head and neck cancer respond to Keytruda  potentially because they lack natural targeting of T cells to their cancer  PDS0101 s ability to specifically sensitise T cells to cancer antigens without significant toxicity therefore has the potential to unlock significant synergies with PD 1 inhibitors  such as Keytruda 
To read the entire report please click on the pdf file below ",2017-07-13,Edison,https://www.investing.com/analysis/netscientific---pds-collaborates-with-merck-200200806,200200806
203790,425306,MRK,2 Companies Making Breakthroughs At The Cutting Edge Of Healthcare,opinion,"Modern medicine has brought with it a large number of breakthrough scientific developments over the past decade  each of which has changed the way individuals in a range of patient populations receive care  Many of these breakthroughs have translated to considerable upside revaluations for the companies spearheading them  With this in mind  here are two companies that are on the edge of breakthrough developments in biotechnology and healthcare space  each of which could be about to  or might already have  change the face of the sector 
The two companies in focus are VBI Vaccines Inc  NASDAQ VBIV  and Merck   Co   Inc   NYSE MRK  
VBI Vaccines  VBIV  is a US based biotechnology company with a pipeline that spans a host of different indications  ranging from infectious diseases to oncology  The company s lead asset is a hepatitis B vaccine called SciBVac  which is currently approved in 15 regions globally and about to embark on a multi region phase III study designed to underpin an approval in the US  Europe and Canada  This asset isn t what qualifies it for this list  however 
Instead  the novel mechanism of action that earns VBI top spot on this list forms the basis of a drug designed to treat a condition called glioblastoma multiforme  or GBM  which is the most common form of brain cancer and is incredibly difficult to treat 
The current standard of care  SOC  therapy in this indication is surgical resection initially  followed by a traditional combination of chemotherapy and radiation treatment  With brain cancer  however  and especially as relates to GBM  the cancerous cells develop into a sort of tentacle like formation that spreads deep into the brain  This makes surgical resection incredibly difficult and  in turn  limits the efficacy of the subsequent chemotherapy and radiation treatment 
So where does VBI come into the picture 
The company is developing a vaccine for a virus called cytomegalovirus  or CMV  The vaccine is a recombinant DNA type vaccine  built using VBI s proprietary envelope Virus Like Particle  or eVLP  platform  and employs a selection of antigens unique to the CMV virus to stimulate the production of CMV specific antibodies in the patient receiving the drug 
Concurrent to this program  the company is also adapting the CMV associated MOA to potentially target GBM based on a body of historical evidence that suggests a link between this form of brain cancer and the CMV viruses 
Specifically  evidence suggests that GBM cancer cells express an antigen that is also expressed by the CMV virus  Using this commonality  the company has created a vaccine that instructs the immune system to create antibodies specific to this expression  Once these antibodies are created  they circulate systemically looking for any cells that express an antigen normally associated with CMV  but also  in this instance associated with GBM  The circulating antibodies recognize the GBM cells as pathogenic   as if they were CM infected cells   and signals the rest of the immune system   T cells  macrophages  etc    to attack and clean up 
What s interesting about this one  then  is that VBI is using the traditional approach to prophylaxis vaccination and adapting it to form the basis of a cancer therapy  If the company can get this asset through the clinical development pathway and successfully past the FDA in the US  it will be the first time a company has used a crossover approach like this to underpin the MOA of a commercialized asset 
This is an early stage program right now  with the company focused primarily on advancing its registration trial for the above noted hepatitis B asset from a resource allocation perspective  With that noted  a phase I study in this indication is underway and we should see some indication of progress   and potential clinical benefit   during 2018 
Next up is Merck  MRK  
Many reading will likely already be familiar with Merck s blockbuster oncology asset  Keytruda  The drug  which first picked up approval in the US at the turn of the decade  has quickly expanded by way of various supplemental New Drug Applications  sNDAs  into a well established SOC in no small cell lung cancer  breast cancer  melanoma and more 
In terms of its impact on the oncology space  it s proven a breakthrough therapy  During June  however  the FDA made a landmark decision that earns the drug not just the title of breakthrough  but potentially revolutionary in the cancer space  and by proxy  earns Merck and Keytruda a spot on this list 
Those familiar with the mechanics of oncology will likely already be familiar with the concept of tumour specific genetic mutations  For those not yet familiar with this concept  the idea is that all cancers  whatever the type  are rooted in a specific genetic mutation  The genetic mutation results in a damaged DNA sequence that  in turn  results in faulty cell production  The production of damaged cells from faulty DNA  as caused by a genetic mutation at mRNA stage  translates to the unchecked proliferation we commonly associate with cancer  and which forms the basis of tumor growth in tissue 
Putting that concept aside for a moment  current SOC treatment in oncology is tissue specific  That is  a physician determines the best course of treatment for a patient based on the tissue in which the cancer resides   breast  pancreas  brain  bone etc  This is somewhat effective  but scientists have long theorized that a more accurate method of treatment allocation might be rooted in the specific genetic mutation that caused the cancer  as opposed to the tissue in which the cancer resides 
Breast cancer can be rooted in the same genetic mutation as lung cancer  for example  but as things stand  a physician will generally prescribe a different course of treatment for each  This is because  up until recently  no company has been able to come up with a drug that has demonstrated efficacy in patients with the same mutation derived cancer  regardless of tissue type  With Keytruda  Merck has done just that 
Well  it s technically not Merck that has proved the concept  The company supplied a consortium of research entities  primarily consisting of Universities in the US  with Keytruda for the latter to conduct a study  and the NIH funded the investigation  The goal was to prove the above hypothesis  The trial investigated the efficacy of Keytruda as administered across a spate of different solid tumor cancers in   importantly   late stage patients  That is patients that have already undergone the SOC combination of chemotherapy and radio action as well as  in many cases  various courses of immunotherapy  In other words  these are patients that have no options available to them outside of a palliative care environment and   in many cases   have weeks or months at the outside to live 
The study enrolled a little over 80 patients based on a specific combination of mutations and gave them all a course of Keytruda  It didn t matter sort of cancer these patients had  so long as it is a solid tumor cancer   only that the cancer was rooted in one of the two specific mutations in question 
In June  the research consortium published the results in the online Journal of Oncology and the results were incredible 
Of the 86 patients enrolled in the study  77  demonstrated stable disease  defined as tumor regression or tumor stability  i e  The tumor got smaller or didn t grow any bigger   In 17  of the patients  the tumor disappeared altogether 
It s difficult to get across how important these results are  Patients with this sort of advanced solid tumor cancer generally see stable disease rates in the single digit percentage bracket  One in ten lives more than five years  In the study outlined above  more than three out of every four patients saw their cancer stop advancing or recede  Just say of one in five were essentially cured   defined as cancer free at follow up  Of course  cancer can return  but this far from negates the importance of this outcome 
In short  this study has shown that mutation specific cancer treatment can stop cancer to a degree that no other type of therapy has been able to before  and can do so in very late stage patients across a spectrum of tissue type cancers 
This is a huge step forward in the oncology landscape  and the FDA agrees  In an unprecedented move  the agency in the US looked at the published data  remember  this data wasn t published by a company and the trial wasn t investigator sponsored  and immediately approved Keytruda as a spectrum wide cancer therapy for patients with the two specific mutations in question 
Expect this approval to bring with it a wave of development stage programs designed to build on the success of Keytruda and bring more mutation specific oncology therapies to market over the next decade ",2017-07-03,Samuel Rae,https://www.investing.com/analysis/two-companies-making-breakthroughs-at-the-cutting-edge-of-healthcare-200198919,200198919
203791,425307,MRK, DAX To Slump On Jobs Data,opinion,"The German index  DAX  is looking to dwindle down on unchanged Eurozone unemployment rate  the blue chip stock has seen marginal movement yesterday on tremendous performance from the Construction  Basic Resources  and Insurance sectors  This is a bit of a refresher as tech stocks continue to take the back foot 
The recent data from the Eurozone unemployment rate were at 9 3   unchanged and it matches the forecasts but analysts are speculating that the DAX will soon sink if the unemployment rate continues to be stagnant and unchanged 
DAX Up by 1 22 
The German index was clearing out this week s way as it manages to climb by 0 55  on Monday  the MDAX was also surging yesterday as it trails behind s DAX s increase at 1 02   and finally  TecDAX was also surfing the waves as it caught 0 87  increase yesterday 
Among the companies under the DAX  this bunch showed resilient on pushing the index on better figures yesterday  Thyssenkrupp AG O N   DE TKAG   was one of the top performers with a whopping 4 92  increase on that session or 1 225 points to 26 100 trading  On the other hand  Commerzbank AG  DE CBKG  O N  also manages to outperform on the recent market  the financial institution manages to tally an increase of 4 27  or 0 445 points at 10 875 
Another financial institution was up yesterday  the Deutsche Bank  DE DBKGn  was also scurrying behind the back of ThyssenKrupp and Commerzbank  it ended yesterday s trading session with a massive 3 67  increase at 0 570 points to 16 095 
DAX Worst Performers
Even with the peak performances from the companies  some fluctuated on the bearish zone  Merck  NYSE MRK  KGaA was one of the worst performers with a decrease of 0 71  or 0 75 points at 105 00  and Jenoptik AG  DE JENG  was also amongst the worst performers with a decrease of 2 46  to 22 400  Lastly  Software AG O N   DE SOWG  joins the two with a slump of 0 78  to 38 050 
MDAX Top Performers
Among the MDAX companies  K S AG NA O N   DE SDFGn   was the top performer amongst others  with a 3 57  increase on the latter trading to 23 220  Leoni AG  DE LEOGn  was also trading a little bit higher at 3 48  at 46 645  and lastly  Bilfinger SE O N   DE GBFG   was trailing behind with 3 016  at 35 350  The worst performer was LEG Immobilien AG  DE LEGn  with a staggering 1 47  dip to 81 100 on the later trade 
TecDAX Top Performers
Nordex SE O N   DE NDXG   was the best company on TecDAX  it manages to increase by a sizable amount of 5 53  to 11 350  Wirecard AG  DE WDIG  was trailing right behind with a 3 02  increase at 57 400  and CompuGroup Medical AG O N   DE COPMa  was also amongst the top performer with gains recorded at 2 32  at 50 270  The worst performer was Sim Solution  its loss as much as 2 78  to 37 43 ",2017-07-05,Trade12,https://www.investing.com/analysis/dax-to-slump-on-jobs-data-200199107,200199107
203792,425308,MRK,ProQR s Usher Syndrome Candidate Gets Orphan Drug Status,opinion,ProQR Therapeutics N V    NASDAQ PRQR   announced that its key pipeline candidate  QRX 411  has been granted orphan drug designation by the FDA and European Medicines Agency  EMA  for the treatment of retinitis pigmentosa  The candidate also targets Usher syndrome  which causes deafness and blindness due to genetic defects in the Usher gene ProQR Therapeutics  share price has been flat in the last six months  underperforming the Zacks classified  industry s increase of 2 7  in the same time frame We note that orphan drug designation is granted to drugs capable of treating diseases that affect less than 200 000 people in the U S  The status makes QRX 411 eligible for seven years and 10 years of marketing exclusivity in the U S  and the EU  respectively  following an approval for Usher syndrome  The designation also makes the company eligible for certain other benefits  including tax credits related to clinical trial expenses  exemption from the FDA user fee and assistance from the FDA in clinical trial design QRX 411 targets severe genetic retinal diseases for which there are no treatments available to restore vision or impede progression of the disease  QRX 411 targets the mutations in the USH2A gene  specifically the pseudo exon 40 mutation  The candidate has shown positive pre clinical data in patients with fibroblasts and the optic cup model for mRNA restoration However  QRX 411 is not the only drug that ProQR is developing  The company is targeting various genetic retinal conditions for which no therapies are currently available  The company is developing therapies for all of the ophthalmology indications using its novel RNA oligonucleotide drug discovery platform The company is currently investigating QR 110 in a Phase 1 2 clinical study in Leber s congenital amaurosis Type 10  The product has already received orphan drug designation in both the US and Europe  and has also been granted Fast Track status by the FDA  ProQR Therapeutics is also developing QRX 1011 for Stargardt s disease and QRX 504 for Fuchs endothelial corneal dystrophy Moreover  ProQR Therapeutics is developing QRX 421 for Usher syndrome Type II  targeting Exon 13 mutations in the USH2A gene ProQR Therapeutics N V  Price and Consensus   Zacks Rank   Stocks to ConsiderProQR Therapeutics currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the healthcare sector include Enzo Biochem  Inc    NYSE ENZ    Sanofi   NYSE SNY   and Merck   Company  Inc    NYSE MRK    Enzo Biochem sports a Zacks Rank  1  Strong Buy  while Sanofi and Merck carry a Zacks Rank  2  Buy   You can see  Enzo Biochem s loss estimates have narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days  The company came up with positive earnings surprise in the last four quarters  with an average beat of 55 83   The share price of the company is up 61 9  so far this year Merck s earnings estimates have remained unchanged for 2017 and moved up from  4 16 to  4 18 for 2018 over the last 30 days  The company came up with positive earnings surprise in the last four quarters  with an average beat of 4 36   The share price of the company is up 9  so far this year Sanofi s earnings estimates have moved up from  3 08 to  3 18 for 2017 and from  3 26 to  3 30 for 2018 over the last 60 days  The company came up with positive earnings surprise in two of the last four quarters  with an average beat of 5 10   The share price of the company is up 18 3  so far this year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-07-05,Zacks Investment Research,https://www.investing.com/analysis/proqr's-usher-syndrome-candidate-gets-orphan-drug-status-200199537,200199537
203793,425309,MRK,Bristol Myers Gets FDA Nod For Orencia s Label Expansion ,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis  PsA  The approval was based on results from two randomized  double blind  placebo controlled trials  Per the data from the trials  Orencia improved  or reduced  disease activity in both TNF naive and exposed patients suffering from increased disease activity  high tender and swollen jointsfor more than seven years Orencia is already indicated for adult patients with moderate to severe active rheumatoid arthritis  RA as well as for reducing signs and symptoms in pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis Sales of Orencia came in at  535 million in the first quarter of 2017  up from  475 million in the year ago quarter  U S  sales in the quarter were up 13  despite unfavorable inventory movement  However  demand was softer in the subcutaneous market in the beginning of the year due to early coverage resets A label expansion of the drug will further boost sales We note that in Sep 2016  Orencia became the first biologic therapy to gain EU approval specifically for the treatment of methotrexate  MTX  na ve RA patients with highly active and progressive disease Competition is stiff in the psoriatic arthritis with the presence of drugs like AbbVie s   NYSE ABBV   Humira and Novartis    NYSE NVS   Cosentyx While Bristol Myers  share price has declined 5 4  year to date  the Zacks classified  industry has gained 10 7  Bristol Myers  key products   Opdivo  Orencia  Eliquis and Sprycel   should continue to fuel the company s top line  Meanwhile  Bristol Myers is working on expanding the label of Opdivo which should boost performance further  The EC recently approved Opdivo as a monotherapy for the treatment of SCCHN in adults  However  Opdivo is facing competitive challenges in the U S  With the FDA approving Merck s   NYSE MRK   Keytruda  for the first line treatment of metastatic nonsquamous NSCLC  the company is expected to see further loss of market share 
Zacks Rank
Bristol Myers currently carries a Zacks Rank  3  Hold   You can see  
Will You Make a Fortune on the Shift to Electric Cars    
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-07-06,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-gets-fda-nod-for-orencia's-label-expansion-200199725,200199725
203794,425310,MRK,Endo  ENDP  To Remove Opioid Pain Drug Opana ER From Market ,opinion,"Endo International plc   NASDAQ ENDP   recently announced that it will withdraw opioid pain medication Opana ER  oxymorphone hydrochloride extended release  from the market following FDA s request in June 
In Mar 2017  the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted in the ratio of 18 to 8 and consented that reformulated Opana ER did not outweigh public health risks 
The FDA asked the Advisory Committees to discuss the pre  and post marketing data about the abuse of Opana ER as well as the product s overall risk benefit profile  The abuse of generic oxymorphone ER and oxymorphone immediate release  IR  products were to be evaluated as well  Few members stated that the benefits are now overshadowed by the continuing public health concerns around the product s misuse  abuse and diversion 
Thereafter  the FDA directed the company to remove the drug from the market in Jun 2017  The move comes in wake of the widespread opioid abuse epidemic 
Opana ER is an opioid agonist indicated for the management of pain severe enough to require daily  around the clock  long term treatment and for which alternative treatment options are inadequate 
In Dec 2011  the FDA approved a new formulation which had the same dosage strengths  color and packaging  Also  the tablet s size remains the same as the original 
Consequently  the company expects to incur a pre tax impairment charge of approximately  20 million in the second quarter of 2017 to write off the remaining net book value of its drug  Sales of the drug were  158 9 million for 2016 and  35 7 million for the first quarter 2017 
Hence  withdrawing the drug from the market will advserly impact the topline  Nevertheless  Endo continues to believe in safety  efficacy and favorable benefit risk profile of OpanaER 

Following the news  the company s shares declined 1 9   Shares of Endo have underperformed the Zacks classified  industry year to date  The stock was down 32 6  compared with the industry s gain of 5 9  
Zacks Rank and Stocks to Consider
Endo currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the healthcare sector include Enzo Biochem  Inc    NYSE ENZ    Sanofi   NYSE SNY   and Merck   Company  Inc    NYSE MRK    While Enzo Biochem sports a Zacks Rank  1  Strong Buy   Sanofi and Merck carry a Zacks Rank  2  Buy   You can see  
Enzo Biochem s loss estimates have narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days  The company delivered positive earnings surprise in the last four quarters  with an average beat of 55 83   The company s shares have moved up 62 1  so far this year 
Merck s earnings estimates have remained unchanged for 2017 and moved up from  4 16 to  4 18 for 2018 over the last 30 days  The company delivered positive earnings surprise in the last four quarters  with an average beat of 4 36  
Sanofi s earnings estimates have moved up from  3 08 to  3 18 for 2017 and from  3 26 to  3 30 for 2018 over the last 60 days  The company posted positive earnings surprise in two of the last four quarters  with an average beat of 5 10   The company s shares have gained 16 7  so far this year 
Will You Make a Fortune on the Shift to Electric Cars    
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-07-07,Zacks Investment Research,https://www.investing.com/analysis/endo-(endp)-to-remove-opioid-pain-drug-opana-er-from-market-200199789,200199789
203795,425311,MRK,Prima Biomed s Intra Tumor Study On Lead Candidate Approved,opinion,Prima Biomed Ltd    NASDAQ PBMD   announced that a new clinical study  INSIGHT  on its lead candidate IMP321 has received regulatory approval for initiation The approval was granted to its German partner  the Institute of Clinical Cancer Research by Paul Ehrlich Institut  PEI   the Federal Institute for Vaccines and Biomedicines for the German Federal Ministry of Health  Moreover  the ethics committee of the company s partner has also approved the study Prima s share price movement so far this year shows that the company has underperformed the Zacks classified  industry  Specifically  the stock declined 17 9  during this period  while the industry gained of 7  Coming back to the latest news  INSIGHT is an open label phase I study evaluating the feasibility and safety of three different administrations of IMP321  viz  intra tumoral  intra peritoneal  and subcutaneous injections in advanced stage solid tumor entities  The study will enroll up to 40 patients in this study group The study is the first of its kind and will investigate whether IMP321  a LAG 3Ig fusion protein  can activate the antigen presenting cells located inside the tumor to boost the body s immune response on directly injecting into a solid tumor site We remind investors that in Jan 2017  the company started dosing patients in a phase IIb AIPAC study evaluating IMP321 in combination with Celgene Corporation s   NASDAQ CELG   Abraxane  paclitaxel   or Abraxane plus placebo in patients with metastatic breast cancer  Moreover  IMP321 is also being evaluated  in combination with Merck   Co   Inc  s   NYSE MRK   PD 1 checkpoint inhibitor Keytruda  in a phase I study  TACTI mel  for the treatment of unresectable or metastatic melanoma In Dec 2016  the company reported positive interim data from the AIPAC  phase II  and TACTI mel studies demonstrating potential of IMP321 in treating multiple types of cancer Going forward  we expect investor focus to remain on further updates by the company on its lead candidate  IMP321 Prima BioMed Ltd Price and Consensus   Zacks Rank   Stock to ConsiderCurrently  Prima carries a Zacks Rank  3  Hold  A better ranked stock in the health care sector is Enzo Biochem  Inc    NYSE ENZ   with a Zacks Rank  1  Strong Buy   You can see  Enzo Biochem s loss estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days  The company posted a positive earnings surprise in each of the four trailing quarters with an average beat of 55 83   Its share price has risen 62 4  so far this year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-09,Zacks Investment Research,https://www.investing.com/analysis/prima-biomed's-intra-tumor-study-on-lead-candidate-approved-200200025,200200025
203806,425322,MRK,Esperion s Combo Cholesterol Candidate Enters Phase III,opinion,Esperion Therapeutics  Inc    NASDAQ ESPR   received positive feedback from the FDA for initiation of a phase III bridging study  evaluating the combination of bempedoic acid  180 mg  and Merck   Co   Inc  s   NYSE MRK   Zetia  ezetimibe   10 mg  for an LDL C or  bad cholesterol  lowering indication Esperion is evaluating bempedoic acid as monotherapy in an ongoing phase III study for an LDL C lowering indication  The bridging study  on initiation  will be conducted alongside the ongoing study and will support approval of once daily  oral combination pill Esperion s year to date share price movement shows that the company has significantly outperformed the Zacks classified  industry  Specifically  the stock surged 249 3  during this period  while the industry increased 10 1  The bridging study will evaluate the combination pill in patients with hypercholesterolemia and with atherosclerotic cardiovascular disease  ASCVD  and or heterozygous familial hypercholesterolemia  HeFH   including high cardiovascular risk primary prevention patients  The primary endpoint of the study was to evaluate the efficacy and safety of the oral administration of the combination therapy in adequately controlling the LDL C Esperion expects to finalize the phase III protocol and initiate the study in the fourth quarter of 2017 with top line data anticipated by the end of 2018  A previously completed phase II study evaluating the combination therapy demonstrated a 48  reduction of LDL C The company also plans to file for regulatory approvals in the U S  and EU for both the monotherapy and combination pill by the first half of 2019 The two therapies strengthen Esperion s portfolio with two separate  convenient and cost effective non statin therapies  which can be administered orally for controlling LDL C  Moreover  the combination pill has potential to address far more patients than bempedoic acid alone Per the press release  approximately 150 million people have elevated LDL C in the U S  and Europe  Of these  an estimated 40 million patients in the U S  are using statins  which is intolerable in 5  to 20  of this population  The successful completion of the studies will be a positive for the company as it will bring the therapies closer to approval Esperion Therapeutics  Inc  Price and Consensus   Zacks Rank   Stocks to ConsiderEsperion currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the healthcare sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Enzo Biochem  Inc    NYSE ENZ    Regeneron sports a Zacks Rank  1  Strong Buy  while Enzo Biochem carries a Zacks Rank  2  Buy   You can see  Regeneron s earnings estimates moved up from  10 17 to  10 52 for 2017 and from  10 90 to  12 10 for 2018  over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters  with an average beat of 0 45   Its share price is up 36 8  so far this year Enzo Biochem s loss estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 30 days  The company came up with positive earnings surprises each of the last four quarters  with an average beat of 55 83   Its shares are up 61 4  so far this year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-06-27,Zacks Investment Research,https://www.investing.com/analysis/esperion's-combo-cholesterol-candidate-enters-phase-iii-200198101,200198101
203807,425323,MRK,Nanoco Group  First Commercial Orders ,opinion,"Nanoco Group  LON NANON  has received its first commercial order for CFQD resin from the company s film partner  Wah Hong  Just as importantly  the CFQD product is now being evaluated by 13 major OEMs for 16 programmes  This gives confidence that revenues are now set to ramp up  as more programs progress through the pipeline and shipment volumes increase  We leave our estimates unchanged and highlight that  while it is still early stages  it does not take aggressive assumptions for earnings to scale and the rating to look very inexpensive  We believe a substantial re rating upwards would be justified as support for our estimates further solidifies 

Seminal moment   pipeline suggests more to come
This is a seminal  and long awaited moment in Nanoco s evolution  The commercialisation process has been protracted  involving a number of steps from initial NDA sales approval  technical specification  technical approval  with a number of iterations  and then commercial negotiations  The good news is that the company is progressing 16 programmes through this commercialisation funnel with 13 OEMs up from 14 and nine respectively in April  Of these we understand that at least four programmes  each of which can supply into multiple models  have progressed to the technical approval stage  Consequently  we should see more programmes progress to commercial orders over the course of this calendar year  Notably  these figures exclude developments with Dow   which according to press reports is now working with two film manufacturers   Kolon  KDX and Merck  NYSE MRK   which is aiming to have its plant operational by the end of 2018 
To read the entire report Please click on the pdf File Below ",2017-06-30,Edison,https://www.investing.com/analysis/nanoco-group---first-commercial-orders-200198455,200198455
203808,425324,MRK,The Zacks Analyst Blog Highlights  Merck  Sanofi  Roche  Esperion And Teva,opinion,"For Immediate Release

	Chicago  IL   July 03  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Merck  NYSE           Sanofi  PA SASY   NYSE           Roche  OTCMKTS           Esperion  NASDAQ          and Teva  NYSE          

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Friday s Analyst Blog  

Pharma Stock Roundup  Sanofi RA Drug Gets EU Nod  Merck CETP Inhibitor Surprises 

	This week s highlights include positive data on Merck s  NYSE         CETP inhibitor while Sanofi  NYSE          gained EU approval for its rheumatoid arthritis  RA  drug which has blockbuster potential 

Recap of the Week s Most Important Stories

Merck s CETP Inhibitor Meets Endpoint in REVEAL Study    Merck provided an update on its CETP inhibitor  anacetrapib  The company said that anacetrapib met the primary endpoint in the REVEAL  Randomized EValuation of the Effects of Anacetrapib through Lipid modification  outcomes study and showed a significant reduction in major coronary events compared to placebo in patients at risk for cardiac events who are already receiving an effective LDL C lowering regimen  Read more     

	The news comes as a bit of a surprise considering other companies like Lilly  Roche and Pfizer  NYSE PFE  have had some high profile setbacks with their CETP inhibitors and the class was more or less written off  Merck itself seems to be adopting a cautious attitude as it intends to discuss the results with external experts to see whether it should seek regulatory approval  The safety profile was found to be consistent with that seen in earlier studies 

	So far in 2017  Merck has lagged the Zacks categorized  industry with shares gaining 9 3  while the industry is up 13 5  

Sanofi Regeneron RA Drug Gets EU Approval   Sanofi and partner Regeneron gained EU approval for their RA drug Kevzara  Kevzara is approved for use in combination with methotrexate  MTX  for the treatment of moderately to severely active RA in adult patients who have responded inadequately to  or who are intolerant to one or more disease modifying anti rheumatic drugs  DMARDs   such as MTX 

	Kevzara  an IL 6R antibody  was approved in the U S  in May this year  While Kevzara has blockbuster potential  the RA market is highly crowded given the presence of treatments like Humira and Xeljanz among others  However  the patient population is huge with many patients spending years on different treatments without achieving their treatment goals  With RA affecting about 1 3 million Americans and 2 9 million people in Europe  Kevzara represents a new treatment option for patients  Read more     

	Sanofi is a Zacks Rank  2  Buy  stock  The company has outperformed the Zacks categorized Large Cap Pharmaceuticals industry year to date with the company gaining 19 1   You can see   

Roche s Data on Hemophilia Drug   Roche s  OTCMKTS          experimental hemophilia treatment  emicizumab  delivered positive results in a couple of late stage pivotal studies  A substantial and clinically meaningful reduction in bleeds was observed in the studies  The once weekly subcutaneous treatment was evaluated for hemophilia A with inhibitors to factor VIII  However  side effects remain a concern especially given the death of a patient that was reported earlier this year in February 

Esperion Up on Regulatory Update   Lipid management company  Esperion  NASDAQ           saw its shares rising on news that the FDA has confirmed the regulatory pathway for the company s once daily  oral combination pill of bempedoic acid 180 mg and ezetimibe 10 mg  Esperion intends to commence a single pivotal bridging study by year end based on feedback from the agency  Top line results from this study are expected the end of next year  Regulatory filings for bempedoic acid as well as the combination are expected in the first half of 2019 

	With this development  Esperion now has two convenient  cost effective  complementary  non statin  once daily  oral LDL C lowering therapies in late stage development with confirmed regulatory pathways  Read more     

Priority Review for J J Xarelto Label Expansion    J J got priority review for its efforts to expand Xarelto s label to include a 10 mg once daily dose for reducing the risk of VTE after at least six months of standard anticoagulant therapy  With the FDA granting priority review  a response should be out by Oct 28  2017  Approval of the 10 mg dose will provide physicians with an additional dosing option apart from the currently approved 20 mg 

Teva Xenon Drug Fails in Mid Stage Study   Teva  NYSE         and partner Xenon suffered a pipeline setback with their experimental post herpetic neuralgia  PHN  treatment  topical TV 45070  failing in a mid stage proof of concept study  The study failed to meet the primary as well as secondary endpoints  The data will be analyzed further to determine the path forward  We note that TV 45070 had previously failed in a mid stage study in pain due to osteoarthritis of the knee  Read more     

EU Approvals for Novartis   The European Commission  EC  expanded the use of Novartis  Zykadia  ceritinib  to include the first line treatment of patients with advanced non small cell lung cancer  NSCLC  whose tumors are ALK positive  Approval was expected considering a positive opinion was received from the Committee for Medicinal Products for Human Use  CHMP  in May  FDA approval for the first line indication was granted in May  Read more     

	The EC also gave its nod to the company s biosimilar version of Enbrel  Sandoz  a Novartis division  got approval for the use of Erelzi for all indications of the reference medicine  Enbrel  including rheumatoid arthritis  psoriasis  and psoriatic arthritis  Read more     

	The NYSE ARCA Pharmaceutical Index declined 2  over the last five trading sessions  Among major stocks  AstraZeneca was down 3 5   Over the last six months  AstraZeneca was up 28 9  while Bristol Myers was down 3 9   See the last pharma stock roundup here     

5 Trades Could Profit  Big League  from Trump Policies

	If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 

	Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-07-02,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-merck,-sanofi,-roche,-esperion-and-teva-200198820",200198820
203820,425336,MRK,Glaxo s  GSK  Shingles Candidate Phase III Data Positive,opinion,GlaxoSmithKline plc   NYSE GSK   announced positive top line results from a phase III revaccination study on its shingles vaccine candidate  Shingrix  in older patients The Zoster 048 study administered Shingrix in patients aged 50 years or older who have been vaccinated against shingles with the currently available live attenuated vaccine  Merck   Co   Inc  s   NYSE MRK   Zostavax at least five years prior to being vaccinated with Shingrixas well as in previously unvaccinated patients The performance of the company s shares has been on par with the Zacks classified  industry so far this year  The stock and the industry  both has rallied 13 2  in that period The data demonstrated non inferiority of Shingrix to Zostavax  thereby meeting the primary objective of the study  Shingrix achieved a similar immune response in both Zostavax vaccinated and unvaccinated patient cohorts  The vaccine was administered intramuscularly two months apart in older adults  The data also showed that Shingrix was well tolerated in both patient cohorts when assessed up to a month after its second dose The data from the Zoster 048 study were presented to the US Centers for Disease Control and Prevention s Advisory Committee on Immunization Practices Shingrix is under review in the U S   EU and Canada last year  The regulatory submission was based on data from a clinical trial program comprising two phase III studies   ZOE 50 and ZOE 70   that evaluated the safety  efficacy and immunogenicity of the candidate in more than 37 000 individuals  Results showed that in addition to reducing the incidence of shingles  the candidate was able to reduce the overall incidence of postherpetic neuralgia Glaxo will submit this data that highlights the benefits of revaccination with Shingrix for protection against shingles to the FDA  Shire believes that Zostavax provides protection against shingles but that eventually wanes over time Shingrix is also being evaluated in immuno compromised patient populations  including solid and hematological cancer patients  hematopoietic stem cell and renal transplant recipients and HIV infected people In a separate press release  Glaxo announced that a U S  jury has ruled in its favor in a patent infringement lawsuit covering its blood pressure drug Coreg against Teva Pharmaceutical Industries Limited   NYSE TEVA   The court has ordered Teva to pay Glaxo more than  235 million for deliberately infringing the patent by selling a generic version of Coreg with a label indicating it could be used for treating chronic heart failure  The payment includes  234 1 million in lost profits and an additional  1 4 million in royalties Teva is unhappy with the court s decision and is considering appealing against it GlaxoSmithKline PLC Price   Zacks Rank and Stock to ConsiderGlaxoSmithKline currently carries a Zacks Rank  3  Hold  A better ranked stock in the healthcare sector is VIVUS  Inc    NASDAQ VVUS   sporting a Zacks Rank  1  Strong Buy   You can see  VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233 69  Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/glaxo's-(gsk)-shingles-candidate-phase-iii-data-positive-200196954,200196954
203821,425337,MRK,Stocks To Fight Cancer  Why Immunotherapy Is A Gamechanger,opinion," 1     What Is the ASCO Conference And Why Is It Important  5     What Has Changed In The World Of Oncology Over The Years  9     What Cancers Is Immunotherapy Focused On Now  10     Incyte  INCY   Combination Trials 13     Are Both Large And Small Companies Working Together or Seperate  15     bluebird bio  BLUE   Leukemia Lymphoma research 19     What To Watch For In the Future of Oncology 21     Episode Roundup   make sure to check back for part IIThe world of health care is changing fast  and nowhere is that more the case than in the world of cancer research  This space is seeing huge developments  and companies are making great strides in treating a variety of cancers 
This is definitely an exciting area  and one that investors will want to watch in the months and years ahead too  But in an industry like this which is dominated by dense medical jargon how do find out what the real trends are and which companies you really need to keep an eye on these days 
In order to discuss this topic in more detail  we were lucky enough to have   the CEO of Loncar Investments which is the index provider for the Immunotherapy ETF  CNCR   in studio for this edition of to tell us more about this corner of the biotech market  Brad was in Chicago for the ASCO Conference  which is basically the most important cancer research event of the year 
In this podcast  Brad clues me in on why this conference is so important to not just the health care community at large  but something that investors need to pay attention to as well  We also discuss some of the big trends in the world of cancer research as of late  and what is on the horizon for this quickly changing space 
Companies to Watch
Brad also discusses a few companies that he has his eye on in the immunotherapy world right now  One that he discussed was Incyte  INCY   a firm that is working in conjunction with Merck  MRK  on lung cancer treatment  while we also talk about how other big names in the health care world such as Pfizer  NYSE PFE  are looking at similar partnerships with smaller biotech players too 
We also talk about bluebird bio  BLUE   a company that is doing research on the worlds of leukemia and lymphoma  Brad explains to us what is so unique about their approach  but listen to the podcast for more on why he is watching this company these days 
Looking Ahead
I also talk to Brad about what looks to be ahead for the immunotherapy space in the rest of 2017  and what he is focused on for cancer research to close out the year  We also discuss what has changed since  and other health care developments as of late too 
Make sure to check out the podcast for Brad s thoughts  and come back again next time for my chat with the Chief Medical Officer of Kite Pharma  KITE  for an in depth look at how some companies are revolutionizing the world of cancer research 
Bottom Line
But what do you think about the world of immunotherapy  Is this area something you ve considered for your portfolio  Make sure to write us in at podcast   zacks com or find me on Twitter  to give us your thoughts on this  or anything else in the fund market 
But for more news and discussion regarding the world of investing  make sure to be on the lookout for   each and every Thursday   and check out the 
And definitely make sure to check back for part two of this special on immunotherapy  as I will be interviewing an executive at Kite Pharma  KITE  next time 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-06-22,Zacks Investment Research,https://www.investing.com/analysis/stocks-to-fight-cancer:-why-immunotherapy-is-a-gamechanger-200196994,200196994
203822,425338,MRK,The Zacks Analyst Blog Highlights  Novartis  Roche  Shire  Neos And Novo Nordisk,opinion,"For Immediate Release

	Chicago  IL   June 26  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Novartis  NYSE           Roche  OTCMKTS           Shire  NASDAQ           Neos  NASDAQ          and Novo Nordisk  CO NOVOb   NYSE          

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Monday s Analyst Blog  

Pharma Stock Roundup  NVS Scores with Positive Data  Shire ADHD Drug Gets FDA Nod 

	This week s highlights include positive data from Novartis  NYSE         while the FDA approved a couple of attention deficit hyperactive disorder  ADHD  drugs 

Recap of the Week s Most Important StoriesNovartis Eye Drug Hits Endpoints  CANTOS Data Impresses    Novartis  experimental eye drug  RTH528  was found to be non inferior to Regeneron s blockbuster drug Eylea  aflibercept  in a couple of late stage studies  Adverse event rates were also comparable  The studies were conducted in patients with neovascular age related macular degeneration  nAMD   Novartis expects to file for approval next year  If approved  RTH528 could have a competitive edge due to a less frequent dosing regimen 
	Novartis also impressed with data from a late stage study  CANTOS  on ACZ885  canakinumab   Top line data showed that ACZ885 plus standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis  Novartis intends to start discussions with regulatory authorities 
	So far in 2017  Novartis has outperformed the Zacks categorized  industry with shares gaining 18 5  while the industry is up 13 2  Subcutaneous Rituxan Formulation Approved  A subcutaneous formulation of Roche s  OTCMKTS          multi billion dollar drug  Rituxan  gained FDA approval this week  Approval was largely expected considering an FDA advisory panel had voted unanimously in favor of approving the formulation for certain types of blood cancer  Formulated using rHuPH20  a technology licensed from Halozyme  Rituxan Hycela can be administered in five to seven minutes compared to an hour and a half or more for the intravenous formulation FDA Green Light for Shire ADHD Drug  Shire  s  NASDAQ         ADHD drug  Mydayis  has finally gained FDA approval  Mydayis or SHP465  as it was previously referred to  has had a long journey with the FDA initially giving an approvable letter way back in May 2007  At that time  the agency had asked for additional studies  Shire  a key player in the ADHD market  expects to launch the long lasting once daily treatment in the third quarter of 2017  The ADHD market is huge though highly genericized  About 10 5 million adults in the U S  are estimated to have ADHD  Read more     Neos ADHD Drug Too Gets FDA Nod  Shire was not the only company to gain FDA approval for an ADHD drug this week  The FDA also gave its nod to Neos   NASDAQ          Cotempla XR ODT  making it the first and only methylphenidate extended release orally disintegrating tablet to be approved for the treatment of ADHD in patients 6 to 17 years old 
	With this approval  Neos has both a branded methylphenidate as well as a branded amphetamine product available in an extended release orally disintegrating tablet dosage form  Cotempla XR ODT will be launched this Fall Novo Nordisk s Victoza Label Expansion Plans Get FDA Panel Support    Novo Nordisk s  NYSE          Victoza  liraglutide  got a favorable vote from an FDA advisory panel regarding the inclusion of data from the cardiovascular outcomes study LEADER in the drug s label  The Endocrinologic and Metabolic Drugs Advisory Committee  EMDAC  voted 19 0 in favor of the use of Victoza in type II diabetes patients not being associated with excess cardiovascular risk  The panel voted 17 2 in favor of the study providing enough evidence of reduction in cardiovascular risk in type II diabetes patient on Victoza  With cardiovascular disease being a leading cause of death in type II diabetes patients  the addition of a cardiovascular indication would boost Victoza s sales potential  Read more     
	Novo Nordisk is a Zacks Rank  2  Buy  stock  You can see   

	The NYSE ARCA Pharmaceutical Index was up almost 4  over the last five trading sessions with the sector reacting favorably to rumors that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected  Among major stocks  Bristol Myers was up 5 6  while Merck  NYSE MRK  gained 4 5   Over the last six months  AstraZeneca was up 30 1  while Bristol Myers was down 2 4   See the last pharma stock roundup here     

The Best   Worst of Zacks
	Today you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-25,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-novartis,-roche,-shire,-neos-and-novo-nordisk-200197489",200197489
203823,425339,MRK,Bristol Myers Reports Data On Immuno Oncology Drug Empliciti,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced four year follow up data from the phase III study  ELOQUENT 2 on immuno oncology Empliciti during the 22nd Congress of the European Hematology Association in Madrid  Spain The results from the trial showed that Empliciti plus lenalidomide dexamethasone  ELd  continued to demonstrate efficacy in patients with relapsed refractory multiple myeloma  RRMM   compared with patients treated with lenalidomide dexamethasone  Ld  alone The trial randomized 646 patients with RRMM who had one to three prior therapies to receive either ELd  321 patients  or Ld  325 patients  in 28 day cycles until their disease progressed or they withdrew consent ELd therapy maintained a reduction in the risk of disease progression or death of 29   At four years  ELd therapy continued to demonstrate a clinically meaningful and sustained relative improvement of 50  in progression free survival  PFS  rate  21  compared to Ld therapy  14   95  CI  12 1 17 3   Patients receiving ELd therapy also demonstrated an overall response rate  ORR  of 79  among patients receiving Ld therapy alone We note that Empliciti is already approved in the U S  in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies  It gained EU approval in May 2016 The long term efficacy data for Empliciti in patients with advanced multiple myeloma shows the combination of Empliciti with standard lenalidomide dexamethasone treatment can improve patient outcome The company s key oncology products include Opdivo  Sprycel  Yervoy and Empliciti  Bristol Myers Squibb and AbbVie   NYSE ABBV   are co developing Empliciti with the former being solely responsible for commercial activities Meanwhile  Bristol Myers  shares declined 21 0  in the last 12 months  the Zacks classified  industry gained 7 7   The company suffered a setback in Jan 2017 when it decided not to pursue accelerated regulatory pathway for Opdivo plus Yervoy in first line lung cancer in the U S  based on a review of available data  The share price of the company declined significantly on the news  Opdivo is facing stiff competition in the U S  With the FDA approving Merck s   NYSE MRK   Keytruda  for the first line treatment of metastatic nonsquamous NSCLC  the company is expected to suffer further loss of market share 
Zacks Rank   Key Pick
Bristol Myers currently carries a Zacks Rank  3  Hold  
A better ranked stock in the health care sector is VIVUS  Inc    NASDAQ VVUS     which sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates have narrowed from 50 cents to 39 cents for 2017 in the last 60 days  The company delivered positive earnings surprises in the four trailing quarters  with an average beat of 233 69  
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-reports-data-on-immuno-oncology-drug-empliciti-200197800,200197800
203834,425350,MRK,Aduro s Drug Gets Clearance By The FDA For Solid Tumors,opinion,"Aduro Biotech  Inc    NASDAQ ADRO   announced that the FDA has cleared the Investigational New Drug application  IND  for its pipeline candidate ADU S100  MIW815   This candidate will be evaluated in combination with Novartis    NYSE NVS   investigational anti PD 1 checkpoint inhibitor  PDR001  for the treatment of advanced metastatic solid tumors or lymphomas 
Aduro s shares underperformed the Zacks classified  industry year to date  Shares of Aduro declined 13 6  during the period  while the industry witnessed an increase of 1  

Moving ahead  Aduro  an immunotherapy company  in collaboration with Novartis is also planning to initiate a phase Ib trial of ADU S100 in combination with anti PD1 in the second half of 2017  The phase Ib trial is designed to assess the safety and efficacy of ADU S100 administered by intratumoral injection with PDR001 to patients with advanced metastatic solid tumors or lymphomas 
We remind investors that in May 2016  Aduros initiated a phase I  multicenter  dose escalation study to evaluate the safety  tolerability  pharmacokinetics  pharmacodynamics and anti tumor activity of ADU S100 in patients with cutaneously accessible metastatic solid tumors or lymphomas  This study is currently ongoing and the company expects to expand into viscerally accessible lesions in the second half of 2017 
We also remind investors that in Mar 2017  Merck   Co   Inc   s   NYSE MRK   anti PD 1 therapy  Keytruda  received positive opinion from the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  for the treatment of patients with relapsed or refractory classical hodgkin lymphoma  cHL   Aduro Biotech  Inc  Price
    Zacks Rank and Stocks to Consider
Aduro carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector includes VIVUS  Inc    NASDAQ VVUS   sporting a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters  with an average beat of 233 69  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-06-01,Zacks Investment Research,https://www.investing.com/analysis/aduro's-drug-gets-clearance-by-the-fda-for-solid-tumors-200192859,200192859
203835,425351,MRK,Incyte Announces Data On Enzyme Inhibitor With Keytruda,opinion,"Incyte Corporation   NASDAQ INCY   and Merck   Co    NYSE MRK   announced an updated data from the advanced non small cell lung cancer  NSCLC  patient cohort of the ongoing phase I II ECHO 202 study  The study was evaluating Incyte s selective IDO1 enzyme inhibitor epacadostat  in combination with Merck s anti PD 1 therapy Keytruda  pembrolizumab  
Epacadostat is being studied in combination with other immuno oncology agents  In fact  Incyte signed clinical trial collaboration agreements with Merck  Bristol Myers Company   NYSE BMY    AstraZeneca MedImmune   NYSE AZN   and Roche Genentech to evaluate epacadostat with their respective anti PD 1 and anti PD L1 agents in phase I II studies in 2014  Currently  all four of these studies are in progress  Also  Incyte retains global development and commercialization rights to epacadostat for all indications 
In Oct 2015  Incyte and Merck announced an expansion of the companies  ongoing clinical trial collaboration to include ECHO 301  a phase III study evaluating the combination of epacadostat with Keytruda as a first line treatment for patients with advanced or metastatic melanoma In Mar 2017  Incyte and Merck announced details of the companies  planned expansion of the ongoing clinical trial collaboration to include four additional tumor types  evaluating epacadostat plus Keytruda in patients with NSCLC  renal  bladder  and head   neck cancers  Phase III trials in these additional tumor types are expected to be initiated in 2017 
Incyte s share price has increased 31 2  year to date  while the Zacks classified  industry gained 2 8  

Coming back to the release  the study showed an overall response rate  ORR  of 35  among all patients with advanced NSCLC treated with the combination of epacadostat and Keytruda   Notably  complete response was noted in two patients and partial response  PR  in 12 patients   It also demonstrated a disease control rate  DCR  of 63   with 71  of responses ongoing at the time of the data cut off 
Earlier  in Apr 2017  Incyte and Bristol Myers Squibb announced that they will advance their clinical development program  The program will evaluate the combination of Incyte s investigational oral selective IDO1 enzyme inhibitor epacadostat with Bristol Myers  immuno oncology therapy Opdivo in phase III studies 
Moving ahead  the combination will be evaluated for the treatment of first line non small cell lung cancer across the spectrum of PD L1 expression and first line head and neck cancer 
Currently  Incyte and Bristol Myers Squibb are expanding the ECHO 204 phase I II study to include anti PD 1 PD L1 relapsed refractory melanoma cohorts Incyte Corporation Price
    Zacks Rank
Incyte carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-04,Zacks Investment Research,https://www.investing.com/analysis/incyte-announces-data-on-enzyme-inhibitor-with-keytruda-200193274,200193274
203836,425352,MRK,Incyte Provides Updated Data On Cancer Combination Therapies,opinion,Incyte Corporation   NASDAQ INCY   along with partner Bristol Myers Squibb Company   NYSE BMY   announced updated data from phase I II study  ECHO 204  evaluating Incyte s epacadostat in combination with the latter s immune oncology drug Opdivo for the treatment of squamous cell carcinoma of the head and neck  SCCHN  and melanoma  MEL   The data was presented at the annual 2017 meeting of the American Society of Clinical Oncology  ASCO  in Chicago We note that epacadostat is an investigational oral selective IDO1 enzyme inhibitor The combination therapy is being evaluated in multiple advanced solid tumors including SCCHN  treatment na ve MEL  ovarian cancer and colorectal cancer Incyte s share price has increased 23 7  year to date  while the Zacks classified  industry gained 2 8  Per the data  the combination therapy achieved 63  objective response rate  ORR   which includes two complete responses  CRs   in patients with MEL with no prior treatment  The combined disease control rate  DCR  for this indication was 88   The ORR in previously treated patients with SCCHN achieved was 23   including one CR  Combined DCR was 61   However  the responses were recorded irrespective of PD L1 expression and HPV status We remind investors that epacadostat is being studied in combination with other immuno oncology agents  In fact  Incyte signed clinical trial collaboration agreements with Merck   Co   Inc    NYSE MRK    Bristol Myers Company  AstraZeneca plc s   NYSE AZN   MedImmune and Roche s Genentech to evaluate epacadostat with their respective anti PD 1 and anti PD L1 agents in phase I II studies in 2014  Currently  all four of these studies are in progress  Also  Incyte retains global development and commercialization rights to epacadostat for all indications We note that  in April 2017  Incyte and Bristol Myers announced expansion of the ongoing clinical trial collaboration to include include two pivotal programs in non small cell lung cancer  NSCLC  and head   neck cancer  Phase III trials in these additional tumor types are expected to be initiated in 2017 In a separate press release  Incyte provided updated data from another phase I II ECHO 202 study evaluating epacadostat in combination with Merck s anti PD 1 therapy  Keytruda  in multiple tumor cohorts including metastatic or recurrent SCCHN  advanced urothelial bladder cancer  UC  and advanced renal cell carcinoma  RCC  Per the study  ORR data for SCCHN  UC and RCC were 34   35  and 33   respectively while DCR was a respective 61   53  and 50   The data also demonstrated that the combination therapy achieved three CRs in SCCHN and UC  and one CR in RCC  The data showed improved responses than data presented earlier Incyte Corporation Price   Zacks RankIncyte currently holds a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-06-05,Zacks Investment Research,https://www.investing.com/analysis/incyte-provides-updated-data-on-cancer-combination-therapies-200193484,200193484
203843,425359,MRK,Celldex s Immuno Oncology Pipeline Continues To Impress,opinion,On May 25  we issued an updated research report on Hampton  NJ based Celldex Therapeutics  Inc    NASDAQ CLDX    Celldex is a development stage biopharmaceutical company focused on the development and commercialization of immunotherapy technologies and other cancer targeting biologics So far this year  Celldex s share price has been trading below the Zacks categorized  industry  The stock has lost 12 1  compared with an increase of 0 6  for the broader industry Clovis reported results for first quarter 2017 earlier this month  The company s loss of 28 cents per share came in line with the Zacks Consensus Estimate but was narrower on a year over year basis  Revenues rose 15 3  year over year to  1 5 million in the quarter  beating the Zacks Consensus Estimate of  0 57 million  Celldex currently does not have any marketed product in its portfolio and the quarterly revenues were generated mainly under the clinical trial collaboration with Bristol Myers Squibb Company   NYSE BMY   and the research and development agreement with Rockefeller University Celldex s efforts to build its immuno oncology pipeline are impressive  Its lead pipeline candidate  glembatumumab vedotin is currently being evaluated for the treatment of triple negative breast cancer  phase IIb   METRIC study  and metastatic melanoma  phase II   Enrollmentin the METRIC study is expected to be completed in September this year  with data expected in the second quarter of 2018  In the melanoma study  Celldex added two new cohorts  a glembatumumab plus varlilumab arm and a glembatumumab plus checkpoint inhibitor arm  including either Bristol Myers  Opdivo or Merck   Co  Inc  s   NYSE MRK   Keytruda   In the melanoma study  glembatumumab performed well in the single agent setting Meanwhile  Celldex has collaborated with PrECOG and National Cancer Institute  NCI  to develop glembatumumab vedotin for the treatment of uveal melanoma and osteosarcoma  respectively Apart from glembatumumab vedotin  Celldex is developing an immune modulating antibody  varlilumab  designed to enhance a patient s immune response against their cancer  Varlilumab is being evaluated in combination with Opdivo in a phase II study that includes cohorts in five indications  colorectal cancer  ovarian cancer  head and neck squamous cell carcinoma  renal cell carcinoma and glioblastoma Other promising pipeline candidates include CDX 1401 CDX 301  phase II   multiple solid tumors  in collaboration with CITN  and CDX 014  phase I   advanced renal cell carcinoma  among others Importantly  with the Kolltan acquisition in Nov 2016  Celldex gained rights to two of Kolltan s cancer pipeline candidates  CDX 0158  phase I  refractory gastrointestinal stromal tumors GIST and other KIT positive tumors  and CDX 3379  to enter phase II in 2017 in solid tumors   Celldex also acquired Kolltan s multi faceted TAM program While the company is building a strong pipeline  it has suffered its share of setbacks  In Mar 2016  Celldex discontinued the phase III ACT IV study on Rintega for the treatment of patients with newly diagnosed EGFRvIII positive GBM  The discontinuation of a late stage study of this previously lead candidate of the company came as a major blow  The company has also decided not to advance the phase I combination studies of varlilumab with Roche s Tecentriq and varlilumab with Pfizer Inc  s   NYSE PFE   Sutent in renal cell carcinoma to phase II development Nonetheless  analysts are positive about the company s performance in the second quarter of 2017 as loss estimates narrowed 13 33  over the past 30 days  Three estimates moved up while none moved in the opposite direction in the same period Clovis has a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-05-25,Zacks Investment Research,https://www.investing.com/analysis/celldex's-immuno-oncology-pipeline-continues-to-impress-200191625,200191625
203844,425360,MRK,A Week s Worth Of Gains,opinion,"The market s streak of back to back weekly losses came to an end with gusto today  Friday s session may have been rather quiet ahead of a three day weekend  but it couldn t derail a week s worth of positive performances that actually began last Thursday  May 18   As the closing bell rang today  the S P was up 1 4  for the week  while the Dow advanced 1 3  and the NASDAQ jumped 2 1  
For today s session  the S P didn t move very much  but it s 0 03  advance was just enough to complete a seventh straight positive day and finish at a new record of 2415 8  The NASDAQ is right there with its counterpart as it too continued its green streak and reached a new record of 6210 2 after an advance of 0 08   However  the Dow was odd index out today  but only by the slimmest of margins  It was down 0 01  to 21080 3 
In the portfolios  Zacks Counterstrike finally made some buys after thinking about it all week  The portfolio added three names today  Other additions on Friday came from Healthcare Innovators and Income Investor  The highlights section below has specifics on these moves  along with some analysis from Momentum Trader Today s Portfolio Highlights Zacks Counterstrike  Jeremy has been looking to add for a while now  but didn t trust the recent rally enough to pull the trigger  But the market s impressive performance since last week s selloff changed his mind  and today he added three Zacks Rank  1s that the HFTs have yanked lower despite a strong quarter  Give them a look below 
  The editor decided that Potash Corp   POT  was a good way to play the agriculture space as planting season arrives  Shares jumped after the company reported an 80  positive surprise in its late April report  but have since pulled back  He added POT with a 12  allocation as he expects it to move higher again 
  All the cool kids are drinking craft beers these days  which was proved when Craft Brew Alliance  BREW  reported a positive surprise of 50  earlier this month  The stock moved higher after the report but is now hanging around  16  It was added to the portfolio today with a 14  allocation and expectations of moving as high as  20 eventually 
  Same kind of story for Quaker Chemical  KWR   The company surprised to the upside by 12  and then pulled back after an initial move higher  Jeremy added it with a 14  allocation ahead of the next leg higher  But this time he strongly suggests that you use limit orders  since this is a very low volume stock 
The full commentary has a lot more on all these moves Healthcare Innovators  One of the most exciting areas of medical research right now is Immuno Oncology  which uses the body s own immune system to attack malignant cancer cells  Kevin has been looking to get into this space for a while  and today he picked up Incyte  INCY  after reading some encouraging analyst reviews on its data  The company is closest to bringing an IDO inhibitor to market  which has caught the attention of bigger leaders in the space like Bristol Myers and Merck  NYSE MRK   INCY is now a key R D partner of these giants  By the way  the editor is so high on this area that he also bought NewLink Genetics  NLNK   which is a younger  less accomplished version of INCY  Read a lot more about these moves in the full write up Income Investor  The large  multinational companies are having a great year  as they continue to outperform with surging profits quarter after quarter  Its even better if they have a lot of overseas exposure to take advantage of an improving global economy  Neena wants to be part of this lucrative space  so she added iShares Global ETF  IOO  on Friday  The fund invests about 60  of its assets in the U S  and the rest in foreign companies  It also has a decent dividend yield of 2 5   Read the full writeup for more Momentum Trader   As I figured  the market quietly went off into the holiday  virtually unchanged at the highs  The action today capped quiet but positive week for the market as equities rebounded nicely from the spike in volatility last week  The President will finish up his foreign trip and should be back next week to further his tax reform and health care agendas   It seems that the market is increasingly disinterested in what s happening on Capitol Hill  The focus has shifted towards earnings and the Fed  We re on track for a June hike and that s settled down several stomachs   Sleepy end to the week ahead of the holiday weekend  This solemn holiday serves as the unofficial kickoff to summer but don t forget what it really stands for  We re not getting a day off to cook burgers and dogs on grills  we get a day of remembrance for the brave men and women who fought and died for our freedom      Dave Bartosiak
Have a Great Memorial Day Weekend 
Jim GiaquintoBefore You Go   
Have you checked out the Special Reports section of Zacks Ultimate lately  This long weekend is a good time to do just that before the new week begins  Our latest report came out earlier this week  Click the link to find all of our recent offerings  including 
  The 588  Revenue Explosion
  7 Best Stocks for the Next 30 Days
  Making Money on Marijuana 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy  ",2017-05-29,Zacks Investment Research,https://www.investing.com/analysis/a-week's-worth-of-gains-200192005,200192005
203851,425367,MRK,Merck Vs  Sanofi  Which Stock Is A Better Pick Post Q1 Earnings ,opinion,"With first quarter earnings season drawing to a close  here is a look at the performance of a couple of top ranked large cap pharma stocks  Merck   Co   Inc    NYSE MRK   and Sanofi  PA SASY    NYSE SNY    and what lies ahead for the remainder of the year An In Depth Look at 1Q17 Results  Both Merck and Sanofi surpassed earnings expectations though Sanofi s sales fell slightly short of estimates while Merck topped sales estimates as well  Despite the presence of generic competition for drugs like Zetia  Cubicin and Nasonex in the U S  and Remicade in Europe  Merck s oncology  vaccines and animal health segments helped drive growth in the quarter  Anti PD 1 therapy  Keytruda  benefited from its launch in the first line lung cancer setting as well as rapid penetration of head and neck cancer and continued strength in melanoma Four of Sanofi s five key business units recorded growth while headwinds existed in the form of the loss of contribution from the Animal Health segment and a higher tax rate  The company s multiple sclerosis  MS  franchise is doing well and annualizing at  2 billion in sales  Vaccines benefited from strong pediatric combination sales Meanwhile  Diabetes and Cardiovascular unit sales continued to decline  PCSK9 inhibitor  Praluent  continued to be impacted by the challenging payer environment 2017 Outlook  Following the release of strong 1Q results  Merck raised its revenue and earnings outlook for the year  The base business  including vaccines and animal health as well as contribution from new products like Keytruda should help lessen the impact of genericization  Merck is also exploring business development opportunities that will boost its portfolio  with an emphasis on early to mid stage pipeline assets Sanofi  on the other hand  maintained its outlook for the year  The company expects earnings to be stable to down 3   at constant exchange rates  in 2017  The sales decline in the U S  diabetes segment is expected to speed up over the remainder of the year given the challenging payer environment in the country  The segment will feel an incremental effect from the CVS formulary exclusion in the second quarter and the United Health formulary exclusion effective from Apr 1  The company said that Diabetes sales are likely to come in below the minus 4 to minus 8  guidance range Pipeline Catalysts  For any pharma or biotech company  the pipeline is of utmost importance and plays an important role in investment decisions  So  it always makes sense to take a look at a company s pipeline and upcoming catalysts Both Merck and Sanofi have several pipeline catalysts lined up this year  Merck has been working on expanding Keytruda s label into additional indications and has already scored some approvals so far in 2017 that should drive sales going forward  Meanwhile  Merck has several late stage candidates in its pipeline addressing a wide range of diseases including Alzheimer s disease  atherosclerosis  bacterial infection  cancer  diabetes  Ebola  heart failure  and HIV among others  Regulatory decisions this year include for label expansions of Keytruda and medicines containing ertugliflozin  an investigational SGLT2 inhibitor for type II diabetes Sanofi has also been very busy on the R D front with proof of concept and phase III studies covering therapeutic areas like cancer  diabetes  hemophilia  Pompe  asthma and multiple sclerosis among others  Dupixent  which is being positioned by the company as a  pipeline in a product   is expected to move into a phase III study in children with asthma in the second quarter while results from a late stage study in adults are expected in the fourth quarter  An atopic dermatitis study in children  6 11  is slated to commence in the third quarter   A key regulatory event for Sanofi is a decision from the FDA regarding the approval status of experimental rheumatoid arthritis  RA  drug Kevzara  sarilumab   which has blockbuster potential  A response is expected today Estimate Revisions  While 2017 earnings estimates for Merck are up 0 5  over the last 30 days  Sanofi witnessed a 0 3  downward revision in earnings estimates for the year Price and Valuation Perspective  A look at Sanofi s year to date  YTD  price performance shows that the company has outperformed the S P 500 as well as the Zacks categorized  industry    Sanofi is up 21 9  YTD compared to the industry gain of 8 6  
Merck has also performed better than the overall market with shares gaining 8 3  YTD 
Going by the current price to earnings multiple  which is often used to value drug stocks  Sanofi is trading at a P E multiple of 15 7  below the S P 500 P E multiple of 18 1  Merck is also trading at a similar level given its P E multiple of 15 9 Bottom LineAt present  Merck looks like the better pick to us  Although the company does have challenges in the form of generic competition  new products like Keytruda and the strong performance of the base business should provide support  Merck also has a deep pipeline which bodes well for long term growth While Sanofi started the year on the right note beating earnings estimates  sales fell short  Moreover  the diabetes segment remains under pressure  The Praluent injunction litigation appeal also remains an overhang Merck and Sanofi are both Zacks Rank  2  Buy  stocks  You can see  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-21,Zacks Investment Research,https://www.investing.com/analysis/merck-vs.-sanofi:-which-stock-is-a-better-pick-post-q1-earnings-200190584,200190584
203852,425368,MRK,Merck Presents Phase II Data On Chronic Cough Candidate ,opinion,"Merck   NYSE MRK   presented data from a phase II study on its pipeline candidate MK 7264  formerly AF 219  at the American Thoracic Society  ATS  Annual Conference  The study was designed to evaluate the safety  efficacy and therapeutic dose range of MK 7264 for the treatment of chronic cough Data from the study revealed that the highest dose of 50 mg  given twice daily  resulted in reduction of Awake Cough Frequency  coughs hour   the primary endpoint  by 37  from baseline compared to placebo after 12 weeks of treatment  The 50 mg dose also demonstrated a reduction in patient reported cough severity  However  lower doses  7 5 mg and 20 mg  were not statistically significant The company plans a discussion with regulatory agencies for initiating phase III clinical development of MK 7264 by the end of 2017 Shares of Merck have outperformed the Zacks classified  industry in the last year  The stock has gained 15 2  during the period  while the broader industry witnessed an increase of 4 3  We remind the investors that MK 7264 is also being evaluated in a phase II study for idiopathic pulmonary fibrosis  IPF  with cough  Results from the study  presented at the ATS International Conference last year  showed that MK 7264 significantly reduced cough frequency  otably  MK 7264 was added to Merck s portfolio following acquisition of the biotech company Afferent Pharmaceuticals in Jul 2016 According to information provided in the company s press release  chronic cough is estimated to affect about 10  of adults in the U S  With no approved therapies for its treatment  there is significant unmet need in this area We note that Merck has made significant progress with its pipeline and is working on bringing new products to the market  The company has over 10 candidates  including Keytruda  which are in advanced stages of development  It has prioritized its pipeline so that the candidates with highest potential can get the required support Merck   Company  Inc  Price

   Zacks Rank   Key Picks
Merck currently carries a Zacks Rank  2  Buy   Other top placed stocks in the healthcare sector include VIVUS  Inc    NASDAQ VVUS    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Bayer  DE BAYGN  AG   OTC BAYRY    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 30 days  The company posted positive earnings surprises in all four trailing quarters with an average beat of 233 69  
Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10  over last 30 days  The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 0 45  
Bayer s earnings per share estimates increased from  8 19 to  8 75  over the last 30 days for 2017  The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 10 25  
Zacks  2017 IPO Watch List
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time 
One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-23,Zacks Investment Research,https://www.investing.com/analysis/merck-presents-phase-ii-data-on-chronic-cough-candidate-200190978,200190978
203862,425378,MRK,What s In Store For Merck KGaA  MKGAF  In Q1 Earnings ,opinion,"Merck  NYSE MRK  KGaA  is scheduled to report first quarter 2017 earnings results on May 18 
Merck KGaA s share price has increased 15 5  year to date  while the Zacks classified  industry gained 6 5  

The company reports results under three business sectors   Healthcare  Life Science and Performance Materials 
Strong performance at Life Science  which was the catalyst behind sales growth in the last few quarters  is anticipated to continue in the to be reported quarter  In addition  Merck KGaA s 2015 acquisition of Sigma Aldrich was integrated into the Life Science business  The company expects total synergies from the acquisition to amount to   280 million by end of 2018 instead of the originally planned   260 million per year 
Merck KGaA in Apr 2017 announced an agreement to divest its biosimilars business  which was a part of its Healthcare business sector  to Fresenius  The decision to divest biosimilars is aligned with Merck s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines 
The closing is expected in the second half of 2017  subject to regulatory approvals and other customary closing conditions  For the Healthcare sector  the company is counting on its pharmaceutical pipeline and aims to gain approval for one medicine or new indication every year  2017 onwards 
Additionally  the company announced a dividend increase of   0 15 or 14  to   1 20 per share in Apr 2017  The company made this announcement due to higher earnings or following the Sigma acquisition  In fact  the increased dividend represents Merck s strong commitment to deleverage 
Meanwhile  we expect management to shed light on Merck KGaA s pipeline at the conference call 
Currently  Merck KGaA  in collaboration with Pfizer Inc    NYSE PFE    is evaluating Bavencio  avelumab  in several phase III studies for indications such as gastric cancer  platinum resistant refractory ovarian cancer  bladder cancer and advanced renal cell carcinoma  Notably  in May 2017  the FDA approved Bavencio  Injection for advanced or metastatic urothelial carcinoma  UC  In Apr 2017  the FDA also approved Bavencio for intravenous use  for metastatic Merkel cell carcinoma  mMCC  Merck KGaA Price and EPS Surprise   Upcoming Peer Releases
Here are a couple of health care stocks that you may want to consider  as our model shows that they have the right combination of elements   a positive Zacks  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to post an earnings beat this quarter  You can uncover the best stocks to buy or sell before they re reported with our  
Editas Medicine  Inc    NASDAQ EDIT   has an Earnings ESP of  32 26  and a Zacks Rank  3  The company is expected to release results on May 15  You can see  
AstraZeneca PLC   NYSE AZN   has an Earnings ESP of  4 55  and a Zacks Rank  3  The company is expected to release results on July 27 
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-05-12,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-merck-kgaa-(mkgaf)-in-q1-earnings-200188899,200188899
203863,425379,MRK,AstraZeneca Imfinzi Positive In Phase III Lung Cancer Study,opinion,AstraZeneca PLC   NYSE AZN   recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate  Imfinzi  durvalumab   The candidate is meant for the sequential treatment of patients with locally advanced  unresectable  stage III  non small cell lung cancer  NSCLC  The PACIFIC study is a randomized  double blinded  placebo controlled multi center study  It is being conducted in 235 centers across 26 countries  The study met its primary endpoints and demonstrated statistically significant and clinically meaningful progression free survival  PFS   Imfinzi led to significant reductions in the risk of deterioration of health or death  per data from the study  The results also demonstrate a favorable benefit risk profile  Investors should note that Imfinzi is the first immuno oncology medicine to show superior PFS compared to placebo in this patient setting Astrazeneca s shares have significantly outperformed the Zacks classified  industry so far this year  Shares of the company have gained 24 4   while the industry registered an increase of 8 6  We remind investors that earlier this month the FDA granted accelerated approval to Imfinzi for the treatment of previously treated patients with advanced bladder cancer Please note that Roche s   OTC RHHBY   Tecentriq is also approved for bladder cancer as well as for patients unable to tolerate cisplatin containing chemo Per the company s press release  stage III lung cancer affected around 100 000 patients in the G7 countries in 2016  Among them about 50  of these patients have tumors that are unresectable  Thus  approval of Imfinzi will provide the company access to a huge population base of patients affected by the disease We note that Imfinzi is being evaluated as a monotherapy as well as a combination treatment across a wide range of cancers including head and neck  gastric  pancreatic  hepatocellular and blood cancers Among other large cap pharma companies  Bristol Myers Squibb Company s   NYSE BMY   Opdivo and Merck   Co   Inc  s   NYSE MRK   Keytruda are also approved for immuno oncology treatments Astrazeneca  LON AZN  PLC Price    Zacks RankAstraZeneca currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-05-14,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-imfinzi-positive-in-phase-iii-lung-cancer-study-200189219,200189219
203864,425380,MRK,Immune Design  IMDZ  Posts Narrower than Expected Loss In Q1,opinion,"Immune Design Corp    NASDAQ IMDZ   reported first quarter 2017 loss of 50 cents per share  narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a  year ago loss of 61 cents 
  
The company s shares have underperformed the Zacks classified  industry year to date  Shares of Immune Design rallied 10  in the period  while the industry witnessed a gain of 4 9  

Quarter in Detail
Immune Design s total revenue for the first quarter was  5 5 million  up from  1 9 million in the year ago quarter  The increase was primarily due to  5 2 million collaboration revenues received from partner Sanofi   NYSE SNY   for G103  HSV2 therapeutic vaccine   The top line also benefited from product sales of  0 3 million to other third parties  Quarterly revenues were above the Zacks Consensus Estimate of  2 million as well 
Research and development  R D  expenses were up 32 8  to  14 million in the quarter primarily due to the company s progress with the ongoing R D programs  The programs include phase I and phase II studies and increase in personnel costs that are needed to support the company s pipeline 
General and administrative expenses also increased 5 6  to  4 1 million 
Pipeline Update
Immune Design is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   in the field of immuno oncology  Its key pipeline candidates are CMB305 and G100  Presently  CMB305 is being evaluated in soft tissue sarcoma  STS  patients both as monotherapy and in combination with an anti PD L1 antibody  The follow up is continuing in the two fully enrolled monotherapy phase I studies  Meanwhile  the company completed enrolment by the end of the first quarter in the phase II study comparing CMB305 plus Roche Holding  SIX ROG  AG s   OTC RHHBY   Tecentriq with Tecentriq alone 
Furthermore  G100  which is developed on the GLAAS platform  is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study in patients with low grade follicular non Hodgkin lymphoma  FL   Moving ahead  the data from the phase I dose escalation monotherapy study will be presented at ASCO in 2017  Notably  the company completed patient enrolment in the phase II study comparing G100 and low dose radiation  XRT   versus G100 and XRT with the systemic administration of Merck   Co   Inc s   NYSE MRK   anti PD 1 agent  Keytruda  Additionally  the FDA recently granted Orphan Drug Designation for G100 for the treatment of FL  
2017 Outlook
Immune Design continues to anticipate cash to fund operations into the second half of 2018  Immune Design Corp  Price  Consensus and EPS Surprise
    Zacks Rank
Immune Design currently carries a Zacks Rank  3  Hold   You can see  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-17,Zacks Investment Research,https://www.investing.com/analysis/immune-design-(imdz)-posts-narrower-than-expected-loss-in-q1-200190035,200190035
203865,425381,MRK,Incyte  INCY  Announces Positive Data On Enzyme Inhibitor,opinion,"Incyte Corporation   NASDAQ INCY   recently announced that new data was published online from the ongoing trial  ECHO 202 by the American Society of Clinical Oncology  ASCO  in advance of its annual meeting in Chicago  IL  June 2 6  2017 
The trial is evaluating Incyte s selective IDO1 enzyme inhibitor  epacadostat  in combination with Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  pembrolizumab  
Patients previously treated with anti PD 1 or anti CTLA 4 therapies were excluded from this trial 
The data from the trial includes phase I II efficacy and safety data from the following cohorts  non small cell lung cancer  NSCLC   renal cell carcinoma  RCC   bladder cancer  squamous cell carcinoma of the head and neck  SCCHN   triple negative breast cancer  TNBC   and ovarian cancer  OVC   The results from new data showed that epacadostat in combination with Keytruda was well tolerated and preliminary efficacy outcomes for these cohorts demonstrate encouraging clinical activity  both within and across tumor types  which compares favorably with contemporary data in the second line setting 
Concurrently  data from the ECHO 204 trial evaluated the safety and efficacy of epacadostat  in combination with Bristol Myers Squibb s   NYSE BMY   PD 1 immune checkpoint inhibitor Opdivo  The results show that the combination was well tolerated across the studied patients and demonstrates promising clinical responses  particularly in melanoma and with squamous cell carcinoma of the head and neck  SCCHN    The combination is also being evaluated ovarian cancer  OVC   and colorectal cancer  CRC  

Following the news Incyte s shares gained 2 3   Notably  in the past one year the company s shares have rallied 68 8   while the Zacks classified  industry fell 5 8  
The successful development of epacadostat will reduce the company s dependence on Jakafi  Incyte s dependence on a single product  Jakafi  for growth is concerning  Lower than expected sales would be a huge setback for the company 
While we are positive on the company s efforts to expand Jakafi s label  any development regulatory setback could pull down the stock significantly  In Feb 2016  Incyte received a notice letter regarding an abbreviated new drug application seeking approval to market a generic version of Jakafi  Earlier than expected entry of generic versions of Jakafi would be a big blow for the company 
Zacks Rank   Key Pick
Incyte Corporation currently carries a Zacks Rank  4  Sell  
A better ranked stock in the health care sector is VIVUS  Inc    NASDAQ VVUS   which sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-05-18,Zacks Investment Research,https://www.investing.com/analysis/incyte-(incy)-announces-positive-data-on-enzyme-inhibitor-200190112,200190112
203866,425382,MRK,4 Large Cap Drug Stocks To Buy Post Q1 Earnings,opinion,"The first quarter earnings season is drawing to a close with 90 8  of S P 500 stocks having reported results as of May 12  2017  13 of the 16 Zacks sectors recorded earnings growth with total earnings increasing 13 9  from the year ago period on revenue growth of 7 9   While 72 2  beat earnings estimates  66 1  topped revenue expectations with 51 8  surpassing both   The Medical sector is among the sectors that has consistently been recording earnings growth over the last few quarters  The sector  which had recorded earnings growth of 4 5  on revenue growth of 5 2  in Q4  has recorded earnings growth of 5 6  on the back of revenue growth of 6  so far in Q1  A look at the beat ratio shows earnings beat of 85 7  and revenue beat of 69 4  The pharma sector specifically had a mixed quarter with most companies topping earnings expectations but missing on revenues  The first quarter is usually a slow one for pharma and biotech companies for reasons like inventory destocking  fewer shipping days and the Medicare donut hole  Higher discounting in managed care and government channels for preferred access physicians  lower prices for certain drugs  softer scrip growth in the U S   and higher sales occurring in the Medicaid channel are some of the factors that affected drug sales of pharma and biotech companies  Unfavorable currency movement also played a role Over the last three years  revenues in the large cap pharma sector have been on an upward trajectory after being impacted by several factors including the genericization of key blockbuster drugs  Evolving pipelines  increasing contribution from new drugs and the approval of breakthrough treatments are some of the factors that has put this sector back on the growth trajectory 
Moreover  the Zacks categorized  industry is among the top 14  of the 256 Zacks ranked industries  The industry has outperformed the broader market  S P 500  year to date  YTD  as well 
Here is a look at 4 large cap drug stocks that delivered positive earnings surprises in the first quarter and are witnessing upward revisions in earnings estimates for 2017  All these companies are either Zacks Rank  1  Strong Buy  or Zacks Rank  2  Buy  stocks    you can see  Bayer  DE BAYGN  AG   OTC BAYRY    Germany based Bayer has a strong presence in the Life Science fields of health care and agriculture  The company reported better than expected results in the first quarter of 2017    in addition to delivering a positive earnings surprise of 16 7   Bayer also raised its outlook for the year on the back of Covestro s performance  Earnings estimates for 2017 are up 8 2  over the last 30 days  Estimated earnings growth for the current year is 7 6   Bayer has surpassed earnings estimates in three of the last four quarters with a positive surprise of 10 25   YTD  Bayer has outperformed the Zacks categorized Large Cap Pharmaceutical industry with shares gaining 23  compared to the industry gain of 9 5   In addition to being a Zacks Rank  1 stock  Bayer has a  of  B   Our research shows that stocks with a VGM Score of  A  or  B  when combined with a Zacks Rank  1 or  2 offer the best upside potential 
H  Lundbeck A S   OTC HLUYY    Denmark based Lundbeck specializes in psychiatric and neurological disorders  YTD  the company has outperformed the Zacks categorized Large Cap Pharmaceutical industry with shares gaining 25 4   In addition to delivering a positive earnings surprise of 64 52  in the first quarter  Lundbeck raised its outlook for the year  Lundbeck is also a Zacks Rank  1 stock with a VGM score of  B   2017 earnings estimates are up 2 9  over the last 7 days 
Merck   Co   Inc    NYSE MRK    Kenilworth  NJ based Merck is known for its strong presence in the pharmaceuticals and vaccines market  The company also has a presence in the animal health segment  Some of the better known products in Merck s portfolio include Keytruda  Gardasil  Januvia Janumet  Isentress  Vytorin Zetia and Remicade among others  Merck  a Zacks Rank  2 stock  has consistently surpassed earnings expectations over the last four quarters with an average surprise of 4 36   In addition to delivering a positive earnings surprise of 6 02  in Q1  Merck narrowed and raised its outlook for the year  Earnings estimates for 2017 are up 0 3  over the last 30 days  Estimated earnings growth for the current year is 1 7   New product launches especially Keytruda as well as the strong performance of the base business including the animal health segment should help the company combat the impact of generic competition   
Zoetis Inc    NYSE ZTS    Parsippany  NJ based Zoetis is a leading animal health company focused on the discovery  development  manufacturing and marketing of veterinary vaccines and medicines  complemented by diagnostic products  genetic tests  and biodevices  YTD  the company has outperformed the Zacks categorized  industry with shares gaining 11 6  compared to the industry gain of 8 1   The Zacks Rank  2 stock surpassed earnings expectations in each of the last four quarters with an average positive surprise of 9 82  while estimated earnings growth for the current year is 19 2   Earnings estimates for 2017 are up 0 9  over the last 30 days 
Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-18,Zacks Investment Research,https://www.investing.com/analysis/4-large-cap-drug-stocks-to-buy-post-q1-earnings-200190003,200190003
203867,425383,MRK,Merck KGaA  MKGAF  Q1 Earnings Fall Y Y  Revenues Increase,opinion,Merck  NYSE MRK  KGaA  reported first quarter 2017 earnings of  1 28 per American Depositary Share  14 7  lower than the year ago figure of  1 50  Net sales in the reported quarter came in at  4 1 billion   3 86 billion   up 5 3   Organic sales growth of 3 1  was driven by the Healthcare and Life Science segment  Moreover  favorable foreign exchange impacted sales by 2 6  while portfolio changes had a slight negative impact Shares of the company have outperformed the Zacks Classified  industry so far this year  The company rose 14 5  while the industry increased 7  in the same period Segment Sales in DetailThe company reports results under three segments   Healthcare  Life Science and Performance Materials The Healthcare division recorded sales of  1 7 billion  up 5 4  year over year due to a positive impact of 2  of foreign exchange rate  partially offset by a negative 1  impact of portfolio changes  However  organically  sales at the segment were up 4 4   The company received  37 million as milestone payment from Pfizer on receiving approval for Bavencio in the U S As part of the strategy to focus on the discovery and development of innovative pharmaceuticals  the company divested its Biosimilars business in Apr 2017 to Fresenius Erbitux s sales were up 5 3  from the year ago period to  218 million while Rebif sales came in at  415 million  down 1 6  due to negative currency impact  Gonal f sales were down almost 8 5  to  171 million due to continued competitive pressure and unfavorable year over year comparisons  Organically  Erbitux grew 4 3   Rebif and Gonal f posted a decline of 4 0  and 9 6   respectively Sales at the Life Science segment amounted to  1 5 billion  up 7 1  primarily due to growth in all regions and business segments and a favourable foreign exchange effect of 2 4   Moreover  it witnessed a positive portfolio effect of 0 4   due to the acquisition of BioControl  On an organic basis too  the segment witnessed sales growth  up 3 3    The Process Solutions business recorded organic sales growth of 4 8   while organic sales at Applied Solutions improved 4 4   The Research Solutions business registered organic growth of 1  Performance Materials sales were up 3 6  to  645 million  However  organically  the segment witnessed a 0 9  decline in sales Bavencio UpdateMerck KGaA is evaluating lead immuno oncology candidate  avelumab  in a number of phase III studies for several cancer indications under its partnership with Pfizer Inc    NYSE PFE    In Mar 2017  the candidate received approval for the treatment of metastatic Merkel cell carcinoma  mMCC  followed by approval for advanced bladder cancer in May 2017 in the U S  under the tradename Bavencio The drug is under review in Europe for the treatment of mMCC Bristol Myers Squibb Company s   NYSE BMY   Opdivo and Roche Holding  SIX ROG  AG s   OTC RHHBY   Tecentriq are available in the market for the treatment of bladder cancer OutlookMerck KGaA has updated its guidance for 2017  The company updated net sales expectations in the range of  15 5    16 0 billion  On an organic basis  sales are anticipated to grow moderately from the previous year with positive 1  2  impact of currency fluctuations on net sales  The Healthcare segment is expected to witness slight organic sales growth  while organic sales at Life Science are projected to see solid growth  Performance Materials will  however  witness a moderate decline in 2017 Our TakeMerck KGaA s first quarter earnings registered a decline on a year over year basis while sales increased  With the approval of Bavencio for two indications in the U S   the company received a major boost Going ahead  we believe that the approval of Bavencio may boost sales  However  we remain concerned about the challenges it will face from the marketed drugs Merck KGaA Price  Consensus and EPS Surprise   You can see  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-05-18,Zacks Investment Research,"https://www.investing.com/analysis/merck-kgaa-(mkgaf)-q1-earnings-fall-y-y,-revenues-increase-200190309",200190309
203868,425384,MRK,Company News For May 19  2017,opinion,     Shares of L Brands Inc   NYSE LB   advanced 2 7  after the company reported first quarter 2017 earnings of  0 33 per share  surpassing the Zacks Consensus Estimate of  0 29     Pandora Media  Inc  s   NYSE P   shares gained 5 5  following news that Sirius XM was in talks to purchase Pandora Media     Shares of Incyte Corporation   NASDAQ INCY   advanced 6 9  after the company s IDO1 enzyme inhibitor in combo with Merck s   NYSE MRK   anti PD 1 therapy showed positive results     Shire PLC s   NYSE P   shares gained 4 3  after the company revealed strong Phase 3 results for a drug that treats a rare condition which results in swelling under the skin,2017-05-18,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-may-19,-2017-200190253",200190253
203876,425392,MRK,BioLineRx  Multiple Shots On Goal And Multiple Partners ,opinion,"BioLineRX Ltd  NASDAQ BLRX  is currently focused on the development of BL 8040  which is a short peptide antagonist for CXCR4  a chemokine receptor involved with tumor progression  angiogenesis  metastasis and cell survival  BL 8040 is being developed for a variety of solid tumors including pancreatic  gastric and NSCLC  It is also being developed for AML and stem cell mobilization  They are also developing AGI 134  an alpha gal immunotherapy for solid tumors  which is expected to enter the clinic within 12 months  BioLineRx has multiple collaborators including Genentech  Merck  NYSE MRK  and Novartis  NYSE NVS  
Getting closer to registration in stem cell mobilization
BioLineRx is set to initiate a registrational study of BL 8040 in autologous stem cell mobilization in H217 following a recent successful meeting with the FDA  A Phase II in their allogeneic transplantation study is expected to have topline results by the end of 2017  The company reported positive early results from this trial in March where BL 8040 showed a similar level of efficacy with a single injection that G CSF  the current standard of care  shows after four to six injections 
Multiple trials with quality collaborators
Genentech is set to initiate three Phase Ib trials of BL 8040 in combination with atezolizumab in pancreatic  gastric and non small cell lung cancer  NSCLC   BioLineRx has initiated a Phase II trial of BL 8040 in combination with Keytruda in pancreatic cancer in collaboration with Merck  We expect partial results from this trial in H217 with topline results in H218  The company also has a multi year collaboration with Novartis to develop early stage molecules  As part of this  Novartis took an equity stake in BioLineRx which currently stands at around 6  
To read the entire report Please click on the pdf File Below",2017-05-05,Edison,https://www.investing.com/analysis/biolinerx---multiple-shots-on-goal-and-multiple-partners-200187304,200187304
203877,425393,MRK,Incyte  INCY  Q1 Loss Narrower Than Expected  Revenues Beat ,opinion,"Incyte Corporation   NASDAQ INCY   reported first quarter 2017 loss of 96 cents  a penny narrower than the Zacks Consensus Estimate of a loss of 97 cents  Incyte had reported earnings of 12 cents per share in the year ago quarter 
Quarterly revenues were  384 1 million  up 45 8  year over year  and beat the Zacks Consensus Estimate of  353 6 million  The top line was driven by higher sales of Jakafi in the U S  and Iclusig in Europe as well as royalties from ex U S  sales of Jakavi 

Incyte s shares has gained 60 7  in the past one year  while the Zacks classified  industry fell 4 7  
Quarter in Detail
Jakafi sales grew 37   year over year to  251 million  Net product revenue of Iclusig amounted to  14 million  Product royalty revenues from Novartis   NYSE NVS   for the commercialization of Jakafi in ex U S  markets surged 31 8  to  29 million 
Contract revenues rose approximately 55 1  to  90 million 
Research and development  R D  expenses were up significantly to  408 million from  157 million  The increase was primarily due to the expansion of the portfolio as well as upfront and milestone expenses of  209 million related to collaboration and license agreements  Selling  general and administration  SG A  expenses amounted to  87 million  up 33 8  year over year 
2017 Outlook
The company continues to expect Jakafi revenues in the range of  1 020  1 070 million  Iclusig revenues are expected in the range of  60  65 million 
R D expenses are now expected in the range of  1 1 1 billion  up from the earlier forecast of 990 million  1 040 million  SG A expenses are still expected in the range of  340  360 million 
Pipeline Update
A phase III trial evaluating Jakafi in patients with graft versus host disease  GVHD  is underway while the pivotal program evaluating Jakfai in patients with essential thrombocythemia  ET  is likely to be initiated soon  A phase III trial  REACH3 evaluating Jakafi as a treatment for patients with steroid refractory chronic GVHD is expected to begin in 2017 
Incyte also expanded its collaboration with Merck   NYSE MRK    growing the pivotal program studying epacadostat in combination with pembrolizumab to a total of five tumor types  Incyte and Merck will advance four additional tumor types beyond melanoma   non small cell lung cancer  NSCLC   bladder  renal and head   neck cancers   across six phase III trials  These trials are expected to begin in 2017 Additionally  Incyte expanded its collaboration with Bristol Myers Squibb   NYSE BMY   evaluating epacadostat in combination with nivolumab in pivotal studies in two tumor types 
The European Commission approved Olumiant in Feb 2017 for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to  or who are intolerant to  one or more disease modifying anti rheumatic drugs  DMARDs   However  the company suffered a setback when the FDA issued a complete response letter  CRL  for baricitinib in which the FDA indicated that additional clinical data are needed to determine the most appropriate doses  The FDA further stated that additional data are necessary to further characterize safety concerns across treatment arms Incyte Corporation Price and Consensus
 
 
   Our Take
Incyte s first quarter results were encouraging as the company reported a narrower than expected loss and surpassed revenue expectations  The growth in Jakafi sales is driven by patient demand and should boost revenues 
While most of the demand is due to a larger established patient base in myelofibrosis  polycythemia vera is also expected to be a major long term driver of Jakafi growth  This is owing to the larger potential patient population and the possibility for longer duration of treatment  The company exited the first quarter with approximately 10 000 patients being treated with Jakafi  However  the delay in approval of Olumiantin the U S  is disappointing 
Zacks Rank
Incyte Corporation currently carries a Zacks Rank  4  Sell   You can see  
Zacks  2017 IPO Watch List 
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-08,Zacks Investment Research,"https://www.investing.com/analysis/incyte-(incy)-q1-loss-narrower-than-expected,-revenues-beat-200187834",200187834
203878,425394,MRK,Celldex  CLDX  Q1 Loss In Line  Revenues Beat  Shares Up,opinion,"Celldex Therapeutics  Inc    NASDAQ CLDX   posted first quarter 2017 loss of 28 cents per share  which was in line with the Zacks Consensus Estimate but wider than the year ago loss of  35 cents per share  Total revenue in the quarter rose 15 3  year over year to  1 5 million  beating the Zacks Consensus Estimate of  0 57 million  Revenues were generated mainly under the clinical trial collaboration with Bristol Myers Squibb Company   NYSE BMY   and the research and development agreement with Rockefeller University in the quarter Shares rose more than 3  in after hours trading on Tuesday  However  Celldex Therapeutics  shares are down 11 1  so far this year  This compares unfavorably with a 2  increase registered by the Zacks classified industry during this period Research and development expenses declined 5 6  from the year ago period to  25 8 million  General and administrative spend declined 22 6  to  7 2 million At the Mar 31  2017  Celldex had cash  cash equivalents and marketable securities of  167 0 million compared with  189 8 million as of Dec 31  2016  Celldex expects that this cash plus anticipated proceeds from future sales of its common stock under the agreement with Cantor will be enough to fund working capital requirements and planned operations through 2018  However  the guidance assumes that Celldex will pay future Kolltan contingent milestones  if any  in stock and not cash Pipeline UpdateCelldex s most advanced pipeline candidate is glembatumumab vedotin  currently being evaluated for the treatment of triple negative breast cancer  phase IIb   METRIC study  and metastatic melanoma  phase II   Enrolment in the METRIC study is expected to be completed in September this year  with data expected in the second quarter of 2018  In the melanoma phase II study  the company said it will present data from the single agent cohort of glembatumumab vedotin in June at the annual meeting of the American Society of Clinical Oncology  ASCO   The study also includes two new cohorts  a glembatumumab plus varlilumab arm   data expected in fall 2017   and a glembatumumab plus checkpoint inhibitor arm  including either Bristol Myers  Opdivo or Merck   Co  Inc  s   NYSE MRK   Keytruda Apart from glembatumumab vedotin  Celldex has several promising candidates in its pipeline  including varlilumab and CDX 014  phase I advanced renal cell carcinoma  among others Varlilumab is being evaluated in combination with Bristol Myers Opdivo in a phase II study that includes cohorts in five indications   colorectal cancer  ovarian cancer  head and neck squamous cell carcinoma  renal cell carcinoma and glioblastoma  Celldex plans to complete enrolment across all cohorts in the phase II portion of the study in the first quarter of 2018  Meanwhile  the company expects to present data from the phase 1 potion of varlilumab Opdivo combination study at ASCO in June With the Kolltan acquisition in Nov 2016  Celldex gained rights to two of Kolltan s cancer pipeline candidates  CDX 0158  phase I  refractory gastrointestinal stromal tumors GIST and other KIT positive tumors  and CDX 3379  to enter phase II in 2017 in solid tumors  being evaluated as a single agent and in combination with various other drugs like Erbitux  Tarceva  Zelboraf  and Herceptin   Celldex also acquired Kolltan s multi faceted TAM program Celldex carries a Zacks Rank  3  Hold  Celldex Therapeutics  Inc  Price  Consensus and EPS Surprise
    Stock to ConsiderA better ranked stock in the pharmaceutical sector is Akari Therapeutics  Plc   NASDAQ AKTX   with a Zacks Rank  1  Strong Buy   You can see  Shares of Akari Therapeutics have risen 62 3  this year so far Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-09,Zacks Investment Research,"https://www.investing.com/analysis/celldex-(cldx)-q1-loss-in-line,-revenues-beat,-shares-up-200188375",200188375
203879,425395,MRK,PDL BioPharma  Q1 Earnings ,opinion,"PDL BioPharma Inc  NASDAQ PDLI  recently reported Q117 earnings  Its subsidiary Noden Pharma  of which it currently owns 98   started commercialization efforts for the Tekturna franchise in late February with a  40 person salesforce and has co pay cards and 30 day starter pack vouchers in place  It is too early to tell how successful they have been  but physician feedback and recent prescription data have been positive  Also  the company continues to receive royalty payments for Tysabri for longer than expected  it was paid  14 2m in Q117  It is also set to receive  19 5m as part of a patent settlement with Merck  NYSE MRK  related to Keytruda 

Tekturna may have reached the bottom
Tekturna  aliskiren  is a mature product that has had steadily declining sales due to stroke and renal concerns as well as a lack of Novartis detailing  With commercialization efforts by Noden only initiating in late February  it is too early to tell if prescription declines have been slowed or even reversed  but recent data from Wolters Kluwer for the month of March have been positive 
To read the entire report Please click on the pdf File Below",2017-05-10,Edison,https://www.investing.com/analysis/pdl-biopharma---q1-earnings-200188243,200188243
203890,425406,MRK,Here Are Three Companies Addressing A Major Unmet Need In Healthcare,opinion,"Cytomegalovirus  CMV  is one of the most common viruses in the world  It s ubiquitous in all populations  and it s a herpesvirus  meaning it causes a lifelong  persistent infection in its host  In healthy individuals  it s generally asymptomatic  It goes unnoticed in the vast majority of these cases and causes no real issues 
In a certain category of the infected  however  it s a different story  If patients are infected with CMV during or after stem cell transplants  or solid organ transplants  which is very common in both instances  it can be a cause of substantial morbidity and death among patients  If pre natal infection occurs  babies are often born with deformities or mental disability  In immunosuppressed patients  infection can lead to retinitis  hepatitis  pneumonitis  gastroenteritis  or other end organ diseases 
There s a large unmet need for a vaccination  yet to date  none have made it past mid to late stage trials  A number of companies are working to change this right now  Here are three of the most advanced  with a look at the assets under investigation and what to expect going forward from each 
The first company on the list is Merck   Co   Inc   NYSE MRK  
Merck s CMV asset is called letermovir and the company is currently investigating the drug as a potential treatment for the prevention of CMV infection in adult  18 years and older  CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant  HSCT   This is a high risk population  as outlined above  and this program represents the most advanced program in the space right now 
The drug  letermovir  is a once daily antiviral medicine and it is part of a family of drugs called non nucleoside CMV inhibitors  To simplify the mechanism of action  MOA   viruses rely on what s called the viral terminase complex to replicate and proliferate from cell to cell  Terminase packages DNA into viral heads  which then make their way into cells  Letermovir inhibits this process  and theoretically  inhibits the replication of the CMV 
The drug  in October last year  at which point Merck put out a small amount of data and said it would submit for a detailed presentation at a future event  This event turned out to be the   and the data turned out to be very strong  The trial met its primary endpoint of an improvement in clinically significant CMV infection through week 24 post HSCT when compared to placebo  Further  the safety profile of the drug was relatively clean  inducing no real side effects outside of those expected for patients undergoing this procedure 
So what s next 
Merck has to put an application together for submission to the FDA  While we don t have a specific timeframe slated for submission  the company has noted it expects to have the submissions ready before the end of 2017  With fast track designation in place  this means we could see a mid 2018 approval in the US 
Next up  Astellas Pharma Inc  OTC ALPMY  
This Japanese biotech is developing a drug called ASP0113 
Whereas the Merck asset is attempting to inhibit the replication of the virus  this one is more of a traditional vaccine type   it attempts to harness the body s ability to recognize CMV associated antigens to spark an immune response to the virus if and when it presents itself post procedure 
The company pitched ASP0113 against placebo in a phase II study investigating the safety and efficacy of the asset in kidney transplant patients receiving an organ from a CMV seropositive donor  It was a double blind trial and  
Unfortunately for Astellas and its shareholders  the trial didn t turn out as hoped  The drug failed against its primary endpoint of patients having CMV viremia  defined as a plasma viral load of   1000 IU mL through one year after first injection of study drug  It also missed on a couple of secondary endpoints  and while the safety profiles of the placebo and active arms were similar  the latter resulted in more injection site reactions 
That s not the end of the program  however  There are two phase III studies for this one   the above mentioned study in solid organ transplants  in this case  kidney transplants  and a second mirroring that of Merck  investigating the drug in an HSCT indication 
This second trial is set to wrap up during the fourth quarter of this year  While there s justification for pessimism ahead of the results  it s too early to write off the drug  If Astellas can prove efficacy in HSTC patients  there s plenty of room for revaluation as the company carries the drug into a pivotal study in the US 
Closing out the list  VBI Vaccines Inc  NASDAQ VBIV  
This company just  that an update for a phase I clinical study of its own CMV asset  a drug called VBI 1501A  VBI is investigating the vaccine as a potential candidate to prevent congenital CMV infection   the third of the three major risk groups outlined in the introduction to this piece  Pre natal CMV infection affects more live births than Down Syndrome or Fetal Alcohol Syndrome and the direct economic cost of infection exceeds  2 0B annually  Many of the live births affected by the virus will develop serious issues  including blindness and deafness 
Similar in concept to Astellas asset  VBI 1501A incorporates the more traditional antigen driven vaccine model in its construction  It differs from most approved  and in development  vaccines  however  in that it s created using what s called the eVLP platform  The platform is proprietary to VBI and allows for the creation of vaccines that more closely mimic the structure of the virus against which they are trying to trigger an immune response 
Pre clinical models suggest that this vaccine can induce neutralization of CMV up to 32X greater than natural immunity and that it can induce potent neutralization in fibroblasts and epithelial cells  which are two cell types that are susceptible to CMV infection 
The ongoing phase I study is investigating the vaccine in an estimated 125 healthy patients  with safety and tolerability the primary endpoint  However  and of more interest to a biotechnology investor  the trial is set up to also potentially indicate clinical benefit through measuring levels of vaccine induced CMV neutralizing antibodies 
All patients have now been fully dosed  with three doses of immunization  and the latest update announced the unanimous recommendation of a Data and Safety Monitoring Board  DSMB  for continuation  While this recommendation doesn t offer any insight into clinical benefit  it s a good sign that the trial is working towards a primary endpoint hit  which in turn supports the potential advance of the asset into phase II development 
An interim safety report from the trial  which will also address immunogenicity  is set to hit press mid 2017  with the trial set to finish  ",2017-05-03,Samuel Rae,https://www.investing.com/analysis/here-are-three-companies-addressing-a-major-unmet-need-in-healthcare-200186774,200186774
203891,425407,MRK,Merck Vs  Pfizer  Which Stock Looks Better Post Earnings ,opinion,"Both Merck   Co   Inc    NYSE MRK   and Pfizer  Inc    NYSE PFE   reported upbeat first quarter results earlier this week  While  Merck posted better than expected earnings and revenues  Pfizer managed to outpace its earnings estimate but missed on the top line 
Both Pfizer and Merck have a Zacks Rank  3  Hold   but let s see which stock is better positioned in terms of fundamentals  You can see 
Q1 Earnings Performance
For the first quarter  Pfizer reported adjusted earnings per share of 69 cents  beating the Zacks Consensus Estimate by a couple of cents  The bottom line increased 3  from the year ago period  The company s revenues of  12 78 billion fell short of the Zacks Consensus Estimate of  13 04 billion and decreased 2  year over year  Currency movement negatively impacted Pfizer s first quarter revenues by 1  or  116 million   Read More   
Merck posted first quarter earnings of 88 cents per share  surpassing the Zacks Consensus Estimate by 5 cents  However  earnings declined 1 1  from the year ago period  Revenues not only increased 1  year over year to  9 4 billion but also beat the Zacks Consensus Estimate of  9 3 billion  Merck s Pharmaceutical segment s revenues increased 1  year over year to  8 2 billion  offsetting the negative impact of currency movement   Read More   
Price Performance

Shares of both Pfizer and Merck have notched up gains since Nov 8  2016  when Donald Trump won the Presidential election  However  Pfizer is a clear winner on this respect with a return of around 11 5   ahead of the  s advancement of around 9 1   Merck has increased only 4 7  during the same period 
Valuation
Here  we have used  to evaluate these two stocks from a valuation perspective  Typical value investors will look at P E ratios  PEG ratios and Price to Book ratios among others  But  the Zacks Value Score takes many other ratios under consideration and conclusively indicates which stock is relatively more undervalued 

Pfizer has a Value Score of  B   while Merck has a Value Score of  C  

Net Margin
Compared to other industries  drug development companies have relatively higher net margin levels  This is mainly because mature pharma companies like Pfizer and Merck deal in diversified business segments as well as develop and market blockbuster drugs 

The net profit margin  TTM  for Pfizer is 86 3   which is significantly higher than the Large Cap Pharmaceuticals Sector s level of 16 4   Merck has net profit margin TTM of 37 1   significantly lower than that of Pfizer 
Dividend Yield

In the last one year period  the dividend yield for Pfizerwas higher than the Large Cap Pharmaceuticals industry  which offered a yield of 3 5   While Pfizer returned 7 1   Merck had a negative dividend yield of 13 6  during the same period 
Earnings History and Estimate Revisions
Merck delivered positive surprises in all the last four quarters  with an average earnings surprise of 4 4   In comparison  Pfizer delivered an earnings beat in only two of the trailing four quarters and posted an average negative earnings surprise of around 0 4  
When considering estimate revisions  Pfizer s earnings estimate for the current year has improved 0 5  over the last 30 days  Meanwhile  Merck s earnings estimate has advanced by only 0 3  over the same period  
Conclusion
In our comparative analysis  we found that both the two pharma giants have certain positives  Pfizer registered a stronger price performance  delivered a significantly higher dividend yield and has better estimate revisions  In terms of valuation as well  Pfizer is more underpriced than Merck  However  Merck holds an edge over Pfizer only when considering its average positive earnings surprise  Our analysis clearly indicated that Pfizer is better positioned than Merck and thus calls for investors  attention post earnings 
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-05-05,Zacks Investment Research,https://www.investing.com/analysis/merck-vs.-pfizer:-which-stock-looks-better-post-earnings-200187449,200187449
203913,425429,MRK,Roche s  RHHBY  Cancer Drug Gets FDA Nod For Label Expansion ,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   unit  Genentech  announced that its drug Tecentriq  atezolizumab  has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma  mUC    a form of bladder  cancer   who are unable to receive initial treatment with cisplatin chemotherapy 
Tecentriq is already approved for the treatment locally advanced mUC in patients whose disease has progressed after receiving other medicines  either before or after surgery  or after their disease has spread 
Roche s share price shows that the company has outperformed the Zacks classified industry year to date  The stock is up 12 5  compared with the  industry s gain of 5 4  

Also  in October last year  Tecentriq became the first and the only anti PDL1 cancer immunotherapy to be approved by the FDA for the treatment of metastatic non small cell lung cancer  NSCLC  
The label expansion of the drug is expected to boost sales for the company  As per the press release  bladder cancer is the most common type of urothelial carcinoma and about half the people with the advanced form of the disease are unable to receive cisplatin chemotherapy as an initial treatment  thereby leading to a high unmet medical need  Urothelial carcinoma also includes cancers of the urethra  ureters and renal pelvis 
The accelerated approval of Tecentriq was granted based on tumor response rate and duration of response  Also  it was based on Phase II IMvigor210 study  But the final approval will be give only of the drug showsclinical benefit in confirmatory studies 
However  stiff competition in the immunotherapy space with players like Bristol Myers Squibb   NYSE BMY   boasts a robust portfolio with drugs like Opdivo and Yervoy  Merck s   NYSE MRK   Keytruda also poses strong competition with approvals for a varied range of cancers 
Last week  Roche announced that the global randomized phase III study  ALEX  on lung cancer drug Alecensa met its primary endpoint as an initial  first line  treatment  According to the evaluation  Alecensa significantly reduced the risk of disease worsening or death  progression free survival  PFS  compared with Pfizer s   NYSE PFE   Xalkori in patients suffering from anaplastic lymphoma kinase  ALK  positive advanced non small cell lung cancer  NSCLC  Roche Holding AG Price
    Zacks Rank
Roche currently sports a Zacks Rank  1  Strong Buy   You can see  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course  Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-04-17,Zacks Investment Research,https://www.investing.com/analysis/roche's-(rhhby)-cancer-drug-gets-fda-nod-for-label-expansion-200183391,200183391
203919,425435,MRK,Bristol Myers  BMY  Collaborates With Apexigen For Opdivo ,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced a collaboration agreement with clinical stage biopharmaceutical company Apexigen  Inc 
Both the companies will collaborate for a clinical trial to evaluate Bristol Myers Squibb s immuno oncology drug Opdivo in combination with Apexigen s APX005M in patients with advanced solid tumors 
APX005M is an experimental compound  designed to activate CD40  a key immune co stimulatory receptor essential to regulate the activation of both innate and adaptive immune responses against cancer 
Both the companies will collaborate to evaluate the safety  tolerability and preliminary efficacy of APX005M in combination with Opdivo in second line metastatic NSCLC patients who have failed prior chemotherapy  and in metastatic melanoma patients who have failed prior I O therapy 
We remind investors that Opdivo is approved for varied indications in both EU and the U S  Opdivo received approvals for several indications including melanoma  head and neck  lung  kidney and blood cancer  The Opdivo Yervoy regimen is also approved in multiple markets for the treatment of melanoma 
The drug recorded sales of  3 4 billion in 2016  up from  942 million in 2015  Bristol Myers is working on expanding the label of Opdivo further  Opdivo became the first PD 1 inhibitor to be approved for a hematological malignancy   classical Hodgkin lymphoma in both the U S   May 2016  and the EU  Nov 2016   In Nov 2016  Opdivo gained the FDA approval for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 
Label expansion into additional indications would give the product access to a higher patient population and increase the commercial potential of the drug 
However  the company suffered a setback in Jan 2017 when it decided not to pursue accelerated regulatory pathway for the regimen of Opdivo plus Yervoy in first line lung cancer in the U S  based on a review of available data  A potential earlier than expected entry of Merck s   NYSE MRK   Keytruda in combination with chemotherapy will further impact Opdivo sales 
While Bristol Myers  share price decreased 20 8  in the last 12 months  the Zacks classified  industry gained 1 4  

 
Zacks Rank   Stocks to Consider
Bristol Myers currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Heska Corp    NASDAQ HSKA   and Retrophin  Inc    NASDAQ RTRX    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  
Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018 over the last 60 days  The company posted a positive surprise in three of the four trailing quarters with an average beat of 291 54  
Retrophin s loss per share estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018 over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters  with an average beat of 80 55  
Zacks  Best Private Investment Ideas 
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-12,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-(bmy)-collaborates-with-apexigen-for-opdivo-200182608,200182608
203927,425443,MRK,Agenus  AGEN   What s Ahead For The Stock In Q4 Earnings ,opinion,"Agenus Inc    NASDAQ AGEN   is expected to report fourth quarter 2016 results during this month  Last quarter  Agenus delivered a negative earnings surprise of 46 88   Let s see how things are shaping up for the company this quarter Agenus  share price has decreased 6 5  year to date  while the Zacks classified  industry gained 6 1  

Factors at Play
Agenus is an immuno oncology company focused on the discovery and development of checkpoint modulators  vaccines and adjuvants for the treatment of cancer The company earns revenues only through fees received under collaboration and license agreementsCurrently  the company is evaluating AGEN1884 in a phase I study and INCAGN01876 in a phase I II study for the treatment of solid tumors The company has initiated phase I study for OX40 aganist INCAGN1949 in collaboration with Incyte  Agenus has also started phase I study for PD 1 antagonist AGEN2034 and AutoSynVax  Going ahead  the company plans to initiate studies on its second anti CTLA 4 antibody  AGEN2041  in 2017  Agenus also expects to begin combination studies on AGEN2034 and AGEN1884 in the second half of 2017 
In its fourth quarter conference call  investor should remain focus on the company s update on the initiation of combination studies on these antibodies as well as the advancement of additional checkpoint modulator antibodies and vaccines into the clinic in the coming quarters We remind investors that Agenus  lead candidate and several backup antibodies were selected by Merck   Co   Inc    NYSE MRK   for an undisclosed checkpoint target  Under the terms of the agreement  Agenus is eligible to receive up to  100 million in milestone payments  in addition to royalties on worldwide product sales 
In January this year  Agenus entered into a clinical trial collaboration with the National Cancer Institute  NCI  to evaluate Prophage  HSPPC 96   in conjunction with Merck s PD 1 therapy  Keytruda  A phase II study will evaluate the effect of Prophage  in conjunction with Keytruda  on the overall survival rate of patients with newly diagnosed glioblastoma  ndGBM  Surprise History
Agenus  track record has been disappointing so far  The company has surpassed estimates in only once in the trailing four quarters and missed the same in all the other occasions  bringing the average negative surprise to 9 02  
Earnings WhispersOur proven model does not conclusively show that Agenus is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  Unfortunately  this is not the case here as you will see below Zacks ESP  The Earnings ESP for Agenus is 0 00  since the Most Accurate estimate stands in line with the Zacks Consensus Estimate of a loss of 33 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Agenus currently carries a Zacks Rank  3  which when combined with a 0 00  ESP  makes surprise prediction difficult   Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Agenus Inc  Price and EPS Surprise
    Stocks That Warrants a Look
Here are some health care stocks that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter  You can see  
Pacira Pharmaceuticals  Inc    NASDAQ PCRX   has an Earnings ESP of  20  and a Zacks Rank  2  The company is scheduled to release results on Mar 1 
Syndax Pharmaceuticals  Inc    NASDAQ SNDX   has an Earnings ESP of  18 18  and a Zacks Rank  3  The company is scheduled to release results on Mar 2 
A Full Blown Technological Breakthrough in the Making
Zacks  Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report  Driverless Cars  Your Roadmap to Mega Profits Today  In addition to who will be selling them and how the auto industry will be impacted  Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon ",2017-02-27,Zacks Investment Research,https://www.investing.com/analysis/agenus-(agen):-what's-ahead-for-the-stock-in-q4-earnings-200177123,200177123
203944,425460,MRK,Kite Pharma Begins Filing For KTE C19  Presents Data At ASH,opinion,"Kite Pharma  Inc    NASDAQ KITE   announced it has initiated a rolling submission of the Biologic License Application  BLA  for its lead pipeline candidate  KTE C19  to the FDA We note that KTE C19 is the company s anti CD19 chimeric antigen receptor  CAR  T cell therapy Kite Pharma s shares rose 11 1  in the past one month comparing favorably with an increase of 3  for the Zacks classified Biomet Genetic industry   A rolling submission will allow Kite Pharma to submit portions of the regulatory application to the FDA as and when they are completed The BLA is for the treatment for patients with relapsed refractory aggressive B cell non Hodgkin lymphoma  NHL  who are ineligible for autologous stem cell transplant  ASCT  The rolling submission is expected to be completed by the end of the first quarter of 2017  KTE C19  which has been given the brand name axicabtagene ciloleucel  is expected to be launched in 2017 if approved  The regulatory filings for axicabtagene ciloleucel in Europe will be done in 2017 The rolling submission was based on the phase I II study   ZUMA 1   of axicabtagene ciloleucel in patients with refractory diffuse large B cell lymphoma  DLBCL  including primary mediastinal B cell lymphoma  PMBCL  and transformed follicular lymphoma  TFL   All these are types of aggressive NHL  Kite Pharma is looking for a broader label for aggressive NHL including DLBCL  TFL and PMBCL indications In Sep 2016  the company announced encouraging top line results from the phase II part of the ZUMA 1 study  Moreover  the primary analysis of 92 patients with chemorefractory aggressive NHL  DLBCL  TFL and PMBCL   which will include about six months of follow up data  is anticipated in the first quarter of 2017 Kite Pharma is also evaluating KTE C19 in a phase II study  ZUMA 2  in patients with relapsed refractory mantle cell lymphoma  MCL  and in two additional pivotal studies  phase I II  for acute lymphoblastic leukemia  ALL   These studies are ZUMA 3 for adult ALL and ZUMA 4 for pediatric ALL In a separate press release  Kite Pharma announced that it has presented preliminary results from the phase I portion of the ZUMA 3 and ZUMA 4 studies at the annual meeting of the American Society of Hematology  ASH   Data from the studies showed that 82   9 out of 11  of patients enrolled in the studies achieved complete remission  Phase II portions of these studies are expected to be initiated next year Kite Pharma plans to move KTE C19 into a second series of studies for additional indications and earlier lines of therapy in DLBCL patients in 2017  A phase Ib II combination study  ZUMA 6  evaluating KTE C19 plus Genentech s Tecentriq  atezolizumab  in patients with chemorefractory DLBCL commenced in October Note that Kite Pharma inked a collaboration with Genentech  a member of the Roche Holding  SIX ROG  AG   OTC RHHBY   this March  with an aim to evaluate the safety and efficacy of the combination therapy KITE PHARMA INC Price and Consensus
    We note that the development of CAR T cell therapies has been attracting a lot of attention lately with several companies eyeing this field  Juno Therapeutics Inc    NASDAQ JUNO   is also working on developing therapies utilizing the CAR T cell technology  In fact  interest in immunotherapy is building up fast 
The basic concept of cancer immunotherapy or immuno oncology is to utilize certain parts of the immune system to fight the disease  This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body Merck   Co   Inc  s   NYSE MRK   anti PD 1 therapy  Keytruda  is being studied for more than 30 types of cancers  Amgen s Blincyto  a BiTE antibody  gained earlier than expected FDA approval in Dec 2014  Blincyto has the potential to be developed for other hematologic malignancies as well Kite carries a Zacks Rank  3  Hold   You can see  The Best Place to Start Your Stock Search Today  you are invited to download the full list of 220 Zacks Rank  1   Strong Buy   stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5   Strong Sells   and other private research ",2016-12-04,Zacks Investment Research,"https://www.investing.com/analysis/kite-pharma-begins-filing-for-kte-c19,-presents-data-at-ash-200168223",200168223
203945,425461,MRK,VBI Vaccines Has A Proven Solution To A Problem,opinion,"I spend a fair bit of time looking at smaller biotech companies that are working towards providing better treatments for existing diseases 
These companies offer a lot of potential but they also carry a very high level of risk  It is as they say the nature of the beast 
I suppose this is why I find VBI Vaccines Inc  NASDAQ VBIV  so intriguing  The company has the same potential that this sector typically offers but it comes with a lot less risk  I ll explain why in a moment 
VBI is looking to provide a solution for a specific group of patients that are currently not suitable for Hepatitis B vaccination  A  1 billion opportunity 

Source of image  VBI Vaccines Presentation
Hepatitis B is nasty business  The key facts about Hepatitis B according to the World Health Organization are as follows 
  Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease 
  The virus is transmitted through contact with the blood or other body fluids of an infected person 
  An estimated 240 million people are chronically infected with hepatitis B  defined as hepatitis B surface antigen positive for at least 6 months  
  More than 686 000 people die every year due to complications of hepatitis B  including cirrhosis and liver cancer 1 
  Hepatitis B is an important occupational hazard for health workers 
  Hepatitis B is a potentially life threatening liver infection caused by the hepatitis B virus  It is a major global health problem  It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer 
In North American and Europe GlaxoSmithKline s  NYSE GSK  GSK  Engerix B is the current standard of care for Hepatitis B vaccines  Engerix B works fine for young  healthy people 
It is not however suitable for people with liver conditions  diabetics and people over 40 with weaker immune systems 
For these people VBI Vaccines has a solution  I m not talking about a vaccine in development  I m talking about a vaccine  Sci B Vac  that has already been proven to be effective 
This is the lower level of risk that VBI presents which I mentioned earlier 
This point was  forward once again with VBI s press release concerning its Phase IV study on 88 seronegative people  without previous immunity to Hepatitis B   Of the 88 subjects in the study data revealed that 98 8  of participants were seroprotected at Month 3  two months after receiving a second dose of Sci B Vac  and prior to receiving a third dose 
These results should not come as a surprise  Sci B Vac has already been proven through more than 20 clinical trials and has been used by more than 4 500 patients  The vaccine is the standard of care in Israel and has been approved for use in 15 countries 
Therein lies my interest in VBI  A company that has already developed a solution and just needs to bring it to market  A much lower risk business proposition than a typical biotech which is offers potential but more uncertainty 
Bringing this vaccine to market is exactly why VBI Vaccines and SciVac Therapeutics merged earlier this year  SciVac had the vaccine and VBI provided the financial and corporate capability to bring that vaccine to the larger markets in the United States and Europe 
Other Products In The Pipeline
Sci B Vac is not VBI s only product under development  There are also a couple of others which offer potential but more risk   1   CMV  Cytomegalovirus  Vaccine
CMV is a very common virus that impacts one in every two people in many parts of the developing world  Most infections of CMV are  silent  which means that there are no symptoms or signs  You have it but you don t know 
VBI is developing a prophylactic vaccine to prevent cytomegalovirus  CMV  infection 
CMV isn t really a problem for most of us  Where it becomes a problem is when a mother is infected during pregnancy because it can result in serious consequences for the newborn  When this happens it is known as a congenital CMV infection 
5 000 U S  infants will develop permanent problems due to CMV every year on average  Some of these problems are quite severe  including deafness  blindness  and mental retardation 
CMV impacts more births than either Down Syndrome or Fetal Alcohol Syndrome  CMV is a key public health priority that needs a solution and would be a strong candidate for recommended universal vaccination among certain high risk populations 
There is no vaccine for prevention of CMV  VBI is closest in the race to develop one since it is a year to 18 months ahead of its nearest competitor vaccine which is being developed by Merck  NYSE MRK 
Should VBI successfully develop a fully tested and approved vaccine there is likely to be widespread public health support for it 
The market for this product is estimated to be  1 5 billion in the United States  based on number of births and  100 per vaccination  with a similar sized opportunity in developed markets outside the United States  That would give VBI the head start on a  3 billion market 
 2   Glioblastoma Immunotherapy
Glioblastoma is one of the most common and aggressive malignant primary brain tumors that a human can suffer from  In the United States alone  12 000 new cases of Glioblastoma are diagnosed each year 
The current standard of care for GBM is a surgery  followed by radiation and chemotherapy  Unfortunately even with this aggressive treatment  GBM progresses rapidly and is exceptionally lethal  The median patient survival is less than sixteen months 
VBI has applied its eVLP Platform to the development of a glioblastoma therapeutic vaccine candidate  With its unique approach  VBI is trying to create a GBM immunotherapy that will stimulate the patient s own immune system to identify and kill GBM cancer cells  The ultimate goal is to create a commercially viable therapy that is more effective and tolerable than current treatments 
Risks   While I definitely like the reduced amount of risk involved with the Sci B Vac vaccine this opportunity is not risk free  The nature of this industry is one where competition is fierce and changing quickly  Please keep that in mind when investing in these types of companies ",2016-12-06,Christopher Lourenco,https://www.investing.com/analysis/vbi-vaccines-has-a-proven-solution-to-a-problem-200168366,200168366
203960,425476,MRK,Here s Why Immune Design Should Be In Your Portfolio Now,opinion,On Nov 18  2016  we issued an updated report on Immune Design Corp    NASDAQ IMDZ   Immune Design posted a narrower than expected loss in the third quarter while its revenues beat estimates  The top line also improved year over year on the back of milestone payments received under Immune Design s collaboration with Sanofi   NYSE SNY   for the development and commercialization of products for the treatment of peanut allergy  The company reported third quarter results on Nov 9  2016 Immune Design s progress on its pipeline has been quite impressive  The company is currently developing several candidates in the field of immuno oncology using its ZVex and GLAAS platforms  The key products under development include CMB305 and G100  CMB305 is being evaluated for the treatment of soft tissue sarcoma while G100 is being developed for the treatment of Merkel cell carcinoma  MCC  and follicular non Hodgkin s lymphoma  NHL   The comany has a collaboration with Merck  NYSE MRK  for evaluating G100 in combination with the latter s anti PD 1 agent  Keytruda  for the treatment of NHL  Although Immune Design primarily focuses on the development of cancer immunotherapies  it is also making efforts to develop treatments for non oncology diseases Moreover  the company has entered into strategic agreements with other big players like Roche Holding  SIX ROG  AG   OTC RHHBY   and AstraZeneca PLC   NYSE AZN    which not only validate its GLAAS platform  but also provide the company with funds in the form of collaboration and license revenues However  Immune Design is highly dependent on its collaboration partners for its revenues  Since  its revenues mainly comprise fees from collaboration and licensing agreements  excessive dependence on other companies for revenue growth increases its vulnerability  Moreover  the company has been seeing an increase in expenses due to the ongoing R D programs Also  most Immune Design s pipeline candidates are in the early stages of development and consequently several years away from commercialization IMMUNE DESIGN Price    Zacks RankImmune Design currently carries a Zacks Rank  2  Buy   You can see  Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ,2016-11-21,Zacks Investment Research,https://www.investing.com/analysis/here's-why-immune-design-should-be-in-your-portfolio-now-200165835,200165835
203961,425477,MRK,Merck s New Drugs  Cost Management To Fuel Growth In 2017,opinion,On Nov 24  we issued an updated report on Merck   Co   Inc    NYSE MRK   On Oct 25  Merck reported results for the third quarter of 2016  wherein both earnings and revenues beat estimates  The top line also improved year over year on the back of additional sales in Japan which was driven by the timing of shipments before the implementation of a resource planning system in the following quarter  Higher than expected sales of Gardasil and delayed entry of Cubicin generics in the quarter also added to sales  Importantly  the leading drug maker Merck raised both its sales and earnings outlook for the year Merck is striving to bring new products to market  New products  especially Keytruda  is expected to contribute to the top line  The latest FDA approval of Keytruda for the first line treatment of metastatic lung cancer should drive the drug s sales  Keytruda is the first anti PD 1 therapy to gain FDA approval and is being studied for more than 30 types of cancer Moreover  Merck s progress on its pipeline has been quite impressive  The company has an impressive number of late stage candidates targeting multiple disease areas such as atherosclerosis  cancer  diabetes and cardiovascular diseases  It has more than 10 candidates in phase III development alone  A few important ones among them are MK 0859  anacetrapib   cholesterol management   verubecestat  Alzheimer s disease   MK 8228  letermovir   cytomegalovirus infections  and MK 8835  ertugliflozin   type II diabetes  Merck is also focused on controlling its costs  The company generated net cost savings of more than  2 5 billion in 2015 primarily by reducing marketing and administrative and R D expenses A global restructuring program is in place which is aimed at reducing the cost structure and increasing efficiency  It intends to reduce the number of manufacturing sites  including animal health sites  and consolidate other facilities  The company expects annual savings of about  4 0  4 6 billion once the restructuring program is complete On the flip side  generic competition and pricing pressure continue to dampen the top line  Nasonex and Cubicin lost patent exclusivity in 2016  Meanwhile  key drug  Remicade continues to be affected by biosimilar competition with biosimilars benefiting from increased new patient starts as well as patient switching  Remicade sales are expected to continue due to competitive pressures and also increased switching In addition to the impact of genericization of several products  Isentress is being hit by stiff competition and sluggish growth of the integrase class MERCK   CO INC Price    Zacks Rank   Key PicksMerck currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Cambrex Corporation   NYSE CBM    Heska Corporation   NASDAQ HSKA   and Vanda Pharmaceuticals  Inc    NASDAQ VNDA    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  Cambrex s earnings estimates increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19 78   Its share price has increased 5 8  year to date Heska s earnings estimates have increased from  1 13 to  1 35 for 2016 and from  1 38 to  1 53 for 2017 over the last 60 days  The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301 64   Its share price has surged 71 9  year to date Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016  while its earnings estimates have increased from 16 cents to 17 cents for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56 65   Its share price has surged 86 4  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-24,Zacks Investment Research,"https://www.investing.com/analysis/merck's-new-drugs,-cost-management-to-fuel-growth-in-2017-200166652",200166652
203975,425491,MRK,Immune Design  IMDZ  Posts Lower than Expected Q3 Loss ,opinion,"Immune Design Corp    NASDAQ IMDZ   reported third quarter 2016 loss of 60 cents per share  narrower than Zacks Consensus Estimate of 71 cents but significantly wider than the year ago loss of 37 cents  The company s shares gained 22 2  following its third quarter earnings release 

Immune Design s total revenue was  8 2 million  up 76 4  year over year primarily due to a  7 million milestone related to a collaboration with Sanofi   NYSE SNY   to develop and commercialize products for the treatment of peanut allergy  The top line also benefitted from product sales   0 4 million  of glucopyranosyl lipid A  a product from the company s GLAAS platform  to Sanofi and revenues   0 8 million  received under collaboration with Sanofi for the G103 HSV2 therapeutic vaccine Quarterly revenues were also above the Zacks Consensus Estimate of  1 5 million Quarter in DetailResearch and development  R D  expenses were up 35 2  to  11 2 million primarily due to the company s progress with the ongoing R D programs  including phase I and phase II studies General and administrative expenses increased 172 5  to  9 6 million due to the settlement and license agreements with Theravectys related to the acquisition  Oct 2016  of certain present and future intellectual property rights  and Theravectys  Jul 2014 litigation  along with related claims and counterclaims Pipeline UpdateThe company is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   for the treatment of various types of cancer  Key pipeline candidates include CMB305 and G100  CMB305 has been designed under a prime boost approach  involving the sequential dosing of two complementary agents   LV305  from the ZVex platform  and G305 Presently  CMB305 is being evaluated in soft tissue sarcoma  STS  patients both as monotherapy and in combination with an anti PD L1 antibody  While follow up continues in the two fully enrolled monotherapy phase I studies  the same is ongoing in a phase II study comparing CMB305 plus Tecentriq compared with Tecentriq alone A randomized phase II study in collaboration with Merck   Co   Inc    NYSE MRK   for the evaluation of the safety and efficacy of G100  with low dose local radiation and Keytruda  for the treatment of follicular non Hodgkin s lymphoma  NHL  is also currently underway Immune Design intends to submit data from these studies for presentation at American Society of Clinical Oncology in 2017 IMMUNE DESIGN Price  Consensus and EPS Surprise
 

   Zacks Rank   Key Picks
Immune Design currently carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Cambrex Corp    NYSE CBM    which sports a Zacks Rank  1  Strong Buy   You can see  
Cambrex s earnings estimates have increased from  2 46 to  2 60 for 2016 but remained unchanged for 2017 over the last 60 days  The company has posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19 78  
Zacks  Top Investment Ideas for Long Term Profit
How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-11,Zacks Investment Research,https://www.investing.com/analysis/immune-design-(imdz)-posts-lower-than-expected-q3-loss-200164201,200164201
203982,425498,MRK,Immune Design  IMDZ   Stock To Disappoint In Q3 Earnings ,opinion,Immune Design Corp   NASDAQ IMDZ   is scheduled to report third quarter 2016 results after the market closes on Nov 9 In the last reported quarter Immune Design posted a negative surprise of 4 41   The company reported a wider than expected loss in two of the four trailing quarters and a narrower than expected loss on the two other occasions  bringing the positive average surprise to 4   Let s see how things are shaping up for this announcement Factors in PlayBeing a development stage biopharmaceutical company  Immune Design has not generated any product revenue yet  The company earns revenues from collaboration and licensing agreements  the sale of products associated with material transfer and collaboration and supply agreements Investors are expected to focus on the company s progress with its pipeline  Immune Design is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   for the treatment of various types of cancers  Key pipeline candidates include CMB305  solid tumor  and G100  merkel cell carcinoma  CMB305 is currently undergoing an expansion study as a single agent in patients with cancers expressing the NY ESO 1 tumor antigen In addition  a randomized phase II study on CMB305  in combination with Roche Holding s   OTC RHHBY   investigational anti PD L1 therapy  tecentriq  in comparison with tecentriq alone  for locally advanced  relapsed or metastatic soft tissue sarcoma is currently underway Meanwhile  Immune Design is collaborating with Merck   Co   NYSE MRK  to evaluate G100 in combination with Merck s anti PD 1 agent Keytruda  for the treatment of patients with non Hodgkin s lymphoma The safety and efficacy of G100 in combination with low dose local radiation and Keytruda  in patients with follicular non Hodgkin s lymphoma  NHL  is being evaluated in a randomized phase II Study  Data are expected in 2017 Due to numerous ongoing trials  operating expenses are expected to remain high in the quarter  We expect the company to shed light on its progress with these trials during the third quarter call IMMUNE DESIGN Price and EPS Surprise   What Our Model IndicatesOur proven model does not conclusively show that Immune Design is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  This is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 71 cents Please check our  that enables you to find stocks that are expected to come out with earnings surprises Zacks Rank  Although Immune s Zacks Rank  3 increases the predictive power of ESP  its 0 00  ESP makes surprise prediction difficult Note that we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some healthcare companies that you may consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter Synergy Pharmaceuticals  Inc    NASDAQ SGYP   is expected to report results on Nov 14  The company has Earnings ESP of 18 18  and a Zacks Rank  3  You can see  AveXis Inc    NASDAQ AVXS    is scheduled to report results on Nov 10  The company has Earnings ESP of 11 43  and a Zacks Rank  2Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-07,Zacks Investment Research,https://www.investing.com/analysis/immune-design-(imdz):-stock-to-disappoint-in-q3-earnings-200163278,200163278
203983,425499,MRK,What s In Store For Merck KGaA  MKGAF  In Q3 Earnings ,opinion,"Merck  NYSE MRK  KGaA  is scheduled to report third quarter 2016 earnings results on Nov 15  Let s see how things are shaping up for this quarter The company reports results under three business sectors   Healthcare  Life Science and Performance Materials  Strong performance at Life Science  which was the catalyst behind sales growth in the last few quarters  should continue the growth trend in the to be reported quarter as well Sales at the Healthcare division are expected to be driven by products such as Erbitux  Gonal f  and Euthyrox  However  the segment will see a decline in Rebrif sales  which are being hit by negative foreign exchange fluctuations in Latin America The Life Science division has witnessed solid organic sales growth last quarter driven by strong organic growth and synergies  and the integration of the Sigma Aldrich business  This trend should continue in the third quarter as well Sales at Performance Materials are expected to be impacted by persisting destocking in the liquid crystals display industry  Moreover  we expect to see a dip in organic sales  However  the segment will benefit from the acquisition of Sigma Aldrich Hitech business In its last earnings release  the company had raised its guidance for 2016 backed by a strong performance in the first half of the year  Sales are now expected in the range of  14 9  15 1 billion  previous projection   14 8  15 billion   Sales are  however  expected to be hurt by foreign exchange impact of 3 5  due to continued devaluation of the Latin American currencies Moreover  at its 2016 Capital Market Day  the company provided an update on its objectives up to 2018   Beginning 2017  the company aims to gain approval of one medicine or new indication every year  Merck KGaA expects to generate sales of  4 billion from products that are currently in its pipeline by 2022 Merck KGaA  in collaboration with Pfizer Inc    NYSE PFE    is evaluating avelumab in several phase III studies for indications such as gastric cancer  platinum resistant refractory ovarian cancer  bladder cancer and advanced renal cell carcinoma  In Oct 2016  the company s Marketing Authorization Application  MAA  for avelumab for the treatment of metastatic Merkel cell carcinoma  MCC  has been validated by the European Medicines Agency  EMA   Investor focus should be on further updates from the company on the regulatory front MERCK KGAA Price
 

   Stocks that Warrant a LookHere are a couple of health care stocks that you may want to consider  as our model shows that they have the right combination of elements   a positive Zacks  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold    to post an earnings beat this quarter Tokai Pharmaceuticals  Inc    NASDAQ TKAI   has an Earnings ESP of is  18 42  and it carries a Zacks Rank  3 Synergy Pharmaceuticals  Inc    NASDAQ SGYP   has an Earnings ESP of  18 18  and a Zacks Rank  2  You can see  The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ",2016-11-10,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-merck-kgaa-(mkgaf)-in-q3-earnings-200164009,200164009
203993,425509,MRK,Stock Market News For October 25  2016,opinion,"A plethora of acquisitions helped the major indexes settle in the green on Monday  A heavy round of merger announcements included AT T s plan to buy HBO parent company  Time Warner  Strong quarterly earnings results from T Mobile US also lifted the broader markets  but  gains were subdued due to drop in oil prices and a stronger dollar 
	For a look at the issues currently facing the markets  make sure to read today s  article 
	The Dow Jones Industrial Average  DJI  gained 0 4  or 77 32 points  to close at 18 223 03  Early in the session  the blue chip index had been up by as many as 129 points  The S P 500 advanced 0 5  to close at 2 151 33  The benchmark index is around 2  below its all time high set on Aug 15  The tech laden Nasdaq Composite Index added 52 42 points  or 1   to finish at 5 309 83  after touching an intraday high of 5 311 50  
	The CBOE Volatility Index  VIX   widely considered the best gauge of fear in the market  declined 2 4  to settle at 13 02  A total of around 3 3 billion shares were traded on Monday on the NYSE  Advancers outpaced declining stocks on the NYSE  For 57  stocks that advanced  39  declined AT T to Acquire Time Warner
	U S  telecom behemoth AT T Inc  NYSE T      has agreed to acquire media giant Time Warner Inc  NYSE TWX      in an  85 4 billion cash and stock deal  Under the terms of the merger  Time Warner shareholders will receive  107 50 per share  comprising  53 75 in cash and  53 75 in AT T stock 
	AT T expects the deal will diversify its revenue mix  lower capital expenditure and reduce regulatory restrictions  The merger is subject to approval by Time Warner s shareholders and a review by the U S  Department of Justice  read more    
	Meantime  both the U S  presidential candidates have also expressed skepticism on the huge buyout  Lest we forget that such combination brings Time Warner full circle back to the first Dotcom bubble  when it created a merger with AOL  which failed miserably in achieving its goals and resulted in breakup Other Major Deals
	In another deal  Rockwell Collins Inc  NYSE COL      declared that it has entered into a definitive agreement with B E Aerospace Inc      under which the former will acquire the latter for around  6 4 billion in cash and stock  This deal will unite two of the biggest suppliers to airlines and plane makers  read more    
	TD Ameritrade Holding Corp     has also announced a deal to acquire Scottrade Financial Services  Inc  in a cash and stock transaction valued at  4 billion T Mobile Posts Upbeat Q3 Earnings
	While mergers boosted the broader markets  strong corporate results signaled that the trends of quarterly declines are coming to an end  T Mobile US Inc     reported third quarter earnings per share of 27 cents  above the Zacks Consensus Estimate of 22 cents  Revenues increased 17 8  year over year to  9 246 million in the third quarter  but  were slightly below the Zacks Consensus Estimate of  9 441 million  T Mobile US possess a Zacks Rank  3  Hold   You can see  
	A total of 116 S P 500 members have reported third quarter earnings results  Total earnings for these companies are up 3 3  from the same period last year on 1 8  higher revenues  with 80 2  beating EPS estimates and 62 9  coming ahead of revenue estimates  read more    Oil Declines  Stronger Dollar Limits Gains
	Fall in oil prices and a rising dollar  however  capped gains  The WTI crude oil declined 0 7  to close at  50 52 a barrel after Iran wanted to be exempted from an OPEC deal which would trim production levels 
	The U S  dollar  meanwhile  hovered near a nine month high against a basket of major currencies and touched a one week high against the yen on Monday  Dollar gained strength on growing expectations of an imminent Fed rate hike Stocks That Made Headlines
	Merck   Co   Inc     reported third quarter 2016 earnings of  1 07 per share  comfortably surpassing the Zacks Consensus Estimate of 98 cents    
	Under Armour  Inc     reported robust results in third quarter 2016  The company reported earnings per share of 29 cents  beating the Zacks Consensus Estimate of 25 cents    
	Visa Inc     posted fourth quarter fiscal 2016  ended Sep 30  adjusted net income of  1 9 billion or 78 cents per share    
	Sprint Corp     reported impressive financial results for the second quarter of fiscal 2016    
	Eli Lilly and Company s    third quarter results were below expectations with both earnings and sales missing the Zacks Consensus Estimate    
Confidential from Zacks
	This week  Zacks researchers have named 7 other stocks that look to break out even sooner than today s Bull of the Day  You can see these time sensitive tickers free  and access additional trades that are not available to the public ",2016-10-24,Zacks Investment Research,"https://www.investing.com/analysis/stock-market-news-for-october-25,-2016-200160558",200160558
203994,425510,MRK,Transgene  Collaborations  Rights Issue To Drive Growth ,opinion,"During Q316 Transgene  PA TRNG  announced a collaboration agreement with Pfizer  NYSE PFE  and Merck  NYSE MRK  to develop TG4001 in combination with avelumab in a Phase I II trial  the recruitment of the first patient in the multiple dose cohort of Phase I Ib of TG4001 in HBV patients and preclinical data from its vaccinia technology platform  The company plans to raise  48 1m  gross  through a rights issue that will fund operations to the end of 2018  Cash and equivalents at end Q316 amount to  25 4m  We value Transgene at  161 5m or  4 2 share 

Rights issue to fund strategy into first readouts
Transgene announced a rights issue for a planned gross amount of  48 1m  The subscription period will end on 4 November  The company will use funds to continue with its strategy of combining key pipeline assets with immune checkpoint inhibitors  In total  seven clinical trials are due to start before end 2017  with the first readouts expected in H217  With cash and equivalents of  25 4m at end Q316  the company guides FY16 cash burn at  35m 
To read the entire report Please click on the pdf File Below",2016-10-30,Edison,https://www.investing.com/analysis/transgene---business-update-and-q316-results-200161530,200161530
204004,425520,MRK,Roche s Tecentriq Wins FDA Nod For Additional Indication,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the FDA has approved its immuno oncology drug  Tecentriq  atezolizumab   for an additional indication  Tecentriq has been approved for the treatment of metastatic non small cell lung cancer  NSCLC  in patients whose disease has progressed during or following platinum containing chemotherapy  and have progressed on an appropriate FDA approved targeted therapy if their tumor has EGFR or ALK gene abnormalities With this approval  Tecentriq has become the first and only anti PDL1 cancer immunotherapy to be approved by the FDA for the treatment of metastatic NSCLC We note that Tecentriq gained accelerated approval in the U S  in May 2016 for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  whose disease has progressed during or following platinum based chemotherapy  or whose disease has worsened within 12 months of receiving platinum based chemotherapy before or after surgery Roche is currently evaluating Tecentriq in a confirmatory phase III study  IMvigor 211   in comparison to chemotherapy  in patients whose bladder cancer has progressed on at least one prior platinum containing regimen We are encouraged by the latest label expansion of Tecentriq  Per the American Cancer Society  more than 224 000 people are estimated to be diagnosed with lung cancer in 2016 in the U S   with NSCLC accounting for 85  of these cases  Further  it has been estimated that about 60  of lung cancer diagnoses in the U S  are made when the disease is in the most advanced stages ROCHE HLDG LTD Price    Initial uptake of the drug has been encouraging  A label expansion should boost the commercial potential of the drug significantly Meanwhile  Tecentriq is being studied in more than 15 studies in lung cancer  including seven phase III studies in previously untreated  first line  lung cancer  These studies are evaluating the use of Tecentriq alone or in combination with other treatments Tecentriq s recent approval will intensify competition in the lung cancer space  which is already crowded by Bristol Myers Squibb Company s   NYSE BMY   Opdivo and Merck   Co   Inc  s   NYSE MRK   Keytruda  both approved for the treatment of metastatic NSCLC Zacks Rank   a Key PickRoche currently carries a Zacks Rank  5  Strong Sell   A better ranked stock in the health care sector is Incyte Corporation   NASDAQ INCY    sporting a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates for 2016 and 2017 were up a respective 10  and 2 8  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/roche's-tecentriq-wins-fda-nod-for-additional-indication-200159474,200159474
204005,425521,MRK,Merck s Antiviral Medicine Meets Endpoint In Phase III,opinion,Merck   Co   Inc    NYSE MRK   announced that a phase III study on its antiviral pipeline candidate  letermovir met the primary endpoint Letermovir is being developed for the treatment of cytomegalovirus  CVM  infections The study assessed the safety and efficacy of letermovir in preventing clinically significant cytomegalovirus  CMV  infection in CMV seropositive adults who have undergone an allogeneic hematopoietic stem cell transplant  HSCT   The primary endpoint was the percentage of patients with clinically significant CMV infection through 24 weeks after transplant The patients enrolled in the study received letermovir once daily either in the form of an oral tablet or intravenously  The therapy was begun as early as the same day of the HSCT and no later than 28 days post transplant  It continued for about 100 days after the HSCT MERCK   CO INC Price    Merck bought worldwide rights to develop and commercialize letermovir from Germany based AiCuris GmbH   Co KG in 2012  Letermovir enjoys granted orphan designation in the EU as well as in the U S Merck has made significant progress with its pipeline and is working on bringing new products to the market  The company has prioritized its pipeline so that candidates with the highest potential get the required support  Merck presented positive data from two major studies of Keytruda in the first line treatment of patients with metastatic NSCLC at the ESMO 2016 Congress  the annual meeting of the European Society for Medical Oncology this month  Notably  Merck s new products are performing well Merck has also been pursuing acquisitions and business development deals to boost its pipeline  The company is also aiming to increase its presence in the emerging markets  To fulfill its objective  the company plans to launch new products  successfully market its current portfolio of drugs and vaccines  and leverage the market for branded generics Merck currently carries a Zacks Rank  2  Buy   Other favorably ranked stocks in the healthcare sector include Bioblast Pharma Ltd    NASDAQ ORPN    Geron Corporation   NASDAQ GERN   and Exelixis  Inc    NASDAQ EXEL    All the companies sport a Zacks Rank  1  Strong Buy  You can see the  Bioblast Pharma recorded an average positive surprise of 51 66  for the last four quarters  The loss estimates for 2016 and 2017 have narrowed down over the past 60 days Geron has an average positive surprise of 20 78  for the last four quarters Exelixis has an average positive surprise of 9 10  for the trailing four quarters  Its share price has surged more than 100  year to date Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-19,Zacks Investment Research,https://www.investing.com/analysis/merck's-antiviral-medicine-meets-endpoint-in-phase-iii-200159782,200159782
204009,425525,MRK,Merck KGaA Offers Portfolio Updates At Market Day Event ,opinion,"Germany based Merck  NYSE MRK  KGaA  provided an update on its objectives up to 2018 at the company s 2016 Capital Market Day At the Healthcare business  the company aims to obtain approval of one medicine or indication every year starting 2017  Through 2022  Merck expects to generate sales of  2 billion from the products in its pipeline Moreover  the company anticipates filling for avelumab for the treatment of metastatic Merkel cell carcinoma this year  Note that avelumab is being developed in collaboration with Pfizer Inc    NYSE PFE   The Life Science business segment is benefitting from strong demand in the biopharmaceutical space and efficient integration of the Sigma Aldrich acquisition  The company has realized substantial synergies from this buyout much earlier than planned  By 2016 end  it now expects to leverage  105 million in comparison to the originally planned annually recurring cost synergies of  90 million MERCK KGAA Price
    The company has also announced its plans for growth beyond 2018  It expects to generate sales of  4 billion from new products by 2022 Stocks to ConsiderA couple of favorably placed stocks in the health care sector are Incyte Corporation   NASDAQ INCY   and Geron Corporation   NASDAQ GERN    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates for 2016 and 2017 were up a respective 29 4  and 9 8  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  Geron has delivered a positive earnings surprise in each of four trailing quarters  bringing the average beat to 20 78  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaa-offers-portfolio-updates-at-market-day-event-200158851,200158851
204018,425534,MRK,BioLineRx Begins Trial On BL 8040  Keytruda Combination ,opinion,"BioLineRx  Ltd    NASDAQ BLRX   announced the initiation of a phase IIa trial on its lead oncology candidate  BL 8040  in combination with Merck   Co   Inc  s   NYSE MRK   lung cancer drug Keytruda  pembrolizumab   for the treatment of patients with metastatic pancreatic cancer BL 8040 is a short peptide that functions as a high affinity antagonist for CXCR4  a chemokine receptor directly involved in tumor progression  angiogenesis  metastasis and cell survival Phase IIa COMBAT is an open label  multicenter  single arm trial designed to evaluate the safety and efficacy of the combination of BL 8040 and Keytruda in up to 30 patients suffering from metastatic pancreatic adenocarcinoma  the most common type of pancreatic cancer The COMBAT study is also designed to assess the ability of the candidate in improving the infiltration of T cells into the tumor and their reactivity in patients suffering from pancreatic cancer The COMBAT study will be conducted in the U S   Israel and other countries According to the company s press release  in the U S   50 000 patients were diagnosed with pancreatic cancer in 2015  among which pancreatic adenocarcinoma accounted for about 85   This demonstrates the huge market potential for this combination therapy Earlier this month  BioLineRx inked a collaboration agreement with a global pharma company   Genentech  a subsidiary of Roche Holding  SIX ROG  AG   OTC RHHBY     for conducting several phase Ib studies on BL 8040  in combination with atezolizumab  in the treatment of multiple cancer indications BIOLINE RX LTD Price
    Zacks Rank   Key PicksBioLineRx currently carries a Zacks Rank  2  Buy   Another favorably placed stock in the health care sector is Acerus Pharmaceuticals Corporation   OTC TRLPF    which sports a Zacks Rank  1  Strong Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-20,Zacks Investment Research,https://www.investing.com/analysis/biolinerx-begins-trial-on-bl-8040--keytruda-combination-200154798,200154798
204037,425553,MRK,Juno Therapeutics Makes Revolutionary Breakthrough In Cancer Treatment,opinion,"It s about 7 30 Friday morning  and I m just back from a run  I chug a 16 ounce bottle of low fat Quik chocolate milk  because physiologists say it may boost post workout recovery  and it s yummy   As soon as I stop sweating  I ll change my shirt 
Then my wife and I will take our 14 year old daughter about 20 clicks around the Beltway  from our home in Alexandria to Falls Church  for a consultation with a hematologist oncologist 
It s an unsettling experience  hearing from your primary care physician that the results of a blood test indicate  something s off  with your child s blood count  In her case  both her white blood cells and platelets  blood clotting cells  are  mildly  moderately low  
That she s also showing a bit of a rash is actually a good thing  It s a sign that after a period of pretty intense fluctuations in her body temperature  it got as high as 103 8 F   her immune system is fighting back against a viral infection 
Aside from the fever  she s also complained of exhaustion and lethargy  and that her muscles feel weak  She has no appetite  My kid s a year round swimmer  a soccer player  and a newbie to cross country running  She s a worker who demands of herself  athletically and academically 
The test for mononucleosis was negative  Results for mycoplasma pneumonia are still pending  There are other uncertainties that prompted our doctor to refer us to the specialist 
She also advised against using Dr Google to try to narrow down the problem 
Too late 
After all  that s what I do  I m a researcher and a writer  And I m a father and a husband before those things 
It s more difficult to put the brakes on my natural curiosity when the matter becomes as personal as this 
The latest innovation in pediatric oncology has taken the cancer survival and cure rate from 10  in the 1950s to early 1960s to about 80  across all stages and disease categories 
Thankfully  we never go to this stage of the process  because our hematologist oncologist called with the good news that our daughter s blood test revealed that her white blood cell and platelet counts had returned to normal 
But based purely on numbers  kids like my daughter are usually diagnosed with acute lymphocytic leukemia  ALL   which accounts for 75  of pediatric leukemia cases 
 Acute  means it s a fast moving type of leukemia  as opposed to chronic 
 Lymphocytic  or  lymphoblastic  refers to a leukemia that starts in the lymphoid cells  which make different types of white blood cells 
Leukemia that starts in myeloid cells   which lead to red blood cells  platelets  or white blood cells known as granulocytes   is called  myeloid   or myelogenous myeloblastic  leukemia 
According to the Cancer Research Institute  several types of immunotherapy are in various stages of testing for leukemia treatment  These categories include adoptive cell therapy  monoclonal antibodies  therapeutic vaccines  adjuvant immunotherapies  cytokines  and checkpoint inhibitors 
Within the past 12 months  experimental tests of a particular type of checkpoint inhibitor have shown remarkable success   Juno Therapeutic  NASDAQ JUNO  T cell therapy 
In clinical trials at Seattle Children s Hospital  the Fred Hutchinson Cancer Research Center  and hospitals in Philadelphia  New York  and Memphis  the cancer goes away in 90  of patients with ALL that s returned and resists regular drugs 
The usual rate of remission under these circumstances is lower than 10  
The use of human T cells is the most radical approach among several that use the human body s immune system to fight cancer  According to Juno  it  has the potential to revolutionize the way cancer is treated  
Different checkpoint inhibitors developed by Merck  NYSE MRK  and Bristol Myers Squibb Company  NYSE BMY  have been used to treat skin and lung cancers 
Juno s approach to leukemia involves genetically engineering a patient s own T cells to recognize and attack cancer cells  Its first treatment is a chimeric antigen receptor T cell  or CART  known as JCAR015 
Such cell based therapies could be effective  regardless of the type of previous treatments patients have experienced  And they may have few side effects other than a strong fever 
Novartis AG  NYSE NVS  is developing a similar therapy to treat kids with ALL  while Kite Pharma  NASDAQ KITE  is working on one for patients with a type of non Hodgkin s lymphoma 
According to Roots Analysis and The Alliance for Regenerative Medicine  the oncology market for cell therapies is expected to reach  30 billion by 2030  and more than 600 therapies were in clinical trials at the end of 2015 
Juno  a  3 4 billion company that IPO d in December 2014  has a long way to go to get past the  proof of principle  phase  Tests of its T cell therapy so far have been small   with no control groups  no comparisons  but also no other explanation than T cells for why the cancer disappears   according to MIT Technology Review 
Juno s Phase II clinical trial of JCAR015 was placed on  clinical hold  by the U S  Food and Drug Administration  FDA  after two patient deaths in July 
 The fatalities occurred after the addition of chemotherapy drug fludarabine to the pre condition regimen   reports The Fly  Juno proposed to continue the trial using JCAR015 with a different chemotherapy drug  cyclophosphamide  in the pre conditioning step 
In early July  the company submitted a Complete Response to the Clinical Hold to the FDA  including a revised patient informed consent form  revised investigator brochure  and a revised trial protocol  and the  clinical hold  was removed on July 12 
During the company s second quarter conference call  CEO Hans Bishop said that due to the clinical hold  Juno has pushed back the anticipated approval of JCAR015 from 2017 to 2018 
Juno reported a second quarter revenue gain of 120  to  27 6 million  due in large part to a payment from partner Celgene Corp  NASDAQ CELG  as part of 10 year   1 billion deal announced in 2015  Celgene plans to commercialize Juno s cancer and autoimmune disease research 
But the company posted a second quarter loss of  64 6 million   0 64 per share   versus a  29 6 million loss  or  0 35 per share  a year ago 
Its research and development spend surged to  72 1 million  up from  23 9 million a year ago 
Juno shares took a big hit following the FDA s clinical hold in July  falling from north of  40 to around  27 
But the FDA also granted the JCAR015 therapy  breakthrough  designation  which means it could receive approval after just one large clinical trial  It s still on track for approval on an accelerated basis 
Juno s major potential economic advantage   commercializing personalized cellular treatments   is intact 
Get Smart
 This instantiation of Watson  dubbed Watson for Oncology  is an artificial intelligence system that has access to millions of pages of medical textbooks and journal articles  Oncologists at Memorial Sloan Kettering Cancer Center trained the system to provide appropriate treatment recommendations by giving it descriptions of patients and then telling Watson the correct treatment 
  It s  the same way we would train a young doctor by showing how our specialists would treat a certain cancer in a certain person   said Dr  Mark Kris  a Memorial Sloan Kettering lung cancer specialist who s leading the hospital s collaboration with IBM  
Smart Investing ",2016-08-23,Wall Street Daily,https://www.investing.com/analysis/juno-therapeutics-makes-revolutionary-breakthrough-in-cancer-treatment-200149474,200149474
204038,425554,MRK,Merck  The Beauty Of Locking In A Profit,opinion,"In this article dated April 7  2016  I wrote about a hypothetical option trading opportunity in Merck   Company Inc   NYSE MRK   The gist of the idea was to  risk a little  in hopes of making a lot   Unlike many option trades that focus on using short term options  this one used call options with over 6 months left until expiration   in order to give MRK a lot of time to stage some sort of move 
Well MRK moved and the time to  do something  appears to be at hand 
Figure 1 displays the initial trade and the initial risk reward outlook 
Figure 1  Courtesy  
Figure 2 displays the initial trade as of the close on 8 24  As you can see  MRK stock advanced from 55 63 to  62 73 and the option trade was sitting with an open profit of  743   89 8    
Figure 2  Courtesy 
The good news is that this trade has a nice percentage profit and retains further upside potential  The bad news is that the trade could easily turn back into a loser if MRK stock backs off from here  On 8 23 MRK failed to break out to the upside and the next day fell back hard 
So let s consider a simple adjustment to lock in a profit while still allowing for further upside potential 
The Adjustment
The truth is that there are an endless number of ways to adjust any option trade  The choice should be based on one s outlook going forward for the underlying security in question  In this case  I have no real opinion one way or the other regarding where MRK is heading next  But I do know that I do not want to see the current open profit vanish  and I am willing to give MRK the opportunity to move higher still  As a result  the adjustment below involves 
 Buying 1 Oct2016 MRK 50 strike price call
 Selling 4 Oct2016 MRK 50 strike price calls
 Buying 1 Apr2017 MRK 65 strike price call
This adjustment simply exits the original trade and buys a single long call option that can allow us to make more if MRK does in fact move higher between now and April 2017 expiration  240 days from now   The risk curves appear in Figure 3 
Figure 3  Courtesy 
Things To Note 
 This adjusted trade locks in a minimum profit of  523 if MRK is at  65 a share or below 240 days from now 
 The upside potential remains unlimited 
 If MRK rise 2 standard deviations  to roughly  83 a share  the profit can swell to  2 200 or more 
 If MRK collapses the worst case is still a locked in profit of  523 
Summary
One advantage to trading options is the ability to adjust your initial position in order to obtain a more favorable reward to risk ratio  Hopefully this MRK example makes that assertion a little easier to understand ",2016-08-25,Jay Kaeppel,https://www.investing.com/analysis/merck:-the-beauty-of-locking-in-a-profit-200150002,200150002
204049,425565,MRK,Healthcare Stocks  Aug 9 Earnings Roster  XON  PMC   More,opinion,"Medical is one of the 10 sectors in the S P 500 cohort that is expected to record growth in earnings in the second quarter  The sector is likely to post earnings growth of 4 4  on revenue improvement of 7 7    We note that 433 S P companies have already reported their quarterly numbers  with 70 7  of them beating EPS estimates and 52 7  surpassing the top line estimate As per the latest   overall second quarter earnings for the S P 500 companies are expected to be down 3 5  year over year on revenue decline of 0 4  Healthcare is an important component of the Medical sector and is expected follow the earnings growth trajectory in the quarter Here  we take a look at five healthcare stocks scheduled to report their quarterly figures on Aug 9 Based in Germantown  MD  Intrexon Corporation   NYSE XON   is a leader in the synthetic biology field  which applies engineering principles to biological systems  The company is set to report second quarter results  after the closing bell INTREXON CORP Price and EPS Surprise
   We believe that the company s core area   synthetic biology   holds considerable promise  Moreover  partnerships with the likes of Merck  NYSE MRK  KGaA and Fibrocell are likely to yield positive outcomes However  our proven model does not conclusively show that the company is likely to beat estimates  given the combination of a Zacks Rank  2  Buy  and  of 0 00   We note the Most Accurate estimate and Zacks Consensus Estimate for the company is pegged at a loss of 23 cents As per our proven model  a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2 or 3  Hold  to beat estimates  Simultaneously  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions PharMerica Corporation   NYSE PMC    an institutional pharmacy services provider  is dedicated toward providing quality service and innovative pharmacy solutions to institutional customers and patients in long term care settings  The company is slated to report second quarter numbers  before the opening bell PHARMERICA CORP Price and EPS Surprise
   We note that our proven model does not conclusively show that the company is likely to beat earnings  given the combination of a Zacks Rank  3 and Earnings ESP of 0 00  Notably  both the Most Accurate estimate and the Zacks Consensus Estimate stand at 47 cents We also note that PharMerica s results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 20 19  Surgery Partners Inc   NASDAQ SGRY   is a healthcare services company in the U S  The company s outpatient delivery model is focused on providing solutions for surgical and related ancillary care in support of patients and physicians SURGERY PARTNRS Price and EPS Surprise
   Notably  our model does not predict an earnings beat for the company  given the combination of a Zacks Rank  4  Sell  and Earnings ESP of  35 71   We note that the Most Accurate estimate for Surgery Partners stands at 9 cents while the Zacks Consensus Estimate is pegged at 14 cents Civitas Solutions Inc   NYSE CIVI   provides home and community based health services to individuals with intellectual  developmental  physical or behavioral disabilities and other special needs in the U S  The company is scheduled to report third quarter earnings  after market close We believe that the company is poised to benefit from its Human Services and Post Acute Specialty Rehabilitation Services CIVITAS SOLUTNS Price and EPS Surprise
   However  our model does not conclusively show that Civitas is likely to beat earnings  given the combination of a Zacks Rank  3 and Earnings ESP of 0 00   We note that the Most Accurate estimate and the Zacks Consensus Estimate for Civitas stand at 19 cents We also remind investors that Civitas  results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 1 85  Headquartered in Franklin  TN  Healthways Inc   NASDAQ HWAY   provides network delivered solutions and Population Health management services that focus on improving individuals  lifestyle  overall health and productivity  thereby helping them cut down on health related costs HEALTHWAYS INC Price and EPS Surprise
   We believe that Healthways  strong business model accompanied with the introduction of exclusive programs like  SilverSneakers  are significant growth factors  Moreover  solid customer base in both domestic and international markets is likely to drive growth However  our proven model does not conclusively show that the company is likely to beat earnings  given the combination of a Zacks Rank  2 and Earnings ESP of 0 00   We note that the both Most Accurate estimate and the Zacks Consensus Estimate for Healthways is pegged at a penny ",2016-08-07,Zacks Investment Research,"https://www.investing.com/analysis/healthcare-stocks'-aug-9-earnings-roster:-xon,-pmc---more-200146716",200146716
204050,425566,MRK,Merck   Co  Upgraded By Credit Suisse Group AG To  Outperform ,opinion,"Merck   Co   NYSE MRK  was upgraded by equities researchers at Credit Suisse Group AG from a  neutral  rating to an  outperform  rating in a research note issued to investors on Sunday  MarketBeat com reports  The firm currently has a  73 00 price target on the stock  up from their previous price target of  62 00 
Shares of Merck   Co   NYSE MRK  traded up 10 41  during trading on Friday  reaching  63 86  The company s stock had a trading volume of 72 875 999 shares  The company has a market cap of  176 77 billion and a PE ratio of 35 03  Merck   Co  has a 52 week low of  45 69 and a 52 week high of  64 00  The firm s 50 day moving average is  58 24 and its 200 day moving average is  54 69 
Merck   Co   NYSE MRK  last released its quarterly earnings data on Friday  July 29th  The company reported  0 93 earnings per share for the quarter  beating analysts  consensus estimates of  0 91 by  0 02  During the same quarter in the prior year  the firm posted  0 86 earnings per share  The business earned  9 84 billion during the quarter  compared to analysts  expectations of  9 79 billion  The firm s quarterly revenue was up  6  on a year over year basis  On average  equities research analysts predict that Merck   Co  will post  3 74 EPS for the current fiscal year 
The company also recently disclosed a quarterly dividend  which will be paid on Friday  October 7th  Stockholders of record on Thursday  September 15th will be given a dividend of  0 46 per share  The ex dividend date is Tuesday  September 13th  This represents a  1 84 annualized dividend and a dividend yield of 2 88  
Several other analysts also recently weighed in on the stock  BMO Capital Markets raised shares of Merck   Co  from a  market perform  rating to an  outperform  rating and upped their price objective for the company from  62 00 to  72 00 in a research note on Friday   reports  Jefferies Group upped their price objective on shares of Merck   Co  from  50 00 to  53 00 and gave the company a  hold  rating in a research note on Thursday  July 14th  Leerink Swann reaffirmed a  hold  rating and set a  58 00 price objective on shares of Merck   Co  in a research note on Thursday  July 14th  Vetr raised shares of Merck   Co  from a  sell  rating to a  buy  rating and set a  62 26 price objective for the company in a research note on Monday  July 4th  Finally  Argus reaffirmed a  buy  rating on shares of Merck   Co  in a research note on Thursday  June 9th  One research analyst has rated the stock with a sell rating  eleven have given a hold rating and eight have issued a buy rating to the stock  Merck   Co  has an average rating of  Hold  and an average price target of  61 82   68 69  
In related news  insider Weir Mirian M  Graddick sold 30 000 shares of Merck   Co  stock in a transaction dated Friday  July 1st  The shares were sold at an average price of  57 49   63 88   for a total transaction of  1 724 700 00   1 916 333 33   Following the completion of the transaction  the insider now directly owns 162 151 shares of the company s stock  valued at approximately  9 322 060 99   10 357 845 54   The transaction was disclosed in a filing with the SEC  which is available through   Also  EVP Clark Golestani sold 39 877 shares of Merck   Co  stock in a transaction dated Friday  May 20th  The stock was sold at an average price of  54 79   60 88   for a total transaction of  2 184 860 83   2 427 623 14   Following the transaction  the executive vice president now directly owns 17 083 shares of the company s stock  valued at  935 977 57   1 039 975 08   The disclosure for this sale can be found  
Several hedge funds and institutional investors have recently modified their holdings of the company  Americafirst Capital Management LLC bought a new stake in Merck   Co  during the second quarter valued at  115 000  NewSquare Capital LLC increased its stake in Merck   Co  by 14 2  in the second quarter  NewSquare Capital LLC now owns 2 104 shares of the company s stock valued at  121 000 after buying an additional 261 shares in the last quarter  First New York Securities LLC NY bought a new stake in Merck   Co  during the second quarter valued at  121 000  Lowe fs LLC increased its stake in Merck   Co  by 1 8  in the second quarter  Lowe fs LLC now owns 2 619 shares of the company s stock valued at  151 000 after buying an additional 46 shares in the last quarter  Finally  JNBA Financial Advisors increased its stake in Merck   Co  by 3 1  in the second quarter  JNBA Financial Advisors now owns 3 012 shares of the company s stock valued at  174 000 after buying an additional 91 shares in the last quarter 
Merck   Co  Inc is a global healthcare company  The Company offers health solutions through its prescription medicines  vaccines  biologic therapies and animal health products  which it markets directly and through its joint ventures  It operates through one segment  Pharmaceutical  The Company s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures ",2016-08-08,MarketBeat.com,"https://www.investing.com/analysis/merck---co.-(mrk)-upgraded-by-credit-suisse-group-ag-to-""outperform""-200146543",200146543
204051,425567,MRK,The Zacks Analyst Blog Highlights  Intrexon  PharMerica  Surgery Partners  Civitas Solutions And Healthways,opinion,"For Immediate Release

	Chicago  IL   August 09  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog Intrexon Corporation      PharMerica Corporation     Surgery Partners Inc     Civitas Solutions Inc      and Healthways Inc    

	Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Monday s Analyst Blog  

Healthcare Stocks Reporting Q2 Earnings on Tuesday

	Medical is one of the 10 sectors in the S P 500 cohort that is expected to record growth in earnings in the second quarter  The sector is likely to post earnings growth of 4 4  on revenue improvement of 7 7  

	We note that 433 S P companies have already reported their quarterly numbers  with 70 7  of them beating EPS estimates and 52 7  surpassing the top line estimate 
	As per the latest   overall second quarter earnings for the S P 500 companies are expected to be down 3 5  year over year on revenue decline of 0 4  
	Healthcare is an important component of the Medical sector and is expected follow the earnings growth trajectory in the quarter 
	Here  we take a look at five healthcare stocks scheduled to report their quarterly figures on Aug 9 
	Based in Germantown  MD  Intrexon Corporation    is a leader in the synthetic biology field  which applies engineering principles to biological systems  The company is set to report second quarter results  after the closing bell 

   

	We believe that the company s core area   synthetic biology   holds considerable promise  Moreover  partnerships with the likes of Merck  NYSE MRK  KGaA and Fibrocell are likely to yield positive outcomes 
	However  our proven model does not conclusively show that the company is likely to beat estimates  given the combination of a Zacks Rank  2  Buy  and  of 0 00   We note the Most Accurate estimate and Zacks Consensus Estimate for the company is pegged at a loss of 23 cents 
	As per our proven model  a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2 or 3  Hold  to beat estimates  Simultaneously  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions PharMerica Corporation     an institutional pharmacy services provider  is dedicated toward providing quality service and innovative pharmacy solutions to institutional customers and patients in long term care settings  The company is slated to report second quarter numbers  before the opening bell 

   

	We note that our proven model does not conclusively show that the company is likely to beat earnings  given the combination of a Zacks Rank  3 and Earnings ESP of 0 00  Notably  both the Most Accurate estimate and the Zacks Consensus Estimate stand at 47 cents 
	We also note that PharMerica s results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 20 19  Surgery Partners Inc    is a healthcare services company in the U S  The company s outpatient delivery model is focused on providing solutions for surgical and related ancillary care in support of patients and physicians 

   

	Notably  our model does not predict an earnings beat for the company  given the combination of a Zacks Rank  4  Sell  and Earnings ESP of  35 71   We note that the Most Accurate estimate for Surgery Partners stands at 9 cents while the Zacks Consensus Estimate is pegged at 14 cents Civitas Solutions Inc      provides home and community based health services to individuals with intellectual  developmental  physical or behavioral disabilities and other special needs in the U S  The company is scheduled to report third quarter earnings  after market close 
	We believe that the company is poised to benefit from its Human Services and Post Acute Specialty Rehabilitation Services 

   

	However  our model does not conclusively show that Civitas is likely to beat earnings  given the combination of a Zacks Rank  3 and Earnings ESP of 0 00   We note that the Most Accurate estimate and the Zacks Consensus Estimate for Civitas stand at 19 cents 
	We also remind investors that Civitas  results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 1 85  
	Headquartered in Franklin  TN  Healthways Inc     provides network delivered solutions and Population Health management services that focus on improving individuals  lifestyle  overall health and productivity  thereby helping them cut down on health related costs 

   

	We believe that Healthways  strong business model accompanied with the introduction of exclusive programs like  SilverSneakers  are significant growth factors  Moreover  solid customer base in both domestic and international markets is likely to drive growth 
	However  our proven model does not conclusively show that the company is likely to beat earnings  given the combination of a Zacks Rank  2 and Earnings ESP of 0 00   We note that the both Most Accurate estimate and the Zacks Consensus Estimate for Healthways is pegged at a penny 

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

	Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-08-08,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-intrexon,-pharmerica,-surgery-partners,-civitas-solutions-and-healthways-200146972",200146972
204052,425568,MRK,Immune Design  IMDZ  Posts Wider than Expected Q2 Loss,opinion,"Immune Design Corp    NASDAQ IMDZ   reported a second quarter 2016 loss of 71 cents per share  wider than both the Zacks Consensus Estimate of 68 cents and the year ago loss of 54 cents 

Quarter in Detail
Immune Design s total revenue was  1 1 million  down from  1 8 million in the year ago quarter but above the Zacks Consensus Estimate of  1 million  The top line included collaboration revenues from Sanofi   NYSE SNY   related to the development of G103 
Research and development  R D  expenses shot up 34 2  to  11 4 million primarily due to expenditure related to the advancement of the CMB305 and LV305 programs to phase I and phase II clinical trials  and the development of G103  General and administrative expenses were also up 4 5  to  3 9 million IMMUNE DESIGN Price  Consensus and EPS Surprise
   Pipeline Update
The company is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   for the treatment of various types of cancer  Key pipeline candidates include CMB305 and G100  CMB305 has been designed under a prime boost approach  involving the sequential dosing of two complementary agents   LV305  from the ZVex platform  and G305 
A randomized phase II trial on CMB305  in combination with Tecentriq compared to Tecentriq alone  for locally advanced  relapsed or metastatic soft tissue sarcoma  STS  is currently underway  An independent data monitoring committee reviewed safety data from part 1 of the study and advised the company to proceed to part 2  in which patients are being actively enrolled   Early data from a single agent phase I study in 14 patients with STS showed positive results 
Meanwhile  Immune Design is collaborating with Merck   Co  Inc    NYSE MRK   to evaluate G100 and LV305  in combination with Merck s Keytruda  in phase I studies for the treatment of patients with non Hodgkin s lymphoma  NHL  and melanoma  respectively  We remind investors that the company has completed a phase I study on G100 in patients with merkel cell carcinoma  The company presented positive final data from this study in Jun 2016 
The company has also initiated a randomized phase II study evaluating the safety and efficacy of G100 with low dose local radiation  and Keytruda  in patients with follicular NHL  Enrollment is ongoing  Part 1 of the study  dose escalation of G100 with a fixed dose of low dose radiation without Keytruda   is complete and has been deemed safe by an independent data monitoring committee  Part 2  in which patients are currently being randomized to receive G100 and radiation alone or in combination with Keytruda  is in process  Data are expected in 2017 
Going forward  we expect investor focus to remain on further pipeline updates by the company 
Immune Design carries a Zacks Rank  4  Sell   A better ranked stock in the health care sector is Pacira Pharmaceuticals   NASDAQ PCRX    with a Zacks Rank  1  Strong Buy  ",2016-08-10,Zacks Investment Research,https://www.investing.com/analysis/immune-design-(imdz)-posts-wider-than-expected-q2-loss-200147275,200147275
204053,425569,MRK,Intrexon  XON  Reports Wider Loss In Q2  Revenues Increase,opinion,"Intrexon Corporation   NYSE XON   reported a loss of 42 cents per share in second quarter 2016  compared to the year ago figure of 37 cents  Excluding unrealized and realized appreciation  depreciation  in fair value of equity securities  loss came in at 22 cents compared to the prior year tally of 18 cents Total revenue came in at  52 5 million in the quarter  up 17  year over year  Reported revenues were  however  below the Zacks Consensus Estimate of  55 5 million Quarter in DetailIntrexon s revenues primarily consist of collaboration and licensing revenues as well as product revenues and service revenues Collaboration and licensing revenues surged 59 9  to  27 5 million  The increase was primarily attributable to the recognition of deferred revenue from upfront payments received under the May 2015 license and collaboration agreement with Merck  NYSE MRK  KGaA  and from other collaborations signed by Intrexon between Jul 1  2015 and Jun 30  2016 
The upside was also due to increased research and development  R D  services for these collaborations  and the company s progress on existing programs and addition of new ones with existing collaborators Product revenues came in at  10 9 million  down 23 7  from the year ago period  primarily due to a decline in the quantity of livestock previously used in production and live calves sold due to lower demand from customers for these products Service revenues came in at  13 9 million  up 5 1  year over year  primarily due to an increase in the number of in vitro fertilization cycles performed on higher demand R D expenses increased 39 2  to  28 4 million while selling  general and administrative expenses escalated 27 8  to  30 3 million due to an increase in salaries  benefits and other personnel costs Meanwhile  the company continued to enter into new exclusive channel collaborations  ECC  and expanded its existing partnerships  In the reported quarter  Intrexon announced amendments to its ECC with ZIOPHARM Oncology  Inc    NASDAQ ZIOP   in the fields of oncology and graft versus host disease  The move was aimed to improve the alignment between the companies as ZIOPHARM broadens its pipeline and advances multiple therapeutic programs into the clinic Under the partnership with ZIOPHARM  a phase I study on autologous T cells transduced  along with lentivirus  will be initiated to express a CD33 specific chimeric antigen receptor  CAR  in patients with relapsed or refractory acute myeloid leukemia Intrexon is also developing several candidates in partnership with other companies Meanwhile  the company is currently working with both governmental and non governmental organizations for the potential use of Oxitec s OX513A to reduce or eradicate populations of the Aedes aegypti mosquito  the primary vector for dengue  chikungunya and the Zika virus The FDA published final findings of a no significant impact and final environmental assessment on Oxitec s OX513A self limiting mosquito  concluding that a field study of the Friendly Aedes will not result in a significant impact on the environment INTREXON CORP Price
   We expect investor focus to remain on further updates by the company Intrexon is a Zacks Rank  2  Buy  stock  ANI Pharmaceuticals  Inc    NASDAQ ANIP   is another favorably placed stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-10,Zacks Investment Research,"https://www.investing.com/analysis/intrexon-(xon)-reports-wider-loss-in-q2,-revenues-increase-200147268",200147268
204058,425574,MRK,Is Merck Postponing Its Bright Future  ,opinion,"Merck  NYSE MRK  is the seventh largest pharmaceutical company in the world by revenue and market capitalization  It is a DJIA component as well as an S P 500 component 
However  despite its size and significance  its stock price also suffered severely during the last two major stock market crashes of our time   the crash in 2000 and the Great Recession of 2007 2009 
Merck is currently trading slightly below 59 dollars a share  recovering from as low as 20 05 in March  2009  So is this a good time to add Merck to your portfolio  The chart below shows what lies ahead for the stock  according to the  
Merck stock reached an all time high of 96 69 dollars a share in November  2009  What is more important is the fact that this uptrend  which started somewhere in the 1980s  has a very clear  structure  marked with I II III IV V  The theory states that every impulse is followed by a three wave correction in the opposite direction  As visible  this is true  even if we talk about such multi year long trends and patterns 
Wave  II  is a W X Y double zig zag  which takes over eight years to complete  Nevertheless  once a correction is over  the larger trend resumes  It turns out the recovery from 20 05 in 2009 is the start of Merck s wave  III   which usually is the most powerful phase of the trend  The problem is that wave  III  has its own wave structure as well 
In our opinion  the rally we saw in the last seven years is only wave I of  III   Once wave  5  of I of  III  is over  wave I would be a smaller version of wave  I   so the same consequences should follow   a three wave decline in wave II  before the bulls could return in wave III of  III  to take Merck stock to new heights 
If this is the correct count  Merck   Co stock should exceed the top of wave  3  of I at 63 60 and probably approach the 70 dollar mark  However  now does not seem to be right time to be long term bullish  because a major bearish reversal is very likely to occur next  Overall  future looks bright for Merck investors  The next 3 to 5 years  however  do not ",2016-08-02,EWM Interactive,https://www.investing.com/analysis/merck-postponing-its-bright-future-200145610,200145610
204059,425575,MRK,Merck KGaA  MKGAF  Q2 Earnings Fall But View Raised,opinion,Merck  NYSE MRK  KGaA  is a science and technology company specializing in the fields of healthcare  life science and performance materials  The company s portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools  specialty chemicals and high tech materials The company is focused on oncology  multiple sclerosis  infertility  growth disorders  selected cardiovascular and metabolic diseases  women s and children s health  cough and cold as well as everyday health protection The company reports its results in three business sectors   Healthcare  Life Science and Performance Materials The acquisition of Sigma Aldrich led the company to gain access to an attractive set of established brands along with an efficient supply chain to support the delivery of over 300 000 products  thereby enabling it to serve life science customers all over the world The company s lead candidate  avelumab  is being evaluated in phase III studies for several cancer indications  in collaboration with Pfizer  NYSE PFE  We have highlighted some of the key stats from this just revealed announcement below Earnings  The company s second quarter 2016 earnings per American Depositary Receipt  ADR  came in at 80 cents  compared to the year ago figure of 90 cents Revenue  The company posted revenues of  4 3 billion in the reported quarter Key Stats  All three business units continued to perform well  Organic sales growth increased 5 1   driven by Life Science and Healthcare segments  The acquisition of Sigma Aldrich boosted sales in the reported quarter Guidance  For 2016  the company expects net sales in the range of  14 9  15 1 billion  Backed by Sigma Aldrich acquisition  the company expects a positive portfolio effect on sales in the low double digit percentage range  Unfavorable foreign exchange is projected to impact sales by 3 5  MERCK KGAA Price   Check back later for our full write up on earnings report later ,2016-08-04,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaa-(mkgaf)-q2-earnings-fall-but-view-raised-200145983,200145983
204060,425576,MRK,Immune Design  IMDZ   Stock To Disappoint On Q2 Earnings ,opinion,"Immune Design Corp    NASDAQ IMDZ   is scheduled to report second quarter 2016 results after the market closes on Aug 9 
Immune Design has a mixed track record so far  The company reported a wider than expected loss in two of the four trailing quarters and a narrower than expected loss on the two other occasions  with a positive average earnings surprise of 2 5   Let s see how things are shaping up for this announcement 
Factors in Play
Being a development stage biopharmaceutical company  Immune Design has not generated any product revenues yet  The company earns revenues from collaboration and licensing agreements  and the sale of products associated with material transfer  collaboration and supply agreements 
Investors are expected to focus on the company s progress on its pipeline  The company is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   for the treatment of various types of cancer  Key pipeline candidates include CMB305 and G100  CMB305 has been designed under a prime boost approach  involving the sequential dosing of two complementary agents   LV305  from the ZVex platform  and G305 
CMB305 is currently undergoing an expansion study as a single agent in patients with cancers expressing the NY ESO 1 tumor antigen  The completed dose escalation study on CMB305 showed a favorable safety profile  and a positive signal in progression free survival  PFS  related endpoints have been observed 
In addition  a randomized phase II study on CMB305  in combination with Roche Holding s   OTC RHHBY   investigational anti PD L1 therapy  atezolizumab  in comparison with atezolizumab alone  for locally advanced  relapsed or metastatic soft tissue sarcoma is currently underway  Data are expected in the fourth quarter of 2016 
Meanwhile  another candidate  G100  developed using the GLAAS platform  has completed enrolment in a phase I study in patients with merkel cell carcinoma in combination with radiation  Results from the study showed a 50  overall response rate including a pathologic complete response  CR  following single agent G100 alone 
Immune Design is collaborating with Merck   Co    NYSE MRK   to evaluate G100 in combination with Merck s anti PD 1 agent Keytruda  for the treatment of patients with non Hodgkin s lymphoma  A randomized phase Ib II study in patients with follicular non Hodgkin lymphoma in combination with Keytruda is ongoing and results from the study are expected by the first half of 2017 
Due to numerous ongoing trials  operating expenses are expected to remain high in the quarter  We expect the company to shed light on its progress with these trials during the second quarter call IMMUNE DESIGN Price and EPS Surprise
   What Our Model Indicates
Our proven model does not conclusively show that Immune is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  This is not the case here  as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 68 cents 
Zacks Rank   Immune Design currently carries a Zacks Rank  4  Sell    As it is  we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement 
Stock That Warrants a Look
Here is a company you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter 
Impax Laboratories   NASDAQ IPXL   has an Earnings ESP of  3 03  and a Zacks Rank  2  The company is scheduled to report results on Aug 9 ",2016-08-04,Zacks Investment Research,https://www.investing.com/analysis/immune-design-(imdz):-stock-to-disappoint-on-q2-earnings-200146198,200146198
204061,425577,MRK,Upbeat July Jobs Report,opinion,"The Bureau of Labor Statistics  BLS  July non farm payroll report was released this morning to a plurality of sighs of relief   following the manic past 2 months in BLS jobs reads  analysts were a tad reticent to predict big jobs numbers  255K new jobs were added last month  and the unemployment rate stayed at 4 9  
	We also saw positive revisions to the past 2 months  May s paltry 11K jobs was more than doubled to 24K  and even June s robust 287K rose another 5000 jobs to 292K  Private sector employment totaled 217K  and the government added 38K jobs in July 
	The biggest gainers were Professional Business Services at 70K  Leisure and Hospitality reached 45K and Health Services had 43K  The biggest loser in July s labor market was Mining at  6000 jobs 
	Average hourly pay rose 0 3   The labor force participation rate was also up  to 62 8   The broader measure of unemployment and underemployment  the U6  fell even farther below 10  to 9 7   Over the past year  average monthly job growth increased to 206K 
	When your economy produces more than 200 000 jobs per month on average  it s tough to find fault with your labor market  This is what Wednesday s ADP  report of 169K jobs and this morning s BLS numbers more emphatically have stated  Market futures  which were up modestly ahead of the payroll report  have more than doubled since its release ahead of the bell today 
	Part of the reason the Dow swelled from  37 points to  90  by the way  was due to Merck  NYSE MRK   jumping 11  on news that rival Bristol Myers Squibb s  latest cancer treatment failed a late stage study  BMY shares have fallen 17   but it is not a Dow component ",2016-08-04,Zacks Investment Research,https://www.investing.com/analysis/upbeat-july-jobs-report-200146333,200146333
204062,425578,MRK,Shares Of Bristol Myers Falling After Failed Study  While Its Rival Is Surging,opinion,"Shares of Bristol Myers Squibb   NYSE BMY   fell more than 17  in morning trade Friday after its cancer drug failed to meet targets in a late stage study 
The company released few details of the study  called Checkmate 026  but it said that it had not met its primary endpoint of improvement in progression free survival  The drug it was testing  Opdivo  has already been approved to treat some types of cancer  but the company was trying to see if it would be successful in treating advanced non small cell lung cancer 
Company CEO Giovanni Caforio said in a release that he was  disappointed  with the result with the result but management remains  committed to improving patient outcomes through our comprehensive development program  
While BMY was falling  shares of its biggest rival Merck   NYSE MRK   jumped more than 10  at one point  as their drug Keytruda that competes with Opdivo succeeded in a similar trial recently  It should be noted though  Merck played it a bit safer in the patient population it chose  targeting  high expressors  of the PD L1 ligand  which both Keytruda and Opdivo target through inhibition of the PD 1 protein in cancer cells  Bristol Meyers went for a broader patient population  potentially winning in a bigger market but increasing its risk for failure 
With the opening decrease of 17   Bristol Meyers lost about  21 billion in market cap  Year to date shares of the company are more than 8  lower  BMY currently has a Zacks Rank  3  Hold   MRK is currently also a Zacks Rank  3  Hold   but shares of the company are up more than 16  so far this year ",2016-08-05,Zacks Investment Research,"https://www.investing.com/analysis/shares-of-bristol-myers-falling-after-failed-study,-while-its-rival-is-surging-200146455",200146455
204071,425587,MRK,Agenus  AGEN  Reports Narrower than Expected Q2 Loss,opinion,Agenus Inc    NASDAQ AGEN   is a Lexington  MA based development stage company focused on the discovery and development of checkpoint modulators  vaccines and adjuvants for the treatment of cancer Agenus  revenues consist of fees earned under license agreements with its partners  With no approved products in its portfolio  investor focus should remain on the company s pipeline updates Agenus  track record has been disappointing so far  The company has missed estimates in all of the last four quarters  with an average surprise of  54 65  Currently  Agenus has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  Agenus reported narrower than expected loss in the second quarter of 2016  Our consensus called for a loss of 34 cents per share  while the company reported a loss of 24 cents Revenue  Revenues also surpassed expectations  Agenus posted revenues of  6 6 million  compared to our consensus estimate of  6 million Key Stats  Agenus  efforts for the development of its pipeline are pleasing  Agenus received a major boost when the FDA cleared its Investigational New Drug  IND  application for AGEN1884 and INCAGN01876  A phase I study on AGEN1884 and a phase I II study on INCAGN01876 has been initiated to treat solid tumors  The selection of Agenus  lead candidate as well as several backup antibodies by Merck  NYSE MRK  for an undisclosed checkpoint target led the company to receive a milestone payment of  2 million under the terms of the agreement AGENUS INC Price   Check back later for our full write up on earnings report later Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-27,Zacks Investment Research,https://www.investing.com/analysis/agenus-(agen)-reports-narrower-than-expected-q2-loss-200144783,200144783
204072,425588,MRK,Agenus  AGEN  Posts Narrower Than Expected Loss In Q2,opinion,Agenus Inc    NASDAQ AGEN   reported second quarter 2016 loss of 24 cents per share  narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year ago loss of 44 cents Moreover  revenues surged 10  year over year to almost  6 6 million and were slightly above the Zacks Consensus Estimate of  6 million Quarterly HighlightsAgenus  second quarter research and development  R D  expenses were down 9 7  to  22 4 million  Likewise  general and administrative expenses declined 11 2  to  7 1 million Selection of Agenus  lead candidate  along with several backup antibodies  by Merck   Co  Inc    NYSE MRK   for an undisclosed checkpoint target led the company to receive a milestone payment worth  2 million  Under the terms of the agreement  Agenus will receive up to  100 million in milestone payments  in addition to royalties on worldwide product sales Pipeline UpdateAgenus is progressing with the candidates in its pipeline  Currently  the company is evaluating AGEN1884 in a phase I study and INCAGN01876 in a phase I II study for the treatment of solid tumors  The company plans to initiate studies on its second anti CTLA 4 antibody  AGEN2041  in 2017  Agenus also expects to begin combination studies on AGEN2041 and AGEN1884 in the first half of 2017 AGENUS INC Price and EPS Surprise   Our TakeAgenus second quarter results were impressive  with the company reporting a narrower than expected loss and revenues beating estimates  We are encouraged by the company s efforts to develop its pipeline and expect investor focus on further updates by the company Agenus currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Nektar Therapeutics   NASDAQ NKTR   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    Both these stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-28,Zacks Investment Research,https://www.investing.com/analysis/agenus-(agen)-posts-narrower-than-expected-loss-in-q2-200144983,200144983
204082,425598,MRK,Merck KGaA Pfizer Avelumab In JAVELIN Ovarian 100 Study,opinion,Merck  NYSE MRK  KGaA  and its partner Pfizer Inc    NYSE PFE   announced that they have initiated a phase III study   JAVELIN Ovarian 100   on avelumab  in combination with platinum based chemotherapy  for the treatment of patients with locally advanced or metastatic disease with previously untreated epithelial ovarian cancer The study will evaluate the safety and efficacy of avelumab in treatment na ve patients with locally advanced or metastatic ovarian cancer  Stage III or Stage IV   This is the first late stage study evaluating the addition of an immune checkpoint inhibitor to the standard of care treatment for such an aggressive form of cancer In Dec 2015  the two companies had initiated the phase III JAVELIN Ovarian 200 study to assess the superiority of avelumab as monotherapy or in combination with pegylated liposomal doxorubicin  PLD   compared with PLD alone  for the treatment of patients with platinum resistant refractory ovarian cancer We note that in Nov 2014  Merck KGaA had entered into a strategic collaboration with Pfizer to co develop and co commercialize avelumab  Currently  avelumab is being developed for more than 15 types of tumors including breast cancer  gastric gastro esophageal junction cancers  head and neck cancer  melanoma  Merkel cell carcinoma  non small cell lung cancer  ovarian cancer  renal cell carcinoma and urothelial  e g  bladder  cancer The companies intend to commercially launch avelumab in 2017  assuming successful development and a subsequent approval of the candidate  Thereafter  they aim to make at least one additional launch every year through 2022 According to the International Agency for Research on Cancer of the World Health Organization  nearly a quarter of a million women are diagnosed with ovarian cancer worldwide each year The ovarian cancer space is currently crowded by drugs including Lynparza  Doxil  Paraplatin and Avastin among others Investors looking for top ranked stocks in the health care sector may consider GW Pharmaceuticals plc   NASDAQ GWPH   and United Therapeutics Corp    NASDAQ UTHR    Both these stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-07,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaa-pfizer-avelumab-in-javelin-ovarian-100-study-200140647,200140647
204083,425599,MRK,Two Big Pharma Stocks To Watch For In July,opinion,"Back in 1992  lawmakers in the US passed what s called the Prescription Drug User Fee Act  PDUFA   The act sees the the Food and Drug Administration  FDA  collect fees from companies that are looking to submit applications for a new drug to gain marketing approval 
It works like this  the company pays the fee and submits all of the data related to whatever drug it is trying to get approved  This data includes everything from safety  efficacy  manufacturing plans  commerciailzation and marketing strategy etc  The FDA reviews the submission and either accepts it or declines it 
If it accepts it  it will then set what s called a PDUFA date  which is the date by which it aims to give the company an answer relating to the drug in question  95  of the time  the PDUFA date is the date on which we find out whether a drug has an FDA green light  As such  keeping track of the FDA s PDUFA calendar can be a great way to get in ahead of a potential upside catalyst  i e  an approval  in the biotech sector 
With this in mind  here are two companies with PDUFA dates this month  with a look at the drugs in question and what an approval might mean for each 
Shire PLC  NASDAQ SHPG    Lifitegrast
This one s an interesting one  and a little complex  but stick with us  Lifitegrast is a drug targeting a condition called dry eye disease that   as its name suggests   is a disease that causes dry eyes in adults  It s caused by inflammation at the surface of the eye  and is similar  in concept  at least  to something like psoriasis  whereby an immune mediated inflammation causes the plaques associated with the condition  
Lifitegrast aims to block the interaction between something called integrin LFA 1 and ICAM 1  and in doing so  inhibits the inflammatory action that this interaction usually results in  No inflammation  no dry eyes 
Anyway  that s not the complicated part  The complication lies in the development process 
Shire initially submitted an NDA for the drug last year  but the FDA issued what s called a complete response letter  CRL  in October  A CRL is essentially the agency saying that the NDA can t be approved in its current form   in this instance  the agency asked for another trial and a resubmission with the extra trial data included 
Shire quickly put together a phase 3  the data from which supported the initial efficacy hypothesis  and resubmitted the NDA in January  The FDA accepted the NDA for review shortly thereafter  and set a PDUFA of July 22  2016 
The final form NDA has three sets of phase 3 trial data  plus an extra phase 3 looking at long term response  and a phase 2 set of data  with safety write ups as a kicker  It also includes some revised manufacturing details  and as the FDA acceptance in January demonstrates  is ready for a thumbs up or down 
The potential upside here is pretty big  Analysts expect the dry eye disease market to reach  4 6 billion by 2024  up from  2 2 billion in 2014  and expect a large portion of this growth to be driven by   and to paraphrase    the introduction of anti inflammatory drugs such as Shire s Lifitegrast 
Merck   Co Inc   NYSE MRK    Bezlotoxumab
This one is technically not an NDA  it s what s called a biologics licence application  BLA   but that doesn t matter too much to our thesis  The only difference between the two is NDAs are generally based on chemically synthetic products  while BLAs involve drugs or treatments produced from naturally biologics   things like vaccines  gene therapy treatments  etc  Bottom line  they both have PDUFA dates  and that s what s important here 
Bezlotoxumab is targeting the treatment of what s called C  difficile infection  Those reading may already be familiar with the condition   it s caused by a bacterium that already exists in most people s intestines   C  difficile   growing out of control and causing an imbalance  This leads to diarrhea at best  but severe colon inflammation and other more serious side effects at worst 
Bezlotoxumab is designed to pair up with a regimen of antibiotics  the current standard of care in this condition  and complement the regimen s mechanism of action  Specifically  it targets a toxin called C toxin B  which attacks the intestinal wall and creates the inflammation that   in turn   causes the diarrhea 
Unlike the Shire NDA  this one got accepted first time around by the FDA  and it s based on two phase 3s that both seem to show some pretty strong efficacy and safety readouts  Just as with the Shire target  however  this is also a pretty large market  and could serve up a sizeable revenues boost for Merck if the drug picks up an FDA green light 
The C  difficile market is  to hit  1 5 billion by 2024  and since this treatment is designed for administration in line with current SOC  Merck won t have to compete with a first line treatment to gain a sizeable market share 
This is certainly one to watch  with PDUFA set a day later than Shire s on July 23 ",2016-07-07,Samuel Rae,https://www.investing.com/analysis/two-big-pharma-pdufas-to-watch-for-in-july-200140590,200140590
204084,425600,MRK,Agenus  AGEN   What s Ahead For The Stock In Q2 Earnings ,opinion,Agenus Inc    NASDAQ AGEN   is scheduled to report second quarter 2016 results on Jul 28  Last quarter  Agenus delivered a negative earnings surprise of 13 04   Let s see how things are shaping up for the company this quarter Factors at PlayAgenus is an immuno oncology company focused on the discovery and development of revolutionary new treatments that engage the body s immune system to fight cancer  The company has three platform technologies for the development of its candidates   Retrocyte Display  SECANT and phage display   each designed to produce quality human antibodies Given that Agenus does not have any approved product in its portfolio yet  investor focus should remain on pipeline updates by the company  The company has several early to mid stage candidates in its portfolio Agenus received a major boost when the FDA cleared its investigational new drug  IND  application for both AGEN1884 and INCAGN01876 this January  It has initiated a phase I study on AGEN1884 in patients with advanced or refractory cancer and a phase I II study on INCAGN1876 in patients with advanced or metastatic solid tumors  Consequently  research and development expenses are expected to be up sequentially We remind investors that Agenus  lead candidate as well as several backup antibodies had been selected by Merck   NYSE MRK   for an undisclosed checkpoint target  The company received a milestone payment of  2 million under the terms of the agreement  This should be reflected in the company s second quarter results Agenus earns revenues primarily through fees received under collaboration and license agreements  Collaboration agreements with companies like GlaxoSmithKline plc   NYSE GSK   not only provide it with funds in the form of upfront and milestone payments and future royalties  but also validate the company s proprietary product platform  Collaboration revenues should continue to drive the top line in the second quarter as well We expect investors to focus on pipeline updates given by the company during its second quarter earnings call Surprise HistoryAgenus  track record has been disappointing so far  The company has missed estimates in all of the last four quarters  with an average negative surprise of 54 65  AGENUS INC Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that Agenus is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  Unfortunately  this is not the case here as you will see below Zacks ESP  The Earnings ESP for Agenus is 0 00  since the Most Accurate estimate stands in line with the Zacks Consensus Estimate of a loss of 34 cents Zacks Rank  Agenus currently carries a Zacks Rank  3  which when combined with a 0 00  ESP  makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions A Stock That Warrants a LookHere is a health care stock that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter Bristol Myers Squibb Co    NYSE BMY   has an Earnings ESP of  1 49  and a Zacks Rank  1  It is scheduled to report second quarter results on Jul 28 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-25,Zacks Investment Research,https://www.investing.com/analysis/agenus-(agen):-what's-ahead-for-the-stock-in-q2-earnings-200143958,200143958
204091,425607,MRK,Incyte Reports Epacadostat Combination Study Initiation,opinion,"Incyte Corporation   NASDAQ INCY   announced that the first patient has been treated in a phase III study  ECHO 301  evaluating epacadostat in combination with Merck   Co  Inc  s   NYSE MRK   Keytruda for the first line treatment of patients with advanced or metastatic melanoma  We expect investors to react positively to the news 
The randomized  double blind  placebo controlled study will enroll 600 patients  While the two primary endpoints of the study are progression free survival and overall survival  key secondary endpoints include objective response rate  safety and tolerability  Incyte anticipates initial data from the ECHO 301 study in 2018 
According to information provided by the company  in the U S   melanoma accounts for approximately 5  of all new cases of cancer each year  In the EU  there are about 41 000 new cases of melanoma each year  resulting in approximately 11 000 deaths annually 
We note that the ECHO 301 study is sponsored by both Incyte and Merck  Incyte is also collaborating with Merck to evaluate epacadostat in combination with Keytruda in a phase II study  ECHO 202  across multiple tumor types 
Additionally  epacadostat is being evaluated in several phase I and phase II studies in combination with PD 1 and PD L1 inhibitors across a variety of other cancer histologies 
Incyte is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are Bristol Myers Squibb Company   NYSE BMY   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    each carrying a Zacks Rank  1  Strong Buy  ",2016-06-22,Zacks Investment Research,https://www.investing.com/analysis/incyte-reports-epacadostat-combination-study-initiation-200137877,200137877
204092,425608,MRK,Opexa Therapeutics   Moving Closer Towards Abili T Data In SPMS ,opinion,"The Abili T Phase IIb study evaluating Opexa s  NASDAQ OPXA  Tcelna immunotherapy as a treatment for secondary progressive MS  SPMS  is nearing completion  The firm is fully funded to Phase IIb data  which are expected in early Q416 and  if positive  could sharply increase investor and stakeholder interest  Merck  NYSE MRK   the marketer of MS drug Rebif  interferon beta 1a   has an option to in license Tcelna in MS  Our rNPV is  37 7m  vs  35 1m previously   after including  7 0m Q216 net cash  this gives an equity valuation of  44 8m 

To read the entire report Please click on the pdf File Below",2016-06-29,Edison,https://www.investing.com/analysis/opexa-therapeutics---moving-closer-towards-abili-t-data-in-spms-200138943,200138943
204093,425609,MRK,Merck To Acquire Brazilian Animal Health Company For  400M,opinion,Merck   Co  Inc    NYSE MRK   announced that it will acquire the controlling interest in Vall e S A   a Brazil based privately held producer of animal health products Under the terms  Merck s animal health business will acquire 93  of Vall e s shares for  400 million  based on current exchange rates  The transaction is subject to regulatory review and closing conditions  However  Merck has not announced a closing date for the deal Benefits for Merck s Animal HealthUnder this deal  Vall e s extensive product portfolio  consisting of over 100 products across parasiticides  anti infectives and vaccines  for livestock  horses  and companion animals  will be integrated with Merck s animal health segment The acquisition will strengthen Merck s presence in Latin America and help to respond more quickly and effectively to the region s needs  Latin America  which contributes 11  to the world food production  is an important driver of the agriculture industry  A significant number of cattle across the region are vaccinated using Vall e s products We note that Merck has been pursuing strategic acquisitions to boost its animal health  In Nov 2015  the company had acquired Harrisvaccines  Inc   a privately held company that develops  manufactures and sells vaccines for food production and companion animals Merck currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include GW Pharmaceuticals plc   NASDAQ GWPH    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and United Therapeutics Corporation   NASDAQ UTHR    Each of these stocks sports a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-04,Zacks Investment Research,https://www.investing.com/analysis/merck-to-acquire-brazilian-animal-health-company-for-$400m-200140104,200140104
204102,425618,MRK,Viralytics  3 Cavatak Checkpoint Combination Trials ,opinion,"Viralytics Ltd   AX VLA 
Additional data presented at ASCO confirm the potential for synergistic combinations of Cavatak with immune checkpoint inhibitor  ICI  drugs to improve the proportion of cancer patients who respond to ICI therapy  Three Phase Ib trials are underway testing Cavatak in combination with Yervoy or Keytruda in melanoma  lung and bladder cancers  Initial data in April showed an impressive 67  response rate in the first six patients in the MITCI study of Cavatak and Yervoy in melanoma  Further updates on MITCI and initial data from the CAPRA trial of Cavatak plus Keytruda could be potential catalysts for the stock in H216  We maintain our valuation of A 272m  A 1 15 per share  ahead of the anticipated newsflow 

Tumour targeting of iv Cavatak attracted Merck  NYSE MRK  collaboration
Tumour biopsy studies presented at ASCO confirmed successful tumour targeting following iv administration of Cavatak in patients with melanoma  non small cell lung cancer  NSCLC  and bladder cancer  The immune response to infection of the tumour by Cavatak increased levels of immune cell infiltration and the expression of immune checkpoint molecules that are targeted by ICI therapies  Viralytics is collaborating with Merck on the recently initiated Phase Ib Keynote 200  STORM Part B  trial of iv Cavatak in combination with the anti PD 1 ICI drug Keytruda in advanced bladder and lung cancers 
To read the entire report Please click on the pdf File Below",2016-06-10,Edison,https://www.investing.com/analysis/viralytics---three-cavatak-checkpoint-combination-trials-200135222,200135222
204103,425619,MRK,Pfizer Reveals Final Phase III Data On Inotuzumab Ozogamicin,opinion,Pfizer Inc    NYSE PFE   announced final data from the phase III study  INO VATE ALL or Study 1022  on inotuzumab ozogamicin for the treatment of adults with relapsed refractory acute lymphoblastic leukemia  ALL  The open label  randomized study evaluated the safety and efficacy of the candidate  in comparison to investigator choice chemotherapy  in adults  n 326  with relapsed or refractory CD22 positive ALL The study had two primary endpoints   complete response with or without hematologic remission and overall survival  OS   Data from the study revealed an improvement over chemotherapy on a number of measures that included complete hematologic remission and progression free survival  PFS   The study met its first primary endpoint of complete response  but failed to reach statistical significance in its second primary endpoint  However  the second primary endpoint of OS demonstrated a strong trend toward longer OS Results were published in the The New England Journal of Medicine  Moreover  updated data on OS were presented at the annual meeting of the Congress of the European Hematology Association We note that inotuzumab ozogamicin has Breakthrough Therapy designation in the U S  for ALL Moreover  Pfizer  with its partner Merck   Co  Inc    NYSE MRK    announced results from two phase III studies  VERTIS Mono and VERTIS Factorial  on ertugliflozin for the treatment of patients with type II diabetes Ertugliflozin  5 mg and 15 mg daily  was evaluated as monotherapy in the VERTIS Mono study  while the VERTIS Factorial study evaluated the co administration of the candidate with Merck s diabetes drug  Januvia Results from the studies demonstrated statistically significant reductions in A1C  a measure of average blood glucose  for both ertugliflozin doses tested  Data were presented at the Scientific Sessions of the American Diabetes Association The companies have expanded the VERTIS CV study to enable testing for superiority in improving CV outcomes in patients with type II diabetes  They plan to submit New Drug Applications in the U S  for ertugliflozin and the two fixed dose combination tablets   ertugliflozin Januvia  and ertugliflozin metformin   by 2016 end Pfizer currently sports a Zacks Rank  1  Strong Buy   Bristol Myers Squibb Company   NYSE BMY   and ANI Pharmaceuticals  Inc    NASDAQ ANIP   are two other favorably placed stocks in the health care sector  carrying the same Zacks Rank as Pfizer ,2016-06-13,Zacks Investment Research,https://www.investing.com/analysis/pfizer-reveals-final-phase-iii-data-on-inotuzumab-ozogamicin-200135632,200135632
204104,425620,MRK,Merck   Co  Inc  Shares Jump On Positive Lung Cancer Treatment Trial Results,opinion,"Shares of the large pharmaceutical company Merck   Co  Inc    NYSE MRK   were climbing higher Thursday on news that the company s late stage lung cancer treatment showed positive results and outperformed traditional chemotherapy  As of around 3 PM ET MRK was up to  57 61  a jump of 2 71  on the day 
Results came back from the Keynote 024 trial where the drug Keytruda was used as the sole treatment of patients with non small cell lung cancer  Though Merck   Co  didn t release any numbers  the company said that the Keynote 024 trial was stopped because it already proved Keytruda s ability to lengthen progression free survival and overall survival compared to standard chemotherapy treatments 
The trial studied only patients which had tumors that showed high expression of PD L1  the ligand that Keytruda is meant to treat through targeting the PD 1 protein  More details regarding the trial are expected to be released at an undisclosed future time 
As it stands the Keytruda drug is only approved to treat relapsed cases of late stage lung cancer  but the company said it plans to file for a label expansion as soon as it can  The expansion could be a major positive for the company in the company in the coming months  but only time will tell if they are able to get approval from regulators 
Merck   Co  is currently a Zacks Rank  3  Hold  stock  but any further positive trials or label expansion of the Keytruda drug could change that in the future ",2016-06-16,Zacks Investment Research,https://www.investing.com/analysis/merck---co.-inc.-shares-jump-on-positive-lung-cancer-treatment-trial-results-200136458,200136458
204105,425621,MRK,7 Biotech Stocks That Are Buys Right Now,opinion,"Even into the sixth month of the year  the happening yet highly unpredictable biotech sector continues to struggle   the NASDAQ Biotechnology Index is down 20 1  year to date  In addition to weak balance sheets and mounting political pressure on drug prices  the larger issues plaguing the economy are continuing to weigh upon the sector 
Still biotechs retain their charm with investors who unfailingly bet on these stocks when fundamentals are strong and valuations reasonable Mergers and acquisitions continue to dominate the sector with Shire combining with Baxalta earlier this month and rumors of a few biotech companies chasing lucrative deals refusing to die down  Large cap and development stage companies continue to partner across different therapeutic areas like immuno oncology  hepatitis C virus and cardiovascular to bolster their pipelines Moreover  several high profile drugs like Gilead s Genvoya  HIV  among others that gained approval last year should help drive top line growth at these companies  They would also continue to benefit from label expansion of existing drugs Considering these factors  the sector still holds promise and could bounce back in no time particularly when there are significant catalysts lined up for the second half in the form of key new product approvals and major data read outs Though there are a plethora of stocks  some could emerge as winners while others fall by the wayside  Here are seven such biotech stocks which are sanguine buys right now 
Best Biotech Picks
San Diego  CA based Retrophin  Inc    NASDAQ RTRX   is a commercial stage biotech company focused on the development of rare diseases treatments  The company derives revenues from three marketed products   Chenodal  Cholbam and Thiola  The company expects top line data from the phase II study on its lead pipeline candidate sparsentan for the treatment of focal segmental glomerulosclerosis in the third quarter of 2016  This Zacks Rank  1  Strong Buy  stock has seen its current quarter loss per share estimate being narrowed by 3 57  over the past 60 days RETROPHIN INC Price and Consensus   Acorda Therapeutics  Inc    NASDAQ ACOR   is a commercial stage biotech company focused on the development and commercialization of therapies that improve neurological function in people suffering from multiple sclerosis  spinal cord injury and other nervous system disorders  This Ardsley  NY based company s key drug  Ampyra  continues to drive top line growth  Meanwhile  the company continues to progress with its pipeline  The current quarter loss per share of this Zacks Rank  2  Buy  stock has narrowed by 25  over the past 60 days ACORDA THERAPT Price and Consensus   Cambridge  MA based AVEO Pharmaceuticals  Inc    NASDAQ AVEO   is a development stage biotech company that focuses on the development of treatments targeting cancer using its proprietary human response platform  The company has made considerable progress with its lead pipeline candidate  tivozanib  for the treatment of renal cell carcinoma   which is currently in regulatory stage in the EU and in late stage development in the U S  This Zacks Rank  2 stock has seen its current quarter loss per share estimate being narrowed by 22 22  over the past 60 days AVEO PHARMACEUT Price and Consensus   Ligand Pharmaceuticals Incorporated   NASDAQ LGND   is a biotech company with a focus on drug discovery  reformulation and partnering  While the company s Captisol formulation technology has allowed it to enter into several licensing deals  its Jan 2016 OMT acquisition has expanded its partnership portfolio and added a proprietary antibody generating platform  OmniAb  to its technology portfolio  These partnerships not only provide the company with funds in the form of milestone and royalty payments  but are also likely to boost the top line through 2016  The stock of this La Jolla  CA based company has seen its current quarter earnings per share estimate moving up by 3 23  over the past 60 days LIGAND PHARMA B Price and Consensus   Cambridge  MA based BIND Therapeutics  Inc    NASDAQ BIND   is a development stage biotech company focused on the development of novel targeted therapeutics mainly targeting cancer using its proprietary polymeric nanoparticles called Accurins  The company generates revenues in the form of collaboration revenue or government grant revenue  It has agreements with companies like Merck  NYSE MRK  and Pfizer  NYSE PFE  among others  The current quarter loss per share estimate of this Zacks Rank  2 stock has narrowed by 43 24  over the past 60 days BIND THERAPEUTC Price and Consensus   San Diego  CA based Mast Therapeutics  Inc    NYSE MSTX   is a development stage biotech company focused on the development of serious or life threatening diseases with significant unmet needs  Currently  the lead candidate in the company s pipeline  vepoloxamer  also known as MST 188   is in phase III development for the treatment of sickle cell disease and phase II development for the treatment of heart failure with reduced ejection fraction  The current quarter loss per share estimate of this Zacks Rank  2 stock has narrowed by 25  over the past 60 days MAST THERAPEUTC Price and Consensus   Sunesis Pharmaceuticals  Inc    NASDAQ SNSS   is a development stage biotech company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers 
Currently  Qinprezo is the most advanced program  being evaluated for the treatment of relapsed or refractory acute myeloid leukemia  Also  the company is advancing its kinase inhibitor pipeline of novel targeted therapies into the clinic  The current quarter loss per share estimate of this Zacks Rank  2 stock has narrowed by 7 69  over the past 60 days SUNESIS PHARMA Price and Consensus  ",2016-06-16,Zacks Investment Research,https://www.investing.com/analysis/7-biotech-stocks-that-are-buys-right-now-200136672,200136672
204112,425628,MRK,Pfizer  PFE  Presents Data On Utomilumab For Solid Tumors,opinion,Pfizer Inc    NYSE PFE   announced results from a phase Ib study on utomilumab  PF 05082566  for the treatment of advanced solid tumors The dose escalation study evaluated the overall safety  pharmacokinetics  pharmacodynamics and anti tumor activity of utomilumab  in combination with Merck   Co  Inc  s   NYSE MRK   Keytruda  pembrolizumab   in patients  n 23  with advanced solid tumors including non small cell lung cancer  renal cell carcinoma  head and neck cancers  pancreatic cancer  anaplastic thyroid cancer  small cell lung cancer  colon cancer  sarcoma  thymoma and melanoma Data from the study revealed that two patients   one with small cell lung cancer and the other with renal cell carcinoma   confirmed complete response  In addition  partial responses were observed in four patients   one each with renal cell carcinoma  non small cell lung cancer  head and neck cancer and anaplastic thyroid cancer Adverse events related to treatment were reported to be mild and did not appear to increase with higher doses of utomilumab  Moreover  no dose limiting toxicity was reported  Data from the study were presented at the annual meeting of the American Society of Clinical Oncology  ASCO  Meanwhile  utomilumab is being evaluated in several studies in both hematologic cancers and solid tumors  Utomilumab  as monotherapy  is currently being evaluated across multiple tumors  The candidate is also being evaluated in combination with Rituxan  rituximab  for the treatment of lymphoma and in combination with mogamulizumab for the treatment of advanced solid tumors Utomilumab  in combination with other immunotherapies  is also being studied for various solid tumors and hematological malignancies Pfizer currently sports a Zacks Rank  1  Strong Buy   Bristol Myers Squibb Company   NYSE BMY   and ANI Pharmaceuticals  Inc    NASDAQ ANIP   are two other favorably placed stocks in the health care sector  both carrying the same Zacks Rank as Pfizer Want the latest recommendations from Zyes i haveacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-05,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-presents-data-on-utomilumab-for-solid-tumors-200134278,200134278
204113,425629,MRK,Merck  MRK  Reveals Data From Ongoing Studies On Keytruda,opinion,Merck   Co  Inc    NYSE MRK   attended the annual meeting of the American Society of Clinical Oncology  ASCO   where the company presented data on anti PD 1 therapy  Keytruda  pembrolizumab  As a Treatment of Cancer Deficient in DNA Mismatch RepairMerck presented updated findings from a phase II study on Keytruda for the treatment of patients with advanced cancers characterized as deficient for DNA mismatch repair  MMR   The study evaluated the clinical activity of the drug  10 mg kg every two weeks  in patients with previously treated  progressive metastatic disease with or without MMR deficiency Results from the study revealed overall response rates  ORR  of 53  and 57  in patients with MMR deficient advanced non colorectal cancers  and MMR deficient advanced colorectal cancer  respectively  However  patients with MMR proficient advanced colorectal cancer did not respond to the therapy  The safety profile of the drug was consistent with that observed in previous studies Meanwhile  Keytruda is being evaluated in two phase II studies   KEYNOTE 164 and KEYNOTE 158   in patients with previously treated  locally advanced unresectable or metastatic  Stage IV  MMR deficient or microsatellite instability high  MSI H  colorectal cancer  and in patients with advanced tumors classified as MSI H  excluding colorectal carcinoma  Moreover  Merck is evaluating Keytruda in a phase III study  KEYNOTE 177  in a treatment na ve patient population As a Treatment of Advanced MelanomaMerck also presented data from three separate studies on Keytruda   MASTERKEY 265  KEYNOTE 022  and KEYNOTE 029 The MASTERKEY 265  phase 1b  study evaluated the safety  efficacy and tolerability of Keytruda  in combination with Imlygic  talimogene laherparepvec   in patients with previously untreated  unresectable advanced melanoma  The KEYNOTE 022 study  phase I II  evaluated Keytruda  in combination with Tafinlar  dabrafenib  plus Mekinist  trametinib   in patients with advanced melanoma  while the KEYNOTE 029  phase I II  study evaluated the drug  in combination with low dose Yervoy  ipilimumab   in patients with advanced melanoma Data from the MASTERKEY 265 study showed that the combination resulted in a confirmed ORR of 57 1   while the KEYNOTE 029 study demonstrated an ORR of 57  As a Treatment of Non Small Cell Lung CancerMerck announced findings from a phase I II study  KEYNOTE 021  on Keytruda  in combination with Paraplatin  carboplatin  and paclitaxel  with or without Avastin  bevacizumab   in previously untreated patients with non small cell lung cancer  NSCLC   Results from the study revealed an ORR of 48 71   depending on the therapy used Meanwhile  Merck has initiated two phase III studies in patients with previously untreated NSCLC   KEYNOTE 189 and KEYNOTE 407  KEYNOTE 189 will evaluate Keytruda  in combination with a platinum Alimta  pemetrexed  based chemotherapy regimen  in patients with non squamous NSCLC  while the KEYNOTE 407 study will evaluate the drug  in combination with Paraplatin and paclitaxel or nab paclitaxel  in patients suffering from squamous NSCLC We note that Keytruda is currently approved in the U S  for the treatment of patients with unresectable or metastatic melanoma  and for the treatment of patients with metastatic non small cell lung cancer  NSCLC  whose tumors express PD L1 as determined by an FDA approved test with disease progression on or after platinum containing chemotherapy The company generated Keytruda sales of  249 million in the first quarter of 2016  up 200  year over year Merck currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Bristol Myers Squibb Co    NYSE BMY    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Pfizer Inc    NYSE PFE    each sporting a Zacks Rank  1  Strong Buy  ,2016-06-06,Zacks Investment Research,https://www.investing.com/analysis/merck-(mrk)-reveals-data-from-ongoing-studies-on-keytruda-200134303,200134303
204127,425643,MRK,Intrexon  XON  Q1 Loss Wider Than Expected  Revenues Miss,opinion,"Intrexon Corporation   NYSE XON   reported a first quarter 2016 loss of 32 cents per share  much wider than the Zacks Consensus Estimate of a loss of 29 cents  The company had reported earnings of 25 cents per share in the year ago period Total revenue was  43 4 million in the quarter  up 28 3  year over year  Revenues were below the Zacks Consensus Estimate of  44 5 million 
Quarter in Detail
Intrexon s revenues primarily consist of collaboration and licensing revenues  product revenues and service revenues 
Collaboration and licensing revenues surged 62 8  to  24 1 million  The increase was primarily attributable to the recognition of deferred revenue from upfront payments received under the company s May 2015 license and collaboration agreement with Merck  NYSE MRK  KGaA  and from other collaborations signed by Intrexon between Apr 1  2015 and Mar 31  2016  The upside was also due to increased research and development  R D  services for these collaborations and for the progression of programs or the addition of new programs with previously existing collaborators 
Product revenues came in at  8 6 million  down 4 2  from the year ago period  primarily due to a decline in the quantity of livestock previously used in production and live calves sold due to lower demand from customers for these products 
Service revenues came in at  10 7 million  up 7 1  year over year  primarily due to an increase in the number of in vitro fertilization cycles performed on higher demand 
R D expenses decreased 67 4  to  25 9 million while selling  general and administrative expenses escalated 55 2  to  42 9 million due to an increase in salaries  benefits and other personnel costs 
In the reported quarter  the company continued to enter into new exclusive channel collaborations  ECC  and expanded partnership with existing ones  Earlier this year  the company announced that it has expanded its existing partnership with Fibrocell Science  Inc    NASDAQ FCSC   by means of a new ECC for the development of genetically modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint  including arthritis and related conditions 
Several candidates are under development not only in partnership with Fibrocell but with other companies as well  In addition to the three studies that are currently underway  Intrexon anticipates that up to seven investigational new drugs and clinical study initiations with the company s existing ECC partners utilizing its technologies will take place in 2016  subject to FDA approval 
Meanwhile  the company is currently working with both governmental and non governmental organizations for the potential use of Oxitec s OX513A to reduce or eradicate populations of the Aedes aegypti mosquito  the primary vector for dengue  chikungunya  and the Zika virus 
We expect investor focus to remain on updates from the company 
Intrexon is a Zacks Rank  3  Hold  stock  ANI Pharmaceuticals  Inc    NASDAQ ANIP   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  ",2016-05-10,Zacks Investment Research,"https://www.investing.com/analysis/intrexon-(xon)-q1-loss-wider-than-expected,-revenues-miss-200129331",200129331
204128,425644,MRK,Immune Design  IMDZ  Loss Narrower Than Expected In Q1,opinion,"Immune Design Corp    NASDAQ IMDZ   reported a first quarter 2016 loss of 61 cents per share  narrower than the Zacks Consensus Estimate of a loss of 65 cents but wider than the year ago loss of 56 cents 

Quarter in Detail
Immune Design s total revenue was  1 9 million  down 3 9  from the year ago period but above the Zacks Consensus Estimate of  1 million 
Research and development  R D  expenses shot up 41 6  to  10 6 million primarily due to expenditure related to the advancement of the CMB305 and LV305 programs to phase I and phase II clinical trials  and the development of G103  General and administrative expenses were also up 2 9  to  3 9 million 
Pipeline Update
Immune Design continues to progress with its pipeline  The company s  prime boost  immunotherapy candidate  CMB305  involving the sequential dosing of two complementary agents   LV305 from the ZVex platform and G305   has completed the first in human dose escalation study and is currently undergoing an expansion study as a single agent in patients with cancers expressing the NY ESO 1 tumor antigen  Enrolment is ongoing and data from the study is expected to be presented this June 
Alongside  a randomized phase II trial on CMB305  in combination with Roche Holdings    OTC RHHBY   investigational anti PD L1 therapy atezolizumab  compared to atezolizumab alone  for locally advanced  relapsed or metastatic soft tissue sarcoma is currently underway  Data are expected in the fourth quarter of 2016 
We note that the company has achieved full patient enrollment in a phase I study on LV305 as a single agent  wherein the candidate showed a consistently favorable safety profile and an improved clinical benefit profile using progression free survival as an endpoint 
Meanwhile  Immune Design is collaborating with Merck   Co  Inc    NYSE MRK   to evaluate G100 and LV305  in combination with Merck s Keytruda  in phase I studies for the treatment of patients with non Hodgkin s lymphoma and melanoma  respectively  We remind investors that the company has completed a phase I study on G100 in patients with merkel cell carcinoma  with data from the full set of patients indicating a favorable safety profile and consistent clinical efficacy  Data are expected in June  The company has also initiated a randomized trial evaluating the safety and efficacy of G100 and low dose local radiation in patients with low grade follicular lymphoma 
Our Take
Immune Design s narrower than expected loss in the first quarter was encouraging  Going forward though  we expect investor focus to remain on pipeline updates from the company  2016 is expected to be data rich year for Immune Design given several data readouts lined up 
Immune Design carries a Zacks Rank  2  Buy   Another well placed stock in the health care sector is Shire plc   NASDAQ SHPG    carrying the same rank as Immune Design ",2016-05-11,Zacks Investment Research,https://www.investing.com/analysis/immune-design-(imdz)-loss-narrower-than-expected-in-q1-200129432,200129432
204129,425645,MRK,Merck KGaA  MKGAF  Q1 Earnings Increased Y Y,opinion,Merck  NYSE MRK  KGaA  is a science and technology company in healthcare  life science and performance materials  Founded in 1668  it is the world s oldest pharmaceutical and chemical company The company is focused on oncology  multiple sclerosis  infertility  growth disorders  selected cardiovascular and metabolic diseases  women s and children s health  cough and cold as well as everyday health protection The company reports its results in three business sectors   Healthcare  Life Science and Performance Materials The company lead candidate  avelumab  is being evaluated in phase III studies for several cancer indications  in collaboration with Pfizer  NYSE PFE  The recent the acquisition of Sigma Aldrich  NASDAQ SIAL  led the company to gain access to an attractive set of established brands along with an efficient supply chain to support the delivery of over 300 000 products  thereby enabling it to customers all over the world We have highlighted some of the key stats from this just revealed announcement below Earnings  The company s first quarter 2016 earnings per American Depositary Receipt  ADR  came in at  1 5  compared to the year ago figure of 70 cents Revenue  The company posted revenues of  4 billion in the reported quarter Key Stats  All three business units continued to perform well in the first quarter  The acquisition of Sigma Aldrich boosted sales in the reported quarter  For 2016  the company expects net sales in the range of  14 8  15 billion  Backed by the Sigma Aldrich acquisition  the company expects a positive portfolio effect on sales in the low double digit percentage range Check back later for our full write up on earnings report later ,2016-05-19,Zacks Investment Research,https://www.investing.com/analysis/merck-kgaa-(mkgaf)-q1-earnings-increased-y-y-200130857,200130857
204136,425652,MRK,Merck  MRK  Q1 Earnings  Can The Stock Pull A Surprise ,opinion,"Merck   Co  Inc    NYSE MRK   is scheduled to report its first quarter 2016 earnings results on May 5  before the opening bell  Last quarter  Merck had posted a positive earnings surprise of 2 20   Let s see how things are shaping up for the company this quarter New Products to Pick Up PaceMerck will continue to face headwinds in the form of genericization as well as unfavorable currency movement including the impact of the Venezuelan financial crisis However  new products should start contributing significantly from 2016 with performance being driven by products like Keytruda  cancer  and Zepatier  HCV   Strong uptake  launches in additional countries and expansion into additional indications should drive Keytruda sales Other recent product launches in Merck s portfolio include Bridion  reversal of neuromuscular blockade  and Belsomra  insomnia   On the fourth quarter call  Merck had said that customer feedback on Bridion was positive   But  Belsomra  which had started on a good note  has been experiencing flattening scrips  Merck is working on driving Belsomra sales by enhancing its digital and online capabilities and is working with physicians as well Investors will also be focused on the performance of Merck s DPP 4 inhibitor  Januvia  including the impact of pricing pressure and whether it is losing any share to SGLT2 inhibitors Merck is also working on driving Zostavax  vaccine  sales  On the fourth quarter call  Merck said that it continues to invest in direct to consumer advertising for the product and is working to educate customers on the reimbursement for Zostavax  Zostavax s performance in the fourth quarter was disappointing due to a very weak flu season in the U S Meanwhile  Remicade will continue to feel the pressure of biosimilar competition in Europe with sales expected to decline at a rapid pace through 2016  Volume share had declined to 85  in the fourth quarter from about 90  in the third quarter  With biosimilar business wins for new patients growing  Remicade share will continue declining Slowing growth of the integrase class and continued competitor dynamics in the U S  and Europe will affect Isentress sales However  Merck s cost cutting efforts  share buybacks and other strategic initiatives should drive the bottom line Surprise HistoryMerck s performance has been pretty impressive with the company beating earnings expectations consistently  The average earnings beat over the last four quarters is 7 13  
Earnings Whispers Our proven model does not conclusively show that Merck is likely to beat estimates this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  That is not the case here as you will see below Zacks ESP  The   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00  since the Most Accurate estimate is in line with the Zacks Consensus Estimate at 85 cents per share Zacks Rank  Merck carries a Zacks Rank  3  Merck s Zacks Rank  3 when combined with an ESP of 0 00  makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Amicus Therapeutics  Inc    NASDAQ FOLD   has an Earnings ESP of  2 86  and carries a Zacks Rank  3  It is scheduled to report first quarter results on May 3 The Earnings ESP for BIND Therapeutics  Inc    NASDAQ BIND   is  7 14  and it carries a Zacks Rank  3  The company is expected to release first quarter results on May 5 Chiasma  Inc    NASDAQ CHMA   has an Earnings ESP of  4 76  and carries a Zacks Rank  3  It is expected to report first quarter results on Jun 13 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-01,Zacks Investment Research,https://www.investing.com/analysis/merck-(mrk)-q1-earnings:-can-the-stock-pull-a-surprise-200127312,200127312
204137,425653,MRK,Immune Design  IMDZ  Q1 Earnings  What Awaits The Stock ,opinion,"Immune Design Corp    NASDAQ IMDZ   is scheduled to report first quarter 2016 results after the market closes on May 10 
The company has a mixed track record so far  It beat estimates in two of the last four trailing quarters and missed the same on two other occasions  with a positive average earnings surprise of 4 14   Let s see how things are shaping up for this announcement 

Factors in Play
Being a development stage biopharmaceutical company  Immune Design has not generated any product revenues yet  The company earns revenues from collaboration and licensing agreements  and the sale of products associated with material transfer  collaboration and supply agreements 
Investors are expected to focus on the company s progress on its pipeline  The company is developing multiple candidates using its two discovery platforms   ZVex and GLAAS   for the treatment of various types of cancer  Key pipeline candidates include CMB305 and G100  CMB305 has been designed under a prime boost approach  involving the sequential dosing of two complementary agents   LV305  from the ZVex platform  and G305 
CMB305 is currently undergoing an expansion study as a single agent in patients with cancers expressing the NY ESO 1 tumor antigen  Data from the study are anticipated in the first half of 2016  The company also believes that CMB305 has the potential to gain orphan designation in both the U S  and the EU  
In addition  a randomized phase II trial on CMB305  in combination with Roche Holdings    OTC RHHBY   investigational anti PD L1 therapy  atezolizumab  in comparison with atezolizumab alone  for locally advanced  relapsed or metastatic soft tissue sarcoma is currently underway  Data are expected in the fourth quarter of 2016  The company plans to seek for a regulatory approval for CMB305 in the soft tissue sarcoma indication assuming positive results from the ongoing trial 
Meanhwile  another candidate  G100  developed from the GLAAS platform  completed a phase I trial in patients with merkel cell carcinoma  Data are expected in the first half of 2016  Immune Design is collaborating with Merck   Co  Inc    NYSE MRK   to evaluate G100 in combination with Merck s Keytruda  for the treatment of patients with non Hodgkin s lymphoma 
The company recently dosed the first patient in a randomized phase Ib II trial in patients with follicular non Hodgkin lymphoma in combination with Keytruda  Results from the study are expected to be out by the first half of 2017 
Due to the numerous ongoing trials  operating expenses are expected to remain high in the first quarter  We expect the company to shed light on its progress with these trials during the first quarter call 
What Our Model Indicates
Our proven model does not conclusively show that Immune is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  This is not the case here  as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 65 cents 
Zacks Rank  Although Immune Design s Zacks Rank  3 increases the predictive power of ESP  the company s ESP of 0 00  makes surprise prediction difficult 
Note that we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
A Stock that Warrants a Look
Here is a company you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter 
Jazz Pharmaceuticals plc   NASDAQ JAZZ   has an Earnings ESP of  6 11  and a Zacks Rank  3  The company is expected to release first quarter results on May 10 ",2016-05-06,Zacks Investment Research,https://www.investing.com/analysis/immune-design-(imdz)-q1-earnings:-what-awaits-the-stock-200128494,200128494
204144,425660,MRK,Ultimately  S P 500 Earnings Will Have To Start Moving Higher,opinion,"In 2015  the  forward 4 quarter  earnings estimate for the S P 500 turned negative in early April  15 and stayed that way for all of 2015  as rapidly declining Energy estimates and the strong dollar took its toll on S P 500 earnings 
Already in 2016  crude oil has rallied roughly 40  50  off its January February  16 lows and the dollar weakened roughly 7  this past week after the Fed talked about fewer planned rate hikes for 2016 
Stabilizing commodities and a weaker buck are  a good thing   for S P 500 earnings  as Martha Stewart would say  even though the S P 500 earnings data has yet to incorporate the new market trends  Even Financials found a bid later this past week  as perhaps the energy credit scenario   i e  massive defaults   may not be as apocalyptic as originally suspected 
One old saw or maxim learned years ago in investing was that  ultimately  fundamentals must follow technicals  
It looks as if we are seeing sustainable bottoms in groups that have been in downtrends for years  crude oil  copper  gold  and commodities in general  Energy  Transports  etc  Only Biotech has yet to really turn  but its downtrend didn t really start until August  15 with the China correction 
However  S P 500 earnings estimates haven t yet moved  I think the sell wide analysts want to wait and hear what Q1  16 Energy and commodity sector managements guide to for Q2  16 and beyond 
Thomson Reuters S P 500 earnings data  by the numbers   as of Friday  March 18   16  

Forward 4 quarter estimate   120 39 vs last week s  120 67  In the last 4 weeks  the forward estimate has fallen about  1 
P E ratio  17 x 
PEG ratio  still elevated at 15 x    core earnings growth probably closer to 3    4 
S P 500 earnings yield  5 87  down from last week s 5 97   Anytime the S P 500 earnings yield has dipped under 6   the S P 500 has usually corrected 
Year over year growth of 4 quarter estimate   1 08  vs last week s  0 98   This  y y growth rate of the forward 4 quarter estimate  has languished now between  2  and  2  for the last 12 months  and must start to move higher if the S P 500 is to make all time highs 

Analysis   commentary  Most of this weekend s stock market commentary is discussing how overbought the S P 500 is  but it really isn t if that S P 500 forward estimate starts to move higher  And the fact is   as I learned painfully in 2008   the S P 500 forward estimate can remain quite  sticky  until the change is obvious  The fact that crude oil has rallied  the Energy sector is stabilizing  and the dollar is starting to weaken means that forward guidance should get somewhat more optimistic come April  16 s earnings releases  if only by a little bit 
If there is one thing that has been obvious off the post  09 lows  and with the latest generation of Street analysts  earnings estimates don t seem to move higher until the catalysts are obvious  Maybe put another way  there is no P E expansion occurring at all in the market today and earnings growth is all that you are getting 
The Health Care sector didn t really participate in this strong rally the last 6 weeks  Large cap pharma stocks probably represent good value for investors if you can look beyond the Presidential election rhetoric  Biotech hasn t gotten any traction either  but its bear market  while severe  is just 8 months old  Pfizer  NYSE PFE  is our clients  biggest net large cap pharma position  but some clients are long Merck  NYSE MRK  too  A number of large cap pharma names are testing their  200 week moving averages  when looking at the charts   Client positions can change at any time  for fundamental or technical reasons  
After a brutal start to Financials for the first 6 weeks of the year  if Energy and commodities stabilize  I do think Financials still work  The big banks are in great shape from a capital perspective  I still do not know why the sector traded the way it did through the end of February  16  but who would have thought on December 31  15 that as of March 18  16   looking at the SPDR ETFs like Financial Select Sector SPDR  NYSE XLF  and Energy Select Sector SPDR  NYSE XLE    that Financia s would be  5  year to date and Energy would be  5    Long both XLF  XLE 
The sectors that have been a significant drag on the S P 500 for the last 18 months are starting to stabilize  The weak dollar helps immensely too  at first from a psychological or sentiment perspective  but ultimately from an economic perspective 
The catalysts are starting to emerge that can break S P 500 earnings growth from its multi year lethargy  Higher commodity prices  slightly higher core inflation from a wage and price perspective  and a weaker dollar  While these were the exact catalysts for the 1987 Crash in October  1987  today  they could be the catalysts for a continued bull market  Higher commodity prices and higher inflation should be beneficial for S P 500 earnings  particularly after the deflationary decade from 2000 through 2010  and then the Financial constriction that followed ",2016-03-20,Brian Gilmartin,"https://www.investing.com/analysis/ultimately,-sp-500-earnings-have-to-start-to-move-higher-200122151",200122151
204145,425661,MRK,Opexa Therapeutics  Restructuring Sharpens Tcelna Focus ,opinion,"On 2 March Opexa Therapeutics  NASDAQ OPXA  announced it has embarked on a restructuring initiative to prioritize its spending towards completing the ongoing 190 patient Abili T Phase II study of lead candidate Tcelna in secondary progressive multiple sclerosis  SPMS   The company has reduced its overall headcount by about 30   but this does not affect the Abili T study timelines  for which data are expected in early Q416  The restructuring lengthens the company s financial runway into Q117  vs prior guidance of Q416   providing added flexibility around the timing of Tcelna data  Our rNPV is  35 1m  which after including  12 4m Q415 net cash equates to an equity valuation of  6 81 per share 

Abili T final dose in February  data planned in Q416
The final patient dose of Tcelna in the Abili T study was administered in February 2016  and approximately 97  of expected patient visits have been completed to date  Patients receive two annual courses of Tcelna treatment consisting of five subcutaneous injections per year at weeks zero  four  eight  12 and 24  The primary endpoint is the percentage of brain volume change  whole brain atrophy  at 24 months  The firm has guided that it plans to release top line data in early Q416  if data are positive  we anticipate Merck  NYSE MRK  will exercise its option to license into the program  potentially triggering a  25m milestone payment to Opexa 
To read the entire report Please click on the pdf File Below",2016-04-01,Edison,https://www.investing.com/analysis/opexa-therapeutics---restructuring-sharpens-focus-on-tcelna-data-200123649,200123649
204146,425662,MRK,MRK  Maximizing Reward  Minimizing Risk,opinion,"When it comes to trading and investing  knowing what strategy to use when is often half the battle 
Take a look at Merck   Company  NYSE MRK  in Figures 1 and 2  As you can see  following the recent rally MRK is once again  bumping its head  on a familiar resistance area between roughly  56 and  61 
Figure 1   MRK Weekly  Courtesy AIQ TradingExpert 
Figure 2   Courtesy AIQ TradingExpert 
Now different traders may look at these charts and have different reactions  Some might say  it s time to sell  or possibly even say  it s time to sell short   On the other hand others may look at this and say  gee  if it can just break through resistance it could run to a much higher level  
The other side of the equation involves asking how much money a trader is willing to risk in order to express that opinion  So for the sake of example  and as always  please remember that this is an example and not a recommendation  let s say that a trader wants to establish a bullish position in case MRK does manage to breakout to the upside  but that he or she doesn t wish to risk much money 
The Bull Call Backspread
The strategy we will use is an option strategy known most commonly as a  backspread   This strategy involves selling a lower strike price call option and using some or all of the proceeds to buy 2 or higher strike price calls  In our example we also want to give MRK some time to work its way higher  so we will consider longer term rather than shorter term options 
One other note regarding the backspread strategy  At the time the trade is entered  the lower the implied volatility for the options the better  after the position is entered  a rise in volatility can increase the profit potential and or reduce the shorter term risk  and vice versa   As you can see in Figure 3  the implied volatility for MRK options is not at  rock bottom  levels  but it has fallen back down to the low end of the historical range 

Figure 3   Courtesy  
The particulars of our example trade appear in Figure 4 
Figure 4   Courtesy  
Key things to note 
 There are 198 days left until option expiration
 The trade holds unlimited upside potential
 The maximum risk is   826  however  that amount of loss would only be incurred if we are still holding this trade on October option expiration day AND MRK closes on that day at exactly  57 50  In other words  in order to negate that risk all we have to do is resolve to exit the trade prior to October expiration 
Figure 5 looks at the risk involved with this position 

Figure 5   Courtesy  
As you can see  if we resolve to exit the trade by 8 16 for example  the risk curve for this date is represented by the green line in Figures 5 and 6  
 This gives MRK over four months to make some kind of a move to the upside AND
 The worst case loss is approximately   364  this is approximate because a decline in volatility could result in a slightly larger loss and a rise in volatility could result in a slightly small loss  
Also note that we can give MRK a lot of room on the downside  A close look at the risk curve lines in Figure 5 reveal that as MRK price falls lower the dollar risk actual decreases  So if we use the recent low of  47 97 as a stop loss point  by the time MRK falls to that price our risk is only approximately   230  again depending somewhat on any changes in volatility  
Now let s consider the profit potential as displayed in Figure 6 
Figure 6   Courtesy  
As you can see in Figure 6 if MRK moves one standard deviation higher to roughly  64 a share the trade will generate a profit of approximately  1 050  And if MRK was able to break out above the 2015 high of  63 62 and rally two standard deviations then profit potential soars to much higher levels 
Summary
The trade presented herein is an example of a call backspread with a reasonably good reward to risk profile   nothing more  nothing less  That being said please note that I am note  predicting  that MRK will in fact breakout to the upside  The 56 to 61 price range has been a rally killer on numerous occasions in the past and there is no reason to think it can t be again  This is important to consider because the bottom line is that if the stock does not rally further to the upside this trade will lose money 
But not much  And that really is the point  This trade represents an example of one way to play a potential continuation for MRK while essentially only  risking a couple of bucks   Like I said  knowing what strategy to use when is often half the battle ",2016-04-07,Jay Kaeppel,"https://www.investing.com/analysis/mrk:-maximizing-reward,-minimizing-risk-200124348",200124348
204147,425663,MRK,Selvita   Fruitful Partnership With Merck ,opinion,"2016 has started on a positive note for Selvita  WA SLVP  with FY15 results showing excellent organic growth and a second R D development deal with Merck KGaA  NYSE MRK  announced at the end of March  With solid service revenue growth expected to continue  the R D pipeline is progressing and lead product SEL24 should enter Phase I by mid 2016  Other potential catalysts during the next 18 24 months include possible partnership deals for SEL24 or SEL120 and new drug development deals from existing collaborations with H3 Biomedicine and Merck  We raise our valuation to PLN354m  vs PLN333m previously   or PLN27 per share  was PLN25 4  

51  revenue CAGR 2012 2015
2015 was a second profitable year with total revenue reaching PLN56 1m  up 35  year on year  Three year revenue growth corresponds to a CAGR of 51  and we expect double digit total revenue growth to continue  specifically 19  and 12  in 2016 and 2017 respectively  Strong organic sales growth in FY15 translated into increasing profitability with core operating profit of PLN6 8m up 29  and profit after tax of PLN7 7m up 31  year on year  adjusted for employee stock options programme expense and the impact of deferred tax asset changes in 2015  
To read the entire report Please click on the pdf File Below",2016-04-25,Edison,https://www.investing.com/analysis/selvita---fruitful-partnership-with-merck-kgaa-200126339,200126339
204157,425673,MRK,Viralytics Combination ,opinion,"Combination trials gather momentumViralytics is escalating combination trials of its Cavatak oncolytic virotherapy with immune checkpoint inhibitors  ICI   adding a collaboration with Merck  N MRK  to study IV Cavatak combined with Keytruda in advanced lung and bladder cancers to its portfolio of ongoing trials combining intralesional Cavatak with Keytruda or Yervoy in melanoma patients  Cavatak has the potential to markedly improve the proportion of patients who respond to ICI therapy and we expect it to continue to attract attention from big pharma  We value Viralytics at A 192m or A 1 04 per share 

Viralytics and Merck collaborate on combination trialViralytics and Merck will collaborate on a clinical trial combining intravenous  IV  Cavatak with Merck s marketed anti PD1 checkpoint inhibitor Keytruda  pembrolizumab  in lung and bladder cancer  The Phase Ib trial  which we expect to begin in H116  will be the second stage of Viralytics  ongoing STORM trial 
To Read the Entire Report Please Click on the pdf File Below",2015-11-27,Edison,https://www.investing.com/analysis/viralytics-combination-272685,272685
204158,425674,MRK,Opexa Therapeutics  Personalized Immunotherapy For MS ,opinion,"Personalized immunotherapy for MSOpexa s Tcelna immunotherapy is advancing in Phase IIb studies in secondary progressive MS  SPMS   with data expected in H216  The firm is fully funded to Phase II data which  if positive  could sharply increase investor and stakeholder interest  Merck KGaA  N MRK  has an option to in license Tcelna in MS  Opexa  O OPXA  is also developing OPX 212 in neuromyelitis optica  NMO   a rare autoimmune disorder leading to vision loss and paralysis  Opexa plans to file an IND and start a Phase I II study in H116  Our rNPVderived equity valuation is  51m 

ImmPath aims to suppress autoimmune responsesOpexa s core platform  ImmPath  produces patient specific  autologous  T cell immunotherapy following the collection of a patient s own blood  The blood cells are screened against predefined potential self reacting  autoimmune  target proteins  and the dominant self reacting T cell lines are isolated and expanded  An attenuated end product is reinjected into the patient  which aims to suppress these undesired self reacting T cells and thus curb autoimmune disease progression 
To Read the Entire Report Please Click on the pdf File Below",2015-11-30,Edison,https://www.investing.com/analysis/opexa-therapeutics-272921,272921
204159,425675,MRK,Selvita  Emerging Biotech Player ,opinion,"Selvita  WA SLVP   Emerging biotech player2016 could be a transformational year as in house oncology drugs move into Phase I  A fresh Merck KGaA  N MRK  deal could add new candidates to the oncology pipeline  This and continued collaborations help maintain strong service revenues  SEL24 will enter Phase I in H216  dosing expected to begin in July 2016  thereby bringing it closer to a potential deal  Our fair value has increased from PLN275m to PLN333m  from PLN21 to PLN25 4 per share  due to improved operational performance  internal programme advancement  addition of new partnering programmes and cash position 

SEL24 and SEL120 moving closer to the clinicTwo lead cancer candidates have advanced  SEL24 is expected to start Phase I in acute myeloid leukaemia  AML  in H216  SEL120 is expected to begin IND enabling studies in Q216 and move to Phase I in 2017  FLT3 inhibitors are  hot  targets in AML and midostaurin  an FLT3 inhibitor  showed survival benefit of more than four years versus placebo in a Phase III study in AML  data at ASH 2015   This result should be viewed as a positive indicator for SEL24 and improves the partnering deal outlook for the dual PIM FLT3 inhibitor 
To Read the Entire Report Please Click on the pdf File Below",2015-12-09,Edison,https://www.investing.com/analysis/selvita---emerging-biotech-player-375075,375075
204160,425676,MRK,Threshold Pharmaceuticals  Disappointing Data ,opinion,"Disappointing Phase III evofosfamide dataEvofosfamide has not met the primary endpoint of improving overall survival in two Phase III trials in soft tissue sarcoma  STS  and pancreatic cancer  Although some benefit was seen in pancreatic cancer  partner Merck  N MRK  KGaA will not file either indication with regulators and Threshold Pharmaceuticals Inc  O THLD  expects Merck to terminate the agreement  If this occurs  Threshold will consider all options for future evofosfamide development  which could include in combination with checkpoint inhibitors  We have placed our valuation and forecasts under review pending further updates  Threshold is now trading broadly in line with expected YE15 cash of  40 45m  THLD estimates that this should be sufficient to fund operations to end 2016  beyond initial tarloxotinib Phase II data availability  which is expected around mid 2016e 

In the Phase III pancreatic cancer trial evofosfamide combined with gemcitabine did improve overall survival  OS  versus gemcitabine alone  with a death hazard ratio  HR  of 0 84  HR
Despite some activity in pancreatic cancer  partner Merck has decided not to pursue regulatory filing in either indication  Threshold also expects Merck to terminate the evofosfamide agreement  Evofosfamide is currently in a Phase II III trial in lung cancer  in addition to development in other solid tumours and blood cancers  including glioblastoma and multiple myeloma  If Merck terminates  Threshold will consider the options for future evofosfamide development  which could include in combination with checkpoint inhibitors following preclinical data 
To Read the Entire Report Please Click on the pdf File Below",2015-12-10,Edison,https://www.investing.com/analysis/threshold-pharmaceuticals-375428,375428
204166,425682,MRK,Euro Weakens As Greece Negotiations Fail,opinion,European stock markets are expected to open weak as the Greek crisis deepens  Last ditch negotiations will resume on Saturday and will hopefully avert a Greek default and possible exit from the common currency  At any rate  European finance ministers are preparing for a scenario in which the Eurozone must be protected from financial turmoil if the Greek government fails to repay  1 79 billion next Tuesday  Talks broke down on Thursday  showing that neither side may be willing to compromise  In any case  both the Greek and German parliaments must accept the agreement before it is signed  adding another layer of resistance leaders must overcome  A  Grexit   a scenario in which Greek exits the Eurozone may be inevitable if Athens and their creditors fail to find a solution in the coming five days  Yesterday European stock markets showed mixed results  reflecting the market s reactivity to the ongoing drama  The UK s FTSE fell 0 3  as the financial and healthcare sectors came under pressure  The German DAX declined 0 1  as major components such as Merck  NYSE MRK  and Siemens AG  XETRA SIEGn  NA  LONDON 0P6M  show the weakest performance with a 0 4  decline  The French CAC was lower by 0 2  as major consumer names decline  The Italian MIB outperformed its European counterparts with 0 8  increase for the day as shares in the financial sector gain up to 4 8  In Currencies  the euro slightly weakened against the dollar  falling 0 1  to trade 1 1188  The EUR USD has been stuck in a tight range for the third consecutive session  reflecting the fundamentally led markets  So far  the euro is down 1 4  for the week  The U S  dollar slightly weakened against the yen  falling 0 2  to trade at 123 33  As Greece claims the majority of the spotlight  positive U S  economic data could have propelled the dollar by reaffirming the Federal Reserve s data dependent position on an interest rate increase  Data released on Thursday have shown that U S  consumer spending grew at its fastest pace in nearly 6 years  As it currently stands  analysts expect that Federal Reserve will increase borrowing costs in a gradual process that will begin towards the end of the year Crude oil declined 1  on Thursday  falling below  60 per barrel  but has since gained 0 13  to trade at  59 71  Crude oil has been trading within a relatively tight range as it faces pressure from a larger than expected growth in gasoline stockpiles last week despite an overall decline in crude production  The possible nuclear deal with Iran has major consequences for the oil market  If the deal is signed  it is expected that Iran will begin to sell oil in large volumes  a move that may worsen the already oversupplied market Next week will offer some interesting data releases  German inflation data is scheduled to release on Monday  shortly followed by U S  housing data  UK and Canadian GDP data is scheduled to release on Tuesday  However  all eyes are set on Thursday s U S  nonfarm payroll report  detailing the number of jobs added to the U S  market ,2015-06-26,OptionsClick,https://www.investing.com/analysis/euro-weakens-as-greece-negotiations-fail-256337,256337
204167,425683,MRK,Opexa Therapeutics ,opinion,"Personalised MS immunotherapyOpexa Therapeutics  NASDAQ OPXA  is funded through to the H216 readout of its Phase IIb Abili T study of Tcelna in secondary progressive multiple sclerosis  SPMS   SPMS affects 30 45  of the approximately two million worldwide MS patients and an approved treatment could generate more than  5bn in US sales 
Tcelna moving ahead in SPMSTcelna is a personalised immunotherapy developed for the treatment of SPMS  an advanced stage of MS with no safe approved therapy  Tcelna is believed to reduce the quantity and or activity of myelin reactive T cells  MRTCs  that attack myelin  An MS patient s individual therapy is developed by collecting their blood and expanding the MRTCs  which are cryopreserved and attenuated by irradiation before being dosed to the patient five times per year  The reintroduction of attenuated MRTCs  Tcelna  stimulates the immune system to target the undesired MRTCs  Marked MRTC reductions were shown in a Phase I II study 
190 patient Phase IIb study tracking for H216 dataA two year placebo controlled Phase IIb study  Abili T  assessing changes in brain volume by MRI and disability by EDSS is ongoing  86  of total patient visits have occurred and Opexa plans to report top line data in H216  A pooled analysis from 36 SPMS patients from earlier studies showed that c 80  of those completing two years of Tcelna showed no disease progression  Historical control data suggest that 40  of SPMS patients would normally progress  If Abili T is positive  Merck  NYSE MRK  KGaA could exercise its option to license Tcelna  thereby funding future trials  Phase III  and providing Opexa with up to  220m in future payments and 8 15  in tiered royalties 
To Read the Entire Report Please Click on the pdf File Below",2015-08-21,Edison,https://www.investing.com/analysis/opexa-therapeutics-262476,262476
204168,425684,MRK,Cancer Immunotherapy Investing  It s All About The Right Technology,opinion,"For many decades  cancer therapy research has failed or  best case  has led to only marginally effective therapies for most types of cancer  which explains why many investors and even clinicians have lost faith in seeing any substantial advance made in the near future  Today  with the data accumulating from clinical trials  there is no doubt that immunotherapy will change our perspective on cancer treatment and give hope to the millions of patients diagnosed with different cancers every year From a financial point of view  cancer immunotherapy is definitely one of the most exciting fields to invest in for the next decade  and despite the underlying risk  many investors are willing to take the early bird strategy in order to most benefit from the high growth potential 
In this article I will try to give summarize some scientific background to help understand the different current approaches in the cancer immunotherapy  and enable readers to make more informed investing decisions  In this article  I will concentrate on three questions which are  in my opinion  the most important for any biotech investor 

First  which companies are adapting the approaches with proven efficacy from clinical trials 
Second  which approaches are more likely to deliver a cost effective treatment to the market 
Third  in which approaches are safety related disappointments less likely 

These questions will be discussed regarding the main approaches biotechnology companies have adapted to beat cancer  which are  CAR T cells  enhanced affinity TCRs  cancer vaccines and checkpoint inhibitors  Please note that this article will only consider the growth companies listed under Loncar cancer immunotherapy index  Chimeric T cell antigen receptor  CAR T cells   Developing companies  ZIOPHARM Oncology Inc  NASDAQ ZIOP   Kite Pharma  NASDAQ KITE   Juno Therapeutic  NASDAQ JUNO   Bluebird bio Inc  NASDAQ BLUE   Cellectis SA  NASDAQ CLLS  and Bellicum Pharmaceuticals Inc  NASDAQ BLCM  
In this approach  human T cells are genetically modified to have an engineered receptor that recognizes a specific molecule on the surface of tumor cells  these T cells will subsequently attack and destroy the cancer cells  From the few clinical trials conducted in the last three years  this type of immunotherapy has proved highly effective and led in one of these trials to a complete response in 75  of patients suffering from a blood cancer called CLL  which was resistant to chemotherapy  These are by far the most promising results seen in cancer treatment  which explains why so many companies are racing to achieve most advances in this field 
So far  only Kite and Juno have announced clinical data from trials using the CAR T cells  with Cellectis to enter the clinical stage in 2015  and while most of these trials were using CAR T cells of the 2nd generation  Juno is developing other generations  3rd and 4th  which may be more effective  especially in solid tumors  but will unlikely come without a safety cost 
However  it is noteworthy that most trials with CAR T cells were conducted in patients with blood cancers affecting the B cells  mainly ALL and CLL   the reason is simply that B cells have a high specific molecule  CD19  that we can target without damaging other organs  Meanwhile  Juno  Kite and Bellicum are developing CAR T cells to target other molecules  Juno  L1cam  Kite  EGFRvIII  Bellicum  PRAME  found in solid tumors  Nevertheless  achieving a high efficacy here is more challenging than what we have seen in blood cancers  mainly because L1cam and PRAME may be found in normal tissues while EGFRvIII is more tumor specific but it is only found in 30  of patients with Glioblastoma  a brain cancer  
Safety profile is another challenge for CAR T cells therapy  with many patients developing a life threatening reaction known as cytokine syndrome  in which the effective destruction of the tumor cells results in releasing excessive amounts of small molecules  the cytokines  causing symptoms similar to those seen in severe infections  Other deadly reactions may occur when targeting molecules existing in healthy tissues of the vital organs  However  Bellicum and Juno therapeutics are developing their own approaches to minimize this specificity related risk  either by providing their therapeutic cells with a suicide gene that can be triggered any time during the therapy to save patient s life  Bellicum  or by making them able to recognize two different molecules and thereby increasing their tumor specificity and avoiding collateral damage 
After efficacy and safety  comes cost effectiveness as the next issue investors need to consider  This point becomes especially important once you know that most trials have used a patient s own T cells  autologous CAR T cells   meaning that the developing companies will not be able to recognize their potential market size unless they make huge investments in building their advanced facilities in all demographic centers  which will make it very hard to keep a good profit margin  In this term  Ziopharm and Cellectis are developing a cheaper and more innovative solution  which may enable them to produce off the shelf CAR T cells by genetically modifying these cells to prevent their immunoreaction against the patients  healthy tissues  Increased affinity T cell receptors  TCR  Developing companies  Kite  Juno and Adaptimmune Therapeutics Plc  NASDAQ ADAP  
This therapeutic approach is different from CAR T cells by means of enhancing the receptors existing naturally on the T cells in order to break their cancer tolerance  The main advantage of TCRs over CAR T cells is their ability to recognize extracellular and intracellular molecules as well  which will significantly increase the available therapeutic targets 
In clinical trials  increased affinity TCRs have demonstrated significant clinical responses in patients with metastatic melanoma  colorectal carcinoma  and synovial sarcoma  although the response rate was variable and ranged from 12 to 67   Adaptimmune was the first company to announce data from clinical trials  where increased affinity TCRs were used to target a tumor specific protein molecule known as NY ESO 1  These trials have shown a clinical response in over 50  of patients with solid and hematologic tumors 
The main downside of this approach is the lack of success in developing off the shelf therapeutic cells  as these same receptors  TCRs  take a main part in triggering the immune reaction against the host cells  meaning that these T cells must be taken from the patients  own blood   Cancer vaccines Developing companies  Bellicum  Inovio Pharmaceuticals Inc  NASDAQ INO   Oncothyreon Inc  NASDAQ ONTY   Celldex Therapeutics Inc  NASDAQ CLDX   NewLink Genetics Corporation  NASDAQ NLNK  and Northwest Biotherapeutics Inc  NASDAQ NWBO  
Unlike the vaccines we take to prevent diseases  cancer vaccines aim mostly to treat diagnosed cancers  yet they have a similar mechanism  These vaccines aim to break the cancer immune tolerance by processing and reintroducing the cancer cells or their contents in a way that stimulates a natural immune response 
Despite the high potential of the adaptive T cell therapies  CAR T cells and TCRs   the vaccine based immunotherapy is  in my opinion  a more attractive medium to long term investment  Here are the main points  on which I based my thought 

Many cancer vaccines are already in late clinical stages  Phase II and III  what makes them  at least in theory  closer to any possible market entrance 
Most vaccines are being developed as off the shelf therapies  which means less operating expenses and a chance for higher profit margins comparing with the personalized CAR  and TCR  therapies 
Cancer vaccines have shown potency in many types of cancers  whereas the clinical efficacy of the CAR T cells is still restricted to blood cancers 
From clinical trials  vaccines were less likely to cause the serious side effects seen with CAR T cells  cytokine syndrome and organ failure   which makes the latter more vulnerable to safety related disappointments 

As many biotechs have adapted substantially different approaches to develop cancer vaccines  I will try to summarize these main approaches and their possible upsides and downsides 
Bellicum is developing an approach based on genetically engineering patient s dendritic cells  the antigen presenting cells  so they can introduce a protein called PSMA  prostate specific membrane antigen  to the other contents of the immune system in order to treat prostate cancer  Efficacy is still to be proven in clinical trials  but even then  finding specific targets  production complicity and cost effectiveness may be challenging for this approach 
Inovio s vaccines utilize DNA structures that encode cancer specific proteins  Phase I trials have been initiated to test two vaccination products in a variety of cancers  Beside their suitability for universal  off the shelf  commercialization  the main advantage of this approach is its designing flexibility  meaning that one vaccine can be easily engineered to target more than one cancer protein 
Oncothyreon is developing off the shelf protein based vaccine to stimulate an immune response against a cancer specific molecule known as MUC1  This vaccine is being tested in phase I trials in patients with solid tumors 
Celldex is also working on two off the shelf cancer vaccines  the first is a Phase III peptide that targets EGFRvIII  a cancer specific protein   In Phase II trials  this vaccine has increased the 3 years survival rate in patients with Glioblastoma  a brain cancer  to 26  comparing with 18  under current standard therapy  The second vaccine uses a more sophisticated approach to deliver the immune stimulating protein directly to the dendritic cells and is being tested in phase II trials with encouraging data from phase I in multiple tumors 
Newlink took a totally different approach by modifying cancer cells themselves so they can be used as an off the shelf therapy to stimulate the immune response in patients suffering from the same type of cancer  Among the many trials  the best outcomes were seen in phase II trials in patients with Pancreatic cancer  where this cellular vaccine achieved a 120  increase in 3 years survival rate  Despite the concerns associated with the injection of whole cancer cells  this vaccine has a good safety profile with no reported life threatening reactions 
Northwest Biotherapeutics is working on highly personalized cancer vaccines  which require obtaining the patient s own dendritic and tumor cells as well  Apart from the financial challenges surrounding it  this approach has shown by far the best results seen in patients with glioblastoma  a brain cancer   as the patients had a median survival of 3 years  more than triple the usual time with standard of care treatments   
Checkpoints inhibitors
Checkpoints inhibitors are antibodies or small molecules that block specific receptors  known as checkpoint receptors  which help tumor cells escape the body natural immune attack  With proved clinical efficacies and favorable safety profiles  three checkpoints inhibitors were approved from FDA in the last four years  Opdivo   and Yervoy   from Bristol Myers Squibb Company  NYSE BMY  and Keytruda   from Merck  NYSE MRK    Although their clinical benefits are less exciting than these seen in the above mentioned approaches  checkpoints inhibitors have a high potential to be used in combination with other immunotherapies  which may make them an essential ingredient in our future cancer recipe 
However  even when it may be a win win game  investing in checkpoints inhibitors is not that simple as this approach is still dominated by the giant pharmaceutical companies  with only a few biotechs  including Agenus  Tesaro and Newlink genetics  developing similar agents in preclinical stages  
The bottom line
Even if we still can t talk about a cancer cure  there is no doubt that the cancer immunotherapy will change the way we look at this disease in the next decade  Financially  and with the increasing numbers of biotechs engaged in this field  the best what investors can do is to understand what these companies are working on  follow the companies they are most convinced about and most importantly  use the harmless bad news to accumulate shares at lower prices",2015-09-17,Tarek Roustom,https://www.investing.com/analysis/investing-in-cancer-immunotherapy:-choose-the-right-technology-265340,265340
204169,425685,MRK,The Rigging Of The American Market,opinion,"Much of the national debate about widening inequality focuses on whether and how much to tax the rich and redistribute their income downward 
But this debate ignores the upward redistributions going on every day  from the rest of us to the rich  These redistributions are hidden inside the market 
The only way to stop them is to prevent big corporations and Wall Street banks from rigging the market 
For example  Americans pay  for pharmaceuticals than do the citizens of any other developed nation 
That s partly because it s perfectly legal in the U S   but not in most other nations  for the makers of branded drugs to pay the makers of generic drugs to delay introducing cheaper unbranded equivalents  after patents on the brands have expired 
This costs you and me an estimated a year   a hidden upward redistribution of our incomes to Pfizer  Merck  N MRK   and other big proprietary drug companies  their executives  and major shareholders 
We also pay more for Internet service than do the inhabitants of any other developed nation 
The average cable bill in the United States rose 5 percent in 2012  the latest year available   nearly triple the rate of inflation 
Why  Because  of us have no choice of Internet service provider  which allows them to charge us more 
Internet service here costs 3 and a half times more than it does in   for example  where the typical customer can choose between 7 providers 
And U S  cable companies are intent on keeping their monopoly 
It s another hidden upward distribution   from us to Comcast  O CMCSA   Verizon  or another giant cable company  its executives and major shareholders 
Likewise  the interest we pay on home mortgages or college loans is higher than it would be if the big banks that now dominate the financial industry had to work harder to get our business 
As recently as 2000  America s five largest banks held 25 percent of all U S  banking assets  Now they hold    which gives them a lock on many such loans 
If we can t repay  forget using bankruptcy  Donald Trump can go bankrupt four times and walk away from his debts  but the bankruptcy code doesn t allow homeowners or graduates to reorganize unmanageable debts 
So beleaguered homeowners and graduates don t have any bargaining leverage with creditors   exactly what the financial industry wants 
The net result  another hidden upward redistribution   this one  from us to the big banks  their executives  and major shareholders 
Some of these upward redistributions seem to defy gravity  Why have average domestic airfares risen 2 5  over the past  and are now at their the highest level since the government began tracking them in 1995   while fuel prices  the largest single cost for the airlines  have plummeted 
Because America went from nine major carriers ten years ago to just four now  Many airports are now served by one or two 
This makes it easy for airlines to coordinate their fares and keep them high   resulting in another upward redistribution 
Why have food prices been rising  than inflation  while crop prices are now at a six year low 
Because the giant corporations that process food have the power to raise prices  Four food companies control  of beef packing  t of soybean processing  of pork packing  and  of chicken processing 
Result  A redistribution from average consumers to Big Agriculture 
Finally  why do you suppose health insurance is costing us more  and co payments and deductibles are rising 
One reason is big insurers are consolidating into giants with the power to raise prices  They say these combinations make their companies more efficient  but they really just give them power to charge more 
Health insurers are hiking ratesnext year  and their stock values are skyrocketing  the Standard   Poor s 500 Managed Health Care Index recently hit its in more than twenty years  
Add it up   the extra money we re paying for pharmaceuticals  Internet communications  home mortgages  student loans  airline tickets  food  and health insurance   and you get a hefty portion of the average family s budget 
Democrats and Republicans spend endless time battling over how much to tax the rich and then redistribute the money downward 
But if we didn t have so much upward redistribution inside the market  we wouldn t need as much downward redistribution through taxes and transfer payments 
Yet as long as the big corporations  Wall Street banks  their top executives and wealthy shareholders have the political power to do so  they ll keep redistributing much of the nation s income upward to themselves 
Which is why the rest of us must gain political power to stop the collusion  bust up the monopolies  and put an end to the rigging of the American market ",2015-11-02,Robert B. Reich,https://www.investing.com/analysis/the-rigging-of-the-american-market-269876,269876
204170,425686,MRK,Markets Climb On Manufacturing Data ,opinion,"Wall street rose higher on Monday as recently released economic data reports have shown that factory activity improving in a number of key countries  At the same time  the healthcare sector showed marked gains during the session  Despite a monthly decrease in U S  factory activity  October s performance exceeded expectations  The Dow Jones Industrial Average gained 165 2 points  or 0 94   to trade at 17 828 76  The S P 500 index added 24 69 points  or 1 19   to trade at 2 104 05  and the Nasdaq Composite rose 73 4 points  or 1 45   to trade at 5 127 15  Chinese and German data reports have shown that manufacturing in both countries beat prior forecasts  According to Ed Hyland  global investment specialist at J P  Morgan Private Bank  the global economy is on track for continued growth and decreasing fears over a recession  particularly in more developed countries  The end of the U S  earnings reports season has shifted the focus back to economic data releases  The nonfarm payrolls report  scheduled to release on Friday  will hold special significance after the Federal Reserve s recent hints at a December interest rate hike 
European stock markets rose as October s Eurozone manufacturing purchasing managers  index came in above expected forecasts  The German DAX 30 added 100 53 points  or 0 93   to trade at 10 950 67 as all but two components move higher  Commerzbank  DE CBKG  led with a 7 6  gain after posting better than expected results  Deutsche Bank  DE DBKGn  rose 2  while Adidas  DE ADSGN  and Merck  N MRK  fell about 0 3   The French CAC 40 rose 18 55 points  or 0 38   to trade at 4 916 21  Automakers Renault  PA RENA  and Peugeot SA  PA PEUP  gained 3 1  and 0 4   respectively  In the financials sector  Credit Agricole  PA CAGR  and Societe Genrale rose 1 8  and 1 4   The British FTSE 100 remained flat after rebounding from a decline in the mining sector  Rio Tinto  L RIO   Anglo American  L AAL   BHP Billiton  L BLT   Antofagasta  L ANTO  and Randgold Resources  L RRS  fell between 1 4  and 2 2  
This week s upcoming economic data releases continue with Tuesday s interest rate decision from the Australian central Bank  ADP s initial U S  unemployment survey will be released on Wednesday  ahead of the official nonfarm payrolls report on Friday  U S  balance of trade will be released later on Wednesday  followed by a number of data releases from the Bank of England on Thursday  including inflation and an interest rate decision  U S  nonfarm payrolls will be released on Friday  followed by U S  and Canadian unemployment numbers later in the session ",2015-11-03,OptionsClick,https://www.investing.com/analysis/markets-climb-on-manufacturing-270101,270101
204176,425692,MRK,Merck  Bullish With A Stop At  59,opinion,"New 3 month high for Merck   Company Inc  NYSE MRK  shares  Bullish with a stop at  59 
MRK   6 months",2015-05-10,Petros Steriotis,"https://www.investing.com/analysis/merck-(mrk)-weekly-preview-may-11,-2015-251148",251148
204177,425693,MRK,Nasdaq Biotechnology Index Climbing Since 2009,opinion,"Over the past five years  one sector has outperformed all others in the S P 500  healthcare 
Biotech stocks have led the way  with the Nasdaq Biotechnology Index climbing a whopping 520  since early 2009 
The sector s incredible run hasn t dampened enthusiasm for the future  either   continue to receive bullish outlooks  and some are even taking on an air of invincibility 
In early 2015  InvestorPlace dubbed more than half a dozen healthcare stocks  immune  to market declines  And Mario Minotti of Minotti Group Wealth Advisors recently told TheStreet com that he still sees  a lot of growth potential  in biotech right now 
The problem  of course  is that this seemingly unstoppable trend can t last forever  Indeed  a number of healthcare stocks have become extremely overvalued  and eventually they re going to correct  Don t be left holding the bag when they do 
Far From Invincible
This warning is particularly salient for income investors  as healthcare stocks often pay solid dividends and may seem like attractive investments  Yet without doing the proper research  income seekers could end up with serious buyer s remorse 
To avoid falling for supposedly invincible yet overvalued companies  we need to look at valuation metrics  Comparing a company s valuation to the market or to its industry is fine  but it s also important to compare the company s current valuation to its 10 year averages  Let s look at Merck   Co   NYSE MRK  as an example 
Merck is one of the world s largest developers  manufactures  and distributors of pharmaceuticals  Its product categories include heart and respiratory health  infectious diseases  and women s health  At the moment  many of its biggest products are used to fight cancer 
Merck currently yields 3 1   which is nothing to sneeze at  Of course  five year dividend growth of 18  isn t good  but management has bumped the payout every year since 2011 
However  problems arise when we start looking at Merck s valuation 

Currently  the company is trading at a significant premium to the 10 year average of its EV EBITDA ratio  price to sales  P S  ratio  and price to earnings  P E  ratio 
If you need a refresher on EV EBITDA  make sure to check out my colleague   Also remember that you can always find a company s EV EBITDA on the key statistics page at Yahoo  Finance   
You ll notice that Yahoo  Finance lists a different EV EBITDA than my table  which was sourced from Bloomberg  Yahoo  acknowledges that its calculations  made with Capital IQ  may differ from those listed by a company in its reporting 
Either way  it s always worth comparing the current valuation to a longer term average  Even some companies that appear to be trading at a reasonable P E or EV EBITDA might end up being extremely expensive compared to their average 
Bottom line  Don t get caught up in the hype of supposedly invincible stocks  It s always worth doing your own research to see whether a stock actually represents a good buy right now  regardless of the dividend yield or the industry s supposed strength 
Good investing 
by Chris Worthington",2015-06-17,Wall Street Daily,https://www.investing.com/analysis/warning:-top-healthcare-performers-now-overvalued-255362,255362
204178,425694,MRK,What Does The Greek Crisis Mean For Financial Markets ,opinion,"The calendar shows a fair amount of economic data in the coming week  but attention is likely to be focused abroad  After many years  some would say decades  of percolating  the issue of Greece and the Eurozone is coming to a conclusion  I expect this week s theme to be 
What does the Greek crisis mean for financial markets  
Prior Theme Recap
In my last WTWA I predicted that market participants would be focused on the Fed  wondering if they had heard the message from the markets  Some readers commented that Greece was likely to take center stage  They were right at the start of the week  and also at the end when even the most voluble pundits were running out of comments about a predictable Fed meeting  Doug Short s excellent  always captures the story in one great chart 

Feel free to join in my exercise in thinking about the upcoming theme  We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead 
This Week s Theme
The Greece story has been high on the list of worries for several years  Some observers suggest that the underlying problems are better measured in decades 
This coming week features a solid data calendar  but nothing really dominates  The Greek story is both timely and compelling  with the market effects uncertain  It is a perfect paradise for pundits  I expect market observers to be asking 
What does the Greek Crisis mean for financial markets  
The Viewpoints 
There are several basic viewpoints  ranging from best to worst as follows 
An agreement will be reached at the last possible moment   A   I rarely cite anonymous posts  but this group of Amsterdam professors have been informative on this document  with well documented analysis  
A Greek settlement will encourage other European nations to seek concessions 
Greece will default on some payments  but the impact will be quite limited  A new Greek currency will emerge and there will be no  contagion     
Greece will default  leading to a run on banks    
A Greek default spills over to European banks and other sovereign debt  This weighs seriously on the nascent European economic rebound    

Variations on these themes are possible  Here is a   beginning on Monday  And  from ft com   a great way to keep up with events 
And a tongue in cheek look at the  




As always  I have my own ideas in today s conclusion  But first  let us do our regular update of the last week s news and data  Readers  especially those new to this series  will benefit from reading the  
Last Week s Data
Each week I break down events into good and bad  Often there is  ugly  and on rare occasion something really good  My working definition of  good  has two components 
The news is market friendly  Our personal policy preferences are not relevant for this test  And especially   no politics 
It is better than expectations 
The Good
There was plenty of good economic news 
Initial Jobless claims were only 267K  Here is the look  

Building permits are now at the highest pace since 2007  Some of this is multi family building  but from an economic perspective that is OK 
Core CPI is well contained  I am mystified by those who regard this as bad news  While the Fed is not hitting its inflation  target  we should be happy to see restrained inflation in the context of better economic growth  CPI per se is not a growth measure 
The Fed satisfied the markets  It might not have been a surprise  There were plenty of critics  Despite this  the continuing assurance that the path of rate hikes will be gradual is the key takeaway    the leading Fed observer  summarized the meeting as follows 

Bottom Line  Fed policy unchanged as expected  door still open for a rate hike in September  but the lower rate path indicates a modestly more dovish Fed resigned to a persistent low interest rate environment  It s the rate path we need to be watching  not the timing of the first hike 


Leading indicators once again surprised with a gain of 0 7  versus expectations of 0 4    has a complete analysis and critique  including this chart 

Investor sentiment has turned negative  This is a contrarian indicator  so it is good news   several different indicators and notes the protests from those who previously embraced the same measures  If you are going to be fair about an indicator  you need to accept the result when it changes direction  So many sources trumpet this when bulls seem to be  all in  and then fall silent when it changes 

The Bad
There was also some negative data last week  partly on the policy front 
Trade legislation is still mired in Congress  The political lines are shifting  but the fate is uncertain  As I have consistently noted  opinions may vary about worker protection  but this legislation meets our  market friendly  test    
A new government shutdown looming  Here is the early read     
Putin  Playing a nuclear card  The contemplated additions to inventory are small  and within the existing agreements  but why     
Industrial production declined by 0 2  
Housing starts registered a big decline  This was mixed news  given the revisions and the prior month gains   actually called it a  decent report  although the headline number was certainly disappointing 
The Ugly 
Charleston  So bad  so sad  in so many different ways  overshadowing other issues  I expect the story to dominate the Sunday news shows while everyone tries to sort out the implications 
The Silver Bullet 
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  Think of The Lone Ranger 
This week s award goes to Pierre Lapointe  who takes on the crowd that has been worrying about profit margins     This concern has been expensive for many investors  This chart summarizes the argument that it can take many years for declining margins to impact stock prices   Here is  from more than three years ago  This argument never dies  

Noteworthy 
This is an amazing list  particularly when we note that they are business passwords  Even the relatively modern requirement to include some numbers and symbols cannot slow down the creatively lazy   Statista via  

Quant Corner
Whether a trader or an investor  you need to understand risk  I monitor many quantitative reports and highlight the best methods in this weekly update  For more information on each source   

Recent Expert Commentary on Recession Odds and Market Trends
Bob Dieli does a   subscription required  after the employment report and also a monthly overview analysis  He follows many concurrent indicators to supplement our featured  C Score  
  A variety of strong quantitative indicators for both economic and market analysis  While we feature the recession analysis  Dwaine also has a number of interesting market indicators  He recently noted an   although the levels are still not yet worrisome 
  has developed an array of interesting systems  Check out his site for the full story  We especially like his   confirming that there is no recession signal  He gets a similar result from the   featured below   Georg continues to develop new tools for market analysis and timing  including a  to and from the S P 500 

  An update of the regular ECRI analysis with a good history  commentary  detailed analysis and charts  If you are still listening to the ECRI  3  years after their recession call   you should be reading this carefully  Recently the ECRI  to the error in their forecast  but still claims the best overall record  This is simply not true  I rejected their approach in real time during 2011 and also highlighted competing methods that were stronger  Until we know what is inside the black box  I suspect excessive reliance on commodity prices and insistence on unrevised data  we will be unable to evaluate their approach  Doug is more sympathetic in his last update  While I disagree  it will require a longer post to elaborate 
In this week s update Doug notes the ECRI claim of lower growth and more frequent recessions  The two do not necessarily coincide  Recessions do not generally begin with  stalls  but rather with business cycle peaks  Some readers have suggested that I retire this line of discussion from WTWA  I would happily do so if more media sources did a better job with the recession discussion  Until then it provides an important reminder 
Doug s  summary of key indicators watched by the NBER in recession dating shows no evidence of a business cycle peak  Only industrial production shows some weakness 


Some economic activity is not effectively measured  Economic growth is under estimated as a result  Here are   starting with examining the differences between spending and income  I suspect that all of us have contributed some cash to the underground economy  

The Week Ahead
We have a modest week for new data 
The  A List  includes the following 
New home sales  T   An important read on an important sector 
Durable goods  T   Volatile May data  but important for a good read on GDP 
Personal income and spending  Th   Key read on overall economic strength 
Michigan sentiment  F   Great concurrent indicator on spending and employment  with some leading character 
PCE prices  Th   This is the Fed s favorite inflation indicator  with less emphasis on housing  Well worth watching 
Initial jobless claims  Th   The best concurrent news on employment trends  with emphasis on job losses 
The  B List  includes the following 
Existing home sales  M   Less important than new sales  above  but still an interesting read on the sector 
FHFA home prices  T   Covering a wide range of homes  but not followed as widely as other measures 
GDP Q1 third estimate  W   Old news  but it provides a baseline 
Crude oil inventories  W   Current interest in energy keeps this on the list of items to watch 
There is a smidgen of FedSpeak  but it is not very important this week  Anything about Greece will command attention 
How to Use the Weekly Data Updates 
In the WTWA series I try to share what I am thinking as I prepare for the coming week  I write each post as if I were speaking directly to one of my clients  Each client is different  so I have five different programs ranging from very conservative bond ladders to very aggressive trading programs  It is not a  one size fits all  approach 
To get the maximum benefit from my updates you need to have a self assessment of your objectives  Are you most interested in preserving wealth  Or like most of us  do you still need to create wealth  How much risk is right for your temperament and circumstances 
My weekly insights often suggest a different course of action depending upon your objectives and time frames  They also accurately describe what I am doing in the programs I manage 
Insight for Traders 
Felix continued a neutral stance for the three week market forecast  The confidence in the forecast is very low with the continuing extremely high percentage of sectors in the penalty box  Despite the overall market verdict Felix has generally been fully invested in three top sectors  including some foreign exposure  For more information  I have posted a further description     You can sign up for Felix s weekly ratings updates via email to etf at newarc dot com  Felix appears almost every day at Scutify  follow him   
While trading is not gambling  there are some valid lessons   consults a top gambler and identifies some common amateur mistakes  Have you ever engaged in  revenge trading  
Insight for Investors 
I review the themes here each week and refresh when needed  For investors  as we would expect  the key ideas may stay on the list longer than the updates for traders  Major market declines occur after business cycle peaks  sparked by severely declining earnings  Our methods are focused on limiting this risk  Start with our  and follow the links 
We also have a page summarizing many of the   If you read something scary  this is a good place to do some fact checking  Please also check out part one of my new series on risk  Early reactions were good  and more comments are welcome  At least three more installments are planned 
Other Advice 
Here is our collection of great investor advice for this week 
If I had to pick a single most important post  it would be this assessment of market prospects by   He is bullish on the summer prospects for stocks  mostly because of errors in a list of nine popular worries that have weighed on the market  I especially like this one 

9  A market correction is not  due   Perhaps the most important data point of all for the bears to remember is that rallies do not end simply because they ve gone on for a few years and are  due  to correct  Consider the  of 1987 to 2000  which lasted 4 494 days and saw a roughly 585  increase in the S P 500  I would never discourage investors from thinking critically or skeptically about the numbers  and it s human nature to wonder when the party is going to end  But predicting the end just because we ve had a long runup  especially in the face of this encouraging data  That s just self defeating 

Stock Ideas 
Barron s has a   suggesting that some could rise by 50  in the coming year  The basic argument is that expansion of capacity has been controlled and RASM  revenue per available seat mile  strong  While several of the big names are cheap  their favorite is American 
Brian Gilmartin provides  in how to use cash flow to compare dividend stocks  Merck  NYSE MRK  Vs  Pfizer  NYSE PFE    From A Dividend And Free Cash Flow Perspective analyzes two popular stocks  provides ideas about the sector  and helps investors to learn a key element of stock picking 
The six best sectors for the rest of the year   for manufacturing and finance  Good here 
Personal Finance 
Professional investors and traders have been making Abnormal Returns a daily stop for over ten years  The average investor should make time  even if not able to read every day as I do  for a weekly trip on Wednesday  Tadas always has first rate links for investors in this   I especially liked this  about emotions and investing   a topic at the top of the list in conferences with new clients 
Energy 
Is Exxon Mobil  NYSE XOM  the best dividend stock  Tim McAleenan Jr   with a good list of reasons  including noting  all weather flexibility  as the company makes profits in a tough environment 
Thinking about Bonds 
Watch out for bond ETFs that sound good  but have a high bid ask spread  The most liquid ETFs are fine  but some spreads are in the 0 8  range  Chris Dieterich in Barron s 
Has there been a  sideways correction     in the popular Barron s Streetwise column  

In fact  stocks have performed quite well after a quiet start to the year  Paul Hickey of Bespoke Investment Group  looked at the 10 years during which the S P 500 stayed closest to where it had started during the first 117 trading days  He found that it had risen 6 6   on average  in the rest of those 10 years  Says Hickey   A sideways market can be a correction in time  not price  Expect things to drift higher from here  

Final Thought
This section is where I share my own conclusion  I try to add some insight to the evidence  Last week there was some discussion  starting with a complaint from a reader  who obviously had only recently tuned it  that I did not offer specific advice  I hope that the regular audience for WTWA knows that the series is designed with several objectives 
Identify the most important issues
Focus attention on those most relevant for the week ahead
Provide interesting arguments for various perspectives
Explain how your analysis might differ depending upon your time frame
Share my own conclusions  often different for traders and investors    and I have programs doing both 
Anyone expecting a one size fits all  spoon fed approach has come to the wrong place 
How does this apply to Greece  The Greek crisis is a good example of a type of market risk  part of the series I am working on  see the link above   It is an example of something viewed as a binary outcome with a known and certain date for the conclusion  The framework for analysis includes three topics 
The probability of each outcome 
The likely consequences of each outcome 
Market expectations  what is already reflected in market prices  
There is always the chance that the deadline will somehow be extended  Outcomes may also be less binary than they seem  The negotiating parties frequently find creative avenues for compromise as well as delay 
With that background  here is how I am using the framework to think about this risk  My conclusions are based upon a wide variety of sources  In WTWA I do not make an argument for my own viewpoint  but I usually share it 
I rate the chance of a default as quite high  The Greek leadership  encouraged by its constituency  seems unwilling to make concessions  European leaders seem to have reached their limit  Reports from those close to the negotiations have not been encouraging 
I expect the ultimate consequences to be limited  but only after a period of uncertainty  While contagion is unlikely  markets hate uncertainty 
It is always difficult to know what is reflected in current market prices  My conclusion is based upon nearly thirty years of observation of daily trading  My sense is that the Greece effect has  so far  been pretty minor  Most market participants have been trained to expect an eleventh hour resolution    
The average investor should not over react to this  going  all out  of the market for a temporary effect  A trader might try to capture the reaction  We did a little of this in our accounts 
As always  the right trade depends upon your time frame and your agility ",2015-06-22,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-what-does-the-greek-crisis-mean-for-financial-255671,255671
204183,425699,MRK,Ideas On Trading Merck This Week ,opinion,"Merck and Company   MRK  has been moving in a sideways channel that on closer inspection shows a series of higher highs and now also a higher low  An uptrend  Since the start of 2015 it has moved higher quickly and then started a consolidation  A break of that consolidation to the upside carries a target of 68  The RSI on the daily chart is strongly in the bullish zone while the MACD is rising  Both support that break higher  Short interest is low at 1  and the company is expected to report earnings February 4th before the market opens 
MRK Daily
On the longer monthly chart this name gets very interesting  Sitting at 13 year resistance and coming off of a double bottom  the price action is tracing out a bearish Shark harmonic  This pattern has a Potential Reversal Zone PRZ I  at 88 60 and PRZ II at 106 65  not shown   The stock also carries a 2 90  dividend  There is resistance at 63 and then 68 followed by 72 and 76 50 before 80  Support lower comes at 61 75 and 60 30 followed by 58 75 and 56 75 before 53 40 
MRK Monthly
Trade Idea 1  Buy the stock on a move over 63 with a stop at 61 50  A straight buy for the move higher with protection 
Trade Idea 2  Buy the January 30 Expiry 63 Calls  offered at 86 cents late Friday   A short term upside trade with risk defined to the premium paid 
Trade Idea 3  Buy the January 30 Expiry 61 5 63 bullish Risk Reversal  54 cents   A short term upside trade with leverage from the short 61 5 Puts  relying the large Open Interest at the 62 Strike as a speed break should it fall 
Trade Idea 4  Buy the January 2016 Expiry 65 Calls   3 85   A longer term upside trade with defined risk 
Trade Idea 5  Buy the April January 2016 Expiry 65 Call Calendar   3 40   A longer term upside trade  with lowered cost from the short April Calls  The plan would be to roll the short calls out  and up if necessary  as they near Expiration 
Trade Idea 6  Buy the stock and add a February 62 5 60 Put Spread  April 67 5 Covered Call  Collar  16 cents   A longer term upside trade with protection through the earnings event with a low cost  Sell the Put Spread after earnings should the price fall  and if it rises above the Call Strike roll the Calls up and out  preferably for a credit ",2015-01-20,Gregory W. Harmon,https://www.investing.com/analysis/ideas-on-trading-merck-this-week-239097,239097
204186,425702,MRK,Thursday s Swing Trading List  M  MON  MRK  BYD  CBI,opinion,"Here s today s swing trading watch list 

Short Macy s  NYSE M 

Short Monsanto  NYSE MON 


Short Merck   Co  NYSE MRK 


Long Boyd Gaming  NYSE BYD 

Long Chicago Bridge   Iron  NYSE CBI ",2015-03-12,Ryan Mallory,"https://www.investing.com/analysis/swing-trading-watch-list:-m,-mon,-mrk,-byd,-cbi-244760",244760
204187,425703,MRK,Swing Trades To Watch,opinion,"Swing Trading Watch List
Short Macy s  NYSE M 

Short Monsanto  NYSE MON 

Short Merck   Company  NYSE MRK 

Long Boyd Gaming  NYSE BYD 

Long Chicago Bridge   Iron  NYSE CBI ",2015-03-12,Ryan Mallory,https://www.investing.com/analysis/swing-trades-to-watch-244880,244880
204197,425713,MRK,Rating Merck s Plan To Acquire Cubist Pharma,opinion,"Yesterday  December 8th  Merck   Company  NYSE MRK  announced plans to acquire Cubist Pharmaceuticals  NASDAQ CBST  for a total transaction value of  9 5 billion  The two pharmaceutical companies have agreed that 

 Merck will acquire Cubist for  102 per share in cash  which represents a 35 percent premium to Cubist s average stock price for the most recent five trading days  

Cubist is known for creating antibiotics to combat stubborn bacteria  Antibiotics were once viewed as an unprofitable segment of healthcare sector because patients only use the product for specific rather than ongoing treatment  Drugs used to treat chronic illnesses received more attention due to inelastic demand  However  antibiotics are becoming more relevant and profitable with the surge of superbugs  or antibiotic resistant infections Cubist has proved itself to be a key player in combating superbugs  Bacteria morphs as it encounters resistance  and Cubist is working to outpace these mutations  Cubist currently has four drugs in phase 2 and 3 testing that will treat pneumonia  urinary tract infections  and other ailments to add to this portfolio  Michael Bonney  CEO of Cubist  stated  Combining with Merck is an exciting opportunity to accelerate Cubist s established leadership in antibiotics and deliver significant  certain and immediate value to shareholders   Both companies noted how their portfolios will complement each other nicely Once the acquisition is complete  Merck estimates that Cubist will  add more than  1 billion of revenue to its 2015 base   Looking forward  Merck anticipates that the transaction will be  significantly accretive to non GAAP EPS in 2016 and beyond  
One Financial Expert s Opinion
On December 8th  analyst  of Cantor Fitzgerald  a Hold rating on Cubist with a price target of  90  raised from  64  Rivkind based the increase price target on  a 5x multiple applied to 2016 sales of  1 5B  We think that a takeout thesis on the company is quite reasonable given the accretion associated with Cubicin    1 0B net sales per year   but we also believe that some portion of the deal value could be structured via contingent value rights  CVRs  associated with the company s pipeline  similar to other antibiotic deals    She attributed the Hold rating to CVRs being  typically structured around difficult to achieve targets or aggressive time lines  Rivkind s Past RecommendationsRivkind has a history of rating stocks in the pharmaceutical industry such as Salix Pharmaceuticals  NASDAQ SLXP  and Jazz Pharmaceuticals  NASDAQ JAZZ  Since April 2012  Rivkind has rated Salix twelve times  She rated the pharmaceutical company a Buy in April 2012 when shares were  48 10  Last month  Rivkind reiterated her Buy rating when shares were  93 87  Rivkind has a 57  success rate recommending Salix with an average return of  13  per recommendation Jazz Pharmaceuticals has been rated eleven times by Rivkin  In March 2013  she rated Jazz a Buy when shares were  59 11 and continued to issue Buy ratings as shares climbed to  114 38 in December 2013  Because of these cunning recommendations  Rivkind has a 120  average return per Jazz recommendation  In addition  it has helped Rivkind earn a 62  overall success rate over the past year recommending stocks with an average return of  15 3  per recommendation 
Conclusion
Merck and Cubist are excited to merge their portfolios of antibiotics and drugs in the face of superbugs  How will the acquisition affect the stock price ",2014-12-09,Uri Gruenbaum,https://www.investing.com/analysis/rating-merck's-plan-to-acquire-cubist-pharma-235140,235140
204198,425714,MRK,Hall of Fame  Hall of Shame  Best And Worst Recommendations Of  2014,opinion,"by Carly Forster and Sarah Roden 
2014 was an eventful year on Wall Street with many ups and downs  Although many analysts recommendations made in 2014 were profitable  many recommendations were also incorrect  costing investors a lot of money  Out of 47 000 ratings issued  here s our list of the best and worst analyst recommendations made in 2014  measured over a 3 month horizon 
The Best Recommendations 
On June 2  2014   of Citigroup maintained a Buy rating on Puma Biotechnology  NYSE PBYI  with a price target of  123  Werber made the Buy rating after Puma Biotechnology revealed that one of their breast cancer drugs had severe side effects  However  Werber remained optimistic and believed that the drug would become  a part of standard care  On June 2nd   shares closed at  57 06  with shares jumping to  266 25 three months later  This increase helped Werber earn a 344 9  return on the recommendation In 2014  Yaron Werber made 31 successful ratings out of 42 total ratings  earning a 74  overall success rate and a 25 3  average return per recommendation 2  On June 9  2014   of Maxim Group reiterated a Buy rating on Achillion Pharmaceuticals  NASDAQ ACHN   with a  6 price target  Seeing Achillion as an acquisition candidate in the HCV space  Kolbert noted   As they trade today  intra day at  278M market capitalization with over  100M in cash   we see Achillion as a compelling valuation  Shares of  were  4 25 when Kolbert made the recommendation and rose to  12 38 three months later  helping Kolbert to earn 191 2  profit on this recommendation In 2014  Jason Kolbert made 86 successful ratings out of 196 total  earning a 44  overall success rate with a  4 5  average return per recommendation 3  On August 18  2014  analyst  of Wells Fargo initiated coverage on Immune Design  NASDAQ IMDZ  with an Outperform rating and a price target of  17  18  The analyst called IMDZ an attractive company Shares of  were  12 13 each when Abrahams made the recommendation and three months later shares were  34 55  earning Abrahams a 184 8  return for the recommendation In 2014  Brian Abrahams made 29 successful recommendations out of 40 total  earning a 73  overall success rate  He has a  30 3  average return per recommendation 4  On October 20  2014  analyst  of BMO Capital initiatied coverage on Vitae Pharmaceuticals  NASDAQ VTAE  with an Outperform rating and a price target of  11  Birchenough was optimistic about the company s  efficient structure based drug design platform  and  deep pipeline of highly selective small molecule drugs across multiple therapeutic categories   He specifically highlighted  VTP 43742 for autoimmune disease and VTP 34072 for metabolic disease as key value drivers for VTAE over the next 12 months  Shares of  closed at  7 61 when Birchenough made the recommendation in October  The three month horizon is still approaching  but shares last closed at  19 19 on January 6th  earning the analyst a 175 5  return In 2014  Jim Birchenough made 51 successful recommendations out of 72 total  earning a 71  overall success rate recommending stocks  He has a  50 7  average return per recommendation 5  On September 22  2014  analyst  of Roth Capital initiated coverage on Bluebird Bio  NASDAQ BLUE   with a Buy rating and a  50 price target  The analyst noted   Bluebird Bio  Inc   is one of the pioneers of gene therapy  With its proprietary Lentiviral vectors  the company has successfully corrected dysfunctional genes and is well positioned to deliver single treatment based curative therapies for multiple monogenic diseases  in our view  At the time of the recommendation  shares of  closed at  36 49  Three months later  shares shot up to  89 90  helping Chattopadhyay earn a 146 3  profit from the recommendation In 2014  Debjit Chattopadhyay made 42 successful recommendations out of 84 total  earning a 50  overall success rate  He has a  6 4  average return per recommendation 
Worst Recommendations 
1  Robert W  Baird analyst  recommended an Underperform rating on Idenix Pharmaceuticals Inc  formerly IDIX  on April 8  2014  after the company announced that the data from its phase 1 II clinical trial for its IDX21437 nucleotide for the treatment of Hepatitis C was promising However  the analyst was skeptical regarding the safety of the drug s under development  noting  We still believe a long road lies ahead fraught with risks   He explained his Underperform rating  saying the  assets in development do not support the current valuation and provide little upside opportunity  Shares were  5 83 when Skorney made the recommendation and jumped to  24 three months later  Based on a 3 month horizon  Skorney lost a  308 0  return in profit for his Underperform rating on IDIX  After Skorney s position closed  Idenix Pharmaceuticals was acquired by Merck  NYSE MRK  and is no longer an independently publicly traded company   has successfully made 32 ratings out of 56 total over the past year  earning a 57  success rate recommending stocks and a  2 4  average return per recommendation 2  Cantor Fitzgerald analyst  downgraded her rating on Pernix Therapeutics  NASDAQ PTX  from Hold to Sell on January 6  2014  after having concerns over a lawsuit in which the company was sued for breach of contract  The analyst anticipated  a negative reaction in the stock or potential dilution to shareholders from an equity financing event  When Rivkand made the recommendation  shares were priced at  2 22  Three months later  Pernix Therapeutics was priced at  5 04  Based on a 3 month horizon  Rivkind lost a  120 2  return in profit for her Sell rating on  Irina Rivkind has successfully made 57 ratings out of 85 total over the past year  earning a 67  success rate recommending stocks with a  18 5  average return per recommendation 3  On September 10  2014  Bank of America  Merrill Lynch analyst  maintained a Buy rating on Sapphire supplier GT Advanced Tech  formerly GTAT   but cut his price target from  22 to  19 after Apple announced they would not be using Sapphire for its iPhone 6 Sankar did not expect the new iPhone 6 to have Sapphire  however he did believe Apple s use of Sapphire in their devices is more of a matter of  when  than a matter of  if  Shares were  12 78 when Sankar made the recommendation  Before the 3 month position was closed  GT Advanced filed for bankruptcy and trading of the company s stock on the NASDAQ is now currently frozen  Sankar lost a  97 7  return in profit for his Buy rating on GTAT Krish Sankar has successfully made 19 ratings out of 40 total over the past year  earning a 48  success rate recommending stocks with a  3 3  average return per recommendation 4  On August 13   2014  Cowen   Co  analyst  also covered GT Advanced Technologies with an Outperform rating and a  19 price target  citing that  Apple s new products launch could serve as a near term catalyst  The analyst noted   We see late 2015 early 2016 as being the end of the transitional period for GTAT as Apple revenue accelerates and solar polysilicon   ingot revenue normalizes and revenue recognition on material Hyperion revenue is achieved   He continued    We note this range implies a  19x multiple on our 2015 estimates  which is lofty  thus we expect the stock performance to be dependent on additional catalysts such as orders on the announced new products as well as on existing solutions  When Osborne made the recommendation  shares were priced at  16 59  As stated before  GT Advanced filed for bankruptcy before Osborne s 3 month position was closed and trading of the company s stock on the NASDAQ is now currently frozen  Osborne lost a  97 5  return in profit for his Outperform rating on GTAT In the past year  Jeff Osborne has successfully made 18 ratings out of 37 total  earning a 49  success rate recommending stocks and a  5 7  average return per recommendation 5  Wunderlich analyst  reiterated a Buy rating on BPZ Resources  NYSE BPZ  with a  7 00 price target on September 23  2014  after the company released an operations report on September 22  2014 The analyst pointed out the operations report contained good news and bad news  the good news being  that the CX15 7D development well at Corvina was completed earlier than expected allowing BPZ to spud the CX15 10D well on September 14  2014 with completion scheduled for November 2014  and the bad news being  that the Corvina CX15 3D and Albacora A 21D are only producing at 36  of prior levels  suboptimal in our view  Related to this  production from 3Q14 will be lower than volume from 2Q14  Shares were  1 97 when Haas made the recommendation and dropped to  0 22 three months later  Based on a 3 month horizon  Haas lost a  88 3  return in profit for her Buy rating on BPZ Irene Haas has successfully made 23 ratings out of 77 total over the past year  earning a 30  success rate recommending stocks and a  15 9  average return per recommendation Disclosure  All recommendations sourced from TipRanks",2015-01-08,Uri Gruenbaum,https://www.investing.com/analysis/hall-of-fame--hall-of-shame:-best-and-worst-recommendations-of--2014-237837,237837
204212,425728,MRK,Who s Buying Small Caps At P E 84 ,opinion,My  Buy in May  thesis held this central idea  the much awaited and necessary stock market correction had already occurred in the growth indexes suc as the Russell 2000 and NASDAQ Composite  And in May  the strong S P 500 index which was just waiting to go higher  would lift the RUT and the Nasdaq  On May 8  I advised Market Timers that we were starting a campaign to play a bottom in the RUT around 1100  I called it our  50 50  campaign because we were looking for support at the 50 week moving average  just below 1100  and for a bounce to ensue to retrace at least 50  of the March April decline  rally to 1150   We played that rally with TNA fairly well  despite a hiccup with the Tepper Tantrum on May 15 where the RUT actually went down and kissed the February low at 1082  Now the RUT rally has exceeded even my expectations for how quickly it could get back to 1180  I m sure there is a fair amount of  bear hunting  going on  but some of my favorite small caps are acting great for good reasons and I want to buy more  In fact  I did buy one yesterday  But  here s the number that still bothers the bears the most about the RUT  84  That s the 12 month trailing P E for the index  That is worrisome  But here s another number the bears should focus on  19  That s the 12 month forward P E  Here s the data from Friday s Wall Street Journal   Now  of course  I m not saying that I believe the RUT will fulfill those wonderful forward estimates  But that s not the point  The point is that many large investors are piling fresh cash into many small companies that they believe will move from a triple digit P E to a double digit one  or that they believe will be doubling or tripling their sales in the next year  Or that they believe are ripe take over targets where the sub  1 billion company gets taken out for 2 or 3 times that valuation  like hepatitis C drug maker Idenix Pharmaceuticals  NASDAQ IDIX  yesterday getting bought by Merck  NYSE MRK   While many investors wring their hands about valuations  every week I see managers of large portfolios putting money to work in growth stocks like the one I just bought yesterday  And as long as the S P 500 and Nasdaq 100 remain strong  the smaller growth indexes should make new highs this year  probably this summer  Where do you stand on the valuation question for smaller companies    Is it all too much  QE liquidity  driving us toward another bubble  Or is this investor optimism about the economy and earnings that is justified and bound to persist into next year ,2014-06-10,Zacks Investment Research,https://www.investing.com/analysis/who's-buying-small-caps-at-p-e-84-215487,215487
204213,425729,MRK,European indexes kept falling and the rest of them rose,opinion,On Wednesday  the world stock markets had no sharp trend observed  European indexes continued to decline  and other indexes rose  The U S  investors focused on good corporate news and ignored the weak economic data  Shares of most of pharmaceutical manufacturers rose on the news from Bristol Myers Squibb Company  NYSE BMY  about continuation of testing a new medicament for melanoma  Pfizer  NYSE PFE  quotations rose by 1 7   Merck  NYSE MRK  rose by 1 6   Shares of television networks rose due to tighten copyright by the U S  Supreme Court  The producer of genetically modified seeds  Monsanto announced the redemption of its own shares at   10 billion  and they rose up by 5 1   The trading volume of U S  exchanges was 5 7 billion shares yesterday  it is approximately equal to the average monthly level of 5 6 billion Economic data from the U S  were much worse than expected yesterday  The GDP for the first quarter in the third reading has fallen by 2 9   This is the largest quarterly decline in five years and the maximum difference between the second and third estimates since 1976  As it ahs been before  the GDP decline explanation was the negative impact of too cold winter weather  Now the U S  government expects the economic growth in the second quarter by 3  and 2 4  for the whole 2014  That means  it assumes marked acceleration in the second half of the year  Another yesterday indicator   Orders for durable goods in May decreased by 1  while it was expected to grow by 0 5   Weak stats had a negative impact on the U S  Dollar  However  stock the stock market participants ignored it and bought  as expected  that it will delay the U S  interest rates increase more significantly  Today  we expect the U S  unemployment rate for this week and personal income   spending at 12 30 CET  In our opinion  the forecasts are positive  At 17 00 CET we will see regional representative  Fed James Bullard s speech The EU had no significant economic data coming out yesterday and today there are also not expected  The prices decreased due to corporate news  On Wednesday  the French government sold a stake to the GDF Suez at 1 5 billion Euro at the lower boundary of the price range  Today  the European indexes increased slightly  Nikkei has grown up thanks to good information on individual Japanese companies  Today  at 23 30 CET  we will see the inflation  unemployment and retail sales data for May  We believe that their forecasts are positive for the Nikkei  Most of market participants expect the BOJ to continue to stimulating the economy until the end of the year despite reaching the inflation target The grain futures rose before the USDA weekly report today at 11 30 CET  The data on the U S  exports may have the greatest impact on the prices  The Corn sales are expected to increase  Its reserves in the U S  are projected at 3 72 billion bushels  which is the highest in 4 years  the Soyb   at 378 million or at 37 years low  the Wheat   at 598 million  or at 6 years low  The estimate of reserves from the USDA is expected on Monday The Cotton prices plummeted to the minimum of one and a half year on the USDA forecasts for its production growth in U S  by 16  to 15 million bales  compared to last year  The net position on the Cotton at the Intercontinental Exchange  ICE  decreased to 3 year low  While its exchange reserves increased to the maximum of 11 months and totaled 444 6 thousand bales The Coffee prices rose after reports that the largest coffee cooperative in Brazil  Cooxupe  has the harvest at the lower level than expected due to the drought  By the end of last week  it had already handled 27 5   while the last year  in the same period  it have been processed only 13 6   Note that the USDA predicts the world coffee crop decline for the current season by 1  compared to the last season  to 148 7 million bags  We expected a record demand in the amount of 147 7 million bags mainly because of the United States and Russia  This situation may lead to a significant decline in world coffee supplies before the next growing season to a minimum in 2011   32 1 million bags The Copper price has risen thanks to the cumulative reduction of its stocks on the London  New York and Shanghai exchanges by 51  compared to last year  to the lowest level since October 2008 ,2014-06-26,IFC Markets,https://www.investing.com/analysis/european-indexes-kept-falling-and-the-rest-of-them-rose-217545,217545
204238,425754,MRK,Embrace These New ETFs  Don t Play The Waiting Game,opinion,There is a deeply flawed school of thought prominent in the world of exchange traded products and it applies directly to new ETFs and ETNs  Many investors believe they should wait for new funds to mature before getting involved    Mature  means wait for a new ETF to gain assets and sufficient average daily trading volume  though neither metric has ever been scientifically linked to an ETF s total returns   Think about that for a moment  By waiting for Investor A to commit capital to a new ETF  Investor B is succumbing to the same follow the herd mentality that has doomed market participants for years   Here is real world example of what can happen when investors play the waiting game with new ETFs and by  new   it is funds that are less than a year old that are being referred to  The PowerShares S P 500 High Dividend Portfolio  SPHD  debuted on October 18  2012   Although SPHD has yet to reach the overrated  100 million in assets under management threshold  volume is decent at over 60 000 shares per day and only once during the fourth quarter did the midpoint on SPHD s bid ask spread exceed 50 basis points above the ETF s net asset value  Since its debut  SPHD has gained nearly seven percent and has delivered four dividend payments  it pays a monthly dividend  totaling about 41 5 cents per share   To be fair  not all new ETFs merit investors  consideration  but not all of these funds should be ignored  either  At least not simply because they are new  The following rookie ETFs are worth looking at right now and all of them debuted this year   PIMCO Foreign Currency Strategy ETF  FORX  The PIMCO name certainly helps and that is perhaps one reason why the PIMCO Foreign Currency Strategy ETF is off to an impressive start having attracted  26 6 million in AUM in just over a month of trading  FORX is an actively managed ETF  meaning investors will pay up a bit for the privilege of PIMCO management  though an expense ratio of 0 65 percent is decent among actively managed products   FORX invests  in currencies  currency forwards  or fixed income securities denominated in the currencies of foreign  non U S   countries  and  intends to limit its exposure to any one currency to 20  and to maintain a portfolio duration between zero and three years   according to PIMCO   What is attractive about FORX is its allocations to countries that have not engaged in currency debasement via monetary easing  For example  Canada  Norway  Australia and New Zealand combine for nearly 39 percent of the new ETF s weight   Global X SuperDividend U S  ETF  DIV  This one will really get the naysayers going because the Global X SuperDividend U S  ETF is not even a week old  However  DIV is not offering up an opaque concept that warrants a wait and see approach  Rather  the new fund is quite straight forward   Home to 50 stocks that are almost equally weighted  DIV is the U S  complement to the successful Global X SuperDividend ETF  SDIV   SDIV crossed the  100 million AUM level in August and has since more than quadrupled that total  For a moment  think about what would have happened if an investor was thinking about buying SDIV in May 2012 and declined in the essence of waiting for the ETF to reach  100 million in assets   That investor s entry point was about 10 percent and he missed out on three months of dividends because SDIV pays a monthly dividend  There are no guarantees DIV will follow a same trajectory  but Global X does expect DIV will pay a monthly dividend  Investors can take comfort in the fact that DIV is home to plenty of familiar  low beta names such as Dow components AT T  T   Merck  MRK  and Verizon  VZ    WisdomTree Global Corporate Bond Fund  GLCB  For the investor looking for a complement to or a yield above that of the iShares iBoxx   Investment Grade Corporate Bond Fund  LQD   the newly minted WisdomTree Global Corporate Bond Fund is a credible option   GLCB debuted at the end of January and should not be viewed as a high risk version of LQD  U S  issues account for almost 52 percent of the new ETF s weight and half the holdings are rated A or AA with another 21 7 percent garnering a BBB rating  Overall  GLCB offers exposure to 15 countries  including four emerging markets   GLCB s effective duration is 5 54 years with an embedded income yield of 3 72 percent  according to WisdomTree data  The ETF s 30 day SEC yield is 35 basis points higher than LQD s BY The ETF Professor,2013-03-15,Benzinga ,https://www.investing.com/analysis/embrace-these-new-etfs:-don't-play-the-waiting-game-159060,159060
204239,425755,MRK,Trading Merck   Co ,opinion,Here is your Bonus Idea with links to the full Top Ten Merck  MRK Merck is trying to move higher out of a bull flag on its next leg higher out of a Cup and Handle with a target of 55  The Relative Strength Index  RSI  is bullish and the Moving Average Convergence Divergence  MACD  is rising  both supporting more upside price movement  There is resistance at 48 67 and then 53 from 57 50 and 62 30  the last three all prior to 2001  Support lower is found at 46 50 and 45 60 followed by 45  44 50 and 43 50  Trade Idea 1  Buy the stock on a move over 47 50 with a stop at 46 50 Trade Idea 2  Buy the May 48 Calls  offered at 63 cents late Friday  on a move over 47 50 Trade Idea 3  Sell the May 46 Puts  37 cents  on a move over 47 50 Trade Idea 4  Buy the May 46 48 bullish Risk Reversal  26 cents  on a move over 47 50 Trade Idea 5  Buy the June 46 48 bullish Risk Reversal  10 cents  on a move over 47 50 After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday which  moving beyond the April Expiry for options the markets are a bit more damaged and showing more mixed signs of strength and weakness  Gold looks to continue to bounce in a bear flag while Crude Oil sits at long term support resistance but looks better lower  The U S  Dollar Index is again showing signs of strength while U S  Treasuries continue higher  The Shanghai Composite and Emerging Markets remain biased to the downside with the Chinese market potentially ready to reverse that trend  Volatility looks to remain subdues and may have given a key signal on its spike keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  Their charts are mixed though with the QQQ the strongest and the IWM the weakest  Use this information as you prepare for the coming week and trad em well The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-04-22,Gregory W. Harmon,https://www.investing.com/analysis/trading-merck---co.-163967,163967
204258,425774,MRK,ALK Abello  Near Term Driven By U S  Allergy Therapy ,opinion,Investment summary  Value driver remains US2012 guidance for ALK Abello  ALK B CO  is unchanged following a mixed Q3  with declining vaccine sales offset by partner licensing income  A new 2016 strategy should drive long term value  but in the near term the shares are likely to be driven by US allergy tablet commercialisation by Merck   Co  MRK   Two US filings are planned for 2013 Declining Q3 vaccine sales  new updated 2016 strategyQ3 revenues grew 17   local currency  largely driven by partner licensing income   174    but vaccine sales declined 2  owing to the challenging economic environment in Spain and Italy  2012 vaccine sales growth has consequently been lowered to 0 2  local currency  from previous 3 5    However  2012 revenue and EBITDA guidance is unchanged with the lower vaccine sales expected to be offset by partner income  ALK presented a new 2016 strategy focused on simplification  innovation and growth  Previous 2015 DKK3bn revenue and 25  EBITDA targets are maintained Near term will be driven by US allergy tabletsUS partner Merck recently disclosed that the final US Phase III trial investigating the use of allergy tablet GRAZAX met the primary end point  paving the way for US filing in 2013  Merck also plans to file the Ragweed allergy tablets in 2013 and recently announced plans to start a Phase III trial investigating the house dust mite allergy tablets in 2013  The market for these tablets is vast  with  20  of the population affected by respiratory allergies  source  ALK  and estimates that c three million patients in the US are currently treated every year with  allergy shots  Allergy immunotherapy could offer a potential cureAllergy immunotherapy treats the underlying allergy by increasing exposure to the allergen  This aims to reset the immune system  allowing the individual to better tolerate allergen exposure  Allergy immunotherapy is generally used to treat more severe allergies where symptoms cannot be controlled with existing medication Valuation  EV supported by existing businessALK s DKK164m cash implies an EV of c DKK3 9bn  This seems broadly underpinned by ALK s profitable business of marketed allergy immunotherapy products  The US allergy tablets are likely to be the key driver in the near term To Read the Entire Report Please Click on the pdf File Below ,2012-11-15,Edison,https://www.investing.com/analysis/alk-abello:-near-term-driven-by-u.s.-allergy-therapy-143612,143612
204259,425775,MRK,The Best  Dogs Of The Dow  Stocks As Of December 2012 ,opinion,One investment strategy I use on a regular basis is the Dogs of the Dow philosophy  The strategy is simple  buy 10 of the highest yielding stocks from the Dow Jones Index list that also have the lowest price to earnings ratio at the beginning of the year and to hold these stocks for the year  After this period  the investor should sell those stocks that are no longer  Dogs of the Dow  and buy the new  Dogs of the Dow   Below is an updated sheet of the current 10 best Dogs of the Dow  The 10 cheapest stocks have an average dividend yield of 3 83 percent as well as a forward P E ratio of 12 10  The average P B ratio amounts to 2 38 and P S ratio is 1 99 AT T  T  has a market capitalization of  191 64 billion  The company employs 241 130 people  generates revenue of  126 723 billion and has a net income of  4 184 billion  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  27 595 billion  The EBITDA margin is 21 78 percent  the operating margin is 7 27 percent and the net profit margin 3 30 percent    Financial Analysis  The total debt represents 23 95 percent of the company s assets and the total debt in relation to the equity amounts to 61 36 percent  Due to the financial situation  a return on equity of 3 63 percent was realized  Twelve trailing months earnings per share reached a value of  0 77  Last fiscal year  the company paid  1 73 in the form of dividends to shareholders    Market Valuation  Here are the price ratios of the company  The P E ratio is 43 77  the P S ratio is 1 51 and the P B ratio is finally 1 89  The dividend yield amounts to 5 33 percent and the beta ratio has a value of 0 55   Verizon Communications  NVZ  has a market capitalization of  124 26 billion  The company employs 184 500 people  generates revenue of  110 875 billion and has a net income of  10 198 billion  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  29 376 billion  The EBITDA margin is 26 49 percent  the operating margin is 11 62 percent and the net profit margin 9 20 percent     Financial Analysis  The total debt represents 23 93 percent of the company s assets and the total debt in relation to the equity amounts to 153 33 percent  Due to the financial situation  a return on equity of 6 45 percent was realized  Twelve trailing months earnings per share reached a value of  1 07  Last fiscal year  the company paid  1 98 in the form of dividends to shareholders    Market Valuation  Here are the price ratios of the company  The P E ratio is 40 59  the P S ratio is 1 12 and the P B ratio is finally 3 43  The dividend yield amounts to 4 73 percent and the beta ratio has a value of 0 50  Merck   Co   MRK  has a market capitalization of  125 92 billion  The company employs 84 000 people  generates revenue of  48 047 billion and has a net income of  6 392 billion  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  15 478 billion  The EBITDA margin is 32 21 percent  the operating margin is 15 26 percent and the net profit margin 13 30 percent     Financial Analysis  The total debt represents 16 66 percent of the company s assets and the total debt in relation to the equity amounts to 32 13 percent  Due to the financial situation  a return on equity of 11 49 percent was realized  Twelve trailing months earnings per share reached a value of  2 20  Last fiscal year  the company paid  1 52 in the form of dividends to shareholders    Market Valuation  Here are the price ratios of the company  The P E ratio is 18 82  the P S ratio is 2 62 and the P B ratio is finally 2 31  The dividend yield amounts to 4 15 percent and the beta ratio has a value of 0 64  The 10 cheapest stocks of the Dow Jones have an average dividend yield of 3 83 percent as well as a forward P E ratio of 12 10  The average P B ratio amounts to 2 38 and P S ratio is 1 99   Here is the full table with fundamental data Related Stock Ticker Symbols T  VZ  MRK  PFE  GE  JNJ  PG  DD  CVX  JPM,2012-12-26,Dividend Yield,https://www.investing.com/analysis/the-best-'dogs-of-the-dow'-stocks-as-of-december-2012-148845,148845
